<SEC-DOCUMENT>0001493152-26-014687.txt : 20260401
<SEC-HEADER>0001493152-26-014687.hdr.sgml : 20260401
<ACCEPTANCE-DATETIME>20260401164531
ACCESSION NUMBER:		0001493152-26-014687
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260401
DATE AS OF CHANGE:		20260401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JUPITER NEUROSCIENCES, INC.
		CENTRAL INDEX KEY:			0001679628
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				474828381
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41265
		FILM NUMBER:		26829041

	BUSINESS ADDRESS:	
		STREET 1:		1001 NORTH US HWY 1
		STREET 2:		SUITE 504
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		(561) 406-6154

	MAIL ADDRESS:	
		STREET 1:		1001 NORTH US HWY 1
		STREET 2:		SUITE 504
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Jupiter Orphan Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160713
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:JUNS="http://jupiterneurosciences.com/20251231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_030_JUNS_jupiterneurosciences.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001679628 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_068_Segments_5_Segments -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001679628</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="xdx2ixbrl0146" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="xdx2ixbrl0152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-12-31" id="xdx2ixbrl0158" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0164" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0165" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31" id="xdx2ixbrl0175" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="xdx2ixbrl0177" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="xdx2ixbrl0179" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="xdx2ixbrl0181" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:GainOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueStockSplits" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueWarrantExercises" contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueWarrantExercises" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueWarrantExercises" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueCommitmentShares" contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueCommitmentShares" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_custom_ReceivablesforSaleofCommonStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:GainLossOnForgivenessOfAccruedCompensation" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:NoncashFinancingCost" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:DecreaseIncreaseInPrepaidContracts" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:RestrictedStockIssuedForForgivenessOfSalary" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockOptionsIssuedForForgivenessOfSalary" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:NotesPayableRelatedPartyAssignToNotePayable" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:StockIssuedInConnectionInterestPayment" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="xdx2ixbrl0724" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_DerivativeMember" id="xdx2ixbrl0876" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-12-31_us-gaap_DerivativeMember" id="xdx2ixbrl0878" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-12-31" id="xdx2ixbrl0896" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31" id="xdx2ixbrl0898" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1024" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1026" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1028" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1042" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1044" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1046" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1048" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeFiveMember" id="xdx2ixbrl1122" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437" id="xdx2ixbrl1228" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437" id="xdx2ixbrl1230" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437" id="xdx2ixbrl1236" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437" id="xdx2ixbrl1238" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1240" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" contextRef="AsOf2025-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1242" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1286" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1287" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:DeferredTaxAssetsDerivativeLiability" contextRef="AsOf2025-12-31" id="xdx2ixbrl1303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="JUNS:DeferredTaxAssetsDerivativeLiability" contextRef="AsOf2024-12-31" id="xdx2ixbrl1304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl1315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-12-31" id="xdx2ixbrl1366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="xdx2ixbrl1384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember" id="xdx2ixbrl1458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember" id="xdx2ixbrl1461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember" id="xdx2ixbrl1464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember" id="xdx2ixbrl1467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember" id="xdx2ixbrl1471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember" id="xdx2ixbrl1473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember" id="xdx2ixbrl1488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember" id="xdx2ixbrl1489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember" id="xdx2ixbrl1490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="juns-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ReceivablesforSaleofCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ReceivablesforSaleofCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ReceivablesforSaleofCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ReceivablesforSaleofCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-142024-06-14_custom_FifteenForFourForwardStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">JUNS:FifteenForFourForwardStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-14</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_custom_FifteenForFourForwardStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">JUNS:FifteenForFourForwardStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-13_custom_FifteenForFourForwardStockSplitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">JUNS:FifteenForFourForwardStockSplitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-242025-10-24_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-24</xbrli:startDate>
        <xbrli:endDate>2025-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-21_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-09_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-02-26_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-08-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-08-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-152024-03-15_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-15</xbrli:startDate>
        <xbrli:endDate>2024-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-15_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-152024-03-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-15</xbrli:startDate>
        <xbrli:endDate>2024-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-152024-03-15_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-15</xbrli:startDate>
        <xbrli:endDate>2024-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:NoteIIHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-292024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:NoteIIHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-29</xbrli:startDate>
        <xbrli:endDate>2024-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:EmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember_custom_YAIIPNLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:YAIIPNLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-272025-10-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-27</xbrli:startDate>
        <xbrli:endDate>2025-10-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-272025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-27</xbrli:startDate>
        <xbrli:endDate>2025-10-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-012021-12-31_custom_TwelveConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-062022-08-06_custom_TwelveConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-06</xbrli:startDate>
        <xbrli:endDate>2022-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-04_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-11</xbrli:startDate>
        <xbrli:endDate>2022-04-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-11</xbrli:startDate>
        <xbrli:endDate>2022-04-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-242024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-24</xbrli:startDate>
        <xbrli:endDate>2024-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeniorSecuredNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-012024-12-31_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DerivativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-242025-10-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-24</xbrli:startDate>
        <xbrli:endDate>2025-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-232025-04-23_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-23</xbrli:startDate>
        <xbrli:endDate>2025-04-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityOneMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityTwoMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityThreeMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-022024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-02</xbrli:startDate>
        <xbrli:endDate>2024-12-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-04</xbrli:startDate>
        <xbrli:endDate>2024-12-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-242024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-24</xbrli:startDate>
        <xbrli:endDate>2024-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-172024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-17</xbrli:startDate>
        <xbrli:endDate>2024-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-10</xbrli:startDate>
        <xbrli:endDate>2025-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-02_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-022025-07-02_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-02</xbrli:startDate>
        <xbrli:endDate>2025-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-052025-09-05_custom_TwoConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:TwoConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-05</xbrli:startDate>
        <xbrli:endDate>2025-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-05_custom_TwoConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:TwoConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-052025-09-05_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-05</xbrli:startDate>
        <xbrli:endDate>2025-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-05_custom_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-22_custom_WarrantHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-16_custom_WarrantHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-162025-07-16_custom_WarrantHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-16</xbrli:startDate>
        <xbrli:endDate>2025-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-12_custom_WarrantHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-122025-08-12_custom_WarrantHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-12</xbrli:startDate>
        <xbrli:endDate>2025-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RangeEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember13963437">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember13963437">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-19_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">JUNS:TiberendStrategicAdvisorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">JUNS:TiberendStrategicAdvisorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DominantTreasureAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-15</xbrli:startDate>
        <xbrli:endDate>2024-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-15_custom_DominantTreasureAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DominantTreasureAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-182023-12-18_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-18</xbrli:startDate>
        <xbrli:endDate>2023-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-042024-12-04_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-04</xbrli:startDate>
        <xbrli:endDate>2024-12-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-132016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-13</xbrli:startDate>
        <xbrli:endDate>2016-09-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-132016-09-13_custom_LicensingAndRoyaltyAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicensingAndRoyaltyAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-13</xbrli:startDate>
        <xbrli:endDate>2016-09-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DebtForgivenessAndExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DebtForgivenessAndExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-152016-09-15_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-15</xbrli:startDate>
        <xbrli:endDate>2016-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember_country_JP_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:MurdochChildrensResearchInstituteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_country_JP_srt_MaximumMember_custom_MurdochChildrensResearchInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:MurdochChildrensResearchInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-09-012015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:MurdochChildrensResearchInstituteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-01</xbrli:startDate>
        <xbrli:endDate>2015-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_custom_EntityThreeMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ServiceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_ServiceAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">JUNS:PharmaceuticalOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">JUNS:PremiumNutritionalSupplementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-012026-03-31_us-gaap_SubsequentEventMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001679628</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-01</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segments">
      <xbrli:measure>JUNS:Segments</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b>Washington D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_909_edei--DocumentType_c20250101__20251231_zUuTKhiexua2"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000014" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90B_edei--DocumentAnnualReport_c20250101__20251231_zNkhlLYmoKD3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b>ANNUAL
                                            REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>For the fiscal year ended <span style="text-decoration: underline"><span id="xdx_90B_edei--DocumentPeriodEndDate_c20250101__20251231_zmEeZAZEgINd"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000016" name="dei:DocumentPeriodEndDate"><span id="xdx_90B_edei--CurrentFiscalYearEndDate_c20250101__20251231_zuDCVMFEdRCb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000017" name="dei:CurrentFiscalYearEndDate">December
31</ix:nonNumeric></span>, <span id="xdx_90E_edei--DocumentFiscalYearFocus_c20250101__20251231_zFdgdJGNJwce"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000018" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_908_edei--DocumentTransitionReport_c20250101__20251231_zPm7ERew6TU8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b>TRANSITION
                                            REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>For the transition period from _________ to _________</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Commission File Number <span style="text-decoration: underline"><span id="xdx_907_edei--EntityFileNumber_c20250101__20251231_z4kGxHnbEQCb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:EntityFileNumber">001-41265</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20250101__20251231_zjqU03aJzCCi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000021" name="dei:EntityRegistrantName">JUPITER NEUROSCIENCES, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Aptos,sans-serif; width: 49%; text-align: center"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20250101__20251231_z3o4HXnSarc3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Aptos,sans-serif; width: 0.25in">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Aptos,sans-serif; width: 49%; text-align: center"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20250101__20251231_zhtynw9a1b46"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">47-4828381</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">incorporation or organization)</p></td>
    <td style="font: 10pt Aptos,sans-serif">&#160;</td>
    <td><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">(I.R.S. Employer</p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 50%"><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20250101__20251231_zG1ryK33gv8f"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityAddressAddressLine1">1001 North US HWY 1</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20250101__20251231_zLPYjk8YAuC2"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:EntityAddressAddressLine2">Suite 504</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20250101__20251231_zYzi26y4m8rc"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Jupiter</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20250101__20251231_zYynYn7u7ap1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b></p></td>
    <td style="font: 10pt Aptos,sans-serif; vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Aptos,sans-serif; vertical-align: bottom; width: 48%; text-align: center"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20250101__20251231_zlnrAfa0U0A8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">33477</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Aptos,sans-serif; text-align: center"><span style="font-family: Times New Roman,serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Aptos,sans-serif">&#160;</td>
    <td style="font: 10pt Aptos,sans-serif; text-align: center"><span style="font-family: Times New Roman,serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--CityAreaCode_c20250101__20251231_zepWL9q8Co1l"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000029" name="dei:CityAreaCode">(561)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20250101__20251231_zNYqa4epX9sb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:LocalPhoneNumber">406-6154</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 38%; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="width: 0.25in; text-align: center; font-family: Aptos,sans-serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 0.25in; text-align: center; font-family: Aptos,sans-serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 38%; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20250101__20251231_zqGjrOLMqcCa"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000031" name="dei:Security12bTitle">Common
    Stock</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20250101__20251231_zIvPSObpk9r8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000032" name="dei:TradingSymbol">JUNS</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">The
    <span id="xdx_903_edei--SecurityExchangeName_c20250101__20251231_zoiquHLWpie4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Securities registered pursuant to section 12(g) of the Act:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">(Title
    of class)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 100%; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">N/A</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">(Title
    of class)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">Indicate by check
mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
<span style="font-family: Times New Roman,serif"><span id="xdx_905_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_zud8gy35QMC1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000034" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">Indicate by check
mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
<span style="font-family: Times New Roman,serif"><span id="xdx_90C_edei--EntityVoluntaryFilers_c20250101__20251231_zH0WfmCoKOxk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000035" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">Indicate by check
mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. <span id="xdx_90D_edei--EntityCurrentReportingStatus_c20250101__20251231_zE5nYoYrEagg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000036" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> <span style="font-family: Times New Roman,serif">No
</span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">Indicate by check
mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit such files). <span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20250101__20251231_zIxaWx3pzPSa"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000037" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> <span style="font-family: Times New Roman,serif">No
</span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the
definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 46%; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Large accelerated
    filer</span></td>
    <td style="width: 4%; font-family: Aptos,sans-serif"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 46%; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="width: 4%; font-family: Aptos,sans-serif"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20250101__20251231_zB6WrCm2aqWl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000038" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font-family: Aptos,sans-serif"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</span></td>
    <td style="font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Smaller reporting company</span></td>
    <td style="font-family: Aptos,sans-serif"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90C_edei--EntitySmallBusiness_c20250101__20251231_zerenE0anhn6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000039" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Aptos,sans-serif">&#160;</td>
    <td style="font-family: Aptos,sans-serif">&#160;</td>
    <td style="font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Emerging growth company</span></td>
    <td style="font-family: Aptos,sans-serif"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20250101__20251231_zLkv6MnMi0n8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000040" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90A_edei--EntityExTransitionPeriod_c20250101__20251231_z74wgraUDIFg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">Indicate by check
mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report. </span><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_905_edei--IcfrAuditorAttestationFlag_c20250101__20251231_z6t1pcRYUaq7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">If securities
are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included
in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_902_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zCAtic7tofCa"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">Indicate by check
mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received
by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to Sec. 240.10D-1(b). </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman,serif">Indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
<span style="font-family: Times New Roman,serif">No </span><span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_901_edei--EntityShellCompany_dbF_c20250101__20251231_zciNlpF6PHO1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Aptos,sans-serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last
sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<span id="xdx_902_edei--EntityPublicFloat_iI_pn5n6_c20250630_zixPdLxYI9Mh"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000045" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As of March 31, 2026, there were <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_pid_c20260331_zkufC1V28aPk"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-31" id="Fact000046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,281,252</ix:nonFraction></span>
shares of common stock, par value $<span id="xdx_90F_edei--EntityListingParValuePerShare_c20250101__20251231_zm1PNTwmF9Cj"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2025-01-01to2025-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share, of the registrant issued and outstanding.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span id="xdx_90E_edei--DocumentsIncorporatedByReferenceTextBlock_c20250101__20251231_zOCtTchap6Tf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000048" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Table of Contents</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: white">
    <td colspan="2" style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b><a href="#m_01">Part I</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; width: 0.75in; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; width: 0.5in; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    1.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_02"><span style="font-family: Times New Roman,serif; font-size: 10pt">Business</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_03"><span style="font-family: Times New Roman,serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">18</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_04"><span style="font-family: Times New Roman,serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">69</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    1C.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_05"><span style="font-family: Times New Roman,serif; font-size: 10pt">Cybersecurity</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">69</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    2.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_06"><span style="font-family: Times New Roman,serif; font-size: 10pt">Properties</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">70</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    3.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_07"><span style="font-family: Times New Roman,serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">70</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    4.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_08"><span style="font-family: Times New Roman,serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">70</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b><a href="#m_09">Part II</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    5.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_10"><span style="font-family: Times New Roman,serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">71</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    6.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_11"><span style="font-family: Times New Roman,serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">72</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    7.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_12"><span style="font-family: Times New Roman,serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">72</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_13"><span style="font-family: Times New Roman,serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">81</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    8.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_14"><span style="font-family: Times New Roman,serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">82</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    9.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_15"><span style="font-family: Times New Roman,serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">82</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_16"><span style="font-family: Times New Roman,serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">82</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_17"><span style="font-family: Times New Roman,serif; font-size: 10pt">Other Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><a href="#m_18"><span style="font-family: Times New Roman,serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b><a href="#m_19">Part III</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    10.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#m_20">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">83</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    11.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#m_001">Executive Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">89</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    12.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#m_002">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">101</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    13.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#m_003">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    14.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#m_004">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><b><a href="#m_005">Part IV</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    15.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#m_006">Exhibit and Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">106</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">Item
    16.</span></td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#m_007">Form 10-K Summary</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">109</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif">&#160;</td>
    <td style="vertical-align: top; text-align: justify; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt"><a href="#signature">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center; font-family: Aptos,sans-serif"><span style="font-family: Times New Roman,serif; font-size: 10pt">110</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Some of the statements contained in this
Annual Report on Form 10-K may constitute &#8220;forward-looking statements&#8221; for purposes of the federal securities laws. Our forward-looking
statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions
or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221;
&#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221;
&#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 0in; text-align: justify; text-indent: 0.5in">The forward-looking statements
contained in this Annual Report on Form 10-K are based on our current expectations and beliefs concerning future developments and their
potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These
forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that
may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the following risks, uncertainties and other factors:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 16.2pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    substantial amount of indebtedness associated with the convertible promissory notes issued in connection with the Standby Equity
    Purchase Agreement may adversely affect our cash flow and our ability to operate our business, remain in compliance with debt covenants
    and make payments on our indebtedness.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
    trading volume in our common stock may limit or prevent our ability to draw on the Standby Equity Purchase Agreement to pay down
    the convertible promissory notes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not generated meaningful revenue from product sales to date, have incurred significant net losses since our inception, and expect
    to continue to incur significant net losses for the foreseeable future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has
    included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years
    ended December 31, 2025 and 2024.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on
    acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or
    future commercialization efforts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
    additional capital may cause substantial dilution to our stockholders, restrict our operations or require us to relinquish rights
    to our technologies or product candidates.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business and future prospects with the Nugevia brand and our pharmaceutical products are
                                            significantly dependent on our exclusive, worldwide license agreement with Aquanova. Any
                                            adverse development related to this license agreement could materially and adversely affect
                                            our operations, financial condition, and results of operations.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            drug development involves a lengthy and expensive process with an uncertain outcome. The
                                            clinical trials of our product candidate may not demonstrate safety and efficacy to the satisfaction
                                            of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive
                                            results and the results of preclinical studies and early clinical trials may not be predictive
                                            of future results. We may incur additional costs or experience delays in completing, or ultimately
                                            be unable to complete, the development and commercialization of our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have limited resources and are currently focusing the majority of our efforts on developing
                                            JOTROL&#8482; for particular indications. As a result, we may fail to capitalize on other
                                            indications or product candidates that may ultimately have proven to be more profitable.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            face significant competition and if our competitors develop and market technologies or products
                                            more rapidly than we do or that are more effective, safer or less expensive than the products
                                            we develop, our commercial opportunities will be negatively impacted.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 16.2pt"></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be successful in our efforts to develop our proprietary drug delivery platform, JOTROL&#8482;,
                                            to build a pipeline of indications.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials
                                            conducted in locations outside of their jurisdiction.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may face difficulties from changes to current regulations and future legislation.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            success is highly dependent on our ability to attract and retain highly skilled executive
                                            officers and employees.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&#8217;s failure to meet the continued listing requirements of The Nasdaq Capital
                                            Market could result in a delisting of its securities.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            price of our common stock could be subject to rapid and substantial volatility. A &#8220;short
                                            squeeze&#8221; due to a sudden increase in demand for shares of our common stock could lead
                                            to extreme price volatility in shares of our common stock. As a relatively small-capitalization
                                            company with relatively small public float, we may experience greater stock price volatility,
                                            extreme price run-ups, lower trading volume and less liquidity than large-capitalization
                                            companies. In addition, if the trading volumes of our common stock are low, persons buying
                                            or selling in relatively small quantities may easily influence prices of our common stock.
                                            This low volume of trades could also cause the price of our common stock to fluctuate greatly,
                                            with large percentage changes in price occurring in any trading day session. Holders of our
                                            common stock may also not be able to readily liquidate their investment or may be forced
                                            to sell at depressed prices due to low volume trading; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            risks and uncertainties, including those listed under the captions &#8220;<i>Description
                                            of Business</i>,&#8221; &#8220;<i>Risk Factors</i>,&#8221; and &#8220;<i>Management&#8217;s
                                            Discussion and Analysis of Financial Condition and Results of Operations.</i></span></td></tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Should one or more of these risks or uncertainties materialize,
or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">These and other risks are described under the heading &#8220;Risk
Factors&#8221; in this Annual Report on Form 10-K. Those factors and the other risk factors described therein are not necessarily all
of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking
statements. Other unknown or unpredictable factors also could harm our results. Consequently, there can be no assurance that actual results
or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences
to, or effects on, us. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking
statements.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b><span id="m_01"></span>PART I</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_02"></span>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>This Business section, along with
other sections of this Annual Report on Form 10-K, includes statistical and other industry and market data that we obtained from industry
publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and
studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee
the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys
and studies are reliable, we have not independently verified such data and we do not make any representation as to the accuracy of the
information. Unless the context otherwise requires, &#8220;JNS,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the
&#8220;Company&#8221; refers to Jupiter Neurosciences, Inc., a Delaware corporation.</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">Jupiter Neurosciences, Inc. (the
&#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) is a clinical stage research and development company focused on
developing treatments for neuroinflammation through our unique resveratrol platform. Our platform product, JOTROL&#8482;, is an
enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, we are primarily
targeting Parkinson&#8217;s Disease. We are presently in the process of conducting a Phase IIa clinical trial in Parkinson&#8217;s
Disease.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In March 2025, the Company unveiled a new strategic
initiative to introduce Nugevia &#8212; a consumer-oriented product line dedicated to longevity and wellness. This initiative aims
to meet the rising demand for wellness solutions by developing nutritional products that support both consumer health and wellness.
The Company completed the formulations and initial sales through direct-to-consumer (&#8220;DTC&#8221;) social media began in the
second half of the year.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In December 2024, we received gross proceeds of $11
million in a registered public offering (the &#8220;Public Offering&#8221;) of 2,750,000 shares of our common stock, par value $0.0001 per share (&#8220;common stock&#8221;) at a price of $4.00 per share for gross proceeds of $11 million before deducting
underwriting discounts and other related expenses. In connection with the Public Offering, the Company&#8217;s common stock was
registered under Section 12(b) of the Exchange Act and began trading on The Nasdaq Capital Market under the symbol
&#8220;JUNS.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The Company was incorporated in January 2016 under Delaware
law under the name of Jupiter Orphan Therapeutics, Inc. On August 30, 2021, the Company filed a Certificate of Amendment with the State
of Delaware to change its name to Jupiter Neurosciences, Inc.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Business Overview</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is
advancing a therapeutic pipeline targeting central nervous system (&#8220;CNS&#8221;) disorders and rare diseases, while also
expanding into the consumer market with its Nugevia&#8482; product line. Both efforts are powered by JOTROL&#8482;, Jupiter&#8217;s
proprietary, enhanced resveratrol formulation that has demonstrated potential for significantly improved bioavailability in an FDA
regulated Phase I study. The Company&#8217;s therapeutic development pipeline is focused broadly on CNS disorders, presently with a
Phase IIa clinical study in Parkinson&#8217;s disease. The Company&#8217;s Nugevia product line brings cutting edge science to the
supplement space, supporting mental clarity, skin health, and mitochondrial function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed preclinical studies at the University of Miami for Parkinson&#8217;s Disease in 2021. These studies used a
validated mouse model to mimic human disease characteristics. JOTROL&#8482; demonstrated consistent improvements in motor
coordination, endurance, and strength across multiple endpoints in a validated Parkinson&#8217;s disease model, with statistically
significant benefits versus untreated disease controls. The promising results have led the Company to initiate a Phase IIa
clinical trial for Parkinson&#8217;s Disease, which received final IND approval by the FDA in November of 2025 and is expected to
start in the second quarter of 2026, with results anticipated 12 months later. The Company also aims to investigate other CNS
indications, such as Mild Cognitive Impairment (&#8220;MCI&#8221;) and Alzheimer&#8217;s disease, following the Parkinson&#8217;s
study.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
believes, based on pre-clinical and clinical studies, that high doses of resveratrol are necessary for potential therapeutic
effects. Currently available resveratrol products cannot reach these levels without causing severe gastrointestinal side effects.
Human studies evaluating resveratrol in Alzheimer&#8217;s patients (Turner et al 2015) and Friedreich&#8217;s Ataxia patients (Yu et
al 2015) indicate the concentration of resveratrol at its peak (CMax) measured in blood plasma should be 300 ng/ml
or higher for a potential therapeutic effect. A Phase 1 study with 500mg of resveratrol as a maximum dose in the JOTROL&#8482;
formulation showed levels of resveratrol exceeding 800 ng/ml without generating any severe adverse events (AAPS Open 2022).
Resveratrol was shown in the Turner Alzheimer&#8217;s study to cross the blood-brain barrier, possibly indicating a potential for
positive effects on oxidative stress and inflammation. Subsequent analysis published in Molecular Science 2025 (Mousa et al) further
indicates that resveratrol may have an impact on neurodegeneration and neuroinflammation in Alzheimer&#8217;s patients.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Over the past
two years, JOTROL&#8482; has garnered significant interest from Asian organizations. This interest is partly due to resveratrol&#8217;s
use in Asian herbal medicines, recent patent approvals in Hong Kong and China, and China&#8217;s list of rare disease indications where
JOTROL&#8482; could be applicable. Additionally, recent publications in the Journal of Alzheimer&#8217;s Disease and AAPS Open, along
with the projected growth of the Traditional Chinese Medicine market, have contributed to this interest.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company has
entered service agreements with firms in Hong Kong to accelerate product development in Southeast Asia. These agreements aim to leverage
local expertise and networks to facilitate market entry and potential out-licensing deals. The Company entered into an agreement with
Dominant Treasure Health to expand its business development in China, Malaysia, and Singapore, aiming to penetrate the large and challenging
Asian market.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2025, the Company unveiled
a new strategic initiative to introduce Nugevia&#8212;a consumer-oriented product line dedicated to longevity and wellness. This
initiative aims to meet the rising demand for scientifically backed wellness solutions by developing nutritional products that
support both longevity and health span. Positioned within a rapidly growing global industry expected to reach $8 trillion by 2030,
Nugevia products will leverage Jupiter&#8217;s proprietary JOTROL&#8482; technology, a resveratrol-based platform that is designed
to deliver an increase in the bioavailability profile of resveratrol.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The first
products under the Nugevia brand, focusing on supporting longevity and health span are available for sale and shipments began in the
fourth quarter of 2025 through a DTC model. The products are:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Nugevia GLO (&#8220;GLO&#8221;),
    which helps promote and support cellular functions and skin vitality;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Nugevia MND (&#8220;MND&#8221;), which supports cognitive resilience; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Nugevia PWR (&#8220;PWR&#8221;), which helps support mitochondrial function, which is a key for sustained growth and performance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The three debut
formulations&#8212;GLO, MND, and PWR&#8212;are designed to support wellness and longevity through intelligent stacking of synergistic ingredients,
all enhanced for optimal absorption via the JOTROL&#8482; system.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company plans
to market these products in the U.S. and internationally.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Nugevia&#8217;s
launch is a pivotal move to monetize Jupiter&#8217;s proprietary science, support ongoing clinical trials, and capture a share of the
booming longevity market.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company operates through two segments:
(i) the sale of premium nutritional supplements under the Nugevia brand, and (ii) pharmaceutical operations centered on the development
of drug candidates.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Resveratrol</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Resveratrol, a natural antioxidant compound found in foods like red grapes and berries, has been studied for over
50 years by academic institutions as well as by small and large pharmaceutical companies. The multi-functional mechanisms of resveratrol
are well documented in over 20,000 scientific publications. Several of these publications, including a summary paper by AY Berman et al,
published in Precision Oncology 2017, point to the issue of the poor bioavailability that has stopped medical utilization of regular resveratrol
and never received regulatory approval for any indication. We believe the Phase I study we have conducted indicates that we have resolved
the poor bioavailability issue with JOTROL&#8482;.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Based upon available scientific
literature, it appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin family of proteins.
SIRT1 deacetylates histones and nonhistone proteins including transcription factors. The SIRT1-regulated pathway is believed to
affect metabolism, stress resistance, cell survival, cellular senescence, inflammation/immune function, endothelial functions, and
circadian rhythms. Resveratrol has been documented in scientific literature to activate SIRT1, NrF2, NLRP3 inflammasomes and have an
epigenetic mechanism, and therefore, is predicted to benefit diseases affected by abnormal metabolic control, inflammation, and cell
cycle defects. Nonetheless, the administration of currently available resveratrol poses a major challenge for the
pharmaceutical industry, due to its poor solubility and bioavailability, as well as severe gastro-intestinal side effects when taken
at effective dose levels (over 2,000 mg daily).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>JOTROL&#8482;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL&#8482; was developed together
with our technology partner Aquanova, headquartered in Darmstadt, Germany. JOTROL&#8482; is formulated with a unique patented
micellar technology that is projected to increase the bioavailability profile of resveratrol. Manufacturing technology transfers
were completed in 2017, and manufacturing procedures and clinical trial supply manufacturing have been completed at Catalent
Pharmaceutical Services, Inc. (&#8220;Catalent&#8221;), St Petersburg, Florida. Catalent has also completed the manufacturing of the clinical trial supplies for our Phase IIa trial in Parkinson&#8217;s Disease.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">JOTROL&#8482; is a micellar non-aqueous
solution of resveratrol delivered in a softgel capsule. Each capsule includes 100mg of resveratrol. Pre-clinical trials in mice and rats
were conducted comparing JOTROL&#8482; to micronized resveratrol, labeled to have the highest bioavailability in the nutritional market,
to demonstrate that we could achieve a significantly higher bioavailability. A Phase I dose finding pharmacokinetic (&#8220;PK&#8221;)
study in healthy volunteers was completed during the first half of 2021. The study results met our targeted goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase I study demonstrated JOTROL&#8482;&#8217;s potential for higher bioavailability compared to resveratrol used in earlier
clinical trials (e.g., Turner, MCI/Early Alzheimer&#8217;s Disease trial and Yui et al., Friedreich&#8217;s ataxia trial). The
results of this Phase 1 study were published in the Journal of Alzheimer&#8217;s diseases and AAPS Open in February 2022. Subject to
additional discussions with and approval from FDA, we hope to use the results of this study as a cross-reference for other
indications to allow JOTROL&#8482; to be tested in Phase II and Phase III clinical trials. FDA accepted this cross-reference in the
approval of the IND application for the Parkinson&#8217;s Phase IIa trial. The Company has not discussed the use of
cross-referencing in this manner with the FDA or other comparable regulatory authorities for any other indications, and FDA (or any
comparable regulatory authorities) may preclude us from the use of cross-referencing with respect to the results of this study. As a
result, we are presently unable to rely on potential cross-referencing other than the already cleared Phase II a Parkinson&#8217;s
study.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"><b>JOTROL&#8482; Intellectual Property and License Agreement</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We hold an exclusive global license
dated from Aquanova for micellar technologies to develop, manufacture, and sell JOTROL on the terms set forth in the license
agreement. Our Chief Scientific Officer (&#8220;CSO&#8221;), Marshall Hayward, and Aquanova&#8217;s founder, former CEO, and lead
scientist, Darius Benham, invented JOTROL&#8482;. The patent is co-owned by Aquanova and us, with the application assigned to
Aquanova. Filed in Germany on January 29, 2017, the patent (PCT/EP2017/O51659) expires in 2036 and is granted in the USA, Japan,
China, Hong Kong, and specific European countries. The patent covers a solubilization product with resveratrol, polysorbate 80 and
20, MCT, and tocopherols for pharmaceutical use. It includes claims on formulation specifics, micelle size, turbidity, and treatment
applications for diseases like Alzheimer&#8217;s and diabetes. The product is available in various capsule forms and is administered
orally.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our license agreement with Aquanova is
vital, as JOTROL&#8482; is our primary product. Losing this agreement would delay our plans and force us to seek similar licenses, if
available, adversely affecting our business. The agreement grants us worldwide exclusivity to utilize granted and pending patents. Effective
from September 15, 2016, it lasts until patent expiration or ten years after the first commercial sale. We paid an upfront fee of $20,000
and an annual license fee of $75,000 until the first product approval. Milestone payments of $200,000 are due per territory upon regulatory
approval, with royalties set at 5% of net sales. Each party has the option, within 180 days of a US Marketing approval, to demand that
the Company pay a one-time payment of $3 million for reduced royalties of 1.25%. Termination can occur due to material breach or insolvency,
with specific provisions for retaining licenses. Recent amendments include a Debt Forgiveness and Exchange Agreement on December 1, 2021,
where $225,000 of debt was forgiven in exchange for $125,000 cash, a $100,000 promissory note, and stock options.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in; text-align: justify; background-color: white">The Company relies on trade secret
protection and contractual confidentiality obligations to safeguard certain proprietary know-how related to JOTROL&#8482;. The Company
also asserts common law trademark rights in the JOTROL&#8482; name. In January 2025, the Company filed an intent-to-use trademark application
with the U.S. Patent and Trademark Office</p>
<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Product Pipeline</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s pharmaceutical product
pipeline is built around its proprietary platform product, JOTROL&#8482; an enhanced oral formulation of resveratrol. Resveratrol, a natural
compound is optimized in JOTROL&#8482;, which is being evaluated to better understand its therapeutic benefits and its potential relevance
to biological pathways of interest, including those involving oxidative stress, inflammation and mitochondrial issues linked to neurological
conditions. The Company has designated the different indications with project numbers, JNS101 - JNS115. The same JOTROL&#8482; product
is planned to be used in all indications although the number of capsules might vary and be indication specific and may be impacted by
regulatory requirements and other factors not known to us at this time.</p>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><img src="form10-k_001.jpg" alt=""/>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The pipeline chart above shows the indications
that we presently are prioritizing and is subject to the availability of financing as further discussed in the &#8220;Risk Factors&#8221; section. </p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The validity of our product pipeline represented
above relies on the assumptions drawing upon previous preclinical and clinical data conducted by third parties. This data is available
either via public domain or under agreements with our key partners. The Company has not discussed with the FDA its ability to rely on
and reference data from previous third-party trials, such as the Phase II trial in MCI/early Alzheimer&#8217;s disease, conducted by Georgetown
University.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our top priorities are advancing our
clinical studies for JNS115 for Parkinson&#8217;s Disease followed by JNS108 for MCI/early Alzheimer&#8217;s Disease. We executed all
CMC, regulatory, and preparations with investigators including IND approval by FDA for our JNS115 Phase IIa&#160;trial and estimate that
first dosing of patients will occur in the second quarter of 2026. We are also exploring clinical trials of JOTROL for other indications,
including rare diseases. Based on the FDA&#8217;s approval to use our Phase I study in support of the IND for our Phase IIa Parkinson&#8217;s
study, we believe there may be potential to cross-reference the Phase I data for additional indications in the future. However, we have
not discussed this cross-referencing for any other indication with FDA, and we may be precluded from relying on cross-referencing other
than in the Phase IIa Parkinson&#8217;s study.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"><b>&#160;&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>JNS115 Parkinson&#8217;s Disease</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We will be utilizing JOTROL&#8482; for investigating
a treatment for Parkinson&#8217;s Disease (PD).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">People are usually more familiar
with the motor symptoms of Parkinson&#8217;s disease (PD), which are noticeable and used by doctors for diagnosis. The three cardinal
motor symptoms are stiffness (rigidity), slowness (bradykinesia), and resting tremors. Stiffness involves muscle rigidity detected during
examination, while slowness refers to decreased spontaneous and voluntary movement, such as slower walking or reduced facial expression.
Resting tremor is an involuntary shaking that occurs when a limb is relaxed and disappears during movement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">Non-motor symptoms, often called
the &#8220;invisible&#8221; symptoms, can affect almost every body system and vary in severity. These symptoms can significantly impact
quality of life and include autonomic dysfunctions like constipation, low blood pressure, sexual problems, sweating issues, and urinary
problems. While available therapies can treat some symptoms, there is an urgent need for better treatments to improve quality of life
and slow disease progression. Approved medications for motor symptoms include dopamine replacement therapy (levodopa/carbidopa), adenosine
receptor antagonists, amantadine, anticholinergic medications, COMT inhibitors, decarboxylase inhibitors, dopamine agonists, and MAO-B
inhibitors. Researchers are increasingly recognizing the debilitating nature of non-motor symptoms and are working on new therapies,
while doctors manage these symptoms with current treatments.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Upcoming Phase IIa study in Parkinson&#8217;s Disease patients</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has engaged Zina
Biopharmaceuticals to assist with study design, FDA communications, including submission, of an Investigational New Drug (IND)
application and to manage the execution of the trial. Catalent has been engaged to manufacture the JOTROL&#8482; clinical trial
supplies pursuant to the Manufacturing Agreement between Company and Catalent dated September 16, 2020, under which Catalent is to
provide the Company with clinical batches of JOTROL&#8482; using a softgel formulation, which will be for active and placebo batches
for the Parkinson&#8217;s disease study. The study design is described below and has received final IND approval by the FDA. The Company expects
to start the clinical trial in the second quarter of 2026 and have the first study results available twelve months thereafter.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The multicenter, randomized,
double-blind, placebo-controlled study involves approximately 30 participants across three centers in the US. Participants are randomly
assigned to one of three groups to receive either a placebo or JOTROL&#8482; at doses of 200 mg or 400 mg daily for three months. The
study aims to explore JOTROL&#8482;&#8217;s potential to improve energy metabolism in Parkinson&#8217;s Disease. An optional biomarker
sub-study will assess cerebrospinal fluid, requiring additional patient consent. Each patient will be involved in the study for approximately
four to five months, while the overall study including all subsequent analyses will span approximately two years, with initial results
expected within twelve months of first dosing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>JNS108 Mild Cognitive Impairment/early Alzheimer&#8217;s
Disease</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 59.15pt; text-align: justify; text-indent: -20.3pt">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company had previously conducted studies
which used JOTROL&#8482; in our applications for investigating treatment of various segments of Alzheimer&#8217;s disease of which MCI/early
AD is the initial target.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Institute on Aging (&#8220;NIA&#8221;) financed the Company&#8217;s Phase I study with $1.76 million through grant 1R44AG067907-01A1.
Because there were unanticipated higher costs, mostly due to COVID-19 related additional procedures during the Phase I trial, a supplemental
grant of $233,281 was submitted to the NIA in December of 2021. We were awarded the supplemental grant on April 7, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">In April 2021, we submitted
our first grant application to the NIA for full funding of a Phase II trial in MCI and early Alzheimer&#8217;s disease. The Phase II
trial was designed to focus on 3 areas: (1) safety and tolerability; (2) pharmacokinetics and pharmacodynamics, measuring of
responses from 2 different doses versus a placebo; and (3) measuring of effect on multiple biomarkers related to the disease. The
application was not accepted, but we were encouraged by the NIA to refine our application and submit again. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have since submitted 3 grant applications, with budgets of $20 million or higher, to the NIA for full funding of such Phase II trial
but none of those applications were successful. We are planning to submit the next grant application after we have the results from
our Phase IIa study in Parkinson&#8217;s patients as several biomarkers from that trial may apply to
Alzheimer&#8217;s patients as well. However, there can be no assurance that the results of this Phase IIa study will be positive or
that NIA will approve any future grant application.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Early-stage Alzheimer&#8217;s (mild)</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Later stages of Alzheimer&#8217;s are
very difficult to reverse and therefore it is important to start treatment of Alzheimer&#8217;s in the earliest possible stage so the
individuals can continue living normal lives and maintain their independence.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the early stage of Alzheimer&#8217;s,
a person may function independently. He or she may still drive, work, and participate in social activities. Despite this, the person may
feel as if he or she is having memory lapses, such as forgetting familiar words or the location of everyday objects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Symptoms may not be widely apparent at
this stage, but family and close friends may take notice and a doctor would be able to identify symptoms using certain diagnostic tools.
Common difficulties include finding the right word or name, remembering names when meeting new people, and performing tasks in social
or work settings. People may also forget material they just read, lose or misplace valuable objects, and experience increased trouble
with planning or organizing.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">This is the Alzheimer&#8217;s disease
patient category that we plan to include in our grant application for a proposed Phase II clinical trial with the final objective of showing
that JOTROL&#8482; has the potential of slowing and/or possibly stopping the progression of this disease, subject to FDA&#8217;s review
of the clinical trial and the protocol. The effect of JOTROL&#8482; treatment, in the potential Phase II trial, will primarily be measured
through several biomarkers.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Economic burden of Alzheimer&#8217;s disease on society
in USA is generating a very large opportunity</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">According to Alzheimer&#8217;s Association&#8217;s
2020 annual report Alzheimer&#8217;s disease has impacted 5.7 million Americans and that it costs the US $277 billion each year, excluding
the cost of &#8220;unpaid time and effort of the people, mostly women, who are caring for spouses, parents, siblings, and friends with
dementia.&#8221; The Association explained, &#8220;In 2017, 16 million Americans provided an estimated 18.4 billion hours of unpaid care
in the form of physical, emotional and financial support - a contribution to the nation valued at $232.1 billion.&#8221; Any product that
delays the onset of severe Alzheimer&#8217;s disease should represent significant savings to society.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Proposed JNS108 Phase II Clinical Trial for MCI/early
Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to FDA&#8217;s review and
approval, the Phase II trial will be built on utilizing published information from the earlier Turner et al Phase II trial,
completed in 2015 with 119 patients with early Alzheimer&#8217;s disease who were treated with 4 different doses of resveratrol. The
study was conducted by Professor Raymond Turner, MD, Ph.D. at Georgetown University, a member of our Scientific Advisory Board, as
the Principal Investigator. Dr. Turner is the Principal Investigator of our proposed Phase II trial. The study tried 500mg, 1000mg,
1500mg and 2000mg daily doses with each dose taken by the patients over 13 weeks. Only the highest dose of 2000mg (2 X 1g per day)
showed positive results on biomarkers which lead to the conclusion that this study was most likely underdosed for achieving the best
therapeutic effect. Pharmacokinetic analysis showed that the average C-Max of resveratrol in the blood on the highest dose was 181 ng/ml, which
is far from the target of 300ng/ml that we believe is needed for reaching therapeutic effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
team of scientists in the Alzheimer&#8217;s field, Professors Raymond Turner, MD, Ph.D. and Charbel Moussa, Ph.D. from Georgetown
University and Li-Huei Tsai, Ph.D. from MIT have assisted in designing our Phase II a study to address and explore biomarkers. We believe these trial results can guide us to a follow-on studies that might
generate meaningful outcomes for MCI/early Alzheimer&#8217;s disease patients. The Company has not discussed its ability to rely on
and reference the Phase II trial conducted by Georgetown with the FDA nor has it discussed the design of the planned study in MCI
patients with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Proposed JOTROL&#8482; MCI Phase II Study</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the future, the Company hopes to
pursue a phase II, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of JOTROL&#8482; (micellar
resveratrol solubilization formulation) in early Alzheimer&#8217;s disease (&#8220;AD&#8221;) patients. If the study and protocol is
approved by FDA, approximately 105 patients would be enrolled at study centers across the United States. Patients would be
randomized into one of two active treatment arms to receive JOTROL&#8482; 200 mg BID or JOTROL&#8482; 500 mg BID or to a placebo
group. We hypothesize that this proposed study would support JOTROL&#8482; safety and tolerability in
individuals with MCI/early AD.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration: underline">Objectives</span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline">Primary Objective</span>:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To determine the safety and efficacy of JOTROL&#8482; (200 mg resveratrol BID and 500 mg resveratrol BID) for neuroinflammation and biomarkers of MCI/early AD.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To assess safety and tolerability of JOTROL&#8482; in AD-MCI patients by monitoring adverse events (AEs) and serious adverse events (&#8220;SAEs&#8221;) and assessing their relationship to the study drug. Tolerability will be measured by subjects&#8217; ability to remain on treatment. Overall tolerability of the drug will be defined as fewer than 25% discontinuations due to drug-related AEs and SAEs</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">A first efficacy indicator will be stabilization of Abeta 40/42.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Secondary Objectives:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To assess population pharmacokinetics (&#8220;Population PK&#8221;) in the ITT population</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To measure the effect of JOTROL&#8482; on biochemical markers for AD, neurodegeneration, vascular damage, metabolic effects, and neuroinflammation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To determine the effects of JOTROL&#8482; on whole-brain and regional brain atrophy</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To measure the effects of JOTROL&#8482; on functional MRI measures</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To assess cognitive effects of JOTROL&#8482;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">To examine the influence of Apolipoprotein E genotyping on both biomarker and cognitive endpoints</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration: underline">Endpoints</span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Primary Endpoint:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Assessment of safety/tolerability by monitoring AEs and SAEs, assessing their potential relationship to the study drug and Abeta 40/42</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Secondary Endpoints:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Levels of AD relevant biomarkers</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Volumetric MRI and Cortical Disarray Measurement</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Additional experimental biomarkers as stated in protocol, such as those for neuroinflammation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Study Population</b>: Approximately
105 male or female subjects between 55 and 85 years of age with a diagnosis of MCI/early AD will be enrolled. MCI/early AD patients should
be amyloid positive with an AD/MCI clinical diagnosis.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Phase</b>: Phase II Description of
Sites/Facilities Enrolling Participants: Approximately 8 study centers in the USA. Study sites will be determined by competitive selection
of interested and eligible ADCS sites - with experienced study coordinators, raters, and site PIs.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Description of Study Intervention:</b>
Subjects will be randomized 1:1:1 to receive 500 mg bid (1g/day) resveratrol as JOTROL&#8482;; or 200 mg bid (400mg/day) resveratrol as
JOTROL&#8482;; or placebo.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Participant Duration</b>: Treatment
phase will be 6 months with a one month follow up safety visit and safety monitoring over a 6-month period to ensure that patients have
no long-lasting treatment related effects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Rare Orphan Diseases</span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Proposed JNS102 Phase II trial for
Mucopolysaccharidosis Type 1 (&#8220;MPS Type I&#8221; or &#8220;MPS-I&#8221;)</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">JNS102 is investigating JOTROL&#8482; for
the potential treatment of Lysosomal Storage disease areas whereas MPS Type I is the first target.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">MPS-I is divided into three subtypes based
on severity of symptoms. All three types result from an absence or insufficient levels of the enzyme alpha-L-iduronidase. Children who
have parents with MPS-I will carry the defective gene.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">MPS-I patients are presently treated with
an Enzyme Replacement Therapy (&#8220;ERT&#8221;) named Aldurazyme. This requires a weekly infusion of 4 hours per event and costs over
$500,000 per year per patient. The ERT is effective in significantly prolonging life. However, since the ERT does not penetrate the blood
brain barrier, ears, eyes, or joints, it leaves the patients with a gradually worsening quality of life including loss of hearing, blindness
and severe arthritis.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">JNS102 is targeting the specific areas that ERT cannot treat,
with JOTROL&#8482;.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Proposed JNS102 Phase II Clinical Trial</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Preclinical studies conducted at University of Miami in MPS-I mice results showed that a high dose of resveratrol increased the alpha-L-iduronidase which is the critical enzyme that is too low in these patients.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif">&#160;</td>
    <td style="font: 10pt Times New Roman,serif"><span style="font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">IND application for Phase I study
was approved by the FDA.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif">&#160;</td>
    <td style="font: 10pt Times New Roman,serif"><span style="font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Final study details and start to be determined by consultation with the FDA and supportive additional financing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Primary endpoint:</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Safety, tolerability and PK/PD values</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="form10-k_002.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Secondary endpoints to include (subject to FDA acceptance)</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.5in; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Improvement in 6-minute walk distance</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman,serif"><span style="font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Forced vital capacity</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman,serif"><span style="font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Biomarkers, such as alpha-L-iduronidase levels</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman,serif"><span style="font-size: 10pt">iv.</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">MPS-I validated pain survey</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>JNS107 clinical trial for MELAS Syndrome</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">JNS107 is investigating
JOTROL&#8482; as a product candidate to treat MELAS Syndrome.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">MELAS (Mitochondrial Encephalopathy, Lactic
Acidosis, and Stroke-like episodes) syndrome is a rare disorder that begins in childhood, usually between two and fifteen years of age,
and mostly affects the nervous system and muscles. The most common early symptoms are seizures, recurrent headaches, loss of appetite,
and recurrent vomiting. Stroke-like episodes with temporary muscle weakness on one side of the body (hemiparesis) may also occur and this
can lead to altered consciousness, vision and hearing loss, loss of motor skills, and intellectual disability. MELAS is caused by mutations
in mitochondrial DNA. Pre-clinical trials performed with mice at University of Miami showed that JOTROL&#8482; increased mitochondrial
biogenesis in the liver with 70% and in the brain with 30%.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">While symptoms of MELAS syndrome usually
begin between the ages of two and fifteen years, delayed onset cases have also been reported in people aged fifteen to forty years and
older. In approximately 75% of cases, onset of the disorder occurs before the age of 20 years. Symptoms and physical findings associated
with MELAS syndrome vary greatly among affected individuals. The distinguishing feature in MELAS syndrome is the recurrence of stroke-like
episodes. It is currently thought that the deficiency of a compound called nitric oxide in the small blood vessels of the brain may be
responsible for the stroke-like episodes. Short stature and hearing loss may be present and fatigue and difficulty tolerating exercise
may be early symptoms.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">MELAS syndrome is a rare disorder that
affects males and females in equal numbers. Although rare, MELAS syndrome is probably the most common type of mitochondrial myopathy caused
by mutations in mtDNA. Some researchers believe that mitochondrial myopathies may go unrecognized and underdiagnosed in the general population,
making it difficult to determine the true frequency of disorders like MELAS syndrome.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Opportunity for JNS107</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The potential market for JOTROL&#8482;
in the USA includes approximately 80,000 patients<sup>1</sup>. With a projected treatment cost for MELAS syndrome of $75,000 per patient
annually, treating 50,000 patients could generate around $3.75 billion per year. Furthermore, successful clinical trial results may extend
JOTROL&#8482;&#8217;s applicability to other mitochondrial diseases, potentially expanding its market impact. There is no assurance that
JOTROL&#8482; will obtain regulatory approval to treat MELAS syndrome or any other mitochondrial diseases.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is an overview of JNS&#8217;s
competitors in the pharmaceutical industry. Many companies, including the largest pharma companies in the world, are competitors in some
of the disease areas for which we are developing treatments for through our various projects. We will compete with both small and large
companies in each indication we are pursuing.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">There are a multiple of companies, both
smaller biotech&#8217;s as well as large pharmaceutical companies, that are working on solutions for the same indications that we are
pursuing. There is no assurance that we will be able to compete with these companies even if our product is approved in an indication.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Parkinson&#8217;s Disease</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Despite the availability of FDA-approved
treatments for Parkinson&#8217;s disease, no breakthrough therapies have emerged recently to halt disease progression. The most commonly
prescribed treatment is levodopa/carbidopa, which has been used since the late 1960s. Levodopa is absorbed in the intestine and converted
to dopamine in the brain, addressing the dopamine deficiency in Parkinson&#8217;s patients. Carbidopa prevents premature conversion of
levodopa to dopamine outside the brain, reducing side effects like nausea. This combination is available in various forms, including pills,
dissolvable tablets, and a gel infused directly into the intestine.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Levodopa/carbidopa significantly improves
motor symptoms in most patients, especially those with mild symptoms, and remains effective over time. However, as Parkinson&#8217;s progresses,
dosage adjustments may be necessary. Initial side effects can include nausea and vomiting, which can be mitigated by taking the medication
with a small snack or adding extra carbidopa. Other side effects may include drowsiness, low blood pressure, and hallucinations. Despite
these challenges, levodopa/carbidopa remains a cornerstone in managing Parkinson&#8217;s symptoms.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Alzheimer&#8217;s Disease</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Several companies are actively developing
treatments for Alzheimer&#8217;s disease, each with unique approaches and challenges. Biogen&#8217;s Aduhelm, an IV infusion targeting
amyloid-beta plaques, has faced reimbursement issues despite FDA approval, leading to low market penetration and market withdrawal. Eli
Lilly&#8217;s donanemab, targeting a modified form of beta amyloid, recently received FDA approval and is priced at $32,000 annually.
It has shown promise in early Alzheimer&#8217;s patients and is undergoing further trials. Cognition Therapeutics is developing CT1812,
an orally dosed molecule in Phase II, supported by significant NIA grants.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Anavex Life Sciences is advancing Anavex
2-73, a Phase III candidate from their SIGMACEPTOR&#8482; platform, targeting CNS conditions with genomic precision. Eisai and Biogen&#8217;s
Leqembi has received traditional FDA approval, potentially expanding Medicare coverage. Priced at $26,000 per year, Leqembi has shown
benefits for early-stage Alzheimer&#8217;s patients. Despite these advancements, the competitive landscape remains dynamic, with the possibility
of other companies emerging with successful treatment</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Rare Diseases</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">There are several companies that are targeting
the same rare diseases as us. Below is a description of a selection of those companies that we see as our closest competitors. However,
it is possible that another company, that is not listed below, could have a successful product approved before us and have a more effective
treatment.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the MPS-I space, several companies
offer competitive products to Jupiter. Sanofi Genzyme&#8217;s Aldurazyme has been the standard enzyme replacement therapy for nearly 20
years. RegenexBio is developing RGX-111, a gene therapy designed to deliver a functional copy of the IDUA gene to the central nervous
system. Sigilon Therapeutics, Inc. is working on SIG-005, which uses a genetically modified human cell line to express the IDUA enzyme,
with an Investigation New Drug (&#8220;IND&#8221;) application for Phase I submitted to the FDA. Additionally, Sangamo Therapeutics, Inc.
is exploring gene editing products, although no positive results have been published yet. These developments represent significant competition
in the treatment of MPS-I.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span>
https://pmc.ncbi.nlm.nih.gov/articles/PMC8993002/</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the treatment of MELAS, several products
present competition to Jupiter&#8217;s offerings. Cyclerion Therapeutics is advancing CY643, currently in Phase 1B, which evaluates safety
and its impact on mitochondrial dysfunction and cognition. Abliva AB is developing KL1333, which has been granted orphan drug designation
in both the United States and Europe. This product has been tested in healthy volunteers and patients, with a registrational Phase II/III
study initiated in December 2022. These developments underscore the competitive landscape in the search for effective MELAS treatments.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Competitive Advantages</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that we are positioned to outperform
competitors in the pharmaceutical industry for the following reasons:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">We believe that the focus on a new
    product based on resveratrol with potentially higher bioavailability, JOTROL&#8482;, will enable us to explore its use for several
    research pathways and indications, subject to FDA&#8217;s review and approval. Whether such path is viable would depend on
    regulatory submissions and data generated in pre-clinical and clinical trials. We believe that this enables us to have several
    opportunities to obtain regulatory approval in case we are able to show efficacy and safety acceptable to regulatory agencies for
    one or more of our targeted indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">JOTROL&#8482; is an oral product based on a natural compound. Oral delivery of medications is a physician and patient preferred treatment compared with injections and infusions and we expect that our product will have an attractive and affordable price point for reimbursors and patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">We are building a close relationship with key opinion leaders (&#8220;KOLs&#8221;) and patient organizations to facilitate a better understanding of patient needs and thereby design trials targeting solutions to those needs as long as these targets are acceptable to the FDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The natural product resveratrol is well studied with over 20,000 scientific publications to date. Published scientific papers, such as AY Berman et al, indicate that a highly bioavailable product generating less GI side effects may have application in a number of indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Based upon available scientific literature, it appears that resveratrol is an activator of SIRT1, one of the mammalian forms of the sirtuin family of proteins. SIRT1 deacetylates histones and nonhistone proteins including transcription factors. The SIRT1-regulated pathway affects metabolism, stress resistance, cell survival, cellular senescence, inflammation/immune function, endothelial functions, and circadian rhythms. Resveratrol has been documented in scientific literature to activate SIRT1, NrF2, NLR3P inflammasomes and have an epigenetic mechanism and therefore is predicted to benefit diseases affected by abnormal metabolic control, inflammation, and cell cycle defects. Nonetheless, resveratrol application is a major challenge, due to its poor solubility and bioavailability, as well as severe gastro-intestinal side effects when taken at high dose levels (over 2,000 mg daily). In this context, studies have proposed that structural changes in the resveratrol molecule, including glycosylation, alkylation, halogenation, hydroxylation, methylation, and prenylation could lead to the development of derivatives with enhanced bioavailability and pharmacological activity. Resveratrol has never been developed with all the necessary steps to achieve an approval as a pharmaceutical product because of severe gastro-intestinal side effects. This means that we need to take JOTROL&#8482; through the full regulatory NDA requirement to obtain marketing approval. We were able to receive, through a confidential agreement from a major pharmaceutical company, chronic toxicology studies performed with resveratrol, in two different species, that was referenced in our approved Phase I IND application submitted to the FDA. The study was conducted by Charles River Laboratories.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif">&#160;</td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Possible out-licensing for Asian markets is being considered as it may reduce risk and cost of product development in those markets that requires confirming trials in an Asian population, while generating income through milestones and royalty agreements, see &#8220;&#8212;Asian Business Development Activities&#8221; regarding further developments and strategy in the Asian market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Marketing and Commercialization Plan for Therapeutic Drug
Candidates</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company may consider out-licensing
JOTROL&#8482; for pharmaceutical uses to one or more companies that have such commercialization capability in place. We may consider at
any time a complete exit through any proposed acquisition of our company. In case no acceptable M&amp;A offer is presented, and in the
event we were able to obtain FDA regulatory approval for JOTROL&#8482; we might consider marketing and distributing JOTROL&#8482; in the
USA for the rare disease market only and have companies with large sales organizations distribute our product for larger indications.
All international distributions would most likely be out-licensed.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The marketing and sales of orphan drugs
can be relatively fast and effective. We believe, based on discussions with organizations such as the EveryLife Foundation an approval
of a drug for a rare disease is efficiently communicated through social media to KOLs, patient advocacy groups and directly to patients,
which may reduce marketing costs.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have been approached by several large
and mid-size pharmaceutical companies discussing interest in future collaborations once we have more clinical data available for JOTROL&#8482;.
We will try to utilize this interest for out-licensing primarily in the Asian territories while waiting to conduct out-licensing in the
USA and Europe until after Phase II results are obtained.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have participated in several industry
trade shows, such as Biotech Showcase, BIO USA, LSX World, World Orphan Congress, World Symposium for LSD, BIO Hong Kong 2023 and many
others. We plan to continue to participate in those conferences as well as conferences targeting presentations by publicly traded companies.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Operation and Organization</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We are, and plan to stay, primarily a
virtual organization utilizing partnership arrangements for certain functions including but not limited to our R&amp;D, clinical trial
work, regulatory affairs and product manufacturing. A core organization is in place and will be expanded handling Strategy, Project Management,
Clinical Trial Management, Regulatory Affairs, Finance and Business Development. We believe that our core management team structure has
proven experience in utilizing outside resources which allows us to efficiently execute several programs simultaneously in what we believe
to be a very cost-effective way.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>Regulatory Approval of our Drug Product Candidates</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 2pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The FDA and comparable regulatory authorities
in state and local jurisdictions impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture,
marketing, and distribution of drug products. These regulatory authorities and other federal, state, and local entities regulate the research
and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, documentation and record keeping, approval,
advertising and promotion, distribution, post-approval monitoring and reporting, and export and import of our drug candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-indent: 0.5in; text-align: justify">In the United States, the FDA regulates drugs under the Federal
Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), and its implementing regulations. The process of obtaining regulatory approvals
and compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time
and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval
process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal
to approve pending New Drug Applications (&#8220;NDAs&#8221;), withdrawal of an approval, imposition of a clinical hold, issuance of warning
letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before a drug may be marketed
in the United States generally involves the following, among other things:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 18.1pt; text-align: justify; text-indent: -16.15pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">completion of pre-clinical laboratory tests, animal studies
and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations;</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">submission to the FDA of an IND application, which must become
effective before human clinical trials may begin;</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">independent Institutional Review Board (&#8220;IRB&#8221;) approval;</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">performance of adequate and well-controlled human clinical trials
in accordance with good clinical practices (&#8220;GCPs&#8221;) requirements to establish the safety and efficacy of the proposed drug
product for each indication;</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">demonstration that the API and finished drug product are manufactured
under current good manufacturing conditions and meet all applicable standards of identity, strength, quality, and purity;</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">submission to the FDA of an NDA;</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">satisfactory completion of an FDA advisory committee review,
if applicable;</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">FDA review and approval of the NDA, including consideration
of the views of any FDA advisory committee, prior to commercial marketing, promotion or sale of the drug in the United States; and</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">compliance with any post-approval requirements, including the
potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS) or to conduct a post-approval study.</td>
</tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0 2.75pt 0 18.15pt; text-align: justify; text-indent: -16.2pt">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Pre-clinical studies</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Before testing any drug product candidate in humans, the product
candidate must undergo rigorous pre-clinical testing. The pre-clinical developmental stage generally involves laboratory evaluations of
drug chemistry, formulation, and stability, and studies to evaluate toxicity in animals, to assess the potential for adverse events (AEs)
and, sometimes, to establish a rationale for therapeutic use. The conduct of pre-clinical studies is subject to federal regulations and
requirements. An IND sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical
data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">An IND is a request for authorization from the FDA to ship
an investigational product and then administer it to humans for clinical research and must be allowed to proceed by the FDA before human
clinical trials may begin. An IND typically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions
before that time related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor
and the FDA must resolve any outstanding concerns before the clinical trial can begin. Thus, submission of an IND does not guarantee that
FDA will allow human clinical trials to commence.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Clinical trials</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The clinical-trials stage of development involves the administration
of the investigational product to healthy volunteers or patients under the supervision of qualified clinical trial investigators, generally
experienced physicians, in accordance with GCPs, which includes the requirement that all research patients provide their informed consent
for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives
of the clinical trial, dosing procedures and regimens, subject inclusion and exclusion criteria and the parameters to be used to monitor
subject safety and assess efficacy of the investigational product. Each protocol, and any subsequent amendments to the protocol, typically
must be submitted to the FDA as part of the IND. Moreover, each clinical trial must be reviewed and approved by an IRB for each institution
where the clinical trial will be conducted. The IRB also approves the informed consent form that must be provided to each clinical trial
subject or his or her legal representative and must monitor the clinical trial until completed. Human clinical trials are typically conducted
in three sequential phases, which are summarized below at a high level:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 16.2pt">&#9679;</td><td style="text-align: justify">Phase I clinical trials generally involve a small number of healthy volunteers
or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The main purpose
of Phase I clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the drug.</td></tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 16.2pt">&#9679;</td><td style="text-align: justify">Phase II clinical trials involve studies in disease-affected patients to determine
the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information
is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</td></tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 16.2pt">&#9679;</td><td style="text-align: justify">Phase III clinical trials generally involve a larger number of patients at multiple
sites and are designed to provide the data necessary to demonstrate the safety and effectiveness of the product for its intended use,
and to provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments.
The duration of treatment is often extended to mimic the actual use of a product during marketing.</td></tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 6pt 0 0; text-align: justify"><i><span style="text-decoration: underline">FDA Marketing Approval</span></i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Assuming successful completion of required clinical testing,
the results of the pre-clinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry,
manufacture, quality controls, and proposed labeling, are submitted to FDA as part of an NDA requesting approval to market the product
for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The length of the review process may vary but typically takes
around twelve months from the date the NDA is submitted to FDA. FDA conducts a preliminary review of all NDAs to determine whether they
are sufficiently complete to permit substantive review by FDA before accepting them for &#8220;filing.&#8221; FDA may request additional
information from the NDA applicant rather than accept an NDA for filing. If this occurs, the NDA will typically need to be resubmitted
with the additional information requested by FDA. The resubmitted application is also subject to review before FDA accepts it for filing.
Once an NDA submission is accepted for filing, the FDA begins a detailed substantive review. FDA reviews an NDA to determine, among other
things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged, or held meets
standards designed to assure the product&#8217;s continued safety, quality and purity. Under the current guidelines in effect in the
Prescription Drug User Fee Act (PDUFA), the FDA has a goal to review and act on the submission within ten months from the completion
of the preliminary review of a standard NDA for a new molecular entity.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">After evaluating the NDA and all related information, including
FDA advisory committee recommendation, if any, and any inspection reports regarding the manufacturing facilities and clinical trial sites,
FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement
of specific conditions that must be met to secure final approval and may require additional clinical trials or pre-clinical studies in
order for FDA to reconsider the application. Even with submission of this additional information, FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction,
the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing
information for a specific indication(s).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Approval of Rare Diseases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, Scientific Board of Advisors and business advisors have extensive experience in regulatory affairs and clinical development
of product candidates for the treatment of rare diseases, Parkinson&#8217;s disease and Alzheimer&#8217;s disease. The overall regulatory
approval process for product candidates for the treatment of rare diseases are generally conducted with a smaller number of patients
in clinical trials and over a shorter amount of time than more prevalent diseases. There is a documented pathway to obtain accelerated
FDA approval for a rare disease indication if there is no existing treatment for the indication, if a product shows efficacy and has
a good safety profile. There is also a possibility of receiving a Priority Review Voucher (&#8220;PRV&#8221;) from the FDA upon an approval
in pediatric population in a rare disease. One or more of our programs, such as MPS I, will be targeting pediatric patients. The voucher
entitles the bearer to receive FDA&#8217;s review of drug or biological product applications in six months rather than the standard ten
months. The FDA awards a voucher following approval of a treatment for a neglected disease, rare pediatric disease, or medical countermeasure,
upon the treatment meeting the statutory thresholds for such award. The voucher is transferable, and a subsequent holder may use it to
obtain priority review for its own qualifying application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are four specific expedited development pathways that may be applicable to a rare disease indication. We will be evaluating and most
likely applying for one or more of these when we get closer in the FDA approval process. These include the following pathways for the
indications that it is targeting: (1) Priority Review (2) Fast Track (3) Accelerated Approval Pathway and (4) Breakthrough therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Priority
Review</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Priority
Review was authorized in 1992 by PDUFA which created the two-tiered FDA drug review system (standard versus priority). A product candidate
is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement
in safety and effectiveness compared to available therapies. A Priority Review designation means that the goal for the FDA to review
an application is six months, rather than the standard review of 10 months under the PDUFA goals. The FDA determines if a drug receives
a standard or priority review, although sponsors may request a priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fast
Track</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
candidates intended to treat a serious or life-threatening condition and show the potential to an unmet medical need may receive a Fast
track designation. The purpose of this designation is to help make important new drugs available to patients earlier. Any drug being
developed to treat or prevent a condition with no current therapy is directed at an unmet need. If there are available therapies, the
new drug must demonstrate advantages, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Show
    superior effectiveness, effect on serious outcomes or improved effect on serious outcomes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avoid
    serious side effects of the available therapy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    clinically significant toxicity of an available therapy that is common and causes discontinuation of treatment; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    an emerging or anticipated public health need</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fast
Track designation should typically be requested at the time of the IND or after, and no later than the pre-BLA or pre-NDA meeting. Once
in the Fast Track pathway, there are typically more frequent meetings with the FDA to discuss the development plan and appropriate data
needed to support drug approval. The fast track designation may be withdrawn by FDA if it believes that the designation is no longer
supported by data that emerges during the clinical trial process. Drugs in the Fast Track pathway are also eligible for accelerated approval
and priority review if relevant criteria are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accelerated
Approval Pathway</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
in 1992 and updated in 2012, this pathway is available for a drug for a serious or life-threatening illness that provides meaningful
therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical
benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical
endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to
predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatments. If approved based on the accelerated approval pathway, the FDA may require the sponsor
to conduct post-marketing confirmatory clinical trials to ensure that the drug provides the anticipated clinical benefits. If this requirement
is not met, the FDA can withdraw its approval. In addition, promotional materials for product candidates approved under the accelerated
approval pathway are subject to prior review by FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Breakthrough
Therapy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening condition and
preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically
significant endpoints over existing therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there is no guarantee that any designation for an accelerated pathway will lead to an accelerated FDA review or that a pediatric approval
leads to grant of a PRV. Additionally, there can be no guarantee that the Company can be successful in its plans under any FDA review
pathway.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
of Clinical Trial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information.
Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the
clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical
trials after completion. Disclosure of the results of any such clinical trials can be delayed in certain circumstances for an extended
period of time after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding
the progress of development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Post-Approval Requirements</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if an NDA is approved, a product will be subject to certain
post-approval requirements. For example, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards
and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and
promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions
of the approved labeling.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Failure to comply with the applicable FDA post-marketing requirements
may subject manufacturers and distributors to administrative or judicial sanctions. These sanctions could include, among other things,
warning letters, product seizures, total or partial suspension of production or distribution, injunctions, civil money penalties, fines,
restitution, disgorgement, or civil or criminal penalties. Further, the FDA has authority to issue mandatory recalls for medical devices
and biologics, and we may need to undertake a voluntary recall for any of our products that may receive regulatory approval.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Regulation Outside the United States</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In order to market any product outside of the U.S., we must
also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy
and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether
or not a product obtains FDA approval for a product, we would still need to obtain the necessary approvals by the comparable foreign regulatory
authorities before we could commence clinical trials or marketing of any product in those countries or jurisdictions. The approval process
ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review
periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required
to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure
or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Government Regulation of Dietary Supplements</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Dietary Supplement Health and Education Act of 1994 (DSHEA),
amended the FDCA to establish a new framework governing the composition, safety, labeling, manufacturing and marketing of dietary supplements.
Generally, under DSHEA, dietary ingredients (e.g., vitamins; minerals; amino acids; or dietary substances for use by humans to supplement
diet by increasing total dietary intake; or any concentrate, metabolite, constituent, extract or combination of any of the above) that
were marketed in the United States prior to October 15, 1994 as a dietary supplement may be used in dietary supplements without notifying
the FDA. &#8220;New&#8221; dietary ingredients (i.e., dietary ingredients that were &#8220;not marketed in the United States before October
15, 1994&#8221;) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been present
in the food supply as an article used for food without being chemically altered. A new dietary ingredient notification must provide the
FDA evidence of a &#8220;history of use or other evidence of safety&#8221; establishing that use of the dietary ingredient &#8220;will
reasonably be expected to be safe.&#8221; A new dietary ingredient notification must be submitted to the FDA at least 75 days before introducing
the product into interstate commerce. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis
to conclude that a dietary ingredient is reasonably expected to be safe. In addition, manufacturers of dietary supplements must ensure
that ingredients in their products that are not defined as dietary ingredients comply with all the requirements applicable to conventional
foods. For example, fillers and other constituents of the product must be approved as food additives or must be deemed generally recognized
as safe for the conditions of use in order to be sold.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA generally prohibits the marketing of a dietary supplement
with a &#8220;disease claim,&#8221; including claims that the product is intended to treat, cure, mitigate or prevent disease or other
health-related conditions, unless the claim constitutes a permissible &#8220;health claim&#8221; under FDA regulations and guidance. Statements
of &#8220;nutritional support,&#8221; including so-called &#8220;structure/function claims,&#8221; may be permitted on labeling for dietary
supplements, subject to certain requirements being met. Such statements may describe how a particular dietary ingredient affects the structure,
function or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect the structure, function
or well-being of the body, but they may not state that a dietary supplement will reduce the risk or incidence of a disease unless such
claim has been reviewed and approved by the FDA. A company that uses a statement of nutritional support in labeling must possess scientific
evidence substantiating the statement as truthful and not misleading. FDA must be notified of any such statements no later than thirty
days after first marketing the product with the certification that the company possesses the necessary evidence to substantiate any such
statements and must be accompanied by an FDA mandated label disclaimer that &#8220;This statement has not been evaluated by the FDA. This
product is not intended to diagnose, treat, cure or prevent any disease.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the FDA has published detailed current Good Manufacturing
Practice (cGMP), regulations that govern the manufacturing, packaging, and labeling of dietary supplements. The cGMP regulations, among
other things, impose recordkeeping requirements on manufacturers and require dietary supplements to be of appropriate potency, purity
and identity. The cGMP requirements are in effect for all dietary supplement manufacturers, and the FDA conducts inspections of dietary
supplement manufacturers pursuant to these requirements. The FDA has broad authority to enforce the provisions of federal law applicable
to dietary supplements, including, among other things, the authority to issue a public warning or notice of violation letter to a company,
publicize information about illegal products, detain or seize products intended for import, require the reporting of serious adverse events,
require a recall of illegal or unsafe products from the market, and request the Department of Justice initiate a seizure action, an injunction
action or a criminal prosecution in the United States courts for violative conduct.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Nugevia Brand</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company launched Nugevia, a premium
line of longevity and performance supplements to support mental clarity and skin vitality. The Nugevia brand targets
the growing consumer demand for wellness solutions, leveraging Jupiter&#8217;s proprietary JOTROL&#8482; technology&#8212;a
resveratrol-based platform that is designed to provide higher bioavailability of resveratrol.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Nugevia&#8217;s initial product line features
three core formulations, each targeting a major aspect of health and longevity:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 24%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Product Name</b></span></td>
    <td style="width: 2%; padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 24%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Focus Area</b></span></td>
    <td style="width: 2%; padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 48%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Target Consumer Benefit</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">GLO</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Skin beauty</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Support skin beauty and healthy appearance</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">MND</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Cognitive performance</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Support mental clarity, cognitive
    resilience</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">PWR</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Mitochondrial and physical health</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Maintain energy, endurance, muscle recovery</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Nugevia&#8217;s formulations are
built on Jupiter&#8217;s patented JOTROL&#8482; micellar delivery platform, which has shown potential for significantly enhanced
bioavailability and serves as the foundation for the company&#8217;s clinical-stage CNS investigational therapies. The debut
products&#8212;GLO, MND, and PWR&#8212;are formulated to support cellular resilience through synergistic ingredient combinations,
all optimized for absorption via the JOTROL&#8482; system.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Market Positioning and Opportunities</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Nugevia brand will enter the
nutraceutical market as a premium longevity and performance supplement line, capitalizing on a global industry projected to reach $8
trillion by 2030. Powered by JOTROL&#8482;, a patented resveratrol-based platform that is designed to provide greater
bioavailability than standard resveratrol, Nugevia targets health-conscious consumers seeking science-backed solutions for
mitochondrial and physical health, mental clarity, and skin vitality. Products like PWR and GLO address key market
segments&#8212;dietary supplements and functional foods&#8212;driven by rising health awareness, an aging population, and a shift
toward preventive healthcare. The DTC model positions Nugevia to capture high-margin revenue in a competitive but growing market,
leveraging clinical-grade credibility to stand out in a competitive market.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Challenges and Competitive Landscape</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The supplement market is fueled by increasing
lifestyle-related disorders and demand for natural ingredients. However, Nugevia faces challenges including regulatory hurdles, complex
product approvals, and competition from established players offering similar products. Consumer skepticism about resveratrol&#8217;s
historical bioavailability issues and the need for robust scientific validation could impact adoption. Nugevia&#8217;s use of JOTROL&#8482;
alongside ingredients like NovaSOL&#174; Astaxanthin and CoQ10 aims to address these concerns, while strategic partnerships with Aquanova
and endorsements from figures like Annika S&#246;renstam and Chris Webber enhance brand trust. Success will hinge on overcoming market
saturation and proving efficacy to stand out in a crowded field.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Marketing</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company will employ a digital-first
marketing strategy, leveraging a DTC e-commerce platform to reach health-conscious consumers seeking clinically validated wellness solutions.
The Company has appointed Annika S&#246;renstam, a Hall of Fame golfer with over 95 tournament victories, as Nugevia&#8217;s first brand
ambassador, enhancing brand credibility and aligning with the product&#8217;s focus on performance, focus, and longevity. In addition,
the Company has partnered with Chris Webber, five-time NBA All-Star and Hall of Fame inductee, as the Company&#8217;s second official
brand ambassador for Nugevia. Marketing efforts also include tailored campaigns for international markets, with service partners in Hong
Kong developing a specific program for Southeast Asia to address regional consumer preferences.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial launch in the USA
utilized a DTC model, with the Nugevia website serving as the primary sales platform. Following this, the Company aims to
expand distribution to Europe, the Middle East, and Southeast Asia through regional partnerships, capitalizing on the global demand
for longevity solutions.  By combining cutting-edge science, strategic marketing, and a robust manufacturing
process, Nugevia is poised to capture a significant share of the longevity market while supporting Jupiter&#8217;s long-term mission
to advance treatments for CNS disorders.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Competitors</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The longevity and wellness market, driven
by increasing demand for health span extension, is highly competitive, with Nugevia facing established players like ChromaDex (offering
NAD+ precursors like Tru-Niagen), Novos (targeting aging hallmarks with products like NOVOS Core), Timeline&#8217;s urolithin A supplements
and Tally Health (providing personalized longevity supplements and biological age testing). Larger competitors, including Nestle Health
Science (with multiple brands and products), Amway (through Nutrilite&#8217;s Healthy Aging Solution), and L&#8217;Oreal (via its Longevity
Integrative Science initiative), are also expanding into this space, intensifying competition. Nugevia&#8217;s differentiation lies in
its proprietary JOTROL&#8482; technology, which supports higher plasma concentrations (approximately 300 ng/ml) and effective
CNS delivery, positioning it as a premium offering.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Brands like NOVOS, Blueprint, and Perpetua.Life
offer formulas that combine resveratrol with other scientifically backed longevity compounds (e.g., NMN, quercetin, CoQ10, fisetin)
for synergistic effects. In addition, advanced delivery systems such as Liposomal and micellar technologies are widely used by many companies
to enhance the absorption of key actives, similar to Nugevia&#8217;s approach, purity and clinical validation. Furthermore, companies
such as ProHealth, Renue By Science, and Decode Age, who offer similar longevity supplements and sell their products online directly to
consumers, emphasize ingredient purity, bioavailability, multi-ingredient formulations and evidence-based dosing, which is appealing to
the target health-conscious consumers seeking credible, science-backed longevity solutions.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Manufacturing</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Nugevia products will be manufactured
by Aquanova in Germany. The manufacturing process has several steps, which are: (a) ingredient combinations are manufactured as a liquid
solution by Aquanova in Germany, (b) the liquid solutions are shipped to GMP-certified facility in California for encapsulation into softgels
and (c) finished products are sent in bulk to a final packing and fulfillment center, which ships directly to customers. While all steps
except the initial solution preparation can be handled by U.S. suppliers, changing the first step would require a separate agreement with
Aquanova.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The FDA requires that dietary
supplement manufacturers comply with Current Good Manufacturing Practices (&#8220;cGMP&#8221;) under 21 CFR Part 111, ensuring
product safety, quality, and accurate labeling. Jupiter must verify that its manufacturing partners, including those involved in
producing JOTROL&#8482; or sourcing ingredients like CoQ10, meet these standards. Non-compliance, such as contamination or
inconsistent ingredient potency, could lead to product recalls, enforcement actions, fines, or reputational damage. Any lapses in quality control could undermine consumer trust and weaken its
competitive edge in the $451.7 billion nutraceutical market.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Compliance with U.S. FDA Regulations</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the United States, Nugevia
products, classified as dietary supplements, fall under the Dietary Supplement Health and Education Act (DSHEA) of 1994, enforced by
the FDA. The FDA requires that all health claims be substantiated with credible scientific evidence, and any claims related to
Nugevia&#8217;s benefits&#8212;such as mitochondrial support, mental clarity, or skin vitality&#8212;must avoid implying treatment
or prevention of diseases, which would classify the products as drugs subject to stricter pre-market approval. Non-compliance, such
as misleading labeling or unsubstantiated claims, could result in warning letters, product seizures, or injunctions. Additionally,
Jupiter must ensure that JOTROL&#8482;, its proprietary resveratrol delivery system, complies with FDA&#8217;s New Dietary
Ingredient (NDI) notification requirements if deemed novel, a process that can take months and negatively impact the Company&#8217;s
ability to sell Nugevia products. </p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>International Regulatory Variations</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Global expansion introduces regulatory
complexities. In the European Union, the European Food Safety Authority (EFSA) oversees nutraceuticals under the Novel Food Regulation
(EU) 2015/2283. If JOTROL&#8482; or other ingredients like NovaSOL&#174; Astaxanthin are considered novel foods (not consumed in the EU
before May 15, 1997), Jupiter must submit a detailed safety dossier, a costly and time-intensive process that could delay market entry.
In markets like China or Japan, stringent pre-market approvals and ingredient restrictions may require reformulation or additional clinical
studies. Failure to navigate these variations could limit Nugevia&#8217;s global reach or result in costly reformulations, impacting Jupiter&#8217;s
revenue projections.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Post-Market Surveillance and Adverse Event Reporting</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Nugevia products are subject
to post-market surveillance, particularly in the U.S., where manufacturers must report serious adverse events to the FDA within 15 days
under DSHEA. Even rare side effects linked to resveratrol or other ingredients like astaxanthin could trigger investigations, negative
publicity, or product withdrawals. Jupiter must establish robust adverse event reporting systems and ensure transparency to mitigate legal
and reputational risks. Failure to comply could lead to regulatory scrutiny, consumer lawsuits, or loss of market confidence, particularly
given past skepticism about resveratrol&#8217;s safety and efficacy at high doses.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Asian Business Development Activities</b>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;We have entered into service agreements
in the areas of CMC, regulatory affairs and clinical trial management with companies with operations in Southeast Asia. These agreements
are with companies that, we believe, have the knowledge and network in the Southeast Asian market. The agreements are further described
in the section &#8220;Other Material Agreements&#8221;. In addition, we are in active negotiations with Dominant Treasure Health Company
Limited (&#8220;Dominant Treasure&#8221;), a BVI company. Dominant Treasure has demonstrated to us, through several company introductions,
that they have business relationships, either directly or through affiliates, with many Southeast Asian pharmaceutical companies as well
as companies involved in distribution and sales of TCM, Traditional Chinese Medicine. We are therefore planning to engage Dominant Treasure
in active business development in China, Malaysia and Singapore as soon as we have financing in place for their engagement. Dominant Treasure
has already introduced us to three Chinese companies, Beimei Pharma, http://en.beimeiyaoye.com, that specializes in pediatric medications,
Sichuan Kelun Pharmaceutical Co., Ltd., a publicly traded company that is part of the Kelun Industrial Group, https://www.kelun.com/,
and Tianjin Pharmaceuticals, https://en.pharm.com.cn/, that advocates the corporate core values of &#8220;Love, Integrity and Power&#8221;.
TCM products are run in a separate division within Tianjin. The Asian market is very large and hard to penetrate for a small company and
we believe that our strategy with these agreements have the possibility to accelerate an out-licensing deal in the Southeast Asian territories.
However, there are no assurances that this approach will be successful.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our rationale for the strong approach
into the Southeast Asian market is:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Background: Asian countries are not accepting pharmaceutical products to be sold without clinical trial approvals based on trials conducted in an Asian population.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s strategy is to partner with organizations in the territory that can execute much more efficiently than trying to manage the process from USA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">We have already received interest for our JOTROL&#8482; product in the Asian market since resveratrol is listed as a Traditional Chinese Medicine.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The need for a set up that can service this market is imperative for success.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Strategic collaboration agreements have been executed to facilitate an expedited execution of an out-licensing agreement with one or more Chinese or other Southeast Asian pharmaceutical companies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The Company is too small, both financially as well as internal manpower, to manage developments in the territory.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The Company has historically faced financial constraints that have, at times, limited its ability to fulfill certain commitments and complete clinical studies on its planned timeline.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">By utilizing equity as service payments, the company believes that it can get projects finalized without any significant cash outflow.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The service agreements are therefore designed to be a win for both parties, assuming an increase in equity value, in case clinical studies and out-licensing activities will be successful in the territory.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Other Material Agreements</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The agreement with a major pharmaceutical
company, restricted by confidentiality, grants us data access to resveratrol toxicology studies through a letter of reference. Executed
on May 2, 2017, it can only be terminated due to a material breach and there is no time limit on access to this study. The studies were
conducted at Charles River Laboratories, and there are no payments associated with this agreement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 15, 2024, the Company entered
into a Strategic Services Agreement (the &#8220;Dominant Treasure Agreement&#8221;) with Dominant Treasure Health Company Limited (&#8220;Dominant
Treasure&#8221;). Pursuant to the terms of the Dominant Treasure Agreement, Dominant Treasure agreed to provide certain services to the
Company to assist the Company in accelerating the development and distribution of the Company&#8217;s products in the Southeast Asian
market. In exchange for Dominant Treasure&#8217;s services pursuant to the Dominant Treasure Agreement, the Company agreed to pay Dominant
Treasure a one-time payment of $2,300,000 to be delivered after the closing of a minimum of $10,000,000 in gross proceeds from a public
offering. In addition, if Dominant Treasure is involved in generating negotiations and conclusion of a distribution agreement for the
Company in the countries of China (including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee
of 5% of any upfront and/or milestone payments to be received by the Company. If such distribution agreement includes a royalty payment
to the Company, Dominant Treasure will receive 5% of such royalty payment. The Dominant Treasure Agreement has a term of 36 months and
may be terminated at any time upon mutual agreement of the parties.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Service Agreements - Southeast Asia</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 3, 2024, the Company entered into
three service agreements to expand in Southeast Asia; a CRO Services Agreement with Optimize Wellness Limited providing clinical trial
guidance in China, Malaysia, and Singapore, a Regulatory Services Agreement with Regis Healthcare Group Limited providing regulatory strategy
and guidance, and a Product Services Agreement with Longevity Technology Group Limited providing manufacturing guidance. Each of the 3
service agreements has a 3-year term and was paid for with an upfront issuance of 1,162,500 shares of common stock with a fair market
value of $1.33 per share (3,487,500 in the aggregate, with an aggregate fair market value of $4,638,375) as pre-payment for three years
of services, which were registered for resale as part of the initial public offering.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, we are involved in
various legal proceedings arising from the normal course of business activities. We are not presently a party to any litigation the outcome
of which, we believe, if determined adversely to us, would individually or taken together have a material adverse effect on our business,
operating results, cash flows or financial condition.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 22.05pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Facilities</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our corporate headquarters are located at 1001 North US Hwy
1, Suite 504, Jupiter, Florida 33477, where we lease approximately 1,206 rentable square feet of office space. This lease expires on May
31, 2026. Terms of the office lease provide for a base rent payment of $4,258 per month and a share of the building&#8217;s operating
expenses, such as taxes and maintenance, of $600 per month. In September 2021, we added an additional office located at 127 Main Street,
Boston, Massachusetts 02129 for 120 rentable square feet of office space for our Boston-based employees and scientist to utilize as necessary.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We believe that these facilities are adequate for our current
and near-term future needs.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Employees</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, we had a total
of five full-time employees, two full-time consultants, three part-time consultants, and our six Scientific Advisory Board members. Of
these, three were primarily engaged in research or product development and clinical activities.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_03"></span>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>An investment in our securities carries a significant degree
of risk. You should carefully consider the following risks, as well as the other information contained in this Annual Report on Form 10-K,
including our historical financial statements and related notes included elsewhere in this Annual Report on Form 10-K, before you decide
to purchase our securities. Any one of these risks and uncertainties has the potential to cause material adverse effects on our business,
prospects, financial condition and operating results which could cause actual results to differ materially from any forward-looking statements
expressed by us and a significant decrease in the value of our common shares. Refer to &#8220;Cautionary Statement Regarding Forward-Looking
Statements.&#8221;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>We may not be successful in preventing the material adverse
effects that any of the following risks and uncertainties may cause. These potential risks and uncertainties may not be a complete list
of the risks and uncertainties facing us. There may be additional risks and uncertainties that we are presently unaware of, or presently
consider immaterial, that may become material in the future and have a material adverse effect on us. You could lose all or a significant
portion of your investment due to any of these risks and uncertainties.</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Below is a summary of material risks, uncertainties and other
factors that could have a material effect on the Company and its operations:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    substantial amount of indebtedness may adversely affect our cash flow and our ability to operate our business, remain in compliance with debt covenants
    and make payments on our indebtedness.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
    trading volume in our common stock may limit or prevent our ability to draw on the Standby Equity Purchase Agreement to pay down
    the convertible promissory notes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have not generated any meaningful revenue from product sales to date, have incurred significant net losses since our inception, and
    expect to continue to incur significant net losses for the foreseeable future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has
    included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years
    ended December 31, 2025 and 2024.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on
    acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or
    future commercialization efforts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
    additional capital may cause substantial dilution to our stockholders, restrict our operations or require us to relinquish rights
    to our technologies or product candidates.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The actual number of shares of common stock we will issue pursuant to the SEPA, if not terminated and if and when
available, at any one time or in total, is uncertain.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business and future prospects with the Nugevia brand and our pharmaceutical products are significantly dependent on our exclusive,
    worldwide license agreement with Aquanova. Any adverse development related to this license agreement could materially and adversely
    affect our operations, financial condition, and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have entered into Service Agreements with the Asian Partners with respect to services to be provided by the Asian
Partners to us in Asia for the clinical development of JOTROL&#8482; in the &#160;Southeast Asian territory immediately following the
completion of the initial public offering; the shares issued by us in advance for the specific services could have a material negative
impact on our business, financial condition and operating results in case the Asian Partners&#8217; will not perform the services per
the agreements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We entered into a Strategic Service Agreement with DOMINANT TREASURE HEALTH COMPANY LIMITED with respect to strategic
services in Asia, the fees paid by the Company pursuant to which, are non-refundable and not tied to any milestones or performance, and
the foregoing nature of such fees, could have a material negative impact on our business, financial condition and operating results.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited resources and are currently focusing the majority of our efforts on developing JOTROL&#8482; for particular indications.
    As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are
    more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be successful in our efforts to develop our proprietary drug delivery platform, JOTROL&#8482;, to build a pipeline of indications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their
    jurisdiction.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may face difficulties from changes to current regulations and future legislation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success is highly dependent on our ability to attract and retain highly skilled executive officers and employees; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of its
    securities.</span></td></tr>

  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to Our Financial Position, Need for Additional
Capital and Limited Operating History</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We are early in our development efforts, with a limited
operating history, and we have no prescription products approved for commercial sale, which may make it difficult for you to evaluate
our current business and likelihood of success and future viability.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We are an early clinical stage pharmaceutical company
with a limited operating history upon which you can evaluate our business and prospects. We are advancing a therapeutic pipeline
targeting CNS disorders and rare disease, while also expanding into the consumer longevity market with our Nugevia product line. We
are developing one medication to treat rare diseases (MPS I and MELAS) as well as larger indications, Parkinson&#8217;s Disease and
MCI / early Alzheimer&#8217;s disease, which is an unproven and highly uncertain undertaking and involves a substantial degree of
risk.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We commenced operations in January 2016, have no
prescription or therapeutic products approved for commercial sale and have not generated any revenue through our pharmaceutical
operations. We initiated and completed our Phase I clinical trial for our sole product candidate, JOTROL&#8482;, in March 2021.
Subject to additional discussions with and approval from FDA, we hope to use the results of this study as a cross-reference for
other indications where JOTROL&#8482; will be used in Phase IIa and potentially Phase III clinical trials. FDA accepted this
cross-reference in the approval of the IND application for the Parkinson&#8217;s Phase IIa trial. The Company has not discussed the
use of cross-referencing in this manner with the FDA or other comparable regulatory authorities for any other indications, and FDA
(or any comparable regulatory authorities) may preclude us from the use of cross-referencing with respect to the results of this
study. As a result, we are presently unable to rely on potential cross-referencing besides in the already approved Parkinson&#8217;s
study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Since our
inception in 2016, we have devoted substantially all of our focus and financial resources to discovering, identifying and developing
our product candidate, JOTROL&#8482;, including advancing our development program, conducting a preclinical study of our product
candidate and initiating a clinical trial, organizing and staffing our company, business planning, raising capital and securing
related intellectual property rights.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have not yet demonstrated our ability to successfully complete
efficacy clinical trials that can lead to a NDA submission, obtain marketing approvals, manufacture a commercial-scale product, or obtain
a proposal for any out-licensing or distribution agreements. As a result, it may be more difficult for investors to accurately predict
our likelihood of success and viability than it could be if we had a longer operating history.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, we may encounter unforeseen expenses, difficulties,
complications, delays and other known and unknown factors and risks frequently experienced by clinical-stage biopharmaceutical companies
in rapidly evolving fields. We also may need to transition from a company with a research and development focus to a company capable of
supporting commercial activities. We have not yet demonstrated an ability to successfully overcome such risks and difficulties, or to
make such a transition. If we do not adequately address these risks and difficulties or successfully make such a transition, our business
will suffer.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We have not generated any meaningful revenue from
product sales to date, have incurred significant net losses since our inception, and expect to continue to incur significant net
losses for the foreseeable future.</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2025, the Company launched a new strategic initiative to introduce Nugevia, a consumer-focused product line centered on longevity and
wellness. This initiative is intended to address growing demand for wellness solutions through the development
of nutritional products. The Company completed product formulations and commenced initial
direct-to-consumer sales in the fourth quarter of 2025. To date, however, the Company has not generated any meaningful revenue and has
incurred significant net losses since inception. Operations have been funded primarily through private placements of common stock. The
Company has not achieved profitability and continues to experience significant losses and cash flow deficits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">For the fiscal years ended December 31, 2025 and 2024, we
generated net revenues of $21,796 and $0, respectively from product sales and reported net losses of $8,644,897 and $2,439,625, respectively,
and negative cash flow from operating activities of $5,413,736 and $3,911,004, respectively. As noted in our financial statements, as
of December 31, 2025 and 2024, we had an accumulated deficit of $34,667,026 and $26,022,129, respectively.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our product candidate, JOTROL&#8482;, recently completed Phase
I clinical trial that commenced in December 2020. As a result, we expect that it will be several years, if ever, before we receive approval
to commercialize our product and generate revenue from pharmaceutical product sales. Even if we succeed in receiving marketing approval
for and commercializing of our approved product candidate, we expect that we will continue to incur substantial research and development
and other expenses in order to discover, develop and market additional potential products.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We expect to continue to incur significant expenses and increasing
operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period
comparison of our results of operations may not be a good indication of our future performance, particularly since we expect our expenses
to increase if and when our product candidate progresses through clinical development as a product candidate in later stages of clinical
development generally have higher development costs than those in earlier stages, primarily due to the increased size and duration of
later-stage clinical trials. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and
our ability to have our product candidates approved for marketing and to generate revenue. Our prior losses and expected future losses
have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidate
and our ability to achieve and maintain profitability and the performance of our stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our management has concluded that factors raise substantial
doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to
continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our management has concluded that our historical recurring
losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise
substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our
ability to continue as a going concern in its audit report for the fiscal year ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our financial statements do not include any adjustments that
might result from the outcome of this uncertainty. These adjustments would likely include substantial impairment of the carrying amount
of our assets and potential contingent liabilities that may arise if we are unable to fulfill various operational commitments. In addition,
the value of our securities would be greatly impaired. Our ability to continue as a going concern is dependent upon generating sufficient
cash flow from operations and obtaining additional capital and financing. If our ability to generate cash flow from operations is delayed
or reduced and we are unable to raise additional funding from other sources, we may be unable to continue in business. For further discussion
about our ability to continue as a going concern and our plan for future liquidity, see &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8212;Ability to Continue as a Going Concern.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our ability to generate revenue and achieve profitability
depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our
product candidates, if approved.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our business depends entirely on the successful
discovery, development, regulatory approval and commercialization of product candidates for therapeutic uses and/or the
commercialization of products in our DTC Nugevia line. We have no prescription drug products approved for commercial sale and do not
anticipate generating any revenue from sales of prescription drugs for the next several years, if ever. We have not generated meaningful revenue from Nugevia product sales to date.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our ability to generate revenue and achieve profitability
depends on successfully completing clinical development of the JOTROL&#8482; program and future candidates, establishing relationships
with CROs and clinical sites, initiating and completing clinical trials on time, ensuring acceptable safety and efficacy profiles for
FDA or foreign regulatory approval, and obtaining timely marketing approvals. We must also comply with post-marketing commitments, develop
scalable manufacturing processes, and secure reliable supply chains to meet clinical and market demands. Additionally, we need to launch
commercially viable products, ensure continued safety post-approval, gain acceptance from patients, medical professionals, and payors,
and secure adequate reimbursement. We must also develop new candidates, protect our intellectual property, defend against infringement
claims, and enter favorable collaboration agreements. Further, we need additional funding, the ability to address competing therapies
and market developments, manage costs, and attract and retain qualified personnel.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may never be successful in achieving our objectives and,
even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability,
we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would
decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional
necessary capital, grow our business and continue our operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may also experience delays in developing a sustainable,
reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing
our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. Changes in the manufacturing
process or facilities will require further comparability analysis and approval by the FDA before implementation, which could delay our
clinical trials and product candidate development, and could require additional clinical trials, including bridging studies, to demonstrate
consistent and continued safety and efficacy.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We will require substantial additional capital to finance
our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate
one or more of our research and drug development programs or future commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As of December 31, 2025, we had $3,789,342 in cash. Our estimate
as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions
that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances,
some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may
need to seek additional funds sooner than planned.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Developing pharmaceutical products, including conducting
preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our
operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing
activities, particularly as we conduct clinical trials of, and seek marketing approval for, JOTROL&#8482; as well as develop our proprietary
drug delivery platform. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate
incurring significant costs associated with sales, marketing, manufacturing and distribution activities. Our expenses could increase
beyond expectations if we are required by the FDA, the European Medicines Agency (the &#8220;EMA&#8221;) or other regulatory agencies
to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also
arise. Because the design and outcome of our planned and anticipated preclinical studies and clinical trials are highly uncertain, we
cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development
and commercialization of any product candidate we develop. We are not permitted to market or promote JOTROL&#8482;, or any other product
candidate, before we receive marketing approval from the FDA. We also incur additional costs associated with operating as a public company.
Accordingly, we will need to obtain substantial additional funding in order to continue our operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our future capital needs will hinge on multiple factors, including
the scope, progress, and costs of researching and developing our product candidates through preclinical studies and clinical trials, as
well as the timing and outcome of regulatory reviews. The number and nature of additional product candidates we pursue, along with costs
for marketing, manufacturing, and distributing approved products, will also impact funding requirements. Revenue from potential commercial
sales, expenses for building inventory, and costs of hiring staff to support growth will further influence our needs. Additionally, expenses
for patent applications, intellectual property enforcement, and defending related claims, alongside costs to establish collaborations
or in-license new technologies, will play a role. Competing products, milestone payments, royalties, and investments in businesses or
technologies, as well as the costs of implementing internal systems and meeting public company compliance obligations, will also shape
our financial demands. A change in the outcome of any of these or other factors with respect to the development of any of our product
candidates could significantly change the costs and timing associated with the development of that product candidate.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;We currently plan to initiate a Phase II clinical trial
with JOTROL&#8482; in patients with Parkinson&#8217;s Disease, establish a presence in Southeast Asia through service agreements and
advancing the manufacturing of JOTROL&#8482; clinical trial supplies. in support of activities leading up to clinical trials in targeted
indications. Remaining proceeds will be used for general research and development activities, working capital and other general corporate
activities. Advancing the development of JOTROL&#8482; program will require a significant amount of capital. Our cash and cash equivalents
and grants will not be sufficient for us to fund our product candidates through the completion of its development, Phase III clinical
trials, entire regulatory approval process and commercialization. We will need to raise additional capital to fund such activities.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may seek additional capital due to favorable market conditions
or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure
additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product
candidates. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition
and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our
research-stage programs, clinical trials or future commercialization efforts.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Raising additional capital may cause substantial dilution
to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Until such time, if ever, as we can generate substantial revenues,
we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing
arrangements or other sources, which may dilute our stockholders or restrict our operating activities. Adequate additional financing may
not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect
your rights as a stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition,
merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain
investments, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our
ability to conduct our operations and execute our business plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we raise additional funds through upfront payments or milestone
payments pursuant to strategic collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties,
we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed,
we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The actual number of shares of common stock we will
issue pursuant to the SEPA, if not terminated and if and when available, at any one time or in total, is uncertain.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Subject to the terms and conditions of the standby equity
purchase agreement, dated October 24, 2025 (the &#8220;SEPA&#8221;), by and between the Company and YA II PN, LTD, a Cayman Islands exempt
limited partnership (&#8220;Yorkville&#8221;), we issued two convertible notes to Yorkville in connection with advances under the SEPA.
These convertible notes are convertible into shares of our common stock from time to time during their term. The number of shares of common
stock that may be issued upon conversion of the convertible notes will depend on a number of factors, including the market price of our
common stock at the time of conversion. As a result, we cannot predict the total number of shares that may ultimately be issued upon conversion
of the convertible notes, which could result in substantial dilution to our existing stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Low
trading volume in our common stock may limit or prevent our ability to draw on the Standby Equity Purchase Agreement.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a SEPA pursuant to which Yorkville has committed to purchase up to $20 million of shares of our common stock,
subject to certain conditions and limitations. The maximum amount of any individual advance notice under the SEPA is 100% of the
average of the daily traded dollar volume of our common stock on Nasdaq during the five consecutive trading days immediately
preceding an advance notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
if the trading volume of our common stock is low during any such measurement period, the amount we may draw in any single advance, and
the aggregate capital we can raise within any given timeframe, will be correspondingly reduced. There can be no assurance that our common
stock will maintain sufficient trading volume to allow us to access the full commitment under the SEPA when needed. The amount of capital
that may be raised under the SEPA will depend on market conditions, trading volumes, the price of our common stock, and the continued
satisfaction of the applicable limitations and conditions under the SEPA. It is not possible to predict the actual number of shares we
will sell under the SEPA or the actual gross proceeds resulting from those sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to utilize the SEPA could have a material adverse effect on our liquidity and financial condition.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our substantial amount of indebtedness may adversely
affect our cash flow and our ability to operate our business, remain in compliance with debt covenants and make payments on our indebtedness.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As of December 31, 2025, we had outstanding indebtedness in
the principal amount of $6,000,000 and accrued interest of approximately $39,829. Our substantial level of indebtedness increases the
possibility that we may be unable to generate sufficient cash to pay, when due, the principal of, interest on or other amounts due with
respect to our indebtedness. Our indebtedness could have other important consequences to you as a stockholder. For example, it could:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: justify; width: 0.25in">

    </td>
    <td style="text-align: justify; width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">make it more difficult for us to satisfy our obligations with respect to our indebtedness and any failure to comply with the obligations of any of our debt instruments, including financial and other restrictive covenants, could result in an event of default under the debt instruments;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">make us more vulnerable to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flows to fund working capital, capital expenditures, acquisitions and other general corporate purposes;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">place us at a competitive disadvantage compared to our competitors that have less debt; and</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">limit our ability to borrow additional amounts for working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy or other purposes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Any of the above listed factors could materially adversely
affect our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we are at any time unable to generate sufficient cash flow
from operations to service our indebtedness when payment is due, we may be required to attempt to renegotiate the terms of the instruments
relating to the indebtedness, seek to refinance all or a portion of the indebtedness, or obtain additional financing. There can be no
assurance that we would be able to successfully renegotiate such terms, that any such refinancing would be possible or that any additional
financing could be obtained on terms that are favorable or acceptable to us, if at all. Any debt financing that is available could cause
us to incur substantial costs and subject us to covenants that significantly restrict our ability to conduct our business. If we seek
to complete additional equity financings, the interests of existing equity holders may be diluted.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our ability to utilize our net operating loss carryforwards
and certain other tax attributes to offset future taxable income may be limited.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our net operating loss (NOL) carryforwards may be unavailable
to offset future taxable income because of restrictions under U.S. tax law. Our NOLs generated in tax years ending on or prior to December
31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law, and therefore could expire
unused. Under tax legislation commonly referred to as the Tax Cuts and Jobs Act (Tax Act) as amended by the Coronavirus Aid, Relief, and
Economic Security Act (CARES Act), our federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely,
but for taxable years beginning after December 31, 2021, the deductibility of federal NOLs generated in tax years beginning after December
31, 2017 is limited to 80% of our current year taxable income. It is uncertain if and to what extent various states will conform to the
Tax Act. As of December 31, 2025, the Company had federal and state (post-apportioned
basis) net operating losses (&#8220;NOLs&#8221;) of $42.83 million, as well as federal orphan drug credit and research and development
tax credit carryforwards of approximately $1.72 million. Approximately $22.1 million of the foregoing federal and state NOLs will expire
at various dates from 2036 through 2045, if not limited by triggering events prior to such time.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, under Sections 382 and 383 of the Internal Revenue
Code of 1986, as amended (Code), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change
in the corporation&#8217;s ownership by &#8220;5% stockholders&#8221; that exceeds 50 percentage points over a rolling three-year
period), the corporation&#8217;s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change
taxable income may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past,
and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control.
We have not conducted any studies to determine annual limitations, if any, that could result from such changes in ownership. Our ability
to utilize our NOLs and certain other tax attributes could be limited by an &#8220;ownership change&#8221; as described above and consequently,
we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect
on our cash flows and results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Changes in U.S. tax laws and regulations and those which
we are subject to in various tax jurisdictions could adversely affect our business, financial condition and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We operate in multiple jurisdictions and are subject to tax
laws and regulations of the U.S. federal, state and local and foreign governments. New income, sales, use, digital service or other tax
laws, statutes, rules, regulations, or ordinances could be enacted at any time. Those enactments could harm our domestic and international
business operations and our business, financial condition and results of operations. Further, existing tax laws, statutes, rules, regulations
or ordinances could be interpreted, changed, modified or applied adversely to us. These events could require us to pay additional tax
amounts on a prospective or retroactive basis, as well as require us to pay fines and/or penalties and interest for past amounts deemed
to be due. Additionally, new, changed, modified or newly interpreted or applied tax laws could increase our compliance, operating and
other costs, as well as the costs of our offerings. Further, these events could decrease the capital we have available to operate our
business. Any or all of these events may harm our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we expand the scale of our international business activities,
any changes in the U.S. or foreign taxation of such activities may increase our worldwide effective tax rate and harm our business, financial
condition and results of operations. We may be subject to taxation in several jurisdictions around the world with increasingly complex
tax laws, the application of which can be uncertain. The amount of taxes we pay in these jurisdictions could increase substantially as
a result of changes in the applicable tax principles, including increased tax rates, new tax laws or revised interpretations of existing
tax laws and precedents. An increase in our tax liabilities could harm our liquidity and results of operations. In addition, the authorities
in these jurisdictions could review our tax returns and impose additional tax, interest and penalties, and the authorities could claim
that various withholding requirements apply to us or assert that benefits of tax treaties are not available to us, any of which may harm
us and our results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Any shares of common stock we issue under the SEPA,
if not terminated and if and when available, will further dilute our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have issued shares of our common stock to Yorkville pursuant
to the SEPA and we may issue additional shares of our common stock under the SEPA in the future. These issuances have resulted, and any
future issuances will result, in dilution to the ownership interests of our existing stockholders. The number of shares that may be issued
under the SEPA is variable and depends on factors such as the prevailing market price of our common stock and any applicable discounts
under the SEPA, and shares may be issued at prices below the market price, resulting in significant dilution.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to the Launch of the Nugevia Brand</b>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The launch of the Nugevia brand exposes the Company
to a number of business and operational risks that could materially and adversely impact its business</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The launch of the Nugevia brand exposes us to a number of
risks that could materially and adversely affect our business, financial condition, and results of operations. Successfully introducing
a new brand requires significant investment in marketing, product development, supply chain management, and regulatory compliance, and
there can be no assurance that Nugevia will achieve market acceptance or generate anticipated sales. If we fail to execute the launch
effectively, experience delays in product availability, or encounter challenges in maintaining product quality and regulatory standards,
our ability to establish Nugevia as a recognized and trusted brand may be compromised.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Additionally, the introduction of Nugevia may provoke competitive
responses from established market participants, potentially resulting in increased pricing pressure or heightened marketing costs. If
the Nugevia brand does not gain sufficient traction or if we are unable to recover our investment in its development and promotion, our
growth prospects and overall financial performance could be negatively impacted.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our business and future prospects with the Nugevia brand
and our pharmaceutical products are significantly dependent on our exclusive, worldwide license agreement with Aquanova. Any adverse development
related to this license agreement could materially and adversely affect our operations, financial condition, and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our business and future prospects are significantly dependent
on our exclusive, worldwide license agreement with Aquanova AG, a German company (&#8220;Aquanova&#8221;) which grants us rights to develop,
manufacture, distribute, and sell key products, including JOTROL&#8482;. Any adverse development related to this agreement could materially
and adversely affect our operations, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If the license agreement with Aquanova were to be terminated,
limited, or materially altered, we could lose access to essential proprietary technologies, such as Aquanova&#8217;s NovaSOL&#174; formulation
technology, which is critical for the bioavailability and effectiveness of our Nugevia brand. Disputes over contract terms, intellectual
property rights, or performance obligations could result in costly litigation, delays in product development, or loss of commercialization
rights. Additionally, our obligation to pay license fees and royalties under the license agreement represents a significant financial
commitment, and any inability to meet these obligations could jeopardize our rights under the license agreement. The loss or impairment
of this license would require us to seek alternative technologies or partners, which may not be available on favorable terms, if at all,
and could delay or prevent the development and commercialization of our products.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Should we fail to maintain a productive relationship with
Aquanova or if Aquanova experiences operational or financial difficulties, our ability to deliver products to market could be compromised,
negatively impacting our growth prospects and competitive position.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If the Company or its suppliers fails to comply with
FDA or other regulations, it could result in enforcement actions or delays in the Nugevia brand product launch.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The Company is subject to various federal, state, and local
laws, regulations and administrative practices that affect its business. Our suppliers and contract manufacturers are also subject to
such laws and regulations. The safety, formulation, manufacturing, processing, packaging, importation, labeling, promotion, advertising,
and distribution of the Nugevia brand products are subject to regulation by several federal agencies, including the FDA, the FTC, the
USDA, the CPSC and the EPA, as well as by various state and local agencies. If these laws and regulations were violated by our management,
suppliers or distributors, we could be subject to regulatory enforcement action, public warning letters, product recalls, fines, penalties
and sanctions, including injunctions against the future shipment and sale of products, restitution and disgorgement of profits, operating
restrictions. In addition, other public and private actors are increasingly targeting supplement retailers and manufacturers with class
action lawsuits for selling products that allegedly fail to adhere to the requirements of FDCA, DSHEA, and other federal and state statutes
and requirements, including for failing to adhere to current GPMs, making false or misleading product statements, providing inaccurate
ingredient identity and potency, and failing to control or disclose allergens, contaminants, residues and adulterants, as well as for
state common and statutory laws regarding deceptive trade practices.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We could also be the target of claims relating to false or
deceptive advertising in connection with the marketing and advertising of the products we sell, including under the auspices of the FTC,
the consumer protection statutes of some states as well as certain non-government watchdog groups and class action law firms. In addition,
the FDA has aggressively enforced its regulations with respect to structure/function claims (<i>e.g., </i>&#8220;calcium builds strong
bones&#8221;), nutrient content claims (<i>e.g.,</i> &#8220;high in antioxidants&#8221;) and other claims that impermissibly suggest therapeutic
benefits In addition, the number of private consumer class actions relating to false or deceptive advertising against cosmetic, food,
beverage and nutritional supplement manufacturers has increased in recent years. These events could interrupt the marketing and sales
of products in our stores, including our private label products, severely damage our brand reputation and public image, increase the cost
of products in our stores, result in product recalls or litigation, and impede our ability to deliver merchandise in sufficient quantities
or quality to our stores, which could result in a material adverse effect on our business, financial condition, results of operations
and cash flows.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;<b><i>The global nutraceutical market is highly competitive,
with many brands offering products that are similar to Nugevia. Failure to differentiate from competitors could limit market penetration
and revenue potential.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The global nutraceutical market, valued at $458.55
billion in 2024, is highly competitive, with established players like Nestl&#233; Health Science, Amway, and smaller niche brands
vying for market share. Nugevia&#8217;s reliance on resveratrol, despite JOTROL&#8482;&#8217;s potential for enhanced
bioavailability, faces skepticism due to past studies questioning resveratrol&#8217;s efficacy and may require additional clinical
data. Convincing consumers and healthcare professionals of Nugevia&#8217;s superior performance will require effective marketing.
Failure to differentiate from competitors offering similar longevity or beauty-from-within products could limit market penetration
and revenue potential.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The Company is dependent on certain proprietary supply-chain
vulnerabilities with operational and supply chain risks.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The Company&#8217;s dependence on proprietary technology like
JOTROL&#8482; and partnerships, such as with Aquanova for NovaSOL&#174; Astaxanthin, introduces supply chain vulnerabilities. Disruptions
in raw material availability, manufacturing delays, or quality control issues could hinder production timelines and product consistency.
Scaling up manufacturing to meet demand while maintaining pharmaceutical-grade standards poses additional operational challenges. Any
failure to deliver product in a timely manner could erode consumer trust and investor confidence.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If there are intellectual property disputes relating
to the JOTROL&#8482; technology, it could threaten Nugevia&#8217;s market position</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The Company&#8217;s competitive edge hinges on its
patented JOTROL&#8482; technology. However, intellectual property disputes or challenges to JOTROL&#8482; patent validity could
threaten Nugevia&#8217;s market position. Competitors may attempt to develop similar bioavailability-enhancing technologies, which
circumvent the JOTROL&#8482; patented technology. Furthermore, any adverse events linked to Nugevia&#8217;s ingredients, even if rare,
could result in product liability claims, damaging the brand&#8217;s reputation and financial stability.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to the Discovery, Development and Commercialization
of Our Product Candidate</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We are substantially dependent on the success of our
lead product candidate, JOTROL</i>&#8482;<i>, which will be undergoing Phase II clinical trials, subject to FDA&#8217;s review and agreement.
If we are unable to complete development of, obtain approval for and commercialize JOTROL&#8482; for one or more indications in a timely
manner, our business will be harmed.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our future success is dependent on our ability to timely
and successfully complete clinical trials, obtain marketing approval for and successfully commercialize JOTROL&#8482;, our lead product
candidate, through distribution deals with larger pharmaceutical companies. We are investing the majority of our efforts and financial
resources in the research and development of JOTROL&#8482;. We have several pre-clinical trials and one completed Phase I clinical trial
to evaluate the safety and tolerability of JOTROL&#8482; in healthy volunteers. We are preparing for Phase II clinical trials. This will
be our first clinical efficacy trial, and JOTROL&#8482; has not previously been tested in humans with a specific disease although we
can rely on data that exist for resveratrol. The reason for this is that once JOTROL&#8482; is ingested the formulation excipients will
be separated and it is only the active resveratrol that will be circulating in blood plasma. JOTROL&#8482; will require additional clinical
development, expansion of manufacturing capabilities, marketing approval from government regulators, substantial investment and significant
marketing efforts to obtain established distributors before we can generate any revenues from product sales. We are not permitted to
market or promote JOTROL&#8482;, or any other product candidate, before we receive marketing approval from the FDA and comparable foreign
regulatory authorities, and we may never receive such marketing approvals.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The success of JOTROL&#8482; will depend on several factors, including
the following:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the successful and timely completion
    of our clinical trials of JOTROL&#8482;;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the initiation and successful patient enrollment and completion of additional clinical trials of JOTROL&#8482; on a timely basis;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">maintaining and establishing relationships with CROs and clinical sites for the clinical development of JOTROL&#8482;;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the frequency and severity of adverse events in clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">demonstrating efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the timely receipt of any marketing approvals for JOTROL&#8482; from applicable regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the maintenance of existing or
    the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development and,
    if approved, commercialization of JOTROL&#8482;;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">protecting our rights in our intellectual property portfolio;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">our ability to expand JOTROL&#8482; into multiple indications;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">our ability to find partners handling all aspects of commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the successful launch of commercial sales following any marketing approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">a continued acceptable safety profile following any marketing approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the actual market-size, ability to identify patients and the demographics of patients eligible for our product candidates, which may be different than expected;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">commercial acceptance by patients, the medical community and third-party payors, particularly since the product candidates we develop may be novel; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">our ability to compete with other therapies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We do not have control over many of these factors, including
certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights
and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to
one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize
JOTROL&#8482;, which would materially harm our business. If we do not receive marketing approvals for JOTROL&#8482;, we may not be able to
continue our operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>In addition to JOTROL&#8482;, our prospects depend in part
upon discovering, developing and commercializing product candidates in future programs, which may fail or suffer delays that adversely
affect their commercial viability.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our future operating results are dependent on our ability
to successfully develop, obtain regulatory approval for and commercialize product candidates from our research programs, in addition
to our lead product candidate, JOTROL&#8482;. However, research and development related to novel therapeutics is inherently risky. A
product candidate can unexpectedly fail at any stage of preclinical and/or clinical development. The historical failure rate for product
candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable
variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results
that will be obtained in later stage clinical trials of the product candidate.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The success of other product candidates we may develop will
depend on many factors, including the following:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">generating sufficient data to support the initiation or continuation of clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">obtaining regulatory permission to initiate clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">contracting with the necessary parties to conduct clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">successful enrollment of patients in, and the completion of, clinical trials on a timely basis;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the timely manufacture of sufficient quantities of a product candidate for use in clinical trials; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">adverse events in clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Even if we successfully discover and advance any other product
candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described
elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop,
obtain regulatory approval of, commercialize or generate significant revenue from any product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;<b><i>Clinical drug development involves a lengthy and
expensive process with an uncertain outcome. The clinical trials of our product candidate may not demonstrate safety and efficacy to the
satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results and the results
of preclinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience
delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our lead product candidate, JOTROL&#8482;<sup></sup>, is
entering into Phase II clinical trials after completing a Phase I clinical trial in March 2021 and its risk of failure is high. It is
impossible to predict when or if JOTROL&#8482; or any product candidate that we develop will prove effective or safe in humans or will
receive marketing approval. Before obtaining marketing approval from the FDA, EMA or other comparable foreign regulatory authorities
for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate with substantial
evidence the safety and efficacy of such product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Clinical testing is expensive, difficult to design and implement,
can take many years to complete and its ultimate outcome is uncertain. We cannot guarantee that any of our clinical trials will be conducted
as planned or completed on schedule, or at all. Clinical trials can fail at any stage of testing and failure may result from a multitude
of factors, including, among other things, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria
and failure to demonstrate favorable safety or efficacy traits. The outcome of preclinical studies and early-stage clinical trials may
not be predictive of the success of later clinical trials. For example, our product candidates may fail to show the desired safety and
efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical
trials. We may also discover that the half-life of our product candidates renders them unsuitable for the therapeutic applications we
have chosen. As a result, we cannot assure you that any clinical trials that we conduct will demonstrate consistent or adequate efficacy
and safety that is necessary to support marketing approval.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Many companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage
clinical trials, and we cannot be certain that we will not face similar setbacks. Moreover, preclinical and clinical data are often susceptible
to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical
studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. Furthermore, the failure of any of our
product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product
candidates and/or cause the FDA or other regulatory authorities to require additional testing before approving any of our product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have experienced delays in completing our clinical trial
research and may experience additional delays in initiating or completing additional clinical trials. We may also experience numerous
unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of marketing approval or our ability
to commercialize our product candidates, including:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">receipt of feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">clinical trial observations or results that require us to modify the design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">negative or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain drug development programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">obtaining approval from one or more institutional review boards (IRB);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the number of patients required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than anticipated or participants dropping out of these clinical trials at a higher rate than anticipated;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the suspension or termination of our clinical trials for various reasons, including non-compliance with regulatory requirements or a finding that our product candidates have undesirable side effects or other unexpected characteristics or risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">changes to clinical trial protocol;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the cost of clinical trials of our product candidates being greater than anticipated;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates being insufficient or inadequate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">subjects experiencing severe or unexpected drug-related adverse selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice (cGMPs), regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">any changes to our manufacturing process that may be necessary or desired;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or other regulatory requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">regulators revising the requirements for approving our product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we are required to conduct additional clinical trials or
other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical
trials of our product candidates or other testing in a timely manner, if the results of these trials or tests are not positive or are
only modestly positive or if there are safety concerns, we may incur unplanned costs, be delayed in seeking and obtaining marketing approval,
if we receive such approval at all, receive more limited or restrictive marketing approval, be subject to additional post-marketing testing
requirements or have the drug removed from the market after obtaining marketing approval.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Moreover, in the future, principal investigators for our clinical
trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.
Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities.
The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator
has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority
may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial
itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable
foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product
candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we experience delays in the completion of, or termination
of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to
generate product revenues from any of these product candidates will be delayed. Moreover, our product development costs will also increase
if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our
preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all.
We may also determine to change the design or protocol of one or more of our clinical trials, which could result in increased costs and
expenses and/or delays. Any delays in completing our clinical trials will increase our costs, slow down our product candidates development
and approval process and jeopardize our ability to commence product sales and generate revenues.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, many of the factors that cause, or lead to, termination
or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory
approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may
have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we
do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business,
financial condition and prospects significantly.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We have entered into Service Agreements with the Asian
Partners with respect to services to be provided by the Asian Partners to us in Asia for the clinical development of JOTROL&#8482; in the &#160;Southeast
Asian territory immediately following the completion of the initial public offering; the shares issued by us in advance for the specific
services could have a material negative impact on our business, financial condition and operating results in case the Asian Partners&#8217;
will not perform the services per the agreements.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have entered into service agreements for development of
JOTROL&#8482; in the Southeast Asian territory. The agreements are with three contracted companies, namely, Longevity Technology Group Limited,
Regis Healthcare Group Limited, and Optimized Wellness Limited (collectively, the &#8220;Asian Partners&#8221;) that will handle CMC,
regulatory affairs and clinical trial management, respectively. As consideration for these services, on June 3, 2024, the Company issued
1,162,500 shares of common stock (&#8220;Issued Shares&#8221;) to each of the Asian Partners with a fair market value of $1.33 per share
(3,487,500 shares in aggregate, with an aggregate fair market value of $4,638,375), as pre-payment for three years of services. The Issued
Shares are based on certain specified and agreed upon performances to be executed by each of the Asian Partners. However, if the Asian
Partners fail to perform, or underperform, under their respective service agreements with the Company, their Issued Shares will still
be issued and outstanding and registered for sale. If the Company tries to recover some or all of these Issued Shares, or the cash equivalent
if the Issued Shares have been sold by the Asian Partners, based on any type of non-performance of the agreed services, there is no assurance
that the Company&#8217;s attempt to recover will be successful. Accordingly, the Company may be in a position where it issued shares to
the Asian Partners under the service agreements even if the Asian Partners failed to perform, or underperform, without any ability to
have the shares forfeited to the Company. The requirement by the Company to issue the Issued Shares under the service agreements, without
any specific protection against non-performance, could have a material negative impact on our business, financial condition and operating
results.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We entered into a Strategic Service Agreement with DOMINANT
TREASURE HEALTH COMPANY LIMITED with respect to strategic services in Asia, the fees paid by the Company pursuant to which, are non-refundable
and not tied to any milestones or performance, and the foregoing nature of such fees, could have a material negative impact on our business,
financial condition and operating results.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The Company entered into a Strategic Service Agreement with
DOMINANT TREASURE HEALTH COMPANY LIMITED (&#8220;Strategic Services Partner&#8221;) to provide services to advance the business objectives
of the Company in China and Southeast Asia. As consideration for these services, the Company paid $2,300,000 (the &#8220;Fees&#8221;).
The Fees are non-refundable and are not based on performance by the Strategic Services Partner or milestones that must be reached by the
Strategic Services Partner. Accordingly, if the Strategic Services Partner fails to perform, or underperforms, under the Strategic Service
Agreement, the Company would still be obligated to pay the Fees and would not be entitled for any return of the Fees. Accordingly, the
Company is without any ability to get its money back if the Strategic Services Partner fails to perform, or underperforms. The requirement
by the Company to pay the Fees under the Strategic Service Agreement, regardless of any milestones or performance by Strategic Services
Partner, and the non-refundable nature of such Fees could have a material negative impact on our business, financial condition and operating
results.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our product candidates may cause serious adverse events,
toxicities or other undesirable side effects when used alone or in combination with approved products or investigational new drugs that
may result in a safety or risk profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential
or result in significant negative consequences.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We are developing a novel biologically active small molecule
for neurological disorders. As a result, there is uncertainty as to the safety profile of the product candidates we are developing. In
addition, our product candidates could be used in combination with certain other therapies which may have undesirable side effects. If
our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical
trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or
abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient
recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences
may prevent us from achieving or maintaining market acceptance of the affected product candidates and may harm our business, financial
condition and prospects significantly.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Patients in our ongoing and planned clinical trials may in
the future suffer other serious adverse events or other side effects not observed in our preclinical studies or previous clinical trials.
JOTROL&#8482; or other product candidates may be used in pediatric populations for which safety concerns may be particularly scrutinized by regulatory
agencies. In addition, if JOTROL&#8482; is studied in combination with other therapies, it may exacerbate adverse events associated with the
therapy. Patients treated with JOTROL&#8482; or our other product candidates may also be undergoing other therapies which can cause side effects
or adverse events that are unrelated to our product candidates but may still impact the success of our clinical trials. The inclusion
of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications
that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, it is expected that some of the
patients enrolled in our JOTROL&#8482; clinical trial will die or experience major clinical events either during the course of our clinical trials
or after participating in such trials.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If further serious adverse events or other side effects are
observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients
may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether.
We, the FDA, EMA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for
various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects.
Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have
later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product
candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability
versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. Further, if any
of our product candidates obtains marketing approval, toxicities associated with such product candidates previously not seen during clinical
testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications,
warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product
from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation
of regulatory approval based on preclinical studies or early-stage clinical trials.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The outcome of preclinical testing and early clinical
trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements
of the FDA, EMA or other comparable foreign regulatory authorities.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We will be required to demonstrate with substantial evidence
through rigorous, well-designed, and well-controlled clinical trials that our product candidates are safe and effective for use in a diverse
population before we can seek marketing approvals to commercialize any such product candidates. Success in preclinical studies and early-stage
clinical trials does not mean that future clinical trials will be successful. For instance, we do not know whether JOTROL&#8482; will perform
in current or future clinical trials as JOTROL&#8482; has performed in preclinical studies or earlier clinical trials. Product candidates in
clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign
regulatory authorities despite having progressed through preclinical studies. Regulatory authorities may also limit the scope of later-stage
trials until we have demonstrated satisfactory safety, which could delay regulatory approval, limit the size of the patient population
to which we may market our product candidates, or prevent regulatory approval.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In some instances, there can be significant variability in
safety and efficacy results between different clinical trials of the same product candidates due to numerous factors, including changes
in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen
and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may
also be undergoing other therapies and may be using other approved products or investigational new drugs, which can cause side effects
or adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular
patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and
adversely impact, our clinical trial outcomes.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We do not know whether any clinical trials we may conduct
will demonstrate consistent or adequate efficacy and safety sufficient to obtain approval to market any of our product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we experience delays or difficulties in the enrollment
and/or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed
or prevented.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may not be able to initiate or continue clinical trials
for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials
to such trial&#8217;s conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Patient enrollment is
a significant factor in the timing of clinical trials. Our ability to enroll eligible patients may be limited or may result in slower
enrollment than we anticipate.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;We may encounter difficulties in identifying and enrolling
subjects with a stage of disease appropriate for our planned clinical trials and monitoring such subjects adequately during and after
treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects
to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding
and diagnosing subjects may prove costly. Further, the treating physicians in our clinical trials may also use their medical discretion
in advising patients enrolled in our clinical trials to withdraw from our studies to try alternative therapies.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We expect patient enrollment to be affected because our competitors
have ongoing clinical trials for programs that are under development for the same indications as our product candidates, and patients
who would otherwise be eligible for our clinical trials could instead enroll in clinical trials of our competitors&#8217; programs. Patient
enrollment for our current or any future clinical trials may be affected by other factors, including:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">size and nature of the patient population;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">perceived risks and benefits of novel, unproven approaches;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">severity of the disease under investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">availability and efficacy of approved drugs for the disease under investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">patient eligibility criteria for the trial in question as defined in the protocol;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">perceived risks and benefits of the product candidates under study;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidates being studied in relation to other available therapies, including any new products that may be approved or other product candidates being investigated for the indications we are investigating;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">patient referral practices of physicians;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the ability to monitor patients adequately during and after treatment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the activities of KOLs and patient advocacy groups;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">proximity and availability of clinical trial sites for prospective patients; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may have an advanced disease, will not survive the full terms of the clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our inability to enroll a sufficient number of patients for
our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment
delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain
marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients
for our clinical trials, we may have difficulty maintaining participation in our clinical trials through the treatment and any follow-up
periods.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We have limited resources and are currently focusing
the majority of our efforts on developing JOTROL&#8482; for particular indications. As a result, we may fail to capitalize on other indications
or product candidates that may ultimately have proven to be more profitable.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We are currently focusing the majority of our resources and
efforts on developing JOTROL&#8482;. As a result, because we have limited resources, we may forgo or delay the pursuit of opportunities
for other indications or with other product candidates that may have greater commercial potential. Our resource allocation decisions
may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future
research and development activities for JOTROL&#8482; may not yield any commercially viable products. If we do not accurately evaluate
the commercial potential or target markets for JOTROL&#8482;, we may relinquish valuable rights to our product candidates or programs
through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to such product candidates or program.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We face significant competition and if our competitors
develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products
we develop, our commercial opportunities will be negatively impacted.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The biotechnology and biopharmaceutical industries are characterized
by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates.
Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product
candidate. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies
that may become available in the future. We believe that a significant number of products are currently under development, and may become
commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have competitors both in the United States and internationally,
including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging
and start-up companies, universities and other research institutions. We also compete with other organizations to recruit management,
scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business
plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and
in-licensing new product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We expect to face competition from existing products and products
in development for each of our programs. Many of these current and potential competitors have significantly greater financial, manufacturing,
marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology
companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing
biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have
products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading
companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery
and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all these
factors, our competitors may succeed in obtaining approval from the FDA, EMA or other comparable foreign regulatory authorities or in
discovering, developing and commercializing products in our field before we do.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our commercial opportunity could be reduced or eliminated
if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient, have
a broader label, are marketed more effectively, are more widely reimbursed or are less expensive than any products that we may develop.
Our competitors also may obtain marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for their products
more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before
we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant
premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products
developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are
unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be
adversely affected.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Interim, topline and preliminary data from our clinical
trials that we announce or publish may change as more patient data become available and are subject to audit and verification procedures
that could result in material changes in the final data.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">From time to time, we may publicly disclose preliminary,
interim or topline data from our clinical trials, such as the interim data from our Phase I clinical trial of JOTROL&#8482;. These interim
updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject
to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully
evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions
or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remains subject
to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim
analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the
risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.
Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure
of interim data by us or by our competitors in the future could result in volatility in the price of our securities.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Further, others, including regulatory agencies, may not accept
or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently,
which could impact the value of the particular program, the approvability or commercialization of the particular product candidates or
product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical
trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise
appropriate information to include in our disclosure. If the preliminary or topline data that we report differ from late, final or actual
results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize, JOTROL&#8482; or any other product candidates may be harmed, which could harm our business, financial condition, results of operations
and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may not be successful in our efforts to develop
our proprietary drug delivery platform, JOTROL&#8482;, to build a pipeline of indications.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">A key element of our strategy is to leverage our proprietary
drug delivery platform and our ability to expand our pipeline of indications. We are leveraging our proprietary drug delivery platform
and capabilities to create precision medicines for neurological disorders with high levels of unmet need. Although our research and development
efforts to date have resulted in a pipeline product candidate JOTROL&#8482;, this product candidate may not be safe and effective. In
addition, although we expect that our proprietary drug delivery platform will allow us to develop a diverse pipeline across multiple
therapeutic areas, we may not prove to be successful at doing so. Furthermore, we may also find that the uses of our proprietary drug
delivery platform are limited because alternative uses of our therapeutics prove not to be safe or effective. Even if we are successful
in building our pipeline, JOTROL&#8482; may not be suitable for clinical development, including as a result of being shown to have harmful
side effects or other characteristics that indicate that they are unlikely to receive marketing approval or achieve market acceptance.
Further, because our product candidate and development programs are based on our proprietary drug delivery platform, adverse developments
with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value
of our other programs.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, the biotechnology and pharmaceutical industries
are characterized by rapidly advancing technologies. Our future success will depend in part on our ability to maintain a competitive position
with our approach. If we fail to stay at the forefront of technological change in utilizing our proprietary drug delivery platform to
create and develop product candidates, we may be unable to compete effectively. Our competitors may render our approach obsolete or limit
the commercial value of our product candidates, by advances in existing technological approaches or the development of new or different
approaches, potentially eliminating the advantages in our drug delivery process that we believe we derive from our research approach and
proprietary technologies. By contrast, adverse developments with respect to other companies that attempt to use a similar approach to
our approach may adversely impact the actual or perceived value of our proprietary drug delivery platform and potential of our product
candidates. If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have
a material adverse effect on our business and could potentially cause us to cease operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may develop JOTROL&#8482; and potentially other programs
in combination with other therapies, which would expose us to additional risks.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may develop JOTROL&#8482; and potentially other programs, in combination
with one or more currently approved therapies or therapies in development. Patients may not be able to tolerate JOTROL&#8482; or any other
product candidates in combination with other therapies or dosing of JOTROL&#8482; in combination with other therapies may have unexpected
consequences. Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with
other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities
could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply
issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates
are approved for use could themselves fall out of favor. This could result in the need to identify other combination therapies for our
product candidates or our own products being removed from the market or being less successful commercially.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may also evaluate our product candidates in combination
with one or more other therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities.
We will not be able to market and sell any product candidates in combination with any such unapproved therapies that do not ultimately
obtain marketing approval.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If the FDA, EMA or other comparable foreign regulatory authorities
do not approve or revoke their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply
issues arise with the therapies we may choose to evaluate in combination with JOTROL&#8482; or any other product candidate, we may be unable
to obtain approval of or successfully market any one or all of the product candidates we develop.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Additionally, if the third-party providers of therapies or
therapies in development used in combination with our product candidates are unable to produce sufficient quantities for clinical trials
or for commercialization of our product candidate, or if the cost of combination therapies are prohibitive, our development and commercialization
efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The manufacture of drugs is complex, and our third-party
manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability
to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or
prevented.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Manufacturing drugs, especially in large quantities, is complex
and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength,
quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, as well
as sophisticated quality assurance and quality control procedures. Slight deviations anywhere in the manufacturing process, including
filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures or product recalls. When
changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable quality
and efficacy of the products before and after such changes. If our third-party manufacturers are unable to produce sufficient quantities
for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts
would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our product candidates may not achieve adequate market
acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Even if our product candidates receive regulatory approval,
they may not gain adequate market acceptance among physicians, patients, third-party payors and others in the medical community. The degree
of market acceptance of any of our approved product candidates will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the timing of market introduction of the product candidates as well as competitive products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the clinical indications for which a product candidate is approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">restrictions on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or contraindications in labeling, or a risk evaluation and mitigation strategy, if any, which may not be required of alternative treatments and competitor products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the potential and perceived advantages of our product candidates over alternative treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the cost of treatment in relation to alternative treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the availability of an approved product candidate for use as a combination therapy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">relative convenience and ease of administration;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the willingness of the target patient population or their caregivers to try new therapies and of physicians to prescribe these therapies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">patients&#8217; willingness to pay for these therapies in the absence of such coverage and adequate reimbursement;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the effectiveness of sales and marketing efforts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">support from KOLs and patient advocacy groups;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">unfavorable publicity relating to our product candidates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the approval of other new therapies for the same indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If any of our product candidates are approved but do not achieve
an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue
from that product candidate and our financial results could be negatively impacted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
patient population suffering from MPS I and MELAS syndrome is small and has not been established with precision. If the actual
number of patients is smaller than we estimate, our potential revenue and ability to achieve profitability may be adversely
affected. Because the target patient populations of our programs are small and the addressable patient population may be even
smaller, we must be able to successfully identify patients and capture a significant market share to achieve profitability and
growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPS
I and MELAS are rare, genetic neuromuscular disorders. We estimate that MPS I occurs in approximately one in every 100,000 live births
and that the patient population is approximately 2,000 to 3,000 in the United States and approximately 4,000 in Europe. MELAS is one
of the most common mitochondrial diseases, with an estimated incidence of 1 in 4000. We estimate that there are approximately 80,000
patients with MELAS in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our estimates of the size of these patient populations are
based on published studies. Given the small number of patients who have the diseases that we are targeting, it is critical to our ability
to grow and become profitable that we continue to successfully identify patients with these rare diseases. The effort to identify patients
with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be
possible. Various factors may decrease the market size of our product and product candidates, including the severity of the disease, patient
demographics and the response of patients&#8217; immune systems to our product candidates. If the results of these studies or our analysis
of them do not accurately reflect the relevant patient population, our assessment of the market may be inaccurate, making it difficult
or impossible for us to meet our revenue goals, or to obtain and maintain profitability.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Additionally, the potentially addressable patient population
for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may
become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.
Further, even if we obtain significant market share for our product candidates, because the potential target populations are very small,
we may never achieve profitability despite obtaining such significant market share.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Any product candidates we develop may become subject
to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The availability and extent of coverage and adequate reimbursement
by third-party payors including government health administration authorities, private health coverage insurers, managed care organizations
and other third-party payors is essential for most patients to be able to afford expensive treatments. The initial targets in our pipeline
are indications with small patient populations. For product candidates that are designed to treat smaller patient populations to be commercially
viable, the reimbursement for such product candidates must be higher, on a relative basis, to account for the lack of volume. Accordingly,
we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential
market size.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Sales of any of our product candidates that receive marketing
approval will depend substantially, both in the United States and internationally, on the extent to which the costs of such product candidates
will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may
not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may
not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and
reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and
reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product
candidate for which we obtain marketing approval.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">There is significant uncertainty related to third-party payor
coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for
new products are typically made by the Centers for Medicare &amp; Medicaid Services (CMS), an agency within the U.S. Department of Health
and Human Services (HHS). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private
third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party
payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for
the product candidate or at the same level of reimbursement. As a result, the coverage determination process is often time-consuming and
costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor
separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Increasingly, third-party payors are requiring that drug companies
provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such
payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product
candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors
may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved
drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and
cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We
cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available,
what the level of reimbursement will be.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Outside the United States, the commercialization of therapeutics
is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on
cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics
such as our product candidates. In many countries, particularly the countries of the European Union (EU), medical product prices are subject
to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities
can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries,
we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies.
In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix
their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation
could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the
reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable
revenue and profits.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we are unable to establish or sustain coverage and adequate
reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected,
which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party
payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products
for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our business entails a significant risk of product liability
and if we are unable to obtain sufficient insurance coverage, such inability could have an adverse effect on our business and financial
condition. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
of our products.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our business exposes us to significant product liability risks
inherent in the development, testing, manufacturing and marketing of therapeutic treatments. We currently have product liability insurance
that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product
candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore,
clinical trial and product liability insurance are becoming increasingly expensive. As a result, we may be unable to obtain sufficient
insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our
business and financial condition. Also, our insurance policies may have various exclusions, and we may be subject to a product liability
claim for which we have no coverage. We may have to pay any amount awarded by a court or negotiated in a settlement that exceeds our coverage
limitations or that is not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.
Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may
not be available or adequate should any claim arise.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may be sued if any of our product candidates cause or are
perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale post-approval.
Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers
inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state consumer protection
laws. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
to limit testing and commercialization of our products. Even successful defense would require significant financial and management resources.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Regardless of the merits or eventual outcome, liability claims
may result in:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">delays in the development of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">FDA, EMA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">decreased or interrupted demand for our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">injury to our reputation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">withdrawal of clinical trial participants and inability to continue clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">initiation of investigations by regulators;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">costs to defend the related litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">a diversion of management&#8217;s time and our resources;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">substantial monetary awards to trial participants or patients;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">product recalls, withdrawals or labeling, marketing, or promotional restrictions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">loss of revenue;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">exhaustion of any available insurance and our capital resources; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the inability to commercialize any products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;<b>&#160;</b></p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to Regulatory Approval and Other Legal Compliance
Matters</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The regulatory approval processes of the FDA, EMA and
other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable
to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially
harmed.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We currently have no products authorized for commercial distribution
in either the United States, Europe or any other country. All of our product candidates require regulatory clearance or approval. We cannot
begin marketing and selling product candidates until we obtain applicable authorizations from the applicable regulatory agencies.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our product candidates are and will continue to be subject
to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy,
approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs.
Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United
States and in many foreign jurisdictions before a new drug can be approved for marketing. We are not permitted to market JOTROL&#8482; or any
other product candidates as medicines in the United States or other countries until we receive approval of an NDA from the FDA. Prior
to submitting any NDA to the FDA for approval of JOTROL&#8482; we will need to have completed our pre-clinical studies and clinical trials and
demonstrate that JOTROL&#8482; meets all applicable standards of identity, strength, quality, and purity throughout their expiration date. Successfully
completing any clinical program and obtaining approval of an NDA is a complex, lengthy, expensive, and uncertain process, and the FDA
(or other country medicines regulatory body) may delay, limit, or deny approval of product candidates for many reasons. Obtaining approval
by the FDA, EMA and other comparable foreign regulatory authorities is costly, unpredictable, typically takes many years following the
commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates
involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during
the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval
or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse
to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other
data. Even if we eventually complete clinical testing and receive approval for our product candidates, the FDA, EMA and other comparable
foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than
we originally requested or may impose other prescribing limitations or warnings that limit the product&#8217;s commercial potential. We
have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates
will ever obtain regulatory approval. Further, development of our product candidates and/or regulatory approval may be delayed for reasons
beyond our control. We cannot provide any assurance that any product candidates we may develop will progress through required clinical
testing and obtain the regulatory approvals necessary for us to begin selling them.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have not conducted, managed or completed large-scale or
pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. As a result, applications
for our product candidates could fail to receive regulatory approval for many reasons, including the following:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, size, conduct, implementation or results of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, are only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that our product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the FDA, EMA or other comparable foreign regulatory authorities may conclude that our API or finished products do not meet all applicable standards of identity, strength, quality, and purity</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">This lengthy approval process, as well as the unpredictability
of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which
would significantly harm our business, results of operations and prospects. Any delay or failure in seeking or obtaining required approvals
would have a material and adverse effect on our ability to generate revenue from any particular product candidates we are developing and
for which we are seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on
the approved uses or indications for which we may market, promote and advertise the drug or the labeling or other restrictions. In addition,
the FDA has the authority to require a REMS plan as part of approving an NDA, or after approval, which may impose further requirements
or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing
to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use
criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of
the market for the drug and affect reimbursement by third-party payors.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We are also subject to numerous foreign regulatory requirements
governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement.
The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA and EMA approval
described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required
to obtain approval may differ from that required to obtain FDA approval.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The FDA, EMA and other comparable foreign regulatory
authorities may not accept data from trials conducted in locations outside of their jurisdiction.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our clinical trials are planned for undertaking in the
United States. &#160;We may choose to conduct additional clinical trials internationally. The acceptance of study data by the FDA,
EMA or other comparable foreign regulatory authorities from clinical trials conducted outside of their respective jurisdictions may
be subject to certain conditions. In cases where data from United States clinical trials are intended to serve as the basis for
marketing approval in the foreign countries outside the United States, the standards for clinical trials and approval may be
different. There can be no assurance that any United States or foreign regulatory authority would accept data from trials conducted
outside of its applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it
would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and
which may result in our product candidates not receiving approval or clearance for commercialization in the applicable
jurisdiction.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining regulatory approval of our
product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates
in other jurisdictions.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Obtaining and maintaining regulatory approval of our product
candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction.
For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions
must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a
failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in
others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those
in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may
not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate
must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to
charge for our products is also subject to approval.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Obtaining foreign regulatory approvals and establishing and
maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could
delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory
requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability
to realize the full market potential of our potential product candidates will be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval processes for any product candidates that target rare diseases, including MPS I and MELAS are uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the lack of precedent, broad discretion of regulatory authorities, and a multitude of unique factors that impact the regulatory approval
process, the likelihood of the approval of any product candidates that target rare diseases, such as MPS I and MELAS is uncertain,
and we may not be able to anticipate, prepare for or satisfy requests or requirements from regulatory authorities, including completing
and submitting planned Investigational New Drug (IND) and new drug applications (NDA) for our product candidates, in a timely manner,
or at all. For example, MPS I is a rare disease for which there is only one FDA approved therapeutics. In addition, no therapies are
currently approved for MELAS in the United States or the EU. Further, the FDA may determine, after evaluation of our data and analyses,
that such data and analyses do not support an NDA submission, filing or approval. Due to this lack of predictability, we may not have
the resources necessary to meet regulatory requirements and successfully complete a potentially protracted, expensive and wide-ranging
approval process for commercialization of product candidates for rare diseases.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Even if our product candidates receive regulatory approval,
they will be subject to significant post-marketing regulatory requirements and oversight.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Any regulatory approvals that we may receive for our product
candidates will likely require on-going post-marketing surveillance to monitor the safety and efficacy of any such approved product. Any
regulatory approval may also contain significant limitations related to use restrictions for specified age groups, warnings, precautions
or contraindications, and may include burdensome post-approval study or risk management requirements and regulatory inspection. For example,
the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician
training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing
processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping
for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of
safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMP regulations and GCPs for
any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual
review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards.
If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or
frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product,
the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.
In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative
or judicially imposed sanctions, including:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; width: 94%; font-family: Times New Roman,serif"><span style="font-size: 10pt">restrictions on the products, manufacturers or manufacturing process;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">warning or untitled letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">civil and criminal penalties;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">injunctions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">suspension or withdrawal of regulatory approvals, or debarment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">product seizures, detentions, import refusals, or import alerts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">voluntary or mandatory product recalls and publicity requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">total or partial suspension of production; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">imposition of restrictions on operations, including costly new manufacturing requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The occurrence of any event or penalty described above may
inhibit our ability to commercialize our product candidates, if approved, and generate revenue. Furthermore, non-compliance by us or any
future collaborator with regulatory requirements, including safety monitoring and with requirements related to the development of products
for the pediatric population can also result in significant financial penalties.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may not be able to obtain orphan drug designation
or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA,
EMA or other comparable foreign regulatory authorities, from approving competing products.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Regulatory authorities in some jurisdictions, including the
United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the
FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined
as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000
in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the
United States. However, there can be no assurances that we will be able to obtain orphan designations for any of our product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In the United States, orphan drug designation entitles a party
to financial incentives such as opportunities for grant funding towards clinical trial costs, tax credits for qualified clinical testing
expenses, and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval
for the indication for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may
not subsequently approve another application, including a full NDA, to market the same drug for the same indication or use within the
such rare disease indication for seven years, except in limited circumstances.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We intend to seek orphan drug designation for JOTROL&#8482; in MPS I and may seek orphan drug
designation for other product candidates. Even if we obtain orphan drug designation for a product candidate, we may not be able to obtain
or maintain orphan drug exclusivity for that product candidate, nor can we guarantee that any orphan-drug-designated product candidate
will obtain regulatory approval from FDA. Even if we obtain FDA approval, we may not be the first to obtain marketing approval of any
product candidate for which we have obtained orphan drug designation for the same indication or use due to the uncertainties associated
with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval
for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation
was materially defective or if we are unable to ensure that we will be able to manufacture sufficient quantities of the product to meet
the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity
may not effectively protect the product from competition because drugs with different active moieties may be approved for the same condition.
Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition
if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution
to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug
designation neither shortens the development time or regulatory review time of a drug nor gives the product candidate any advantage in
the regulatory review or approval process or entitles the product candidate to priority review.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Where appropriate, we plan to help expedite the product
development and approval process by requesting that FDA or comparable foreign regulatory authorities designate product candidates for
the use of accelerated registration or approval pathways. If we are unable to obtain such designations, we may be required to conduct
additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and
delay the receipt of, necessary marketing approvals. Even if we receive an accelerated development designation from the FDA, if our confirmatory
trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw
accelerated approval.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Where possible, we plan to pursue accelerated development
strategies in areas of high unmet need. We may seek an accelerated approval pathway for one or more of our product candidates. Under the
accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may
grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic
benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate
clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic
effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes
of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other
measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint
is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to
predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases
in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement
from a patient and public health perspective. If granted, accelerated approval is contingent on the sponsor&#8217;s agreement to conduct
post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. Such studies must be commenced prior to or
not later than the time of approval, and the sponsor must conduct such studies with due diligence. If such post-approval studies fail
to confirm the drug&#8217;s clinical benefit, or if the sponsor fails to conduct such studies with due diligence, the FDA may use expedited
procedures to withdraw its approval of the drug.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Prior to seeking such accelerated approval, we will seek feedback
from the FDA and will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after
our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form
of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue
to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide
to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited regulatory designation
(e.g., breakthrough therapy designation), there can be no assurance that such submission or application will be accepted or that any expedited
development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities
could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain
accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer
time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could
harm our competitive position in the marketplace.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If our Nugevia nutritional supplement products do not
have the effects intended or cause undesirable side effects, our business may suffer.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Although the ingredients in our current Nugevia supplement
products are substances for which there is a history of human consumption, they also contain innovative ingredients or combinations of
ingredients. &#160;Although we believe all of such products and the combinations of ingredients in them are safe when taken as directed,
the products could have certain undesirable side effects if not taken as directed or if taken by a consumer that has certain medical conditions.
In addition, such products may not have the effect intended if they are not taken in accordance with certain instructions, which include
certain dietary restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the
effects intended or will not have harmful side effects in an unforeseen way or affect populations differently. If any of our products
or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects,
our business, financial condition, results of operations and prospects would be harmed significantly.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;<b><i>Our competitors may develop nutritional supplement
products that are less expensive, safer or otherwise more appealing, which may diminish or eliminate the commercial success of any potential
product that we may commercialize.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If our competitors (most of whom are larger and have more
resources than we do) develop and bring to market competing nutritional supplement products that are less expensive, safer or otherwise
more appealing than our current Nugevia products and potential future products, or that reach the market before our products, we may not
achieve commercial success. The market may choose to continue utilizing existing products for a number of reasons, including familiarity
with or pricing of these existing products. The failure of any of Nugevia products to compete with products marketed by our competitors
would impair our ability to generate revenue, which could have a material adverse effect on our future business, financial condition,
results of operations, and cash flows. Our competitors may:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">develop and market products that are less expensive, safer, or otherwise more appealing than our products;</td></tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">commercialize competing products before we or our partners can launch our products; and</td></tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">initiate or withstand substantial price competition more successfully than we can.</td></tr></table>

<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our Nugevia products are subject to regulatory requirements
and failure to comply with any regulations could lead to significant penalties or claims, which could materially harm our financial condition
and operating results.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">For example, we are subject to FDA requirements, including
for cGMPs for dietary supplements. Any failure by us or any contract manufacturer to comply with the cGMPs could negatively impact our
reputation and ability to sell our products even after the situation has been resolved. In addition, FDA and other governmental authorities
limit the types of claims that we can make about our products, including nutrition content claims, health claims, and therapeutic claims
and otherwise regulate the marketing of our products. It is possible that our marketing materials, including testimonials about our products,
may be significantly impacted by laws, rules, and regulations governing the marketing of our products and therefore might negatively impact
our sales.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may face difficulties from changes to current regulations
and future legislation.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Governmental agencies throughout the world, including in the
United States, strictly regulate the pharmaceutical, dietary and nutritional supplement and drug and medical product industries. Our business
involves the clinical testing and development of drug product candidates and the marketing and sale of nutritional supplements.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Existing regulatory policies may change, and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States
or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if
we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve
or sustain profitability.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We also cannot predict the likelihood, nature or extent of
government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.
For example, certain policies of the current U.S. administration may impact our business and industry, which could impose significant
burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing
statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how current
and future legislation, executive actions, and litigation, including the executive orders referenced below, will be implemented, and the
extent to which they will impact our business, our clinical development, and the FDA&#8217;s and other agencies&#8217; ability to exercise
their regulatory authority, including FDA&#8217;s pre-approval inspection and timely review of any regulatory filings or applications
we submit to the FDA. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities
in the normal course or constraints on our business operations, including operations of our contractors, our business may be negatively
impacted.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">For example, in March 2010, the Patient Protection and Affordable
Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), was passed, which substantially
changed the way healthcare is financed by both the government and private insurers, and continues to significantly impact the U.S. pharmaceutical
industry. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. For example, various
portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court. Although the Supreme
Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate
a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the
ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and
rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include
work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or
the ACA. We cannot predict how the Supreme Court will rule on these challenges, how future litigation will impact our business, or what
other healthcare measures and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation
or regulation may have on our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, other legislative changes have been proposed
and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers
of up to 2% per fiscal year, effective April 1, 2013, which will remain in effect through 2030. In January 2013, President Obama signed
into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result
in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs,
if approved, and accordingly, our financial operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Moreover, there has been heightened governmental scrutiny
recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional
inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing,
review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for
drug products. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for
Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. At the
federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget
proposals, executive orders and policy initiatives. For example, in 2020, HHS and CMS issued various rules that are expected to impact,
among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit
managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that
affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting
related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects
of the rules. In January 2021, the Biden administration issued a &#8220;regulatory freeze&#8221; memorandum that directs department and
agency heads to review new or pending rules of the prior administration. It is unclear whether these new regulations will be withdrawn
or when they will become fully effective under the Biden administration. The impact of these lawsuits as well as legislative, executive,
and administrative actions of the Biden administration on us and the pharmaceutical industry as a whole is unclear.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">At the state level, legislatures have increasingly passed
legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed
to encourage importation from other countries and bulk purchasing. We are unable to predict the future course of federal or state healthcare
legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare.
These and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material
and adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We expect that the ACA, as well as other healthcare reform
measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price
that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar
reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us
from being able to generate revenue, attain profitability or commercialize our product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional
legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such
changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s
approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing
testing and other requirements. In addition, recent and potential future courts decisions and administrative law cases may result in additional
legal challenges to regulations and guidance issued by federal regulatory agencies, including the FDA, that we have relied on and intend
to rely on in the future. Any such challenges, if successful, could have a material impact on our business. In addition to potential changes
to regulations and agency guidance as a result of legal challenges, these decisions may result in increased regulatory uncertainty and
delays in and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. Additionally,
our ability to develop and market new drug products may be impacted based on current or future litigation in the federal court system
challenging the FDA&#8217;s approval of other companies&#8217; drugs. Depending on the outcome of this type of litigation, our ability
to develop new drug product candidates and to maintain approval of existing drug products could be at risk and our efforts to develop
and market new drug products could be delayed, undermined or subject to protracted litigation.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Further, artificial intelligence (AI)-based platforms and
tools are increasingly being used in the medical industry, including by regulatory authorities, such as the FDA to assist with the review
of regulatory filings and other activities. With new and evolving AI comes a continually changing AI regulatory environment, which may
create additional costs, challenges, and risks that could adversely impact our ability to timely develop and seek approval of our drug
product candidates with FDA, or otherwise have a material adverse impact on our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Risks Related to Data Privacy and Security</span></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We are subject to an evolving array of U.S. and foreign
privacy, and data protection, and data security laws regulations, and standards, and any failure or perceived failure to comply could
result in regulatory investigations, litigation, significant fines and penalties, operational restrictions, and reputational harm.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We collect and process personal information in the course
of operating our business, including in connection with our clinical programs and the direct-to-consumer marketing and sale of our Nugevia
products. In the United States, we may be subject to a patchwork of federal and state laws and regulations governing the privacy and security
of personal information, including state breach notification laws, consumer privacy laws (for example, the California Consumer Privacy
Act of 2018, as amended by the California Privacy Rights Act of 2020 (CCPA)), health information privacy laws, and federal and state consumer
protection laws enforced by regulators such as the Federal Trade Commission and state attorneys general. Businesses that process personal
information of consumers in several states are required, among other things, to make certain disclosures regarding their data collection,
use, and sharing practices, and to honor requests from consumers to exercise rights over their personal information, including the right
to opt out of certain disclosures and the right to limit the use of sensitive personal information. These requirements continue to expand
and diverge across states, increasing the cost and complexity of compliance and the risk of civil penalties for violations thereof.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">To the extent we act as a covered entity or business associate,
we are subject to the Health Insurance Portability and Accountability Act of 1996, as amended, and its implementing regulations (collectively,
HIPAA), which impose privacy, security, and breach notification obligations with respect to protected health information, as well as contractual
requirements and potential civil and criminal penalties for violations. Even where our clinical trial data may benefit from limited exemptions
under certain state consumer privacy laws, our broader activities, such as recruiting, employee information processing, and marketing,
may still be in scope.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Internationally, the collection and use of health data and
other personal information is governed in the EU by the General Data Protection Regulation (GDPR) and by certain EU Member State-level
legislation. The GDPR extends its geographical scope to entities outside of the EU that offer goods or services to, or monitor the behavior
of, individuals within the EU. While our clinical operations are currently based in the United States, we maintain significant business
relationships with international partners, including our exclusive license agreement with Aquanova AG, a German company. To the extent
personal information is exchanged in connection with these relationships, the GDPR and the UK General Data Protection Regulation (UK GDPR),
may apply. Failure to comply with the GDPR may result in fines up to &#8364;20,000,000 or up to 4% of total worldwide annual turnover of
the preceding financial year, whichever is higher, and other administrative penalties. The UK GDPR provides for fines of up to the greater
of &#163;17.5 million or 4% of global turnover. While the EU-U.S. Data Privacy Framework and other transfer mechanisms currently provide
pathways for transatlantic data flows, these frameworks are subject to change and legal challenge, which may require us to implement additional
safeguards at increased cost and with residual risk.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Furthermore, as we pursue our stated plans for international
clinical trials, regulatory submissions to the EMA, out-licensing opportunities in European and Asian markets, and potential commercialization
in foreign jurisdictions, we expect that we will become subject to additional data protection requirements in those jurisdictions. These
may include, among others, data protection laws in China (the Personal Information Protection Law, or PIPL), Singapore (the Personal Data
Protection Act, or PDPA), and Australia (the Privacy Act 1988), each of which imposes distinct compliance obligations, restrictions on
cross-border data transfers, and significant penalties for noncompliance.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">With the GDPR, CCPA, state comprehensive privacy laws, and
other laws, regulations and other obligations imposing new and burdensome obligations, and with substantial uncertainty over the interpretation
and application of these evolving requirements, we may face challenges in addressing their requirements and making necessary changes to
our policies and practices, and may incur significant costs and expenses in an effort to do so. Additionally, our reliance on third parties,
such as CROs, CMOs, clinical sites, vendors, or other service providers, creates additional risk and could have an adverse effect on our
business and data if such parties fail to comply with applicable privacy and security requirements or our policies, or otherwise suffer
a security incident. Any failure or perceived failure by us or our service providers to comply with applicable privacy or data protection
obligations, or to protect personal information against unauthorized access, use, or disclosure, could result in investigations, enforcement
actions, litigation (including class actions), significant fines and damages, the suspension of data processing, orders to change our
practices, and reputational harm, any of which could adversely affect our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Inadequate funding for the FDA, the U.S. Securities
and Exchange Commission (SEC) and other government agencies could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing
normal business functions on which the operation of our business may rely, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The ability of the FDA to review and approve new products
can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and
accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in
recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including
those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Disruptions at the FDA and other agencies may also slow the
time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.
For example, in recent years, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC,
had to furlough critical employees and stop critical activities. In addition, in 2025, the federal government implemented workforce reductions
across the Department of Health and Human Services, including layoffs affecting FDA employees and resulting in a reduction in the FDA&#8217;s
full-time workforce. Although FDA review staff were described as exempt from direct cuts, the loss of personnel may have contributed to
reported slowdowns, reduced responsiveness, and operational strain within the FDA. If a prolonged government shutdown or personnel reduction
occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have
a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or personnel reductions
could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our relationships with healthcare professionals, clinical
investigators, CROs and third-party payors in connection with our current and future business activities may be subject to federal and
state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy
and security laws, which could expose us to significant losses, including, among other things, criminal sanctions, civil penalties, contractual
damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future
earnings.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Healthcare providers and third-party payors play a primary
role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements
with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud
and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through
which we research, as well as market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable
federal and state healthcare laws and regulations may include the following:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, also imposes obligations, including mandatory contractual terms, on covered entities, which are health plans, healthcare clearinghouses, and certain health care providers, as those terms are defined by HIPAA, and their respective business associates and their subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, reporting obligations with respect to covered recipients will be expanded to include physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and certified nurse midwives for payments and transfers of value made during the previous year; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance regulations promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing; state and local laws that require the registration of pharmaceutical sales and medical representatives; state laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Efforts to ensure that our current and future business arrangements
with third parties will comply with applicable healthcare and data privacy laws and regulations will involve substantial ongoing costs,
and may require us to undertake or implement additional policies or measures. We may face claims and proceedings by private parties, and
claims, investigations and other proceedings by governmental authorities, relating to allegations that our business practices do not comply
with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations,
and it is possible that courts or governmental authorities may conclude that we have not complied with them, or that we may find it necessary
or appropriate to settle any such claims or other proceedings. In connection with any such claims, proceedings, or settlements, we may
be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment,
exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting
obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our
operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.
Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance
with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded
healthcare programs.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;<b><i>Our employees, independent contractors, consultants,
commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and requirements.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;We are exposed to the risk that our employees, independent
contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other
improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to
the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data
or disclose unauthorized activities to us. In particular, research, sales, marketing and business arrangements in the health care industry
are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer
incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code
of conduct, but it is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement,
imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight
and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring
of our operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;I<b><i>f we fail to comply with environmental, health
and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect
on our business.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We are subject to numerous environmental, health and safety
laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous
materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials.
Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and
wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting
from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.
We also could incur significant costs associated with civil or criminal fines and penalties.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Although we maintain workers&#8217; compensation insurance
to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this
insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or
toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including
chemicals and biological materials.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, we may incur substantial costs in order to comply
with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair
our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial
fines, penalties or other sanctions.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our business activities may be subject to the U.S. Foreign
Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain
foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability
to compete in foreign markets and subject us to liability if we violate them.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our business activities are subject to the U.S. Foreign Corrupt
Practices Act of 1977, as amended (FCPA), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and
similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. These laws generally prohibit
companies and their employees, agents, representatives, business partners, and third-party intermediaries from, directly or indirectly,
offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to recipients in the public
or private sector in order to influence official action or otherwise obtain or retain business. Our business is heavily regulated and
therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other
countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials
under the FCPA. Recently, the SEC and DOJ have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical
companies.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We sometimes leverage third parties to assist with the conduct
of our business abroad. We, our employees, agents, representatives, business partners and our third-party intermediaries may have direct
or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities and may be held liable
for the corrupt or other illegal activities of these employees, agents, representatives, business partners or third-party intermediaries
even if we do not explicitly authorize such activities. We cannot assure you that all of our employees, agents, representatives, business
partners and third-party intermediaries will not take actions in violation of applicable law for which we may be ultimately held responsible.
As we increase our international sales and business, our risks under these laws may increase.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">These laws also require that we make and keep books and records
that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting
controls and compliance procedures designed to prevent violations of anti-corruption laws. There is no certainty that all of our employees,
agents, representatives, business partners and third-party intermediaries, or those of our affiliates, will comply with applicable laws
and regulations, for which we may be ultimately held responsible.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Violations of these laws and regulations could result in whistleblower
complaints, fines, severe civil or criminal sanctions, settlements, prosecution, enforcement actions, damages, adverse media coverage,
investigations, loss of export privileges, disgorgement, and other remedial measures and prohibitions on the conduct of our business including
our ability to offer our products in one or more countries. Responding to any investigation or action will likely result in a materially
significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees. As a general
matter, investigations, enforcement actions and sanctions could damage our reputation, our brand, our international activities, our ability
to attract and retain employees and our business, prospects, operating results and financial condition.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, our products may be subject to U.S. and foreign
export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or
our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales
and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays
in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether.
Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments,
and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties
could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation
or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such
regulations, could result in decreased use of our products by, or in our decreased ability to export our products to, existing or potential
customers with international operations. Any decreased use of our products or limitation on our ability to export or sell our products
would likely adversely affect our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to Employee Matters, Managing Our Growth
and Other Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our success is highly dependent on our ability to attract
and retain highly skilled executive officers and employees.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">To succeed, we must recruit, retain, manage and motivate qualified
clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly
dependent on the principal members of our management and scientific and medical staff, particularly Marshall Hayward, our Co-Founder and
Chief Scientific Officer. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level,
it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more
of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. We do not maintain
&#8220;key person&#8221; insurance for any of our executives or other employees. We could in the future have difficulty attracting and
retaining experienced personnel and may be required to expend significant financial resources in our employee recruitment and retention
efforts.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Many of the other biotechnology companies that we compete
against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry
than we do. They also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of
these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract
and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will
be limited and the potential for successfully growing our business will be harmed.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Additionally, we rely on our scientific founders and other
scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. These
advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that
may limit their availability to us. In addition, these advisors and consultants typically will not enter into non-compete agreements with
us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore,
our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete
with ours. In particular, if we are unable to maintain consulting relationships with our scientific founders or if they provide services
to our competitors, our development and commercialization efforts will be impaired and our business will be significantly harmed.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we are unable to establish sales or marketing capabilities
or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market
our product candidates that obtain regulatory approval.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We currently do not have and have never had a marketing or
sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and
other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which
we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Establishing an internal sales or marketing team with technical
expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming and will
require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing
and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to
market, if we do not have arrangements in place with third parties to provide such services, which is our preferred marketing and sales
strategy, on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third
parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems
or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third
parties relating to the proposed collaboration and such arrangements may prove to be less profitable than commercializing the product
on our own. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully
commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations.
If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or
more third parties, our future product revenue will suffer, and we may incur significant additional losses.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>In order to successfully implement our plans and strategies,
we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As of December 31, 2025, we had a total of five full-time
employees, two full-time consultants and one part-time consultant, plus our six Scientific Advisory Board members. Of these, three were
primarily engaged in research or product development and clinical activities. In order to successfully implement our development and commercialization
plans and strategies, and as we transition into operating as a public company, we expect to hire additional managerial, operational, sales,
marketing, financial and other personnel, as reflected in our organization chart represented in our Operation and Organization section.
Future growth would impose significant added responsibilities on members of management, including:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">managing our internal development efforts effectively, including the clinical, FDA, EMA and other comparable foreign regulatory agencies&#8217; review process for JOTROL&#8482; and any other product candidates, while complying with any contractual obligations to contractors and other third parties we may have; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our future financial performance and our ability to successfully
develop and, if approved, commercialize JOTROL&#8482; and other product candidates will depend, in part, on our ability to effectively manage
any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities
in order to devote a substantial amount of time to managing these growth activities.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We currently rely, and for the foreseeable future will continue
to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key
aspects of our research and development, clinical development and manufacturing. We cannot assure you that the services of independent
organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified
replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services
provided by third-party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and
we may not be able to obtain marketing approval of JOTROL&#8482; and any other product candidates or otherwise advance our business. We cannot
assure you that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants
on economically reasonable terms, or at all.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we are not able to effectively expand our organization
by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks
necessary to further develop and commercialize JOTROL&#8482; and other product candidates and, accordingly, may not achieve our research, development
and commercialization goals.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to Cybersecurity and Information Technology
Disruptions</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;<b><i>Our information technology systems and those of
any of our CROs, clinical sites, manufacturers, vendors, and other partners are subject to cybersecurity threats and other disruptions
that could adversely affect our operations and the development and commercialization of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;We and our third-party partners rely on information
technology systems to conduct research and development, manage clinical and manufacturing operations, and support corporate functions.
Despite the implementation of security measures designed to protect these systems, given their size and complexity and the increasing
amounts of information maintained on our internal information technology systems, and those of our third-party CROs, contract development
and manufacturing organizations (&#8220;CDMOs&#8221;), other contractors (including sites performing our clinical trials) and consultants,
these systems are vulnerable to damage, disruption or unauthorized access arising from service interruptions, system malfunction, natural
disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional
actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious
third parties. Such cyber-attacks may include supply chain attacks, the deployment of harmful malware, ransomware (including ransomware-as-a-service),
denial-of-service attacks, social engineering, credential harvesting, business email compromise, and other means designed to affect service
reliability and threaten the confidentiality, integrity and availability of information. The frequency, sophistication, and severity of
such threats continue to increase and those of our third-party service providers remain at risk.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Any such incident may compromise our system infrastructure
or lead to the loss, unavailability, destruction, alteration, prevention of access to, disclosure, or dissemination of, or damage or unauthorized
access to, our data (including trade secrets or other confidential information, intellectual property, proprietary business information,
and personal information) or data that is processed or maintained on our behalf, or other assets, which could result in financial, legal,
business and reputational harm to us. We have also received phishing attacks, and companies have, in general, experienced an increase
in phishing and social engineering attacks from third parties. The increase in remote and hybrid working arrangements further increases
security threats.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">A material cybersecurity incident or other significant disruption
affecting us or our third parties could result in the loss, unavailability, alteration, or unauthorized access to confidential, proprietary,
or personal information; liability, financial harm and reputational damage; increased costs, including incident response and remediation;
regulatory investigations and enforcement actions; and the delay in development and commercialization of our product candidates. We cannot
assure you that our data protection efforts and our investment in information technology, or the efforts or investments of CROs, CDMOs,
consultants or other third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss,
destruction, unavailability, alteration or dissemination of, or damage or unauthorized access to, our data and other data processed or
maintained on our behalf or other assets that could have a material adverse effect upon our reputation, business, operations or financial
condition.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, the growing use of artificial intelligence and
machine learning technologies, both by malicious actors seeking to circumvent security measures and by us and our service providers in
the course of business operations, introduces new and evolving cybersecurity risks. AI-powered attacks may be more difficult to detect
and may circumvent traditional security controls. Furthermore, if we or our third-party service providers use AI tools that process or
have access to our confidential information, clinical trial data, or other sensitive data, the use of such tools could create additional
vectors for data exposure if not properly secured and governed.&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;Notifications and follow-up actions related to a security
incident could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. We expect
to incur significant costs in an effort to detect and prevent security incidents, and we may face increased costs and requirements to
expend substantial resources in the event of an actual or perceived security incident. In addition, the SEC&#8217;s cybersecurity disclosure
rules require us to disclose material cybersecurity incidents and describe our cybersecurity risk management, strategy, and governance,
which may increase the costs and complexity of managing cybersecurity events and could result in reputational harm if we are required
to disclose a material incident.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;While we maintain a cybersecurity risk management program
and seek to implement and require appropriate security measures, we cannot eliminate all risk, and our insurance coverage may not be adequate
to cover all losses or liabilities.. In addition, such insurance may not be available to us in the future on economically reasonable terms,
or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending
a suit, regardless of its merit, could be costly and divert management attention.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, we have recently launched our Nugevia direct-to-consumer
nutraceutical business, which involves the collection, storage, and processing of consumer personal information, including names, shipping
addresses, email addresses, and payment card data through our e-commerce platform. A security breach affecting our e-commerce systems
or those of our third-party payment processors, fulfillment providers, or website hosting services could result in the unauthorized access
to or theft of customer payment information and personal data, exposing us to liability under the Payment Card Industry Data Security
Standard (PCI DSS), state consumer protection and data breach notification laws, and potential claims from affected consumers. Our direct-to-consumer
marketing efforts may also rely on social media platforms and third-party brand ambassadors, and any security incident affecting those
channels or relationships could harm our brand reputation and customer trust.&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees and executives may use artificial intelligence tools in ways that expose our confidential information, intellectual property,
or clinical data to third parties, and the evolving regulatory and legal landscape around artificial intelligence could adversely affect
our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees and executives may use commercially available artificial intelligence tools, including generative AI platforms, in connection
with their work. If our personnel inadvertently submit confidential information, proprietary research data, clinical trial data, or trade
secrets to external AI platforms, that information may be exposed to third parties or incorporated into publicly accessible AI outputs,
potentially compromising our intellectual property, our patent position, or our obligations under confidentiality agreements. The legal
and regulatory framework governing AI tools remains uncertain and rapidly evolving, including with respect to ownership of AI-generated
outputs and potential infringement of third-party intellectual property rights. We have not adopted a formal AI use policy, and any failure
to manage these risks appropriately could have a material adverse effect on our business, financial condition, and results of operations.</span></p>



<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our operations are vulnerable to interruption by fire,
earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm
our business.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our facilities are located in Jupiter, Florida. We have not
undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, blizzard, fire,
earthquake, power loss, terrorist activity, pandemics or other disasters and do not have a recovery plan for such disasters. In addition,
we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses
or damages incurred by us could harm our business. Also, our contract development and manufacturing organizations&#8217; (CDMOs) and suppliers&#8217;
facilities are located in multiple locations where other natural disasters or similar events which could severely disrupt our operations,
could expose us to liability and could have a material adverse effect on our business. The occurrence of any of these business disruptions
could seriously harm our operations and financial condition and increase our costs and expenses.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>A variety of risks associated with marketing our product
candidates internationally could materially adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may seek regulatory approval of our product candidates
outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries.
These risks include navigating differing regulatory requirements and reimbursement systems, as well as coping with unexpected changes
in tariffs, trade barriers, price and exchange controls, and other regulatory demands. We may also encounter economic challenges such
as inflation or political instability in certain foreign markets. Compliance with local tax, employment, immigration, and labor laws for
employees living or traveling abroad will be necessary, alongside managing foreign taxes, including payroll withholding.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Foreign currency fluctuations could increase our operating
expenses and reduce revenue, adding further complexity to our international operations. We may experience difficulties in staffing and
managing foreign operations, particularly in countries where labor unrest is more common than in the United States, leading to workforce
uncertainty. There is also the potential for liability under the Foreign Corrupt Practices Act (FCPA) or similar foreign regulations.
Enforcing our contractual and intellectual property rights may be challenging, especially in countries that do not provide the same level
of protection as the United States. Additionally, production shortages could arise from disruptions in raw material supply or manufacturing
capabilities abroad, and business interruptions could result from geopolitical actions such as war and terrorism. Collectively, these
and other risks related to international operations could materially and adversely affect our ability to achieve or maintain profitable
operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The certificate of incorporation, as amended, and amended
and restated bylaws provides that state or federal court located within the state of Delaware will be the sole and exclusive forum for
substantially all disputes between us and our stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial
forum for disputes with us or our directors, officers or other employees.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Section IX of our certificate of incorporation, as
amended, and Section 7.4 of our amended and restated bylaws provides that &#8220;unless the corporation consents in writing to the
selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the
Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the
Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii) any action asserting a claim arising pursuant to any
provision of the DGCL, or (iv) any action asserting a claim governed by the internal affairs doctrine shall be a state or federal
court located in the county in which the principal office of the corporation in the State of Delaware is established, in all cases
subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. Notwithstanding the
foregoing, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange
Act of 1934, as amended, the Securities Act of 1933, as amended, or any claim for which the federal courts have exclusive or
concurrent jurisdiction.&#8221; Therefore, the exclusive forum provision in our certificate of incorporation, as amended, and our
amended and restated bylaws will not relieve us of our duty to comply with the federal securities laws and the rules and regulations
thereunder, and stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">This exclusive forum provision may limit a stockholder&#8217;s
ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which
may discourage lawsuits against us or our directors, officers or other employees. In addition, stockholders who do bring a claim in the
state or federal court in the State of Delaware could face additional litigation costs in pursuing any such claim, particularly if they
do not reside in or near Delaware. The state or federal court of the State of Delaware may also reach different judgments or results than
would other courts, including courts where a stockholder would otherwise choose to bring the action, and such judgments or results may
be more favorable to us than to our stockholders. However, the enforceability of similar exclusive forum provisions in other companies&#8217;
certificates of incorporation have been challenged in legal proceedings, and it is possible that a court could find this type of provision
to be inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings. If a court were to
find the exclusive forum provision contained in our certificate of incorporation, as amended, and our amended and restated bylaws to be
inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>By purchasing our common stock, you are bound by the
fee-shifting provision contained in our amended and restated bylaws, which may discourage you to pursue actions against us and could discourage
stockholder lawsuits that might otherwise benefit the Company and its stockholders.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Section 7.4 of our amended and restated bylaws provides that
&#8220;if any action is brought by any party against another party, relating to or arising out of these Bylaws, or the enforcement hereof,
the prevailing party shall be entitled to recover from the other party reasonable attorneys&#8217; fees, costs and expenses incurred in
connection with the prosecution or defense of such action.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our amended and restated bylaws provide that for this section,
the term &#8220;attorneys&#8217; fees&#8221; or &#8220;attorneys&#8217; fees and costs&#8221; means the fees and expenses of counsel to
the Company and any other parties asserting a claim subject to Section 7.4 of the amended and restated bylaws, which may include printing,
photocopying, duplicating and other expenses, air freight charges, and fees billed for law clerks, paralegals and other persons not admitted
to the bar but performing services under the supervision of an attorney, and the costs and fees incurred in connection with the enforcement
or collection of any judgment obtained in any such proceeding.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We adopted the fee-shifting provision to eliminate or decrease
nuisance and frivolous litigation. We intend to apply the fee-shifting provision broadly to all actions except for claims brought under
the Exchange Act and Securities Act.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">There is no set level of recovery required to be met by a
plaintiff to avoid payment under this provision. Instead, whoever is the prevailing party is entitled to recover the reasonable attorneys&#8217;
fees, costs and expenses incurred in connection with the prosecution or defense of such action. Any party who brings an action, and the
party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited
to former and current stockholders, Company directors, officers, affiliates, legal counsel, expert witnesses and other parties, are subject
to this provision. Additionally, any party who brings an action, and the party against whom such action is brought under Section 7.4 of
our amended and restated bylaws, which could include, but is not limited to former and current stockholders, Company directors, officers,
affiliates, legal counsel, expert witnesses and other parties, would be able to recover fees under this provision.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In the event you initiate or assert a claims against us, in
accordance with the dispute resolution provisions contained in our amended and restated Bylaws, and you do not, in a judgment prevail,
you will be obligated to reimburse us for all reasonable costs and expenses incurred in connection with such claim, including, but not
limited to, reasonable attorney&#8217;s fees and expenses and costs of appeal, if any. Additionally, this provision in Section 7.4 of
our amended and restated bylaws could discourage stockholder lawsuits that might otherwise benefit the Company and its stockholders.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">THE FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED
BYLAWS IS NOT INTENDED TO BE DEEMED A WAIVER BY ANY HOLDER OF COMMON STOCK OF THE COMPANY&#8217;S COMPLIANCE WITH THE U.S. FEDERAL SECURITIES
LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER. THE FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS DO
NOT APPLY TO CLAIMS BROUGHT UNDER THE EXCHANGE ACT AND SECURITIES ACT.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our worldwide exclusive license agreement with Aquanova
for JOTROL&#8482; is critical to our business. If we were to lose the license agreement, it could disrupt our ability to commercialize
our Nugevia product line or pharmaceutical drug candidates.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We hold a worldwide license for JOTROL&#8482;, utilizing Aquanova&#8217;s
proprietary micellar technology. Aquanova jointly owns with us an international patent filed on January 29, 2017, titled &#8220;Resveratrol
Solubilization Product for Pharmaceutical Purposes&#8221; (PCT/EP2017/051659). The patent, with a priority date of June 16, 2016, and
an expiration in 2036, has been examined by the International Preliminary Examining Authority of the Patent Cooperation Treaty (PCT).
All 15 claims were deemed novel, inventive, and industrially applicable, leading to the patent&#8217;s approval in the United States,
select European Union countries, Japan, China, and Hong Kong.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The JOTROL&#8482; license agreement with Aquanova is
critical to our operations, as JOTROL&#8482; is a proprietary, enhanced resveratrol formulation that has demonstrated the potential
for significantly improved bioavailability. Termination or loss of this license agreement would significantly disrupt our ability to
commercialize our Nugevia product line or pharmaceutical drug candidates. Such a disruption could delay our development and
commercialization efforts, resulting in a material adverse effect on our business, financial condition, and operational results.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our success depends on our ability to protect our intellectual
property and our proprietary technologies.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our commercial success depends in part on our ability to obtain
and maintain patent protection and trade secret protection for JOTROL&#8482; and other product candidates, proprietary technologies and
their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our
proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies
and their uses that are important to our business. We also seek to protect our proprietary position by acquiring or in-licensing relevant
issued patents or pending applications from third parties.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Pending patent applications cannot be enforced against third
parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only
to the extent the issued claims cover the technology. There can be no assurance that our patent applications or the patent applications
of our licensor will result in additional patents being issued or that issued patents will afford sufficient protection against competitors
with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated
by third parties.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Even issued patents may later be found invalid or unenforceable
or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future
protection for our and our licensor&#8217;s proprietary rights is uncertain. Only limited protection may be available and may not adequately
protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly
protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition
and results of operations</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Obtaining and maintaining patent protection involves significant
risks and uncertainties. The USPTO and foreign patent agencies require strict compliance with procedural, documentary, fee payment, and
other provisions during the patent process, and noncompliance can lead to the abandonment or lapse of a patent or application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. There is no guarantee that patent applications will result
in issued patents. Even if granted, patents may be challenged, invalidated, modified, revoked, circumvented, or deemed unenforceable,
potentially offering no competitive advantage. Competitors, often with substantially greater resources and significant investments in
competing technologies, may seek or already hold patents that could limit, interfere with, or eliminate our ability to develop, use, and
sell our potential product candidates. Additionally, public policy pressures on the U.S. government and international bodies may push
to restrict patent protection scopes for successful disease treatments due to global health concerns. Furthermore, patent laws in countries
outside the United States may be less favorable to patentees compared to those upheld by U.S. courts, enabling foreign competitors to
more easily create, develop, and market competing products.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The patent prosecution process is also expensive and time-consuming,
and we and our licensor may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in
a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensor
will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, although we enter into non-disclosure and confidentiality
agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific
collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements
and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Given the amount of time required for the development, testing
and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates
are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If the scope of any patent protection we obtain is not
sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or
identical product candidates would be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The patent position of biopharmaceutical companies generally
is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result,
the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent
applications and those of our licensor may not result in patents being issued which protect our product candidates or which effectively
prevent others from commercializing competitive product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Moreover, the coverage claimed in a patent application can
be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we
own or in-license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection,
prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents
that we own or in-license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges
by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable
patents. Our competitors or other third parties may be able to circumvent our patents or the patents of our licensors by developing similar
or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition,
results of operations and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The issuance of a patent is not conclusive as to its inventorship,
scope, validity or enforceability, and our patents or the patents of our licensor may be challenged in the courts or patent offices in
the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved
in opposition, derivation, revocation, reexamination, post-grant review (PGR) and inter partes review (IPR), or other similar proceedings
challenging our owned patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope
of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party
patent rights. Moreover, our patents or the patents of our licensor may become subject to post-grant challenge proceedings, such as oppositions
in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and
patent applications and those of our licensor. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims
being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar
or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also
may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable
to us. In addition, if the breadth or strength of protection provided by our patents and patent applications or the patents and patent
applications of our licensor is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license,
develop or commercialize current or future product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Intellectual property rights do not necessarily address
all potential threats to our competitive advantage.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The future strength of our intellectual property protection
is uncertain, as IP rights have inherent limitations and may not fully safeguard our business or competitive position. For instance, others
may develop similar products that fall outside the scope of our patents, or we or our licensors may not have been the first to invent
or file for certain technologies. Competitors could independently develop or replicate our technologies without infringing our rights,
and some of our pending patent applications may never be granted. Additionally, research conducted by others in countries where we lack
patent protection could lead to competing products in key markets. We may also fail to develop new patentable technologies, be adversely
affected by third-party patents, or choose to rely on trade secrets that others later patent. Any of these outcomes could materially harm
our business, operations, and future prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our commercial success depends significantly on our
ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe
their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our commercial success depends in part on avoiding infringement
of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject
to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other
entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our
product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount
of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical
industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or
corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the
fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As the biopharmaceutical industry expands and more patents
are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.
Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published,
we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be
certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications
can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product
candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult
because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing
the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe
is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import
our products that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in
the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties
would be time consuming and could:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">result in costly litigation that may cause negative publicity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">divert the time and attention of our technical personnel and management;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">cause development delays;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">subject us to significant liability to third parties; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-family: Times New Roman,serif"><span style="font-size: 10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Although no third-party has asserted a claim of patent infringement
against us as of the date of this Annual Report, others may hold proprietary rights that could prevent our product candidates from being
marketed. These claims could be alleged to cover JOTROL&#8482; in certain treatment indications. While we believe that these patents are difficult
to enforce and that we would have valid defenses to these claims of patent infringement, we cannot be certain that we would prevail in
any dispute and we cannot be certain how an adverse determination would affect our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">It is possible that a third party may assert a claim of patent
infringement directed at any of our product candidates. Any patent-related legal action against us claiming damages and seeking to enjoin
commercial activities relating to our products, treatment indications, or processes could subject us to significant liability for damages,
including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our
product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial
diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license
required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future
strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access
to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates, treatment indications,
or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or
the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm
our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may
cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Parties making claims against us may be able to sustain the
costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there
is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from
the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise
have a material adverse effect on our business, results of operations, financial condition and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may in the future pursue invalidity proceedings with respect
to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal
proceedings may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities.
In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and
if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of
our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct
such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we
can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent proceedings could
compromise our ability to compete in the marketplace. If we do not prevail in the patent proceedings the third parties may assert a claim
of patent infringement directed at our product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may not be successful in obtaining or maintaining
necessary rights to our product candidates through acquisitions and in-licenses.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Many pharmaceutical companies, biotechnology companies, and
academic institutions may have patents and patent applications potentially relevant to our business. We may find it necessary or prudent
to obtain licenses to such patents from such third-party intellectual property holders, for example, in order to avoid infringing these
third-party patents. We may also require licenses from third parties for certain technologies for use with future product candidates.
We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights
from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual
property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party
intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage
over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies
that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party
intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable
to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights
we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on
our business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may be involved in lawsuits to protect or enforce
our patents or our licensor&#8217;s patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or
our licensor&#8217;s patents could be found invalid or unenforceable if challenged in court.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Competitors may infringe our intellectual property rights.
To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming.
In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable
and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third-party to
enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent or the patent of our licensor
is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, lack of sufficient written description, non-enablement, or obviousness-type double
patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent
withheld relevant information from the USPTO or made a misleading statement during prosecution.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Third parties may also raise similar invalidity claims before
the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include re-examination, PGR, IPR, derivation
proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). The outcome following legal assertions
of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that
there is no invalidating prior art, of which we, our licensor, and the patent examiners are unaware during prosecution. There is also
no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of
a claim in our patents and patent applications or the patents and patent applications of our licensor, which may, nonetheless, ultimately
be found to affect the validity or enforceability of a claim. If a third-party were to prevail on a legal assertion of invalidity or unenforceability,
we would lose at least part, and perhaps all, of the patent protection on our technology or proprietary drug delivery platform, or any
product candidates that we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial
condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, if the breadth or strength of protection provided
by our patents and patent applications or the patents and patent applications of our licensor is threatened, it could dissuade companies
from collaborating with us to license, develop or commercialize current or future product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Even if resolved in our favor, litigation or other legal proceedings
relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management
personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have
a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating
losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may
not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to
compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation or other proceedings.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, the issuance of a patent does not give us the
right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented
product and practicing our own patented technology.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Intellectual property litigation may lead to unfavorable
publicity that harms our reputation and causes the market price of our common stock to decline.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">During the course of any intellectual property litigation,
there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other
interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value
of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common
stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material
adverse effect on our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Derivation proceedings may be necessary to determine
priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights
from the prevailing party.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Derivation proceedings provoked by third parties or brought
by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications
or those of our licensor. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights
to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable
terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability
to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third
parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Changes in U.S. patent law, or laws in other countries,
could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As is the case with other pharmaceutical companies, our success
is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve
a high degree of technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time consuming
and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries
may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent
applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced
in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation
that is unfavorable to us.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">For example, the U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent
owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination
of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the
U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change
in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain
or license in the future.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may be subject to claims challenging the inventorship
or ownership of our patents and other intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may also be subject to claims that former employees or
other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against
these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even
if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and
other employees.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;<b><i>Patent terms may be inadequate to protect our
competitive position on our product candidates for an adequate amount of time.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Patents have a limited lifespan. In the United States, if
all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional
filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents
covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide
us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we do not obtain patent term extension for our product
candidates, our business may be materially harmed.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Depending upon the timing, duration and specifics of FDA marketing
approval of our product candidates, one or more of our U.S. patents or those of our licensor may be eligible for limited patent term restoration
under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch- Waxman Amendments permit
a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review
process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory
review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product
approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended.
Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However,
we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration
of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent
protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any
such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and
our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development
and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may not be able to protect our intellectual property
rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Filing, prosecuting and defending patents in all countries
throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States
can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property
rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from
practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in
and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection,
but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents,
the patents of our licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Many companies have encountered significant problems in protecting
and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement
of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or
our licensor&#8217;s patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business,
could put our patents or the patents of our licensors at risk of being invalidated or interpreted narrowly and our patent applications
or the patent applications of our licensor at risk of not issuing and could provoke third parties to assert claims against us. We may
not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly,
our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Many countries have compulsory licensing laws under which
a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against
government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially
diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business,
our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely
affected.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection depends
on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Periodic maintenance fees, renewal fees, annuity fees and
various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various
points over the lifetime of our patents and/or applications and those of our licensors. We have systems in place to remind us to pay these
fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent
offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application
process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured
by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations
in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of
patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If our trademarks and trade names are not adequately
protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We intend to use registered or unregistered trademarks for
JOTROL&#8482; and Nugevia, to brand and market ourselves and our products. Our trademarks applications for JOTROL&#8482; and Nugevia,
may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect
our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets
of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity
and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by
owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade
names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be
able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related
to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial
costs and diversion of resources and could adversely affect our financial condition or results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we are unable to protect the confidentiality of our
trade secrets, our business and competitive position would be harmed.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We rely on trade secrets, unpatented know-how, and proprietary
information to maintain our competitive edge, taking steps like entering confidentiality agreements with third parties and invention agreements
with employees, consultants, and advisors, but there is no guarantee these agreements are fully executed or will prevent breaches. Enforcing
claims against illegal disclosure or misappropriation of trade secrets is costly, time-consuming, and uncertain, especially as some courts,
both in the U.S. and abroad, may be reluctant to protect trade secrets, and third parties could independently obtain or develop similar
information, using it to compete against us without restriction. Failure to secure patent protection before disclosure or to maintain
confidentiality could diminish the value of our proprietary information, jeopardize patentability, and harm our competitive position.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our Nugevia product line may have limited intellectual property
protection, which could make it easier for competitors to replicate our products and harm our competitive position. Our Nugevia product
line operates outside the scope of our pharmaceutical license with Aquanova AG and may have different or lesser intellectual property
protections than JOTROL&#8482;. The nutraceutical and dietary supplement industry is highly competitive, with relatively low barriers
to entry. Unlike our pharmaceutical product candidate JOTROL&#8482;, which benefits from patent protection, the Nugevia product line
may rely primarily on trade secrets, trade dress, and trademarks for intellectual property protection. These forms of intellectual property
are generally more difficult to enforce than patents and may not provide the same level of exclusivity or protection against competitors.
Competitors may be able to develop and market substantially similar products without infringing our intellectual property rights. As
a result, we may be unable to prevent competitors from eroding our market share in the nutraceutical space, which could have a material
adverse effect on our business, financial condition, and results of operations related to the Nugevia product line.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may be subject to claims that we or our employees
have wrongfully used or disclosed alleged confidential information or trade secrets.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We enter into non-disclosure and confidentiality agreements
with third parties, such as scientific collaborators, CROs, manufacturers, consultants, and potential partners, to protect proprietary
information, but we may face litigation if a third party claims we or our employees breached these agreements by misusing or disclosing
their trade secrets. Defending such claims, regardless of merit, could incur significant legal costs, divert employee resources, cause
negative publicity, and potentially halt commercialization of our product candidates. Even if successful, litigation could be costly,
distract management, and risk compromising our confidential information during discovery, while larger adversaries with greater resources
may sustain complex intellectual property litigation more effectively. Such disputes could lead to substantial damages, delay development
efforts, and hinder our ability to raise funds, materially impacting our business, financial condition, and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may be subject to claims that we have wrongfully
hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or
trade secrets of their former employers.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As is common in the pharmaceutical industry, in addition to
our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants,
and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services
to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees
or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers
or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims,
in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our
business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction
to our management team and other employees.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our rights to develop and commercialize our technology
and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have entered into a license agreement with Aquanova pursuant
to which we have acquired the exclusive right to certain patents and patent applications in micellar technologies that revolutionizes
the bioavailability profile of resveratrol to treat certain rare diseases and Alzheimer&#8217;s disease by eliminating the severe gastro-intestinal
side effects experienced at effective dose levels of resveratrol. We may enter into additional license agreements in the future with others
to advance our research or allow commercialization of product candidates. These and other licenses may not provide exclusive rights to
use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or
commercialize our technology and products in the future.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, subject to the terms of any such license agreements,
we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent
applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and
patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests
of our business. If our licensor fails to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent
applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products
that are subject of such licensed rights could be adversely affected.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our licensor may have relied on third-party consultants or
collaborators or on funds from third parties such that our licensor are not the sole and exclusive owners of the patents we in-licensed.
If other third parties have ownership rights to our in-licensed patents, they may be able to license such patents to our competitors,
and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">It is possible that we may be unable to obtain additional
licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby
giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and
resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology,
all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize
the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly.
We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing
methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales,
or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties,
which could be significant.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we fail to comply with our obligations in the agreements
under which we license intellectual property rights from Aquanova or otherwise experience disruptions to our business relationships with
our licensors, we could lose license rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Disputes with our licensor. Aquanova, or potential licensors,
particularly regarding our complex licensing agreement with Aquanova, may arise over issues such as the scope of rights granted, potential
infringement of the licensor&#8217;s intellectual property not covered by the agreement, our ability to sublicense or assign rights, our
diligence obligations, or the inventorship, ownership, and priority of inventions created jointly with licensors or partners. These disagreements
could lead to interpretations that narrow our rights to intellectual property or increase our financial and operational obligations, significantly
impacting our business, financial condition, and prospects. If licensors conclude we have breached these agreements, they may terminate
them, stripping us of the ability to develop and commercialize affected products. Termination or failure of underlying patents to provide
intended exclusivity could allow competitors to market identical products, severely harming our competitive position, business, and operational
outcomes.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The patent protection and patent prosecution for some
of our product candidates may be dependent on third parties.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">While we normally seek to obtain the right to control prosecution,
maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities
for patents relating to our product candidates are controlled by our licensor, potential licensors or collaboration partners. If any of
our licensor, potential licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications
in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product
candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop
and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using
and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications
we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees,
our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Intellectual property discovered through government
funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference
for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S.
manufacturers.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We have patent applications, in addition to the in-licensed
patent from Aquanova, that were generated through the use of U.S. government funding or grants, and may acquire or license in the future
intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole
Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include
a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S.
government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive
licenses to any of these inventions to a third-party if it determines that: (1) adequate steps have not been taken to commercialize the
invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements
for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). If the U.S. government exercised its march-in
rights in our future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be
forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be
no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has
the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file
an application to register the intellectual property within specified time limits. Intellectual property generated under a government
funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.
In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these
inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that
provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been
made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States
or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability
to contract with non-U.S. product manufacturers for products covered by such intellectual property.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to Our Dependence on Third Parties</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We rely, and expect to continue to rely, on third parties
to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion
of such trials, research and studies, which may harm our business.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We rely on third parties, such as CROs, clinical data management
organizations, medical institutions, and clinical investigators, to conduct our clinical trials for JOTROL&#8482; and other product candidates,
as we lack the ability to independently manage these trials. These third parties, who are not our employees, play a significant role in
trial execution and data analysis, but we have limited control over their resource allocation, and they may prioritize other entities,
including competitors, or terminate engagements, potentially delaying our drug development. Despite reduced control, we remain responsible
for ensuring trials comply with GCP standards enforced by the FDA and EMA, and failure to meet these or cGMP requirements for trial products
could render data unreliable, necessitating additional trials and delaying marketing approvals. Performance failures by these third parties
or distributors, who handle drug storage and distribution for our Company, could further hinder clinical development, approval, or commercialization,
leading to losses and reduced revenue potential.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We contract with Aquanova and Catalent for the production
of JOTROL&#8482; for our ongoing clinical trial and other product candidates, and expect to continue to do so for additional clinical
trials and ultimately for commercialization. This reliance on Aquanova and Catalent increases the risk that we will not have sufficient
quality and quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development
or commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We lack the internal infrastructure to manufacture our product
candidates for development and commercialization, relying entirely on Aquanova and Catalent to manufacture our preclinical and clinical
trial supplies of JOTROL&#8482;. Currently, we depend on these companies as our only third-party manufacturer while evaluating possible
other suppliers, but switching manufacturers could delay our supply chain, impacting JOTROL&#8482;&#8217;s development and increasing
costs. Without long-term supply agreements, we purchase drug products on a purchase order basis, leaving us vulnerable to suppliers ceasing
or altering terms at any time. An unexpected loss of supply due to manufacturing, storage, or other issues could disrupt, delay, or terminate
ongoing clinical trials, requiring us to restart or repeat studies.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our reliance on third-party manufacturers for commercial supply,
if our product candidates gain marketing approval, introduces risks such as failure to meet our schedule or specifications, prioritization
of other products by contractors, termination of agreements at inconvenient times, or breaches of contract. Additional risks include non-compliance
with current Good Manufacturing Practices (cGMPs), mislabeling of clinical supplies, delayed delivery to trial sites or commercial vendors,
and misappropriation of our proprietary information, including trade secrets. These issues could lead to clinical trial interruptions,
lost sales, or compromised intellectual property, significantly affecting our operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We are developing our supply chain by establishing framework
agreements with CDMOs to secure necessary quantities of active pharmaceutical ingredients and drug products. However, we may fail to establish
these agreements or ensure redundant supply to mitigate disruptions. Our CDMOs&#8217; compliance with cGMP regulations and other regulatory
requirements is critical, as their failure to meet FDA, EMA, or similar standards could prevent or revoke manufacturing approvals, forcing
us to seek alternative facilities. Such transitions would require new regulatory inspections, delaying development, approval, or market
entry of our product candidates.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Non-compliance by us or our manufacturers with regulations
could result in sanctions like fines, injunctions, civil penalties, approval withdrawals, license revocations, product seizures, or criminal
prosecutions, all of which could severely impact our product supply and business. Our dependence on third-party manufacturers may reduce
future profit margins and hinder our ability to commercialize approved product candidates in a timely and competitive manner.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We rely on Catalent Pharmaceutical Services, Inc. as our
sole manufacturer for JOTROL&#8482; clinical trial supplies, and any disruption to this relationship could significantly delay our clinical
development programs. We currently rely on Catalent Pharmaceutical Services, Inc. as our sole contract manufacturer for JOTROL&#8482;
clinical trial supplies. We do not have a backup manufacturer for JOTROL&#8482;, and establishing relationships with alternative manufacturers
would require significant time and resources, including the need to transfer manufacturing technology and obtain regulatory approval
for any new manufacturing facility. If Catalent is unable or unwilling to continue manufacturing JOTROL&#8482; for any reason, including
due to capacity constraints, regulatory compliance issues, natural disasters, business disruptions, financial difficulties, or a change
in Catalent&#8217;s business priorities, we may be unable to obtain sufficient quantities of JOTROL&#8482; to conduct our clinical trials
on schedule or at all. Any delay or inability to obtain clinical trial supplies could significantly delay our clinical development programs,
increase our costs, and have a material adverse effect on our business, financial condition, and prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We rely on third parties, including a network of collaborators
and brand ambassadors, an advertising agency, and social media content creators to help promote and accelerate sales of our recently launched
Nugevia product line, and our business could be adversely affected if these third parties fail to comply with applicable FDA (and other)
regulatory requirements or are ineffective in their ability to help promote the Nugevia products to customers.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We depend in part on collaborators, social media content creators,
two celebrity brand ambassadors, and other third parties to help drive traffic to our website and the sale of our products. As a result,
our ability to maintain and increase commercial interest in our Nugevia products is not entirely within our control, and it is possible
that these third parties may fail to successfully or meaningfully help drive sales of our products. Further, a failure by these third
parties to comply with FDA, FTC, or other applicable regulatory requirements, such as requirements regarding the promotion, marketing
and sale of our products, could result in regulatory enforcement action by FDA (or other governmental authorities) or other adverse events,
which could interrupt the marketing and sales of our products, severely damage our brand reputation and public image, increase the cost
of our products, result in product recalls, market withdrawals or litigation and impede our ability to deliver our products, any of which
could result in a material adverse effect on our business, financial condition and results of operations. &#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may rely on third-party manufacturers and distributors
for our Nugevia product line, and any failure by these third parties to perform could adversely affect our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">To the extent we rely on third-party manufacturers or distributors
for the production and distribution of our Nugevia products, our business could be adversely affected if these third parties fail to meet
their contractual obligations, experience manufacturing delays or disruptions, fail to comply with applicable regulatory requirements,
or otherwise fail to perform satisfactorily. Any such failures could result in product shortages, delays in product delivery, quality
control issues, or regulatory enforcement actions, any of which could harm our reputation, reduce sales of our Nugevia products, and have
a material adverse effect on our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our reliance on third parties may require us to
share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated
or disclosed.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;Because we currently rely on third parties in the course
of our business, we may share our proprietary technology and confidential information, including trade secrets, with them. We seek to
protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements,
collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants
prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to
use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to
share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are
intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given
that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets,
a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would
impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and
prospects.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities,
and subject us to other risks.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We may periodically explore acquisition opportunities and
strategic partnerships, such as licensing or acquiring complementary products, intellectual property, technologies, or businesses. These
endeavors carry significant risks, including increased operating expenses and cash needs, assumption of additional debt or liabilities,
and the issuance of equity securities. Integrating acquired operations, intellectual property, or personnel may pose challenges, diverting
management&#8217;s focus from existing programs. Retaining key employees, maintaining critical business relationships, and uncertainties
about the other party&#8217;s prospects, products, or regulatory approvals present further risks. Additionally, we may fail to generate
sufficient revenue from acquired technologies or products to achieve our objectives or offset acquisition and maintenance costs. In addition,
if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations,
incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we decide to establish collaborations, but are not
able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our drug development programs and potential commercialization
of product candidates require significant additional funding, which may lead us to pursue collaborations to enhance capabilities, accelerate
research, or out-license rights for certain indications. These relationships could involve non-recurring charges, increased expenditures,
issuance of dilutive securities, or management disruptions. We face intense competition in securing collaborators, and the complex, time-consuming
negotiation process depends on factors like the collaborator&#8217;s resources, expertise, and evaluation of clinical trial results, regulatory
approval likelihood, market potential, manufacturing complexities, competing drugs, intellectual property uncertainties, and general market
conditions. Alternative candidates or technologies may be deemed more attractive, and our early-stage candidates may not be viewed as
viable for collaboration, potentially limiting our ability to form partnerships.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If we cannot secure collaborations on acceptable terms or
at all, we may need to curtail development, delay programs, reduce marketing efforts, or fund activities independently, requiring additional
capital that may not be available. Recent consolidations among large pharmaceutical companies have reduced potential collaborators, and
even successful collaborations may impose restrictions on future agreements. Failure to secure sufficient funds or partnerships could
hinder our ability to develop or commercialize product candidates, impacting our ability to generate revenue.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may enter into collaborations with third parties
for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize
on the market potential of these product candidates.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Collaborations with third parties for the development or commercialization
of our product candidates involve limited control over the resources and efforts our collaborators dedicate, posing risks such as inadequate
performance, deprioritization, or termination of programs due to clinical trial outcomes, strategic shifts, acquisitions, or competing
priorities. Collaborators may delay trials, underfund programs, abandon candidates, or develop competing products, potentially undermining
our candidates&#8217; success. Exclusive rights granted to collaborators could restrict our ability to partner with others, and their
failure to properly manage our intellectual property may invite litigation or jeopardize proprietary information. Disputes, termination
of agreements, or non-compliance with laws by collaborators could delay development, necessitate additional capital, or lead to costly
legal proceedings, while their control over shared intellectual property may limit our exclusivity. Additionally, reliance on a network
of expert advisors for our development efforts carries the risk that these experts may cease collaboration, hindering our ability to address
muscle disease needs and develop our proprietary delivery platform.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Even if we are able to commercialize our product candidates,
the products may not receive coverage and adequate reimbursement from third-party payers, which could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our ability to commercialize any products successfully will
depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available
from government authorities, private health insurers, health maintenance organizations and third-party payers. Patients who are prescribed
medications for the treatment of their conditions generally rely on third-party payers to reimburse all or part of the costs associated
with their prescription drugs. Coverage and adequate reimbursement from government health care programs, such as Medicare and Medicaid,
and private insurers are essential to new product acceptance of any approved product. In the event we obtain marketing approval, patients
are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of
the cost of our product candidates. A key trend in the United States healthcare industry and elsewhere is cost containment. Government
authorities and other third-party payers have attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if
reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price
of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only
at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. There
may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than
the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, obtaining coverage does
not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
sales and distribution. Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover our costs, and may
only be temporary.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Risks Related to Ownership of Our Securities</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The Company&#8217;s failure to meet the continued listing
requirements of The Nasdaq Capital Market could result in a delisting of its securities.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our common stock is currently listed for trading on The Nasdaq
Stock Market LLC (&#8220;Nasdaq&#8221;). On March 21, 2025, the Company received a written notice from the Listing Qualifications Department
of Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule
5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;), as the closing bid price of the Company&#8217;s common stock was below $1.00
per share for 30 consecutive business days.. Listing Rule 5550(a)(2) requires the registrant to maintain a minimum bid price of $1.00
USD per share for its securities listed on the NASDAQ, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid
price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the
Company&#8217;s shares for the 30 consecutive business days prior to that notice (February 6, 2025 through March 20, 2025), the Company
did not meet the Minimum Bid Price Requirement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Subsequently, on February 26, 2026, the Company received additional
written notices (the &#8220;Notices&#8221;) from Nasdaq indicating that the Company is not in compliance with (i) the Minimum Bid Price
Requirement and (ii) the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550(b)(2) (the &#8220;MVLS
Requirement&#8221;). Based on the closing bid price of the Company&#8217;s common stock for the 30 consecutive business days prior to
the Notices (January 13, 2026 through February 25, 2026), the Company did not meet the Minimum Bid Price Requirement. In addition, based
on Nasdaq&#8217;s review of the Company&#8217;s market value of listed securities for the 30 consecutive business days ended February
26, 2026, the Company did not meet the MVLS Requirement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Pursuant to Nasdaq Listing Rules 5810(c)(3)(A) and 5810(c)(3)(C),
the Company has 180 calendar days, or until August 25, 2026, to regain compliance with both the Minimum Bid Price Requirement and the
MVLS Requirement. To regain compliance with the Minimum Bid Price Requirement, the Company&#8217;s common stock must have a closing bid
price of at least $1.00 per share for a minimum of 10 consecutive business days (or such longer period, up to 20 consecutive business
days, as Nasdaq may require). To regain compliance with the MVLS Requirement, the Company&#8217;s market value of listed securities must
be at least $35 million for a minimum of 10 consecutive business days.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If the Company does not regain compliance with the Minimum
Bid Price Requirement by August 25, 2026, the Company may be eligible for an additional 180-day compliance period, provided that it meets
all other initial listing standards for The Nasdaq Capital Market, other than the Minimum Bid Price Requirement, and provides written
notice of its intention to cure the deficiency, including, if necessary, by effecting a reverse stock split. If the Company does not regain
compliance with the MVLS Requirement within the applicable compliance period, Nasdaq will provide notice that the Company&#8217;s common
stock is subject to delisting. In such event, the Company may appeal the delisting determination to a hearings panel.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The receipt of the Notices has no immediate effect on the
listing of the Company&#8217;s common stock, and the common stock will continue to trade on Nasdaq under the symbol &#8220;JUNS&#8221;
during the applicable compliance periods. The Company intends to actively monitor its compliance with Nasdaq continued listing requirements
and may consider available options to regain compliance, including, without limitation, effecting a reverse stock split. However, there
can be no assurance that the Company will be successful in regaining or maintaining compliance with the Nasdaq continued listing requirements.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If Nasdaq delists the Company&#8217;s common stock,
the Company&#8217;s liquidity and market price could be affected.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our common stock is currently listed on Nasdaq. If we do not
regain compliance, our common stock may begin trading on an over-the-counter market, such as the OTCQB or the OTC Pink. Trading on such
markets is characterized by lower trading volumes, fewer market makers and greater price volatility compared to trading on a national
securities exchange. As a result, a delisting could reduce the liquidity of our common stock, result in decreased institutional investor
interest and may impair a stockholder&#8217;s ability to sell or purchase shares of our common stock. In addition, delisting could impair
our ability to raise additional capital.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The price of our common stock could be subject to rapid
and substantial volatility.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">There have been instances of extreme stock price run-ups followed
by rapid price declines and strong stock price volatility with recent initial public offerings, especially among those with relatively
smaller public floats. As a relatively small-capitalization company with relatively small public float, we may experience greater stock
price volatility, extreme price run-ups, lower trading volume and less liquidity than large-capitalization companies. In particular, the
common stock may be subject to rapid and substantial price volatility, low volumes of trades and large spreads in bid and ask prices.
Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance and financial condition
or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, if the trading volumes of our common stock are
low, persons buying or selling in relatively small quantities may easily influence prices of our common stock. This low volume of trades
could also cause the price of our common stock to fluctuate greatly, with large percentage changes in price occurring in any trading day
session. Holders of our common stock may also not be able to readily liquidate their investment or may be forced to sell at depressed
prices due to low volume trading. Broad market fluctuations and general economic and political conditions may also adversely affect the
market price of our common stock. As a result of this volatility, investors may experience losses on their investment in our common stock.
A decline in the market price of our common stock also could adversely affect our ability to sell additional shares or common stock or
other securities and our ability to obtain additional financing in the future. No assurance can be given that an active market in our
common stock will develop or be sustained. If an active market does not develop, holders of our common stock may be unable to readily
sell the common stock they hold or may not be able to sell their common stock at all.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>A &#8220;short squeeze&#8221; due to a sudden increase
in demand for shares of our common stock could lead to extreme price volatility in shares of our common stock</i>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Investors may purchase shares of our common stock to hedge
existing exposure or to speculate on the price of our common stock. Speculation of the price of our common stock may lead to long and
short exposures. To the extent aggregate short exposure exceeds the number of shares of our common stock available for purchase on the
open market, investors with short exposure may have to pay a premium to repurchase shares of our common stock for delivery to lenders
of our common stock. Those repurchases may in turn, dramatically increase the price of our common stock until additional shares of our
common stock are available for trading or borrowing. This is often referred to as a &#8220;short squeeze.&#8221; A proportion of our
common stock has been, and may continue to be, traded by short sellers which may increase the likelihood that our common stock will be
the target of a short squeeze. A short squeeze could lead to volatile price movements in shares of our common stock that are unrelated
or disproportionate to our operating performance and, once investors purchase the shares of our common stock necessary to cover their
short positions, the price of our common stock may rapidly decline. Investors that purchase shares of our common stock during a short
squeeze may lose a significant portion of their investment.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>The market price of our common stock may be volatile,
and you could lose all or part of your investment.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The market price of our common stock may fluctuate significantly
due to factors often beyond our control and unrelated to our operating performance, including the timing and results of preclinical studies
and clinical trials for our product candidates or those of competitors, the success or announcements of competitive products, regulatory
actions, changes in our growth rate compared to competitors, developments or disputes over patents or proprietary rights, key personnel
changes, significant acquisitions or collaborations, changes in financial estimates or analyst recommendations, market conditions in the
pharmaceutical and biotechnology sectors, changes in healthcare payment systems, additional financing efforts, sales of our stock by insiders
or other stockholders, and general economic, political, industry, and market conditions. The limited public float of our stock may increase
price volatility, and the stock market, particularly for pharmaceutical and biotechnology companies, has historically experienced extreme
price and volume fluctuations, which could lead to substantial losses for investors. Any of these risks could materially and adversely
affect our stock price.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If securities or industry analysts do not publish research
or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and
trading volume could decline.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The trading market for our common stock will be influenced
by the research and reports that securities or industry analysts publish about us, our business or our market. We do not currently have
and may never obtain research coverage by securities or industry analysts. If no or few securities or industry analysts commence coverage
of us, the stock price would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts
who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance
or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or
more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets,
which in turn could cause our stock price or trading volume to decline.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our operating results may fluctuate significantly, which
makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our operating results may fluctuate significantly due to factors
such as variable upfront and milestone payments from license or collaboration agreements, changes in stock-based compensation expenses
driven by stock price volatility, and costs related to research and development, clinical trial enrollment, and manufacturing. Additional
factors include expenditures for acquiring new technologies, outcomes and timing of clinical trials for JOTROL&#8482; or other product
candidates, competition, regulatory delays, demand variability, reimbursement policies, and our ability to commercialize products or maintain
partnerships. Global economic and political volatility, unforeseen disruptions, and accounting changes may further contribute to fluctuations.
These factors make our future operating results unpredictable, rendering period-to-period comparisons unreliable and potentially causing
our results or guidance to fall below analyst or investor expectations, which could lead to a substantial decline in our stock price,
even if we meet previously stated guidance</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our principal stockholders and management own a significant
percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As of December 31, 2025, our executive officers, directors,
holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 59% of our common stock. These
stockholders, acting together, may be able to control matters requiring stockholder approval. For example, they may be able to control
elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate
transactions. This concentration of ownership control may delay, discourage or prevent a change of control, including unsolicited acquisition
proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders, entrench our management
and board of directors or delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders
may desire. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders
and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium
value for their common stock, and might affect the prevailing market price for our common stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Our common stock may be subject to the &#8220;penny
stock&#8221; rules in the future. It may be more difficult to resell securities classified as &#8220;penny stock.&#8221;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our common stock may be subject to &#8220;penny stock&#8221;
rules (generally defined as non-exchange traded stock with a per-share price below $5.00) in the future. While our common stock is not
currently considered &#8220;penny stock&#8221; since it is listed on the Nasdaq, if we are unable to maintain that listing and our common
stock is no longer listed on the Nasdaq, unless we maintain a per-share price above $5.00, our common stock will become &#8220;penny stock.&#8221;
These rules impose additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons
other than those who qualify as &#8220;established customers&#8221; or &#8220;accredited investors.&#8221; For example, broker-dealers
must determine the appropriateness for non-qualifying persons of investments in penny stocks. Broker-dealers must also provide, prior
to a transaction in a penny stock not otherwise exempt from the rules, a standardized risk disclosure document that provides information
about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer
quotations for the penny stock, disclose the compensation of the broker-dealer and its salesperson in the transaction, furnish monthly
account statements showing the market value of each penny stock held in the customer&#8217;s account, provide a special written determination
that the penny stock is a suitable investment for the purchaser, and receive the purchaser&#8217;s written agreement to the transaction.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Legal remedies available to an investor in &#8220;penny stocks&#8221;
include the ability to seek cancellation of the purchase and a refund of the investment if the stock was sold in violation of federal
or state securities laws, such as the requirements outlined above. Additionally, if the &#8220;penny stock&#8221; was sold through fraudulent
means, the investor may have the right to pursue legal action against the individuals or firms responsible for the fraud, seeking damages
for any losses incurred. These requirements may have the effect of reducing the level of trading activity, if any, in the secondary market
for a security that becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements
may discourage broker-dealers from effecting transactions in our securities, which could severely limit the market price and liquidity
of our securities. These requirements may restrict the ability of broker-dealers to sell our common stock and may affect your ability
to resell our common stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Many brokerage firms will discourage or refrain from recommending
investments in penny stocks. Most institutional investors will not invest in penny stocks. In addition, many individual investors will
not invest in penny stocks due, among other reasons, to the increased financial risk generally associated with these investments. For
these reasons, penny stocks may have a limited market and, consequently, limited liquidity. We can give no assurance at what time, if
ever, our common stock will not be classified as a &#8220;penny stock&#8221; in the future.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If the benefits of any proposed acquisition do not meet
the expectations of investors, stockholders or financial analysts, the market price of our Common Stock may decline.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">If the benefits of any proposed acquisition do not meet the
expectations of investors or securities analysts, the market price of our common stock prior to the closing of the proposed acquisition
may decline. The market values of our common stock at the time of the proposed acquisition may vary significantly from their prices on
the date the acquisition target was identified.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">In addition, broad market and industry factors may materially
harm the market price of our common stock irrespective of our operating performance. The stock market in general has experienced price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected.
The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence in the
market for retail stocks or the stocks of other companies which investors perceive to be similar to us could depress our stock price regardless
of our business, prospects, financial conditions or results of operations. A decline in the market price of our securities also could
adversely affect our ability to issue additional securities and our ability to obtain additional financing in the future.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Changes in accounting principles and guidance, or their
interpretation, could result in unfavorable accounting charges or effects, including changes to our previously filed financial statements,
which could cause our stock price to decline.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We prepare our financial statements in accordance with GAAP.
These principles are subject to interpretation by the SEC and various bodies formed to interpret and create appropriate accounting principles
and guidance. A change in these principles or guidance, or in their interpretations, may have a significant effect on our reported results
and retroactively affect previously reported results.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>As an &#8220;emerging growth company&#8221; under the
JOBS Act, we are permitted to rely on exemptions from certain disclosure requirements.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As an &#8220;emerging growth company&#8221; under the JOBS
Act, we are permitted to rely on exemptions from certain disclosure requirements, which we intend to utilize. For as long as we maintain
this status, we are not required to obtain an auditor&#8217;s report on our internal control over financial reporting pursuant to Section
404(b) of the Sarbanes-Oxley Act. Additionally, we are exempt from complying with any Public Company Accounting Oversight Board requirements
regarding mandatory audit firm rotation or providing a supplement to the auditors&#8217; report with additional information about the
audit and financial statements, such as an auditor discussion and analysis. Furthermore, we are not obligated to submit certain executive
compensation matters to stockholder advisory votes, including &#8220;say-on-pay&#8221; and &#8220;say-on-frequency&#8221; votes, nor are
we required to disclose specific executive compensation details, such as the correlation between executive compensation and company performance
or comparisons of the chief executive officer&#8217;s compensation to the median employee compensation.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As an emerging growth company under the JOBS Act, we have
elected to use the extended transition period for adopting new or revised accounting standards, delaying compliance until required for
private companies. This may make our financial statements less comparable to those of companies adhering to these standards. We will remain
an emerging growth company until the earliest of: (i) annual gross revenue reaching $1.235 billion; (ii) the market value of our non-affiliate-held
common stock reaching $700.0 million as of the last business day of our most recently completed second fiscal quarter; (iii) issuing over
$1.0 billion in non-convertible debt in the prior three years; or (iv) the fifth anniversary of our initial public offering. Relying on
these exemptions may reduce the attractiveness of our securities, potentially leading to a less active trading market and increased price
volatility.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>If we are unable to maintain effective internal control
over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and have an adverse
effect on the value of our securities.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As a public company, we are required to maintain internal
control over financial reporting and to report any material weaknesses in such internal control. Further, we are required to report any
changes in internal controls on a quarterly basis. In addition, we are required to furnish a report by management on the effectiveness
of internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. We will design, implement, and test the
internal controls over financial reporting required to comply with these obligations. If we identify material weaknesses in our internal
control over financial reporting, if we are unable to comply with the requirements of Section 404 in a timely manner or assert that our
internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an
opinion as to the effectiveness of its internal control over financial reporting when required, investors may lose confidence in the accuracy
and completeness of our financial reports and the value of our securities could be negatively affected. We also could become subject to
investigations by the Commission or other regulatory authorities, which could require additional financial and management resources</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>As an emerging growth company, our auditor will not
be required to attest to the effectiveness of our internal controls.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our independent registered public accounting firm will not
be required to attest to the effectiveness of our internal control over financial reporting while we are an emerging growth company. This
means that the effectiveness of our financial operations may differ from our peer companies in that they may be required to obtain independent
registered public accounting firm attestations as to the effectiveness of their internal controls over financial reporting and we are
not. While our management will be required to attest to internal control over financial reporting and we will be required to detail changes
to our internal controls on a quarterly basis, we cannot provide assurance that the independent registered public accounting firm&#8217;s
review process in assessing the effectiveness of our internal controls over financial reporting, if obtained, would not find one or more
material weaknesses or significant deficiencies. Further, once we cease to be an emerging growth company and cease to be a smaller reporting
company (as described below), we will be subject to independent registered public accounting firm attestation regarding the effectiveness
of our internal controls over financial reporting. Even if management finds such controls to be effective, our independent registered
public accounting firm may decline to attest to the effectiveness of such internal controls and issue a qualified report.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We believe we will be considered a smaller reporting
company and will be exempt from certain disclosure requirements, which could make our Common Stock less attractive to potential investors.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">We qualify as a &#8220;smaller reporting company&#8221; under
Rule 12b-2 of the Exchange Act, defined as an issuer (not an investment company, asset-backed issuer, or majority-owned subsidiary of
a non-smaller reporting company parent) with either: a public float of less than $250 million as of the last business day of its most
recently completed second fiscal quarter, or, for initial registration statements, a public float of less than $250 million within 30
days of filing, or annual revenues of less than $100 million with a public float of zero or less than $700 million for the most recent
fiscal year with audited financial statements. As a smaller reporting company, we benefit from scaled disclosure requirements, including
no Compensation Discussion and Analysis in proxy statements, providing only two years of financial statements, and omitting the selected
financial data table. These reduced disclosures may make our common stock less attractive to investors, potentially impacting our stockholders&#8217;
ability to sell shares.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We incur significant increased costs as a result of
operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">As a public company, we incur significant legal, accounting,
and compliance costs, particularly under the Sarbanes-Oxley Act, which requires effective disclosure and financial controls. These obligations
demand substantial management time and increase our legal and financial expenses, including challenges in obtaining directors&#8217; and
officers&#8217; liability insurance, potentially hindering our ability to attract qualified board members. Compliance with Section 404
of the Sarbanes-Oxley Act requires evaluating and testing our internal controls over financial reporting, and, after our emerging growth
company or smaller reporting company status ends, obtaining an auditor&#8217;s attestation. This necessitates additional accounting staff
and resources. Failure to comply with Section 404, or identification of material weaknesses in our controls, could lead to SEC sanctions,
investigations, or a decline in our securities&#8217; value. Delays or disruptions in implementing enhanced systems and controls may impair
our ability to prepare accurate financial statements, potentially affecting our internal control effectiveness, auditor reports, and access
to capital markets.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Shares eligible for future sale may adversely affect
the market.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">From time to time, certain of our stockholders may be eligible
to sell all or some of their shares of common stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144
promulgated under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, non-affiliate stockholders may
sell freely after six months, subject only to the current public information requirement. Affiliates may sell after six months, subject
to the Rule 144 volume, manner of sale (for equity securities), current public information, and notice requirements. Of the approximately
34,446,455 shares of our common stock and 1,626,037 restricted stock units outstanding as of December 31, 2025, 6,350,000 shares are tradable
without restrictions. Given the limited trading of our common stock, resale of even a small number of shares of our common stock pursuant
to Rule 144 or an effective registration statement may adversely affect the market price of our common stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Anti-takeover provisions contained in our certificate
of incorporation, as amended, and amended and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our Certificate of Incorporation and amended bylaws include
provisions that could delay or prevent changes in control or management without board approval, such as prohibiting cumulative voting
in director elections, limiting minority stockholders&#8217; ability to elect candidates, and granting the board exclusive authority to
fill director vacancies, preventing stockholder appointments. The board can issue preferred stock with terms set without stockholder approval,
potentially diluting hostile acquirers, and directors are protected by limited liability and indemnification provisions. Only the board&#8217;s
majority can call special stockholder meetings, and removing directors requires a two-thirds stockholder vote. Advance notice requirements
for nominating directors or proposing matters at meetings may deter potential acquirers from pursuing control. These provisions could
delay hostile takeovers or management changes, potentially limiting opportunities for stockholders to receive a premium for their securities
and affecting the price investors are willing to pay.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We may be subject to securities litigation, which is
expensive and could divert management attention.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">The market price of our common stock may be volatile and,
in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action
litigation. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility
in recent years and we may be the target of this type of litigation in the future. Securities litigation against us could result in substantial
costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We have never paid dividends on our common stock and
have no plans to do so in the future.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Holders of shares of our common stock are entitled to receive
such dividends as may be declared by our board of directors. To date, we have paid no cash dividends on our shares of common stock and
we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, to
provide funds for operations of our business. Therefore, any return investors in our common stock may have will be in the form of appreciation,
if any, in the market value of their shares of common stock. See &#8220;Dividend Policy.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>We will indemnify and hold harmless our officers and
directors to the maximum extent permitted by Delaware law.</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Our certificate of incorporation provides that we will indemnify
and hold harmless our officers and directors against claims arising from our activities, to the maximum extent permitted by Delaware law.
If we were called upon to perform under our indemnification obligations, then the portion of our assets expended for such purpose would
reduce the amount otherwise available for our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_04"></span>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_05"></span>ITEM 1C. CYBERSECURITY</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_98A_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-JVFZB_zHb4gwyt2kYg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000051-01" escape="true" id="Fact000051" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><b>Cybersecurity Risk Management and Strategy</b></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<div id="xdx_C08_gBFCRMPFAIAMT-JVFZB_zJi0iBtHx4Cd"><ix:continuation continuedAt="ConU000051-02" id="ConU000051-01"><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The cybersecurity risk management program,
processes and strategy described in this section are limited to the personal and business information belonging to or maintained by the
Company (collectively, &#8220;Confidential Information&#8221;), our own <span id="xdx_90A_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zrbfYFno3HD2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000052" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">third-party</ix:nonNumeric></span> critical systems and services supporting or used by
the Company (collectively, &#8220;Critical Systems&#8221;), and service providers.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We will develop and implement a cybersecurity
risk management program intended to protect the confidentiality, integrity, and availability of our Confidential Information and Critical
Systems. <span id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_z2TWOGcqSxAe" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Our cybersecurity risk management program will be <span id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zHurfh1n0cN9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrated</ix:nonNumeric></span> into our overall enterprise risk management program and includes
a cybersecurity incident response plan.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cybersecurity risk management program
shall include:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">risk assessments designed to help identify material cybersecurity risks to our Confidential Information, Critical Systems and the broader enterprise information technology environment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">cybersecurity awareness and spear-phishing resistance training of our employees, and senior management;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">a vendor management policy for service providers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250101__20251231_zqtrQTGFAkOl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000055" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">We have <span id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zOjkOTyYRyxd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000056" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">no</ix:nonNumeric></span>t identified risks from known
cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely
to materially affect us, including our operations, business strategy, results of operations, or financial condition.</ix:nonNumeric></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><span id="xdx_C09_gBFCRMPFAIAMT-JVFZB_znhPxRqcYWN1"><ix:continuation id="ConU000051-02">&#160;</ix:continuation></span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_980_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250101__20251231_gBFCRBODOTB-TVDHY_z4QEU3vU2Qo6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000060-01" escape="true" id="Fact000060" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><b>Cybersecurity Governance</b></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_90B_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zSK2sVTZ78y5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000061" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">Our<span id="xdx_90F_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zGfmqmLvkr9i" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000062" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"> executive management team, along with
our managed information technology service provider</ix:nonNumeric></span>, is responsible for assessing and managing risks from cybersecurity threats to the
Company, including our Confidential Information and Critical Systems</ix:nonNumeric></span>. The team has primary responsibility for our overall cybersecurity
risk management program. Our management team works closely with our information technology service provider.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C0F_gBFCRBODOTB-TVDHY_zPfMq8urmOvg"><ix:continuation continuedAt="ConU000060-02" id="ConU000060-01">&#160;</ix:continuation></span></p>

<div id="xdx_C0A_gBFCRBODOTB-TVDHY_ziC0neLAP1kb"><ix:continuation continuedAt="ConU000060-03" id="ConU000060-02"><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management team meets with our information
technology service provider periodically to discuss then-current cybersecurity issues, which may include efforts to prevent, detect, mitigate,
and remediate cybersecurity risks and incidents through various means, including threat intelligence and other information obtained from
governmental, public or private sources, and external service providers engaged by us; and alerts and reports produced by security tools
deployed in the information technology environment including a spear-phishing report.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zemqe6ytrWa3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000063" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our Board considers cybersecurity risk
as part of its risk oversight function and oversight of cybersecurity and other information technology risks</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board oversees management&#8217;s
implementation of our cybersecurity risk management program. Our executive management team is responsible for updating the Board, as necessary,
regarding significant cybersecurity incidents.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board also receives periodic reports
from management on our cybersecurity risks and cybersecurity risk management program.</p>

</ix:continuation></div><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C0D_gBFCRBODOTB-TVDHY_zouNQRn9Hwfe"><ix:continuation id="ConU000060-03">&#160;</ix:continuation></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_06"></span>ITEM 2. PROPERTIES</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters are located
at 1001 North US Hwy 1, Suite 504, Jupiter, Florida 33477, where we lease approximately 1,206 rentable square feet of office space. This
lease expires on May 31, 2026. Terms of the office lease provide for a base rent payment of $4,258 per month and a share of the building&#8217;s
operating expenses, such as taxes and maintenance, of $600 per month. In September 2021, we added an additional office located at 127
Main Street, Boston, Massachusetts 02129 for 120 rentable square feet of office space for our Boston-based employees and scientist to
utilize as necessary.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that these facilities are adequate
for our current and near-term future needs.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_07"></span>ITEM 3. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 22.05pt; background-color: white">From time to
time, we are involved in various legal proceedings arising from the normal course of business activities. We are not presently a party
to any litigation the outcome of which, we believe, if determined adversely to us, would individually or taken together have a material
adverse effect on our business, operating results, cash flows or financial condition. Defending such proceedings is costly and can impose
a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty,
and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources, and other factors.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 22.05pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_08"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b><span id="m_09"></span>PART II</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_10"></span>ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Market Information</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on The Nasdaq
Capital Market and its stock symbol is &#8220;JUNS.&#8221; The closing price of our common stock on The Nasdaq Capital Market on March 30, 2026 was $0.3248.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Holders</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 31, 2026, there were 36,281,252 shares of common stock issued and outstanding, and we had approximately 29 holders of record of our common stock. The number of record
holders does not include beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Dividends</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not declared or paid any cash
dividends on our common stock since our inception, and do not currently anticipate paying cash dividends in the foreseeable future. We
intend to retain future earnings, if any, for reinvestment in the development and expansion of our business.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Securities Authorized for Issuance Under Equity Compensation
Plans</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s stockholders approved
the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) on January 4, 2016. Under the 2016 Plan, as modified, 8,437,500 shares of common
stock are authorized for issuance to employees, officers, directors, consultants. The 2016 Plan authorizes the grant of nonqualified stock
options and incentive stock options, restricted stock awards, restricted stock units, stock appreciation rights, under the 2016 Plan.
The Company does not intend to make any grants under the 2016 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors and stockholders
of the Company approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) on September 17, 2021. Under the 2021 Plan, 1,125,000
shares of common stock are authorized for issuance to employees, directors and independent contractors (except those performing services
in connection with the offer or sale of the Company&#8217;s securities in a capital raising transaction, or promoting or maintaining a
market for the Company&#8217;s securities. The 2021 Plan authorizes equity-based and cash-based incentives for participants. On July 22,
2022, the Board of Directors increased the shares authorized in the 2021 Plan, increasing the plan to 1,710,000. The Company does not
intend to make any grants under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors and stockholders
of the Company approved the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;) on October 4, 2023. Under the 2023 Plan, 4,012,785
shares of common stock are authorized for issuance to employees, directors and independent contractors (except those performing services
in connection with the offer or sale of the Company&#8217;s securities in a capital raising transaction, or promoting or maintaining a
market for the Company&#8217;s securities) of the Company or its subsidiaries. As of March 31, 2026, there were 1,047,135 shares available
for issuance under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors and stockholders
of the Company approved the 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;) on December 19, 2025. Under the 2025 Plan, 5,250,000
shares of common stock are authorized for issuance to employees, directors and independent contractors (except those performing services
in connection with the offer or sale of the Company&#8217;s securities in a capital raising transaction, or promoting or maintaining a
market for the Company&#8217;s securities) of the Company or its subsidiaries. As of March 31, 2026, there were 5,250,000 shares available
for issuance under the 2025 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Recent Sales of Unregistered Securities</i></b>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Type</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Type of Award</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Quantity</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Price</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 19%; font-family: Times New Roman,serif"><span style="font-size: 10pt">A service provider</span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 14%; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">April 23, 2025</span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 8%; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 25%; font-family: Times New Roman,serif"><span style="font-size: 10pt">Common Stock</span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 10%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">78,186</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="width: 10%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">0.64</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">A service provider</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">April 23, 2025</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Common Stock</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">25,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">0.64</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The above issuances/sales were made pursuant
to an exemption from registration as set forth in Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under
the Securities Act.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Purchases of Equity Securities by the Issuer and Affiliated
Purchasers</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Transfer Agent</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s transfer agent is
Equiniti Trust Company. The transfer agent&#8217;s address is 1110 Centre Pointe Curve, Suite 101, Mendota Heights, Minnesota 55120, and
its telephone number is (800) 401-1957.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_11"></span>ITEM 6. [RESERVED]</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_12"></span>ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Special Note Regarding Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>All statements other than statements
of historical fact included in this Annual Report on Form 10-K, including, without limitation, statements under &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; regarding the Company&#8217;s financial position, business
strategy and the plans and objectives of management for future operations, are forward-looking statements. When used in this Annual Report
on Form 10-K, words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;
and similar expressions, as they relate to us or the Company&#8217;s management, identify forward-looking statements. Such forward-looking
statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company&#8217;s
management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors
detailed in our filings with the SEC.</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto
contained elsewhere in this Annual Report on Form 10-K. Certain information contained in the discussion and analysis set forth below includes
forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires, &#8220;JNS,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221; refers to Jupiter Neurosciences, Inc.</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Business Overview</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 60pt">Jupiter Neurosciences, Inc. is a
clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is advancing a therapeutic
pipeline targeting CNS disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product
line. Both efforts are powered by JOTROL&#8482;, Jupiter&#8217;s proprietary, enhanced resveratrol formulation that has demonstrated
potential for improved bioavailability compared to standard resveratrol. The Company&#8217;s therapeutic development pipeline is
focused broadly on CNS disorders, presently with a planned Phase IIa clinical study in Parkinson&#8217;s disease. The
Company&#8217;s Nugevia product line brings clinical-grade science to the supplement space, supporting mental clarity,
healthy-looking skin, and longevity.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company completed preclinical
studies at the University of Miami for Parkinson&#8217;s Disease in 2021. These studies used a validated mouse model to mimic human disease
characteristics. The promising results have led the Company to initiate a Phase IIa clinical trial for Parkinson&#8217;s Disease, which
received final IND approval by the FDA in November of 2025 and is expected to start in the second quarter of 2026, with results anticipated
12 months later. The Company also aims to investigate other CNS indications, such as MCI and
Alzheimer&#8217;s disease, following the Parkinson&#8217;s study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
believes, based on pre-clinical and clinical studies, that high doses of resveratrol are necessary for potential therapeutic effects.
Currently available resveratrol products cannot reach these levels without causing severe gastrointestinal side effects. Human studies
evaluating resveratrol in Alzheimer&#8217;s patients (Turner et al 2015) and Friedreich&#8217;s Ataxia patients (Yu et al 2015) indicate
the concentration of resveratrol at its peak (CMax) measured in blood plasma should be 300 ng/ml or higher for a potential therapeutic
effect. A Phase 1 study with 500mg of resveratrol as a maximum dose in the JOTROL&#8482; formulation showed levels of resveratrol exceeding
800 ng/ml without generating any severe adverse events (AAPS Open 2022). Resveratrol was shown in the Turner Alzheimer&#8217;s study to
cross the blood-brain barrier, possibly indicating a potential for positive effects on oxidative stress and inflammation. Subsequent analysis
published in Molecular Science 2025 (Mousa et al) further indicates that resveratrol may have an impact on neurodegeneration and neuroinflammation
in Alzheimer&#8217;s patients.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Over the past two years, JOTROL&#8482;
has garnered significant interest from Asian organizations. This interest is partly due to resveratrol&#8217;s use in Asian herbal medicines,
recent patent approvals in Hong Kong and China, and China&#8217;s list of rare disease indications where JOTROL&#8482; could be applicable.
Additionally, recent publications in the Journal of Alzheimer&#8217;s Disease and AAPS Open, along with the projected growth of the Traditional
Chinese Medicine market, have contributed to this interest.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has entered service agreements
with firms in Hong Kong to accelerate product development in Southeast Asia. These agreements aim to leverage local expertise and networks
to facilitate market entry and potential out-licensing deals. The Company entered into an agreement with Dominant Treasure Health to expand
its business development in China, Malaysia, and Singapore, aiming to penetrate the large and challenging Asian market.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">During 2025, the Company launched Nugevia,
a premium line of longevity and performance supplements to support longevity, mental clarity and skin vitality. The Nugevia brand
targets the growing consumer demand for science-backed wellness solutions, leveraging Jupiter&#8217;s proprietary JOTROL&#8482; technology&#8212;a
resveratrol-based platform with an improvement in bioavailability profile of resveratrol.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Nugevia&#8217;s initial product line features
three core formulations, each targeting a major aspect of wellness and longevity:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 24%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Product Name</b></span></td>
    <td style="width: 2%; padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 24%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Focus Area</b></span></td>
    <td style="width: 2%; padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 48%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Target Consumer Benefit</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">GLO</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Skin beauty</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Support skin beauty and healthy appearance</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">MND</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Cognitive performance</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Supports mental clarity, cognitive
    resilience</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">PWR</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Mitochondrial and physical health</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Maintains energy, endurance, muscle recovery</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Nugevia&#8217;s formulations are
built on Jupiter&#8217;s patented JOTROL&#8482; micellar delivery platform, which has shown potential for significantly enhanced
bioavailability and serves as the foundation for the company&#8217;s clinical-stage CNS therapies. The debut products&#8212;GLO,
MND, and PWR&#8212;are formulated to support wellness and longevity through synergistic ingredient combinations, all optimized for
absorption via the JOTROL&#8482; system.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 24, 2025, the Company
entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) and related Registration Rights Agreement with YA II PN,
Ltd. (&#8220;Yorkville&#8221;), providing the Company the right, but not the obligation, to sell up to $20.0&#160;million of common
stock from time to time, subject to customary conditions, including an effective resale registration statement. In connection with
the SEPA, Yorkville agreed to provide up to $6.0&#160;million of pre-paid advances via convertible promissory notes. On October 27,
2025, the Company received $3,720,000&#160;and issued a $4.0&#160;million note (7% original issue discount, &#8220;OID&#8221;). A
second $1,860,000&#160;tranche was received in December 2025, upon registration effectiveness and receipt of stockholder approval,
against a $2.0&#160;million note (7% OID). The notes bear interest at&#160;8% (increasing to&#160;18% upon default), mature
on&#160;October 24, 2026, and are convertible at $1.50&#160;per share, subject to proportional anti-dilution and price-protection
adjustments (not below a contractual floor).&#160;Beginning January 7, 2026, and monthly thereafter, the Company must repay
one-tenth (1/10) of the then-outstanding principal plus accrued interest (a 5% premium applies to cash
repayments).&#160;Installments may be satisfied via SEPA advances without the premium, and SEPA proceeds must be applied first to
repay the notes until they are repaid in full. On February 20, 2026, the Company and Yorkville entered into an Omnibus Amendment
(the &#8220;Amendment&#8221;). Among other changes, the Amendment revises the terms of the convertible promissory notes to defer the
commencement of monthly installment payments to April 1, 2026, effectively providing an extension of approximately three months.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2024, we received gross proceeds
of $11 million in a registered public offering (&#8220;Public Offering&#8221;) of 2,750,000 shares of our common stock at a price of $4.00 per share for gross proceeds of $11 million before deducting underwriting discounts
and other related expenses. In connection with the Public Offering, the Company&#8217;s common stock was registered under Section 12(b)
of the Exchange Act and began trading on The Nasdaq Capital Market under the symbol &#8220;JUNS.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Financial Position</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">For the fiscal years ended December 31,
2025 and 2024, we generated net revenues of $21,796 and $0, respectively from product sales and reported net losses of $8,644,897 and
$2,439,625, respectively, and negative cash flow from operating activities of $5,413,736 and $3,911,004, respectively. As noted in our
financial statements, as of December 31, 2025 and 2024, we had an accumulated deficit of $34,667,026 and $26,022,129, respectively. There
is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative
cash flows from operations as well as our dependence on private equity and financings. See &#8220;Risk Factors&#8212;We have a history
of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern
and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the
fiscal years ended December 31, 2025 and 2024.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Year Ended December 31, 2025 Compared to Year Ended
December 31, 2024</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Revenue</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">There was net revenue of $21,796
during the year ended December 31, 2025. Net revenue consisted of product sales from the Company&#8217;s Nugevia consumer product
line, which launched in the second half 2025. Gross sales were $24,874, offset by discounts of $1,777 and returns of
$1,301. Cost of goods sold through commercial products was $4,231, resulting in gross profit of $17,565. There was no revenue from
product sales during the years ended December 31, 2024 as Nugevia was launched in 2025.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development (&#8220;R&amp;D&#8221;)
expenses were $2,086,574 for the year ended December 31, 2025, compared to $492,660 for the year ended December 31, 2024. The increase
is driven primarily by $810,019 in consulting and professional fees, $438,425 in payroll and stock-based compensation, and $345,470 in
clinical trial supplies and miscellaneous costs as the Company prepared for initiation of its Phase IIa Parkinson&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">R&amp;D expenses related to the development
of JOTROL&#8482;, which is the platform product used in each indication defined in our product pipeline.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative expenses were
$6,839,712 for the year ended December 31, 2025 compared to $2,598,622
for the year ended December 31, 2024, an increase of $4,241,090 or approximately 163%. The increase is primarily related to the increase
in employee salaries of approximately $1,730,902, consulting and professional services of approximately $908,363, investor relations of
approximately $472,923, and other general and administrative costs of $1,108,902.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Interest Expense</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest expenses were $66,020 for the
year ended December 31, 2025, compared to $248,366 for the year ended December 31, 2024, decrease of $182,346, or approximately 73%. During
2024, interest expense included $147,705 related to the combined convertible Notes I, II, and III, and $15,013 related to the amortization
of debt discounts. In 2025, interest expense is primarily attributable to accrued interest on the SEPA and interest expense on our corporate
credit card and the note payable to our Chief Executive Officer, Christer Ros&#233;n, which was repaid during 2025.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Gain on Change in Fair Value of Convertible Notes</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The 2025 convertible promissory notes issued in connection with the SEPA were marked to market, and the change in fair value of the convertible
notes was recorded as a gain of $281,932 in the year ended December 31, 2025.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Loss on Change in Fair Value of Derivative Liability</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and at each quarter
end during the year, the variable conversion options embedded in our convertible notes were marked to market, and the change in fair value
of the derivative was recorded as a loss of $53,257. These notes were fully paid off in the year
ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Gain on Extinguishment of Debt</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended 2024, the Senior
Secured Convertible Note was amended several times with materially different economics and subsequently paid off, thus requiring for the
recording of debt as an extinguishment and re-recording the debt with the amended terms. This resulted in a gain on extinguishment
of debt in the year ended December 31, 2024 of $857,723.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Liquidity and Capital Resources;
Plan of Operations</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, we had cash and
cash equivalents of $3,789,342. Our cash equivalents are held in high yield savings account. Since inception, we have incurred net losses
and negative cash flows from operations. On December 31, 2025, we had an accumulated deficit of $34,667,026.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, we have financed our
operations primarily by selling common stock and convertible debt. On October 24, 2025, the Company entered into a Standby Equity
Purchase Agreement (&#8220;SEPA&#8221;) and related Registration Rights Agreement with YA II PN, Ltd. (&#8220;Yorkville&#8221;),
providing the Company the right, but not the obligation, to sell up to $20.0&#160;million of common stock from time to time, subject
to customary conditions, including an effective resale registration statement. In connection with the SEPA, Yorkville agreed to
provide $6.0&#160;million of pre-paid advances via convertible promissory notes. During the year ended December 31, 2025, the
company received aggregate proceeds of $5,100,000, which is net of $420,000 of issuance discounts and $480,000 of financing costs
associated with the transaction. During the year ended December 31, 2025, the Company received aggregate proceeds of $22,251 from
sales of common stock under the SEPA which were used to pay interest on the convertible promissory notes.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 2, 2024, the Company priced
its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share. The offering closed on December 4, 2024,
and the Company started trading on the Nasdaq Capital Market under the ticker symbol &#8220;JUNS&#8221;. The Company sold 2,750,000 shares
of its Common Stock to the underwriters and yielded proceeds of $9,725,213, net of underwriters and other fees of $1,274,787.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">For the fiscal years ended December 31,
2025 and 2024, we generated net revenues of $21,796 and $0, respectively from product sales and reported net losses of $8,644,897 and
$2,439,625, respectively, and negative cash flow from operating activities of $5,413,736 and $3,911,004, respectively. As noted in our
financial statements, as of December 31, 2025 and 2024, we had an accumulated deficit of $34,667,026 and $26,022,129, respectively. There
is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative
cash flows from operations as well as our dependence on private equity and financings. See &#8220;Risk Factors&#8212;We have a history
of operating losses, our management has concluded that factors raise substantial doubt about our ability to continue as a going concern
and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the
fiscal years ended December 31, 2025 and 2024.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our failure to raise capital as and when
needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we
will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the scope, rate of progress and costs of our drug delivery, preclinical development activities, laboratory testing and clinical trials for our drug candidate;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the number and scope of clinical programs we decide to pursue;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the scope and costs of manufacturing development and commercial manufacturing activities;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the extent to which we acquire or in-license other drug candidate and technologies;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the cost, timing and outcome of regulatory review of our drug candidate;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the cost and timing of establishing sales and marketing capabilities, if our drug candidate receives marketing approval;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our drug candidate;</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the costs associated with being a public company; and</span></td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="vertical-align: top; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">the cost associated with commercializing our drug candidate, if it receives marketing approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">If we raise additional funds by issuing
equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional
covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase
our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing
or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional
funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may
also be required to sell or license to other parties rights to develop or commercialize our drug candidate that we would prefer to retain.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">See &#8220;Risk Factors&#8221; for additional
risks associated with our capital requirements.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Cash Flows for the Years Ended December 31, 2025 and
2024</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table shows a summary of
our cash flows for the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Years Ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(5,413,736</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(3,911,004</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5,433,568</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">7,652,036</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net increase (decrease) in cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">19,832</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,741,032</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cash - beginning of the period</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,769,510</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28,478</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Cash - end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,789,342</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,769,510</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Net Cash Used in Operating Activities:</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash used in operating activities
was $5,413,736 for the year ended December 31, 2025, compared to $3,911,004 for the year ended December 31, 2024, representing an increase
in cash used of $1,502,732, primarily driven by a higher net loss of $8,644,897 in 2025 compared to $2,439,625 in 2024. This increase was partially
offset by higher non-cash addbacks, including an increase of $577,608 in stock-based compensation (from $1,840,908 to $2,418,516), an
increase of $712,054 in amortization of prepaid contracts (from $54,612 to $766,666), and $222,521 of stock-based payments related to
financing activities associated with the SEPA and the convertible promissory notes, partially offset by a $281,932 gain on the change
in fair value of convertible notes in 2025 with no comparable activity in 2024. These impacts were further offset by the absence of prior
year non-cash items, including an $857,723 gain on extinguishment of debt, a $53,257 loss on change in fair value of derivative liability,
and $43,288 of amortization of debt discounts, along with working capital changes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Net Cash Used in Investing Activities:</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">No net cash was provided by or used in
investing activities during the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Net Cash Provided by Financing Activities:</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities was $5,433,568 for the year ended December 31, 2025, compared to $7,652,036 for the year ended December 31, 2024, representing
a decrease of $2,218,468, primarily due to the absence of $9,725,213 in IPO proceeds, net of costs, in 2025 compared to 2024. This decrease
was partially offset by $5,580,000 in proceeds from the issuance of convertible promissory notes, net of costs, issued in connection with
the SEPA in 2025, a $2,102,797 reduction in repayments of notes payable, and lower related party note repayments of $37,552, partially
offset by a $150,000 decrease in proceeds from the sale of common stock and a $138,500 decrease in related party note proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Off-balance sheet financing arrangements</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have no obligations, assets or liabilities
which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated
entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose
of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any
special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Asian Business Development Activities</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company initiated business development
activities in the Asian region beginning in October of 2021. The Company has a strong strategic interest in accelerating the drug development
and potential commercialization efforts of JOTROL&#8482; in this market. Our Chairman &amp; CEO, Christer Ros&#233;n, presented in person,
our company&#8217;s status and pipeline at the BIOHK 2023 in Hong Kong in September of 2023. The presentation led to several follow-on
meetings, and we have recently agreed to service agreements in the areas of business development, CMC (Chemistry, Manufacturing, and Controls),
regulatory affairs and clinical trial management. These agreements are further described in the section &#8220;Other Material Agreements&#8221;.
The Asian market is very large and hard to penetrate for a small company and we believe that our strategy with these agreements is cost
effective and have the possibility to accelerate an out-licensing deal in the Southeast Asian territories. However, there are no assurances
that this approach will be successful.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The agreements executed are very similar
in nature that include an equity investment in our company by the other party and in turn the company issued equity in form of shares
of common stock, in lieu of cash, for 3 years of services from each company.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company believes these agreements
to be favorable for both parties based on the cash position of the company and the need for these activities to be executed and enabling
the possibility of a one or more out-licensing agreements in the territory.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Contractual obligations</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have any long-term capital lease
obligations, operating lease obligations or long-term liabilities, except as follows:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 30, 2021, the Company executed
a lease agreement for office space in Jupiter, Florida. The term of the lease is sixty-one months commencing May 1, 2021 rent free until
June 1, 2021. Fixed annual rent amounts are as follows:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Lease Period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Annual Fixed Rent</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%">6/1/2021-5/31/2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">45,396</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>6/1/2022-5/31/2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">46,758</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>6/1/2023-5/31/2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,158</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>6/1/2024-5/31/2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,608</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>6/ l/2025-5/31/2026</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">51,096</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b><i>Standby Equity Purchase Agreement
and Convertible Promissory Notes</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;On October
24, 2025, we entered into the SEPA with Yorkville. Pursuant to the SEPA, we have the right, but not the obligation, to issue and sell
to Yorkville, from time to time, up to $20.0 million of shares of our Common Stock (the &#8220;SEPA Shares&#8221;), subject to certain
limitations and conditions set forth in the SEPA.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the SEPA, we
may request, and Yorkville may, in its sole discretion, elect to provide, one or more prepaid advances (each, a &#8220;Prepaid Advance&#8221;
and collectively, the &#8220;Prepaid Advances&#8221;), pursuant to which Yorkville would advance funds to us and we would issue to Yorkville
a promissory note evidencing such Prepaid Advance. We requested, and Yorkville funded, two Prepaid Advances in an aggregate amount of
$6.0 million as described below. Each Prepaid Advance is expected to be repaid through the issuance of SEPA Shares at a price per share
determined in accordance with the terms of the SEPA, which is generally based on a discount to the prevailing market price of our common
stock during a specified pricing period, unless earlier repaid in cash at our option, subject to the terms of the SEPA. Accordingly, the
number of SEPA Shares issuable upon settlement of any Prepaid Advance will depend on the market price of our Common Stock at the time
of such settlement and cannot be determined at the time such Prepaid Advance is made or thereafter until settlement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As consideration for Yorkville&#8217;s
commitment to purchase common stock at the Company&#8217;s direction pursuant the SEPA, the Company (i) paid to Yorkville a cash &#8220;structuring
fee&#8221; in the amount of $25,000 and (ii) upon execution of the SEPA, issued to Yorkville 131,909 Commitment Shares, which have a total
aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#8217;s $20.0 million aggregate purchase commitment under the SEPA (each
Commitment Share valued at approximately $1.5162 per share, representing the VWAP on October 23, 2025, the trading day immediately prior
to the date of execution of the SEPA, rounded to the nearest whole share).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the SEPA, and subject
to the conditions set forth therein, Yorkville provided us with a Prepaid Advance of $6.0 million, funded in two tranches, in exchange
for our issuance of convertible promissory notes (each, a &#8220;Convertible Note&#8221; and collectively, the &#8220;2025 Convertible
Notes&#8221; or &#8220;2025 Notes&#8221;). On October 27, 2025, we received the first tranche of the Prepaid Advance in the amount of
$3,720,000 and issued to Yorkville a Convertible Note in the principal amount of $4.0 million (the &#8220;First Convertible Note&#8221;),
which was issued with an original issue discount of 7.0%. The First Convertible Note is initially convertible into shares of our Common
Stock at a fixed conversion price of $1.50 per share.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Subsequently, upon satisfaction of the
applicable conditions, on December 23, 2025 we received the second tranche of the Prepaid Advance in the amount of $1,860,000 and issued
to Yorkville a Convertible Note in the principal amount of $2.0 million (the &#8220;Second Convertible Note&#8221;), which was issued
with an original issue discount of 7.0% and is initially convertible into shares of our common stock at a fixed conversion price of $1.50
per share.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest accrues on the outstanding balance
of each Convertible Note at a rate of 8% per annum, subject to an increase to 18% upon the occurrence of certain events of default, and
each Convertible Note matures on October 24, 2026.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We and Yorkville also entered into a registration
rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to file with the U.S. Securities and Exchange
Commission (the &#8220;SEC&#8221;) a registration statement registering the resale by Yorkville of the SEPA Shares, including SEPA Shares
issuable upon settlement of the Prepaid Advances. On November 26, 2025, we filed a registration statement on Form S-1 (File No. 333-291832)
with the SEC (the &#8220;Registration Statement&#8221;) for the resale by Yorkville of 10,000,000 SEPA Shares, which was declared effective
by the SEC on December 11, 2025.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this Annual Report,
we have issued and sold approximately 1.1 million SEPA Shares to Yorkville pursuant to the SEPA, including SEPA Shares issued in connection
with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds to us of approximately
$625,748. We may continue to issue SEPA Shares to Yorkville pursuant to the SEPA, including in connection with any outstanding
or future Prepaid Advances or conversions of Convertible Notes, subject to the terms and conditions of the SEPA.</p>

<p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;</p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Senior Secured Note</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On April
11, 2022, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an accredited
investor for the sale of the Company&#8217;s convertible notes. Pursuant to the terms of the Purchase Agreement, on April 11, 2022,
the Company received aggregate gross proceeds of $1,000,000 and issued (i) a 10% Original Issue Discount Senior Secured Convertible
Note in the principal amount of $1,111,111.11 (the &#8220;Note&#8221; or &#8220;Note II&#8221;) and (ii) 514,403 shares of common stock, par value $0.0001
per share (the &#8220;Shares&#8221;), of the Company.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>The Note</i></b>.
The aggregate principal amount of the Note is $1,111,111, and the Company received gross proceeds of $1,000,000 after giving effect to
the original issue discount of 10%. The Note bore interest at a rate of 10% per year, payable monthly in arrears, and mature 12 months
from issuance.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 29, 2024, the Company, the Holder
of the Note II and the CEO entered into an amendment in which the CEO agreed to exchange 685,867 shares issued to the Holder in exchange
for his related party notes that accrued interest at 3% that are due from the Company in an aggregate principal amount of $266,667 and
the Holder agreed to forfeit all rights to all additional future shares from the Company that would of become due upon a qualified offering
as well as the conversion option. Therefore, the principal amount of the note was increased to $1,377,778 and the exchange debt follows
the requirements of Note II. In addition, the Holder agreed to extend the note maturity date to August 11, 2024. The note shall be designated
as a 10% original issue discount secured note (&#8220;Senior Secured Note&#8221;) moving forward. The Senior Secured Note and interest
will become due and payable upon the earliest of the maturity date or upon the occurrence of a qualified event. The note is recorded on
the balance sheet under note payable. As a result of the conversion feature of the note being removed the Company recorded a one-time
gain on the modification of the debt of $951,868 and a new derivative liability of $407,494 was recorded related to the Senior Secured
Note.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 8, 2024, the Company, and the
Holder of the Senior Secured Note entered into an amendment to extend the maturity date of the Senior Secured Note to October 11, 2024.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 15, 2024, the Company, and
the Holder of the Senior Secured Note entered into an amendment to extend the maturity date of the Senior Secured Note to December 10,
2024. During December 2024, the Company fully repaid the Senior Secured Note pursuant to the terms in the amount of $2,102,797. On April
29, 2024, the Company, the Holder of the Note II and the CEO entered into an amendment in which the CEO agrees to exchange 685,867 shares
issued to the Holder in exchange for his related party notes that accrued interest at 3% that are due from the Company in an aggregate
principal amount of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company that would of
become due upon a qualified offering as well as the conversion option. Therefore, the principal amount of the note was increased to $1,377,778
and the exchange debt follows the requirements of Note II. In addition, the Holder agreed to extend the note maturity date to August 11,
2024. The note shall be designated as a 10% original issue discount secured note (&#8220;Senior Secured Note&#8221;) moving forward. The
Senior Secured Note and interest will become due and payable upon the earliest of the maturity date or upon the occurrence of a qualified
event. The note is recorded on the balance sheet under note payable. As a result of the conversion feature of the note being removed the
Company recorded a one-time gain on the modification of the debt of $951,868 and a new derivative liability of $407,494 was recorded related
to the Senior Secured Note.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">During December 2024, the Company fully
repaid the Senior Secured Note pursuant to the terms in the amount of $2,102,797.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>The Shares</i></b>. In
connection with the issuance of Note II, the Company issued 514,403 shares of common stock to the holder with a fair market value of
$2.16 per share (aggregate value of $1,111,111) as additional consideration for the holder lending $1,000,000 to the Company. The
514,403 shares have a relatively fair value of $310,000.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement related to the
Note was amended to provide that upon closing, the purchaser will receive 133.33% coverage (i.e. the face amount of the Note, i.e., $1,111,111.11
divided by the lesser of (i) the price/share of the last issuance of solely common stock (including options) of the Company, i.e., $5.00/share
or (ii) the price per share of common stock (or if units are issued in the Qualified Offering, the price of units sold in the Qualified
Offering), in shares of common stock of the Company (or if units are issued in the Qualified Offering, units). The number of shares to
be received at closing shall be determined by using clause (i) above.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In light of the foregoing, the holder
shall receive an additional number of shares of common stock, such that it shall have received the number of shares of common stock of
the aggregate value of $1,111,111 divided by the lesser of (i) the price/share of the last issuance of solely common stock (including
options) of the Company, i.e., $5.00/share or (ii) the price per share of common stock (or if units are issued in the Qualified Offering,
the price of units sold in the Qualified Offering), in shares of common stock of the Company (or if units are issued in the Qualified
Offering, units) (&#8220;Share True Up&#8221;). The Share True Up was forfeited as a result of the April 29, 2024 agreement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Ancillary
Agreements</i></b>. In connection with the Company&#8217;s obligations under the Note, the Company entered into a security agreement and
intellectual property security agreement with the holder, pursuant to which the Company granted a security interest on all assets of the
Company, including all intellectual property of the Company, for the benefit of the holders, to secure the Company&#8217;s obligations
under the Note and the other transaction documents. In addition, the holder was granted piggyback registration rights for the shares of
common stock issued under the Purchase Agreement and shares of common stock issuable upon conversion of the Note (collectively, &#8220;Registrable
Securities&#8221;). At any time while there are any Registrable Securities of holder outstanding, if the Company proposes to register
any of its securities either for its own account or for the account of other security holders (other than a registration statement relating
solely to employee benefit plans on Form S-8 or a Commission Rule 145 transaction on Form S-4), the holder is entitled to include its
Registrable Securities in the registration. Notwithstanding, the Company and underwriters in an underwritten registration may exclude
some or all of the Registrable Securities from the underwritten registration if the underwriters believe that including the Registrable
Securities would adversely affect the underwritten offering.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">At any time within
the 12 months closing, upon any issuance by the Company or any of its subsidiaries of debt or common stock or common stock equivalents
for cash consideration, indebtedness or a combination of units thereof, other than in an underwritten public offering (a &#8220;Subsequent
Financing&#8221;), the investor will have the right to participate up to its investment amount in the Note, but not more than 25% of the
Subsequent Financing, on the same terms, conditions and price provided for in the Subsequent Financing.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Until the Company has consummated a Qualified
Offering which results in a listing of the common stock onto a national securities exchange, if the Company engages in any future financing
transactions with a third-party investor, if the holder determines that the terms of the subsequent investment are preferable in any respect
to the terms of the securities of the Company issued to the Holder pursuant to the terms of the Purchase Agreement, the holder will have
the right to amend and restate such securities to include the preferable term or terms.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Notes Payable, related party</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company&#8217;s Chief Executive Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to
the CEO as of December 31, 2024 was $146,432. The loan was due on demand and accrues interest at 3% per year. Accrued interest
relating to the loan was $1,064 as of December 31, 2024, and is included in accrued interest on the accompanying 2024 balance
sheets. The Company fully settled the debt in 2025 by repaying a total of $150,782, $146,432 in principal and $4,350 in accrued
interest. The Company repaid a total of $100,000 during the year ended December 31, 2024, $83,880 in principal and $16,120 in
accrued interest.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On April
29, 2024, the Company, the Holder of the Note II and the CEO entered into an amendment in which the CEO agreed to exchange 685,869
shares issued to the Holder in exchange for his related party notes that accrued interest at 3% that are due from the Company in an
aggregate principal amount of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company
that would have become due upon a qualified offering and the conversion feature of the note. In addition, the Holder agreed to
extend the note maturity date to August 11, 2024. The note shall be designated as a 10% original issue discount secured note
(&#8220;Senior Secured Note&#8221;) moving forward. The note and interest will become due and payable upon the earliest of the
maturity date or upon the occurrence of a qualified event.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Other Related Party Transactions</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Accrued compensation includes partially
accrued salaries to executives since inception. Since inception, executive salaries have been paid in cash when the Company&#8217;s cash
flow has permitted such payment.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 15, 2024, a former executive
agreed to forgive $100,000 of accrued compensation in exchange for 49,605 options to purchase common stock and 7,500 restricted stock
units, The options to purchase common stock have a strike price of $1.33. The option had a grant date fair value of $50,000. The Company
recorded a gain on the forgiveness of accrued compensation in the amount of $40,000.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and 2024, $64,105
was due to a Company wholly owned by the Company&#8217;s Chief Financial Officer, who also is an option holder, respectively. The amount
is included in accrued compensation on the Company&#8217;s balance sheets.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Share Issuances</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 3, 2024, the Company issued 1,162,500
shares of common stock to each of Optimize Wellness Limited, Regis Healthcare Group Limited, and Longevity Technology Group Limited (collectively,
&#8220;Asian Partners&#8221;) with a fair market value of $1.33 per share (3,487,500 shares in aggregate, with an aggregate fair market
value of $4,638,375), as pre-payment for 3 years of services.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 3, 2024, the Company sold 112,500
shares of common stock to the Asian Partners for $1.33 per share, with each Selling Stockholder purchasing 37,500 shares of common stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 2, 2024, the Company priced
its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share. The offering closed on December 4, 2024,
and the Company started trading on the Nasdaq Capital Market under the ticker symbol &#8220;JUNS&#8221;. The Company sold 2,750,000 shares
of its Common Stock to the underwriters and yielded proceeds of $9,725,213, net of underwriters and other fees of $1,274,787.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon the closing of the offering on December
4, 2024, the outstanding principle and all unpaid accrued interest, totaling $109,216, of the Notes I converted into an aggregate of 227,447
share of common stock of the Company at $2.80, which is 70% of the offering price of $4.00.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 23, 2025, the Company issued
103,186 shares of common stock, with an aggregate fair value of $66,000, as consideration for services rendered related to media and investor
relations activities, strategic communications support, enhancement to the Company&#8217;s market visibility and shareholder engagement.
The fair value of the shares issued was determined based on the market price of the Company&#8217;s common stock at the date of issuance
and is included general and administrative expenses in the accompanying 2024 condensed consolidated statement of operations.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective June 22, 2025, the Company entered
into an amendment with a warrant holder for a warrant to purchase&#160;109,376&#160;shares of Common Stock. The amendment extended the
warrant&#8217;s exercise period through August 31, 2025, and clarified the exercise mechanism applicable to the warrant. The effects of
the warrant modification were de minimis.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 16, 2025 the Company entered into
an amendment with a warrant holder who holds&#160;1,249,999&#160;warrants that clarified the exercise mechanisms. Concurrently with the
amendment, the warrant holder exercised the warrants via a cashless exercise and received&#160;913,299&#160;shares of Common Stock. Pursuant
to the amendment, the Company agreed to issue the warrant holder&#160;86,700&#160;shares of Common Stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 12, 2025, the Company received
an exercise notice from a warrant holder who holds&#160;109,376&#160;warrants. The warrant was exercised via a cashless exercise, and
the warrant holder received&#160;30,547&#160;shares of Common Stock. Pursuant to the amended warrant agreement, the Company agreed to
issue the warrant holder&#160;56,954&#160;shares of Common Stock.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 24, 2025, As consideration
for Yorkville&#8217;s commitment to purchase common stock at the Company&#8217;s direction pursuant the SEPA, the Company issued to Yorkville
131,909 Commitment Shares, which have a total aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#8217;s $20.0 million aggregate
purchase commitment under the SEPA (each Commitment Share valued at approximately $1.5162 per share, representing the VWAP on October
23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October 24,
2025, we entered into the SEPA with Yorkville. Pursuant to the SEPA, we have the right, but not the obligation, to issue and sell to Yorkville,
from time to time, up to $20.0 million of shares of our Common Stock (the &#8220;SEPA Shares&#8221;), subject to certain limitations and
conditions set forth in the SEPA.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the SEPA, we
may request, and Yorkville may, in its sole discretion, elect to provide, one or more prepaid advances (each, a &#8220;Prepaid Advance&#8221;
and collectively, the &#8220;Prepaid Advances&#8221;), pursuant to which Yorkville would advance funds to us and we would issue to Yorkville
a promissory note evidencing such Prepaid Advance. We requested, and Yorkville funded, two Prepaid Advances in an aggregate amount of
$6.0 million as described below. Each Prepaid Advance is expected to be repaid through the issuance of SEPA Shares at a price per share
determined in accordance with the terms of the SEPA, which is generally based on a discount to the prevailing market price of our common
stock during a specified pricing period, unless earlier repaid in cash at our option, subject to the terms of the SEPA. Accordingly, the
number of SEPA Shares issuable upon settlement of any Prepaid Advance will depend on the market price of our Common Stock at the time
of such settlement and cannot be determined at the time such Prepaid Advance is made or thereafter until settlement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As consideration for Yorkville&#8217;s
commitment to purchase common stock at the Company&#8217;s direction pursuant the SEPA, the Company (i) paid to Yorkville a cash &#8220;structuring
fee&#8221; in the amount of $25,000 and (ii) upon execution of the SEPA, issued to Yorkville 131,909 Commitment Shares, which have a total
aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#8217;s $20.0 million aggregate purchase commitment under the SEPA (each
Commitment Share valued at approximately $1.5162 per share, representing the VWAP on October 23, 2025, the trading day immediately prior
to the date of execution of the SEPA, rounded to the nearest whole share).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the SEPA, and subject
to the conditions set forth therein, Yorkville provided us with a Prepaid Advance of $6.0 million, funded in two tranches, in exchange
for our issuance of convertible promissory notes (each, a &#8220;Convertible Note&#8221; and collectively, the &#8220;2025 Convertible
Notes&#8221; or &#8220;2025 Notes&#8221;). On October 27, 2025, we received the first tranche of the Prepaid Advance in the amount of
$3,720,000 and issued to Yorkville a Convertible Note in the principal amount of $4.0 million (the &#8220;First Convertible Note&#8221;),
which was issued with an original issue discount of 7.0%. The First Convertible Note is initially convertible into shares of our Common
Stock at a fixed conversion price of $1.50 per share.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Subsequently, upon satisfaction of the
applicable conditions, on December 23, 2025 we received the second tranche of the Prepaid Advance in the amount of $1,860,000 and issued
to Yorkville a Convertible Note in the principal amount of $2.0 million (the &#8220;Second Convertible Note&#8221;), which was issued
with an original issue discount of 7.0% and is initially convertible into shares of our common stock at a fixed conversion price of $1.50
per share.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest accrues on the outstanding balance
of each Convertible Note at a rate of 8% per annum, subject to an increase to 18% upon the occurrence of certain events of default, and
each Convertible Note matures on October 24, 2026.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We and Yorkville also entered into a registration
rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to file with the U.S. Securities and Exchange
Commission (the &#8220;SEC&#8221;) a registration statement registering the resale by Yorkville of the SEPA Shares, including SEPA Shares
issuable upon settlement of the Prepaid Advances. On November 26, 2025, we filed a registration statement on Form S-1 (File No. 333-291832)
with the SEC (the &#8220;Registration Statement&#8221;) for the resale by Yorkville of 10,000,000 SEPA Shares, which was declared effective
by the SEC on December 11, 2025.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date of this Annual Report,
we have issued and sold approximately 1.1 million SEPA Shares to Yorkville pursuant to the SEPA, including SEPA Shares issued in connection
with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds to us of approximately
$625,748. We may continue to issue SEPA Shares to Yorkville pursuant to the SEPA, including in connection with any outstanding
or future Prepaid Advances or conversions of Convertible Notes, subject to the terms and conditions of the SEPA.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 2, 2024, the Company priced
its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share. The offering closed on December 4, 2024,
and the Company started trading on the Nasdaq Capital Market under the ticker symbol &#8220;JUNS&#8221;. The Company sold 2,750,000 shares
of its Common Stock to the underwriters and yielded proceeds of $9,725,213, net of underwriters and other fees of $1,274,787.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The financial statements of the Company
have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;US GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Business Segments</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company uses the &#8220;management approach&#8221; to
identify its reportable segments in accordance with ASC 280, Segment Reporting. The management approach requires companies to report segment
financial information consistent with the information regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) for
purposes of making operating decisions and assessing performance.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Chief Executive
Officer serves as the CODM. The CODM evaluates financial performance and allocates resources based on the operating results of the
Company&#8217;s reportable segments. Effective October 1, 2025, the Company operates through two reportable segments: (i) its premium nutritional supplements, and (ii) pharmaceutical operations
focused on drug candidates for CNS.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The CODM assesses segment performance primarily based on segment
net loss (income). Selling, general and administrative expenses are directly attributable to segments or allocated based on reasonable
and consistently applied methodologies. Corporate and other expenses that are not allocated to reportable segments consist primarily of
public company costs, certain executive compensation, certain stock-based compensation, interest income (expense), other income (expense),
and income taxes.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The identification of two reportable segments reflects the
manner in which the CODM reviews financial information and allocates resources. Prior-period information has been recast to conform to
the current presentation.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Preparing financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that materially affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues
and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Changes in estimates are recorded in the
period in which they become known. The Company bases its estimates on historical experience and other assumptions, which include both
quantitative and qualitative assessments that it believes to be reasonable under the circumstances.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Significant estimates during the
years ended December 31, 2025 and 2024, respectively, include valuation of stock-based compensation, uncertain tax positions,
valuation of debt instruments, and the valuation allowance on deferred tax assets.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Research and
development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on
an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities are
based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial
statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs for the fiscal
years ended December 31, 2025 and 2024 were $2,086,574 and $492,660, respectively.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company records stock-based compensation equal to the grant date fair value of the stock awards issued. For stock
options issued to employees, non-employees and members of our board of directors for their services on our board of directors, the Company
estimates the grant-date fair value of options using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock
consistent with the expected life of the option, risk-free interest rates, and, for grants prior to our initial public offering, the value
of the common stock. For awards subject to time-based vesting, the Company recognized stock-based compensation expense, on a straight-line
basis over the requisite service period, which is generally the vesting term of the award. As of December 31, 2025 and 2024, stock-based
compensation expenses totaled $2,418,516 and $1,840,908, respectively, and includes expenses associated with shares issued to service providers and warrant holders.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Clinical Trial Expenses</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As part of the process of preparing our
financial statements, the Company is required to estimate expenses resulting from obligations under contracts with vendors, clinical research
organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of
these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the
periods over which materials or services are provided under such contracts. The Company&#8217;s objective is to reflect the appropriate
trial expenses in the financial statements by matching those expenses with the period in which services are performed and efforts are
expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing
of various aspects of the trial. The Company determines accrual estimates based on estimates of services received and efforts expended
that take into account discussion with applicable personnel and outside service providers as to the progress or state of consummation
of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its
estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based on the facts and circumstances known
at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and
other third-party vendors. Although the Company does not expect the estimates to be materially different from amounts actually incurred,
understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and
may result in reporting amounts that are too high or too low for any particular period.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Convertible Notes with and without Embedded Derivative
Liabilities</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has entered into convertible
notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by
the holder, into shares of common stock at a fixed discount to the price of the common stock at or around the time of conversion upon
certain trigger events. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded
components of those contracts qualify as derivatives. This accounting treatment requires that the carrying amount of any derivatives
be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as
a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense.
Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value at the conversion, repayment, or
exercise date and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_13"></span>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_14"></span>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Reference is made to pages F-1 through
F-26 comprising a portion of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_15"></span>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As previously reported in the Company&#8217;s
Current Report on Form 8-K filed with the Securities and Exchange Commission on April 21, 2025, which disclosure is incorporated herein
by reference, on April 16, 2025, Assurance Dimensions, LLC resigned as the Company&#8217;s independent registered public accounting firm,
and the Audit Committee of the Board of Directors approved the engagement of Cherry Bekaert LLP as the Company&#8217;s new independent
registered public accounting firm, effective as of April 16, 2025.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_16"></span>ITEM 9A. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Evaluation of Disclosure Controls and Procedures</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Disclosure controls are procedures that
are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such
as this Annual Report on Form 10-K, is recorded, processed, summarized, and reported within the time period specified in the SEC&#8217;s
rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated
to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer (our
&#8220;Certifying Officers&#8221;), the effectiveness of our disclosure controls and procedures as of December 31, 2025, pursuant to Rule
13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of December 31, 2025, our disclosure
controls and procedures were ineffective due to a deficiency in our ability to adequately segregate responsibility over financial transaction processing and
reporting. Based on the number of personnel available to serve the Company&#8217;s accounting function, management believes
we are not able to adequately segregate responsibility over financial transaction processing and reporting. Further, the Company does
not have a formal internal control environment in place and operating effectively.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not expect that our disclosure controls
and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and
operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.
Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits
must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation
of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances
of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Management&#8217;s Report on Internal Control Over Financial
Reporting</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 14d-14(f). Our internal
control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">All internal control systems, no matter
how well designed, have inherent limitations and may not prevent or detect misstatements. Therefore, even those systems determined to
be effective can only provide reasonable assurance with respect to financial reporting reliability and financial statement preparation
and presentation. In addition, projections of any evaluation of effectiveness to future periods are subject to risk that controls become
inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Management assessed the
effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2025. In making the assessment,
management used the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO &#8211; 2013) in
Internal Control-Integrated Framework. Based on its assessment, management concluded that, as of December 31, 2025, our
Company&#8217;s internal control over financial reporting was deficient due to our inability to adequately segregate responsibility
over financial transaction processing and reporting. Based on the number of personnel available to serve the Company&#8217;s accounting function, management believes
we are not able to adequately segregate responsibility over financial transaction processing and reporting. Further, the Company does
not have a formal internal control environment in place and operating effectively. As such, we have identified these issues as material
weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future that may
cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If our remediation
of such material weaknesses is not effective, or if we fail to develop and maintain an effective system of internal controls and internal
control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations
could be materially and adversely affected and the market price of our common stock could be negatively affected, which could require
additional financial and management resources.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Changes in Internal Control over Financial Reporting</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no changes in our internal
control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent
fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_17"></span>ITEM 9B. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December 31, 2025,
no director or officer of the Company <span id="xdx_907_eecd--Rule10b51ArrAdoptedFlag_dbF_c20250101__20251231_z9VWs2eeWCLj" title="Rule 10b5-1 Arrangement Adopted [Flag]" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90D_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250101__20251231_zLTAlnOBbrog" title="Non-Rule 10b5-1 Arrangement Adopted [Flag]" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000065" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000067" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>, <span id="xdx_90E_ecustom--Rule10b51ArrModifiedFlag_dbF_c20250101__20251231_zRG1U6rEB9Ui" title="Rule 10b5-1 Arrangement Modified [Flag]" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90F_ecustom--NonRule10b51ArrModifiedFlag_dbF_c20250101__20251231_zeZsiqzgToo9" title="Non-Rule 10b5-1 Arrangement Modified [Flag]" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000069" name="JUNS:Rule10b51ArrModifiedFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000071" name="JUNS:NonRule10b51ArrModifiedFlag">modified</ix:nonNumeric></ix:nonNumeric></span></span>, or <span id="xdx_901_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250101__20251231_zqQTP2QJ4yb8" title="Rule 10b5-1 Arrangement Terminated [Flag]" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_904_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250101__20251231_zauwEimoFyfk" title="Non-Rule 10b5-1 Arrangement Terminated [Flag]" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000073" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000075" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule
10b5-1 trading arrangement&#8221; as each term is defined in Item 408(a) of Regulation S-K.<sup>4</sup></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_18"></span>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT
PREVENT INSPECTIONS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b><span id="m_19"></span>PART III</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_20"></span>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Officers and Directors</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth the names
and ages of the members of our Board of Directors and our executive officers and the positions held by each. Our Board of Directors elects
our executive officers annually by majority vote. Each director&#8217;s term continues until his or her successor is elected or qualified
at the next annual meeting, unless such director earlier resigns or is removed. In addition, the following table sets forth the names
and ages of the members of our Science Advisory Board.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 31%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 8%; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Age</b>&#160;</span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 57%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><b><i>Executive Officers and Directors:</i></b></span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Christer Ros&#233;n</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">74</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chairman of Board, Chief Executive Officer and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Saleem Elmasri</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">40</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Financial Officer and Secretary</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Marshall Hayward, Ph.D.</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">71</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Scientific Officer and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Alexander Ros&#233;n</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">35</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Administrative Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Alison D. Silva</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">47</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">President, Chief Business Officer, and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Nicholas H. Hemmerly</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">43</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Julie Kampf</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">64</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Allison W. Brady</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">55</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Holger Weis</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">63</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Independent Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Biographical information concerning our
executive officers and directors listed above is set forth below.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Executive Officers</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Christer Ros&#233;n.</i></b>
Mr. Ros&#233;n, 74, is our Co-Founder and has served as our Chief Executive Officer and Chairman of our Board of Directors since
June 2015. From January 1998 through March 2015, Mr. Ros&#233;n founded and served as the Chief Executive Officer and Chairman of
EffRx Pharmaceuticals. Mr. Ros&#233;n together with Marshall Hayward, our Chief Scientific Officer, held the same positions at
EffRx, where Mr. Rosen invented, and led the development through FDA and EU approvals of a drug treating
osteoporosis, Binosto<sup>&#174;</sup>. Binosto<sup>&#174;</sup> is distributed in several parts of the world and gave Mr.
Ros&#233;n a full insight into all aspects of pharmaceutical development, regulatory paths and distribution. He has decades of
entrepreneurial experience and has founded, funded, and created start-ups in industries ranging from entertainment, hospitality,
information technology, nutritional retail and pharmaceuticals. Mr. Ros&#233;n is a graduate of Malmo Trade Schools/Lund
University, Sweden, with a degree in Computer Sciences in 1971. We believe Mr. Ros&#233;n is qualified to serve as Chairman of our
Board of Directors due to his extensive experience in the pharmaceutical industry and as an entrepreneur.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Saleem Elmasri.</i></b> Mr. Elmasri,
40, has served as our Chief Financial Officer and Secretary since January 1, 2023. Since September 2020, he has served as Managing Partner
at Titan Advisory Services LLC, a boutique advisory firm focused on providing collaborative and customized financial operations and CFO
services to early-stage companies. Since November 2025, Mr. Elmasri has served as chief financial officer for both Drugs Made In America
Acquisition Corp. and Drugs Made In America Acquisition II Corp. He previously served as a director of Liberty Star Uranium &amp; Metals
Corp. from August 2023 to December 2025, where he served on the nominating, compensation, and audit committees. Mr. Elmasri also served
as a director of Trans American Aquaculture, Inc. from March 2024 to December 2024, where he was chair of the audit committee. He also
served as chief financial officer for Bright Green Corporation from February 2022 to December 2024. From September 2020 to April 2021,
Mr. Elmasri was a consultant to DLA LLC, a professional services firm providing clients internal audit, accounting advisory, and corporate
finance services. From June 2019 to August 2020, he was Managing Director at DLA LLC. From September 2007 to March 2018, Mr. Elmasri worked
as Senior Director for Pine Hill Group LLC, a boutique accounting and transaction advisory firm, From March 2018 to June 2019, he worked
as Senior Director for Pine Hill Group LLC, a boutique accounting and transaction advisory firm. From September 2007 to March 2018, Mr.
Elmasri worked as Senior Manager for PricewaterhouseCoopers LLP (&#8220;PwC&#8221;), a Big-4 Accounting and Global Professional Services
firm. Mr. Elmasri is a CPA and seasoned business professional who has a passion for delivering meaningful and measurable value to clients
through practical solutions. He has over 15 years of experience in financial and management consulting. Mr. Elmasri began his career at
PwC and worked on several of the firm&#8217;s Fortune 500 clients, primarily focused on the Life Sciences and Pharmaceutical industry.
From PwC, he transitioned to lead advisory practices at boutique consulting firms, specializing in transaction and complex accounting
advisory. Mr. Elmasri received B.S. degrees in Accounting and Finance from Rutgers University in 2007.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Marshall Hayward, Ph.D.</i></b>
Dr. Hayward, 71, is one of our Co-Founders, serves as our Chief Scientific Officer, and has served as a member of our Board of Directors
since 2015. Since 2013, Dr. Hayward has served as the founder and managing member of Marshall Hayward Associates LLC. From 2003 to 2013,
Dr. Hayward served as the Chief Scientific Officer of EffRx Pharmaceuticals, where he was instrumental in all aspects of the development
and approvals of the Binosto&#174; product. Dr. Hayward received a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign
in 1982, where he conducted postdoctoral research in molecular biology. Dr. Hayward received a B.S. degree (in Biochemistry with High
Honor) from the Honors College of Michigan State University in 1977. Dr. Hayward does not hold, and has not previously held, any directorships
in any reporting companies. We believe Dr. Hayward is qualified to serve on our Board of Directors due to his extensive experience in
the pharmaceutical industry and scientific background.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Alexander Ros&#233;n.</i></b>
Mr. Ros&#233;n, 35, is a Co-Founder and our Chief Administrative Officer and has been with Jupiter Neurosciences, Inc. since its inception.
Previously, Mr. Ros&#233;n held the position of Head of Administration at X-Vax Technology, Inc. from November 2020 to June 2021. From
February 2019 to November 2020, Mr. Ros&#233;n served as the Controller at X-Vax Technology, Inc. Mr. Ros&#233;n attended Halmstad
University, Sweden from 2009 to 2012. Mr. Ros&#233;n does not hold, and has not previously held, any directorships in any reporting
companies.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Alison D. Silva.</i> </b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Silva, 47, who has been a member of our Board of Directors since 2018, has now expanded her role to include President and Chief
Business Officer since September 1, 2021. Previously, Ms. Silva was the Chief Executive Officer of Cotinga Pharmaceuticals, formerly
Critical Outcome Technologies, from December 2016 through August 2021, and served as president from June 2016 to December 2026. She
has served on the Board of Directors of Cotinga Pharmaceuticals since 2015, and management consultant to several organizations,
including EMA Wellness and The Orphan Group. Before joining Cotinga, Alison co-founded The Microbiome Company in 2013, later
rebranded to Synlogic Therapeutics, where she served as Executive Vice President and Chief Operating Officer until June 2016. Other
relevant positions include co-founder and Vice President, Development at Marina Biotech; co-founder and Director at The Orphan
Group; Director, Drug Development at Cequent Pharmaceuticals; COO at SLA Pharma; and various other positions in biotech and pharma.
Ms. Silva obtained her undergraduate degree in Biology from Clark University in 2001 and her graduate degree from Clark University,
through a direct study program with the University of Massachusetts Medical School in 2002.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Independent Directors</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Allison W. Brady.</i> </b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Brady, 55, has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. She is co-founder of Gene Spotlight,
Inc., a non-profit dedicated to raising money to sponsor medical research for rare diseases, and she has served on its board since January
2012. Since January 2024, Ms. Brady has served on the Board of Advisors at University of Pennsylvania&#8217;s school of Social Policy
&amp; Practice and is currently the Fundraising Chair of its Power of Penn campaign. Ms. Brady received a BAS from University of Pennsylvania
in 1993. She also received a PR Strategy Certificate in 2021 from Cornell University. Ms. Brady does not hold, and has not previously
held, any directorships in any reporting companies. Gene Spotlight is presently the largest outside investor in the Company We believe
Ms. Brady is qualified to serve on our Board of Directors due to her board experience.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Nicholas H. Hemmerly.</i></b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Hemmerly, 43, has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Mr. Hemmerly has been Managing
Director and Co- Head of Investment Banking for Clear Street LLC since June 2023. Mr. Hemmerly has over 18 years of investment banking
experience with broad transactional experience having completed approximately $25 billion of debt and equity transactions. Prior to joining
Clear Street Mr. Hemmerly was Head of Investment Banking at Bridgeway Capital Partners, a merchant banking firm, from January 2020 to
June 2023 From March 2016 to February 2020 Mr. Hemmerly was the Director, Head of Life Sciences at PricewaterhouseCoopers LLC where he
led U.S. M&amp;A and capital raising in the life sciences space with a focus on specialty and generic pharmaceuticals as well as healthcare
consumer products and contract manufacturing. From June 2014 to March 2016, Mr. Hemmerly was a Vice President at Jefferies LLC with a
focus on executing M&amp;A and financing transactions within the pharmaceutical and life sciences sectors. Prior experience includes
investment banking roles in JPMorgan Chase &amp; Co.&#8217;s Healthcare Group as well as JMP Securities LLC&#8217;s Healthcare Group.
Mr. Hemmerly began his investment banking career as an analyst with Wachovia Securities. Mr. Hemmerly has also served as an independent
director for Liberty Star Uranium &amp; Metals Corp since September 2022. We believe Mr. Hemmerly is qualified to serve on our Board
of Directors due to his extensive experience in the investment banking, life sciences and pharmaceutical sectors.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Julie Kampf.</i></b> Ms. Kampf,
64, has served as an independent director at Jupiter Neurosciences, Inc. since September 2021. Ms. Kampf is the founder and chief executive
officer of JBK Associates International Inc., an executive search firm focused on the life science industry, which she founded in 2003.
Ms. Kampf has served as a director of EOM Pharmaceuticals since April 2022, where she chairs its compensation committee. Ms. Kampf also
served as a director of Marizyme, Inc., a Florida-based biotechnology company, from February 2021 to May 2024. Ms. Kampf has received numerous awards, including having been recognized
as one of New Jersey&#8217;s Best 50 Women in Business, an Enterprising Woman of The Year, an Ernst &amp; Young Entrepreneurial Winning
Woman and a Brava Smart CEO Winner. In 2013 and 2009, Julie was recognized as one of the PharmaVoice 100 &#8216;most inspiring people
in the Life Science Industry&#8217;.&#160; Ms. Kampf received a B.A. in Political Science from the University of Rhode Island in 1983.
Ms. Kampf does not hold, and has not previously held, any directorships in any reporting companies. We believe Ms. Kampf is qualified
to serve on our Board of Directors due to her experience as a director in the pharmaceutical and biotechnology industries, as well as
her extensive business experience.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Holger Weis<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></i></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Mr. Weis, 63, has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. From December 2020 through
June 2025, he served as an independent director of Alaunos Therapeutics, Inc. where he served as Chair of the Audit Committee and as
a member of the Compensation Committee. He was appointed as chairman of the board of directors in September 2023, and was subsequently
appointed Chief Executive Officer of Alaunos Therapeutics, Inc. in July 2025 and relinquished his duties on the Audit and Compensation
Committees. He is the principal of Weis Advisors, Inc., a company that provides consulting services to life science companies, since
founding the company in April 2018. Between December 2011 and April 2018, Mr. Weis served many roles at DemeRx, Inc. including COO, CFO,
President as well as a Consultant. From August 2010 to November 2011 Mr. Weis served as CFO for EnSA Holdings, LLC. Prior to his time
at EnSA Holdings, LLC. Mr. Weis served as Vice President &amp; CFO, Secretary and Treasurer at NovaVision, Inc. from January 2006 to
August 2010. Prior to that, he served as the Chief Financial Officer &amp; Treasurer of GMP Companies, Inc., a company that develops
and commercializes pharmaceutical, medical device and diagnostic technologies, from 2000 to 2005. Earlier in his career, Mr. Weis served
as a Senior Manager at Ernst &amp; Young, a multinational professional services company, from 1986 to 2000. Mr. Weis received a Bachelor
of Business Administration in Accounting from the University of Georgia in 1985 and is a Certified Public Accountant. We believe Mr.
Weis is qualified to serve on our Board of Directors due to his experience in the life science industry and extensive financial background.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Family Relationships</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">There are no family relationships among
any of our directors or executive officers, except that Christer Ros&#233;n, our Chief Executive Officer, is the father of Alexander
Ros&#233;n, our Chief Administrative Officer.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">No executive officer, member of the board
of directors or control person of our Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the
past 10 years.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Board Leadership Structure and Board&#8217;s Role in Risk
Oversight</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not separated the positions of
Chairman of the Board and Chief Executive Officer. Christer Ros&#233;n has served as our Chairman of the Board of Directors and Chief
Executive Officer since January 1, 2016. We believe that combining the positions of Chairman and Chief Executive Officer allows for focused
leadership of our organization which benefits us in our relationships with investors, customers, suppliers, employees and other constituencies.
We believe that consolidating the leadership of the Company under Mr. Ros&#233;n is the appropriate leadership structure for our Company
and that any risks inherent in that structure are balanced by the oversight of our other independent directors on our Board. However,
no single leadership model is right for all companies and at all times. The Board recognizes that depending on the circumstances, other
leadership models, such as the appointment of a lead independent director, might be appropriate. Accordingly, the Board may periodically
review its leadership structure. In addition, the Board holds executive sessions in which only independent directors are present.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board is generally responsible for
the oversight of corporate risk in its review and deliberations relating to our activities. Our principal source of risk falls into two
categories, financial and product commercialization. The audit committee oversees management of financial risks; our Board regularly reviews
information regarding our cash position, liquidity and operations, as well as the risks associated with each. The Board regularly reviews
plans, results and potential risks related to our business. The Board is also expected to oversee risk management as it relates to our
compensation plans, policies and practices for all employees including executives and directors, particularly whether our compensation
programs may create incentives for our employees to take excessive or inappropriate risks which could have a material adverse effect on
the Company.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As required under the Nasdaq Marketplace
Rules, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively
determined by the board of directors. Our Board of Directors considered certain relationships between our directors and us when determining
each director&#8217;s status as an &#8220;independent director&#8221; under Rule 5605(a)(2) of the Nasdaq Marketplace Rules. Based upon
such definition and SEC regulations, the Company&#8217;s Board of Directors has affirmatively determined that currently three of its seven
directors (Christer Ros&#233;n, Marshall Hayward, Ph.D., and Alison D. Silva) are non-independent directors of the Company and four
of its seven directors (Nicholas H. Hemmerly, Julie Kampf, Allison W. Brady, and Holger Weis) are &#8220;independent&#8221; directors
under Nasdaq listing standards. Therefore, the Board of Directors has determined that a majority of the members of our Board of Directors
are &#8220;independent&#8221;.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Committees of the Board of Directors</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Audit Committee</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have established an audit committee
(&#8220;Audit Committee&#8221;), which consists of three independent directors: Holger Weis, Allison W. Brady and Nicholas Hemmerly. Mr.
Weis is the chair of the Audit Committee. Mr. Weis qualifies as an audit committee financial expert under SEC rules and as a financially
sophisticated audit committee member under the Nasdaq Capital Market rules. Our Audit Committee operates under a written charter that
is reviewed annually. A copy of the charter is posted on the Corporate Governance section of our website, at <i>www.jupiterneurosciences.com</i>.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Audit Committee is authorized to:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">approve and retain the independent auditors to conduct the annual audit of our financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">review the proposed scope and results of the audit;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">review and pre-approve audit and non-audit fees and services;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">review accounting and financial controls with the independent auditors and our financial and accounting staff;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">review and approve transactions between us and our directors, officers and affiliates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">recognize and prevent prohibited non-audit services;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">establish procedures for complaints received by us regarding accounting matters; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">oversee internal audit functions, if any.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Compensation Committee</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have established a compensation committee
(&#8220;Compensation Committee&#8221;), which consists of three independent directors: Nicholas H. Hemmerly, Julie Kampf and Allison Brady.
Mr. Hemmerly is the chair of the Compensation Committee. Our Compensation Committee operates under a written charter that is reviewed
annually.<sup>7</sup> A copy of the charter is posted on the Corporate Governance section of our website, at <i>www.jupiterneurosciences.com</i>.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Compensation Committee is authorized
to:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">review and determine the compensation arrangements for management;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">establish and review general compensation policies with the objective to attract and retain superior talent, to reward individual performance and to achieve our financial goals;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">administer our incentive compensation and benefit plans and purchase plans;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">oversee the evaluation of the Board of Directors and management; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">review the independence of any compensation advisers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Nominating and Corporate Governance Committee</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We have established a nominating and corporate
governance committee (&#8220;Nominating and Corporate Governance Committee&#8221;), which consists of three independent directors: Julie
Kampf, Holger Weis and Nicholas H. Hemmerly. Ms. Kampf is the chair of the Nominating and Corporate Governance Committee. Our Nominating
and Corporate Governance Committee operates under a written charter, a copy of which is posted on the Corporate Governance section of
our website, at <i>www.jupiterneurosciences.com</i>.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The functions of the Nominating and Corporate
Governance Committee, among other things, include:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">identifying individuals qualified to become board members and recommending director;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">nominees and board members for committee membership;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">developing and recommending to our board corporate governance guidelines;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">review and determine the compensation arrangements for directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">overseeing the evaluation of our board of directors and its committees and management.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Director Nominations</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our full Board of Directors recommends
candidates for nomination for election at the annual meeting of the stockholders. We have not formally established any specific, minimum
qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees
for director, the Board of Directors considers educational background, diversity of professional experience, knowledge of our business,
integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Board and Committee Meetings and Director Attendance</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended December 31, 2025,
the Board held six meetings, the Audit Committee held four meetings, the Compensation Committee held one meeting, and the Nominating
and Governance Committee held no meetings. During 2025, each director attended more than 75% of the combined meetings of the Board and
each committee on which he or she served.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Compensation Committee Interlocks and Insider Participation</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">None of our executive officers currently
serves, or in the past year has served, as a member of the Board of Directors or compensation committee of any entity that has one or
more executive officers on our Board of Directors or Compensation Committee. For a description of transactions between us and members
of our Compensation Committee and affiliates of such members, please see &#8220;Certain Relationships and Related Party Transactions&#8221;.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Code of Ethics</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has adopted a Code of Ethics
and Business Conduct that applies to all of its directors, officers (including our principal executive officer, principal financial officer,
principal accounting officer or controller, and any person performing similar functions) and employees. The Code of Ethics and Business
Conduct is available on our website at <i>www.jupiterneurosciences.com</i>.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Compensation Recovery Policy</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 26, 2025, the Board of Directors
approved a new compensation recovery policy (the &#8220;Clawback Policy&#8221;) in compliance with SEC and Nasdaq rules and regulations.
The Clawback Policy provides that in the event we are required to prepare an &#8220;Accounting Restatement&#8221; (as defined in the Clawback
Policy), we shall, subject to certain limited exceptions as described in the Clawback Policy, recover certain incentive-based compensation
from executive officers who are or have been designated as an &#8220;officer&#8221; by the Board of Directors in accordance with Exchange
Act Rule 16a-1(f). Compensation that shall be recovered under the Clawback Policy generally includes &#8220;Incentive-Based Compensation&#8221;
(as defined in the Clawback Policy) received during the three-year period prior to the &#8220;Accounting Restatement Determination Date&#8221;
(as defined in the Clawback Policy) that exceeds the amount that otherwise would have been received by the &#8220;officer&#8221; had such
compensation been determined based on the restated amounts in the financial restatement. Under the Clawback Policy, &#8220;Incentive-Based
Compensation&#8221; includes any compensation that is granted, earned, or vested based, in whole or in part, upon the attainment of a
Financial Reporting Measure (as defined in the Clawback Policy).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Policy Prohibiting Insider Trading and Related Procedures.</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted an insider trading
policy governing the purchase, sale, and other dispositions of the Company&#8217;s securities by directors, senior management, and employees.
A copy of the insider trading policy is filed as an exhibit to this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 24.3pt">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Communications with the Board</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Stockholders and other interested parties
can send communications to one or more members of the Board by writing to the Board or specific directors or group of directors at the
following address: Jupiter Neurosciences, Inc. Board of Directors, c/o Corporate Secretary, 1001 North US Hwy 1, Suite 504, Jupiter, FL
33477. Any communication will be promptly distributed by our Corporate Secretary to the individual director or directors named in the
communication or to all directors if addressed to the entire Board.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Indemnification and Limitation on Liability of Officers
and Directors</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation provides
that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in
the future be amended. In addition, our certificate of incorporation provides that our directors will not be personally liable for monetary
damages to us for breaches of their fiduciary duty as directors, except to the extent such exemption from liability or limitation thereof
is not permitted by the Delaware General Corporation Law (&#8220;DGCL&#8221;).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our certificate of incorporation also
permits us to maintain insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless
of whether Delaware law would permit such indemnification. We have purchased a policy of directors&#8217; and officers&#8217; liability
insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances
and insures us against our obligations to indemnify our officers and directors.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">These provisions may discourage stockholders
from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing
the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit
us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement
and damage awards against officers and directors pursuant to these indemnification provisions.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that these provisions and the
insurance are necessary to attract and retain talented and experienced officers and directors.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_001"></span>ITEM 11. EXECUTIVE COMPENSATION</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>2025 Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The following summary compensation table
provides information regarding the compensation earned during our fiscal years ended December 31, 2025 and 2024 to certain of our executive
officers, who we collectively refer to as our &#8220;named executive officers&#8221; or &#8220;NEOs&#8221;.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font-family: Times New Roman,serif"><span style="font-size: 10pt"><b>Name and Principal Position</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Salary ($)</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Bonus ($)</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Stock</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Awards</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>($)</b></p></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Option</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Awards</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>($)(1)</b></p></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Non-</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Equity</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Incentive</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Plan</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Compensation</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>($)</b></p></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Non-</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>qualified</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Deferred</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Compensation</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Earnings</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>($)</b></p></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>All</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Other</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Compensation</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>($)</b></p></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Total</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>($)</b></p></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 34%; font-family: Times New Roman,serif"><span style="font-size: 10pt">Christer Ros&#233;n</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="width: 7%; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">441,000</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">210,000</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">20,407</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(2)</sup>&#160;</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="width: 4%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">671,407</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">134,750</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">19,326</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(2)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">154,076</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Saleem Elmasri</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">240,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">72,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">102,128</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(3)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">414,128</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">127,006</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">127,006</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Marshall Hayward</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">176,400</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">50,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">16,145</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(4)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">242,445</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Scientific Officer</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">107,800</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">107,800</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Alexander Ros&#233;n</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">252,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">72,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">15,665</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(4)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">339,665</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Administration Officer</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">77,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">26,655</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(4)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">103,655</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Alison Silva</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2025</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">315,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">45,000</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">255,320</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(3)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">16,779</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(5)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">632,099</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Chief Business Officer and President</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">96,250</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif"><sup>&#160;</sup></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">42,294</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><sup>(5)</sup>&#160;</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">$</span></td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">138,544</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Amounts reflect the aggregate grant-date fair value of stock awards computed in accordance with the Financial Accounting Standards Board&#8217;s Accounting Standards Codification Topic 718. See Note 6 &#8211; Stockholders&#8217; Equity (Deficit) &#8211; Stock Options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Includes healthcare benefits and 401(k) contribution of $20,407 and $19,326, respectively, for the fiscal years ended December 31, 2025 and 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">On July 2, 2025, the Compensation
    Committee of the board of directors (the &#8220;Compensation Committee&#8221;) of Jupiter Neurosciences, Inc. (the
    &#8220;Company&#8221;), after review of the Company&#8217;s Final 2025 Budget, approved equity incentives to compensate certain
    officers of the Company for their role in the success of the Company&#8217;s initial public offering completed in December 2024 and
    their willingness to forgo additional compensation and forgive debts owed to them by the Company. The equity incentives approved by the Compensation Committee consisted of stock options granted to the following individuals pursuant to the
    Company&#8217;s 2023 Equity Incentive Plan: Alison Silva, Chief Business Officer, received a grant of 255,320 options and Saleem
    Elmasri, Chief Financial Officer, received a grant of 102,128 options. The stock options have an exercise price of $1.19 per share,
    representing the closing price of the Company&#8217;s common stock on the Nasdaq Stock Market on the date of grant. The stock
    options have a ten (10) year term and vest in equal installments over a three (3) year period beginning on the grant date of July 2,
    2025, subject to the officers&#8217; continued employment at the time of vesting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Includes healthcare benefits and 401(k) contribution of $15,665 and $26,655, respectively, for the fiscal years ended December 31, 2025 and 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">(5)</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Includes healthcare benefits and 401(k) contribution of $16,779 and $42,294 respectively, for the fiscal years ended December 31, 2025 and 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Executive Compensation Philosophy</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board of Directors determines the
compensation given to our executive officers in their sole determination. Our Board of Directors reserves the right to pay our executives
or any future executives a salary, and/or issue them shares of common stock issued in consideration for services rendered and/or to award
incentive bonuses which are linked to our performance, as well as to the individual executive officer&#8217;s performance. This package
may also include long-term stock-based compensation to certain executives, which is intended to align the performance of our executives
with our long-term business strategies. Additionally, while our Board of Directors has not granted any performance-based stock options
to date&#160;, the Board of Directors reserves the right to grant such options in the future, if the Board in its sole determination believes
such grants would be in the best interests of the Company.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Incentive Bonus</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors may grant incentive
bonuses to our executive officers in its sole discretion, if the Board of Directors believes such bonuses are in the Company&#8217;s best
interest, after analyzing our current business objectives and growth, if any, and the amount of revenue we are able to generate each month,
which revenue is a direct result of the actions and ability of such executives.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Long-Term, Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In order to attract, retain and motivate
executive talent necessary to support the Company&#8217;s long-term business strategy we may award our executives and any future executives
with long-term, stock-based compensation in the future, at the sole discretion of our Board of Directors.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>NEO Employment Agreements</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Employment Agreement with Christer Ros&#233;n, dated
as of September 1, 2021</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Ros&#233;n&#8217;s agreement provides
that he will serve as the Chief Executive Officer of the Company and provides that he will be paid an annual base salary of $420,000.
Mr. C. Ros&#233;n is eligible to receive an annual cash bonus, with the target amount of the bonus equal to 50% of the base salary in
the year to which the bonus relates, and the actual amount of the bonus may be greater or less than the target amount, and will ultimately
be determined by the Board.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Amended Employment Agreement with Christer Ros&#233;n, dated
as of September 2, 2021</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in"><b></b>Mr. Rosen&#8217;s employment
agreement was amended to update the term of his employment to expire on the earlier of the third anniversary of the date of signing and
the termination of his employment in accordance with the terms of the agreement. The amendment also clarifies that the executive&#8217;s
statements and assurances apply not only to shares of common stock issued to Mr. Rosen but also to stock options granted to him.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Amended Employment Agreement with
Christer Ros&#233;n, dated as of December 18, 2023</i>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Ros&#233;n&#8217;s employment agreement
was amended on December 18, 2023. The amendment reduces Mr. C. Ros&#233;n&#8217;s annual base salary from $420,000 to $84,000, effective
retrospectively to October 1, 2023, until the time that the Company has raised additional capital from the sale of its securities in the
amount of $1,500,000 (the &#8220;Reduction Period&#8221;). Upon the expiration of the Reduction Period, the base salary shall be adjusted
to be 105% the original base salary. The remainder of the original agreement shall remain in full force. Upon the expiration of the Reduction Period, which occurred on December 4, 2024, the base salary was adjusted to
be 105% the original base.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Employment Agreement with Marshall Hayward, dated as of
September 1, 2021</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Hayward&#8217;s agreement provides
that he will serve as the Chief Scientific Officer of the Company and that he will be paid an annual base salary of $336,000. Dr. Hayward
is eligible to receive an annual cash bonus, with the target amount of the bonus equal to 30% of the base salary in the year to which
the bonus relates, and the actual amount of the bonus may be greater or less than such target amount, and will ultimately be determined
by the Board.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Amended Employment Agreement with Marshall Hayward, dated
as of September 29, 2021 </i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">Dr. Hayward&#8217;s employment agreement
was amended to update the term of his employment to expire on the earlier of the third anniversary of the date of signing and the termination
of his employment in accordance with the terms of the agreement. The amendment also clarifies that the executive&#8217;s statements and
assurances apply not only to shares of common stock issued to Dr. Hayward but also to stock options granted to him.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Amended Employment Agreement with
Marshall Hayward, dated as of December 18, 2023</i>&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Dr. Hayward&#8217;s employment agreement
was amended on December 18, 2023. The amendment reduces Dr. Hayward&#8217;s annual base salary from $336,000 to $67,200, effective
retrospectively to October 1, 2023, until the time that the Company has raised additional capital from the sale of its securities in the
amount of $1,500,000 (the &#8220;Reduction Period&#8221;). Upon the expiration of the Reduction Period, the base salary shall be adjusted
to be 105% the original base salary. The remainder of the original agreement shall remain in full force.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amended
Employment Agreement with Marshall Hayward, dated as of February 1, 2025 </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hayward&#8217;s employment agreement was amended on February 1, 2025. The amendment increased Dr. Hayward&#8217;s annual base salary
from $67,200 to $176,400. The previously planned increase to $352,800 never went into effect.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreement with Alexander Rosen, dated as of June 1, 2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rosen&#8217;s agreement provides that he will serve as the Chief Administrative Officer of the Company and that he will be paid an
annual base salary of $240,000. Mr. Rosen is eligible to receive an annual cash bonus, with the target amount of the bonus equal to 30%
of the base salary in the year to which the bonus relates, and the actual amount of the bonus may be greater or less than such target
amount, and will ultimately be determined by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><i>Amended Employment Agreement
with Alexander Rosen, dated as of September 29, 2021</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Mr. Rosen&#8217;s employment agreement was amended to update the term of his employment to expire on the earlier of the third anniversary
of the date of signing and the termination of his employment in accordance with the terms of the agreement. The amendment also clarifies
that the executive&#8217;s statements and assurances apply not only to shares of common stock issued to Mr. Rosen but also to stock options
granted to him.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amended
Employment Agreement with Alexander Rosen, dated as of December 18, 2023</i>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rosen&#8217;s employment agreement was amended on December 18, 2023. The amendment reduces Mr. Rosen&#8217;s annual base salary from
$240,000 to $48,000 effective retrospectively to October 1, 2023, until the time that the Company has raised additional capital from
the sale of its securities in the amount of $1,500,000 (the &#8220;Reduction Period&#8221;). Upon the expiration of the Reduction
Period, the base salary shall be adjusted to be 105% the original base salary. The remainder of the original agreement shall remain
in full force. Upon the expiration of the Reduction Period, which occurred on December 4, 2024, the base salary was adjusted to
be 105% the original base.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreement with Alison Silva, dated as of September 1, 2021</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Silva&#8217;s agreement provides that she will serve as the President and Chief Business Officer of the Company and that she will be
paid an annual base salary of $300,000. Ms. Silva is eligible to receive an annual cash bonus, with the target amount of the bonus equal
to 30% of the base salary in the year to which the bonus relates, and the actual amount of the bonus may be greater or less than such
target amount, and will ultimately be determined by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Amended Employment Agreement with Alison Silva, dated as of September
29, 2021</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Ms. Silva&#8217;s employment agreement
was amended to update the term of her employment to expire on the earlier of the third anniversary of the date of signing and the termination
of her employment in accordance with the terms of the agreement. The amendment also clarifies that the executive&#8217;s statements and
assurances apply not only to shares of common stock issued to Ms. Silva but also to stock options granted to her.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amended
Employment Agreement with Alison Silva, dated as of December 18, 2023</i>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Silva&#8217;s employment agreement was amended on December 18, 2023. The amendment reduces Ms. Silva&#8217;s annual base salary from
$300,000 to $60,000, effective retrospectively to October 1, 2023, until the time that the Company has raised additional capital
from the sale of its securities in the amount of $1,500,000 (the &#8220;Reduction Period&#8221;). Upon the expiration of the
Reduction Period, the base salary shall be adjusted to be 105% the original base salary. The remainder of the original agreement
shall remain in full force. Upon the expiration of the Reduction Period, which occurred on December 4, 2024, the base salary was adjusted to
be 105% the original base.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Provisions Applicable to All NEO Employment Agreements</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the employment agreements described
above has a term of three years, which will be automatically extended for one or more additional terms of one year each unless either
party provides notice to the other party of their desire to not so renew the term at least 30 days prior to the expiration of the then-current
term. Each of the agreements is &#8220;at will,&#8221; meaning that either party may terminate the employment at any time and for any
reason, subject to the provisions of the applicable agreement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each executive is entitled to fringe benefits
consistent with the practices of the Company, and to the extent the Company provides similar benefits to the Company&#8217;s executive
officers, and is entitled to be reimbursed for all reasonable and necessary out-of-pocket business, entertainment and travel expenses
incurred in connection with the performance of their duties.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each agreement may be terminated by the
Company at any time, either with or without &#8220;Cause&#8221;, and by the applicable executive any time, either with or without &#8220;Good
Reason&#8221;. &#8220;Cause&#8221; is defined as (i) violation of any material written rule or policy of the Company for which violation
any employee may be terminated pursuant to the written policies of the Company reasonably applicable to an executive employee; (ii) misconduct
by the applicable executive to the material detriment of the Company; (iii) the applicable executive conviction (by a court of competent
jurisdiction, not subject to further appeal) of, or pleading guilty to, a felony; (iv) the applicable executive&#8217;s gross negligence
in the performance of their duties and responsibilities to the Company as described in the agreement; or the applicable executive&#8217;s
material failure to perform their duties and responsibilities to the Company as described in the agreement (other than any such failure
resulting from their incapacity due to physical or mental illness or any such failure subsequent to the applicable executive delivered
a notice of termination without Cause by the Company or delivering a notice of termination for Good Reason to the Company), in either
case after written notice from the Board to the applicable executive of the specific nature of such material failure and such executive&#8217;s
failure to cure such material failure within 10 days following receipt of such notice.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#8220;Good Reason&#8221; is defined as
(i) at any time following a Change of Control (as defined below), a material diminution by the Company of compensation and benefits (taken
as a whole) provided to the applicable executive immediately prior to a Change of Control; (ii) reduction in base salary or target or
maximum bonus, other than as part of an across-the-board reduction in salaries of management personnel; (iii) the relocation of the applicable
executive&#8217;s principal executive office to a location more than 50 miles further from their principal executive office immediately
prior to such relocation; or (iv) a material breach by the Company of any of the terms and conditions of the agreement which the Company
fails to correct within 10 days after the Company receives written notice from the applicable executive of such violation.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">A &#8220;Change of Control&#8221; will
be deemed to have occurred if, after the effective date of the applicable agreement, (i) the beneficial ownership (as defined in Rule
13d-3 under the Exchange Act) of securities representing more than 50% of the combined voting power of the Company is acquired by any
&#8220;person&#8221; as defined in sections 13(d) and 14(d) of the Exchange Act (other than the Company, any subsidiary of the Company,
or any trustee or other fiduciary holding securities under an employee benefit plan of the Company), (ii) the merger or consolidation
of the Company with or into another corporation where the stockholders of the Company, immediately prior to the consolidation or merger,
would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, shares representing in the aggregate 50% or more of the combined voting power of the securities of the corporation
issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any) in substantially the same proportion
as their ownership of the Company immediately prior to such merger or consolidation, or (iii) the sale or other disposition of all or
substantially all of the Company&#8217;s assets to an entity, other than a sale or disposition by the Company of all or substantially
all of the Company&#8217;s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned
directly or indirectly by stockholders of the Company, immediately prior to the sale or disposition, in substantially the same proportion
as their ownership of the Company immediately prior to such sale or disposition.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Company terminates any executive&#8217;s
employment for &#8220;Cause&#8221;, or the applicable executive terminates their employment without &#8220;Good Reason&#8221;, then the
Company will pay to the applicable executive any unpaid base salary and benefits then owed or accrued, and any unreimbursed expenses,
any unvested portion of any equity granted to the applicable executive under the agreement or any other agreements with the Company will
immediately be forfeited as of the termination date without any further action of the parties; and all of the parties&#8217; rights and
obligations under the applicable agreement cease, other than such rights or obligations which arose prior to the termination date or in
connection with such termination, and subject to those provisions which survive the termination.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">If the Company terminates the applicable
executive&#8217;s employment without &#8220;Cause&#8221;, or the applicable executive terminates their employment with &#8220;Good Reason&#8221;,
the Company will pay to the applicable executive any base salary and benefits then owed or accrued and any unreimbursed expenses; the
Company will pay to the applicable executive an amount in cash equal to the target annual performance bonus for which they would have
been eligible with respect to the year in which termination of their employment occurs multiplied by a portion of the year for which the
agreement was in place; the Company will continue to pay to the applicable executive the base salary that would have been paid to them
for the following 12 month period, assuming that the agreement and the term had remained in effect; any equity grant already made to the
applicable executive will, to the extent not already vested, be deemed automatically vested; and all of the parties&#8217; rights and
obligations under the agreement cease, other than such rights or obligations which arose prior to the termination date or in connection
with such termination, and subject to those provisions which survive the termination.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements also provides for
certain &#8220;gross-up payments&#8221; being payable to the applicable executive if it is determined that any payment or benefit provided
to the executive under the agreement or otherwise, whether or not in connection with a Change of Control would constitute an &#8220;excess
parachute payment&#8221; within the meaning of section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;),
such that the payment would be subject to an excise tax under section 4999 of the Code.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements contains customary
confidentiality provisions, and customary provisions relating to intellectual property created by the executive (i.e., a &#8220;work-made-for-hire&#8221;
provision).</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements also contains a
customary non-solicitation provision, wherein the executive agrees that they shall not, directly or indirectly solicit or discuss with
any employee of Company the employment of such Company employee by any other commercial enterprise other than Company, nor recruit, attempt
to recruit, hire or attempt to hire any such Company employee on behalf of any commercial enterprise other than Company, provided that
this provision does not prohibit the executive from undertaking a general recruitment advertisement provided that the foregoing is not
targeted towards any person identified above, or from hiring, employing or engaging any such person who responds to such general recruitment
advertisement. This provision applies for three years.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements also contains a
customary non-compete provision, wherein the executive agrees that they will not, directly or indirectly: (i) engage in any other business,
association or relationship of any kind with any business which provides, in whole or in part, the same or similar services and/or products
offered by Company as part of its existing or developing businesses which directly or indirectly competes with Company; nor (ii) solicit
or accept, or induce any person to reduce goods or services to Company, or in any manner assist others in the solicitation, acceptance,
or inducement of, any business transactions with Company&#8217;s existing and prospective clients, accounts, suppliers and/or other persons
or entities with whom Company has had business relationships (or whom Company had specifically identified for a prospective business relationship).
This provision applies for nine months.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements contains a &#8220;Blue
Pencil&#8221; provision, wherein if a court of competent jurisdiction determines that any of the non-solicit or non-compete provisions
are unenforceable, the court may substitute an enforceable restriction in place of any restriction deemed unenforceable.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements is governed by
Florida law, and contains customary representations and warranties and other miscellaneous provisions.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Elements of Compensation</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our NEOs were provided with the following
primary elements of compensation in 2025 and 2024:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Base Salary</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Christer Ros&#233;n and Marshall Hayward
received a fixed base salary in an amount determined by the Board of Directors based on a number of factors, including:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The nature, responsibilities and duties of the officer&#8217;s position;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The officer&#8217;s expertise, demonstrated leadership ability and prior performance;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The officer&#8217;s salary history and total compensation, including annual cash bonuses and long-term incentive compensation; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">The competitiveness of the market for the officer&#8217;s services.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 22.05pt">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">See &#8220;&#8212;2025 Summary Compensation
Table.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Stock Option Grants</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 2, 2025, the Company granted non-qualified
stock options to purchase 102,128 of common stock to Saleem Elmasri, CPA at an exercise price of $1.19 per share.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 2, 2025, the Company granted non-qualified
stock options to purchase 255,320 of common stock to Alison Silva at an exercise price of $1.19 per share.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Other Benefits</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2025 and 2024 our NEOs were reimbursed
for healthcare expenses. The amounts paid to our NEOs in respect of these benefits is reflected above in &#8220;&#8212;2025 Summary Compensation
Table.&#8221;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>2023 Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Overview</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors and stockholders
holding a majority of the Company&#8217;s voting capital approved and adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;)
on October 4, 2023, respectively. The 2023 Plan authorizes the issuance of up to an aggregate maximum of 4,012,785 shares of the common
stock, subject to adjustment as described in the 2023 Plan. The 2023 Plan shall be administered by the Board or one or more committees
appointed by the Board or another committee (&#8220;Administrator&#8221;). The Administrator, in its discretion, selects the individuals
to whom awards may be granted, the time or times at which such awards are granted, and the terms of such awards. The 2023 Plan authorizes
the Company to grant stock options, stock appreciation rights, restricted shares, restricted share unit, cash awards, other awards, and
performance-based awards. Awards may be granted to the Company&#8217;s officers, employees, directors and consultants.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The purpose of 2023 Plan is to promote
the success of the Company and to increase stockholder value by providing an additional means through the grant of awards to attract,
motivate, retain and reward selected employees and other eligible persons. The Board may, at any time, terminate or, from time to time,
amend, modify or suspend this 2023 Plan, in whole or in part. To the extent then required by applicable law or any applicable stock exchange
or required under the Internal Revenue Code to preserve the intended tax consequences of the 2023 Plan, or deemed necessary or advisable
by the Board, the 2023 Plan and any amendment to the 2023 Plan shall be subject to stockholder approval. Unless earlier terminated by
the Board, the 2023 Plan will terminate 10 years from the date of adoption.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Authorized Shares</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">A total of 4,012,785 shares of the Company&#8217;s
common stock are authorized for issuance pursuant to the 2023 Plan. Subject to adjustment as provided in the 2023 Plan, the maximum aggregate
number of shares that may be issued under the 2023 Plan will be cumulatively increased on January 1, 2024 and on each subsequent January
1, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately
preceding December 31, or (ii) an amount determined by the Board.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, if any award issued pursuant
to the 2023 Plan expires or becomes exercisable without having been exercised in full, is surrendered pursuant to an exchange program,
as provided in the 2023 Plan, or, with respect to restricted stock, restricted stock units (&#8220;RSUs&#8221;), performance units or
performance shares, is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased shares (or for awards other
than stock options or stock appreciation rights the forfeited or repurchased shares) which were subject thereto will become available
for future grant or sale under the 2023 Plan (unless the 2023 Plan has terminated). With respect to stock appreciation rights, only shares
actually issued pursuant to a stock appreciation right will cease to be available under the 2023 Plan; all remaining shares under stock
appreciation rights will remain available for future grant or sale under the 2023 Plan (unless the 2023 Plan has terminated). Shares that
have actually been issued under the 2023 Plan under any award will not be returned to the 2023 Plan and will not become available for
future distribution under the 2023 Plan; provided, however, that if shares issued pursuant to awards of restricted stock, restricted stock
units, performance shares or performance units are repurchased by the Company or are forfeited to the Company due to the failure to vest,
such shares will become available for future grant under the 2023 Plan. Shares used to pay the exercise price of an award or to satisfy
the tax withholdings related to an award will become available for future grant or sale under the 2023 Plan. To the extent an award under
the 2023 Plan is paid out in cash rather than shares, such cash payment will not result in reducing the number of shares available for
issuance under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing and, subject
to adjustment as provided in the 2023 Plan, the maximum number of shares that may be issued upon the exercise of incentive stock options
will equal the aggregate share number stated above, plus, to the extent allowable under Section 422 of the Internal Revenue Code of 1986,
as amended, and regulations promulgated thereunder, any shares that become available for issuance under the 2023 Plan in accordance with
the foregoing.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Plan Administration</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board or one or more committees appointed
by the Board will administer the 2023 Plan. In addition, if the Company determines it is desirable to qualify transactions under the 2023
Plan as exempt under Rule 16b-3 of the Securities Exchange Act of 1934, as amended, such transactions will be structured with the intent
that they satisfy the requirements for exemption under Rule 16b-3. Subject to the provisions of the 2023 Plan, the administrator has the
power to administer the 2023 Plan and make all determinations deemed necessary or advisable for administering the 2023 Plan, including
the power to determine the fair market value of the Company&#8217;s common stock, select the service providers to whom awards may be granted,
determine the number of shares covered by each award, approve forms of award agreements for use under the 2023 Plan, determine the terms
and conditions of awards (including the exercise price, the time or times at which the awards may be exercised, any vesting acceleration
or waiver or forfeiture restrictions and any restriction or limitation regarding any award or the shares relating thereto), construe and
interpret the terms of the 2023 Plan and awards granted under it, prescribe, amend and rescind rules relating to the 2023 Plan, including
creating sub-plans and modify or amend each award, including the discretionary authority to extend the post-termination exercisability
period of awards (provided that no option or stock appreciation right will be extended past its original maximum term), and to allow a
participant to defer the receipt of payment of cash or the delivery of shares that would otherwise be due to such participant under an
award. The administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial institution
or other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may be surrendered
or cancelled in exchange for awards of the same type which may have a higher or lower exercise price or different terms, awards of a different
type or cash, or by which the exercise price of an outstanding award is increased or reduced. The administrator&#8217;s decisions, interpretations
and other actions are final and binding on all participants.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Eligibility</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Awards under the 2023 Plan, other than
incentive stock options, may be granted to employees (including officers) of the Company or a subsidiary, members of the Company&#8217;s
Board, or consultants engaged to render bona fide services to the Company or a subsidiary. Incentive stock options may be granted only
to employees of the Company or a subsidiary.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Stock options may be granted under the
2023 Plan. The exercise price of options granted under the 2023 Plan generally must at least be equal to the fair market value of the
Company&#8217;s common stock on the date of grant. The term of each option will be as stated in the applicable award agreement; provided,
however, that the term may be no more than 10 years from the date of grant. The administrator will determine the methods of payment of
the exercise price of an option, which may include cash, shares or other property acceptable to the administrator, as well as other types
of consideration permitted by applicable law. After the termination of service of an employee, director or consultant, they may exercise
their option for the period of time stated in their option agreement. In the absence of a specified time in an award agreement, if termination
is due to death or disability, the option will remain exercisable for 12 months. In all other cases, in the absence of a specified time
in an award agreement, the option will remain exercisable for three months following the termination of service. An option may not be
exercised later than the expiration of its term. Subject to the provisions of the 2023 Plan, the administrator determines the other terms
of options.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Stock Appreciation Rights</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Stock appreciation rights may be granted
under the 2023 Plan. Stock appreciation rights allow the recipient to receive the appreciation in the fair market value of the Company&#8217;s
common stock between the exercise date and the date of grant. Stock appreciation rights may not have a term exceeding 10 years. After
the termination of service of an employee, director or consultant, they may exercise their stock appreciation right for the period of
time stated in their stock appreciation right agreement. In the absence of a specified time in an award agreement, if termination is due
to death or disability, the stock appreciation rights will remain exercisable for 12 months. In all other cases, in the absence of a specified
time in an award agreement, the stock appreciation rights will remain exercisable for three months following the termination of service.
However, in no event may a stock appreciation right be exercised later than the expiration of its term. Subject to the provisions of the
2023 Plan, the administrator determines the other terms of stock appreciation rights, including when such rights become exercisable and
whether to pay any increased appreciation in cash or with shares of the Company&#8217;s common stock, or a combination thereof, except
that the per share exercise price for the shares to be issued pursuant to the exercise of a stock appreciation right will be no less than
100% of the fair market value per share on the date of grant.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Restricted Stock</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Restricted stock may be granted under
the 2023 Plan. Restricted stock awards are grants of shares of the Company&#8217;s common stock that vest in accordance with terms and
conditions established by the administrator. The administrator will determine the number of shares of restricted stock granted to any
employee, director or consultant and, subject to the provisions of the 2023 Plan, will determine the terms and conditions of such awards.
The administrator may impose whatever conditions to vesting it determines to be appropriate (for example, the administrator may set restrictions
based on the achievement of specific performance goals or continued service to the Company); provided, however, that the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. Recipients of restricted stock awards
generally will have voting and dividend rights with respect to such shares upon grant without regard to vesting, unless the administrator
provides otherwise. Shares of restricted stock that do not vest are subject to the Company&#8217;s right of repurchase or forfeiture.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">RSUs may be granted under the 2023 Plan.
RSUs are bookkeeping entries representing an amount equal to the fair market value of one share of the Company&#8217;s common stock. Subject
to the provisions of the 2023 Plan, the administrator determines the terms and conditions of RSUs, including the vesting criteria and
the form and timing of payment. The administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business
unit or individual goals (including continued employment or service), applicable federal or state securities laws or any other basis determined
by the administrator in its discretion. The administrator, in its sole discretion, may pay earned RSUs in the form of cash, in shares
of the Company&#8217;s common stock or in some combination thereof. Notwithstanding the foregoing, the administrator, in its sole discretion,
may accelerate the time at which any vesting requirements will be deemed satisfied.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Performance Units and Performance
Shares</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Performance units and performance shares
may be granted under the 2023 Plan. Performance units and performance shares are awards that will result in a payment to a participant
only if performance goals established by the administrator are achieved or the awards otherwise vest. The administrator will establish
performance objectives or other vesting criteria in its discretion, which, depending on the extent to which they are met, will determine
the number or the value of performance units and performance shares to be paid out to participants. The administrator may set performance
objectives based on the achievement of Company-wide, divisional, business unit or individual goals (including continued employment or
service), applicable federal or state securities laws or any other basis determined by the administrator in its discretion. After the
grant of a performance unit or performance share, the administrator, in its sole discretion, may reduce or waive any performance criteria
or other vesting provisions for such performance units or performance shares. Performance units shall have an initial dollar value established
by the administrator on or prior to the grant date. Performance shares shall have an initial value equal to the fair market value of the
Company&#8217;s common stock on the grant date. The administrator, in its sole discretion, may pay earned performance units or performance
shares in the form of cash, in shares or in some combination thereof.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Non-Employee Directors</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The 2023 Plan provides that all non-employee
directors will be eligible to receive all types of awards (except for incentive stock options) under the 2023 Plan. The 2023 Plan includes
a maximum limit of $750,000 of equity awards that may be granted to a non-employee director in any fiscal year, increased to $1,500,000
in connection with his or her initial service. For purposes of this limitation, the value of equity awards is based on the grant date
fair value (determined in accordance with accounting principles generally accepted in the United States). Any equity awards granted to
a person for their services as an employee, or for their services as a consultant (other than as a non-employee director), will not count
for purposes of the limitation. The maximum limit does not reflect the intended size of any potential compensation or equity awards to
the Company&#8217;s non-employee directors.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Non-transferability of Awards</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless the administrator provides otherwise,
the 2023 Plan generally does not allow for the transfer of awards and only the recipient of an award may exercise an award during their
lifetime. If the administrator makes an award transferrable, such award will contain such additional terms and conditions as the administrator
deems appropriate.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Certain Adjustments</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the event of certain changes in the
Company&#8217;s capitalization, to prevent diminution or enlargement of the benefits or potential benefits available under the 2023 Plan,
the administrator will adjust the number and class of shares that may be delivered under the 2023 Plan or the number, and price of shares
covered by each outstanding award and the numerical share limits set forth in the 2023 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Dissolution or Liquidation</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the event of the Company&#8217;s proposed
liquidation or dissolution, the administrator will notify participants as soon as practicable and all awards will terminate immediately
prior to the consummation of such proposed transaction.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Merger or Change in Control</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The 2023 Plan provides that in the event
of the Company&#8217;s merger with or into another corporation or entity or a &#8220;change in control&#8221; (as defined in the 2023
Plan), each outstanding award will be treated as the administrator determines, including, without limitation, that (i) awards will be
assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof)
with appropriate adjustments as to the number and kind of shares and prices; (ii) upon written notice to a participant, that the participant&#8217;s
awards will terminate upon or immediately prior to the consummation of such merger or change in control; (iii) outstanding awards will
vest and become exercisable, realizable or payable, or restrictions applicable to an award will lapse, in whole or in part, prior to or
upon consummation of such merger or change in control and, to the extent the administrator determines, terminate upon or immediately prior
to the effectiveness of such merger or change in control; (iv) (A) the termination of an award in exchange for an amount of cash or property,
if any, equal to the amount that would have been attained upon the exercise of such award or realization of the participant&#8217;s rights
as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction
the administrator determines in good faith that no amount would have been attained upon the exercise of such award or realization of the
participant&#8217;s rights, then such award may be terminated by the Company without payment) or (B) the replacement of such award with
other rights or property selected by the administrator in its sole discretion; or (v) any combination of the foregoing. The administrator
will not be obligated to treat all awards, all awards a participant holds, or all awards of the same type, similarly. In the event that
awards (or portion thereof) are not assumed or substituted for in the event of a merger or change in control, the participant will fully
vest in and have the right to exercise all of their outstanding options and stock appreciation rights, including shares as to which such
awards would not otherwise be vested or exercisable, all restrictions on restricted stock and RSUs will lapse and, with respect to awards
with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all
other terms and conditions met, in all cases, unless specifically provided otherwise under the applicable award agreement or other written
agreement between the participant and the Company or any of the Company&#8217;s subsidiaries or parents, as applicable. If an option or
stock appreciation right is not assumed or substituted in the event of a merger or change in control, the administrator will notify the
participant in writing or electronically that the option or stock appreciation right will be exercisable for a period of time determined
by the administrator in its sole discretion and the vested option or stock appreciation right will terminate upon the expiration of such
period.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">For awards granted to an outside director,
the outside director will fully vest in and have the right to exercise all of their outstanding options and stock appreciation rights,
all restrictions on restricted stock and RSUs will lapse and, for awards with performance-based vesting, unless specifically provided
for in the award agreement, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other
terms and conditions met.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Clawback</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Awards will be subject to any Company
clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association
on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection
Act or other applicable laws. The administrator also may specify in an award agreement that the participant&#8217;s rights, payments or
benefits with respect to an award will be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain
specified events. The Board may require a participant to forfeit, return or reimburse the Company all or a portion of the award or shares
issued under the award, any amounts paid under the award and any payments or proceeds paid or provided upon disposition of the shares
issued under the award in order to comply with such clawback policy or applicable laws.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>Amendment and Termination</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The administrator has the authority to
amend, suspend or terminate the 2023 Plan provided such action does not impair the existing rights of any participant. The 2023 Plan automatically
will terminate on October 4, 2033, unless it is terminated sooner.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards as of December 31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of December
31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options exercisable (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options unexercisable (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option exercise price ($/share)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option expiration date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares or units of stock that have not vested (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market value of shares or units that have not vested ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Christer Ros&#233;n</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2,003,678</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 5%; text-align: center">2029-2033</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">497,392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Saleem Elmasri</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">666,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2032-2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66.292</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marshall Hayward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,245,098</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2026-2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">389,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Alexander Ros&#233;n</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,171,688</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2029-2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alison Silva</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">870,871</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">255,320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2028-2035</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><b>Director Compensation</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Prior to our 2024 initial public offering,
we did not have a formal policy to compensate our non-employee directors. Following our initial public offering, our non-employee directors
are eligible to receive the following cash retainers and equity awards. The retainers will be payable in four equal installments in each
calendar quarter and will be payable within five business days of the end of each calendar quarter, and with such amount for any partial
calendar quarter being appropriately prorated.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Annual Retainer for Board Membership</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 82%; text-align: left">Annual service on the board of directors</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Additional Annual Retainer for Committee Membership</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Annual service as member of the audit committee (other than chair)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annual service as chair of the audit committee</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Annual service as member of the compensation committee (other than chair)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annual service as chair of the compensation committee</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Annual service as member of the nominating and corporate governance committee (other than chair)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annual service as chair of the nominating and corporate governance committee</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon initial election to our board of
directors, each non-employee director will be granted an option to acquire up to 18,000 shares of the common stock at an exercise price
of $5.00 per share (subject to customary adjustments), which options shall vest ratably over 36 months, subject to the director continuing
to serve as a director of the Company during such period, pursuant to the Option Award Agreement. During the term of the independent director
agreements, the Company will reimburse each director for all reasonable out-of-pocket expenses incurred by the director in attending any
in-person meetings, provided that the director complies with the generally applicable policies, practices and procedures of the Company
for submission of expense reports, receipts or similar documentation of such expenses. Any reimbursements for allocated expenses (as compared
to out-of-pocket expenses of the director in excess of $500) must be approved in advance by the Company.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Other than as set forth in the table below
and as described more fully below, we did not pay any compensation or make any equity awards or non-equity awards to any of our non-employee
directors during 2025. Directors may be reimbursed for travel and other expenses directly related to their activities as directors. Directors
who also serve as employees receive no additional compensation for their service as directors. During 2025, each of Christer Ros&#233;n,
our Chief Executive Officer, Marshall Hayward, our Chief Scientific Officer, and Alison Silva, our President and Chief Business Officer,
was a member of our board of directors, as well as an employee, and therefore, received no additional compensation for their services
as a director. See &#8220;&#8212;2025 Summary Compensation Table&#8221; for more information about compensation to our NEOs for 2025 and
2024. The following table presents the total compensation for each person who served as a non-employee director during 2025 and 2024.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white"><i>2025 and 2024 Director
Compensation Table</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    Earned or Paid in Cash ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Awards ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards
                                            ($)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicholas
    H. Hemmerly</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julie
    Kampf</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holger
    Weis</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allison
    W. Brady</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><i>Director Agreements</i></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 8, 2021, the Company entered
into Independent Director Agreements with each of Allison Brady, Holger Weis, Julie Kampf and Nick Hemmerly (each, a &#8220;Director&#8221;)
relating to their service as independent directors of the Company.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to each of the agreements, the
Director agreed to serve as an independent director of the Company and to perform the duties consistent with such position. In addition,
pursuant to their respective agreements, Ms. Brady agreed to serve as a member of the Compensation Committee and Audit Committee; Mr.
Weis agreed to serve as a member of the Nomination Committee and the Chairman of the Audit Committee; Ms. Kampf agreed to serve as a member
of the Compensation Committee and as Chairman of the Nomination Committee of the Board; and Mr. Hemmerly agreed to serve as Chairman of
the Compensation Committee as well as a member of the Audit Committee and Nominating Committee.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the Directors confirmed that the
Director is independent (as such term has been construed under Delaware law with respect to directors of Delaware corporations and the
OTC Markets, the NASDAQ Stock Exchange and the New York Stock Exchange). Each Director also confirmed that, to their knowledge, (a) that
Director does not possess material business, close personal relationships or other affiliations, or any history of any such material business,
close personal relationships or other affiliations, with the Company&#8217;s significant equity or debt holders or any of their respective
corporate affiliates that would cause that Director to be unable to (i) exercise independent judgment based on the best interests of the
Company or (ii) make decisions and carry out that Director&#8217;s responsibilities as a director of the Company, in each case in accordance
with the terms of the Company&#8217;s governing documents and applicable law, and (b) that they have no existing relationship or affiliation
of any kind with any entity that the applicable Director knows to be a competitor of the Company.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements continues until
the earliest of (a) such time as the Director resigns or is removed in accordance with the Company&#8217;s governing documents, and (b)
the death of the Director.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Directors are compensated as follows
under their respective agreements:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the Directors will be paid $30,000
annually for their service as directors, to be paid $7,500 each calendar quarter, with the amount for any partial calendar quarter being
appropriately prorated. In addition, the Company agreed that, on October 1, 2021, the Company will issue to each Director an option to
acquire up to 67,500 shares of the common stock at an exercise price of $1.33 per share, which options will vest ratably over 36 months
subject to the applicable Director continuing to serve as a director of the Company during such period. The option grants were made pursuant
to an Option Award Agreement as attached to each of their respective agreements.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the applicable agreements
provide that the Directors will be compensated as follows in connection with their service on Committees of the Board.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Ms. Brady: For as long as Ms. Brady serves as a member of the Compensation Committee, Ms. Brady will be paid $5,000 annually to be paid $1,250 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Ms. Brady serves as a member of the Audit Committee, Ms. Brady will be paid $5,000 annually to be paid $1,250 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Mr. Weis:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif; text-align: justify">&#9675;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Mr. Weis serves as Chairman of the Audit Committee, Mr. Weis will be paid $10,000 annually to be paid $2,500 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify">&#9675;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Mr. Weis serves as a member of the Nominating Committee, Mr. Weis will be paid $4,000 annually to be paid $1,000 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Ms. Kampf:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif; text-align: justify">&#9675;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Ms. Kampf serves as a member of the Compensation Committee, Ms. Kampf will be paid $5,000 annually to be paid $1,250 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify">&#9675;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Ms. Kampf serves as
    Chairman of the Nominating Committee, Ms. Kampf will be paid $7,500 annually and $1,875 each calendar quarter, with the amount for
    any partial calendar quarter being appropriately prorated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0 0 0 0.9in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">Mr. Hemmerly:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="font-family: Times New Roman,serif; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif; text-align: justify">&#9675;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Mr. Hemmerly serves as a member of the Audit Committee, Mr. Hemmerly will be paid $5,000 annually to be paid $1,250 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify">&#9675;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Mr. Hemmerly serves as Chairman of the Compensation Committee, Mr. Hemmerly will be $10,000 annually to be paid $2,500 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify">&#9675;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">For as long as Mr. Hemmerly serves as a member of the Nominating Committee, Mr. Hemmerly will be paid $4,000 annually to be paid $1,000 each calendar quarter, with the amount for any partial calendar quarter being appropriately prorated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Each of the agreements contains customary
confidentiality provisions, and customary provisions relating to intellectual property created by the executive (i.e., a &#8220;work-made-for-hire&#8221;
provision. Each of the agreements is governed by Delaware law and contains customary representations and warranties and other miscellaneous
provisions.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_002"></span>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth information
regarding the beneficial ownership of our common stock as of March 31, 2026 by:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">each of our executive officers and directors that beneficially owns shares of our common stock; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif; text-align: justify">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">all our executive officers and directors as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">In the table below, percentage ownership
is based on 36,281,252 shares of our common stock issued and outstanding as of March 31, 2026. Unless otherwise noted below, the address
for each beneficial owner listed on the table is c/o Jupiter Neurosciences, Inc., 1001 North US Hwy 1, Suite 504, Jupiter, FL 33477. We
have determined beneficial ownership in accordance with the rules of the SEC. We believe, based on the information furnished to us, that
the persons and entities named in the tables below have sole voting and investment power with respect to all shares of common stock that
they beneficially own, subject to applicable community property laws.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Name and Address of Beneficial Owner</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Amount and</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Nature of</b></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>Shares Beneficial Ownership (1)</b></p></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-family: Times New Roman,serif; text-align: center"><span style="font-size: 10pt"><b>Percentage of Class</b></span></td>
    <td style="padding-bottom: 1pt; font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><b><i>Executive Officers and Directors:</i></b></span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 60%; font-family: Times New Roman,serif"><span style="font-size: 10pt">Christer Ros&#233;n</span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 16%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">13,080,566</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif"><span style="font-size: 10pt">(2)</span></td>
    <td style="width: 2%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 1%; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 16%; font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">33.7</span></td>
    <td style="width: 1%; font-family: Times New Roman,serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Marshall Hayward, Ph.D.</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">4,015,175</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">10.7</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Saleem Elmasri</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">732,712</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">2.0</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Alison D. Silva</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">983,648</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(5)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">2.6</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Alexander Ros&#233;n</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">1,789,099</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(6)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">4.8</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Nicholas H. Hemmerly</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">289,287</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(7)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Julie Kampf</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">259,868</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(8)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Allison W. Brady</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">270,409</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(9)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Holger Weis</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">277,436</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(10)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">All executive officers and directors as a group (9 persons)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">21,698,200</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(11)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">49.0</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt"><b><i>Other 5% Stockholders:</i></b></span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Claes Wahlestedt, M.D., Ph.D.</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">3,120,885</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(12)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">8.5</span></td>
    <td style="font-family: Times New Roman,serif">%</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">Shaun Brothers</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">1,939,736</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">(13)</span></td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: right"><span style="font-size: 10pt">5.6</span></td>
    <td style="font-family: Times New Roman,serif">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif"><span style="font-size: 10pt">*</span></td>
    <td style="font-family: Times New Roman,serif"><span style="font-size: 10pt">less than 1%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    percentages in the table have been calculated based on 36,281,252 shares of our common stock outstanding on March 31, 2026. To calculate
    a stockholder&#8217;s percentage of beneficial ownership, we include in the numerator and denominator the common stock outstanding
    and all shares of our common stock issuable to that person in the event of the exercise of outstanding options and other derivative
    securities owned by that person which are exercisable within 60 days of March 31, 2026. Common stock options and derivative securities
    held by other stockholders are disregarded in this calculation. Therefore, the denominator used in calculating beneficial ownership
    among our stockholders may differ. Unless we have indicated otherwise, each person named in the table has sole voting power and sole
    investment power for the shares listed opposite such person&#8217;s name.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    2,003,678 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,020,098 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    666,420 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    870,871 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,171,688 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    193,737 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    176,993shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    170,659 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    180,855 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares of common stock beneficially owned by Christer Ros&#233;n, Marshall Hayward, Ph.D., Saleem Elmasri, Alison D. Silva, Alexander
    Ros&#233;n, Nicholas H. Hemmerly, Julie Kampf, Allison W. Brady, and Holger Weis, as shown in the table above and in the footnotes
    to such table.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    289,609 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    326,319 shares of common stock that may be acquired within 60 days of March 31, 2026 upon exercise of vested options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Securities Authorized for Issuance under Equity Compensation
Plans</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">The following table provides information
as of December 31, 2025, regarding our compensation plans under which equity securities are authorized for issuance:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Plan category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options, warrants and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options, warrants and rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(c)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">8,254,974</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">9,893,319</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,948,928</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.20</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,203,902</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.02</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,893,319</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s stockholders approved
the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) on January 4, 2016. Under the 2016 Plan, as modified, 8,437,500 shares of common
stock are authorized for issuance to employees, officers, directors, consultants. The 2016 Plan authorizes the grant of nonqualified stock
options and incentive stock options, restricted stock awards, restricted stock units, stock appreciation rights, under the 2016 Plan.
The Company does not intend to make any additional grants under the 2016 Plan. As of March 31, 2026, there were 2,156,184 shares available
for issuance under the 2016 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors and stockholders
of the Company approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) on September 17, 2021. Under the 2021 Plan, 1,125,000
shares of common stock were initially authorized for issuance to employees, directors and independent contractors (except those performing
services in connection with the offer or sale of the Company&#8217;s securities in a capital raising transaction, or promoting or maintaining
a market for the Company&#8217;s securities) of the Company or its subsidiaries. The 2021 Plan authorizes equity-based and cash-based
incentives for participants. On July 22, 2022, the Board of Directors increased the shares authorized for issuance pursuant to the 2021
Plan to 1,710,000. The Company does not intend to make any grants under the 2021 Plan. As of March 31, 2026, there were 1,440,000 shares
available for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors and stockholders
of the Company approved the 2023 Plan on October 4, 2023. Under the 2023 Plan, 4,012,785 shares of common stock were authorized for issuance
to employees, directors and independent contractors (except those performing services in connection with the offer or sale of the Company&#8217;s
securities in a capital raising transaction, or promoting or maintaining a market for the Company&#8217;s securities) of the Company or
its subsidiaries. As of March 31, 2026, there were 1,047,135 shares available for issuance under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Board of Directors and stockholders
of the Company approved the 2025 Equity Incentive Plan (the &#8220;2025 Plan&#8221;) on December 19, 2025. Under the 2025 Plan, 5,250,000
shares of common stock are authorized for issuance to employees, directors and independent contractors (except those performing services
in connection with the offer or sale of the Company&#8217;s securities in a capital raising transaction, or promoting or maintaining a
market for the Company&#8217;s securities) of the Company or its subsidiaries. As of March 31, 2026, there were 5,250,000 shares available
for issuance under the 2025 Plan.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_003"></span>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Policies and Procedures for Related Party Transactions</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Under Item 404 of SEC Regulation S-K,
a related person transaction is any actual or proposed transaction, arrangement or relationship or series of similar transactions, arrangements
or relationships, including those involving indebtedness not in the ordinary course of business, to which we or our subsidiaries were
or are a party, or in which we or our subsidiaries were or are a participant, in which the amount involved exceeded or exceeds the lesser
of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years and in which any of our directors,
nominees for director, executive officers, beneficial owners of more than 5% of any class of our voting securities, or any member of the
immediate family of any of the foregoing persons, had or will have a direct or indirect material interest.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We recognize that transactions between
us and any of our directors or executives or with a third party in which one of our officers, directors or significant shareholders has
an interest can present potential or actual conflicts of interest and create the appearance that our decisions are based on considerations
other than the best interests of our Company and stockholders.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Audit Committee of the Board of Directors
is charged with responsibility for reviewing, approving and overseeing any transaction between the Company and any related person (as
defined in Item 404 of Regulation S-K), including the propriety and ethical implications of any such transactions, as reported or disclosed
to the Audit Committee by the independent auditors, employees, officers, members of the Board of Directors or otherwise, and to determine
whether the terms of the transaction are not less favorable to us than could be obtained from an unaffiliated party</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, we engage in transactions
with related parties. The following is a summary of the related party transactions for the fiscal years ended December 31, 2025 and 2024
requiring disclosure pursuant to Item 404 of Regulation S-K.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Notes Payable, related party</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Chief Executive
Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to the CEO as of December 31, 2024
was $146,432. The loan was due on demand and accrues interest at 3% per year. Accrued interest relating to the loan was $1,064 as of
December 31, 2024, and is included in accrued interest on the accompanying 2024 balance sheets. The Company fully settled the debt
in 2025 by repaying a total of $150,782, $146,432 in principal and $4,350 in accrued interest. The Company repaid a total of
$100,000 during the year ended December 31, 2024, $83,880 in principal and $16,120 in accrued interest.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 29, 2024, the Company, the
Holder of the Note II and the CEO entered into an amendment in which the CEO agreed to exchange 685,869 shares issued to the Holder
in exchange for his related party notes that accrued interest at 3% that are due from the Company in an aggregate principal amount
of $266,667 and the Holder agreed to forfeit all rights to all additional future shares from the Company that would have become due
upon a qualified offering and the conversion feature of the note. In addition, the Holder agreed to extend the note maturity date to
August 11, 2024. The note shall be designated as a 10% original issue discount secured note (&#8220;Senior Secured Note&#8221;)
moving forward. The note and interest will become due and payable upon the earliest of the maturity date or upon the occurrence of a
qualified event.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Other Related Party Transactions</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Accrued compensation includes partially
accrued salaries to executives since inception. Since inception, executive salaries have been paid in cash when the Company&#8217;s cash
flow has permitted such payment.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 15, 2024, a former executive
agreed to forgive $100,000 of accrued compensation in exchange for 49,605 options to purchase common stock and 7,500 restricted stock
units, The options to purchase common stock have a strike price of $1.33. The option had a grant date fair value of $50,000. The Company
recorded a gain on the forgiveness of accrued compensation in the amount of $40,000.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and 2024, $64,105
was due to a Company wholly owned by the Company&#8217;s Chief Financial Officer, who also is an option holder, respectively. The amount
is included in accrued compensation on the Company&#8217;s balance sheets.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Titan Consulting Agreement</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 31, 2022, the Company entered
into a Master Services Agreement with Titan Advisory Services LLC (&#8220;Titan&#8221;), which is wholly-owned by Mr. Elmasri and his
wife, pursuant to which Titan will provide certain services to the Company (the &#8220;MSA&#8221;). The MSA provides that the specific
services (the &#8220;Services&#8221;) will be described in separate Scopes of Work (&#8220;SOW&#8221;) which will constitute a part of
the MSA. The term of the MSA continues until 30 days after either party notifies the others that it desires to terminate the MSA.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Services, which commenced on January
1, 2023, are to be provided by Saleem Elmasri, and include Mr. Elmasri serving as the Chief Financial Officer of the Company, and having
the following responsibilities: (i) overall financial strategy implementation and execution; (ii) overseeing forecasts and budgeting;
(iii) overseeing the Company&#8217;s finance/accounting department; (iv) financial reporting; and (v) overseeing tax compliance. Separately,
Mr. Elmasri has also been named as the Secretary of the Company.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The MSA agreement provides that the Company
shall pay Titan a monthly fee in the amount of $25,000 (annual fee in aggregate of $300,000 per year) and that Mr. Elmasri will be issued
an option to acquire 562,500 shares of common stock, pursuant to a separate option agreement. 25% of the options are vested upon issuance,
with the balance to vest in equal quarterly installments over the following 24 months, and the option has a 10-year term. The exercise
price for the shares of common stock will be $1.33. The options will accelerate and vest immediately upon a merger, acquisition or other
transaction that will be deemed a change of control of the Company. Titan and Mr. Elmasri will be eligible to participate in additional
incentive equity or cash compensation alongside the Company&#8217;s other executives, at the sole discretion of the Company. Any additional
resources used by Titan to provide the Services, subject to prior approval by the Company, will be billed to the Company at between $150
and $250 per hour, and the Company has also agreed to reimburse Titan for all reasonable out-of-pocket expenses that Titan incurs in providing
the Services.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The MSA includes a customary confidentiality
provision for the benefit of the Company, and also includes a non-solicitation provision pursuant to which each party agrees that during
the term of the MSA and for a period of one year thereafter, neither party will, without the prior written consent of the other, engage
in any way, employ, hire, or otherwise do business with any employee or former employee of the other party.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The MSA provides that the Company will
be solely responsible for the contents of the information it provides to Titan in connection with the MSA, and the Company makes customary
representations and warranties regarding such information. The Company also agreed in the MSA to indemnify Titan, its principals, employees
and representatives, from and against any claims, losses, damages or any other liability arising from or as a result of (i) Titan performing
the Services or any other services requested by the Company, (ii) any claim by the Company or any third party of any misrepresentation
or reliance on any information resulting from the Services; (iii) any claim by the Company or any third party or governmental agency brought
under the federal securities laws or other statutes, state statute, or common law, or otherwise, or (iv) any claim by the Company or any
third party in connection with the sale or issuance of any shares of the Company&#8217;s stock, or other equity or debt of the Company.
The maximum liability of Titan that may arise out of the Services is limited to the total fees paid to Titan for a particular SOW, unless
Titan is found to be grossly negligent in its duties or acts with willful misconduct.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The MSA contains customary miscellaneous
provisions, including a no-assignment provision, and an agreement to submit any disputes to mediation, or thereafter to arbitration if
the mediation is not successful.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2023, Titan agreed to reduce
the monthly fee to $20,000 per month until the time that the Company has raised additional capital from the sale of its securities in
the amount of $1,500,000.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 18, 2023, Titan agreed to
reduce the monthly fee to $5,000 per month, effective retrospectively to October 1, 2023, until the time that the Company has raised additional
capital from the sale of its securities in the amount of $1,500,000 (the &#8220;Reduction Period&#8221;). Upon the expiration of the Reduction
Period, the base salary shall be adjusted to be 105% the original base salary. Such adjustment did not go into effect.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 17, 2024, the parties agreed that the Company would pay to Titan a monthly fee in the amount of $20,000
(amounting to an aggregate annual fee of $240,000). Titan is not owed any additional fees upon a termination or change in control. In
addition, Titan is eligible for cash bonuses and additional equity compensation, at the Company&#8217;s discretion.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on the Nasdaq
Capital Market. Under applicable rules of the Nasdaq Capital Market, a director will only qualify as an &#8220;independent director&#8221;
if, in the opinion of the listed company&#8217;s board of directors, that person does not have a relationship that would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes
of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit
committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory
fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Board of Directors
has affirmatively determined that currently three of its seven directors (Christer Ros&#233;n, Marshall Hayward, Ph.D., and Alison D.
Silva) are non-independent directors of the Company and four of its seven directors (Nicholas H. Hemmerly, Julie Kampf, Allison W. Brady,
and Holger Weis) are independent directors of the Company as defined in the Nasdaq standards. Therefore, a majority of the members of
our Board of Directors are independent.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"><b><span id="m_004"></span>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Audit Committee has appointed Cherry
Bekaert LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ended December 31, 2025 and Assurance
Dimensions, LLC as the Company&#8217;s independent registered public accounting firm for the fiscal year ended December 31, 2024. The
following is a summary of fees paid or to be paid to Cherry Bekaert and Assurance Dimensions for the fiscal years ended December 31, 2025
and 2024.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify">Audit Fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">112,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">84,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">All Other Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Audit Fees</i>. Audit fees consist
of fees billed for professional services rendered for the audit of our year-end financial statements and services that are normally provided
by our independent registered public accounting firm in connection with regulatory filings. The above amounts include interim procedures
and audit fees, as well as attendance at Audit Committee meetings.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Audit-Related Fees.</i> Audit-related
services consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of
our financial statements and are not reported under &#8220;Audit Fees.&#8221; These services include attest services that are not required
by statute or regulation and consultations concerning financial accounting and reporting standards.</p>


<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Fees</i>. Tax fees consist of fees billed for tax planning services and tax advice. The board of directors must specifically approve
all other tax services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>All
Other Fees</i>. Other services are services provided by the independent registered public accounting firm that do not fall within the
established audit, audit-related, and tax services categories. The board of directors preapproves specified other services that do not
fall within any of the specified prohibited categories of services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Approval
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
formation of our Audit Committee, all of the foregoing services were pre-approved by our Audit Committee. Our Audit Committee will pre-approve
all auditing services and permitted non-audit services to be performed for us by our auditors, including the fees and terms thereof (subject
to the de minimis exceptions for non-audit services described in the Exchange Act which are approved by the Audit Committee prior to
the completion of the audit).&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_005"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_006"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following documents are filed as part of this Annual Report on Form 10-K:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_001">Report of Independent Registered Public Accounting Firm Cherry Bekaert LLP, PCAOB ID: 677</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><a href="#mfin_01">Report of Independent Registered Public Accounting Firm Assurance Dimensions, LLC PCAOB ID: 5036</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_02">Balance
    Sheets as of December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_03">Statements
    of Operations for the Years Ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_04">Statements
    of Changes in Stockholders&#8217; Equity (Deficit) for the Years Ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_05">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_06">Notes
    to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements Schedules</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    financial statements schedules are omitted because they are not applicable or the amounts are immaterial and not required, or the
    required information is presented in the financial statements and notes thereto beginning on page F-1 of this Annual Report on Form
    10-K.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    hereby file as part of this Annual Report on Form 10-K the exhibits listed in the Exhibit Index below. Exhibits which are incorporated
    herein by reference can be inspected and copied at the public reference facilities maintained by the SEC, 100 F Street, N.E., Room
    1580, Washington, D.C. 20549. Copies of such material can also be obtained from the Public Reference Section of the SEC, 100 F Street,
    N.E., Washington, D.C. 20549, at prescribed rates or on the SEC website at www.sec.gov.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Incorporation of the Company dated December 30, 2015 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s
    Registration Statement on Form S-1 filed with the SEC on October 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315225028789/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation of Jupiter Neurosciences, Inc. (incorporated by reference to Exhibit 3.1 of the
    Company&#8217;s Current Report on 8-K filed with the SEC on December 22, 2025).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-2.htm" style="-sec-extract: exhibit">Certificate
    of Validation of the Company dated July 9, 2021 (including Certificate of Amendment to Certificate of Incorporation of the Company)
    (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October
    12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-3.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation of the Company dated August 30, 2021 (incorporated by reference to Exhibit 3.3 of the
    Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221031850/ex3-4.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation of the Company dated November 19, 2021 (incorporated by reference to Exhibit 3.4 of the
    Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on December 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315222002313/ex3-5.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation of the Company dated January 25, 2022 (incorporated by reference to Exhibit 3.5 of the
    Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on January 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224027145/ex3-6.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation of the Company dated June 14, 2024 (incorporated by reference to Exhibit 3.6 of the
    Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on July 12, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex3-4.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws (incorporated by reference to Exhibit 3.4 of the Company&#8217;s Registration Statement on Form S-1 filed with
    the SEC on October 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Description of Capital Stock.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/ex4-1.htm" style="-sec-extract: exhibit">Form of Convertible Promissory Note issued to YA II PN, Ltd. (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 27, 2025)+#</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315225024454/ex4-1.htm" style="-sec-extract: exhibit">Form of Amended and Restated Convertible Promissory Note issued to YA II PN, Ltd. (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 19, 2025).+#</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315226007624/ex4-3.htm" style="-sec-extract: exhibit">Omnibus Amendment to the Convertible Promissory Notes issued to YA II PN, Ltd., dated February 20, 2026, between Jupiter Neurosciences, Inc. and YA II PN, Ltd. (incorporated by reference to Exhibit 4.3 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on February 20, 2026). #</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-1.htm" style="-sec-extract: exhibit">Jupiter
    Orphan Therapeutics, Inc. 2021 Equity Incentive Plan&#8224; (incorporated by reference to Exhibit 10.1 of the Company&#8217;s
    Registration Statement on Form S-1 filed with the SEC on October 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-2.htm" style="-sec-extract: exhibit">Employment
    Agreement, dated as of September 1, 2021, between the Company and Christer Ros&#233;n (incorporated by reference to Exhibit 10.2
    of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-3.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Christer Ros&#233;n (incorporated
    by reference to Exhibit 10.3 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12,
    2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-4.htm">Amendment No. 2 to Executive Employment Agreement, dated as of December 18, 2023, between the Company and Christer Ros&#233;n&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-4.htm" style="-sec-extract: exhibit">Employment Agreement, dated as of September 1, 2021, between the Company and Marshall Hayward, Ph.D. (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-5.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Marshall Hayward, Ph.D.
    (incorporated by reference to Exhibit 10.5 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October
    12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10.7*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-7.htm">Amendment No. 2 to Executive Employment Agreement, dated as of December 18, 2023, between the Company and Marshall Hayward, Ph.D.&#8224;</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-6.htm" style="-sec-extract: exhibit">Employment
    Agreement, dated as of June 6, 2021, between the Company and Alexander Ros&#233;n (incorporated by reference to Exhibit 10.6 of
    the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-7.htm" style="-sec-extract: exhibit">Amendment No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Alexander Ros&#233;n (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-8.htm" style="-sec-extract: exhibit">Employment
    Agreement, dated as of September 1, 2021, between the Company and Alison Silva (incorporated by reference to Exhibit 10.8 of the
    Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-9.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Alison D. Silva (incorporated by reference to Exhibit
    10.9 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10.12</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-12.htm">Amendment No. 2 to Executive Employment Agreement, dated as of December 18, 2023, between the Company and Alison D. Silva.&#8224;</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-10.htm" style="-sec-extract: exhibit">Employment
    Agreement, dated as of June 1, 2021, between the Company and Dana Eschenburg Perez (incorporated by reference to Exhibit 10.10 of
    the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-11.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to Executive Employment Agreement, dated as of September 29, 2021, between the Company and Dana Eschenburg Perez (incorporated
    by reference to Exhibit 10.11 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12,
    2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-12.htm" style="-sec-extract: exhibit">Independent Director Agreement, dated as of September 8, 2021, between the Company and Nicholas H. Hemmerly (incorporated by reference to Exhibit 10.12 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-13.htm" style="-sec-extract: exhibit">Independent
    Director Agreement, dated as of September 8, 2021, between the Company and Julie Kampf (incorporated by reference to Exhibit 10.13
    of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-14.htm" style="-sec-extract: exhibit">Independent
    Director Agreement, dated as of September 8, 2021 between the Company and Allison W. Brady (incorporated by reference to Exhibit
    10.14 of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221025154/ex10-16.htm" style="-sec-extract: exhibit">Independent
    Director Agreement, dated as of September 8, 2021, between the Company and Holger Weis (incorporated by reference to Exhibit 10.16
    of the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on October 12, 2021)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-16.htm" style="-sec-extract: exhibit">License
    Agreement with Aquanova AG (incorporated by reference to Exhibit 10.16 of the Company&#8217;s Registration Statement on Form S-1/A
    filed with the SEC on November 9, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-17.htm" style="-sec-extract: exhibit">Grant
    Agreement between Company and National Institute on Aging (incorporated by reference to Exhibit 10.17 of the Company&#8217;s
    Registration Statement on Form S-1/A filed with the SEC on November 9, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-18.htm" style="-sec-extract: exhibit">Agreement
    between Company and Murdoch Children&#8217;s Research Institute (incorporated by reference to Exhibit 10.18 of the Company&#8217;s
    Registration Statement on Form S-1/A filed with the SEC on November 9, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-19.htm" style="-sec-extract: exhibit">Manufacturing
    Agreement between Company and Catalent (incorporated by reference to Exhibit 10.19 of the Company&#8217;s Registration Statement on
    Form S-1/A filed with the SEC on November 9, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-20.htm" style="-sec-extract: exhibit">Agreement
    between the Company and Syneos Health (incorporated by reference to Exhibit 10.20 of the Company&#8217;s Registration Statement on
    Form S-1/A filed with the SEC on November 9, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315221027617/ex10-21.htm" style="-sec-extract: exhibit">Material
    Transfer Agreement between the Company and University of Miami (incorporated by reference to Exhibit 10.21 of the Company&#8217;s
    Registration Statement on Form S-1/A filed with the SEC on November 9, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315222024119/ex10-30.htm" style="-sec-extract: exhibit">Research
    Agreement, dated July 1, 2022, between the Company and University of Miami (incorporated by reference to Exhibit 10.30 of the
    Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on August 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315222034319/ex10-31.htm" style="-sec-extract: exhibit">Amendment
    to the Securities Purchase Agreement, dated as of October 10, 2022, between the Company and Puritan Partners LLC (incorporated by reference to Exhibit
    10.31 of the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on December 2, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315222034319/ex10-32.htm" style="-sec-extract: exhibit">Second
    Amendment to the Securities Purchase Agreement, dated as of November 10, 2022, between the Company and Puritan Partners LLC
    (incorporated by reference to Exhibit 10.32 of the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on
    December 2, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315223000795/ex10-33.htm" style="-sec-extract: exhibit">Master
    Services Agreement, dated as of December 27, 2022, between the Company and Titan Advisory Services (incorporated by reference to
    Exhibit 10.33 of the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on January 6,
    2023)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315223001540/ex10-35.htm" style="-sec-extract: exhibit">Third
    Amendment to the Securities Purchase Agreement, dated as of January 13, 2013, between the Company and Puritan Partners LLC
    (incorporated by reference to Exhibit 10.35 of the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on
    January 17, 2023)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224027145/ex10-35.htm" style="-sec-extract: exhibit">CRO
    Services Agreement, dated June 3, 2024, between the Company and Optimize Wellness Limited (incorporated by reference to Exhibit
    10.35 of the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on July 12, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224027145/ex10-36.htm" style="-sec-extract: exhibit">Regulatory
    Services Agreement, dated June 3, 2024, between the Company and Regis Healthcare Group Limited (incorporated by reference to Exhibit
    10.36 of the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on July 12, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224027145/ex10-37.htm" style="-sec-extract: exhibit">Product
    Services Agreement, dated June 3, 2024, between the Company and Longevity Technology Group Limited (incorporated by reference to
    Exhibit 10.37 of the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on July 12, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224027145/ex10-40.htm" style="-sec-extract: exhibit">Jupiter
    Neurosciences, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.40 of the Company&#8217;s Registration
    Statement on Form S-1/A filed with the SEC on July 12, 2024)&#8224;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224046734/ex10-1.htm" style="-sec-extract: exhibit">Tenth
    Amendment, dated as of November 15, 2024, between Puritan Partners LLC and the Company (incorporated by reference to Exhibit 10.1
    of the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 19, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224048687/ex10-1.htm" style="-sec-extract: exhibit">Underwriting
    Agreement, dated as of December 2, 2024, between the Company and the certain underwriter set forth in the signature page thereto
    (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 4, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224050801/ex10-1.htm" style="-sec-extract: exhibit">Strategic
    Services Agreement, dated December 15, 2024, by and between the Company and Dominant Treasure Health Company Limited (incorporated
    by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 19, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224050881/ex10-1.htm" style="-sec-extract: exhibit">Scope
    of Work, dated December 17, 2024, by and between Jupiter Neurosciences, Inc. and Titan Advisory Services LLC (incorporated by reference
    to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 20, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/ex10-1.htm" style="-sec-extract: exhibit">Standby Equity Purchase Agreement, as of&#160;October 24,&#160;2025, between Jupiter Neurosciences, Inc. and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 27, 2025). +#</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315225024454/ex10-3.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to the Standby Equity Purchase Agreement, as of November 19, 2025, between Jupiter Neurosciences, Inc. and YA II PN, Ltd.
    (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 19,
    2025) +#</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, as of&#160;October 24,&#160;2025, between Jupiter Neurosciences, Inc. and YA II PN, Ltd. (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 27, 2025) +</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315225028789/ex10-1.htm" style="-sec-extract: exhibit">Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 22, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000164117225001261/ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics and Business Conduct (incorporated by reference to Exhibit 14.1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1679628/000164117225001261/ex19-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Policy on Insider Trading (incorporated by reference to Exhibit 19.1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-1.htm">Consent of Cherry Bekaert LLP</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23.2*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex23-2.htm">Consent of Assurance Dimensions, LLC</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#poa">Power
    of Attorney (included on the signature page)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Principal Executive Officer and Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex97-1.htm">Compensation Recovery Policy.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Furnished herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;
Management contracts, compensation plans and arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">+ Certain portions of this exhibit (indicated by &#8220;[***]&#8221;)
have been redacted pursuant to Regulation S-K Item 601(a)(6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"># Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes
to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_007"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><b></b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><a href="#mm_001">Report of Independent Registered Public Accounting Firm Cherry Bekaert LLP, PCAOB ID: <span id="xdx_90C_edei--AuditorFirmId_c20250101__20251231_zPRV1OSeUWBa"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000076" name="dei:AuditorFirmId">677</ix:nonNumeric></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center">F-2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_01">Report
    of Independent Registered Public Accounting Firm Assurance Dimensions, LLC PCAOB ID: <span id="xdx_900_edei--AuditorFirmId_c20240101__20241231_zkuidwEKPrA1"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000077" name="dei:AuditorFirmId">5036</ix:nonNumeric></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_02">Balance
    Sheets as of December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_03">Statements
    of Operations for the Years Ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_04">Statements
    of Changes in Stockholders&#8217; Equity (Deficit) for the Years Ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_05">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2025 and 2024</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mfin_06">Notes
    to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="mm_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter,
Florida</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheet of Jupiter Neuroscience, Inc. (the &#8220;Company&#8221;) as of December 31, 2025, and the
related statements of operations, stockholders&#8217; equity, and cash flows the year ended December 31, 2025, and the related notes.
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles
generally accepted in the United States of America.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial
Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to
the financial statements, the Company has recurring losses and negative cash flows from operations that raise substantial doubt about
its ability to continue as a going concern. Management&#8217;s evaluations of the events and conditions and management&#8217;s plans
regarding those matters are also described in Note 2. The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90C_edei--AuditorName_c20250101__20251231_zwdswl7hUpmf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000078" name="dei:AuditorName">Cherry Bekaert LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--AuditorLocation_c20250101__20251231_zrUXLRQKHk92"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000079" name="dei:AuditorLocation">Tampa, Florida</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="mfin_01"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter
Neurosciences, Inc</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheet of Jupiter Neurosciences, Inc, (the Company) as of December 31, 2024, and the related statements
of operations, stockholders&#8217; equity (deficit), cash flows for the year ended December 31, 2024, and the related notes (collectively
referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31,
2024, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company had a net loss of approximately $2,440,000 and cash used in operating activities of approximately
$3,911,000 for the year ended December 31, 2024 as well as an accumulated deficit of approximately $26,022,000 as of December 31, 2024.
These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard
to these matters are described in Note 2. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><img src="form10-k_004.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorLocation_c20240101__20241231_zDJmUsYPkywj"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000080" name="dei:AuditorLocation">Coral Springs, Florida</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">March 28, 2025</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b><span id="xdx_90F_edei--AuditorName_c20240101__20241231_zdhOnRHgJxD6"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000081" name="dei:AuditorName">ASSURANCE
DIMENSIONS, LLC</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>also
d/b/a McNAMARA and ASSOCIATES, LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>TAMPA
BAY: 4920 W Cypress Street, Suite 102 | Tampa, FL 33607 | Office: 813.443.5048 | Fax: 813.443.5053</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>JACKSONVILLE:
7800 Belfort Parkway, Suite 290 | Jacksonville, FL 32256 | Office: 888.410.2323 | Fax: 813.443.5053</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>ORLANDO:
1800 Pembrook Drive, Suite 300 | Orlando, FL 32810 | Office: 888.410.2323 | Fax: 813.443.5053</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>SOUTH
FLORIDA: 3111 N. University Drive, Suite 621 | Coral Springs, FL 33065 | Office: 754.800.3400 | Fax: 813.443.5053</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">www.assurancedimensions.com</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#8220;Assurance
Dimensions&#8221; is the brand name under which Assurance Dimensions, LLC including its subsidiary entities McNamara and Associates,
LLC (referred together as &#8220;AD LLC&#8221;) and AbitOs Advisors, LLC (&#8220;AbitOs Advisors&#8221;), provide professional services.
AD LLC and AbitOs Advisors practice as an alternative practice structure in accordance with the AICPA Code of Professional Conduct and
applicable laws, regulations, and professional standards. AD LLC is a licensed independent CPA firm that provides attest services to
its clients, and AbitOs Advisors provides tax and business consulting services to their clients. AbitOs Advisors, and its subsidiary
entities are not licensed CPA firms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="mfin_02"></span>BALANCE
SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_111_zStO8DRbXOEj" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231_zunZrrrsjX6c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, <br/> 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20241231_zy8QWORypkr8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, <br/> 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--Cash_i02I_pp0p0_maACz4Mq_zHlmBkOdqMU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,789,342</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,769,510</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsReceivableNetCurrent_i02I_pp0p0_maACz4Mq_z6hEcjeFoPB9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account
    receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,637</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_i02I_pp0p0_maACz4Mq_zQTyzCS9tWgh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    contracts</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">766,667</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">766,667</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InventoryNet_i02I_pp0p0_maACz4Mq_z2jupkKmil5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory,
    net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,790</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsCurrent_i02I_pp0p0_maACz4Mq_zlW5W0Gh2jp7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,542</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">114,086</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACz4Mq_maAzps7_ztYwyBPLtIa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,824,978</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,650,263</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzps7_zfXMzrpN9uVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right of use asset, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,214</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,642</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseNoncurrent_i01I_maAzps7_zhvW6nlOCwX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    contracts, noncurrent</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2025-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">712,055</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2024-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,478,721</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherAssetsNoncurrent_i01I_maAzps7_zmCLJGBK1dgh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,783</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,783</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_pp0p0_mtAzps7_z3g8dxLW3JJ" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,564,030</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,202,409</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
    and Stockholders&#8217; Deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0p0_maLCzKRH_zvKv9wkzcuFh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable and accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">638,646</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">396,483</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--DeferredCompensationLiabilityCurrent_i02I_pp0p0_maLCzKRH_zoOZRK1mtQyl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,397,357</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,415,093</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_i02I_pp0p0_maLCzKRH_zS5LsanXnTKi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,829</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,064</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredRevenue_i02I_pp0p0_maLCzKRH_zAThY0adfOm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2025-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">735</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0135">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCzKRH_z57HZ66OuKq6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,082</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NotesPayableCurrent_i02I_pp0p0_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzKRH_zeFk4WWTWCDd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    payable, related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0140">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000141" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">146,432</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ConvertibleNotesPayableCurrent_i02I_pp0p0_maLCzKRH_z5ArWaTyso32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    notes payable, fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,298,068</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_maLCzKRH_zsTF3mLrmWcf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0146">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0147">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_maLz7bB_mtLCzKRH_zhcWaEQCcDO4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,395,882</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,009,154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pp0p0_maLz7bB_zjhwncAPu1Kj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0152">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--Liabilities_i01TI_pp0p0_mtLz7bB_maLASEzBIs_zxTAFOxhCvni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,395,882</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,030,401</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzBIs_zmWFziukCbGd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and Contingencies (Note 8)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0158">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0159">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&#8217;
    Deficit:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PreferredStockValue_i02I_pp0p0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_maSEzSrw_zBJsiOp4n9tk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    A preferred stock, par value $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20251231_zRHuu3kJhlmj" title="Series A preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_z4JuIepQmHM4" title="Series A preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20251231_z6lcLd9gkHD5" title="Series A preferred stock, shares authorized"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zHUnAFPVeGhi" title="Series A preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20251231_zUBqGvrr3Lq1" title="Series A preferred stock, shares issued::XDX::-"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20241231_z2YIgzxow4i3" title="Series A preferred stock, shares issued::XDX::-"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20251231_z1ut59offqg3" title="Series A preferred stock, shares outstanding::XDX::-"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20241231_zUkDgkMAIHfd" title="Series A preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0175"><span style="-sec-ix-hidden: xdx2ixbrl0177"><span style="-sec-ix-hidden: xdx2ixbrl0179"><span style="-sec-ix-hidden: xdx2ixbrl0181">nil</span></span></span></span></span></span></span></span> shares issued and outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0164">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0165">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzSrw_zL8jJGFedYOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_z7AMn3IiT57c" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zNXut7cmEDGa" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_z4D7bzD5fdO4" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></span>
    and <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zgG7jKKVQf7j" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000,000</ix:nonFraction></span> shares authorized, respectively; <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20251231_zLaRWY6AoIW7" title="Common stock, share issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zFpVbgKpqfBi" title="Common stock, share outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,446,455</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20241231_z5QvMM3ZrbZ8" title="Common stock, share issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zuLfMoxIi8wd" title="Common stock, share outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,103,860</ix:nonFraction></ix:nonFraction></span></span>
    issued and outstanding, respectively</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,444</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,310</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzSrw_zgk7HME3zoZc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,831,730</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,190,827</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzSrw_zPFa7onvc6f6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">34,667,026</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,022,129</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzSrw_maLASEzBIs_zYs7qzsDlGTk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&#8217; deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,831,852</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,172,008</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzBIs_zaSx87sISYRb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders&#8217; deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,564,030</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,202,409</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="mfin_03"></span>STATEMENTS
OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_113_zVIiGvLkoBE" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231_zHM0iJJNqFK5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20240101__20241231_zth9fBGtTjjk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Year Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Dec-25</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Dec-24</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_i01_pp0p0_d0_maGPzxRk_zawHpznQqLL2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
Revenues, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2025-01-01to2025-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,796</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact000215" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">-</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CostOfGoodsAndServicesSold_msGPzxRk_zNFr6oTAGuB5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--GrossProfit_iT_mtGPzxRk_maOILzra7_zlHdKs4Jm1cf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Profit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,565</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0221">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzzLd_zpebmmF4CsAc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,086,574</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">492,660</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzzLd_zap1umCzEoSk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,839,712</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,598,622</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzzLd_msOILzra7_zc25eOtFr4ug" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,926,286</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,091,282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzra7_maNILzaqG_z7iJ2AWQMa58" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,908,721</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,091,282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Income (Expenses):</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--InvestmentIncomeInterest_i01_pp0p0_maNIEzsr7_zheWP4MTVSu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0241">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2024-01-012024-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,557</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_i01_pp0p0_maNIEzsr7_zlYdOsEbYwDk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on change in fair value of derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="From2024-01-012024-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">53,257</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_pp0p0_maNIEzsr7_zWlHOH8xIOA1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on change in fair value of convertible notes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">281,932</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0248">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_i01N_pp0p0_di_msNIEzsr7_zNvQNy0mqcHc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-01to2025-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,020</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">248,366</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_ecustom--GainOnExtinguishmentOfDebt_i01_pp0p0_maNIEzsr7_zj5uqJTAuTr6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on extinguishment of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0253">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:GainOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">857,723</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OtherIncome_i01_pp0p0_maNIEzsr7_zeAZZwgJk0vd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,912</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherIncome" contextRef="From2024-01-012024-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">90,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_maNILzaqG_mtNIEzsr7_zMKJujFPI32f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other expenses, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">263,824</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">651,657</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzaqG_zqsKd1D4wST6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    income (loss)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,644,897</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,439,625</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per common share:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_i01_z6xol6ROyC8e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_i01_zOKy0DmN73Kc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.25</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicOtherDisclosuresAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of common shares outstanding:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zCrZtM6eslz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,628,588</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,783,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_zcfORUCRiwB5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,628,588</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,783,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mfin_04"></span><b>STATEMENTS
OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (DEFICIT</b>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_114_z7D5W7e78Xdk" summary="xdx: Statement - Statements of Changes in Stockholders' Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zUzoElnut1Ta" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zoaDRwN6XgU6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--ReceivablesforSaleofCommonStockMember_za3sQzEFdVY1" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zCRat6xwIzul" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_zN5G070nFGYb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_437_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zjeBA8xdGooh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    31, 2023</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbEQrtg05Bli" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,526,405</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,652</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,778,498</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,582,504</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,801,354</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_ziBpzSWcOCCi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0291">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,840,908</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,840,908</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary_zugszFfv1cvg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of restricted stock units for forgiveness of accrued salary</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary_zVv6tJwPC4Cb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of stock options for forgiveness of accrued salary</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" contextRef="From2024-01-012024-12-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zxOiIuTqQwm5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock issued for consulting agreements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk4KOyt1BG8l" title="Restricted stock issued for consulting agreement, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,487,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">349</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zLbK2JNT2fOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale of common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT78PTTDXIs2" title="Sale of common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">112,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,989</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zfnhg7bUOhLf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock issued in connection with automatic conversion of convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Stock issued in connection with automatic conversion of convertible notes, shares" id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRCe5jcoT0e3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">227,447</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,843</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,866</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts_zqgepMT3cmhe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock sold in offering, net of offering costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Stock sold in offering, net of offering costs, shares" id="xdx_986_ecustom--StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFNTu7p4S2y2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,750,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,724,938</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" contextRef="From2024-01-012024-12-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,725,213</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueStockSplits_zNtxiH0YDh23" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciling
    shares due to forward stock split</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzPQqkeKceDg" title="Reconciling shares due to forward stock split, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000347" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zIGbYkggEtQb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Balance, shares" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0351">-</span></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000352" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,439,625</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,439,625</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_430_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zDh8QziA4A4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z560zsJ4mQbd" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000361" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,103,860</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,190,827</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,022,129</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,172,008</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zwsuUNTFs4Bg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zHipUsJGxtue" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--ReceivablesforSaleofCommonStockMember_zM9n3mLpUFo1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z7qZr1dLhaGl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_z9HZC7Pyd5tb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables
    for Sale of Common</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20250101__20251231_eus-gaap--StockholdersEquity_iS_zs6hJJSS59Y" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUusVB7CtUl2" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,103,860</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,190,827</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,022,129</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,172,008</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_znwokKXOxUQ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,139,908</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,139,908</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zxwpVASGIdYa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    issued for services rendered</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPlS59WYMD56" title="Shares issued for services rendered, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,186</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,990</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-01to2025-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueWarrantExercises_znBvNUpRfox8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    issued for warrant exercises</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesWarrantExercises_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfKt7P3uPKci" title="Shares issued for warrant exercises, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodSharesWarrantExercises" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">943,846</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueWarrantExercises" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueWarrantExercises" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zXbTWj33TOgk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    issued in connection with warrant amendments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zynV5u0oRDTd" title="Shares issued in connection with warrant amendments, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">143,654</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,593</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2025-01-01to2025-12-31" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,608</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest_zZKfEeetPXZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for payment of interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zarEQCRuYFw5" title="Issuance of common stock for payment of interest, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,519</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,521</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueCommitmentShares_zXvT06ySxTs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitment
    shares issued in connection with SEPA</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesCommitmentShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZM5RieItZt9" title="Commitment shares issued in connection with SEPA, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodSharesCommitmentShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000415" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">131,909</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueCommitmentShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueCommitmentShares" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,987</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodValueCommitmentShares" contextRef="From2025-01-01to2025-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zx27AuTm7Bqh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000420" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,644,897</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000421" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,644,897</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_439_c20250101__20251231_eus-gaap--StockholdersEquity_iE_zx5zdje8dlO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0HmbuoL788l" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000429" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,446,455</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,444</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,831,730</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,667,026</ix:nonFraction></b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000427" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,831,852</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="mfin_05"></span>STATEMENTS
OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_112_zil5d5GxwHY3" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250101__20251231_zGKFiuj2jHnf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zPNM4wpNh9zg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Flows from Operating Activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUzAQk_z7RQfziGF6Wi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000434" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,644,897</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,439,625</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used in operating activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_i02N_di_msNCPBUzAQk_zhDk3mE8s8mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on change in fair value of derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="From2024-01-012024-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,257</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msNCPBUzAQk_zxb1i3j4bLrf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gain on change in fair value of convertible notes</p></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,932</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AmortizationOfDebtDiscountPremium_i02_pp0p0_maNCPBUzAQk_zowsomaFAja8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of debt discounts</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0446">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,288</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_pp0p0_di_msNCPBUzAQk_z5967MKlDvy1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    (Gain) on extinguishment of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000450" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">857,723</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_ecustom--GainLossOnForgivenessOfAccruedCompensation_i02N_pp0p0_di_msNCPBUzAQk_zGgXKenYjZy5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on forgiveness of accrued compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:GainLossOnForgivenessOfAccruedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_ecustom--GainLossOnAmortizationOfPrepaidContracts_i02_pp0p0_maNCPBUzAQk_zS3spGwxzP7c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of prepaid contracts</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:GainLossOnAmortizationOfPrepaidContracts" contextRef="From2025-01-01to2025-12-31" id="Fact000455" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">766,666</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:GainLossOnAmortizationOfPrepaidContracts" contextRef="From2024-01-012024-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,612</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--NoncashFinancingCost_i02_pp0p0_maNCPBUzAQk_zllSrHlWCyJ" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Non-cash financing cost</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:NoncashFinancingCost" contextRef="From2025-01-01to2025-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaidInKindInterest_i02_pp0p0_maNCPBUzAQk_zSialpsao3Od" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense paid through sale of common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,521</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i02_maNCPBUzAQk_zS3qvI69jyxa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,418,516</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,840,908</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z5P6nveqmNE8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in operating assets and liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzAQk_zXjofB8ikEFe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in accounts receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2025-01-01to2025-12-31" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,637</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DecreaseIncreaseInPrepaidContracts_i03N_di_msNCPBUzAQk_z0Yb5J8wFZy8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Decrease (increase) in prepaid contracts</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="JUNS:DecreaseIncreaseInPrepaidContracts" contextRef="From2024-01-012024-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,300,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i03N_di_msNCPBUzAQk_zIq0HZ6aew8e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Increase in prepaid and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2024-01-012024-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,826</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUzAQk_zJkVKPbOtDV6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2025-01-01to2025-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,790</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_di_msNCPBUzAQk_zp1GwG7mRT76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,544</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--IncreaseDecreaseInOperatingLeaseRightOfUseAsset_i03N_di_msNCPBUzAQk_zuTqDIwhf9s8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in operating lease right of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="From2025-01-01to2025-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,654</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="From2024-01-012024-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInDeferredRevenue_i03_maNCPBUzAQk_z1eKI15sM316" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in deferred revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2025-01-01to2025-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">735</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUzAQk_zkRombo0B862" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in accounts payable and accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,163</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">149,530</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInDeferredCompensation_i03_maNCPBUzAQk_zq7NO8fld89k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decrease
    in accrued compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,736</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2024-01-012024-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,948</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInInterestPayableNet_i03_maNCPBUzAQk_zQ4NBzoFtUmg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2025-01-01to2025-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,765</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2024-01-012024-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,368</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_maCCERCzq0C_mtNCPBUzAQk_zhB0JKcvt6Me" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,413,736</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,911,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Flows from Financing Activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromNotesPayable_i01_maNCPBUz8FI_zuhuMLzTJuA3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from note payable, related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-012024-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--RepaymentsOfNotesPayable_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_msNCPBUz8FI_z1WTDjflbYB5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    on notes payable, related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,432</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,880</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--RepaymentsOfNotesPayable_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_msNCPBUz8FI_zMWrYCvwB2Cl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    on notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0512">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,102,797</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RepaymentsOfConvertibleDebt_i01N_pp0p0_di_msNCPBUz8FI_zKijgt8oADce" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment on convertible note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2024-01-012024-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromOtherDebt_i01_maNCPBUz8FI_zVviwbc5Mapb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceeds from issuance convertible note payable, net</p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="From2025-01-01to2025-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,580,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0519">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_pp0p0_maNCPBUz8FI_z4GV9REbEuU4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from offering, net of offering costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-012024-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,725,213</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUz8FI_zILeVIcxIfw5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from sale of common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_maCCERCzq0C_mtNCPBUz8FI_zqnHGzvLvvRk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,433,568</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,652,036</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCzq0C_zI4N01yiZne5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Change in Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,832</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,741,032</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
    of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,769,510</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,478</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">End
    of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,789,342</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,769,510</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    disclosure of cash flow information:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--CashPaidForInterest_i01I_pp0p0_zLL9EDLHfaP9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:CashPaidForInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,426</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:CashPaidForInterest" contextRef="From2024-01-012024-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">147,776</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
    of Non-Cash Investing and Financing Activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--RestrictedStockIssuedForForgivenessOfSalary_i01_pp0p0_zssA4XJlYVNj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock issued for forgiveness of salary</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:RestrictedStockIssuedForForgivenessOfSalary" contextRef="From2024-01-012024-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--StockOptionsIssuedForForgivenessOfSalary_i01_pp0p0_z3SDc6zzdQqa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    options issued for forgiveness of salary</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockOptionsIssuedForForgivenessOfSalary" contextRef="From2024-01-012024-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--NotesPayableRelatedPartyAssignToNotePayable_i01_pp0p0_z0VZToAHaF9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable, related party assign to Note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:NotesPayableRelatedPartyAssignToNotePayable" contextRef="From2024-01-012024-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">266,667</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--StockIssuedInConnectionWithConvertiblePromissoryNotes_i01_pp0p0_z2SLmkJL8nbg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issued in connection with convertible promissory notes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedInConnectionWithConvertiblePromissoryNotes" contextRef="From2025-01-01to2025-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedInConnectionWithConvertiblePromissoryNotes" contextRef="From2024-01-012024-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">636,866</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedInConnectionInterestPayment_i01_pp0p0_zGpCIoKEnnEg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issued in connection interest payment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:StockIssuedInConnectionInterestPayment" contextRef="From2025-01-01to2025-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,521</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="mfin_06"></span>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000563" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zkaqbdOSusRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_820_zSCgFWkrLLz7">Organization and Description of Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jupiter Neurosciences, Inc. (the
&#8220;Company&#8221;) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company
incorporated in Delaware in January 2016. The Company is advancing a therapeutic pipeline targeting central nervous system
(&#8220;CNS&#8221;) disorders and rare diseases, while also expanding into the consumer longevity market with its
Nugevia&#160;product line. Both efforts are powered by JOTROL<sup>&#8482;</sup>, the Company&#8217;s proprietary, enhanced
resveratrol formulation that has demonstrated potential for significantly improved bioavailability. The Company&#8217;s prescription
pipeline is focused broadly on CNS disorders, presently with a planned Phase IIa clinical study in Parkinson&#8217;s disease. The
Company&#8217;s Nugevia product line brings clinical-grade science to the supplement space, supporting mental clarity, skin health,
and mitochondrial function.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the State of Delaware to change
its name from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL&#8482;
has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation,
without causing gastrointestinal side effects. We expect JOTROL&#8482;, based on the results of our Phase I study, will resolve the major
obstacle of resveratrol&#8217;s poor bioavailability, which has been documented in various scientific articles describing previously
conducted human trials with resveratrol as well as preclinical trial results in mice and rats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, the Company increased the number of authorized shares of common stock, $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240614_zNYxCPLhKgL9" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-14" id="Fact000565" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614_z2y5H3zV9Ap5" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-14" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000,000</ix:nonFraction></span> from
<span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220125_znQ20TeeMcT4" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-01-25" id="Fact000569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, the Company effected a <span id="xdx_90C_eus-gaap--StockholdersEquityNoteStockSplit_c20240614__20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_znjBukBJeCS" title="Stock split"><ix:nonNumeric contextRef="From2024-06-142024-06-14_custom_FifteenForFourForwardStockSplitMember" id="Fact000571" name="us-gaap:StockholdersEquityNoteStockSplit">fifteen-for-four</ix:nonNumeric></span> (15:4) forward stock split whereby the Company (i) increased the number of issued
and outstanding shares of common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zH9H0etQnlqe" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-14_custom_FifteenForFourForwardStockSplitMember" id="Fact000573" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, from <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240613__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zloG6gOnJ9O" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-13_custom_FifteenForFourForwardStockSplitMember" id="Fact000575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,033,706</ix:nonFraction></span> to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zRRuBduY2sg" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-14_custom_FifteenForFourForwardStockSplitMember" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,126,413</ix:nonFraction></span> and (ii) increased by a ratio of fifteen-for-four
(15:4) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the forward stock split
were made to the Company&#8217;s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the forward stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2025, the Company increased the number of authorized shares of common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251219_zrkepVSD6p4b" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-19" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value per share, to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251219_zahwbiG0QpJ1" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-19" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></span>
from <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614_zCxDixqZ9Dg1" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-14" id="Fact000583" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000,000</ix:nonFraction></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial
Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company&#8217;s sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241201__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHzAi6Tl2CX3" title="Sale of shares of common stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-12-012024-12-31_us-gaap_CommonStockMember" id="Fact000585" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,750,000</ix:nonFraction></span> shares of Common Stock at a price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7qFBpTjcv17" title="Stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000587" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share for gross proceeds of $11 million
before underwriting discounts and other related expenses in a registered initial public offering (the &#8220;IPO&#8221;). Net proceeds,
after deducting underwriting discounts, commissions, and offering-related expenses, were approximately $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pp0d_c20241201__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzEuhHsyTJu5" title="Underwriting discounts, commissions and offering expenses"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-12-012024-12-31_us-gaap_CommonStockMember" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,725,213</ix:nonFraction></span>. In connection with
the Public Offering, the Company&#8217;s Common Stock began trading on The Nasdaq Capital Market under the symbol &#8220;JUNS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Standby Equity Purchase Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2025, the Company entered into
a standby equity Purchase Agreement, pursuant to which the Company has the right to sell to an investor up to $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20251024__20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zaauQy9MfXqc" title="Sale of stock, consideration received on transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-10-242025-10-24_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember" id="Fact000591" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million of its common
stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zSPxR4RPzijj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, subject to certain limitations and conditions. See <i>Note 5 &#8211; Convertible Debt and Derivative
Liability </i><span style="text-decoration: underline">for further details.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasdaq
Minimum Bid Price Compliance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">On March 21, 2025, the Company received a notification letter
from Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2),
which requires listed securities to maintain a minimum closing bid price of $<span id="xdx_90C_ecustom--MinimumClosingBidPrice_iI_pid_c20250321__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zujTFSbKzJbe" title="Minimum closing bid price"><ix:nonFraction name="JUNS:MinimumClosingBidPrice" contextRef="AsOf2025-03-21_us-gaap_CommonStockMember" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for at least 30 consecutive business days.
Based on the 30 consecutive business days from February 6, 2025 through March 20, 2025, the Company&#8217;s Common Stock failed to meet
this requirement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
the Company was provided 180 calendar days, or until September 17, 2025, to regain compliance by maintaining a minimum closing bid price
of at least $<span id="xdx_90B_ecustom--MinimumClosingBidPrice_iI_pid_c20250917_zOk7dM55NNnl" title="Minimum closing bid price"><ix:nonFraction name="JUNS:MinimumClosingBidPrice" contextRef="AsOf2025-09-17" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for a minimum of 10 consecutive business days. On July 9, 2025, the Company received a written notice from
the Nasdaq stating that the Company has since regained compliance with Listing Rule 5550(a)(2) because the closing bid price of the Company&#8217;s
Common Stock has been $<span id="xdx_90B_ecustom--MinimumClosingBidPrice_iI_pid_c20250709__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKoatpASfT61" title="Minimum closing bid price"><ix:nonFraction name="JUNS:MinimumClosingBidPrice" contextRef="AsOf2025-07-09_us-gaap_CommonStockMember" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> USD per share or greater for a period of thirteen (13) days (June 18, 2025 to July 8, 2025).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2026, the Company received two written notices from the Listing Qualifications Department of Nasdaq notifying the Company
that (i) the listing of the Company&#8217;s Common Stock was not in compliance with the minimum bid price requirement as set forth under
Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the
Common Stock was less than $<span id="xdx_907_ecustom--MinimumClosingBidPrice_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAnOMgoC0367" title="Minimum closing bid price"><ix:nonFraction name="JUNS:MinimumClosingBidPrice" contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember" id="Fact000601" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for the previous 30 consecutive business days, and (ii) for the 30 consecutive business days
ended February 26, 2026, the Company&#8217;s market value of listed securities closed below the $<span id="xdx_90B_eus-gaap--AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbwAyRGo4zTh" title="Market value of listed securities closed"><ix:nonFraction name="us-gaap:AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember" id="Fact000603" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">35</ix:nonFraction></span> million threshold required for continued
listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until August 25, 2026, to regain compliance by
maintaining a minimum closing bid price of at least $<span id="xdx_909_ecustom--MinimumClosingBidPrice_iI_pid_c20260825_zhYcGx2xrge1" title="Minimum closing bid price"><ix:nonFraction name="JUNS:MinimumClosingBidPrice" contextRef="AsOf2026-08-25" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for a minimum of 10 consecutive business days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000607" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zGby4y30t9X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_820_zzJfldraoCD9">Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000609" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zwruQE1u12a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United
States of America (&#8220;U.S. GAAP&#8221;). U.S GAAP contemplates continuation of the Company as a going concern. For the year
ended December 31, 2025 and 2024, the Company had net revenues from product sales of $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20250101__20251231_zUkBEI5QnIHh" title="Net revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2025-01-01to2025-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,796</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zvrY4vFIRGwl" title="Net revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively and incurred a net
loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20251231_zHh4As08zab4" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,644,897</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zpw3Bs3ivFkj" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000617" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,439,625</ix:nonFraction></span>,
respectively. Net cash used in operations for the years ended December 31, 2025 and 2024 was $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20251231_z455uyRWDbBj" title="Net cash flows from operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000619" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,413,736</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zMVVATkHhtC9" title="Net cash flows from operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,911,004</ix:nonFraction></span>,
respectively. As of December 31, 2025 and 2024, the Company had an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_z78fTrKn9Aba" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,667,026</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20241231_zUaFiIEL5fib" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,022,129</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative
cash flows from operations as well as our dependence on private equity and financings. The
Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However,
there is no assurance the Company will be successful. These conditions raise substantial doubt
about the Company&#8217;s ability to continue as a going concern for a period of at least twelve months from the date of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000627" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zT7GDUZkWdN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States
of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000629" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zeHMnNtEfAb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Segment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the &#8220;management approach&#8221; to identify its reportable segments in accordance with ASC 280, Segment Reporting.
The management approach requires companies to report segment financial information consistent with the information regularly reviewed
by the Chief Operating Decision Maker (&#8220;CODM&#8221;) for purposes of making operating decisions and assessing performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company&#8217;s Chief Executive
Officer serves as the CODM. The CODM evaluates financial performance and allocates resources based on the operating results of the Company&#8217;s
reportable segments. Effective October 1, 2025, the Company operates through two reportable segments: (i) its premium nutritional supplements,
and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM assesses segment performance primarily based on segment net loss (income). Selling, general and administrative expenses are directly
attributable to segments or allocated based on reasonable and consistently applied methodologies. Corporate and other expenses that are
not allocated to reportable segments consist primarily of public company costs, certain executive compensation, certain stock-based compensation,
interest income (expense), other income (expense), and income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
identification of two reportable segments reflects the manner in which the CODM reviews financial information and allocates resources.
Prior-period information has been recast to conform to the current presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000631" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_z71Fe3Gq1gai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues
and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other
assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
estimates during the years ended December 31, 2025 and 2024, respectively, include valuation of stock-based compensation, uncertain tax
positions, the valuation of debt instruments, and the valuation allowance on deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000633" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9uzzPpbcwEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid
investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents consist
primarily of cash on deposit with financial institutions and amounts held in high-yield savings accounts. The Company maintains its
cash balances with high-credit-quality financial institutions. At times, such balances may exceed federally insured limits provided
by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). In 2025, the Company has implemented a deposit insurance program
in the Company&#8217;s primary account, whereby funds in excess of FDIC insurance limits are insured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the cash balances not subject to insurance or that exceed the FDIC limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20251231_z2XBGEHdTW4k" title="Cash FDIC limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2025-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were
$<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20251231_zrb52hWhkjVj" title="Cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2025-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_900_eus-gaap--CashUninsuredAmount_iI_c20241231_zdi2rs3X13h" title="Cash uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact000639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,519,510</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000641" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zBgutkNtGN7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out (&#8220;FIFO&#8221;) method.
Inventory consists primarily of raw materials, work-in-process, and finished goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically reviews inventory quantities on hand and records reserves for excess, obsolete, or slow-moving inventory based on
its assessment of forecasted demand, product shelf life, market conditions, and other factors. Inventory reserves are recorded as a reduction
of inventory and are based on management&#8217;s estimates regarding the recoverability of inventory balances. If actual demand or market
conditions differ from those projected by management, additional inventory write-downs may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000643" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zctLCczDjsM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zL4bxtMLJEki">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recognized when
control of promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to
be entitled to in exchange for those goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines revenue recognition through
the following five-step model: (i) identification of the contract with a customer; (ii) identification of the performance obligations
in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations;
and (v) recognition of revenue when, or as, the Company satisfies a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Product Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates revenue from the sale of its
products. Product revenue is recognized when control of the product is transferred to the customer, which generally occurs upon shipment
or delivery, depending on the terms of the arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recorded net of variable consideration,
including estimates for product returns, rebates, chargebacks, discounts, and other allowances. The Company estimates variable consideration
at the time of sale based on historical experience, current market conditions, and contractual terms, and includes such estimates in the
transaction price only to the extent that it is probable that a significant reversal of revenue will not occur in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates whether it is the principal
or agent in its arrangements and records revenue on a gross or net basis accordingly. Shipping and handling activities are considered
fulfillment activities, and the related costs are recorded in cost of goods sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000645" name="JUNS:PrepaidContractsPolicyTextBlock"><p id="xdx_841_ecustom--PrepaidContractsPolicyTextBlock_zUjYtMyKAlug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepaid
Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
contracts generally represent service agreements which the Company would receive services over a period of time and are expensed as the
services are received. The Company&#8217;s prepaid contracts are related to service agreements that span over three years, therefore
the expense will be recognized over the three year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000647" name="JUNS:OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock"><p id="xdx_84C_ecustom--OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_zm1fAWpp2DAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepaid
Expenses and Other Current Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets generally represent payments made for goods or services to be received within one year and are expensed
as the related benefit is received.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000649" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOo5FZckfc4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the years ended December 31, 2025 and 2024 were $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20251231_z4bv9rhUXN2f" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,086,574</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zPLzHX7co2N8" title="Research and development costs"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">492,660</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000655" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zYzetmBaJwui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of December 31, 2025 and
2024, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had no material
amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company is subject
to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not currently
under examination by any tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000657" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zv4AC6zD9c9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
Per Share of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock, as calculated using the treasury method. In computing the basic and
diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations
due to the fact that when a net loss exists, dilutive shares are not included in the calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there were <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zK558zCe6Ttk" title="Warrants Outstanding"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" id="Fact000659" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> warrants outstanding, <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z7iZQKQBF9wi" title="Restricted stock units"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,626,037</ix:nonFraction></span> restricted stock units and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg6EHqelJngb" title="Number of stock options"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,726,093</ix:nonFraction></span> stock options. These securities
are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZ4WJ1KhMMmb" title="Warrants Outstanding"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,359,375</ix:nonFraction></span> warrants outstanding, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzqvaEojyWX" title="Restricted stock units"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,626,037</ix:nonFraction></span> restricted stock units and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfitikcTDajk" title="Number of stock options"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,633,988</ix:nonFraction></span> stock options. These
securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000671" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlwYPch16Jje" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records stock-based compensation equal to the grant date fair value of the stock awards issued. For stock options issued to
employees, non-employees and members of our board of directors, the Company estimates the grant-date fair value of options using the
Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with
respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the
option, risk-free interest rates, and, for grants prior to our initial public offering, the value of the common stock. For awards
subject to time-based vesting, the Company recognized stock-based compensation expense, on a straight-line basis over the requisite
service period, which is generally the vesting term of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000673" name="JUNS:ClinicalTrialExpensesPolicyTextBlock"><p id="xdx_84E_ecustom--ClinicalTrialExpensesPolicyTextBlock_zP79s9OeFwDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000675" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztnATQTFkhUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value of Financial Instruments and Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their
short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current
interest rates available for debt with similar terms and maturities are substantially the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value of Financial Instruments and Fair Value Measurements, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
see Note 5 - Convertible Debt and <span id="xdx_908_ecustom--DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_zjcfYYWrQ0Ce" title="Derivative liabilities current not disclosed flag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000677" name="JUNS:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">Derivative Liability</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000679" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_zdrcpHOOBB16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative
Instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 815, Derivatives and Hedging (&#8220;ASC Topic 815&#8221;), establishes accounting and reporting standards for derivative instruments
and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or
losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt,
the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any
discounts and records a net gain or loss on debt extinguishment. On January 1, 2020, the Company adopted ASU 2017-11 under which down-round
Features in Financial Instruments will no longer cause derivative treatment. The Company applies the modified prospective method of adoption.
There were no cumulative effects on adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000681" name="JUNS:ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock"><p id="xdx_840_ecustom--ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_zOs0iAUFwPz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Notes with Embedded Derivative Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into shares of common stock at a fixed discount to the price of the common stock at
or around the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those
contracts or any potential embedded components of those contracts qualify as derivatives. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000683" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zYwY2r4SabCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based
on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit
rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present
value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000685" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIAJishjMKl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the
periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted
accounting principles and do not believe that any new or modified principles will have a material impact on the Company&#8217;s reported
financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&#8217;s
financial management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer serves as the CODM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. ASU 2023-09 enhances income tax disclosures by
adding more granular, jurisdiction-specific information, especially for investors and analysts. The amendments in ASU 2023-09 are
effective for public business entities for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09
effective January 1, 2025 on a prospective basis. The Company plans to adopt this update during the year ended December 31, 2026.
Beyond the expanded, required disclosures, management does not believe that this will have a material impact on the Company&#8217;s
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued accounting pronouncements that are not yet effective have been deemed immaterial or nonapplicable.</span></p>

</ix:nonNumeric><p id="xdx_85A_z15nw5BRSDUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000687" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z20AIeyHahVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82A_z3EEY0BLU5T3">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to
the CEO as of December 31, 2024 was $<span id="xdx_904_eus-gaap--LoansPayable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zClC1YMMPeqj"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,432</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The loan was due on demand and accrues interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_znIZoz0lUyUc"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per year. Accrued interest relating to the loan was $<span id="xdx_907_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zGVYBwrcK944"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,064</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of December 31, 2024, and is included in accrued interest on the accompanying 2024 balance sheets. The Company fully settled the
debt in 2025 by repaying a total of $<span id="xdx_900_eus-gaap--RepaymentsOfLongTermDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zZSpWG7aIkr6"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2025-01-012025-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,782</ix:nonFraction></span></span>,
$<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zoEIpUJU4mI3"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,432</ix:nonFraction></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
principal and $<span id="xdx_901_ecustom--InterestPayable_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zmZcu48NNGn7"><ix:nonFraction name="JUNS:InterestPayable" contextRef="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,350</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
accrued interest. The Company repaid a total of $<span id="xdx_90C_eus-gaap--RepaymentsOfLongTermDebt_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z2sjP4lcQRKc"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebt" contextRef="From2024-01-012024-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during
the year ended December 31, 2024, $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zL29YPmsObl8"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,880</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
principal and $<span id="xdx_909_ecustom--InterestPayable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zMmiuRTuemse"><ix:nonFraction name="JUNS:InterestPayable" contextRef="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,120</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2024, a former executive agreed to forgive $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlivuOi7dgY4" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-03-152024-03-15_us-gaap_EmployeeStockOptionMember" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> of accrued compensation in exchange for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoAXJuehQ9b5" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-03-15_us-gaap_EmployeeStockOptionMember" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,605</ix:nonFraction></span> options to purchase common
stock and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTTK7P8i3pbk" title="Restricted stock units"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000702" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span> restricted stock units, The options to purchase common stock have a strike price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQQDoT0jjmo" title="Strike price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span>. The option had a grant date
fair value of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240315__20240315_znOfnj052yCd" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-03-152024-03-15" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>. The Company recorded a gain on the forgiveness of accrued compensation in the amount of $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMr4kMoafU92" title="Accrued compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-03-152024-03-15_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2024, the Company, the Holder of the Note II (See Note 5 &#8211; Convertible Debt and Derivative Liability) and the CEO entered
into an amendment in which the CEO agreed to exchange <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_z92gUHdyldH7"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">685,867</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares issued to the Holder in exchange for his related party
notes that accrued interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_zOOoRaUJLkf6"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
that are due from the Company in an aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentIssuedPrincipal_c20240429__20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_z2ZCsUxB3h1b"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2024-04-292024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember" id="Fact000711" format="ixt:numdotdecimal" decimals="0" unitRef="USD">266,667</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the Holder agreed to forfeit all rights to all additional
future shares from the Company that would of become due upon a qualified offering as well as the conversion option. Therefore, the principal
amount of the note was increased to $<span id="xdx_908_eus-gaap--ConvertibleDebt_iI_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zjSwVA8L8mq7"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,377,778</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the exchange debt follows the requirements of Note II.
See Note 5 &#8211; Convertible Debt and Derivative liability &#8211; Senior Secured Note &#8211; Formerly known as the Convertible Debt
I for more details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000714" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zi02KV5Bsx3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_821_zLEg1k9D97eb">Accounts Payable and Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000716" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgF4I1hpM9Df" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zbvC12QToor1">Schedule
of Accounts Payable and Accrued Expenses</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20251231_zbJtFhDt9NRe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zJk7rN6r3MZ6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALz5RX_zLxVIbAUWVDa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,130</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,676</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maAPAALz5RX_zXMhhWaW5k5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">467,167</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,271</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_maAPAALz5RX_zwP7LvlqRHM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALz5RX_zTf5RJXeUFQk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
    cards</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,349</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,536</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALz5RX_ztQsVW3e5Dn1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accounts payable and accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">638,646</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,483</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zONAsDpMPiM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2025 and 2024, $<span id="xdx_902_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zDkx5Hll3iH4" title="Accounts payable and accrued expenses owned"><span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zVz5vWzlra1f" title="Accounts payable and accrued expenses owned"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-12-31_srt_ChiefFinancialOfficerMember" id="Fact000733" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31_srt_ChiefFinancialOfficerMember" id="Fact000735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,105</ix:nonFraction></ix:nonFraction></span></span>
was due to a Company wholly owned by the Company&#8217;s Chief Financial Officer, who also is an option holder, respectively. The amount
is included in accrued compensation on the Company&#8217;s balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>Accrued
compensation of $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zYkzNTQTzn7j" title="Accrued compensation"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="AsOf2025-12-31_custom_EmploymentAgreementsMember" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,397,357</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zwg5Itr6Osf3" title="Accrued compensation"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="AsOf2024-12-31_custom_EmploymentAgreementsMember" id="Fact000739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,415,093</ix:nonFraction></span>
as of December 31, 2025 and 2024, respectively, includes accrued salaries and health benefits to executives since inception and
board fees. Since inception, executive salaries have been paid in cash when the Company&#8217;s cash flow has permitted such
payment. By November 2022 the Company stopped paying salaries, although they continued to accrue, in an effort to conserve cash and
starting in the fourth quarter of 2023, the Company&#8217;s executives agreed to reduce their salaries by <span id="xdx_904_ecustom--ConserveCashPercentage_iI_dp_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zPqHfmDqeHjk"><ix:nonFraction name="JUNS:ConserveCashPercentage" contextRef="AsOf2023-12-31_custom_EmploymentAgreementsMember" id="Fact000740" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>%
until an initial public offering to limit the Company&#8217;s compensation expenses. During December 2024, the Company returned to
paying salaries due to the completion of the initial public offering. See Note 3 &#8211; Related Party Transactions for details
related to forgiveness of accrued compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000742" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_z55ZLjxq6GNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82B_zE7PrBDPX4x5">Convertible Debt and Derivative Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standby
Equity Purchase Agreement and 2025 Convertible Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) and related Registration Rights Agreement
with YA II PN, Ltd. (&#8220;Yorkville&#8221;), providing the Company the right, but not the obligation, to sell up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20251024__20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_z9cwqs2naPYb" title="Sale of stock, consideration received on transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-10-242025-10-24_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember" id="Fact000744" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span>&#160;million
of common stock from time to time, subject to customary conditions, including an effective resale registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the SEPA, Yorkville agreed to provide up to $<span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn5n6_c20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__dei--LegalEntityAxis__custom--YAIIPNLtdMember_zaqq9xkLJYM" title="Pre-paid advances via convertible promissory notes"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember_custom_YAIIPNLtdMember" id="Fact000746" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span>&#160;million of pre-paid advances via convertible promissory notes (the
&#8220;2025 Notes&#8221;). On October 27, 2025, the Company received $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0d_c20251027_z4edf7yy5ipj" title="Received debt amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-10-27" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,000</ix:nonFraction></span>&#160;and issued a $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20251027__20251027_zGawVMCyfmeb" title="Proceeds from issuance of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2025-10-272025-10-27" id="Fact000750" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span>&#160;million note (<span id="xdx_907_ecustom--DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_iI_pid_dp_uPure_c20251027_zHU0c3bdfAs3" title="Original issue discount percentage"><ix:nonFraction name="JUNS:DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" contextRef="AsOf2025-10-27" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>% original
issue discount, &#8220;OID&#8221;). A second $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0d_c20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zXM7uEVAmKWg" title="Received debt amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,860,000</ix:nonFraction></span>&#160;tranche was received in December 2025, upon registration effectiveness and
receipt of stockholder approval, against a $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20251027__20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z9x4DrExgXuc" title="Proceeds from issuance of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2025-10-272025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact000756" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span>&#160;million note (<span id="xdx_90A_ecustom--DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_iI_pid_dp_uPure_c20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zN2tLY3DMp9a" title="Original issue discount percentage"><ix:nonFraction name="JUNS:DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" contextRef="AsOf2025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>% OID). The notes bear interest at&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20251027_zVexUaXwtMDk" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2025-10-27" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% (increasing to&#160;<span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20251027_zoh5Gwzr8Q08" title="Default interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-10-27" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>%
upon default), mature on&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20251027__20251027_zc6lgkThrb86" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2025-10-272025-10-27" format="ixt:datemonthdayyearen" id="Fact000764" name="us-gaap:DebtInstrumentMaturityDate">October 24, 2026</ix:nonNumeric></span>, and are convertible at $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20251027_zonevFYqNhBe" title="Debt instrument, convertible, conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-10-27" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span>&#160;per share, subject to proportional anti-dilution and
price-protection adjustments (not below a contractual floor).&#160;<span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20251027__20251027_z93PKPYyuqEg" title="Repayments of debt description"><ix:nonNumeric contextRef="From2025-10-272025-10-27" id="Fact000768" name="us-gaap:DebtInstrumentDescription">Beginning January 7, 2026, and monthly thereafter, the Company must
repay one-tenth (1/10) of the then-outstanding principal plus accrued interest (a 5% premium applies to cash repayments).</ix:nonNumeric></span>&#160;Installments
may be satisfied via SEPA advances without the premium, and SEPA proceeds must be applied first to repay the notes until they are repaid
in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for Yorkville&#8217;s commitment to purchase common stock at the Company&#8217;s direction pursuant
the SEPA, the Company (i) paid to Yorkville a cash &#8220;structuring fee&#8221; in the amount of $<span id="xdx_900_ecustom--StructuringFee_iI_c20251023_z424tF4py8Cg"><ix:nonFraction name="JUNS:StructuringFee" contextRef="AsOf2025-10-23" id="Fact000769" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> and (ii) upon execution of the
SEPA, issued to Yorkville <span id="xdx_90D_ecustom--CommitmentShares_iI_c20251023_zLV8fYfJyIuf"><ix:nonFraction name="JUNS:CommitmentShares" contextRef="AsOf2025-10-23" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">131,909</ix:nonFraction></span> Commitment Shares, which have a <span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20250101__20251231_zSOPNkR1lVp8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000771" name="us-gaap:OtherCommitmentsDescription">total aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#8217;s
$20.0 million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $1.5162 per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 20, 2026, the Company and Yorkville entered into an Omnibus Amendment (the &#8220;Amendment&#8221;). Among other changes, the
Amendment revises the terms of the convertible promissory notes to defer the commencement of monthly installment payments to April 1,
2026, effectively providing an extension of approximately three months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Convertible Notes include features that allow for settlement through either (i) cash repayment or (ii) issuance of common stock at variable
or fixed conversion prices, subject to certain contractual terms, including a floor price and installment-based repayment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Convertible Notes are classified as a Level III liability within the fair value hierarchy, as their valuation
is based on significant unobservable inputs and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the fair value option for the Convertible Notes upon issuance. As such, the Convertible Notes are measured at fair value
at inception and remeasured at each reporting date, with changes in fair value recognized in earnings. The fair value of the Convertible
Notes was determined using a Monte Carlo simulation model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
valuation approach incorporates multiple potential stock price paths over the contractual term, the Company&#8217;s ability to settle
in shares or cash, the note holder&#8217;s ability to convert at a fixed price, variable conversion features tied to market prices, and
contractual floors and share caps.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model simulates a large number of potential outcomes and calculates the expected fair value based on probability-weighted results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convertible notes accounted for under the fair value election are each debt host financial instruments containing
embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently
remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the 2025
Notes are recorded as a component of Other (expense) income in the consolidated statements of operations, except that the change in estimated
fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income.
The instrument specific credit risk associated with the 2025 Notes was de minimis. As a result of electing the fair value method, issuance
costs related to the 2025 Notes, including the structuring fee and the commitment fee were expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000773" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock"><p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zZjmGzpO4Tqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following key assumptions were used in the valuation at each measurement date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_ztawSNgjk8B8" style="display: none">Schedule of Key
Assumptions in Valuation Measurement</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Assumption</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Issuance (Oct 24, 2025)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 24, 2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 22%">Stock Price (VWAP)</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">$<span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_z6zqdjmPkC2d" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-10-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember" id="Fact000775" format="ixt:numdotdecimal" decimals="INF" unitRef="Segments">1.50</ix:nonFraction></span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center">$<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zz2rgLQAc6If" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Segments">1.09</ix:nonFraction></span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center; padding-left: 0.75pt">$<span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zEq8fow7nKKa" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Segments">0.99</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Volatility</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">~<span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zw33tuNrwNCf" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-10-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">65</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">~<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zMR8jk3hI3bi" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">65</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt">~<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zVPFAZN72g2k" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-31_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">65</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-Free Rates</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zkBe8G0ONahf" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.4</ix:nonFraction></span>% &#8211; <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zWPF9urOxwe2" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.5</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zIYQNgWk4G9g" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.5</ix:nonFraction></span>% &#8211; <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zgAx6149QJnk" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.6</ix:nonFraction></span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zcBydmO7hgP2" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.4</ix:nonFraction></span>% &#8211; <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zkoIh03rIg2h" title="Convertible debt instrument, measurement input"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.7</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation Technique</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte Carlo Simulation</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte Carlo Simulation</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt">Monte Carlo Simulation</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z7uIzzqoNuE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility
was estimated using a combination of the Company&#8217;s historical volatility and that of comparable publicly traded companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At issuance, the initial
convertible promissory note was measured at a fair value of $<span id="xdx_909_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20251231_zhTXwFh1zHPc" title="Convertible promissory note fair value"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2025-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,914,515</ix:nonFraction></span>. As of December 24, 2025, concurrent with the second tranche,
the fair value of the 2025 Notes was remeasured to $<span id="xdx_90D_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20241231_zj0cuRCDGFle" title="Convertible promissory note fair value"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2024-12-31" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,225,670</ix:nonFraction></span>. As of December 31, 2025, the fair value of the 2025 Notes was $<span id="xdx_904_eus-gaap--NotesPayableFairValueDisclosure_iI_c20251231_z46Mkq8Lhhag" title="Notes payable fair value"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="AsOf2025-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,298,068</ix:nonFraction></span>.
Changes in fair value during the period were recognized in the Statements of Operations as Gain on change in fair value of convertible
notes. The original issue discounts totaling $<span id="xdx_900_ecustom--OriginalIssueDiscounts_iI_c20241231_zlNdrgN4XVKf" title="Original issue discounts"><ix:nonFraction name="JUNS:OriginalIssueDiscounts" contextRef="AsOf2024-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,000</ix:nonFraction></span> were incorporated into the initial and subsequent fair value measurements of the
2025 Notes. As of December 31, 2025, the outstanding principal balance on the 2025 Notes is $<span id="xdx_90C_eus-gaap--OtherNotesPayableCurrent_iI_c20251231_zbR9XVQ7FBTd" title="Outstanding principal balance"><ix:nonFraction name="us-gaap:OtherNotesPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2025, the Company recognized a net gain on change in fair value of convertible notes of $<span id="xdx_905_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250101__20251231_z9avYYW6CwA9"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2025-01-01to2025-12-31" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,932</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2025,
the Company incurred $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231_zukm9Z5JmYEg" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2025-12-31" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,723</ix:nonFraction></span> of interest expense and paid $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250101__20251231_zjokPsK6xFp3" title="Sale of stock, consideration received on transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-01-01to2025-12-31" id="Fact000812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,251</ix:nonFraction></span> through the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231_ztAZRNDl5h0g" title="Sale of stock, consideration received on transaction, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-01to2025-12-31" id="Fact000814" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares of common stock at an average price
of approximately $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20251231_zfqtBafAWCx5" title="Sale of stock exercise price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-12-31" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span> through the SEPA. As of December 31, 2025, $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20251231_z9DZVfhcEaY4" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,829</ix:nonFraction></span> is accrued in Accrued interest on the Company&#8217;s balance
sheets.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; Convertible Debt and Derivative Liability, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Debt I</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
August and December 2021, the Company issued convertible notes (collectively, &#8220;Notes I&#8221;) totaling $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zc5AToFmsBjg"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527,650</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
originally maturing on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20210801__20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zfdhuziK0eW1"><ix:nonNumeric contextRef="From2021-08-012021-12-31_custom_TwelveConvertiblePromissoryNotesMember" format="ixt:datemonthdayyearen" id="Fact000820" name="us-gaap:DebtInstrumentMaturityDate">July
31, 2022</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, with an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_z8gCZqYa7xoe"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
Notes I featured an automatic conversion feature upon an IPO into Common Stock at <span id="xdx_903_ecustom--OfferingPricePercentage_iI_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5vfmYrKpESd"><ix:nonFraction name="JUNS:OfferingPricePercentage" contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember_us-gaap_IPOMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the IPO price. Various amendments extended the maturity, ultimately to December 31, 2024, and increased the interest rate to&#160;10%.
In December 2024, following a successful IPO, the then outstanding principal and accrued interest totaling </span>$<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zB88PXUP0BJi"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,852</ix:nonFraction></span>
Notes I converted into <span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220806__20220806__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zYxjLGWIAeEe"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2022-08-062022-08-06_custom_TwelveConvertiblePromissoryNotesMember" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,447</ix:nonFraction></span>
shares of Common Stock at $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241204__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebtOneMember_zOLPUgFCrZlg"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-12-04_custom_ConvertibleDebtOneMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> Convertible Debt II</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 11, 2022, the Company issued a senior secured convertible note (&#8220;Note II&#8221;) and&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zq8gYmcVDmE8" title="Principal amount shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">514,403</ix:nonFraction></span>&#160;shares of Common Stock
for net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zyVsGAwQ5Wx" title="Common stock for net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">977,333</ix:nonFraction></span>&#160;($<span id="xdx_904_eus-gaap--OriginationOfLoanToPurchaseCommonStock_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zakPbx9FsH14" title="Origination costs"><ix:nonFraction name="us-gaap:OriginationOfLoanToPurchaseCommonStock" contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>&#160;less origination costs and an embedded discount). Note II had an original principal
of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_z2bneYZvT3S9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,111,111</ix:nonFraction></span>. The original terms of Note II included, among other provisions, penalties and stock conversions at substantial discounts
upon default or qualified offerings. Various amendments were executed which extended principal repayment dates and increased repayment
premiums resulting in losses on debt extinguishment totaling $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zbwAXYt656m7"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31_custom_SeniorSecuredNoteConvertibleDebtTwoMember" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">887,946</ix:nonFraction></span>&#160;in 2023. On April 24, 2024, Note II was further modified,
removing the conversion feature, increasing principal to $1,377,778, and extending the maturity, resulting in a gain on modification
of $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240424__20240424__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zN8HHSB32Wmj" title="Gain on modification"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-04-242024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">951,868</ix:nonFraction></span>&#160;and an increase to derivative liability of $<span id="xdx_90B_eus-gaap--DerivativeLiabilities_iI_c20240424__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_ztNSckt2diCf" title="Derivative liabilities"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,494</ix:nonFraction></span>. Note II was fully repaid in December 2024 for $<span id="xdx_90F_eus-gaap--SeniorNotes_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteMember_zzszHWyRywvg" title="Senior notes"><ix:nonFraction name="us-gaap:SeniorNotes" contextRef="AsOf2024-12-31_custom_SeniorSecuredNoteMember" id="Fact000839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,102,797</ix:nonFraction></span>, which
included all outstanding principal and accrued interest</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Debt III</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2023, the Company issued a convertible note (&#8220;Note III&#8221;) with a principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zky8d8N4k0V5" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>
in connection with an investor relations settlement, maturing <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20230301__20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYctXbPjbXv9" title="Maturity date"><ix:nonNumeric contextRef="From2023-03-012023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:datemonthdayyearen" id="Fact000843" name="us-gaap:DebtInstrumentMaturityDate">February
28, 2026</ix:nonNumeric></span> and a compounding <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zuJr3fzcomMj" title="Annual percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
annual interest rate. In December 2024, the then outstanding balance of Note III totaling
$<span id="xdx_90A_ecustom--ConvertibleAmountIntoSharesOfCommonStock_c20230301__20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqNQHHaqXjA2" title="Convertible amount into shares of common stock"><ix:nonFraction name="JUNS:ConvertibleAmountIntoSharesOfCommonStock" contextRef="From2023-03-012023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,386</ix:nonFraction></span>
was fully repaid, which included all then outstanding principal and accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, $<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20241201__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwAr5QCMZr74" title="Repayments of convertible debt"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2024-12-012024-12-31_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,705</ix:nonFraction></span>,
was included in interest expense for the combined convertible Notes I, II and III on the accompanying 2024 statements of operations.
These notes were paid in full in December 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; Convertible Debt and Derivative Liability, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_905_ecustom--DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_z7MrmsBuRRql" title="Derivative liabilities not disclosed flag"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000851" name="JUNS:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">Derivative
Liability</ix:nonNumeric></span> Pursuant to Convertible Debt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Notes, the Company determined that the terms of Notes contain an embedded conversion option to be
accounted for as a derivative liability due to the Holder having the potential to gain value upon IPO. Accordingly, the embedded conversion
option contained in Notes was accounted for as derivative liability and debt discount at the date of issuance and has been adjusted to
fair value through earnings at each reporting date. The fair value of the embedded conversion option was determined using the Monte Carlo
valuation model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the derivative liabilities were revalued, and a $<span id="xdx_901_ecustom--GainsOnExtinguishmentOfDebt_c20240101__20241231_zyXcAxUKzA94"><ix:nonFraction name="JUNS:GainsOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">857,723</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adjustment
was recorded as a gain on extinguishment of debt to other expenses reflected in the accompanying statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also recorded $<span id="xdx_90F_ecustom--DerivativeGainLossOnDerivative_di_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqrCzGuaMc4a"><ix:nonFraction name="JUNS:DerivativeGainLossOnDerivative" contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtMember" id="Fact000853" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">53,257</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a loss on the change in the fair value of the derivative
liability for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000855" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zxaosV9PMzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the derivative liability of Notes I, Note II and Note III was estimated using the Monte Carlo Valuation model at issuance
and each reporting period with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zJTLW9kZTMRe">Schedule
of Fair Value Derivative Liability</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzgg7OvEqJEf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTWGlRIHYyTh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPPcuzvNQns1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeCx1gVz7Dr5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityofIPOMember_zhRIXkuHMCsc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none">Derivative liability, measurement input</td>
    <td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">60</td><td style="display: none; text-align: left">%</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_z6LK6yUlME65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; Convertible Debt and Derivative Liability, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Derivative
Liability Pursuant to Convertible Debt, continued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000862" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zkpSEa8BkWqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity of the derivative liabilities and the 2025 Notes, which represent the Level III fair value measurements, is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zQ1soMR95y4i" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Derivative Liability</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zkWV7fx884c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Liability</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025 Notes</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--DerivativeLiabilities_iS_zv7mgTsyHe4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_DerivativeMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,505,398</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><p style="margin: 0">-</p></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_zf0qLnzUCsmi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value change</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember" id="Fact000866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,257</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_z0n48GcePhLe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment
    of derivative liability - Note II</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember" id="Fact000868" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,359,362</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--DerivativeFairValueOfIssuance_zMnjWj8rj6gk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value at issuance on April 29, 2024 - Senior Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:DerivativeFairValueOfIssuance" contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember" id="Fact000870" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,494</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RepaymentOfDerivativeLiability_zGA2cgMwOX7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:RepaymentOfDerivativeLiability" contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">606,787</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">-</p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DerivativeFairValueOfIssuance_zYmBfffLxOd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-bottom: 1pt">Fair value at issuance</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right"><ix:nonFraction name="JUNS:DerivativeFairValueOfIssuance" contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember" id="Fact000874" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,494</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zRW5qL6goF13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="margin: 0">-</p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zA96k6M7cCoh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold; padding-bottom: 2.5pt">Derivative liability Balance </td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Issuance of the 2025 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeFairValueOfIssuance_c20250101__20251231_z6c6mFrRavmj" title="Issuance of the 2025 Notes" style="width: 14%; text-align: right"><ix:nonFraction name="JUNS:DerivativeFairValueOfIssuance" contextRef="From2025-01-01to2025-12-31" id="Fact000880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,580,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--GainLossDerivativeInstrumentsNetPretax_c20250101__20251231_z6CKR0DBCaO5" title="Fair value change" style="text-align: right">(<ix:nonFraction name="JUNS:GainLossDerivativeInstrumentsNetPretax" contextRef="From2025-01-01to2025-12-31" id="Fact000882" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">281,932</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Balance at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_ecustom--GainsLossesOfExtinguishmentOfDebt_iE_c20250101__20251231_z4gZnyRxcYhd" title="Balance at December 31, 2025" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="JUNS:GainsLossesOfExtinguishmentOfDebt" contextRef="AsOf2025-12-31" id="Fact000884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,298,068</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin-top: 0; margin-bottom: 0"></p>

</ix:nonNumeric><p id="xdx_8A7_z2mSmHACZcga" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000886" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zQGf1aAT0CZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_821_z87whnGTb7S2">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zG5x0qPt3uOi" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000,000</ix:nonFraction></span> shares of common stock and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zAFdRhxKI5Ib" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> shares of preferred stock. The Company had <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231_z4zWjqx7lDT5" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zE0IA1GrOvmf" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,446,455</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock issued and outstanding as of December 31, 2025. There was <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20251231_zcKDFJDbtu5g" title="Preferred stock, shares issued::XDX::-"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20251231_zmYqnMyN8Q8c" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0896"><span style="-sec-ix-hidden: xdx2ixbrl0898">no</span></span></span></span> preferred stock issued and outstanding as of December
31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On October 24, 2025, As consideration
for Yorkville&#8217;s commitment to purchase common stock at the Company&#8217;s direction pursuant the SEPA, the Company, upon execution
of the SEPA, issued to Yorkville <span id="xdx_90E_ecustom--CommitmentShares_iI_c20251024_zgzNgvfMm5Jk" title="Commitment shares issued"><ix:nonFraction name="JUNS:CommitmentShares" contextRef="AsOf2025-10-24" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">131,909</ix:nonFraction></span> Commitment Shares, which have a total aggregate dollar value equal to $<span id="xdx_90E_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20251024_zUmFTyQB4YKb" title="Commitment shares issued value"><ix:nonFraction name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="AsOf2025-10-24" id="Fact000902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>, or 1.0% of Yorkville&#8217;s
$<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20251024__20251024_zr3Q9X4848eb" title="Purchase commitment"><ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="From2025-10-242025-10-24" id="Fact000904" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $<span id="xdx_905_ecustom--PurchaseCommitmentPerShare_iI_pid_c20251024_zQT5Kg6BmsTh" title="Purchase commitment per share"><ix:nonFraction name="JUNS:PurchaseCommitmentPerShare" contextRef="AsOf2025-10-24" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.5162</ix:nonFraction></span> per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On April 23, 2025, the Company issued&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250423__20250423__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUQWNfaeIZmb" title="Number of shares issued for service rendered"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-04-232025-04-23_us-gaap_CommonStockMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">103,186</ix:nonFraction></span>&#160;shares
of common stock, with an aggregate fair value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250423__20250423__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYpXnjxYfhC6" title="Shares issued for services rendered"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-232025-04-23_us-gaap_CommonStockMember" id="Fact000910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></span>, as consideration for services rendered related to media and investor relations
activities, strategic communications support, enhancement to the Company&#8217;s market visibility and shareholder engagement. The fair
value of the shares issued was determined based on the market price of the Company&#8217;s common stock at the date of issuance and is
included general and administrative expenses in the accompanying 2024 condensed consolidated statement of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into a three 36-month service agreement with three different entities. The Company issued an
aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXqS2fU3MFMd" title="Number of restricted shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,487,500</ix:nonFraction></span>
restricted shares of common stock, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityOneMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKwDyz7i2gE1" title="Number of restricted shares issued"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityTwoMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ0UOAS2b5c6" title="Number of restricted shares issued"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityThreeMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3zjAQ0G1se9" title="Number of restricted shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityOneMember_us-gaap_IPOMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityTwoMember_us-gaap_IPOMember" id="Fact000916" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityThreeMember_us-gaap_IPOMember" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,162,500</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>
restricted shares of common stock to each entity. The shares were registered upon the Company&#8217;s offering that closed in
December 2024. In addition, each of the entities purchased <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zroF6PRagc89" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,500</ix:nonFraction></span>
shares each of the Company&#8217;s common stock at a price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zejSB4UeA4F1" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000922" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span>
per share prior to the occurrence of the Company&#8217;s offering. As of December, 31, 2024, the Company issued <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrDGspk8nJHg" title="Aggregate sale of common stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000924" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">112,500</ix:nonFraction></span>
common stock and the Company received an aggregate of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5Ej78PzTJ6c" title="Aggregate sale of common stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span>
for the sale of the Company&#8217;s common stock from the three entities. These shares were also registered upon the closing of the
Company&#8217;s offering. The aggregate value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240603__20240603__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zay8tZNEUaMi" title="Number of restricted shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_IPOMember" id="Fact000928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,638,375</ix:nonFraction></span>
related to the <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9BE5tST4Vi" title="Number of restricted shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,487,500</ix:nonFraction></span>
restricted shares will be recognize as compensation expense from the date the obligations are met with the remaining expense being
amortized over the remaining term of the 36-months per the services agreements. As of December 31, 2025 and 2024, the Company
recorded compensation expense for services provided of $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250101__20251231_z3xMMwWSMXy6" title="Compensation expense for services"> <ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,546,117</ix:nonFraction> </span>and $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231_zLwt9URRUpY4" title="Compensation expense for services"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">893,781</ix:nonFraction></span>, respectively
related to the restricted shares issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 &#8211; Convertible Debt and Derivative Liability for shares issued upon the conversion of the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 8 &#8211;
Commitment and Contingencies &#8211; Service agreements for details related to sale of common stock per the service agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; Stockholders&#8217; Equity (Deficit), continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Closing
of Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2024, the Company priced its initial public offering of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241202__20241202__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhDATFx95iSi" title="Number of shares for sale"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-12-022024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,750,000</ix:nonFraction></span> shares of common stock at a price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20241202__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8SOxlpJOBk" title="Stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share. The
offering closed on December 4, 2024, and the Company started trading on the Nasdaq Capital Market under the ticker symbol &#8220;JUNS&#8221;.
The Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znOe1LbWrKlc" title="Sale of shares of common stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember" id="Fact000940" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,750,000</ix:nonFraction></span> shares of its Common Stock to the underwriters and yielded proceeds of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2k3alHBdUof" title="Gross proceeds from offering"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember" id="Fact000942" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,725,213</ix:nonFraction></span>, net of underwriters and
other fees of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPRdladm3EZ6" title="Net proceeds from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember" id="Fact000944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,274,787</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants stock awards to officers, employees, directors, and other key persons pursuant to its 2021 Equity Incentive Plan (&#8220;the
Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025 and 2024, the Company recognized stock-based compensation of $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZiDnEsUWEEg" title="Stock based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,418,516</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLXhU9NG0ene" title="Stock based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">947,124</ix:nonFraction></span>, respectively,
related to vested stock options. There was $<span id="xdx_901_eus-gaap--StockOptionPlanExpense_c20250101__20251231_zucCT5kiYDFj" title="Unvested stock options expense"><ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">697,835</ix:nonFraction></span> unvested stock options expense as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2024, the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240124__20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJYonpO63oRb" title="Granted stock option purchase shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-242024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000952" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> stock options to a consultant with an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240124__20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zalcYpiFldR1" title="Stock option exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-242024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000954" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span> per share. The option had
a grant date fair value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF9vQs8o45K1" title="Grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,560</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 17, 2024, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240417__20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z84ue6jJaW5f" title="Granted stock option purchase shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-172024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000958" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,500</ix:nonFraction></span> stock options to a consultant with an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240417__20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zviUY4yWYtr9" title="Stock option exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-172024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000960" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span> per share. The option had a
grant date fair value of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbqXyleDtdYk" title="Grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000962" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,459</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 10, 2025, the Company granted&#160;<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZy9qsNaIsi7" title="Granted stock option purchase shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span>&#160;stock options
to a consultant with an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z03rLzrZRXP6" title="Stock option exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.97</ix:nonFraction></span>&#160;per share and a grant date fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zN2ciPXaMxbf" title="Grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,168</ix:nonFraction></span>, and a&#160;<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdYeOkL276Ye" title="Stock optons term"><ix:nonNumeric contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000970" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span>-year term. The&#160;<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzK0eq38uyR6" title="Shares vesting percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000972" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%
of the stock options vest immediately on the grant date, with the remaining&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKtDBMMR0qXk" title="Stock options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">187,500</ix:nonFraction></span>&#160;options vesting in equal monthly installments
ratably beginning in July 2025 through May 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2025, the Compensation Committee approved the grant of an
aggregate of&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zWcqWFzRU6i6" title="Stock options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-07-02_custom_BoardOfDirectorsMember" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">357,448</ix:nonFraction></span>&#160;stock options issued to certain executives. The stock options have an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_z27zRM49V2w2" title="Stock options exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-07-02_custom_BoardOfDirectorsMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.19</ix:nonFraction></span>&#160;per
share, representing the closing price of the Company&#8217;s Common Stock on Nasdaq on the date of grant.&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250702__20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zJEBocLQPuy1" title="Vesting period description"><ix:nonNumeric contextRef="From2025-07-022025-07-02_custom_BoardOfDirectorsMember" id="Fact000980" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The stock options have
a 10-year term and vest in equal installments over a three (3) year period beginning on the grant date of July 2, 2025, subject to the
officers&#8217; continued employment at the time of vesting.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 5, 2025, the Company granted an aggregate of&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zrUmD6rqLCuf" title="Stock granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-09-052025-09-05_custom_TwoConsultantsMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">374,755</ix:nonFraction></span>&#160;stock
options to two consultants with an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zHu3IN2TmAP" title="Share price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-05_custom_TwoConsultantsMember" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.23</ix:nonFraction></span>&#160;per share and a grant date fair value of $<span id="xdx_908_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zAbMwqauwLnl" title="Fair value of grant date"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-09-052025-09-05_custom_TwoConsultantsMember" id="Fact000986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,900</ix:nonFraction></span>.&#160;The stock options
have a 10 year term and&#160;<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zFk0JjqYmcTf" title="Stock options vest percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-09-052025-09-05_custom_TwoConsultantsMember" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% of the stock options vest immediately on the grant date, with&#160;<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_z4GDjMOnyxhb" title="Option vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2025-09-05_custom_TwoConsultantsMember" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">281,066</ix:nonFraction></span>&#160;options vesting in equal
monthly installments until September 5, 2027. The Company also granted&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zCKRPbMmiyuc" title="Stock option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-09-052025-09-05_custom_ConsultantsMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,902</ix:nonFraction></span>&#160;stock options to one of the consultants with
an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zYdAWJK9Ufx7" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-09-05_custom_ConsultantsMember" id="Fact000994" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.23</ix:nonFraction></span>&#160;per share and a grant date fair value of $<span id="xdx_90C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zOwY6oMsIzPc" title="Fair value of grant date"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-09-052025-09-05_custom_ConsultantsMember" id="Fact000996" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>, and a&#160;<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z6ApslNrAQ1f" title="Vested, term"><ix:nonNumeric contextRef="From2025-09-052025-09-05_custom_ConsultantsMember" format="ixt-sec:duryear" id="Fact000998" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span>&#160;year term that vest solely upon
achievement of performance conditions as follows:&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zqNcLYW7jGy3" title="Vested performance description"><ix:nonNumeric contextRef="From2025-09-052025-09-05_custom_ConsultantsMember" id="Fact001000" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">(a) 15% per Ambassador (maximum of three) referred by consultant and subsequently
engaged by the Company, (b) 20% if consultant is instrumental in arranging a distribution arrangement not previously pursued by the Company,
on terms acceptable to the Company, (c) 20% when such Distribution Contract achieves $1 million in annual sales and (d) 15% when the consultant
arranges the first Celebrity Golf Tournament featuring Nugevia on terms and conditions acceptable to the Company.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2025, in connection with the SEPA and 2025 Convertible
Promissory Notes, the Company issued&#160;<span id="xdx_90F_ecustom--CommitmentShares_iI_c20251024_zNDfLoJMluVb" title="Commitment shares issued"><ix:nonFraction name="JUNS:CommitmentShares" contextRef="AsOf2025-10-24" id="Fact001002" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">131,909</ix:nonFraction></span>&#160;commitment shares with an aggregate value of $<span id="xdx_904_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20251024_zNxQkP1GHkJf" title="Commitment shares issued value"><ix:nonFraction name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" contextRef="AsOf2025-10-24" id="Fact001004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> to the Investor, Yorkville,
representing 1.0% of Yorkville&#8217;s $<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20251024__20251024_z4LIZuQB8RQk" title="Purchase commitment"><ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="From2025-10-242025-10-24" id="Fact001006" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">20.0</ix:nonFraction></span> million aggregate purchase commitment under the SEPA, valued at approximately $<span id="xdx_905_ecustom--PurchaseCommitmentPerShare_iI_pid_c20251024_zA9mR6R6aVul" title="Purchase commitment per share"><ix:nonFraction name="JUNS:PurchaseCommitmentPerShare" contextRef="AsOf2025-10-24" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.5162</ix:nonFraction></span> per
share, representing the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the
nearest whole share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 &#8211; Related Party Transactions above for details related to options issued for forgiveness of accrued salaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001010" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGIcZinqgHIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity for the year ended December 31, 2025 and 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_z6s3DH6Vjt58" style="display: none">Schedule of Stock Option
Activity</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Contractual Term (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zRXeh9xhB171" title="Number of options, outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,336,883</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zAukIBM7RD9a" title="Weighted average exercise price, outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zppaUwdvfs8i" title="Weighted average contractual term (years), outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001016" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.9</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zH7OrpvCEv7i" title="Aggregate intrinsic value, outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,316,119</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z94ZxPCocGK7" title="Number of options, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31" id="Fact001020" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">297,105</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zdJVy0WjK3R9" title="Weighted average exercise price, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zEty7Y8rB6V9" title="Number of options, exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zrQyyt533Jfi" title="Weighted average exercise price, exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1026">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231_zzcFG4oHYwNf" title="Number of options, forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zHaH71PxMTjk" title="Number of options, outstanding, beginning balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,633,988</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zvA4b86SDtvd" title="Weighted average exercise price, outstanding, beginning balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_zkWFd1akaaZg" title="Weighted average contractual term (years), outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact001034" name="JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">6.3</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zT6GrXlqqjmh" title="Aggregate intrinsic value, outstanding, beginning balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="Fact001036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,921,147</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zx6zKK9KnB01" title="Number of options, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-01to2025-12-31" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,092,105</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_z5zfkOTmdqn8" title="Weighted average exercise price, granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-01to2025-12-31" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20251231_z1MkBB8ZEwCg" title="Number of options, exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231_z86Tb45OlHj3" title="Weighted average exercise price, exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250101__20251231_zn602cdUyKfl" title="Number of options, forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zUFZwOun8Rwc" title="Weighted average exercise price, forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231_zN1uQNHqhced" title="Number of options, outstanding, ending balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,726,093</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zAXwfxu9PzVf" title="Weighted average exercise price, outstanding, ending balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_zcgFvM8TTbh6" title="Weighted average contractual term (years), outstanding"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact001054" name="JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">5.4</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_z9pjfgVpYrej" title="Aggregate intrinsic value, outstanding, ending balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-12-31" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,772,167</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20251231_zJdfhzxO7qE9" title="Number of options, exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,874,222</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zWYnYIKqUDv7" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_z92T0zqxWbE6" title="Weighted average contractual term (years), exercisable"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact001062" name="JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm">5.1</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231_zeFIKVBO2SH5" title="Aggregate intrinsic value, exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-12-31" id="Fact001064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,765,237</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zS8GgP8525Tf" title="Number of options, exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,297,412</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zEvqKuMoU601" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001068" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.01</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_z6wDBZRYZwrb" title="Weighted average contractual term (years), exercisable"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact001070" name="JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm">6.18</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240101__20241231_ze5LAHb52fya" title="Aggregate intrinsic value, exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-12-31" id="Fact001072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,768,543</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zP0Gz6TLUdhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001074" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVtEFPVOCc4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarized information about employee stock options outstanding as of December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zr5t7TYd9Hvg" style="display: none">Schedule of Employee
Stock Options Outstanding</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Outstanding Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Vested Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding at December 31,</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Number Exercisable at December 31, 2025</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9lUQANknNKg" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeOneMember" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zinDiVfAqRFl" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeOneMember" id="Fact001078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,000</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z8FXJSD6j8Mj" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001080" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">0.25</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zw0U37LS9Vk8" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeOneMember" id="Fact001082" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,000</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY9qy9o8xny5" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001084" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">0.25</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zIX9lQRSzhM5" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeTwoMember" id="Fact001086" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.74</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxuUjg0j3Yj8" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeTwoMember" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,657,560</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_znkzTAYxxTog" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001090" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.07</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2Ilpmuw6nc6" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeTwoMember" id="Fact001092" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,657,560</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeQlgjxhvdOk" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001094" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.07</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zAuYWQpnOaTl" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeThreeMember" id="Fact001096" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.80</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4AmDF0JAXia" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeThreeMember" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,783,243</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zyixcQx7zNw9" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001100" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.29</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXqsfaTF4yV1" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeThreeMember" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,783,243</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zq1ybB4jri56" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001104" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.29</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zJaiFwLYgekh" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeFourMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.97</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zL3SV54Piocj" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeFourMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zP2ebCzUk369" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001110" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.42</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWZVbDDqB2cg" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeFourMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,412</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zU6mdI1AkD81" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001114" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.42</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zot74KmHnvC8" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeFiveMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.19</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zioSbChcwch2" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeFiveMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">357,448</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zLtyDdRqBKo1" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeFiveMember" format="ixt-sec:duryear" id="Fact001120" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.51</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoeu40klWFdh" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zLehGVqy7CU7" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeSixMember" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.23</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zGKnSBD394G5" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeSixMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484,657</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zh8fC6psLWqd" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeSixMember" format="ixt-sec:duryear" id="Fact001128" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.68</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zzJuRHQAMwkg" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeSixMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,822</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zUhk8TBWNbhh" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeSixMember" format="ixt-sec:duryear" id="Fact001132" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.68</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z2BLbDR5XzAa" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeSevenMember" id="Fact001134" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zWH2r7yjm8Sc" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeSevenMember" id="Fact001136" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,461,935</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z426LmVrFrL6" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeSevenMember" format="ixt-sec:duryear" id="Fact001138" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.08</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z5vKDzu3cQG6" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeSevenMember" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,461,935</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z9xUocfrltd4" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeSevenMember" format="ixt-sec:duryear" id="Fact001142" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.08</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zCWfff1o9cy3" title="Exercise price" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2025-01-012025-12-31_custom_RangeEightMember" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.16</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zZJ3jv16r4I9" title="Number of options, outstanding" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_RangeEightMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,250</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_ziA6nWOzWg7g" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeEightMember" format="ixt-sec:duryear" id="Fact001148" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.46</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zwtWFplqtor5" title="Vested options, number exercisable" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_RangeEightMember" id="Fact001150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,250</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zc4bj9IuSAEg" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RangeEightMember" format="ixt-sec:duryear" id="Fact001152" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.06</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231_zCPuvhn7yym4" title="Number of options, outstanding" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,726,093</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zTvaVvrr1C67" title="Outstanding options, weighted average remaining life"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact001156" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.43</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231_zwJCzoNZt6Q3" title="Vested options, number exercisable" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,874,222</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zjxE8JNl1o0h" title="Vested options, weighted average remaining life"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact001160" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.10</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Outstanding Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Vested Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding at December 31,</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2024</b></p></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Number Exercisable at December 31, 2024</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqTYltrcy2e" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-12-31_custom_RangeOneMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqw3dafNIj4i" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeOneMember" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,000</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXLu86SLEExa" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001166" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.25</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIS07948AUSd" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeOneMember" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">675,000</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z7EWagbSK6La" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeOneMember" format="ixt-sec:duryear" id="Fact001170" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.25</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAcYrs8Y3Hfi" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-12-31_custom_RangeTwoMember" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.74</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zCM9gIgDE8P9" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeTwoMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,657,560</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrSrDnU8V5Ra" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001176" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.32</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxBDMkBYO4Cg" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeTwoMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,657,562</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zYMES0ehNuBi" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeTwoMember" format="ixt-sec:duryear" id="Fact001180" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.32</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zy2B6FbHG1n3" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-12-31_custom_RangeThreeMember" id="Fact001182" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.8</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zOek3sbcecfc" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeThreeMember" id="Fact001184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,783,243</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmhEz33Ddbad" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001186" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.54</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zSRCp95gzeYd" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeThreeMember" id="Fact001188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,783,238</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2GAh69BQpWg" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeThreeMember" format="ixt-sec:duryear" id="Fact001190" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.54</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCn9DZQlTZah" title="Exercise price" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-12-31_custom_RangeFourMember" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zvvoIopKWEn2" title="Number of options, outstanding" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeFourMember" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,461,935</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWG4ksZui5B9" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001196" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.33</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zxPtzl915dFj" title="Vested options, number exercisable" style="font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeFourMember" id="Fact001198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,125,362</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zY8qsfToPjp5" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeFourMember" format="ixt-sec:duryear" id="Fact001200" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.31</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zHw1l0f826xe" title="Exercise price" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" contextRef="From2024-01-012024-12-31_custom_RangeFiveMember" id="Fact001202" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.16</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zPg6UNOzYGl6" title="Number of options, outstanding" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_RangeFiveMember" id="Fact001204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,250</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zMSqF69o5gdf" title="Outstanding options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeFiveMember" format="ixt-sec:duryear" id="Fact001206" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.71</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoLf6vkragPg" title="Vested options, number exercisable" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_RangeFiveMember" id="Fact001208" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,250</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zkEq1e4Jf2Tg" title="Vested options, weighted average contractual term"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RangeFiveMember" format="ixt-sec:duryear" id="Fact001210" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.71</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231_zerA8b9MNhE8" title="Number of options, outstanding" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,633,988</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zOQakm3BnRX4" title="Outstanding options, weighted average remaining life"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact001214" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.25</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_z40TkNgv43fb" title="Vested options, number exercisable" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,297,412</ix:nonFraction></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_ztNWIX9ty3ze" title="Vested options, weighted average remaining life"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact001218" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.15</ix:nonNumeric></span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z11pWrNP2Rdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001220" name="JUNS:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_z0pCHvqoj6pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s warrant activity for the year ended December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z5tHIdeRHBYk" style="display: none">Schedule of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNc8RiNKKA5f" title="Number of shares, outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,359,375</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgijBH4VCrZ4" title="Weighted average exercise price per share, outstanding, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjCprZX2OrMi" title="Weighted average remaining life (years), outstanding" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember13963437" format="ixt-sec:duryear" id="Fact001226" name="JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife">0.93</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xMF0O7JPfj" title="Number of shares, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAfBgjnckLoj" title="Weighted average exercise price per share, forfeited" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN4XT3EFXoQl" title="Number of shares, exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,359,375</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFlhOc9kK5Lj" title="Weighted average exercise price per share, exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUDZPLcUEEQ9" title="Number of shares, forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3bziOzm6Xw2" title="Weighted average exercise price per share, forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5Parh01sAAg" title="Number of shares, outstanding, ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcCMUXTurClc" title="Weighted average exercise price per share, outstanding, ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1242">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zFuTkXtT4jv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 22, 2025, the Company entered into an amendment with
a warrant holder for a warrant to purchase&#160;<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250622__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zFx8WviDoIY6" title="Warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-06-22_custom_WarrantHolderMember" id="Fact001244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,376</ix:nonFraction></span>&#160;shares of Common Stock. The amendment extended the warrant&#8217;s exercise
period through August 31, 2025, and clarified the exercise mechanism applicable to the warrant. The effects of the warrant modification
were de minimis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2025 the Company entered into an amendment with a warrant
holder who holds&#160;<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_ztrwTGbW5xw9" title="Warrant outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-07-16_custom_WarrantHolderMember" id="Fact001246" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,249,999</ix:nonFraction></span>&#160;warrants that clarified the exercise mechanisms. Concurrently with the amendment, the warrant holder
exercised the warrants via a cashless exercise and received&#160;<span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20250716__20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zmu2wAJsbMIk" title="Warrant exercised"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2025-07-162025-07-16_custom_WarrantHolderMember" id="Fact001248" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">913,299</ix:nonFraction></span>&#160;shares of Common Stock. Pursuant to the amendment, the Company
agreed to issue the warrant holder&#160;<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zu12vCWSuwkf" title="Warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-07-16_custom_WarrantHolderMember" id="Fact001250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,700</ix:nonFraction></span>&#160;shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2025, the Company received an exercise notice from a
warrant holder who holds&#160;<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_z5JWD2Vil4T4" title="Warrant outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-08-12_custom_WarrantHolderMember" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">109,376</ix:nonFraction></span>&#160;warrants. The warrant was exercised via a cashless exercise, and the warrant holder received&#160;<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20250812__20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_z9GQniyL2Ska" title="Warrant exercised"><ix:nonFraction name="JUNS:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2025-08-122025-08-12_custom_WarrantHolderMember" id="Fact001254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,547</ix:nonFraction></span>&#160;shares
of Common Stock. Pursuant to the amended warrant agreement, the Company agreed to issue the warrant holder&#160;<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zRuStVjLlfK8" title="Warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-08-12_custom_WarrantHolderMember" id="Fact001256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,954</ix:nonFraction></span>&#160;shares of
Common Stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; Stockholders&#8217; Equity (Deficit), continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbnIzLlSxlEb" title="Number of restricted shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-03-152024-03-15_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001258" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span> restricted stock units with a grant date value of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeCEm65kbQa7" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001260" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span> per unit in exchange for the forgiveness
of accrued compensation. The restricted stock units shall vest on the earlier event of either the expiration of the lock-up period by
the underwriters after the initial public offering or in the event of change of control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of both December 31, 2025 and December 31, 2024, the Company had an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8tXdzNlTON1" title="Number of restricted shares issued, shares"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXtLszgDoFtf" title="Number of restricted shares issued, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734" id="Fact001262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,626,037</ix:nonFraction></ix:nonFraction></span></span>
restricted stock units outstanding with an aggregate fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPXVVSEwPRRg" title="Restricted stock fair value"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxtITuAyDTHi" title="Restricted stock fair value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734" id="Fact001266" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734" id="Fact001268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,195,550</ix:nonFraction></ix:nonFraction></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001270" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zKkXI6Ax61Dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_820_zIFy3S9284ea">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001272" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWIb6w9Br8Bj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5qxT8107y54" style="display: none">Schedule
of Income Tax Provision</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250101__20251231_zN1Ha8w5zSy7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20241231_z4FLovEWDX4g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_zI1kBVw0Jnl3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001274" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact001275" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zqkq7gT8gjml" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact001277" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.19</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact001278" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.07</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maKL001_z69qxdumrLX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001280" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.66</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2024-01-012024-12-31" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.33</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zx9GBimZ1Wkc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">39.84</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact001284" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">20.74</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zd1Y4tCFDLC9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1286">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zf4GVfqFp4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; Income Taxes, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001289" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0oE4sZ2PzCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s deferred tax assets is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B0_zFdtRsfRho29" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231_ztuQUysEC5qh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zdn1x65jeUYi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGze87_zyqf3c82unn2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S
    Federal and State net operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2025-12-31" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,473,294</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact001292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,083,545</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGze87_zaSwqbyCuPY5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2025-12-31" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,423,288</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact001295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,272,925</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_maDTAGze87_zgaey9eS7Jg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2025-12-31" id="Fact001297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,012</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2024-12-31" id="Fact001298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,288</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGze87_z8SH1dvo1NV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
    drug credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2025-12-31" id="Fact001300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,682,207</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="AsOf2024-12-31" id="Fact001301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,060,118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsDerivativeLiability_iI_maDTAGze87_zP09qyBV7u4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGze87_znXhwig8fdQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2025-12-31" id="Fact001306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,699</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,481</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGze87_maDTANz4iX_zcWR93tE6dPa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-12-31" id="Fact001309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,046,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,059,357</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz4iX_zcDqd2p7xaK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact001312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,046,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,059,357</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz4iX_z911dkGdqv9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Deferred Tax Asset</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1316">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zJGf3EyY77U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2025, the Company had federal and state (post-apportioned basis) net operating losses (&#8220;NOLs&#8221;)
of $43.14 million, as well as federal orphan drug credit and research and development tax credit carryforwards of approximately $1.72
million. Approximately $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20251231_zwgbot2GWaYe" title="Operating loss carryforward"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact001318" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">22.3</ix:nonFraction></span> million of the foregoing federal and state NOLs will expire at various dates from 2036 through 2045, if not limited
by triggering events prior to such time. Under the provisions of the Internal Revenue Code, changes in ownership of the Company, in certain
circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular,
Section 382 of the Internal Revenue Code (&#8220;Section 382&#8221;) imposes limitations on an entity&#8217;s ability to use NOLs upon
certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income,
then the Company will pay more taxes than if it were otherwise able to fully utilize its NOLs. The Company may experience ownership changes
in the future as a result of subsequent shifts in ownership of the Company&#8217;s capital stock that the Company cannot predict or control
that could result in further limitations being placed on the Company&#8217;s ability to utilize its federal NOLs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance, if needed, reduces deferred tax assets to the amount
expected to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company
assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings history, expected
future earnings, carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the
likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the
extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable
income, exclusive of reversing taxable temporary differences, to outweigh objective negative evidence of recent financial reporting losses.
Based on these criteria and the relative weighting of both the positive and negative evidence available, management continues to maintain
a full valuation allowance against its net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001320" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z952iJVkqXY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_826_zigE454ea6yd">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable
outcome in any specific period could have a material adverse effect on the Company&#8217;s results of operations for that period or future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2022, Tiberend Strategic Advisors (&#8220;Tiberend&#8221;), an entity that the Company had previously engaged as a communications
and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging
non-payment by the Company under a services agreement (the &#8220;Services Agreement&#8221;) with Tiberend in the amount of $<span id="xdx_907_eus-gaap--OtherLiabilities_iI_c20220719__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TiberendStrategicAdvisorsMember_zE4ml6Setc82" title="Non-payment amount"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2022-07-19_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember" id="Fact001322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,400</ix:nonFraction></span>.
The Company and Tiberend entered into a full settlement and release agreement in exchange for a $<span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20230331__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TiberendStrategicAdvisorsMember_zu2OUmvQFyd5" title="Convertible promissory note"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-03-31_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember" id="Fact001324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> convertible promissory note
in March 2023. As of December 31, 2024, the note was fully repaid. See Note 5 &#8211; Convertible Debt and Derivative Liability &#8211;
Convertible Debt III for details associated with the note issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Office
Lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2021, the Company entered into a <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210501_zaAdOVt49Z7l" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2021-05-01" format="ixt-sec:durmonth" id="Fact001326" name="us-gaap:LesseeOperatingLeaseTermOfContract">61</ix:nonNumeric></span>-month operating lease for office space for a base rent of $<span id="xdx_901_eus-gaap--PaymentsForRent_c20210501__20210501_zTW79l6b0nyf" title="Base rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-05-012021-05-01" id="Fact001328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,783</ix:nonFraction></span> subject to a <span id="xdx_90D_ecustom--OperatingLeaseYearlyEscalationPercentage_iI_pid_dp_uPure_c20210501_zXP622lgsFe4" title="Operating lease yearly escalation percentage"><ix:nonFraction name="JUNS:OperatingLeaseYearlyEscalationPercentage" contextRef="AsOf2021-05-01" id="Fact001330" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% yearly escalation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the Company&#8217;s operating lease right-of-use asset, net (ROU) is $<span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_zLQ0vuy3oo74" title="Operating lease right-of-use asset, net"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact001332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,214</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_zBffG8IzKrp" title="Operating lease right-of-use asset, net"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,642</ix:nonFraction></span>, respectively,
and the total lease liability is $<span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_c20251231_zRyqgG2tiQ8f" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,247</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--OperatingLeaseLiability_iI_c20241231_zsWsNimhwdM5" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,329</ix:nonFraction></span>, respectively, based on an incremental borrowing rate of <span id="xdx_907_ecustom--OperatingLeaseIncremetalBorrowingRate_dp_c20250101__20251231_zSGmwdibyI58" title="Operating lease incremetal borrowing rate"><span id="xdx_90F_ecustom--OperatingLeaseIncremetalBorrowingRate_dp_c20240101__20241231_zm6guN5rHych" title="Operating lease incremetal borrowing rate"><ix:nonFraction name="JUNS:OperatingLeaseIncremetalBorrowingRate" contextRef="From2025-01-01to2025-12-31" id="Fact001340" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="JUNS:OperatingLeaseIncremetalBorrowingRate" contextRef="From2024-01-012024-12-31" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.81</ix:nonFraction></ix:nonFraction></span></span>% at lease inception.</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001344" name="JUNS:ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock"><p id="xdx_896_ecustom--ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_z5kCvA4ZX23h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z7QmEYvo2gF6" style="display: none">Schedule
of Operating Lease Right-of-use Asset and  Liability</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_zJlOlxba3tJd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20241231_z9Jgz4Y349F" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use asset (&#8220;ROU&#8221;) is summarized below:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maOLROUzjlN_za62rp1rN3lj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
lease ROU</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" contextRef="AsOf2025-12-31" id="Fact001346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact001347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msOLROUzjlN_znVCgBvnVIc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
accumulated reduction</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:OperatingLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2025-12-31" id="Fact001349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,795</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:OperatingLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact001350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,367</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzjlN_zbzCbLowLBM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
of ROU, net </b>&#160; &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact001352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,214</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,642</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability related to the ROU asset is summarized below:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--OperatingLeaseLiabilityGross_iI_maOLLzx0H_zr8PnbLINXb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:OperatingLeaseLiabilityGross" contextRef="AsOf2025-12-31" id="Fact001355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="JUNS:OperatingLeaseLiabilityGross" contextRef="AsOf2024-12-31" id="Fact001356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ReductionOfOperatingLeaseLiability_iNI_di_msOLLzx0H_zZz2fBCISKW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
of lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:ReductionOfOperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,762</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:ReductionOfOperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,680</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzx0H_zPjY7f1GJEcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,329</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zeeS0Dstonz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001364" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK9S51ku6N01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease liability payments under non-cancelable operating lease
at December 31, 2025 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zc44k8gm9GXi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20251231_zzuhWvY6rVK2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20241231_zZiY9GW3byKk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPztZn_zqW1PNRo1zJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,476</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPztZn_zBinXdQXUfI1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-12-31" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,290</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact001370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,290</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPztZn_zfUBqoLEwlo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-12-31" id="Fact001372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,290</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact001373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,766</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zYa7afb3L3j8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    imputed interest &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-12-31" id="Fact001375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact001376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_z39pbEWmLQLc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001378" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,329</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzH2R_zf4gvsdgRykk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact001382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,082</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzH2R_zW1ovI42HEvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact001385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzH2R_z9aX4bp1rUo7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,329</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zlufLEKsCF9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; Commitments and Contingencies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Office
Lease, continued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into a month-to-month lease for office space in Charlestown, MA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
expenses of $<span id="xdx_90D_ecustom--RentalExpenses_c20250101__20251231_zgGFcpIMWtGf" title="Operating leases rent expenses"><ix:nonFraction name="JUNS:RentalExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact001390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,972</ix:nonFraction></span> and $<span id="xdx_900_ecustom--RentalExpenses_c20240101__20241231_zNQwMQb0CoMk" title="Operating leases rent expenses"><ix:nonFraction name="JUNS:RentalExpenses" contextRef="From2024-01-012024-12-31" id="Fact001392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,740</ix:nonFraction></span> for the years ended December 31, 2025 and 2024, respectively, are included in general and administrative
expenses on the accompanying statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant
has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements
have a <span id="xdx_904_ecustom--AgreementTerm_dtY_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zFmf9b9DxB4h" title="Agreements term"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_ConsultingAgreementsMember" format="ixt-sec:duryear" id="Fact001394" name="JUNS:AgreementTerm">2</ix:nonNumeric></span>-year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company&#8217;s
Board of Directors and are granted on an individual agreement basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2024, the Company entered into a Strategic Services Agreement (the &#8220;Dominant Treasure Agreement&#8221;) with
Dominant Treasure Health Company Limited (&#8220;Dominant Treasure&#8221;). Pursuant to the terms of the Dominant Treasure
Agreement, Dominant Treasure agreed to provide certain services to the Company to assist the Company in accelerating the
Company&#8217;s desire to get its products developed and distributed in the Southeast Asian market. In exchange for Dominant
Treasure&#8217;s services pursuant to the Dominant Treasure Agreement, the Company agreed to pay Dominant Treasure a one-time
payment of $<span id="xdx_90B_eus-gaap--PaymentsToSuppliers_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zzJ19Ej1iyFf" title="Payment for services"><ix:nonFraction name="us-gaap:PaymentsToSuppliers" contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,300,000</ix:nonFraction></span>.
In addition, if Dominant Treasure is involved in generating negotiations and conclusion of a distribution agreement for the Company
in the countries of China (including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee of <span id="xdx_905_eus-gaap--ManagementAndServiceFeesRate_dp_uPure_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zNnHjB14Y23f" title="Success fee percentage"><ix:nonFraction name="us-gaap:ManagementAndServiceFeesRate" contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember" id="Fact001398" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of any upfront and/or milestone payments to be received by the Company. If such an agreement will include a royalty payment to the
Company, Dominant Treasure will receive <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zlZ9F1el0Ukb" title="Royalty fee percentage"><ix:nonFraction name="JUNS:RoyaltyPercentage" contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember" id="Fact001400" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of such royalty payment. The Dominant Treasure Agreement has a term of <span id="xdx_902_ecustom--AgreementTerm_dtM_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zD1pKRzkjsgd" title="Agreements term"><ix:nonNumeric contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember" format="ixt-sec:durmonth" id="Fact001402" name="JUNS:AgreementTerm">36</ix:nonNumeric></span>
months and may be terminated at any time upon mutual agreement of the parties. The one-time payment of $<span id="xdx_902_eus-gaap--PrepaidExpenseCurrent_iI_c20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zl7VoPCistdk" title="Prepaid expense"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-15_custom_DominantTreasureAgreementMember" id="Fact001404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,300,000</ix:nonFraction></span>
was accounted for as a prepaid contract and will be expensed over a three-year period. For the years ended December 31, 2025 and
December 31, 2024, the Company recorded prepaid contract expense of $<span id="xdx_906_ecustom--PrepaidContractExpenses_c20250101__20251231_z8pNmBAmuDu" title="Prepaid contracts expense"><ix:nonFraction name="JUNS:PrepaidContractExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact001406" format="ixt:numdotdecimal" decimals="0" unitRef="USD">766,667</ix:nonFraction></span>
and $<span id="xdx_908_ecustom--PrepaidContractExpenses_c20240101__20241231_zMSMntVmy6d7" title="Prepaid contracts expense"><ix:nonFraction name="JUNS:PrepaidContractExpenses" contextRef="From2024-01-012024-12-31" id="Fact001408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,612</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
Employment Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s standard executive employment agreements have a stated term of six years. Per the agreements, employees are eligible
for a discretionary annual performance bonus, determined by the Board of Directors. If the Company terminates an employee without cause,
the employee is entitled to a pro-rated pay out of the annual performance bonus based on days worked in the fiscal year, severance of
twelve months of the base salary, and automatic vesting of unvested equity grants. If the employee terminates with good reason, as defined
in the employment contract, the employee is entitled to automatic vesting of unvested equity grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, <span id="xdx_90D_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zWFUYt2KGG0l" title="Salary payment description"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_ExecutiveEmploymentAgreementsMember" id="Fact001410" name="us-gaap:RestructuringAndRelatedActivitiesDescription">the Company began consistently paying salaries at 50% of the salaries reflected in the respective employment agreements. As of
September 2021, the Company began paying full salaries. Throughout 2022, the Company returned to paying partial salaries and by October
2023 the company stopped paying 100% in an effort to conserve cash.</ix:nonNumeric></span> See Note 3 &#8211; Related Party Transactions for details related
to forgiveness of accrued compensation during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20231218__20231218__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z9d84721NLPf" title="Salary payment description"><ix:nonNumeric contextRef="From2023-12-182023-12-18_custom_ExecutiveEmploymentAgreementsMember" id="Fact001412" name="us-gaap:RestructuringAndRelatedActivitiesDescription">On
December 18, 2023, various employees agreed to reduce their annual base salary to 20% of their original base salary effective October
1, 2023 until the time the Company raises additional capital from securities in the amount of $1,500,000 (the &#8220;Reduction Period&#8221;).
Upon the expiration of the Reduction Period, the bases salaries shall adjust to be 105% of their original base salary as set forth in
their original agreements.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 4, 2024, <span id="xdx_900_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zY7kbRR4KdXc" title="Salary payment description"><ix:nonNumeric contextRef="From2024-12-042024-12-04_custom_ExecutiveEmploymentAgreementsMember" id="Fact001414" name="us-gaap:RestructuringAndRelatedActivitiesDescription">the base salaries was adjusted to 105% of the original base salaries and the Company started paying a 100% of the
salaries.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; Commitments and Contingencies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Licensing
and Royalty Agreements -</i> Aquanova AG</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 13, 2016, the Company entered into a Development, Collaboration and License Agreement (&#8220;License Agreement&#8221;)
with Aquanova AG, a German company in the field of development, manufacturing and selling of colloidal formulas. The License
Agreement resulted in the creation of the pharmaceutic product, JOTROL&#8482;. The Chief Scientific Officer of the Company and
Aquanova&#8217;s founder, former CEO, and lead scientist, Darius Benham, are the joint inventors of
JOTROL&#8482;. Aquanova is assignee on the patents in the United States, the European Union, China and Japan whereas the Company is
obligated to maintain the patents. The agreement grants ownership to the Company for regulatory approvals and the sole and exclusive
worldwide right to develop, manufacture and commercialize all products, including JOTROL&#8482;. Aquanova is granted the exclusive
license to conduct formulation development and manufacturing. The agreement also defines fees owed to Aquanova for product and
formulation development and licensing of the products. The Company is required to pay Aquanova an annual license fee of $<span id="xdx_909_ecustom--LicenseFee_c20160913__20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_z7QnXt1KzkL9"><ix:nonFraction name="JUNS:LicenseFee" contextRef="From2016-09-132016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember" id="Fact001415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
acceptance of the product formulation by both parties, with the license fee requirement ending in the year of marketing
authorization approval (&#8220;MMA&#8221;) in a single territory. MMA has not yet been received as of the period ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2025 and 2024, $<span id="xdx_90E_ecustom--AccruedLicenseFees_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zNr4alnqSShh"><ix:nonFraction name="JUNS:AccruedLicenseFees" contextRef="AsOf2025-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember" id="Fact001416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90F_ecustom--AccruedLicenseFees_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zfnldRwXQ4Yd"><ix:nonFraction name="JUNS:AccruedLicenseFees" contextRef="AsOf2024-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
accrued license fees are included in accounts payable and accrued expenses on the balance sheet, respectively. Upon receipt of
approval of the MMA in each territory (e.g., United States, European Union, China, Japan), the Company will pay $<span id="xdx_908_eus-gaap--OtherCommitment_iI_c20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MinimumMember_z1F7UHrJzzBd"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MinimumMember" id="Fact001418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
Aquanova per territory an MMA approval is received, up to a max of $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MaximumMember_zk1SQFVhrCXf"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MaximumMember" id="Fact001419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company shall pay Aquanova a royalty of <span id="xdx_90C_ecustom--RoyaltyPercentage_dp_uPure_c20160913__20160913__us-gaap--TypeOfArrangementAxis__custom--LicensingAndRoyaltyAgreementsMember_zjKNcEMlUddg"><ix:nonFraction name="JUNS:RoyaltyPercentage" contextRef="From2016-09-132016-09-13_custom_LicensingAndRoyaltyAgreementsMember" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of net sales in each territory through the later of ten years after the first commercial sale, the first date there is no valid
claim within the Aquanova patent rights, or the date of expiration of the MMA in each territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">On December 1, 2021, the Company and Aquanova entered into
a Debt Forgiveness and Exchange Agreement, pursuant to which $<span id="xdx_909_ecustom--AccruedAndOutstandingObligations_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zAqiAypCVokk" title="Accrued and outstanding obligations"><ix:nonFraction name="JUNS:AccruedAndOutstandingObligations" contextRef="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember" id="Fact001422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,000</ix:nonFraction></span> of accrued and outstanding obligations owed to Aquanova under the
License Agreement were forgiven in exchange for $<span id="xdx_90B_eus-gaap--Cash_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_z9UJOC8I0Jy9" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember" id="Fact001424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> in cash, a $<span id="xdx_90C_ecustom--PromissoryNote_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zQ9Inlbgy54g" title="Promissory note"><ix:nonFraction name="JUNS:PromissoryNote" contextRef="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember" id="Fact001426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> promissory note, and the issuance of stock options to Aquanova.
As of December 31, 2025, $<span id="xdx_900_ecustom--AccruedLicenseFees_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zpgooreWIFtb" title="Accrued license fees"><ix:nonFraction name="JUNS:AccruedLicenseFees" contextRef="AsOf2025-12-31_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember" id="Fact001428" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> in accrued license fees are recorded in accounts payable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is an option (exercisable by either party) to require the Company to pay a one-time royalty of $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20160915__20160915__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zaDAu90Niu9i" title="Royalty amount"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2016-09-152016-09-15_custom_LicenseAgreementsMember_custom_AquanovaAGMember" id="Fact001430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>
within 180 days of United States marketing approval, with subsequent royalty payments reduced to <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20160915__20160915__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zkMOytbl5cx8" title="Royalty payments percentage"><ix:nonFraction name="JUNS:RoyaltyPercentage" contextRef="From2016-09-152016-09-15_custom_LicenseAgreementsMember_custom_AquanovaAGMember" id="Fact001432" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.25</ix:nonFraction></span>%,
in accordance with the terms set forth above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Murdoch
Children&#8217;s Research Institute</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2015, the Company entered into a Global Development and License Agreement (&#8220;License Agreement II&#8221;) with Murdoch
Children&#8217;s Research Institute (&#8220;MCRI&#8221;), an Australian Institute at the Royal Children&#8217;s Hospital in Australia,
with the know-how in the process of using pharmaceutical grade Resveratrol for the treatment of Friedreich&#8217;s ataxia. The License
Agreement II is for both parties to work jointly to develop an appropriate delivery system and conduct clinical trials for the purpose
of product approval in the treatment of Friedreich&#8217;s ataxia and worldwide commercialization by the Company. The License Agreement
II grants an exclusive worldwide license to the Company to use the MCRI know-how for developing, manufacturing and commercializing the
product for proposed treatment for Friedreich&#8217;s ataxia. MCRI is granted an irrevocable, royalty free, worldwide license to use
the product inventions and patent rights for internal research and development. Upon receipt of approval of the MMA in each territory
(e.g., United States, European Union, China, Japan), the Company will pay $<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MinimumMember_zjBGSuLPAOcf"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember_country_JP_srt_MinimumMember" id="Fact001433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to MCRI per each territory up to a maximum of $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember_zvdo48vqMuA8"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_country_JP_srt_MaximumMember_custom_MurdochChildrensResearchInstituteMember" id="Fact001434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
MMA has not yet been received as of September 30, 2024. The Company shall pay MCRI a royalty of <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20150901__20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember_z2sO3Ykg2awa"><ix:nonFraction name="JUNS:RoyaltyPercentage" contextRef="From2015-09-012015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember" id="Fact001435" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of net sales in each territory until the product is no longer sold in the respective territory. </span>The Company has presently put
all R&amp;D efforts associated with the treatment of Friedreich&#8217;s Ataxia on hold.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Service Providers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the services received under the licensing agreements noted above, a substantial portion of the research and development (&#8220;R&amp;D&#8221;)
expense included in the statement of operations is incurred pursuant to short term service and consulting agreements with third party
providers for research, development, testing and manufacturing services. The agreements generally provide termination, at any time by
either party without cause, upon a 30-day written notice, unless otherwise disclosed below. There are no pending milestone payments due
as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Service
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into three <span id="xdx_900_ecustom--AgreementTerm_dtM_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zCipDpsP0bhj"><ix:nonNumeric contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember" format="ixt-sec:durmonth" id="Fact001436" name="JUNS:AgreementTerm">36</ix:nonNumeric></span>-month service agreements with three different entities. The Company issued an aggregate
of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgwOZcPdjLD5" title="Number of restricted shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember" id="Fact001438" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,487,500</ix:nonFraction></span> restricted shares of common stock, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__dei--LegalEntityAxis__custom--EntityThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z71nm19xhkU"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_custom_EntityThreeMember_us-gaap_CommonStockMember" id="Fact001439" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,162,500</ix:nonFraction></span> restricted shares of common stock to each entity. The shares were to be registered
upon an IPO as long as an IPO happens no later than March 31, 2025. Either party is able to terminate the respective agreement with no
liability upon the occurrence of i) the Company failing to raise at least $10 million in gross proceeds from an IPO prior to May 31,
2025, ii) if either party is involved in any illegal activity or iii) at any time as long as both parties agree to it. The shares were
registered in the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially recognized stock-based compensation expense from the effective date of the agreement through the date the
obligations were met with the remaining expense being amortized over the remaining term of the <span id="xdx_900_ecustom--AgreementTerm_dtM_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zchpZqkmzOdg"><ix:nonNumeric contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember" format="ixt-sec:durmonth" id="Fact001440" name="JUNS:AgreementTerm">36</ix:nonNumeric></span>-months
per the services agreements. Upon the occurrence of the initial public offering the Company recorded stock- based compensation
expense for services provided of $<span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zuRC2mEoJrD1"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_ServiceAgreementsMember" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">779,411</ix:nonFraction></span>,
and through December 31, 2024 the Company recorded an additional stock-based compensation expense of $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_ztRj5UDkPEH3"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31" id="Fact001442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,373</ix:nonFraction></span>
for a total stock-based compensation expense of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zwwL2Ukhfxw"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_ServiceAgreementsMember" id="Fact001443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">893,784</ix:nonFraction></span>.
For the year ended December 31, 2025, the Company recorded $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zF31rTDyWTyd" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_ServiceAgreementsMember" id="Fact001445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,546,117</ix:nonFraction></span>
stock-based compensation expense and the remaining future stock-based compensation expense as of December 31, 2025 is $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20251231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zkNuS7SLqiAg" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_us-gaap_ServiceAgreementsMember" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,198,474</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, each of the entities agreed to purchase <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0u9m9pmSD74" title="Purchase of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember" id="Fact001449" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,500</ix:nonFraction></span> shares each of the Company&#8217;s common stock at a price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdm3m5dQV41d"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember" id="Fact001450" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction></span> per share
prior to the occurrence of the IPO and these shares were registered in the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001452" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_z0ThKYsbqii2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_821_zFlud64cDJy3">Segment Report</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer serves as the Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM evaluates financial
performance and makes resource allocation decisions based on the operating results of the Company&#8217;s reportable segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2025, the Company operates through <span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uSegments_c20251001__20251001_zeFHsr2NsiG4" title="Number of reportable segments"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-10-012025-10-01" id="Fact001454" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segments">two</ix:nonFraction></span> reportable segments under ASC 280, Segment Reporting: (i) its premium nutritional supplements, and (ii) pharmaceutical operations
focused on drug candidates for CNS and rare orphan diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Premium
Nutritional Supplements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
segment includes all activities related to the commercialization and sale of the Company&#8217;s Nugevia product line. Activities within
this segment primarily consist of marketing, distribution, sales, customer support, and related supply chain management associated with
Nugevia products.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
segment includes all activities related to the research, development, and regulatory advancement of JOTROL&#8482;, the Company&#8217;s
proprietary resveratrol-based therapeutic candidate, which is being developed to address unmet medical needs and improve patient outcomes.
Activities within this segment primarily consist of clinical development, regulatory, manufacturing development, intellectual property
protection, and related research and development functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM assesses segment performance and allocates resources based on segment net loss (income), which represents the primary measure of
profit or loss reviewed. The CODM does not evaluate segments using discrete asset or liability information. Accordingly, total assets
are reported on a consolidated basis in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation
Methodology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
are attributed to each reportable segment based on the nature of the activity and the function to which the expense relates. Costs that
are directly identifiable with a specific segment are recorded to that segment. Selling, general and administrative expenses that benefit
both segments are allocated using reasonable and consistently applied methodologies that reflect the estimated level of effort or resources
consumed by each segment. These allocation methodologies may include time and effort analyses, headcount, relative revenue, or other
activity-based measures, depending on the underlying cost driver.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation methodologies are reviewed periodically and refined as necessary to reflect changes in the business. The Company believes
such allocations are reasonable and consistent with the manner in which the CODM evaluates segment performance and makes resource allocation
decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
and other expenses consist primarily of public company costs (including board, investor relations, and SEC reporting expenses), certain
executive compensation, certain stock-based compensation, interest income (expense), other income (expense), and income taxes. These
costs are not allocated to reportable segments because they are not included in the measures reviewed by the CODM for purposes of assessing
segment performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001456" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zvRI8LIbbUIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
information for the year ended December 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z5Rl4GydSAMl">Schedule
of Segment Reporting Information</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalOperationsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zemW6h1G5BPa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical Operations</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PremiumNutritionalSupplementsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zttCJRuYxnx9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Premium Nutritional Supplements</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49E_20250101__20251231__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zTd7UOnNttPf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Reportable Segments</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zxTYVIjYQMM6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    / Other</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49D_20250101__20251231_zX0Hi5JO93Fc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Total</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zQmGzYooq7Ia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember" id="Fact001459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,796</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember" id="Fact001460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,796</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1461">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-01to2025-12-31" id="Fact001462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,796</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_zsatqpRywO6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember" id="Fact001466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2025-01-01to2025-12-31" id="Fact001468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,231</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_znQtTcNM6Qof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember" id="Fact001470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,086,574</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember" id="Fact001472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,086,574</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,086,574</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_zhb9978HSvy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
    general and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember" id="Fact001476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">817,554</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember" id="Fact001477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,179,492</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember" id="Fact001478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,997,046</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember" id="Fact001479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,842,666</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,839,712</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--SegmentNetLoss_zptM7uFlbuKd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
    net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:SegmentNetLoss" contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember" id="Fact001482" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,904,128</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:SegmentNetLoss" contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember" id="Fact001483" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,161,927</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="JUNS:SegmentNetLoss" contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember" id="Fact001484" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,066,055</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(<ix:nonFraction name="JUNS:SegmentNetLoss" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember" id="Fact001485" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,842,666</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(<ix:nonFraction name="JUNS:SegmentNetLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001486" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,908,721</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_zqOlJyeyXXXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other interest
    income (expense), net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1488">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1489">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember" id="Fact001491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,824</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,824</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zLPqSxsOwCe6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember" id="Fact001494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,904,128</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember" id="Fact001495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,161,927</ix:nonFraction></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember" id="Fact001496" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,066,055</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember" id="Fact001497" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,578,842</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001498" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,644,897</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zgkxfDgYJQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001500" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zqz8B85AiAy" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_z2WDLPwZ0283">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SEPA
Activity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to year end and through March 31, 2026, we have issued and sold
approximately <span><span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260101__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zQ7ytTknTee6" title="Sale of stock number of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2026-01-012026-03-31_us-gaap_SubsequentEventMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1.1</ix:nonFraction></span></span> million SEPA Shares to Yorkville pursuant to the SEPA, including SEPA
Shares issued in connection with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds
to us of approximately $<span><span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_pid_c20260101__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zA1fg7jAMaba" title="Proceeds from conversion debt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2026-01-012026-03-31_us-gaap_SubsequentEventMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">625,748</ix:nonFraction></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasdaq
Compliance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 26, 2026, the Company received two
written notices from the Listing Qualifications Department of Nasdaq notifying the Company that (i) the listing of the Company&#8217;s
Common Stock was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued
listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the Common Stock was less than $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0cmbfKIk0i3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for
the previous 30 consecutive business days, and (ii) for the 30 consecutive business days ended February 26, 2026, the Company&#8217;s
market value of listed securities closed below the $<span id="xdx_900_eus-gaap--AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQBWD4Ks59W5" title="Market value of listed securities closed"><ix:nonFraction name="us-gaap:AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember" id="Fact001508" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">35</ix:nonFraction></span> million threshold required for continued listing on The Nasdaq Capital Market under
Nasdaq Listing Rule 5550(b)(2). The Company has 180 calendar days, or until August 25, 2026, to regain compliance with both the minimum bid price
requirement and the market value of listed securities requirement. To regain compliance with the minimum bid price requirement, the Company&#8217;s
common stock must have a closing bid price of at least $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8wnI1NmGwDg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember" id="Fact001510" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction> </span>per share for a minimum of 10 consecutive business days (or such longer period,
up to 20 consecutive business days, as Nasdaq may require). To regain compliance with the market value of listed securities requirement,
the Company&#8217;s market value of listed securities must be at least $<span id="xdx_90F_eus-gaap--AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx0i3qDfoTld" title="Market value of listed securities closed"><ix:nonFraction name="us-gaap:AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember" id="Fact001512" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">35</ix:nonFraction></span> million for a minimum of 10 consecutive business days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2025 Notes Amendment</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 20, 2026, the Company and Yorkville
entered into an Omnibus Amendment. Among other changes, the Amendment revises the terms of the 2025 Convertible Promissory Notes to defer
the commencement of monthly installment payments to April 1, 2026, effectively providing an extension of approximately three months.</p>
</ix:nonNumeric><p id="xdx_815_zNtaFX3atk93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="signature"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 1.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
    NEUROSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    A<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pril 1</span>, 2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christer Ros&#233;n</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&#233;n</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="poa"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below hereby appoints Christer Ros&#233;n as attorney-in-fact with full power of substitution to execute
in the name and on behalf of the registrant and each such person, individually and in each capacity stated below, one or more amendments
to the Annual Report on Form 10-K, which amendments may make such changes in the report as the attorney-in-fact acting deems appropriate
and to file any such amendment to the Annual Report on Form 10-K with the Securities and Exchange Commission. Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 28%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 54%; padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; padding-right: 0.8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christer Ros&#233;n</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board and Chief Executive Officer (principal executive officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&#233;n</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Saleem Elmasri</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (principal financial officer and principal accounting officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saleem
    Elmasri</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Marshall Hayward, Ph.D.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marshall
    Hayward, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alison D. Silva</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alison
    D. Silva</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<i>s/
    Nicholas H. Hemmerly</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicholas
    H. Hemmerly</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Julie Kampf</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julie
    Kampf</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Allison W. Brady</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allison
    W. Brady</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Holger Weis</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    1, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holger
    Weis</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 139; Options: NewSection Last; Value: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<!-- Field: Set; Name: xdx; ID: xdx_088_labels -->
<!-- eJxTckxJySzJzM9LzFHwSUxKzSlW0lHKKCkpsNLXLy8v16tIKsrRyy9K1zcyMDDWL8rPSdUvSC3KzE8JLkksKgHrIFKDa14KRDkvl1JpsW56YmKBVXBJfnJ2Rn5OSmpRsWthaWZJJdAwp8ScxLzkVCQWLxcA29s4sg== -->
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--  
       -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of our capital stock is based upon our amended and restated certificate of incorporation, as amended, our amended
and restated bylaws, as amended, and applicable provisions of law, in each case as currently in effect. This discussion does not purport
to be complete and is qualified in its entirety by reference to our certificate of incorporation, as amended, and our amended and restated
bylaws, copies of which are filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2026, our authorized capital stock consists of (i) 500,000,000 shares of common stock, par value $0.0001 per share (&ldquo;Common
Stock&rdquo;), and (ii) 5,000,000 shares of preferred stock, par value $0.0001 per share (&ldquo;Preferred Stock&rdquo;). At March 31,
2026, we had 36,281,252 shares of Common Stock issued and outstanding and no shares of Preferred Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2026, there were 31 holders of record of our Common Stock and no holders of record of our Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of our common stock are entitled to one vote for each share held on all matters to be voted on by the Company&rsquo;s stockholders.
There shall be no cumulative voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of shares of our common stock are entitled to dividends when and as declared by the Board from funds legally available therefor
if, as and when determined by the Board of Directors of the Company in their sole discretion, subject to provisions of law, and any provision
of the Company&rsquo;s Certificate of Incorporation, as amended from time to time. There are no preemptive, conversion or redemption
privileges, nor sinking fund provisions with respect to the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our common stock will
be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of or provision for
all of our debts and other liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fully
Paid and Non-assessable</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors shall have the authority to authorize the issuance of the preferred stock from time to time in one or more classes
or series, and to state in the resolution or resolutions from time to time adopted providing for the issuance thereof the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 51.3pt; text-align: justify; text-indent: -18.9pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of each class or series of the preferred stock may vary from the shares of any other class or series thereof in any respect. The
Board of Directors may increase the number of shares of the preferred stock designated for any existing class or series by a resolution
adding to such class or series authorized and unissued shares of the preferred stock not designated for any existing class or series
of the preferred stock and the shares so subtracted shall become authorized, unissued and undesignated shares of the preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of Our Certificate of Incorporation, as Amended, and Our Amended and Restated Bylaws, as Amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our certificate of incorporation, as amended, and our amended and restated bylaws, as amended (&ldquo;bylaws&rdquo;), could make it
more difficult to acquire us by means of a merger, tender offer, proxy contest, open market purchases, removal of incumbent directors
and otherwise. These provisions, which are summarized below, are expected to discourage types of coercive takeover practices and inadequate
takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits of increased
protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure
us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of these proposals could result in
an improvement of their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 26.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal
of Directors.</I> Our amended and restated bylaws provide that directors may be removed prior to the expiration of their terms by the
affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the issued and outstanding stock entitled to
vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vacancies</I>.
Our amended and restated bylaws provide the exclusive right of our board of directors to elect a director to fill a vacancy created by
the expansion of the board of directors or the resignation, death, or removal of a director, which prevents stockholders from being able
to fill vacancies on our board of directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preferred
Stock.</I> Our certificate of incorporation, as amended, authorizes the issuance of up to 5,000,000 shares of preferred stock with such
rights and preferences as may be determined from time to time by our board of directors in their sole discretion. Our board of directors
may, without stockholder approval, issue series of preferred stock with dividends, liquidation, conversion, voting or other rights that
could adversely affect the voting power or other rights of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
of Bylaws.</I> The certificate of incorporation, as amended, and amended and restated bylaws provide that the bylaws may be altered,
amended or repealed by the Board of Directors by an affirmative vote of a majority of the Board of Directors at any regular meeting of
the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
of Liability</I>. The certificate of incorporation provides for the limitation of liability of, and providing indemnification to, our
directors and officers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Stockholders Meeting</I>. The amended and restated bylaws provide that a special meeting of the stockholders may only be called by a
majority of the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nominations
of Directors</I>. The amended and restated bylaws provide for advance notice procedures that stockholders must comply with in order to
nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&rsquo; meeting, which may discourage
or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise
attempting to obtain control of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exclusive
Forum Provision</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
IX of our certificate of incorporation, as amended, and Section 7.4 of our amended and restated bylaws provide that &ldquo;unless
the corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative
action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by
any director, officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii) any
action asserting a claim arising pursuant to any provision of the DGCL, or (iv) any action asserting a claim governed by the
internal affairs doctrine shall be a state or federal court located in the county in which the principal office of the corporation
in the State of Delaware is established, in all cases subject to the court&rsquo;s having personal jurisdiction over the
indispensable parties named as defendants. Notwithstanding the foregoing, the exclusive forum provision will not apply to suits
brought to enforce any liability or duty created by the Exchange Act of 1934, as amended, the Securities Act of 1933, as amended, or
any claim for which the federal courts have exclusive or concurrent jurisdiction.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
choice of forum provision may limit a bondholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and
employees. Alternatively, a court could find these provisions of our certificate of incorporation, as amended, and our amended and restated
bylaws to be inapplicable or unenforceable in respect of one or more of the specified types of actions or proceedings, which may require
us to incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business
and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee
Shifting Provision</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.4 of our amended and restated bylaws provides that &ldquo;if any action is brought by any party against another party, relating to
or arising out of these Bylaws, or the enforcement hereof, the prevailing party shall be entitled to recover from the other party reasonable
attorneys&rsquo; fees, costs and expenses incurred in connection with the prosecution or defense of such action.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated bylaws provide that for this section, the term &ldquo;attorneys&rsquo; fees&rdquo; or &ldquo;attorneys&rsquo; fees
and costs&rdquo; means the fees and expenses of counsel to the Company and any other parties asserting a claim subject to Section 7.4
of the amended and restated bylaws, which may include printing, photocopying, duplicating and other expenses, air freight charges, and
fees billed for law clerks, paralegals and other persons not admitted to the bar but performing services under the supervision of an
attorney, and the costs and fees incurred in connection with the enforcement or collection of any judgment obtained in any such proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted the fee-shifting provision to eliminate or decrease nuisance and frivolous litigation. We intend to apply the fee-shifting provision
broadly to all actions except for claims brought under the Exchange Act and Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no set level of recovery required to be met by a plaintiff to avoid payment under this provision. Instead, whoever is the prevailing
party is entitled to recover the reasonable attorneys&rsquo; fees, costs and expenses incurred in connection with the prosecution or
defense of such action. Any party who brings an action, and the party against whom such action is brought under Section 7.4 of our amended
and restated bylaws, which could include, but is not limited to former and current shareholders, Company directors, officers, affiliates,
legal counsel, expert witnesses and other parties, are subject to this provision. Additionally, any party who brings an action, and the
party against whom such action is brought under Section 7.4 of our amended and restated bylaws, which could include, but is not limited
to former and current shareholders, Company directors, officers, affiliates, legal counsel, expert witnesses and other parties, would
be able to recover fees under this provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event you initiate or assert a claims against us, in accordance with the dispute resolution provisions contained in our amended and
restated bylaws, and you do not, in a judgment prevail, you will be obligated to reimburse us for all reasonable costs and expenses incurred
in connection with such claim, including, but not limited to, reasonable attorney&rsquo;s fees and expenses and costs of appeal, if any.
Additionally, this provision in Section 7.4 of our amended and restated bylaws could discourage shareholder lawsuits that might otherwise
benefit the Company and its shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
FEE SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS IS NOT INTENDED TO BE DEEMED A WAIVER BY ANY HOLDER OF COMMON STOCK
OF THE COMPANY&rsquo;S COMPLIANCE WITH THE U.S. FEDERAL SECURITIES LAWS AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER. THE FEE
SHIFTING PROVISION CONTAINED IN THE AMENDED AND RESTATED BYLAWS DO NOT APPLY TO CLAIMS BROUGHT UNDER THE EXCHANGE ACT AND SECURITIES
ACT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Transfer Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
transfer agent is Equiniti Trust Company. The transfer agent address is 1110 Centre Pointe Curve, Suite 101, Mendota Heights, Minnesota
55120, and its telephone number is (800) 401-1957.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>ex10-4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: right; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.4</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to Executive Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
as of December 18, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment to Executive Employment Agreement (this &ldquo;Amendment&rdquo;) dated as of the date first set forth above (the &ldquo;Amendment
Date&rdquo;) is entered into by and between Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) and Christer Ros&eacute;n (the &ldquo;Executive&rdquo;). The Company and Executive may collective be referred to as the &ldquo;Parties&rdquo; and each individually
as a &ldquo;Party&rdquo;.</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Parties are the parties to that certain Executive Employment Agreement, dated as of June 1, 2021 (the &ldquo;Original Agreement&rdquo;),
and now desire to amend the Original Agreement as set forth herein and pursuant to Section 14 of the Original Agreement the Parties may
amend the Original Agreement in writing;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the promises and of the mutual covenants and agreements hereinafter set forth, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Defined
                                            Terms.</U> Defined terms used herein without definition shall have the meanings given in
                                            the Original Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to Section 14 of the Original Agreement, the Original Agreement is hereby amended by adding
                                            the following to the end of Section 2 of the Original Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, for the period from October 1, 2023, until the time that the Company has raised additional capital from the sale of its
securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;), the Base Salary shall be reduced to $84,000 on an annual
basis. Upon the expiration of the Reduction Period, the Base Salary shall be adjusted to be 105% the original Base Salary as set forth
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the fact that this Amendment is being executed on the Amendment Date, the Parties acknowledge
                                            and agree that the amendment to the Original Agreement as set forth in Section 2(a) shall
                                            be operative and effective as of the date of the commencement of the &ldquo;Reduction Period&rdquo;
                                            as set forth in Section 2(a), and shall operate to reduce the Base Salary from such date
                                            and during the remainder of the Reduction Period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Remainder
                                            in Force</U>. Other than as amended herein, the Original Agreement shall remain in full force
                                            and effect until terminated in accordance with its terms. Any reference in the Original Agreement
                                            to the &ldquo;Agreement&rdquo; shall now be deemed a reference to the Original Agreement
                                            as amended by this Amendment.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2.4pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            headings in this Amendment are for reference only and shall not affect the interpretation
                                            of this Amendment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Amendment and the rights and obligations of the Parties shall be governed by and construed
                                            and enforced in accordance with the laws of the State of Florida without giving effect to
                                            any choice or conflict of law provision or rule (whether of the State of Florida or any other
                                            jurisdiction).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Amendment may be executed in counterparts, each of which shall be deemed an original, but
                                            all of which together shall be deemed to be one and the same agreement. A signed copy of
                                            this Amendment delivered by facsimile, e-mail or other means of electronic transmission shall
                                            be deemed to have the same legal effect as delivery of an original signed copy of this Amendment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 17.9pt 0 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signatures
appear on following page]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 17.9pt 0 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3.7pt 2.65pt 0 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed as of the Amendment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Alison Silva</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Alison Silva</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD><P STYLE="margin: 0">President &amp; Chief Business <FONT STYLE="letter-spacing: -0.1pt">Officer</FONT></P>



</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive: Christer <FONT STYLE="letter-spacing: -0.2pt">Ros&eacute;n</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Christer Ros&eacute;n</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Christer <FONT STYLE="letter-spacing: -0.2pt">Ros&eacute;n</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>4
<FILENAME>ex10-7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: right; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.7</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to Executive Employment Agreement</FONT></P>

<P STYLE="margin-top: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
as of December 18, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment to Executive Employment Agreement (this &ldquo;Amendment&rdquo;) dated as of the date first set forth above (the &ldquo;Amendment
Date&rdquo;) is entered into by and between Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) and Marshall Hayward (the &ldquo;Executive&rdquo;). The Company and Executive may collective be referred to as the &ldquo;Parties&rdquo; and each individually
as a &ldquo;Party&rdquo;.</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Parties are the parties to that certain Executive Employment Agreement, dated as of June 1, 2021 (the &ldquo;Original Agreement&rdquo;),
and now desire to amend the Original Agreement as set forth herein and pursuant to Section 14 of the Original Agreement the Parties may
amend the Original Agreement in writing;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the promises and of the mutual covenants and agreements hereinafter set forth, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Defined
                                            Terms.</U> Defined terms used herein without definition shall have the meanings given in
                                            the Original Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to Section 14 of the Original Agreement, the Original Agreement is hereby amended by adding
                                            the following to the end of Section 2 of the Original Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, for the period from October 1, 2023, until the time that the Company has raised additional capital from the sale of its
securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;), the Base Salary shall be reduced to $67,200 on an annual
basis. Upon the expiration of the Reduction Period, the Base Salary shall be adjusted to be 105% the original Base Salary as set forth
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the fact that this Amendment is being executed on the Amendment Date, the Parties acknowledge
                                            and agree that the amendment to the Original Agreement as set forth in Section 2(a) shall
                                            be operative and effective as of the date of the commencement of the &ldquo;Reduction Period&rdquo;
                                            as set forth in Section 2(a), and shall operate to reduce the Base Salary from such date
                                            and during the remainder of the Reduction Period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Remainder
                                            in Force</U>. Other than as amended herein, the Original Agreement shall remain in full force
                                            and effect until terminated in accordance with its terms. Any reference in the Original Agreement
                                            to the &ldquo;Agreement&rdquo; shall now be deemed a reference to the Original Agreement
                                            as amended by this Amendment.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2.4pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            headings in this Amendment are for reference only and shall not affect the interpretation
                                            of this Amendment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Amendment and the rights and obligations of the Parties shall be governed by and construed
                                            and enforced in accordance with the laws of the State of Florida without giving effect to
                                            any choice or conflict of law provision or rule (whether of the State of Florida or any other
                                            jurisdiction).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Amendment may be executed in counterparts, each of which shall be deemed an original, but
                                            all of which together shall be deemed to be one and the same agreement. A signed copy of
                                            this Amendment delivered by facsimile, e-mail or other means of electronic transmission shall
                                            be deemed to have the same legal effect as delivery of an original signed copy of this Amendment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 17.9pt 0 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signatures
appear on following page]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 17.9pt 0 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3.7pt 2.65pt 0 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed as of the Amendment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Christer Ros&eacute;n</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Christer Ros&eacute;n</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive: Marshall Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Marshall Hayward</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Marshall Hayward</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>5
<FILENAME>ex10-12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: right; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.12</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
to Executive Employment Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated
as of December 18, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Amendment to Executive Employment Agreement (this &ldquo;Amendment&rdquo;) dated as of the date first set forth above (the &ldquo;Amendment
Date&rdquo;) is entered into by and between Jupiter Neurosciences, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) and Alison
Silva (the &ldquo;Executive&rdquo;). The Company and Executive may collective be referred to as the &ldquo;Parties&rdquo; and each individually
as a &ldquo;Party&rdquo;.</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Parties are the parties to that certain Executive Employment Agreement, dated as of June 1, 2021 (the &ldquo;Original Agreement&rdquo;),
and now desire to amend the Original Agreement as set forth herein and pursuant to Section 14 of the Original Agreement the Parties may
amend the Original Agreement in writing;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the promises and of the mutual covenants and agreements hereinafter set forth, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Defined
                                            Terms.</U> Defined terms used herein without definition shall have the meanings given in
                                            the Original Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendment</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to Section 14 of the Original Agreement, the Original Agreement is hereby amended by adding
                                            the following to the end of Section 2 of the Original Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, for the period from October 1, 2023, until the time that the Company has raised additional capital from the sale of its
securities in the amount of $1,500,000 (the &ldquo;Reduction Period&rdquo;), the Base Salary shall be reduced to $60,000 on an annual
basis. Upon the expiration of the Reduction Period, the Base Salary shall be adjusted to be 105% the original Base Salary as set forth
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the fact that this Amendment is being executed on the Amendment Date, the Parties acknowledge
                                            and agree that the amendment to the Original Agreement as set forth in Section 2(a) shall
                                            be operative and effective as of the date of the commencement of the &ldquo;Reduction Period&rdquo;
                                            as set forth in Section 2(a), and shall operate to reduce the Base Salary from such date
                                            and during the remainder of the Reduction Period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Remainder
                                            in Force</U>. Other than as amended herein, the Original Agreement shall remain in full force
                                            and effect until terminated in accordance with its terms. Any reference in the Original Agreement
                                            to the &ldquo;Agreement&rdquo; shall now be deemed a reference to the Original Agreement
                                            as amended by this Amendment.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.05pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2.4pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            headings in this Amendment are for reference only and shall not affect the interpretation
                                            of this Amendment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Amendment and the rights and obligations of the Parties shall be governed by and construed
                                            and enforced in accordance with the laws of the State of Florida without giving effect to
                                            any choice or conflict of law provision or rule (whether of the State of Florida or any other
                                            jurisdiction).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Amendment may be executed in counterparts, each of which shall be deemed an original, but
                                            all of which together shall be deemed to be one and the same agreement. A signed copy of
                                            this Amendment delivered by facsimile, e-mail or other means of electronic transmission shall
                                            be deemed to have the same legal effect as delivery of an original signed copy of this Amendment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 17.9pt 0 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signatures
appear on following page]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 17.9pt 0 0.05pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3.7pt 2.65pt 0 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed as of the Amendment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jupiter Neurosciences, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Christer Ros&eacute;n</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Christer Ros&eacute;n</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive: Alison Silva</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>/s/ Alison Silva</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Alison Silva</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
of Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements of Jupiter Neurosciences, Inc. on Form S-1 (No. 333-291832)
and on Form S-8 (No. 333-293466) of our report, dated April 1, 2026, with respect to our audit of the financial statements as of December
31, 2025 and for the year then ended. Our report includes an explanatory paragraph regarding the existence of substantial doubt concerning
the Company&rsquo;s ability to continue as a going concern. We also consent to reference to our firm under the caption &ldquo;Experts&rdquo;
in such registration statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Cherry Bekaert LLP</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tampa,
    Florida</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2026</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>7
<FILENAME>ex23-2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT ACCOUNTANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Jupiter Neurosciences, Inc. of our report
dated March 28, 2025, relating to our audit of the financial statements as of December 31, 2024 and for the year ended December
31, 2024, which appears in the Registration Statement on Form S-1 of Jupiter Neurosciences, Inc. for the year then ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to our firm under the caption &ldquo;Experts&rdquo; in the Prospectus, which is part of this Registration
Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-2_001.jpg" ALT="" STYLE="height: 43px; width: 211px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assurance
Dimensions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coral
Springs, Florida</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">April 1, 2026</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULES
13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Christer Ros&eacute;n, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2025 of Jupiter Neurosciences, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
April 1, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD>
    <TD STYLE="width: 50%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (principal executive officer)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULES
13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Saleem Elmasri, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2025 of Jupiter Neurosciences, Inc.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
April 1, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Saleem Elmasri</I></FONT></TD>
    <TD STYLE="width: 50%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saleem
    Elmasri</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (principal financial officer and principal accounting officer)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of Jupiter Neurosciences, Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended December
31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Christer Ros&eacute;n,
Chief Executive Officer of the Company, and I, Saleem Elmasri, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 1, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christer Ros&eacute;n</I></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christer
    Ros&eacute;n</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (principal executive officer)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 1, 2026</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Saleem Elmasri</I></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saleem
    Elmasri</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (principal financial officer and principal accounting officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except
to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the &ldquo;Exchange Act&rdquo;). Such certification will not be deemed to be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>ex97-1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLAWBACK
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Jupiter Neurosciences, Inc. Clawback Policy (this &ldquo;<B>Policy</B>&rdquo;) was approved effective as of March 25, 2025 (the &ldquo;<B>Effective
Date</B>&rdquo;) by the Compensation Committee (the &ldquo;<B>Committee</B>&rdquo;) of the Board of Directors (the &ldquo;<B>Board</B>&rdquo;)
of Jupiter Neurosciences, Inc. (the &ldquo;<B>Company</B>&rdquo;). This Policy is adopted pursuant to and intended to comply with Rule
5608 (Recovery of Erroneously Awarded Compensation) of The Nasdaq Stock Market LLC (&ldquo;<B>Nasdaq</B>&rdquo;) so long as the Company&rsquo;s
securities are listed on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose
and Policy Statement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is committed to conducting business with integrity in accordance with high ethical standards and in compliance with all applicable
laws, rules, and regulations. This includes the Company&rsquo;s commitment to comply with all laws, rules, and regulations applicable
to the presentation of the Company&rsquo;s financial information to the public and to the recovery of erroneously awarded incentive-based
compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, the Committee has adopted this Policy to provide that, in the event the Company is required to prepare an accounting restatement
due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required
accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial
statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in
the current period (each, as applicable, a &ldquo;<B>Restatement</B>&rdquo;), the Company will recover reasonably promptly the amount
of any &ldquo;erroneously awarded compensation&rdquo; &ldquo;received&rdquo; by an &ldquo;executive officer,&rdquo; in each case as such
terms are defined in this Policy, if and to the extent required by any federal or state law, rule or regulation, or rule, regulation,
policy or listing standard of the Securities and Exchange Commission (&ldquo;<B>SEC</B>&rdquo;) or any securities exchange on which the
Company&rsquo;s securities are listed, including without limitation, Nasdaq Rule 5608 (Recovery of Erroneously Awarded Compensation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any change in any federal or state law, rule or regulation, or rule, regulation, policy or listing standard of the SEC or
any securities exchange on which the Company&rsquo;s securities are listed after the Effective Date, which requires the Company to recover
compensation from an executive officer, the Company will seek recovery under this Policy to the extent required by such laws, rules,
regulations or listing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Administration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee has full power, authority, and sole and exclusive discretion to reasonably construe, interpret, and administer this Policy.
The Committee will interpret this Policy consistent with Nasdaq Rule 5608 (Recovery of Erroneously Awarded Compensation) and any guidance
issued thereunder, the rules and regulations of the SEC, and any other applicable laws, rules or regulations governing the mandatory
recovery of compensation, as such laws, rules or regulations may change, be interpreted, or evolve from time to time. All determinations
and decisions made by the Committee will be made in its reasonable discretion and will be final, conclusive, and binding on all affected
individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;<B>Committee</B>&rdquo; as used in this Policy means the Compensation Committee of the Board, or in the absence of such a
committee, a majority of the &ldquo;independent directors&rdquo; (as defined under Nasdaq Rule 5605(a)(2)) serving on the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to all &ldquo;incentive-based compensation&rdquo; &ldquo;received&rdquo; by a person, in each case as such terms are defined
in this Policy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    beginning service as an &ldquo;executive officer,&rdquo; as such term is defined in this Policy, and who served as an executive officer
    at any time during the performance period for that incentive-based compensation;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
    the Company has a class of securities listed on Nasdaq or another national securities exchange or a national securities association;
    and</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the three completed fiscal years immediately preceding the date that the Company is required to prepare the Restatement, plus any
    transition period (that results from a change in the Company&rsquo;s fiscal year) within or immediately following those three completed
    fiscal years; provided, however, that a transition period between the last day of the Company&rsquo;s previous fiscal year-end and
    the first day of its new fiscal year that comprises a period of nine to 12 months would be deemed a completed fiscal year; and provided,
    further, that the Company&rsquo;s obligation to recover erroneously awarded compensation is not dependent on if or when the restated
    financial statements are filed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify; text-indent: -16.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of determining the relevant recovery period, the date that the Company is required to prepare a Restatement is the earlier to
occur of (i) the date the Company&rsquo;s Board, a committee of the Board, or the officer or officers of the Company authorized to take
such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare
a Restatement; or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare a Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers Covered by Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy covers the Company&rsquo;s current and former executive officers who received erroneously awarded compensation regardless of whether
the executive officer committed misconduct or contributed to the error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;<B>executive officer</B>&rdquo; as used in this Policy means the Company&rsquo;s:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">president;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">principal
    financial officer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">principal
    accounting officer (or if there is no such accounting officer, the controller);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
        other officer who performs a policy-making function; or</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other person who performs similar policy-making functions for the Company and executive officers of the Company&rsquo;s parents or
    subsidiaries if such individuals perform such policy-making functions for the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Policy-making
function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes
of this Policy would include at a minimum executive officers identified by the Company pursuant to Item 401(b) of SEC Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authority
and Obligation to Recover Erroneously Awarded Compensation; Exceptions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a Restatement, the Company must reasonably promptly recover any &ldquo;erroneously awarded compensation,&rdquo; as such
term is defined in this Policy, in compliance with this Policy, except to the extent one of the three conditions below is met and the
Committee has made a determination that recovery would be impracticable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered and the Company has
    made a reasonable attempt to recover any amount of erroneously awarded compensation, has documented such reasonable attempt(s) to
    recover and provided that documentation to Nasdaq.</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
    would violate home country law where that law was adopted prior to November 28, 2022, and the Company has obtained an opinion of
    home country counsel, acceptable to Nasdaq, that recovery would result in such a violation and has provided such opinion to Nasdaq.</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
    would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company,
    to fail to meet the requirements of Section 401(a)(13) or 411(a) of the U.S. Internal Revenue Code and regulations thereunder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Erroneously
Awarded Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;<B>erroneously awarded compensation</B>&rdquo; as used in this Policy means that amount of &ldquo;incentive-based compensation&rdquo;
received that exceeds the amount of &ldquo;incentive-based compensation&rdquo; that otherwise would have been received had it been determined
based on the restated amounts, and must be computed without regard to any taxes paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
incentive-based compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is
not subject to mathematical recalculation directly from the information in a Restatement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount must be based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon
    which the incentive-based compensation was received; and</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.45in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;<B>incentive-based compensation</B>&rdquo; as used in this Policy means any compensation that is granted, earned, or vested
based wholly or in part upon the attainment of a financial reporting measure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;<B>financial reporting measures</B>&rdquo; as used in this Policy means measures that are determined and presented in accordance
with the accounting principles used in preparing the Company&rsquo;s financial statements, and any measures that are derived wholly or
in part from such measures. Financial reporting measures include, without limitation, stock price and total shareholder return, and may
include non-GAAP financial measures. A financial reporting measure need not be presented within the Company&rsquo;s financial statements
or included in an SEC filing to constitute a financial reporting measure for this purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive-based
compensation is deemed &ldquo;<B>received</B>&rdquo; as such term is used in this Policy by an executive officer in the Company&rsquo;s
fiscal period during which the financial reporting measure specified in the incentive-based compensation award is attained, even if the
payment or grant of the incentive-based compensation occurs after the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the generality of the foregoing, &ldquo;incentive-based compensation&rdquo; is intended to be interpreted and construed broadly and includes
with respect to any plan that takes into account incentive-based compensation (other than a tax-qualified plan) any amount contributed
to a notional account based on erroneously awarded compensation and any earnings accrued to date on that notional account. Such plans
include without limitation long-term disability plans, life insurance plans, supplemental executive retirement plans and other compensation,
if it is based on incentive-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
clarity and the avoidance of doubt, &ldquo;incentive-based compensation&rdquo; does not include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">base
    salary (other than any base salary increase earned wholly or in part based on the attainment of a financial reporting measure, which
    increase is subject to recovery as incentive-based compensation hereunder);</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bonuses
    paid solely at the discretion of the Committee or Board that are not paid from a &ldquo;bonus pool&rdquo; that is determined by satisfying
    a financial reporting measure performance goal;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bonuses
    paid solely upon satisfying one or more subjective standards (e.g. demonstrated leadership) and/or completion of a specified employment
    period;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-equity
    incentive plan awards earned solely upon satisfying one or more strategic measures (e.g., consummating a merger or divestiture),
    or operational measures (e.g., completion of a project); and</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equity
    awards for which the grant is not contingent upon achieving any financial reporting measure performance goal, and vesting is contingent
    solely upon completion of a specified employment period and/or attaining one or more non-financial reporting measures.&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Method
of Recovery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee will determine, in its reasonable discretion, the method for recovering incentive-based compensation hereunder, which may include,
without limitation, any one or more of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    reimbursement of cash incentive-based compensation previously paid;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeking
    recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancelling
    or rescinding some or all outstanding vested or unvested equity-based awards;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adjusting
    or withholding from unpaid compensation, deferred compensation, or other set-off;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancelling
    or setting-off against planned future grants of equity-based awards; and/or</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method required or authorized by applicable law or contract.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enforceability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the adoption of this Policy, the Company will take steps to implement an agreement to this Policy by all current and future
executive officers. In furtherance of the foregoing, each executive officer subject to this Policy is required to sign and return to
the Company the Acknowledgement Form attached hereto as <U>Exhibit A</U> pursuant to which such executive officer will agree to be bound
by the terms and comply with this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Policy
Not Exclusive</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
recovery under this Policy is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the
Company pursuant to the terms of any other clawback or recovery policy or any similar policy in any employment agreement, incentive or
equity compensation plan or award or other agreement and any other legal rights or remedies available to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the generality of the foregoing, to the extent that the requirements under the provisions of Section 304 of the Sarbanes-Oxley Act of
2002 are broader than the provisions in this Policy, the provisions of such law will apply to the Company&rsquo;s Chief Executive Officer
and Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will not indemnify or agree to indemnify any executive officer or former executive officer against the loss of erroneously awarded
compensation nor will the Company pay or agree to pay any insurance premium to cover the loss of erroneously awarded compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective
Date</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is effective as of the Effective Date and applies to all incentive-based compensation received by the Company&rsquo;s current
and former executive officers on or after the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Required
Disclosures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will file all disclosures with respect to this Policy in accordance with the requirements of the federal securities laws, including
the disclosure required by the applicable SEC filings, and will provide all required SEC and other disclosures regarding this Policy
and in the event of a Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
and Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee may amend, modify, or terminate this Policy in whole or in part at any time in its sole discretion and may adopt such rules
and procedures that it deems necessary or appropriate to implement this Policy or to comply with Nasdaq Rule 5608 (Recovery of Erroneously
Awarded Compensation) and any other applicable laws, rules, and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Successors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all current and former executive officers of the Company and their respective beneficiaries,
heirs, executors, administrators, or other legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adopted
by the Compensation Committee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
the Board of Directors of Jupiter Neurosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
March 25, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JUPITER
NEUROSCIENCES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLAWBACK
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACKNOWLEDGEMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Jupiter Neurosciences,
Inc. Clawback Policy (the &ldquo;<B>Policy</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to
the Policy and that the Policy will apply both during and after the undersigned&rsquo;s employment with Jupiter Neurosciences, Inc.,
and its direct and indirect subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
by signing below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any erroneously
awarded compensation (as defined in the Policy) to Jupiter Neurosciences, Inc. and its direct and indirect subsidiaries to the extent
required by, and in a manner permitted by the Policy.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 42%; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $Z NX# 2(  A$! Q$!_\0
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M?^>_AK_P4/\ _'J/^'DOQI_Y[^&O_!0__P >KY<_#]:/P_6CZI1_E0?6:O\
M,SZC_P"'DOQI_P">_AK_ ,%#_P#QZC_AY+\:?^>_AK_P4/\ _'J^7/P_6C\/
MUH^J4?Y4'UFK_,SZC_X>2_&G_GOX:_\ !0__ ,>H_P"'DOQI_P">_AK_ ,%#
M_P#QZOES\/UH_#]:/JE'^5!]9J_S,^H_^'DOQI_Y[^&O_!0__P >H_X>2_&G
M_GOX:_\ !0__ ,>KY<_#]:/P_6CZI1_E0?6:O\S/J/\ X>2_&G_GOX:_\%#_
M /QZC_AY+\:?^>_AK_P4/_\ 'J^7/P_6C\/UH^J4?Y4'UFK_ #,^H_\ AY+\
M:?\ GOX:_P#!0_\ \>H_X>2_&G_GOX:_\%#_ /QZOES\/UH_#]:/JE'^5!]9
MJ_S,^H_^'DOQI_Y[^&O_  4/_P#'J/\ AY+\:?\ GOX:_P#!0_\ \>KY<_#]
M:/P_6CZI1_E0?6:O\S/J/_AY+\:?^>_AK_P4/_\ 'J/^'DOQI_Y[^&O_  4/
M_P#'J^7/P_6C\/UH^J4?Y4'UFK_,SZC_ .'DOQI_Y[^&O_!0_P#\>H_X>2_&
MG_GOX:_\%#__ !ZOES\/UH_#]:/JE'^5!]9J_P S/J/_ (>2_&G_ )[^&O\
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M;\1?BC=2ZE:/I6L^%]4TO3I],T^2VMY9[CRS&D=NV6B3(< -TQ[UXO&"%7(
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M8[]:H>(/VD?AK\0_$?Q(TW7%TO2_"VL:]H]Y;:E8Z-*MUJMK!())Q<D9+'Y
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M-"/QYX^\1>)6^(DMC_;%_-??91I*R>49'+;=WFC.,]<"L#_AU#"_/_"S9O\
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M'_#J"+_HILO_ ()%_P#CU?H%11]=K_S!]3H?RGY^_P##J"+_ **;+_X)%_\
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M"1?_ (]1_P .H(O^BFR_^"1?_CU?H%11]=K_ ,P?4Z'\I^?O_#J"+_HILO\
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MP+!T5T/S]_X=01DY/Q-E_P#!*/\ X]1_PZ@CQ_R4V7\=%7_X]7Z!44?7*_\
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M1+]H/_H>/"__ (+V_P#B:]\\OWH\OWH^M2_EC]R#ZDOYY?>SP/\ X1+]H/\
MZ'CPO_X+V_\ B:/^$2_:#_Z'CPO_ ."]O_B:]\\OWH\OWH^M2_EC]R#ZDOYY
M?>SP/_A$OVA/^AX\+_\ @N;_  H_X1+]H3_H>/"__@N?_"O?/+]Z/+]Z/K4O
MY5]R#ZDOYY?>SP/_ (1+]H3_ *'CPO\ ^"Y_\*/^$2_:$_Z'CPO_ ."Y_P#"
MO?/+]Z/+]Z/K4OY5]R#ZDOYY?>SP/_A$OVA/^AX\+_\ @N?_  I/^$3_ &A/
M^AW\+_\ @O;_ .)KWWR_>CR_>CZU+^5?<@^I+^>7WL\#_P"$2_:#_P"AX\+_
M /@O;_XFC_A$OV@_^AX\+_\ @O;_ .)KWSR_>CR_>CZU+^6/W(/J2_GE][/
M_P#A$OV@_P#H>/"__@O;_P")H_X1+]H/_H>/"_\ X+V_^)KWSR_>CR_>CZU+
M^6/W(/J2_GE][/ _^$2_:#_Z'CPO_P""]O\ XFC_ (1+]H/_ *'CPO\ ^"]O
M_B:]\\OWH\OWH^M2_EC]R#ZDOYY?>SP/_A$OVA/^AW\+_P#@O;_"C_A$OVA/
M^AX\+_\ @N?_  KWSR_>CR_>CZU+^5?<A_4H_P \OO9X'_PB7[0G_0\>%_\
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MT244S=QTI](T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^>OV8_P#D<_C!_P!C&W_LU>[WVIV^D:=<7EW*L%K;1--+*W1$
M49)/T ->#_LQG_BL_C#_ -C&W_LU>K?$]MGPW\4-G &DW)Y_ZY-7H8M<V)MZ
M?DCQ\')QPO,NE_S90\&_'/P-X_U-M/\ #_B>QU.^52YMXRROCV# 9_"NX$Z$
M9)[XKXV^$/@#6]4\-^!/'>I+IND>'/#.C7%S;3Z<6EOKM?+;EQ@*N.H7+9QC
MO6=\+_B)JDWQ#T:*PUW69-+UC0[ZYD@U77$OYI"L9>.<QH!]G?C[@QCI@8JY
MX2+E)4Y;&,,PG&*=2&Y]:^-O'ND?#[3(=2UJY>VLY;J*S#I$TA\R1MJ A>>O
M?'%.\7>/M$\!VEG<ZY?_ &&"[NX[&%C&\F^:0X11M!QGU/%?&UU8ZM=_LSZ-
MXOU'Q+J?B#4=9U.P6.SU"X#V\1BNG$80=BW1CDDUNVGCK6;SP3;:A>>(M3_X
M2R7QU9V>L6$ET4CL0)F5;>-,D+&5';[Y'-5]27*I*5];?\$7]HRY^64;:7_X
M!]G>>%P"?FH^U)C.X8QG-?$OB#6?$\&D^./&<7C76HV\/^+A96VG"ZQ:B,SH
M&#KSD8? !X'I77ZKXMO](_:,B74]>N]3L+[5H[/3H='UE42R?9@VUU9]64DY
M+?0U@\(^DEU-8YCIK%[H^K3,@ ))Y]C33.N#@YP,G@]*^&],^(NLSZ?H7BE/
M'.H3^.+_ ,5+I\_AG[5F!8#.4,'V4]!M&=V >>O%.USQ%XIL?#WBSQO%XUUD
M2Z+X\DTFVT\W0-KY'VA-RLO\7$FT ] M7]3:^*0O[24G:,7<^O-%^(FC>(/%
M>O>'K*Z>35-#,/VZ-H658_,7<F&(PW'ITK?O]5MM.LI[NYF6*VMXVEED8'"*
M!DD_0 UX#\<_"!\$>&9;GPOJT>D7^KZT-0U);G5?L4^IJ%):&.Y8_)@8P!C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:10Q1HD:QK'PJ@ !0.F/2K(&* ,4M<VO4])))604444#"BBB@ HHHH ****
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MMC]HW_H ^"O_  (F_P#BJ^@<&C!H^LK_ )]Q^[_@A]3?_/R7WGS]_;'[1O\
MT ?!7_@1-_\ %4?VQ^T;_P! 'P5_X$3?_%5] X-&#1]97_/N/W?\$/J;_P"?
MDOO/G[^V/VC?^@#X*_\  B;_ .*H_MC]HW_H ^"O_ B;_P"*KZ!P:,&CZRO^
M?<?N_P""'U-_\_)?>?/W]L?M&_\ 0!\%?^!$W_Q5']L?M&_] 'P5_P"!$W_Q
M5?0.#1@T?65_S[C]W_!#ZF_^?DOO/G[^V/VC?^@#X*_\")O_ (JC^V/VC?\
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M]L?M&_\ 0!\%?^!$W_Q5?0.#1@T?65_S[C]W_!#ZF_\ GY+[SY^_MC]HW_H
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MV/VC?^@#X*_\")O_ (JOH'!HP:/K*_Y]Q^[_ ((?4W_S\E]Y\_?VQ^T;_P!
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MX /1_P -I?#S_GKJG_@ ]>[_ &5/[J_]\T?94_NK_P!\T<U/^4/8X[_GZO\
MP'_@GA'_  VE\//^>NJ?^ #T?\-I?#S_ )ZZI_X /7N_V5/[J_\ ?-'V5/[J
M_P#?-'-3_E#V.._Y^K_P'_@GA'_#:7P\_P">NJ?^ #T?\-I?#S_GKJG_ ( /
M7N_V5/[J_P#?-'V5/[J_]\T<U/\ E#V.._Y^K_P'_@GA'_#:7P\_YZZI_P"
M#T?\-I?#S_GKJG_@ ]>[_94_NK_WS1]E3^ZO_?-'-3_E#V.._P"?J_\  ?\
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M6VH6L-S:2QW-M,N^.:%PZLIZ$$<5E.FX:]#OP^+I8C1.TENGNB]1BHXYP_\
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MGAK3A;"'2190M(GDXQLG(WINP,X]\8KV[!(Z\T9QV&:KVLR/[-PRO[IXQ/\
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M;;:991C AMUV@GU)ZDGU/-;JQL.< &FYJ.D#.&#E5:GBI<S[=%_F)'"(U"H
MJ#C %3@8I #BG5@>PE8****!A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q]\#OCQX#\(:_\
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M4?\ #6/PI_Z&^W_[\S?_ !%=U_PK?PI_T+>E?^ <?_Q-'_"M_"G_ $+>E?\
M@''_ /$T?N>S"V/_ )HG"_\ #6/PI_Z&^W_[\3?_ !%+_P -9?"K_H;[;_OQ
M-_\ $5W/_"M_"G_0MZ5_X!Q__$T?\*W\*?\ 0MZ5_P" <?\ \31^Y[,+8_\
MFB<+_P -8_"K/_(WVW_?B;_XBG?\-9_"O_H;[;_OQ-_\17<?\*W\*?\ 0MZ5
M_P" <?\ \32_\*V\*?\ 0MZ5_P" <?\ A0W1[,5L?_-$X7_AK+X5?]#?;?\
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M<)_?7\Z\J_X9O\-_\_\ K'_@<]*/V<?#B_\ +]K!_P"WYZ.2C_._N#ZQF/\
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M^&<?#><?;]8_\#GI\E#^=_<'UC,?^?"_\"_X!ZK]H3^^OYT?:$_OK^=>6?\
M#-WAS_G_ -8_\#GH_P"&;O#G_/\ ZQ_X'/1[.C_._N%]8S'_ )\+_P "_P"
M>I_:$_OK^='VA/[Z_G7E8_9P\-[B#?ZP/^WYZ7_AF_PWG_C_ -8_\#GH]G1_
MG?W#^L9B_P#EPO\ P+_@'J?VA/[Z_G1]H3^^OYUY8/V;O#AZ7^L?^!ST?\,W
M>'/^?_6/_ YZ7)0_G?W!]8S'_GPO_ O^ >J?:$_OI^='VA/[Z?G7E@_9Q\.
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MJ_8]V\.>)X_$&BVNI?9Y[&.X7=Y%XGERI[,O8UL&50-^1@#/6OEJVEMGT'P
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M[0S8QG S^=);1P!I/(C103R$ Z^^*\BNOC/K:P7^K0Z7:2>';.^-G*6G;SV
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MH5N+&41F6V9C#*"N0R9Y]B*XRY^/]VOB&2."SM9=.COQ9>49&^TL,[3+TV@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*VHWJZ7-=?;9-*5QY+RY!R>^,@'&:==_!32+JZO+M;Z\@O+B_74(KA"NZW<
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M=_T"O_P)'J_F_P"R?SH\W_9/YUY1_P *,U'_ *'K6_\ O[1_PHS4?^AZUO\
M[^T>SI?\_/P']=QW_0*__ D>K^;_ +)_.CS?]D_G7E'_  HS4?\ H>M;_P"_
MM'_"C-1_Z'K6_P#O[1[.E_S\_ 7UW'?] K_\"1ZOYO\ LG\Z/-_V3^=>4?\
M"C-1_P"AZUO_ +^T?\*,U'_H>M;_ ._M'LZ7_/S\ ^NX[_H%?_@2/5_-_P!D
M_G1YO^R?SKRC_A1FH_\ 0]:W_P!_:/\ A1FH_P#0]:W_ -_:/9TO^?GX!]=Q
MW_0*_P#P)'J_F_[)_.CS?]D_G7E'_"C-1_Z'K6_^_M'_  HS4?\ H>M;_P"_
MM'LZ7_/S\ ^NX[_H%?\ X$CU?S?]D_G1YO\ LG\Z\H_X49J/_0]:W_W]H_X4
M9J/_ $/6M_\ ?VCV=+_GY^ ?7<=_T"O_ ,"1ZOYO^R?SH\W_ &3^=>4?\*,U
M'_H>M;_[^T?\*,U'_H>M;_[^T>SI?\_/P#Z[CO\ H%?_ ($CU?S?]D_G1YO^
MR?SKRC_A1FH_]#UK?_?VC_A1FH_]#UK?_?VCV=+_ )^?@'UW'?\ 0*__  )'
MJ_F_[)_.CS?]D_G7E'_"C-1_Z'K6_P#O[1_PHS4?^AZUO_O[1[.E_P _/P#Z
M[CO^@5_^!(]7\W_9/YT>;_LG\Z\H_P"%&:C_ -#UK?\ W]I#\#=1'_,]:Y_W
M]H]G2_Y^?@#QN.7_ #"O_P "1ZP9<CA?UH\]>!D?G7DW_"CM1_Z'K7/^_E<E
M\2_!6J^ /#(U:+QCK-V4GC3RI)2%P6 )XYXJXTJ<WRJ>IA6S/%4*;JU,/:*U
M;YD?0S2<'G./RKBO''Q2TCP9LAE<W6I2'9#86PWRR,>@P.@/J:XL^-_%'Q+
ML/"5N^GZ6!LFUR\C/S= 1$IP2?>NR\#_  JTCP=(UP$>^U63YI=0NSOE<GK@
MGH/\\TE1A2=ZNXXXZOF"4<$N6/63_3N<A!X,\3?%5UN_%MP=&T4MNCT.V;YI
M!G@RM_,?RKU/0?#NG^'K"*RT^UBMK>,86.,8'UK66) 1E1FI/+7TK*I5E/39
M'H87+J6'?M'[TWNWK_PPR,8(['%2T@4#IVIU8GJB4M%% PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"^/>?^2;:)_X,_\ [*@_$/X]G_FFVB?^#/\ ^RI_5)=U]Z']=AV?W,]^Q2$
MUX&/B%\>\?\ )-M$S_V$Q_\ %4?\+"^/8_YIMHGX:E_]E2^J3[K[T'UV'9_<
MSWP  TO%>!'XA?'S/_)-M$_\&0_^*H_X6'\>_P#HFVB_^#+_ .RH^J3[K[T+
MZ[#L_N9[Y@'N:,8[FO!!\0OCV?\ FFVB?^#+_P"RH_X6'\>_^B;:)_X,A_\
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M_P"B;:)_X,O_ +*C_A8?Q[_Z)MHG_@S_ /LJ/JD^Z^]!]<I]G]S/?-HHVBO
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MR/XM_%WP%X9UVQ\*^-4E$=U&MXLTMN9+9 &(7>PY'(],>]<]_P +"^/1R/\
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M#6\D CA\T 1"VR$\K8<[B/QJ88)ST4NWXFLLQY+^YU/O(OD?_7IOF <GD@\
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M[!^R9XKNO''CSXE:U?6YM=1F;3(KR#O'/% \;CUQN0D9]:^B?[&L#<VDWV2
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M%3Q<\,]&II_@8>O_ !0^*6D^.])\-6^E^%C+K$4]S9-+<W!"QQA2PD8+U^;
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MG'2N=/[17CS _P"+)>)/^^S_ /&Z/^&B?'G_ $1+Q)^+'_XW6O+B=N9?>O\
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MC[_HB7B7_OL__&Z/JM3R^]?YA];I]G]S/HBBOG?_ (:-\??]$2\2_P#?9_\
MC='_  T;X^_Z(EXE_P"^S_\ &Z/JM3R^]?YA];I]G]S/HBBOG?\ X:-\??\
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M%A%#9>=.D8:6VB*CYX.P &2.>U:.KW.FZ!XPAU>SNM+\1I>36D$VGW&'NX6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S D # 2(  A$! Q$!_\0
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MC*TZ@]* ,74M;CTJXB@-C?W4DJ%U2T@\S ! )//')%5?^$L_ZE_7_P#P"_\
MLJMS_P#(VV?_ %Z2_P#H2UL#K0!SG_"6?]2_K_\ X!?_ &5'_"6?]2_K_P#X
M!?\ V5=)10!S?_"6?]2_K_\ X!?_ &5'_"6?]2_K_P#X!?\ V5=)10!S?_"6
M?]2_K_\ X!?_ &5'_"6?]2_K_P#X!?\ V5=)10!S?_"6?]2_K_\ X!?_ &5'
M_"6?]2_K_P#X!?\ V5=)10!S?_"6?]2_K_\ X!?_ &5'_"6?]2_K_P#X!?\
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MW#!_$&G[P3C(SZ9H YW_ (2S_J7]?_\  +_[*C_A+/\ J7]?_P# +_[*NBW
M]ZS-*UNPUB2[2RG\QK.8P3C:1L<=N>OUH H?\)9_U+^O_P#@%_\ 94?\)9_U
M+^O_ /@%_P#95T18?GTI10!SG_"6?]2_K_\ X!?_ &5'_"6?]2_K_P#X!?\
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M>'O^@U8?]_U_QKR[R;;_ )]X!_VR7_"CR+?_ )]X/^_*_P"% 'J/_"6>'O\
MH-6'_?\ 7_&C_A+/#W_0:L/^_P"O^->7>1;_ //O!_WY7_"CR+?_ )]X/^_*
M_P"% 'J/_"6>'O\ H-6'_?\ 7_&C_A+/#W_0:L/^_P"O^->7>1;_ //O!_WY
M7_"CR+?_ )]X/^_*_P"% 'J/_"6>'O\ H-6'_?\ 7_&C_A+/#W_0:L/^_P"O
M^->7>1;_ //O!_WY7_"CR+?_ )]X/^_*_P"% 'J/_"6>'O\ H-6'_?\ 7_&C
M_A+/#W_0:L/^_P"O^->7>1;_ //O!_WZ7_"CR;?_ )]X/^_2_P"% 'J/_"6>
M'O\ H-6'_?\ 7_&C_A+/#W_0:L/^_P"O^->7>1;_ //O!_WZ7_"CR+?_ )]X
M/^_2_P"% 'J/_"6>'O\ H-6'_?\ 7_&C_A+/#W_0:L/^_P"O^->7>3;_ //O
M!_WZ7_"CR+?_ )]X/^_*_P"% 'J/_"6>'O\ H-6'_?\ 7_&C_A+/#W_0:L/^
M_P"O^->7>1;_ //O!_WZ7_"CR+?_ )]X/^_2_P"% 'J/_"6>'O\ H-6'_?\
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M>'O^@U8?]_U_QH_X2SP]_P!!JP_[_K_C7EWDV_\ S[P?]^E_PH\BW_Y]X/\
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M5)/XENK2"^DN=%GA>SC261&F7YD8D94]\8JGX\;_ (IZ+CG[9#QZ&M'Q8_\
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M#7!'_(-U3_P"D_PHW7'_ $#=4_\  )_\* +.\>M&\>M5MUQ_T#=4_P# )_\
M"C=<?] W5/\ P"?_  H L[QZT;QZU6W7'_0-U3_P"?\ PHW7'_0-U3_P"?\
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M7,EM=O>2)J5MD)>(@4D'LR]"*N9N/^@9J?\ X O_ (4;KC_H&ZI_X!/_ (4
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MN/\ H&ZI_P" 3_X4 6=X]:-X]:K;KC_H&ZI_X!/_ (4;KC_H&ZI_X!/_ (4
M6-_O5'5+*748($AO);62*42K)&N<D<8([BILW'_0-U3_ , G_P *-US_ - W
M5/\ P"?_  H JQZ)8)HC:0Z-):N&+[F^8L3DGV.355M"N)[,:?>:Q<3:> %,
M015=E'16D')' _*M3=<_] W5/_ *3_"C-Q_T#-4_\ G_ ,* ">#?8M:V\OV5
M"OE@J@;:N,8 /M5;1]-?1]-%A%?/*B ^2[QKF///;[W/K5G=<?\ 0-U3_P
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M QY_^1LL_P#KTE_]"6M@=:QY_P#D;;/_ *])?_0EK8'6@ (!ZB@*!T %+10
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MCU% %FBJOVVW"*QN8MIY5C(,$>HJPO- #J*** "DV@]12T4  &*0@'MUI:*
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M9,%N!Y@_=G&<'\Q]* -:BJQNK=460SQ;6&0V\8(]13FN(D9 TR*S_<!8#?\
M3UH GHJA>:E9V-K/<W-S%'%!&TLK%_N*O4D#TKF8_&MQ+96FIMH%ZFE7<R1Q
MW#R+OVN=JNT8&0IR/?F@#M:*J_:84#!KB+]V,O\ ..![^@I?MEN-I^T1?.-R
M_O!\P]1[4 6:*K"]MMBO]IBVL.&+C!JP#0 M%%% !3=N>O-.HH 0 #I7.^._
M^1/O?K'_ .AK71USGCO_ )$^]^L?_H:T =&.E% Z44 %%%% !1110 4AZ4M(
M>E &//\ \C;9_P#7I+_Z$M; ZUCS_P#(V6?_ %Z2_P#H2UL#K0 M%(2!UIOF
M* 22,#J>U #)G";G).%4DX&>U>,Z!HVJ6GPY\/RS:=<_:-&UDWD]J8OWC1;F
MR5'<@,#^%>T&2,_QK^='F1_WU_.@#R:;2KB31=4O+C3[EX-6\11WBVYA)?[.
M-H+,O;*J3BN=U?PAK\7AJZL+BUGO(M*NX[725BB)9X3()&D/T4A?PKWO>G_/
M1?SH\Q/^>B_]]4 >81^&;?Q)X_\ $8U2WOUTVXAM2@&Z.*XV+\P;U ..*S?$
M-E<Q^(9]0\-Z=J6G>)(KQ+=(XHF^RWT ( >0_=QMSDGTKV'?'WD4_P# J-\?
M_/1?^^J //;1IA>>/=UE>*+E<V[- <3 1;/E]?FK!MO":VOPNAU)M*O;W6H]
M-2T-M<,Q,2[AO"IZ<9(') Q7L&^/_GHO_?5&^/KO7/UH \*L=&F#K<7GAR_N
M;:#74N 'T\(6B:(@[(@<*-V"5'3C/-+-I-Q!!!]JT74I=!CU&^\^UM[?=(OF
MX\N4(1\P R/8U[IYB?\ /1?^^J-\?_/1?^^J /"K[PO&$U0C0;\3C18([(S(
MTLJ3JQ(&X<;U78"1TQC-6-2T4"XUQ!I%Y;R76I6]U#>I8>9%M$6?W@ZNA<'<
MO4$YKV[S(_\ GHO_ 'U2&1/^>B_]]4 >*SZ;IRGP.WB/0?+0VMVDUG%&[XZE
M0%'(!SG';/M5&T\.:G;+:6/B72-7OC-:Q#3GM,9@*R$B)W.3&?NDM[8KV"^T
M'3K[7K+696E-Y9 B!EN755SU^4'!SWXK5C950 NN?K0!Y+8>!4U/PIXM@MK%
MK36+NXG2&:8,-T9*LH!/56(//OFGZG?:QK&@>'M-M+#6;#5H;B&"^MT1D18E
MP)"6'RE<#((.:]:WQ_\ /1?SHWI_?7_OJ@#Q*#PN+;1FO;70;DO;ZV[7\1B;
MS+FQ\PL%4$_.OW6([X-/BTR>RU*VUD:'>-HR:Y.]M;1VNZ1+=X"IQ'U"-(>G
M3O7M1>,_\M%_[ZHWQ_\ /1<^N: /GRVTG3GAT6#5O#]X9FT>\C-NUNQD,@D'
MEX Z8W8!XYS7M?A*SO+#PKI%KJ!9KR&U2.<LVX[@O.3W/:DD\/:9)XDCU]C-
M_:"1^4KBZ<*$[KL!VD?A6R)$'\:_G0!)13?-C_OK^=)YL?\ ?7\Z 'T4SS4_
MOK_WT*7<.#V]: '44@((R#F@L!WH "0*YCQ?XLB\-V\,<,+7NJW9\NQL8_OS
M/_11U)I?%WBJ'PY;11PV[7NK7;&.RL(_OS/ZGT0=S5/PGX1N=/O)M>UZ5;SQ
M%>#]],/N0)VBB'91Z]Z ,NS^&D6J6EQ?>*;B2Z\07A5VNX7*&R(Y58?[H7U[
MUI:!X@OK'5D\,>)G7^T@";.] VQZA&.X])!_$OXBNTQ\N*Q/$'AVS\2:6UE>
M(Z ,'BFC.V2!Q]UT;L10!M @TZN!\-^)-1TK6$\*^+9!_:!S]@U'&(]00?RD
M'=>]=X#F@!U%(3@9-(&!. <F@!DS"-"YSA>3@9KR2UTS4/\ A#K"Z^P78?3M
M?>^EMVC(E:$R,=RJ>O# X^M>N&1#_&OYT%XSSYBY^M 'DZ:9<?V7K&ISZ==/
M!JOB"&[CMC 3(;=77+%>HRH)P>U<_J_A+7D\-7=G<VD]S!I=RMOHR1(69XFE
M$C2?@F%[=#7O&^/KYBY^M&^/_GHO_?5 'F/_  CEMXC\?>(%U.WU :9<6UL$
M W1QW!49*MZXR.*HZ_I[QZ[<:AX?LM2T[Q%%<I;QI;Q,;:^A! #29^7 7(SV
MQ7KF^/O(O_?5&^/M(O\ WU0!YU;"X%S\00;.\4W66MR83B8"'9\I[_-QC\:Q
M=/\ "*P?"T7TFEWEWKD>F?91;3LV8QN^944=/4@=1Q7K_F)_ST7_ +ZHWQ]?
M,7/^]0!X58:0R-%)/X;U"XMH-=CN@)-."9B>$*=D?11O )'L,U++I=W';)]L
MT74IM&CU2^-U:PP;W_>G]W,$/WP/F'J,Y&*]P\R/_GHO_?5'F1Y_UB_]]4 >
M#ZAX6\MM1V:!J.Y-'MTLO.W2R),LI;&X<;PA7Z=*N:CHJ_;]85M)OK5KN_M[
MN&_BL?,B51%G]ZO5T+@[E]3FO;-\?_/0?]]4C.A'$@_[ZH \5N=.T]E\$?\
M"1:#L5K>[CEM((W;  RI" Y )^;';(JDOAN_AM=/L=<T35[OS=/1++[.0S0R
M"5V5&?\ Y9$*T>6_V<<U[!>Z#IU]K-IJT[SF\M,B%DNF55SU^4'!SWR.:U8Y
M%P=S@?\  A0!Y)IG@:/4= \80P:<]GJUS--'!<S!OGC.U@ 3U4E>34VJZCJ^
MM:'H&FVUAK-AJ\=U##?0Q(T:I$,+*=X^7;@9!!S7K&^/_GHOYT;X_P#GHO\
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M5G//'6LZ77+2+438%;AKH1^;L2(G*>H]: +']DZ=_P ^B?\ ?;_XT?V3I_\
MSZ)_WV_^-5UUVQDTZ>^AE:6*WR)45#O0CJ"O4&K5G>17MC!=Q;A'-&)%W#G!
MH ;_ &3IW_/HG_?;_P"-']DZ=_SZ)_WV_P#C5G//-&10!6_LG3_^?1/^^W_Q
MH_LG3_\ GT3_ +[?_&K(.3@&J-EJUO>W5W;Q"57M6"R>8NWDC(Q0!+_9.G?\
M^B?]]O\ XT?V3IW_ #Z)_P!]O_C5G(]>?2C(_O ]^* *W]DZ=_SZ)_WV_P#C
M1_9.G?\ /HG_ 'V_^-6>*,CUH K?V3IW_/HG_?;_ .-']DZ=_P ^B?\ ?;_X
MU9R/6C(]: *W]DZ=_P ^B?\ ?;_XT?V3IW_/HG_?;_XU9R/6C(]: *W]E:?_
M ,^:?]]O_C3DGE\.+)J>ES30FW'FRP>:S13(.60J2<9&<$8P<5/D>M4M8;_B
M1:C@_P#+K+_Z": /;X)%E@CD48#J& ],BL#Q1XGAT&.*&&$WVKW9V65A&WSR
MMZG^Z@ZEC5'Q#XL3P]ING6MK ;W6[V)4L;%.LC8'S-_=0=2:?X4\'R:5+-K&
ML3K?>(;P9N;HCB,=HHQ_"@_7O0!+X8\+2Z=--K.L2K>^(;M?W]P/N1+VBB'\
M*#]>IKJE^Z,T*,*!2T %(>E+10!A>)?#5EXGTI["_C.S=OBE0X>!QT=#V8?_
M %JY_P -^(M0TG5T\*^+)5.H ?\ $OU#&U+]!_*0=QWKO#R".M8GB3PSI_B;
M26L-1C)4$/%*AP\+CHZ'L10!L,P*$$X->5^*;VYUGQ#?6<MQ,FF63K L$4A3
MSGVAF=R,$@;@H&>Q-2ZAXD\1>'=)O]#U"=#K44#3:7J+IA+]$P2I[++M&"._
M45D&^CU*]O;^(YBN95F7'^U&A_K0!!_9.G8Q]D3_ +[?_P"*H_LG3O\ GT3_
M +[?_&K.1ZT9'K0!6_LG3O\ GT3_ +[?_&C^R=._Y]$_[[?_ !JSD>M&1ZT
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M_H(H M[SZT;SZU#O^M&_ZT 3;SZT;SZU#O\ K1O^M $V\^M)N]ZBW_6C?]:
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M#_ONO?\ [%:_\^T/_?L4?8K7_GVA_P"_8H \ _MG3O\ G_@_[[H_MG3O^?\
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M_A#M-_Y[ZE_X'2_XT =#17/?\(=IO_/?4O\ P.E_QH_X0[3?^>^I?^!TO^-
M'0US?CPD>#K[ S]P_P#CZT__ (0[3?\ GOJ7_@=+_C3)/!6D2 +,U]*FX-LD
MO)&4X.1D$\T =$ISFG4U1C/2G4 %%%% !1110 4=:** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !9 P # 2(  A$! Q$!_\0
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MV/\ "*(X_P"$L>3_ *XZ5>R?^@PFL!_V_P#]GJV7 ^)NDD#M%#.W\HZJR_\
M!13]GF'.?B-;-_N6-TW\HJ.9=T.S['31_MD?">4E4U[468#/_(OZCC\_L^*C
MD_;-^%$7WM:U+'K_ &#?_P#QBO1?AK\2O#OQ<\'V/BKPK?\ ]J:#?;_L]WY+
MQ"3:Q5B%<!NH(Z=JZNJU)/!I/VX/@["0)/$=[&3TW:'?C/\ Y!J&7]NWX(0,
M%E\92PDC/[S1K]0/J3!@5[_44MO%.,2QI(/1U!HU&>#1_MZ? )R WQ+TN GM
M<13Q?^A1BM2R_;0^!FH$"#XJ>&&)XPU^J_SQ7JESX6T6\4K<:/83J>HDM48'
M\Q6!??!7X>ZEN-WX$\-7);@F72+=B?Q*4:@4;#]H7X7:HBO;?$;PK*&Z8UFW
M!/X%ZZ:Q\<>'-556LM?TR\#=#;WL;Y_)J\TUC]C3X&Z\6-Y\+/#+LW5HK!8F
M_-,$5Q6K_P#!-W]G[4L_9O!#:/(>LFF:C<PM^>\TO>#0^FU8,H*D$'D$=Z=7
MQS=?\$R_!%FSR>&?'WQ"\+W)/RO:Z\SA?H",_F:S+O\ 8G^-_AN,'P?^U!XF
M.PDQV^N0&:,?4ASG\J+OL%EW/MC-)NKX3O/#G[=GP_V?8?$G@WXA6\?)22&.
M&1_8EEC/Y&L2]_;F_:.^%@)^(O[/4T]G%Q)>Z09E1O4[@)5J>>VZ"Q^A'.:-
MM?"W@_\ X*[?"K5IA;>)= \2>%+K.&#VZW*)_O%"&'_?-?17P\_:Y^#WQ0*I
MX>^(.BW%P>!;7-Q]FFSZ;)=I)^F::G%]0LT>P45''(D\:NC!T895E.01Z@U)
M6@@HHHH *0]*6D/2@#C_  Y_R4'QA_NV7_HMJ[&N.\.?\E!\8?[ME_Z+:NQK
M.&WWC>X4445H(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBH99DMXGDD=4C0%F9C@ #J2: )>!574-1M=*L9KR]N8K.UA4O)/<2!(XU'4L
MQX ]S7R%^T5_P4S^&_P=^TZ3X8<>/_%$>4\G3I0+*!_^FD_(./1-WU%?FA\9
M/VH/BU^U5K\5AK&H7=W;7$NVS\+Z'&ZV^2> (ERTC<XRV36$JJCHM66HMGZ'
M_M$?\%4/ OPX-UH_P\MU\>>($RAO%8QZ; WO)]Z7'HG'^U7YI_&+]H7XD_M(
MZ[Y_BS6[W655MT&D6:,MK!Z;($XS_M')/K7U1^S?_P $IO%'C,6FL_%*[D\(
M:,V'&BVI5M0F7KASRL/'U8>@K]*_A9\"_ GP3T*+2_!OAJRT:!%P\Z1AIYCW
M:24Y9CWY/TQ6=IU/BT15XQV/YWY[62TF>&>&2"9#AHY5*,I]"#R*9@5Z1\>_
M$+_$+XX^/O$8.4U'6[J:/C/R>857\, 5PRZ6[>OY5P.44[7.E)LHTV1MD;-Z
M FM1=&<GHU;7@_P1/XH\8:#HT*%I-0O[>U ]=\BK_(TE.+=A\K/W:_9*\'_\
M('^S3\-]%*;'AT6WED4C!#R+YK9]\N:]=JKI]E%IEA:V<"[(+>)88U]%4  ?
MD*M5[*5E8X HHHJ@"BBB@ HI,T9H 6BBB@ HHHH \]^(/P!^''Q2MY(_%?@G
M1=:9^LT]HHF_"10''X&ODKXN_P#!)7P+K]K/=?#_ %:[\+:ERT=E?L;JS8_W
M<G]X@]\M]*^]Z3MUK*5.,MT-2<=C\4[Z3X__ +&'BI-&.OZQH R9((_/-UIU
MVH_B17RC#U& 1WQ7TW\&/^"H5ZKP6'Q.\.*T9PIUG1%((_VG@8\_\ /X5Z7_
M ,% O$_AOQ%X0TWP@GDW_B*.^2[S'AFLXPK!MQ_A+9 V]\<]*^$9/ .!Q'7R
M&*S/ZG7=*,[V_JQ[='">WIJ<HV/V0\#_ !!\._$O08-:\,ZO;:SIDP^6:V?.
MT_W6'56]B :Z/BOR+^ _CSQ!\!_'5GJVDS2_V?-*L>H:?NQ%=1$X.1_> Y#=
M>*_6VTN4O;6&XB.8Y4#J?4$9%>[E^80QT&XZ-;GG8G#2P[5]F6:0]*6D/2O7
M.0X_PY_R4'QA_NV7_HMJ[ ]*X_PY_P E!\8?[ME_Z+:NQK.&WWC>X@%+17E'
M[4'QJMOV?_@=XH\9S,HN[2V,6GQ-_P M;N3Y85 [_,02/135-VU%N>KT5^<_
M[._Q5^+OP4^._P .M!^,/B_4/$>C?$W0$N;(Z@?ETZ_8[E@''#8VJ?\ KHO'
M%?HQ2C+F&U80#%!KC_BYJWB+0/ACXGU+PEIZZIXFM-/FFTZS89\V8*2HQW.>
MW?IWK\[/V=OB"GQULY8/'W[3/C?P+\59+J5&T-ITTVUMR&.P1QNFQQT^4D'.
M1CC)'*SL"5]3]1**I:9;2V6FVEM<7+WD\,21R7$@ :5@ "Y Z$GG\:Y_XJZI
MX@T/X:^)M0\)Z<NJ^)K73YI=.LFZ2SA"47'?GMWZ=ZL1UM%?EU^SO\1!\=+:
MXM_B%^TOXV\!?%22ZE3^PC.FFVMN=QV".-TV/V^4D'/&.,G]-]*M)K'2[.WG
MNGO9X84CDN9  TS!0"Y XR2,_C41ES*XVK%ZBN2^*^H7.D_"_P 87UE.]K>6
MNCWD\$\9PT<BP.58'U! /X5X!_P37^(OB?XH?LUQ:WXMUV]\1:N=7NH3>7\F
M^38H3:N?09/YT^;6P6TN?5E%?%_[#GQ3\7^/?C=\?M+\1>([_6M.T761!IMM
M=R[DM(_-G&U!C@851^%?9XZ41?,K@U86BO@C]M_XH>)?#W[5OPC\(6WQ(U3X
M>>#];LF.K75A>);+&/.<>86<%0> N3QS5;X)_%#X@V_[85OX)\&?$C4OC/\
M"\6AEUC5M1CCGCTY]C':+J-0K,&"8 /._&.,U/.D[#Y=+GZ 445@^./%^G>
M/"&L^)-7G6WTS2K22\N)&(&$12Q SW.,#W(K0DWJ*_+#P?\ M%?&GP7K'P\^
M._C3Q-J,_P +O&GB.[LI_#S_ /'MIUH[;8) .W&\KS_RR[[J_4F&9+B))(W5
MXG 964Y!!Z$&HC+F&U8FI,T&ORL^&/[5WQ@\ _%GXB>-=>U/4O&GPFT'Q++H
MFMV4LGF2:5#)-)Y-S$@&0J;-IY]CC(-$I*-K@E<_52BOB7XX_'+6YOVN_P!G
M.Q\'^+KG_A"?%,1N+BWL9A]FU",LQ5F&.>,5]LYXH3O<&K .E'45X'^VG^T=
M/^S'\%+OQ1I]E'J&NW=S'IVFPSY\L3.&.]P.H558X[G KR_P'^R_\8?B)X3L
M/$_C?]H3Q?H_B34X$O/[/\-F.WLK'>-RQ[,8?&1G@<Y'/6ARUL@MU/LVBLCP
MMI5UH7AO2M.O]2EUF^M+6."?49U"R73JH#2L!P"Q&3CN:S?BAJ%SI/PT\6WM
MG,]M=VVD7<T,\9PT;K"Y5@?4$ U8CJ:*_*#]FOXQP_$7P%:ZA\1OVL/%'@[Q
M3)?- -'2ZC^:,%1&W,9/S$D=:_5>SC,%K#&96F*H%,K]7P.I]S41ES*Z&U8G
MXHS7.^/[R?3O WB&[M96@N8=/GDBE3[R,(V((]P:YGPSX(NM0\-:3?KXK\01
MWD]G%,7:\$B;VC!)*,I!&3TK*51J?*E?2Y2BFKW/2,4M<1\./%&H:RNM:5K)
MCDU;1;TVDL\*;$N%*AXY0N3M)5AD=B#7;'H:TA-35T2TXNS#(I:X+POK%[=_
M%+QM837,DEE9P:>;>!C\L9=)"Y ]R!GZ5W>ZE":DKKNU]SL#5@S2 G)KRGXE
MW_B2+X@>'8?#^H2PF&RNKV33L Q7YC:,>4WH2K-@CH<5IZQX_?Q+HNEV7A><
M+JVN(WE2NN391*=LTKKGJARH&>7P.QK'ZQ%2E%K5?CML:>S=D^_X'HHHQ7GG
MP&UF]U[X5:)>ZC>SZC>/YZO=7./,DVS2*"V.,X45Z"#S6T)J<5)=5<S<>63C
MV%S1FO#(O$VCS^,/%]OXB\=7FC2VFH^5;VB:G]G5(?*0C"^F2W->S:0L46EV
MJPW,EY#Y:E+B63>TBD9#%N^?6LZ=55&[="I1Y=R[GI1F@G%>&_"[QEKFBZ9:
M:EXCU*75-"UB]N(A>7+#.G3"X>..-CQ^Z<* "?NMP>M.=90DHM;_ / ",7)-
MH]RZ8HZ9KAGU>\'QIBTP7,G]G'0&N3;9^3S?M 7?CUQQ7<]JN$U.]NCL3:P4
M9SQ7G_Q1U/4M,DT8K+>V?A]Y9/[6O=.0M/ H3,?0$JA;.YE&1QTS6GX(T_2P
MCW^D:_?:Q:S+LQ/J#74:GKD;B2K>V?PJ%4O-PML5RZ7.OI"12;JX;Q9K%[9_
M$CP/8P7,D5I=_;3<0J?EEV0@IGZ$YJYS4%=]TOO=A)7.[I, 4>E<5\1O$M]I
M"Z-I>D/'%J^LW?V2">9=RVZA"\DNW^(JJ\*>"2,TYS4(W8HIR=D=KFD_"N+/
MPW=8]X\4>(?MOWOM)OR1G_KECR\>VVG?#;Q/>^(=/U.UU/8VJ:1?R:=<RQC:
MDS( 5D [;E93CL<UFJCNDU:Y7+I=,[+% H(YKQ23Q-XDT;XD>,=66^N=2\.Z
M7-;P76CB/>886@5VGAQSN4G++SE<XP114JJG:ZW?_!",7*]CVS.,4F,&O._'
M?B>9=3\ 2Z3J!%EJ6K*DC0,"L\)AD8 ^HR ?PKT2JA44VTN@G%I)OJ*.*3.:
MY3XE7>MV7A*YET".1[T.@<P('E6+</,:-3PSA<X![UC^"+/0]5N(;[2?%.K:
MG/;Y\ZWN=1=R>HQ+"WW>?]D<BI=6T^1+^O(:CI<]%HHHKH($/'TH!XKP_P".
M/[7OP_\ @7%-:ZCJ/]KZ^H.W1M+(DGW?]-#]V,?[QS[&OSL^._[:'Q/^.?VG
M3H+L^$/"\F5_LS2I"LDJ>DTW#-D=0,+[5P5L;2HZ2>IO"A.ILC[G_:#_ &_?
MAK\"OM&G6UV?&'BB/*_V3I$@98F])IN53Z<MQTK\R_V@?VQOBI^T7)-::IJK
M:#X;8_+H6D,T4##MYK9W2G_>./:K_@O]DCXC^-M(35=&\&ZE=Z?*3LN#%L63
MU(W$9'O77VO[#GQ84#/@B]'U*?\ Q5>74QM6?PP=O1G7&A".[1\O^$_"NDS:
M[8Q^()KVST3>/M4NG0K+.J?],U8JI)Z<G Z\U]_? K]JG]G']G73C'X0^'GB
M!=09=LVLWT4,M[-]9"WRC_97 ]J\QC_8A^*X _XHF\'_  ./_P"*I[?L/?%I
MNG@JZ_[^Q#_V:N:&*Q$'I3?W,U=&F]Y+[S]*?V>?V@-+_:+\'WGB31M)O],T
M^"\:R7[>%#2.JJ6("D\#<*ZKXJ>(?^$2^&?BK6M^Q['2[FX1B<898V*_KBO/
M_P!D#X77WPB^!&A:#JMH;#5F>:ZO+=B"4D>0\$@D'Y0M0_MGZJ=-_9W\2VZL
M5EU(16"D?[<@S_XZ&KWIUG##NK/1I7_ \]04JO)'O8_%Z#PU)<$RR#,DA+L?
M<\DU=B\)DX^3]*]BM/!F%'R?I6A#X-Z?)^E?G4\T\SZ:.#?8\9B\(G'W*]H_
M8X^&W]O?M,>!4:/*65V=0?(XQ"C./U JTG@["_<_2O4OV:?%_A_X*?$6X\1Z
M]9WDZ"Q>WM_L48=E=F7)()'&T$9J\+F495X*<K*ZN*MA&J<G%79^FO%+Q7S/
M+^WKX%60B/1]==?[QMT'Z;ZKM^WOX4WD1^'M9=.S$1C/X9K[EYK@E_R\1\_]
M3KO[#/J#)]*3FOEL_M[>'B3L\+:LP[$O&/ZU$W[>VD'[G@[4S_O7$0J'G&!7
M_+Q?C_D5]1Q'\A]4Y HS7RA)^WG;$?NO!%V?^NE^@_DAJG<?MW7;C_1O!80_
M]-;W=_)164L]R^/_ "\_!_Y%K+L2_L?BCZZ_&EXKXON?VX?%LI86WA?2XAV,
MLLCG\@163>?MA_$>\4B"VTFR..#';,W_ *$QKFEQ'@([2;^7^=C6.5XF73\3
M[FS1FOS]O?VDOBKJ8(.O):@]K6TC3'XX)_6N=O\ XA?$'6@PO?%VL2HW5!<L
MB_3"XK@J<5X2/P)O[E^IT1R:N]VC]&+[5[+3(C)>7<-K&.KSR*@'XDUPWB']
MH+X>^&69;WQ58&5?^6=N_G,?;Y :^ )=#O=1?==W-Q<L3G,TK/\ S-36W@]1
MCY0!]*\JMQ>_^74$O5W_ ,CMAD?\\CZK\2?MR>%+!&71-(U/6IN@+J+>/ZY.
M3^E>*>.?VJOB%X]22UL'B\,6#\%=/R9F'O*>1_P'%<M8>#/.8+%"\KYX6-2Q
M/Y5W_AOX'^(M893;:).$/269?+3\S7B5<^S''>Y23=^B7^6OXG?#+L+A_>G;
MYO\ I'D.G>&))W:6;=+*YW-)(2S,?4D]:V/^$21DY0?E7TSX<_9;U"14;5+^
M"R7O' OF./QX%>L>%_@IX8\+,DJ6(O;I>1/=_.0?8=!^51A>'\TQDN::Y(]V
M]?N6OWE5<SPE!6C[S\O\SY4^$7[,5YXU\06=_JMJ]EX?MY%ED,JE6N<'(1!Z
M'')K[E1%BC544!5&  , "A4"  #:HZ 4['!K]0RS+:>6TO9Q=V]V^I\ABL7+
M%SYFK);(?2'I10>E>T<1Q_AS_DH/C#_=LO\ T6U=C7'>'/\ DH/C#_=LO_1;
M5V-9PV^\;W$/2OD/]LC]G;Q]^T_\2/A[X:CC6P^%.FW/VW6KZ.^2.XED.1A(
M^22JC"DC@R$]J^O:3 JFE)68)V/A/]I;_@GGJ/B?P/97_@/QGXMUWQOHEW%<
M:5%XJUXW$$:AAO"%U'EM\J,#G^#'>OLKX?W6O7?@K1)?%-E'IWB1K2/^T;:&
M5942<* ^UEX()!(]C71#%+244G= W<Y[QW-XB@\(:K+X2@LKGQ(D#-80:BY2
MWDE'(5V'(!Z9'K7PU^T?\#?C9^U;X=LM#U?X,>#/".KFYCDE\6MKD=Q- H/S
M! B!RI'8Y^F>1^@M&*;CS:,$['-_#CPM/X&^'_AOP[=:A)JMQI6GP64E[+]Z
M=HXPI<_7%2^.)O$$/A'5I/"<-G<^(TMV:PAU!BMO)*/NJY'(4],BN@HJA'Y]
M_M'_  1^-G[57AJTT'5_@OX+\*:LUQ&\GBY]<CN)K90?FV!$#E2."#GCMGD?
M;?PR\)S^ OAWX:\.76HR:M<Z3I\%E)?2_>G:- I8_7%=0.E!J5%)W'?H9OB+
M0[?Q+X?U/1[O/V74+66TFV]=DB%6Q^!-?#OP3^%/[2W[(N@ZSX&\'>$_"OQ#
M\+->RWFF:G>:M]BDB+@#$B'D_=!('?.&YK[UHI.-W<$['S!^Q7^S+XC^!-EX
MQ\1>-]2L]0\;>,=0_M#4(]/R8+899A&K'&X[I&)[= ,]:^GATHQ2TTDE9 W<
M^0_VD?V9/$WQ<_:V^$/C2'1].U;P3H$+0ZS'?RQD$&1VQY+9\P<KQBJ\/[.'
MCS]GK]HN+Q9\&+2TN?AMXB;/B3P=)=K;16\G ,]LK?*#CY@!CHR]",?8><=J
M,Y[4N57N%V)U6OFC]NKX7_$GXW_#'3_ O@&VMQ9:K?QG7+VXNUA\JU1@=@4\
MOEL,0/[F.]?3-%4U=6!.Q\5?$S_@FYHFM_!B\\*Z+XV\:7D]E9YTC3-6ULRZ
M:EQ&I\L& KM5<Y Q]W=7NW[*VB>//"_P.\-:#\2+2&V\3Z1#]@>2"Z6X6>&/
MB*3<O?9@$>JY[UZ_2;N:E12=T%VQ!7R9^R+^S3XC^&VJ_'"'Q[I%A+HOC+6G
MN;6W$Z7"7%LS3[A(HZ961>#Z^U?6E+0TFTQ'YU:'^P/\0OAO^U;X$U;0+Y-8
M^$OAK4VO=-BO+U1-I<$I9I;=4/+ .001U'H<U^BF12TF*<8J.PV[[GBG[6O[
M.5K^U!\(+OPA)?G2=1CG2]TZ_*;EBN$! WCJ48,RG'/.1TKR'P'J_P"U]\./
M"MGX6N_A]X/\9MIL2VEMKS:]]F,T:C:C21XR2!C)PI./7FOLD=*#TI..MQ7Z
M&1X7?5Y/#>ER:_';0:XUK&;Z.S),*3[1Y@0GDJ&SC/:JGQ$T>Z\1> /$VDV2
M+)>WVF75K KMM#2/$RJ">PR1S71T58'YV_LY?!'X]?L^?#A/"Y^"W@7Q9(EW
M)=KJ6I:Q")LOM^7[AX&WCGO7Z!Z/+=SZ592:A;I:W[PHUQ!&^]8Y"HW*&[@'
M(SWQ5^BIC'E5AMW,'QKIEQK?A#6].M K7-W9301!C@%F0@9/;DUR^@7_ (RL
M="T[2X_"L%O+;6L<'VJZU)#$&5 N=J L1D=.*]$_E1G'TK&4.:7-=I[#4K*U
MCF?!'A ^%;.]DN+DWNJ:C<-=WMUMVAY2 ,*.R* % ]!73D\4'I1U%:QBHJRV
M);;=V<9X=\-7NF_$7Q;J\ZK]BU&&R2W8,"28D</D=N6%=E_#2YI.AJ814%9>
M;^]W&VV<CJGAV\N?B1HNLQJAL;6QN8)6+?,'=D*X'?[IK0T7P;I&AZQJ>K6%
MDD%]J;![F7).XCT!^[D\D#&2<GFM\TGM25.-W*VM[_A8?,[6.(^#'A74/!7P
MVTG1M42.._MS-YBQ/O4;IG<8/?AA7;XY-*3BC-5&*A%06R$VVW(\OTBS\2^%
M/$/BF6'PP-5MM2U$W<,\=]%'\GEHN"K<@Y4_G7H6E7-S=:?#->69T^Y89>V,
MBR&,^FY>#^%7?QH_6HA3]GHF_P"OD-RYMP8<8KA/A]X'?3?AV/#^N6T4HDDN
MA- 2'1DDF=QR/]EA]#7>TG2G*"E)2?9K[["3:6AY7X,\"^(]"^)DMYJ$T=_H
MEII)T^QOGDS<2*9A(%E7U4?+N'W@ 3SFO5:***5.-)<L1RDY.[,'Q!J6KZ:U
MM_9VC?VO&Y(E"W20O'Z'#\,/QS7+^&?#.IGQ]<^(7TN/PY9-:&VDLXYED>\D
MWAA+($^4;1D Y+'<<^E>BXH Q2E34I*3>W]=@4K*UA/X:X_Q+X;O=3\>^$=5
M@16L]-^U_:&+X(\R(*N!WY%=@>3BESR*J<5-6?D_N=Q)M"UR7CWPA-XFMM/N
M+"X2TUC2[I;RRFE!,9< JR.!SM920<<]ZZPG%&3Z4YP4XV8)N+NCB1XE\7/;
MB/\ X1%8[PG9YC:C$;<''W\CYROMMS5WP#X1?PGI5TMS<+>:G?W<E_>SHNU7
MFD/(4=E  4>PKIQ]:=41I6:;;;7>W^0W+2R5A,5QOA+PU?:5XS\8ZC<H@M=3
MGMWMR&!+!(0C9';D5V9H%7*"DU?H)2:37<\>U7X8ZU8>-?#O]CI;OX3MM3.I
MR0R2%9;*0HZND8Z-&Q?=C^$@XX->P8ZTM+4TZ4:=[=1RFY6OT,G7KS4K&P,V
MF:<NJ7"L/]':X$)9>Y#$$9]CCZUPVK^'-8\6^*M!U(:*OAR?3KE;B;4C<1O/
M-$ 0UOB,\JV1G<< =.:].[4F>*4Z:F]7IVT_R&I6V1YS\5_CUX.^#>FF?7]2
M4W9_U6FVN)+F0]L(#P/<X%?"WQG_ &R_B!\4VN-.\/%_!V@ME-MH^;N9?]N7
M^'Z)CZFOMR^_9C^%^J7\U[>>$+.[O)V+RW$TDKNY/<L7R:6/]F'X6Q?=\&:>
M/^^__BJ\;%T<?7NJ<E&/J_\ ([:-3#4]9)M_+_,_-7X6?LP>+OBU?YTK39)+
M=G_?ZG>$K"I[EG/WC[#)-?='P6_8;\$?#,V^H:W GBG74PPDND_T:)O]B(\'
MZMGZ"OH?2M(L]#T^WL;"VCM+.!!'%!$NU44= !5WO5X7+*=&TJCYI>>WR1-;
M%2J:1T0V.-8T5$4*JC  & !Z5)117NG"%%%% #"<#)KY3_:_\<:=XEM=/\(V
M$XNY[>Y%U>F,ADC(4A4)_O?,3CM7U!JND6FM6C6U[&9K=OO)O90?K@BN33X)
M^!D)*>&[-23DX!'/YUXN:8?$XJ@Z.':5]V[_ *';A*M*C452JF[=CX#MO"JJ
MH^4?E5Z/PPH_@_2OO+_A2_@G.?\ A'K3/K\W^- ^"_@O_H 6WYM_C7YX^$\Q
M?_+R/WO_ "/IUG6&7V)?A_F?"H\-*5^[5"[\("3HGZ5]]?\ "F/!G_0 MOS;
M_&@?!GP7_P!"_:_CN_QJ5PEF*=_:1^]_Y#>=89_8E^'^9^? \# G[M2IX)4=
M5%?H,OPB\'KTT&V_')_K4Z?"[PG$05\/V.1TS$#_ #K=<*8][U8_C_D9_P!L
MX=;0?X?YGY[KX.C4\@?E4\?A!&'RJ7^@S7Z&P^!/#L( CT6Q4#IBW7_"K*>%
M]'BY32[)3TR($']*T7"&*?Q5U]S_ ,T2\[I+:F_O/SRA\&,YPEO(Y]%0FM&U
M^'5_<G$6EW4AQG A;_"OT)BT^V@&([>-!_LH!4P10.% 'TKHCP=+[>(_#_@F
M3SU?9I_C_P  ^"K3X+^);H#RO#M\P/K 1_.MVR_9S\870^71C%_UUD5/YFOM
MC'TI<5UPX.PZ^.K)^EE_F82SRJ_A@E]Y\C6'[*WB><#SVL;7_>EW?R%=)IO[
M)-QQ]NUN&+VMX2V/SQFOI7'TI>G6O0I\*9;#XHN7JW^ECGEG&*ELTO1?YW/$
MM,_97\.VP_TO4+V[/^SMC'\C76:7\"O!>FA,:,EPR]&N'9S^/.#7?@4I%>M1
MR7+J'P45\U?\SBGCL34^*;_+\C.T_P /:;I>/L>GVUL0, Q0JI_,"M$ =A2X
MI"*]:%.$%RP5CB<G)W;'4445J(**** "BBB@#C_#@_XN#XP_W;+_ -%M77CI
M5"TT>TL]3OK^*(K=7HC$[[B=VP$+QT& 3TK0J8JR'N%%%%4(**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  I ,H# 2(  A$! Q$!_\0
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M<?M0>!M(\,Z'I>H^,/&_AG7C!I?Q/-D]E!;V,,L92]DN&5299(LHT"Y+D'<
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6OG.:/+'?FGT4 -V#TI<#TI:*!6/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex23-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-2_001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M40O(O^TD32N/=156). U;Q=\:/BUX5UCXK?#CQ);:+X:T]9;GPQX3FTQ)O\
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))^GY4^EI ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>juns-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGB+bP9z5Z8GekhvWB/bSkK7yIiUo7d5iWwg0fGcWsG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:JUNS="http://jupiterneurosciences.com/20251231" elementFormDefault="qualified" targetNamespace="http://jupiterneurosciences.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit" id="StatementsOfChangesInStockholdersEquityDeficit">
          <link:definition>00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
          <link:definition>999014 - Disclosure - Organization and Description of Business</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999016 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
          <link:definition>999017 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability" id="ConvertibleDebtAndDerivativeLiability">
          <link:definition>999018 - Disclosure - Convertible Debt and Derivative Liability</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
          <link:definition>999019 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999020 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999021 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SegmentReport" id="SegmentReport">
          <link:definition>999022 - Disclosure - Segment Report</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999023 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>999024 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
          <link:definition>999025 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables" id="ConvertibleDebtAndDerivativeLiabilityTables">
          <link:definition>999026 - Disclosure - Convertible Debt and Derivative Liability (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables" id="StockholdersEquityDeficitTables">
          <link:definition>999027 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999028 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999029 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SegmentReportTables" id="SegmentReportTables">
          <link:definition>999030 - Disclosure - Segment Report (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" id="OrganizationAndDescriptionOfBusinessDetailsNarrative">
          <link:definition>999031 - Disclosure - Organization and Description of Business (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999032 - Disclosure - Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999033 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" id="ScheduleOfAccountsPayableAndAccruedExpensesDetails">
          <link:definition>999034 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" id="AccountsPayableAndAccruedExpensesDetailsNarrative">
          <link:definition>999035 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails" id="ScheduleOfKeyAssumptionsInValuationMeasurementDetails">
          <link:definition>999036 - Disclosure - Schedule of Key Assumptions in Valuation Measurement (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails" id="ScheduleOfFairValueDerivativeLiabilityDetails">
          <link:definition>999037 - Disclosure - Schedule of Fair Value Derivative Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails" id="ScheduleOfDerivativeLiabilityDetails">
          <link:definition>999038 - Disclosure - Schedule of Derivative Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" id="ConvertibleDebtAndDerivativeLiabilityDetailsNarrative">
          <link:definition>999039 - Disclosure - Convertible Debt and Derivative Liability (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999040 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails" id="ScheduleOfEmployeeStockOptionsOutstandingDetails">
          <link:definition>999041 - Disclosure - Schedule of Employee Stock Options Outstanding (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999042 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative">
          <link:definition>999043 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" id="ScheduleOfIncomeTaxProvisionDetails">
          <link:definition>999044 - Disclosure - Schedule of Income Tax Provision (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
          <link:definition>999045 - Disclosure - Schedule of Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999046 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" id="ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails">
          <link:definition>999047 - Disclosure - Schedule of Operating Lease Right-of-use Asset and Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" id="ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails">
          <link:definition>999048 - Disclosure - Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999049 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails" id="ScheduleOfSegmentReportingInformationDetails">
          <link:definition>999050 - Disclosure - Schedule of Segment Reporting Information (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative" id="SegmentReportDetailsNarrative">
          <link:definition>999051 - Disclosure - Segment Report (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999052 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="juns-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="juns-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="juns-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="juns-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <element id="JUNS_ReceivablesforSaleofCommonStockMember" name="ReceivablesforSaleofCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_FifteenForFourForwardStockSplitMember" name="FifteenForFourForwardStockSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StandbyEquityPurchaseAgreementMember" name="StandbyEquityPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_NoteIIHolderMember" name="NoteIIHolderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_EmploymentAgreementsMember" name="EmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_YAIIPNLtdMember" name="YAIIPNLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_TwelveConvertiblePromissoryNotesMember" name="TwelveConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ConvertibleDebtOneMember" name="ConvertibleDebtOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember" name="SeniorSecuredNoteConvertibleDebtTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_SeniorSecuredNoteMember" name="SeniorSecuredNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_EntityOneMember" name="EntityOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_EntityTwoMember" name="EntityTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_EntityThreeMember" name="EntityThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_TwoConsultantsMember" name="TwoConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_WarrantHolderMember" name="WarrantHolderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeFiveMember" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeSixMember" name="RangeSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeSevenMember" name="RangeSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RangeEightMember" name="RangeEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_TiberendStrategicAdvisorsMember" name="TiberendStrategicAdvisorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ConsultingAgreementsMember" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DominantTreasureAgreementMember" name="DominantTreasureAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ExecutiveEmploymentAgreementsMember" name="ExecutiveEmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_LicenseAgreementsMember" name="LicenseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_AquanovaAGMember" name="AquanovaAGMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_LicensingAndRoyaltyAgreementsMember" name="LicensingAndRoyaltyAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DebtForgivenessAndExchangeAgreementMember" name="DebtForgivenessAndExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_LicenseAgreementsTwoMember" name="LicenseAgreementsTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_MurdochChildrensResearchInstituteMember" name="MurdochChildrensResearchInstituteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PharmaceuticalOperationsMember" name="PharmaceuticalOperationsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PremiumNutritionalSupplementsMember" name="PremiumNutritionalSupplementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_GainOnExtinguishmentOfDebt" name="GainOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" name="StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" name="StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" name="StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" name="StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodValueStockSplits" name="StockIssuedDuringPeriodValueStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodValueWarrantExercises" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodSharesWarrantExercises" name="StockIssuedDuringPeriodSharesWarrantExercises" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodValueCommitmentShares" name="StockIssuedDuringPeriodValueCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodSharesCommitmentShares" name="StockIssuedDuringPeriodSharesCommitmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_GainLossOnForgivenessOfAccruedCompensation" name="GainLossOnForgivenessOfAccruedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_GainLossOnAmortizationOfPrepaidContracts" name="GainLossOnAmortizationOfPrepaidContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_NoncashFinancingCost" name="NoncashFinancingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DecreaseIncreaseInPrepaidContracts" name="DecreaseIncreaseInPrepaidContracts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_CashPaidForInterest" name="CashPaidForInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RestrictedStockIssuedForForgivenessOfSalary" name="RestrictedStockIssuedForForgivenessOfSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockOptionsIssuedForForgivenessOfSalary" name="StockOptionsIssuedForForgivenessOfSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_NotesPayableRelatedPartyAssignToNotePayable" name="NotesPayableRelatedPartyAssignToNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes" name="StockIssuedInConnectionWithConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedInConnectionInterestPayment" name="StockIssuedInConnectionInterestPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_Rule10b51ArrModifiedFlag" name="Rule10b51ArrModifiedFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_NonRule10b51ArrModifiedFlag" name="NonRule10b51ArrModifiedFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PrepaidContractsPolicyTextBlock" name="PrepaidContractsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" name="OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ClinicalTrialExpensesPolicyTextBlock" name="ClinicalTrialExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" name="ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" name="ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_MinimumClosingBidPrice" name="MinimumClosingBidPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" name="DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_InterestPayable" name="InterestPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_AccountsPayableAndAccruedExpensesAbstract" name="AccountsPayableAndAccruedExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_AccountsPayableAndAccruedExpensesTable" name="AccountsPayableAndAccruedExpensesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="JUNS_ConserveCashPercentage" name="ConserveCashPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DerivativeFairValueOfIssuance" name="DerivativeFairValueOfIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RepaymentOfDerivativeLiability" name="RepaymentOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_GainLossDerivativeInstrumentsNetPretax" name="GainLossDerivativeInstrumentsNetPretax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_GainsLossesOfExtinguishmentOfDebt" name="GainsLossesOfExtinguishmentOfDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" name="DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StructuringFee" name="StructuringFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_CommitmentShares" name="CommitmentShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OriginalIssueDiscounts" name="OriginalIssueDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OfferingPricePercentage" name="OfferingPricePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ConvertibleAmountIntoSharesOfCommonStock" name="ConvertibleAmountIntoSharesOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" name="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_GainsOnExtinguishmentOfDebt" name="GainsOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DerivativeGainLossOnDerivative" name="DerivativeGainLossOnDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PurchaseCommitmentPerShare" name="PurchaseCommitmentPerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DeferredTaxAssetsDerivativeLiability" name="DeferredTaxAssetsDerivativeLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" name="OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OperatingLeaseLiabilityGross" name="OperatingLeaseLiabilityGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ReductionOfOperatingLeaseLiability" name="ReductionOfOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OperatingLeaseYearlyEscalationPercentage" name="OperatingLeaseYearlyEscalationPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OperatingLeaseIncremetalBorrowingRate" name="OperatingLeaseIncremetalBorrowingRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RentalExpenses" name="RentalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_AgreementTerm" name="AgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PrepaidContractExpenses" name="PrepaidContractExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_LicenseFee" name="LicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_AccruedLicenseFees" name="AccruedLicenseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_AccruedAndOutstandingObligations" name="AccruedAndOutstandingObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PromissoryNote" name="PromissoryNote" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_SegmentNetLoss" name="SegmentNetLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_GrossSalesMember" name="GrossSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DiscountsMember" name="DiscountsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ReturnsMember" name="ReturnsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StockIssuedInConnectionWithConvertibleDebt" name="StockIssuedInConnectionWithConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_ThreeForOneForwardStockSplitMember" name="ThreeForOneForwardStockSplitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OneForTwoReverseStockMember" name="OneForTwoReverseStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PercenatgeOfOfferingPrice" name="PercenatgeOfOfferingPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_OfferingPrice" name="OfferingPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DebtInstrumentInterestDescription" name="DebtInstrumentInterestDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_CommonStockIssuedPercentage" name="CommonStockIssuedPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_NotesThreeMember" name="NotesThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_NotesOneTwoAndThreeMember" name="NotesOneTwoAndThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_DerivativeFairValueAdjustmentOfDateofAmendment" name="DerivativeFairValueAdjustmentOfDateofAmendment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_EmployeeAndConsultantsMember" name="EmployeeAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_MeasurementInputProbabilityofIPOMember" name="MeasurementInputProbabilityofIPOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StatementOfIncomeLocationBalanceAxis" name="StatementOfIncomeLocationBalanceAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="JUNS_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_EmbeddedConversionAndSettlementFeatures" name="EmbeddedConversionAndSettlementFeatures" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_PaymentPremiumFeature" name="PaymentPremiumFeature" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StandbyEquityPurchaseAgreementRelatedDerivative" name="StandbyEquityPurchaseAgreementRelatedDerivative" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="JUNS_StraightDebtComponent" name="StraightDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>juns-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#Cover" roleURI="http://jupiterneurosciences.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#BalanceSheets" roleURI="http://jupiterneurosciences.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://jupiterneurosciences.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfOperations" roleURI="http://jupiterneurosciences.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfChangesInStockholdersEquityDeficit" roleURI="http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfCashFlows" roleURI="http://jupiterneurosciences.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPolicies" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#RelatedPartyTransactions" roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiability" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficit" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxes" roleURI="http://jupiterneurosciences.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingencies" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReport" roleURI="http://jupiterneurosciences.com/role/SegmentReport" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SubsequentEvents" roleURI="http://jupiterneurosciences.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiabilityTables" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficitTables" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxesTables" roleURI="http://jupiterneurosciences.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReportTables" roleURI="http://jupiterneurosciences.com/role/SegmentReportTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpensesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfKeyAssumptionsInValuationMeasurementDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfFairValueDerivativeLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfDerivativeLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfEmployeeStockOptionsOutstandingDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfIncomeTaxProvisionDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfDeferredTaxAssetsDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfSegmentReportingInformationDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReportDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainOnExtinguishmentOfDebt" xlink:label="loc_JUNSGainOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_JUNSGainOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnForgivenessOfAccruedCompensation" xlink:label="loc_JUNSGainLossOnForgivenessOfAccruedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_JUNSGainLossOnForgivenessOfAccruedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnAmortizationOfPrepaidContracts" xlink:label="loc_JUNSGainLossOnAmortizationOfPrepaidContracts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_JUNSGainLossOnAmortizationOfPrepaidContracts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NoncashFinancingCost" xlink:label="loc_JUNSNoncashFinancingCost" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_JUNSNoncashFinancingCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DecreaseIncreaseInPrepaidContracts" xlink:label="loc_JUNSDecreaseIncreaseInPrepaidContracts" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_JUNSDecreaseIncreaseInPrepaidContracts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_JUNSIncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_JUNSIncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="999014 - Disclosure - Organization and Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPolicies" xlink:title="999015 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/RelatedPartyTransactions" xlink:title="999016 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses" xlink:title="999017 - Disclosure - Accounts Payable and Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability" xlink:title="999018 - Disclosure - Convertible Debt and Derivative Liability" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficit" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReport" xlink:title="999022 - Disclosure - Segment Report" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="999025 - Disclosure - Accounts Payable and Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables" xlink:title="999026 - Disclosure - Convertible Debt and Derivative Liability (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables" xlink:title="999027 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxesTables" xlink:title="999028 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReportTables" xlink:title="999030 - Disclosure - Segment Report (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="999031 - Disclosure - Organization and Description of Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999033 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="999034 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:title="999035 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails" xlink:title="999036 - Disclosure - Schedule of Key Assumptions in Valuation Measurement (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails" xlink:title="999037 - Disclosure - Schedule of Fair Value Derivative Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails" xlink:title="999038 - Disclosure - Schedule of Derivative Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" xlink:title="999039 - Disclosure - Convertible Debt and Derivative Liability (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999040 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails" xlink:title="999041 - Disclosure - Schedule of Employee Stock Options Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999042 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999043 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="999044 - Disclosure - Schedule of Income Tax Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999045 - Disclosure - Schedule of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DeferredTaxAssetsDerivativeLiability" xlink:label="loc_JUNSDeferredTaxAssetsDerivativeLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_JUNSDeferredTaxAssetsDerivativeLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative" xlink:title="999046 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" xlink:title="999047 - Disclosure - Schedule of Operating Lease Right-of-use Asset and Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="loc_JUNSOperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:to="loc_JUNSOperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_JUNSOperatingLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:to="loc_JUNSOperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseLiabilityGross" xlink:label="loc_JUNSOperatingLeaseLiabilityGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_JUNSOperatingLeaseLiabilityGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ReductionOfOperatingLeaseLiability" xlink:label="loc_JUNSReductionOfOperatingLeaseLiability" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_JUNSReductionOfOperatingLeaseLiability" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" xlink:title="999048 - Disclosure - Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999049 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:title="999050 - Disclosure - Schedule of Segment Reporting Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative" xlink:title="999051 - Disclosure - Segment Report (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative" xlink:title="999052 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>juns-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#Cover" roleURI="http://jupiterneurosciences.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#BalanceSheets" roleURI="http://jupiterneurosciences.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://jupiterneurosciences.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfOperations" roleURI="http://jupiterneurosciences.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfChangesInStockholdersEquityDeficit" roleURI="http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfCashFlows" roleURI="http://jupiterneurosciences.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPolicies" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#RelatedPartyTransactions" roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiability" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficit" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxes" roleURI="http://jupiterneurosciences.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingencies" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReport" roleURI="http://jupiterneurosciences.com/role/SegmentReport" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SubsequentEvents" roleURI="http://jupiterneurosciences.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiabilityTables" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficitTables" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxesTables" roleURI="http://jupiterneurosciences.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReportTables" roleURI="http://jupiterneurosciences.com/role/SegmentReportTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpensesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfKeyAssumptionsInValuationMeasurementDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfFairValueDerivativeLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfDerivativeLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfEmployeeStockOptionsOutstandingDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfIncomeTaxProvisionDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfDeferredTaxAssetsDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfSegmentReportingInformationDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReportDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCash_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapOtherAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherAssetsNoncurrent_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapInterestPayableCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapDeferredRevenue_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableCurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ReceivablesforSaleofCommonStockMember" xlink:label="loc_JUNSReceivablesforSaleofCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_JUNSReceivablesforSaleofCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" xlink:label="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" xlink:label="loc_JUNSStockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" xlink:label="loc_JUNSStockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueStockSplits" xlink:label="loc_JUNSStockIssuedDuringPeriodValueStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueStockSplits_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="loc_JUNSStockIssuedDuringPeriodValueWarrantExercises_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueWarrantExercises_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesWarrantExercises_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesWarrantExercises_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" xlink:label="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueCommitmentShares" xlink:label="loc_JUNSStockIssuedDuringPeriodValueCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueCommitmentShares_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesCommitmentShares" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesCommitmentShares_60" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnForgivenessOfAccruedCompensation" xlink:label="loc_JUNSGainLossOnForgivenessOfAccruedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_JUNSGainLossOnForgivenessOfAccruedCompensation_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnAmortizationOfPrepaidContracts" xlink:label="loc_JUNSGainLossOnAmortizationOfPrepaidContracts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_JUNSGainLossOnAmortizationOfPrepaidContracts_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NoncashFinancingCost" xlink:label="loc_JUNSNoncashFinancingCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_JUNSNoncashFinancingCost_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapPaidInKindInterest_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DecreaseIncreaseInPrepaidContracts" xlink:label="loc_JUNSDecreaseIncreaseInPrepaidContracts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_JUNSDecreaseIncreaseInPrepaidContracts_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_JUNSIncreaseDecreaseInOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_JUNSIncreaseDecreaseInOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_70" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_70" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:to="loc_us-gaapProceedsFromNotesPayable_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:to="loc_us-gaapProceedsFromOtherDebt_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_70" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CashPaidForInterest" xlink:label="loc_JUNSCashPaidForInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_70" xlink:to="loc_JUNSCashPaidForInterest_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RestrictedStockIssuedForForgivenessOfSalary" xlink:label="loc_JUNSRestrictedStockIssuedForForgivenessOfSalary_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" xlink:to="loc_JUNSRestrictedStockIssuedForForgivenessOfSalary_70" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockOptionsIssuedForForgivenessOfSalary" xlink:label="loc_JUNSStockOptionsIssuedForForgivenessOfSalary_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" xlink:to="loc_JUNSStockOptionsIssuedForForgivenessOfSalary_70" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NotesPayableRelatedPartyAssignToNotePayable" xlink:label="loc_JUNSNotesPayableRelatedPartyAssignToNotePayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" xlink:to="loc_JUNSNotesPayableRelatedPartyAssignToNotePayable_70" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes" xlink:label="loc_JUNSStockIssuedInConnectionWithConvertiblePromissoryNotes_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" xlink:to="loc_JUNSStockIssuedInConnectionWithConvertiblePromissoryNotes_70" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedInConnectionInterestPayment" xlink:label="loc_JUNSStockIssuedInConnectionInterestPayment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_70" xlink:to="loc_JUNSStockIssuedInConnectionInterestPayment_70" xlink:type="arc" order="42" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="999014 - Disclosure - Organization and Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPolicies" xlink:title="999015 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/RelatedPartyTransactions" xlink:title="999016 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses" xlink:title="999017 - Disclosure - Accounts Payable and Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability" xlink:title="999018 - Disclosure - Convertible Debt and Derivative Liability" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficit" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity (Deficit)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReport" xlink:title="999022 - Disclosure - Segment Report" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="999025 - Disclosure - Accounts Payable and Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables" xlink:title="999026 - Disclosure - Convertible Debt and Derivative Liability (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables" xlink:title="999027 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxesTables" xlink:title="999028 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReportTables" xlink:title="999030 - Disclosure - Segment Report (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="999031 - Disclosure - Organization and Description of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_FifteenForFourForwardStockSplitMember" xlink:label="loc_JUNSFifteenForFourForwardStockSplitMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_JUNSFifteenForFourForwardStockSplitMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementMember" xlink:label="loc_JUNSStandbyEquityPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSStandbyEquityPurchaseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_MinimumClosingBidPrice" xlink:label="loc_JUNSMinimumClosingBidPrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_JUNSMinimumClosingBidPrice_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:label="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_160" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetIncomeLoss_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="loc_JUNSDerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_JUNSDerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_110" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999033 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NoteIIHolderMember" xlink:label="loc_JUNSNoteIIHolderMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSNoteIIHolderMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansPayable_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_InterestPayable" xlink:label="loc_JUNSInterestPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_JUNSInterestPayable_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharesIssued_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleDebt_130" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="999034 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:title="999035 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccountsPayableAndAccruedExpensesTable" xlink:label="loc_JUNSAccountsPayableAndAccruedExpensesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSAccountsPayableAndAccruedExpensesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_JUNSAccountsPayableAndAccruedExpensesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_JUNSAccountsPayableAndAccruedExpensesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EmploymentAgreementsMember" xlink:label="loc_JUNSEmploymentAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSEmploymentAgreementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConserveCashPercentage" xlink:label="loc_JUNSConserveCashPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSConserveCashPercentage_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails" xlink:title="999036 - Disclosure - Schedule of Key Assumptions in Valuation Measurement (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaapValuationTechniqueAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapValuationTechniqueAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaapValuationTechniqueDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapValuationTechniqueAxis" xlink:to="loc_us-gaapValuationTechniqueDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaapValuationTechniqueDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapValuationTechniqueAxis" xlink:to="loc_us-gaapValuationTechniqueDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MonteCarloModelMember" xlink:label="loc_us-gaapMonteCarloModelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapValuationTechniqueDomain" xlink:to="loc_us-gaapMonteCarloModelMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails" xlink:title="999037 - Disclosure - Schedule of Fair Value Derivative Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails" xlink:title="999038 - Disclosure - Schedule of Derivative Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeFairValueOfIssuance" xlink:label="loc_JUNSDerivativeFairValueOfIssuance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSDerivativeFairValueOfIssuance_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RepaymentOfDerivativeLiability" xlink:label="loc_JUNSRepaymentOfDerivativeLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSRepaymentOfDerivativeLiability_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossDerivativeInstrumentsNetPretax" xlink:label="loc_JUNSGainLossDerivativeInstrumentsNetPretax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSGainLossDerivativeInstrumentsNetPretax_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainsLossesOfExtinguishmentOfDebt" xlink:label="loc_JUNSGainsLossesOfExtinguishmentOfDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSGainsLossesOfExtinguishmentOfDebt_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" xlink:title="999039 - Disclosure - Convertible Debt and Derivative Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementMember" xlink:label="loc_JUNSStandbyEquityPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSStandbyEquityPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SecuritiesPurchaseAgreementMember" xlink:label="loc_JUNSSecuritiesPurchaseAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSSecuritiesPurchaseAgreementMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_YAIIPNLtdMember" xlink:label="loc_JUNSYAIIPNLtdMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSYAIIPNLtdMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TwelveConvertiblePromissoryNotesMember" xlink:label="loc_JUNSTwelveConvertiblePromissoryNotesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSTwelveConvertiblePromissoryNotesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleDebtOneMember" xlink:label="loc_JUNSConvertibleDebtOneMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSConvertibleDebtOneMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SeniorSecuredNoteConvertibleDebtTwoMember" xlink:label="loc_JUNSSeniorSecuredNoteConvertibleDebtTwoMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSSeniorSecuredNoteConvertibleDebtTwoMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SeniorSecuredNoteMember" xlink:label="loc_JUNSSeniorSecuredNoteMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSSeniorSecuredNoteMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertiblePromissoryNoteMember" xlink:label="loc_JUNSConvertiblePromissoryNoteMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSConvertiblePromissoryNoteMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_270" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_270" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" xlink:label="loc_JUNSDebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSDebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_270" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_270" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_270" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_270" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_270" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_270" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StructuringFee" xlink:label="loc_JUNSStructuringFee_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSStructuringFee_270" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CommitmentShares" xlink:label="loc_JUNSCommitmentShares_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSCommitmentShares_270" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription_270" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures_270" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure_270" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OriginalIssueDiscounts" xlink:label="loc_JUNSOriginalIssueDiscounts_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSOriginalIssueDiscounts_270" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherNotesPayableCurrent_270" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_270" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_270" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_270" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_270" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_270" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_270" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OfferingPricePercentage" xlink:label="loc_JUNSOfferingPricePercentage_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSOfferingPricePercentage_270" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_270" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_270" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_270" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_270" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OriginationOfLoanToPurchaseCommonStock" xlink:label="loc_us-gaapOriginationOfLoanToPurchaseCommonStock_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOriginationOfLoanToPurchaseCommonStock_270" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_270" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_270" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_270" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaapSeniorNotes_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSeniorNotes_270" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleAmountIntoSharesOfCommonStock" xlink:label="loc_JUNSConvertibleAmountIntoSharesOfCommonStock_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSConvertibleAmountIntoSharesOfCommonStock_270" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_270" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="loc_JUNSDerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSDerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_270" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainsOnExtinguishmentOfDebt" xlink:label="loc_JUNSGainsOnExtinguishmentOfDebt_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSGainsOnExtinguishmentOfDebt_270" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeGainLossOnDerivative" xlink:label="loc_JUNSDerivativeGainLossOnDerivative_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSDerivativeGainLossOnDerivative_270" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999040 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails" xlink:title="999041 - Disclosure - Schedule of Employee Stock Options Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeOneMember" xlink:label="loc_JUNSRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeTwoMember" xlink:label="loc_JUNSRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeThreeMember" xlink:label="loc_JUNSRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeFourMember" xlink:label="loc_JUNSRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeFiveMember" xlink:label="loc_JUNSRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeSixMember" xlink:label="loc_JUNSRangeSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeSevenMember" xlink:label="loc_JUNSRangeSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeEightMember" xlink:label="loc_JUNSRangeEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="loc_JUNSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_JUNSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_310" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999042 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999043 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityOneMember" xlink:label="loc_JUNSEntityOneMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityOneMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityTwoMember" xlink:label="loc_JUNSEntityTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityTwoMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityThreeMember" xlink:label="loc_JUNSEntityThreeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityThreeMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_UnderwritingAgreementMember" xlink:label="loc_JUNSUnderwritingAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSUnderwritingAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultantMember" xlink:label="loc_JUNSConsultantMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSConsultantMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_BoardOfDirectorsMember" xlink:label="loc_JUNSBoardOfDirectorsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSBoardOfDirectorsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TwoConsultantsMember" xlink:label="loc_JUNSTwoConsultantsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSTwoConsultantsMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultantsMember" xlink:label="loc_JUNSConsultantsMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSConsultantsMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_WarrantHolderMember" xlink:label="loc_JUNSWarrantHolderMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSWarrantHolderMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_410" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_410" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_410" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_410" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_410" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_410" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CommitmentShares" xlink:label="loc_JUNSCommitmentShares_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSCommitmentShares_410" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaapPurchaseCommitmentRemainingMinimumAmountCommitted_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPurchaseCommitmentRemainingMinimumAmountCommitted_410" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount_410" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PurchaseCommitmentPerShare" xlink:label="loc_JUNSPurchaseCommitmentPerShare_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSPurchaseCommitmentPerShare_410" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_410" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_410" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_410" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_410" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_410" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_410" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_410" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_410" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_410" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_410" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_410" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_410" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense_410" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_410" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_410" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_410" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_410" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_410" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_410" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_410" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_410" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_410" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_410" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_410" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_410" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_410" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_410" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesWarrantsExercised_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesWarrantsExercised_410" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="999044 - Disclosure - Schedule of Income Tax Provision (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999045 - Disclosure - Schedule of Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative" xlink:title="999046 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" xlink:title="999047 - Disclosure - Schedule of Operating Lease Right-of-use Asset and Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" xlink:title="999048 - Disclosure - Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999049 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapProductLiabilityContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceAgreementsMember" xlink:label="loc_us-gaapServiceAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapServiceAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultingAgreementsMember" xlink:label="loc_JUNSConsultingAgreementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSConsultingAgreementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DominantTreasureAgreementMember" xlink:label="loc_JUNSDominantTreasureAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSDominantTreasureAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ExecutiveEmploymentAgreementsMember" xlink:label="loc_JUNSExecutiveEmploymentAgreementsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSExecutiveEmploymentAgreementsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseAgreementsMember" xlink:label="loc_JUNSLicenseAgreementsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSLicenseAgreementsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicensingAndRoyaltyAgreementsMember" xlink:label="loc_JUNSLicensingAndRoyaltyAgreementsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSLicensingAndRoyaltyAgreementsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DebtForgivenessAndExchangeAgreementMember" xlink:label="loc_JUNSDebtForgivenessAndExchangeAgreementMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSDebtForgivenessAndExchangeAgreementMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseAgreementsTwoMember" xlink:label="loc_JUNSLicenseAgreementsTwoMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSLicenseAgreementsTwoMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TiberendStrategicAdvisorsMember" xlink:label="loc_JUNSTiberendStrategicAdvisorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_JUNSTiberendStrategicAdvisorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AquanovaAGMember" xlink:label="loc_JUNSAquanovaAGMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSAquanovaAGMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_MurdochChildrensResearchInstituteMember" xlink:label="loc_JUNSMurdochChildrensResearchInstituteMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSMurdochChildrensResearchInstituteMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityThreeMember" xlink:label="loc_JUNSEntityThreeMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityThreeMember_280" xlink:type="arc" order="282" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_JP" xlink:label="loc_countryJP_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryJP_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_170" xlink:type="arc" order="174" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_180" xlink:type="arc" order="184" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOtherLiabilities_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPaymentsForRent_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseYearlyEscalationPercentage" xlink:label="loc_JUNSOperatingLeaseYearlyEscalationPercentage_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSOperatingLeaseYearlyEscalationPercentage_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseIncremetalBorrowingRate" xlink:label="loc_JUNSOperatingLeaseIncremetalBorrowingRate_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSOperatingLeaseIncremetalBorrowingRate_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RentalExpenses" xlink:label="loc_JUNSRentalExpenses_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSRentalExpenses_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AgreementTerm" xlink:label="loc_JUNSAgreementTerm_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSAgreementTerm_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToSuppliers" xlink:label="loc_us-gaapPaymentsToSuppliers_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPaymentsToSuppliers_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementAndServiceFeesRate" xlink:label="loc_us-gaapManagementAndServiceFeesRate_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapManagementAndServiceFeesRate_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RoyaltyPercentage" xlink:label="loc_JUNSRoyaltyPercentage_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSRoyaltyPercentage_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PrepaidContractExpenses" xlink:label="loc_JUNSPrepaidContractExpenses_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSPrepaidContractExpenses_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:label="loc_us-gaapRestructuringAndRelatedActivitiesDescription_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapRestructuringAndRelatedActivitiesDescription_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseFee" xlink:label="loc_JUNSLicenseFee_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSLicenseFee_340" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccruedLicenseFees" xlink:label="loc_JUNSAccruedLicenseFees_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSAccruedLicenseFees_340" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOtherCommitment_340" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccruedAndOutstandingObligations" xlink:label="loc_JUNSAccruedAndOutstandingObligations_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSAccruedAndOutstandingObligations_340" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapCash_340" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PromissoryNote" xlink:label="loc_JUNSPromissoryNote_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSPromissoryNote_340" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapRoyaltyExpense_340" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_340" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_340" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_340" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapShareBasedCompensation_340" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_340" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_340" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:title="999050 - Disclosure - Schedule of Segment Reporting Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PharmaceuticalOperationsMember" xlink:label="loc_JUNSPharmaceuticalOperationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_JUNSPharmaceuticalOperationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PremiumNutritionalSupplementsMember" xlink:label="loc_JUNSPremiumNutritionalSupplementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_JUNSPremiumNutritionalSupplementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateAndOtherMember" xlink:label="loc_us-gaapCorporateAndOtherMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateAndOtherMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ReportableGeographicalComponentsMember" xlink:label="loc_srtReportableGeographicalComponentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_srtReportableGeographicalComponentsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaapCorporateNonSegmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapCorporateNonSegmentMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SegmentNetLoss" xlink:label="loc_JUNSSegmentNetLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_JUNSSegmentNetLoss_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative" xlink:title="999051 - Disclosure - Segment Report (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative" xlink:title="999052 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementMember" xlink:label="loc_JUNSStandbyEquityPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSStandbyEquityPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" xlink:label="loc_us-gaapAssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:label="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_FifteenForFourForwardStockSplitMember" xlink:label="loc_JUNSFifteenForFourForwardStockSplitMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_JUNSFifteenForFourForwardStockSplitMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>juns-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ReceivablesforSaleofCommonStockMember" xlink:label="JUNS_ReceivablesforSaleofCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ReceivablesforSaleofCommonStockMember" xlink:to="JUNS_ReceivablesforSaleofCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ReceivablesforSaleofCommonStockMember_lbl" xml:lang="en-US">Receivables for Sale of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_FifteenForFourForwardStockSplitMember" xlink:label="JUNS_FifteenForFourForwardStockSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_FifteenForFourForwardStockSplitMember" xlink:to="JUNS_FifteenForFourForwardStockSplitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_FifteenForFourForwardStockSplitMember_lbl" xml:lang="en-US">(15:4) Forward Stock Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementMember" xlink:label="JUNS_StandbyEquityPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StandbyEquityPurchaseAgreementMember" xlink:to="JUNS_StandbyEquityPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NoteIIHolderMember" xlink:label="JUNS_NoteIIHolderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NoteIIHolderMember" xlink:to="JUNS_NoteIIHolderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_NoteIIHolderMember_lbl" xml:lang="en-US">Note II Holder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EmploymentAgreementsMember" xlink:label="JUNS_EmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EmploymentAgreementsMember" xlink:to="JUNS_EmploymentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_EmploymentAgreementsMember_lbl" xml:lang="en-US">Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_YAIIPNLtdMember" xlink:label="JUNS_YAIIPNLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_YAIIPNLtdMember" xlink:to="JUNS_YAIIPNLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_YAIIPNLtdMember_lbl" xml:lang="en-US">YA II PN, Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TwelveConvertiblePromissoryNotesMember" xlink:label="JUNS_TwelveConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_TwelveConvertiblePromissoryNotesMember" xlink:to="JUNS_TwelveConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_TwelveConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">Twelve Convertible Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleDebtOneMember" xlink:label="JUNS_ConvertibleDebtOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertibleDebtOneMember" xlink:to="JUNS_ConvertibleDebtOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConvertibleDebtOneMember_lbl" xml:lang="en-US">Convertible Debt I [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SeniorSecuredNoteConvertibleDebtTwoMember" xlink:label="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember" xlink:to="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember_lbl" xml:lang="en-US">Senior Secured Note Convertible Debt II [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SecuritiesPurchaseAgreementMember" xlink:label="JUNS_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SecuritiesPurchaseAgreementMember" xlink:to="JUNS_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SeniorSecuredNoteMember" xlink:label="JUNS_SeniorSecuredNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SeniorSecuredNoteMember" xlink:to="JUNS_SeniorSecuredNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_SeniorSecuredNoteMember_lbl" xml:lang="en-US">Senior Secured Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertiblePromissoryNoteMember" xlink:label="JUNS_ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertiblePromissoryNoteMember" xlink:to="JUNS_ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MonteCarloModelMember" xlink:label="us-gaap_MonteCarloModelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MonteCarloModelMember" xlink:to="us-gaap_MonteCarloModelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MonteCarloModelMember_lbl" xml:lang="en-US">Valuation Technique, Monte Carlo Pricing Model [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeMember" xlink:to="us-gaap_DerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeMember_lbl" xml:lang="en-US">Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityOneMember" xlink:label="JUNS_EntityOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EntityOneMember" xlink:to="JUNS_EntityOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_EntityOneMember_lbl" xml:lang="en-US">Entity One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityTwoMember" xlink:label="JUNS_EntityTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EntityTwoMember" xlink:to="JUNS_EntityTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_EntityTwoMember_lbl" xml:lang="en-US">Entity Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityThreeMember" xlink:label="JUNS_EntityThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EntityThreeMember" xlink:to="JUNS_EntityThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_EntityThreeMember_lbl" xml:lang="en-US">Entity Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_UnderwritingAgreementMember" xlink:label="JUNS_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_UnderwritingAgreementMember" xlink:to="JUNS_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultantMember" xlink:label="JUNS_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConsultantMember" xlink:to="JUNS_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_BoardOfDirectorsMember" xlink:label="JUNS_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_BoardOfDirectorsMember" xlink:to="JUNS_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TwoConsultantsMember" xlink:label="JUNS_TwoConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_TwoConsultantsMember" xlink:to="JUNS_TwoConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_TwoConsultantsMember_lbl" xml:lang="en-US">Two Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultantsMember" xlink:label="JUNS_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConsultantsMember" xlink:to="JUNS_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_WarrantHolderMember" xlink:label="JUNS_WarrantHolderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_WarrantHolderMember" xlink:to="JUNS_WarrantHolderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_WarrantHolderMember_lbl" xml:lang="en-US">Warrant Holder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeOneMember" xlink:label="JUNS_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeOneMember" xlink:to="JUNS_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeTwoMember" xlink:label="JUNS_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeTwoMember" xlink:to="JUNS_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeThreeMember" xlink:label="JUNS_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeThreeMember" xlink:to="JUNS_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeFourMember" xlink:label="JUNS_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeFourMember" xlink:to="JUNS_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeFiveMember" xlink:label="JUNS_RangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeFiveMember" xlink:to="JUNS_RangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeFiveMember_lbl" xml:lang="en-US">Range Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeSixMember" xlink:label="JUNS_RangeSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeSixMember" xlink:to="JUNS_RangeSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeSixMember_lbl" xml:lang="en-US">Range Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeSevenMember" xlink:label="JUNS_RangeSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeSevenMember" xlink:to="JUNS_RangeSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeSevenMember_lbl" xml:lang="en-US">Range Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeEightMember" xlink:label="JUNS_RangeEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeEightMember" xlink:to="JUNS_RangeEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RangeEightMember_lbl" xml:lang="en-US">Range Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceAgreementsMember" xlink:label="us-gaap_ServiceAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceAgreementsMember" xlink:to="us-gaap_ServiceAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xml:lang="en-US">Service Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TiberendStrategicAdvisorsMember" xlink:label="JUNS_TiberendStrategicAdvisorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_TiberendStrategicAdvisorsMember" xlink:to="JUNS_TiberendStrategicAdvisorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_TiberendStrategicAdvisorsMember_lbl" xml:lang="en-US">Tiberend Strategic Advisors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultingAgreementsMember" xlink:label="JUNS_ConsultingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConsultingAgreementsMember" xlink:to="JUNS_ConsultingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConsultingAgreementsMember_lbl" xml:lang="en-US">Consulting Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DominantTreasureAgreementMember" xlink:label="JUNS_DominantTreasureAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DominantTreasureAgreementMember" xlink:to="JUNS_DominantTreasureAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DominantTreasureAgreementMember_lbl" xml:lang="en-US">Dominant Treasure Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ExecutiveEmploymentAgreementsMember" xlink:label="JUNS_ExecutiveEmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ExecutiveEmploymentAgreementsMember" xlink:to="JUNS_ExecutiveEmploymentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ExecutiveEmploymentAgreementsMember_lbl" xml:lang="en-US">Executive Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseAgreementsMember" xlink:label="JUNS_LicenseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicenseAgreementsMember" xlink:to="JUNS_LicenseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_LicenseAgreementsMember_lbl" xml:lang="en-US">License Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AquanovaAGMember" xlink:label="JUNS_AquanovaAGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AquanovaAGMember" xlink:to="JUNS_AquanovaAGMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_AquanovaAGMember_lbl" xml:lang="en-US">Aquanova AG [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_JP" xlink:label="country_JP" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_JP_lbl" xml:lang="en-US">JAPAN</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicensingAndRoyaltyAgreementsMember" xlink:label="JUNS_LicensingAndRoyaltyAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicensingAndRoyaltyAgreementsMember" xlink:to="JUNS_LicensingAndRoyaltyAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_LicensingAndRoyaltyAgreementsMember_lbl" xml:lang="en-US">Licensing And Royalty Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DebtForgivenessAndExchangeAgreementMember" xlink:label="JUNS_DebtForgivenessAndExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DebtForgivenessAndExchangeAgreementMember" xlink:to="JUNS_DebtForgivenessAndExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DebtForgivenessAndExchangeAgreementMember_lbl" xml:lang="en-US">Debt Forgiveness and Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseAgreementsTwoMember" xlink:label="JUNS_LicenseAgreementsTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicenseAgreementsTwoMember" xlink:to="JUNS_LicenseAgreementsTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_LicenseAgreementsTwoMember_lbl" xml:lang="en-US">License Agreements II [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_MurdochChildrensResearchInstituteMember" xlink:label="JUNS_MurdochChildrensResearchInstituteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_MurdochChildrensResearchInstituteMember" xlink:to="JUNS_MurdochChildrensResearchInstituteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_MurdochChildrensResearchInstituteMember_lbl" xml:lang="en-US">Murdoch Childrens Research Institute [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PharmaceuticalOperationsMember" xlink:label="JUNS_PharmaceuticalOperationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PharmaceuticalOperationsMember" xlink:to="JUNS_PharmaceuticalOperationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_PharmaceuticalOperationsMember_lbl" xml:lang="en-US">Pharmaceutical Operations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ReportableGeographicalComponentsMember" xlink:label="srt_ReportableGeographicalComponentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ReportableGeographicalComponentsMember" xlink:to="srt_ReportableGeographicalComponentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ReportableGeographicalComponentsMember_lbl" xml:lang="en-US">Reportable Geographical Components [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PremiumNutritionalSupplementsMember" xlink:label="JUNS_PremiumNutritionalSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PremiumNutritionalSupplementsMember" xlink:to="JUNS_PremiumNutritionalSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_PremiumNutritionalSupplementsMember_lbl" xml:lang="en-US">Premium Nutritional Supplements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateAndOtherMember" xlink:label="us-gaap_CorporateAndOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateAndOtherMember_lbl" xml:lang="en-US">Corporate Segment and Other Operating Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNonSegmentMember" xlink:to="us-gaap_CorporateNonSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateNonSegmentMember_lbl" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Account receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid contracts, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Deficit:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Series A preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Series A preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Series A preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Series A preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, share outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Product Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expenses):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Loss on change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Gain on change in fair value of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainOnExtinguishmentOfDebt" xlink:label="JUNS_GainOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainOnExtinguishmentOfDebt" xlink:to="JUNS_GainOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_GainOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Net loss per common share:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" xlink:label="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" xlink:to="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary_lbl" xml:lang="en-US">Issuance of restricted stock units for forgiveness of accrued salary</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" xlink:label="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" xlink:to="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary_lbl" xml:lang="en-US">Issuance of stock options for forgiveness of accrued salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock issued for consulting agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock issued for consulting agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock issued in connection with automatic conversion of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock issued in connection with automatic conversion of convertible notes, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" xlink:label="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" xlink:to="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts_lbl" xml:lang="en-US">Stock sold in offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" xlink:label="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" xlink:to="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares_lbl" xml:lang="en-US">Stock sold in offering, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueStockSplits" xlink:label="JUNS_StockIssuedDuringPeriodValueStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueStockSplits" xlink:to="JUNS_StockIssuedDuringPeriodValueStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodValueStockSplits_lbl" xml:lang="en-US">Reconciling shares due to forward stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US">Reconciling shares due to forward stock split, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services rendered, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="JUNS_StockIssuedDuringPeriodValueWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="JUNS_StockIssuedDuringPeriodValueWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodValueWarrantExercises_lbl" xml:lang="en-US">Shares issued for warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="JUNS_StockIssuedDuringPeriodSharesWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="JUNS_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodSharesWarrantExercises_lbl" xml:lang="en-US">Shares issued for warrant exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Shares issued in connection with warrant amendments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Shares issued in connection with warrant amendments, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" xlink:label="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" xlink:to="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest_lbl" xml:lang="en-US">Issuance of common stock for payment of interest</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" xlink:label="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" xlink:to="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares_lbl" xml:lang="en-US">Issuance of common stock for payment of interest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueCommitmentShares" xlink:label="JUNS_StockIssuedDuringPeriodValueCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueCommitmentShares" xlink:to="JUNS_StockIssuedDuringPeriodValueCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodValueCommitmentShares_lbl" xml:lang="en-US">Commitment shares issued in connection with SEPA</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesCommitmentShares" xlink:label="JUNS_StockIssuedDuringPeriodSharesCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesCommitmentShares" xlink:to="JUNS_StockIssuedDuringPeriodSharesCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodSharesCommitmentShares_lbl" xml:lang="en-US">Commitment shares issued in connection with SEPA, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2_lbl" xml:lang="en-US">Loss on change in fair value of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Gain on change in fair value of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss (Gain) on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnForgivenessOfAccruedCompensation" xlink:label="JUNS_GainLossOnForgivenessOfAccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainLossOnForgivenessOfAccruedCompensation" xlink:to="JUNS_GainLossOnForgivenessOfAccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="JUNS_GainLossOnForgivenessOfAccruedCompensation_lbl" xml:lang="en-US">Gain on forgiveness of accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnAmortizationOfPrepaidContracts" xlink:label="JUNS_GainLossOnAmortizationOfPrepaidContracts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainLossOnAmortizationOfPrepaidContracts" xlink:to="JUNS_GainLossOnAmortizationOfPrepaidContracts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_GainLossOnAmortizationOfPrepaidContracts_lbl" xml:lang="en-US">Amortization of prepaid contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NoncashFinancingCost" xlink:label="JUNS_NoncashFinancingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NoncashFinancingCost" xlink:to="JUNS_NoncashFinancingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_NoncashFinancingCost_lbl" xml:lang="en-US">Non-cash financing cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Interest expense paid through sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DecreaseIncreaseInPrepaidContracts" xlink:label="JUNS_DecreaseIncreaseInPrepaidContracts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DecreaseIncreaseInPrepaidContracts" xlink:to="JUNS_DecreaseIncreaseInPrepaidContracts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="JUNS_DecreaseIncreaseInPrepaidContracts_lbl" xml:lang="en-US">Decrease (increase) in prepaid contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Increase in prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Increase in other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Decrease in operating lease right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase in deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US">Decrease in accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Increase in accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable, related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment on convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="us-gaap_ProceedsFromOtherDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherDebt" xlink:to="us-gaap_ProceedsFromOtherDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherDebt_lbl" xml:lang="en-US">Proceeds from issuance convertible note payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from offering, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Change in Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CashPaidForInterest" xlink:label="JUNS_CashPaidForInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_CashPaidForInterest" xlink:to="JUNS_CashPaidForInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_CashPaidForInterest_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Non-Cash Investing and Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RestrictedStockIssuedForForgivenessOfSalary" xlink:label="JUNS_RestrictedStockIssuedForForgivenessOfSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RestrictedStockIssuedForForgivenessOfSalary" xlink:to="JUNS_RestrictedStockIssuedForForgivenessOfSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RestrictedStockIssuedForForgivenessOfSalary_lbl" xml:lang="en-US">Restricted stock issued for forgiveness of salary</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockOptionsIssuedForForgivenessOfSalary" xlink:label="JUNS_StockOptionsIssuedForForgivenessOfSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockOptionsIssuedForForgivenessOfSalary" xlink:to="JUNS_StockOptionsIssuedForForgivenessOfSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockOptionsIssuedForForgivenessOfSalary_lbl" xml:lang="en-US">Stock options issued for forgiveness of salary</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NotesPayableRelatedPartyAssignToNotePayable" xlink:label="JUNS_NotesPayableRelatedPartyAssignToNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NotesPayableRelatedPartyAssignToNotePayable" xlink:to="JUNS_NotesPayableRelatedPartyAssignToNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_NotesPayableRelatedPartyAssignToNotePayable_lbl" xml:lang="en-US">Notes payable, related party assign to Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes" xlink:label="JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes" xlink:to="JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes_lbl" xml:lang="en-US">Stock issued in connection with convertible promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedInConnectionInterestPayment" xlink:label="JUNS_StockIssuedInConnectionInterestPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedInConnectionInterestPayment" xlink:to="JUNS_StockIssuedInConnectionInterestPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedInConnectionInterestPayment_lbl" xml:lang="en-US">Stock issued in connection interest payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_Rule10b51ArrModifiedFlag" xlink:label="JUNS_Rule10b51ArrModifiedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_Rule10b51ArrModifiedFlag" xlink:to="JUNS_Rule10b51ArrModifiedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_Rule10b51ArrModifiedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Modified [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NonRule10b51ArrModifiedFlag" xlink:label="JUNS_NonRule10b51ArrModifiedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NonRule10b51ArrModifiedFlag" xlink:to="JUNS_NonRule10b51ArrModifiedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_NonRule10b51ArrModifiedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Modified [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Debt and Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Business Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PrepaidContractsPolicyTextBlock" xlink:label="JUNS_PrepaidContractsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PrepaidContractsPolicyTextBlock" xlink:to="JUNS_PrepaidContractsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_PrepaidContractsPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Contracts</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" xlink:label="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" xlink:to="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ClinicalTrialExpensesPolicyTextBlock" xlink:label="JUNS_ClinicalTrialExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ClinicalTrialExpensesPolicyTextBlock" xlink:to="JUNS_ClinicalTrialExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ClinicalTrialExpensesPolicyTextBlock_lbl" xml:lang="en-US">Clinical Trial Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" xlink:label="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" xlink:to="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Convertible Notes with Embedded Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_lbl" xml:lang="en-US">Schedule of Key Assumptions in Valuation Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Employee Stock Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:label="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:to="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:label="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:to="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Right-of-use Asset and Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Underwriting discounts, commissions and offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_MinimumClosingBidPrice" xlink:label="JUNS_MinimumClosingBidPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_MinimumClosingBidPrice" xlink:to="JUNS_MinimumClosingBidPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_MinimumClosingBidPrice_lbl" xml:lang="en-US">Minimum closing bid price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:label="us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:to="us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_lbl" xml:lang="en-US">Market value of listed securities closed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xml:lang="en-US">Net revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash flows from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash uninsured amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Number of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xml:lang="en-US">Derivative liabilities current not disclosed flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_InterestPayable" xlink:label="JUNS_InterestPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_InterestPayable" xlink:to="JUNS_InterestPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_InterestPayable_lbl" xml:lang="en-US">[custom:InterestPayable-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Strike price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Debt Instrument, Issued, Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">License fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Credit cards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccountsPayableAndAccruedExpensesTable" xlink:label="JUNS_AccountsPayableAndAccruedExpensesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AccountsPayableAndAccruedExpensesTable" xlink:to="JUNS_AccountsPayableAndAccruedExpensesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_AccountsPayableAndAccruedExpensesTable_lbl" xml:lang="en-US">AccountsPayableAndAccruedExpensesTable [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts payable and accrued expenses owned</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConserveCashPercentage" xlink:label="JUNS_ConserveCashPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConserveCashPercentage" xlink:to="JUNS_ConserveCashPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConserveCashPercentage_lbl" xml:lang="en-US">[custom:ConserveCashPercentage-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Convertible debt instrument, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Derivative liability, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems_lbl" xml:lang="en-US">Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Balance at December 31, 2023</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_3_lbl" xml:lang="en-US">Fair value change</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Extinguishment of derivative liability - Note II</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeFairValueOfIssuance" xlink:label="JUNS_DerivativeFairValueOfIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeFairValueOfIssuance" xlink:to="JUNS_DerivativeFairValueOfIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DerivativeFairValueOfIssuance_lbl" xml:lang="en-US">Issuance of the 2025 Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RepaymentOfDerivativeLiability" xlink:label="JUNS_RepaymentOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RepaymentOfDerivativeLiability" xlink:to="JUNS_RepaymentOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RepaymentOfDerivativeLiability_lbl" xml:lang="en-US">Repayment of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Derivative liability Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossDerivativeInstrumentsNetPretax" xlink:label="JUNS_GainLossDerivativeInstrumentsNetPretax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainLossDerivativeInstrumentsNetPretax" xlink:to="JUNS_GainLossDerivativeInstrumentsNetPretax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_GainLossDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Fair value change</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainsLossesOfExtinguishmentOfDebt" xlink:label="JUNS_GainsLossesOfExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainsLossesOfExtinguishmentOfDebt" xlink:to="JUNS_GainsLossesOfExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="JUNS_GainsLossesOfExtinguishmentOfDebt_lbl" xml:lang="en-US">Balance at December 31, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Pre-paid advances via convertible promissory notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" xlink:label="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" xlink:to="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_lbl" xml:lang="en-US">Original issue discount percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Annual percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt instrument, convertible, conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Repayments of debt description</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StructuringFee" xlink:label="JUNS_StructuringFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StructuringFee" xlink:to="JUNS_StructuringFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StructuringFee_lbl" xml:lang="en-US">[custom:StructuringFee-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CommitmentShares" xlink:label="JUNS_CommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_CommitmentShares" xlink:to="JUNS_CommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_CommitmentShares_lbl" xml:lang="en-US">[custom:CommitmentShares-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Other Commitments, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible promissory note fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xml:lang="en-US">Notes payable fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OriginalIssueDiscounts" xlink:label="JUNS_OriginalIssueDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OriginalIssueDiscounts" xlink:to="JUNS_OriginalIssueDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OriginalIssueDiscounts_lbl" xml:lang="en-US">Original issue discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="us-gaap_OtherNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Outstanding principal balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Sale of stock, consideration received on transaction, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Sale of stock exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OfferingPricePercentage" xlink:label="JUNS_OfferingPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OfferingPricePercentage" xlink:to="JUNS_OfferingPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OfferingPricePercentage_lbl" xml:lang="en-US">[custom:OfferingPricePercentage-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xml:lang="en-US">Principal amount shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Common stock for net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OriginationOfLoanToPurchaseCommonStock" xlink:label="us-gaap_OriginationOfLoanToPurchaseCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OriginationOfLoanToPurchaseCommonStock" xlink:to="us-gaap_OriginationOfLoanToPurchaseCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OriginationOfLoanToPurchaseCommonStock_lbl" xml:lang="en-US">Origination costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain on modification</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_3_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotes" xlink:to="us-gaap_SeniorNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorNotes_lbl" xml:lang="en-US">Senior notes</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleAmountIntoSharesOfCommonStock" xlink:label="JUNS_ConvertibleAmountIntoSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertibleAmountIntoSharesOfCommonStock" xlink:to="JUNS_ConvertibleAmountIntoSharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ConvertibleAmountIntoSharesOfCommonStock_lbl" xml:lang="en-US">Convertible amount into shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayments of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_lbl" xml:lang="en-US">Derivative liabilities not disclosed flag</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainsOnExtinguishmentOfDebt" xlink:label="JUNS_GainsOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainsOnExtinguishmentOfDebt" xlink:to="JUNS_GainsOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_GainsOnExtinguishmentOfDebt_lbl" xml:lang="en-US">[custom:GainsOnExtinguishmentOfDebt]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeGainLossOnDerivative" xlink:label="JUNS_DerivativeGainLossOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeGainLossOnDerivative" xlink:to="JUNS_DerivativeGainLossOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DerivativeGainLossOnDerivative_lbl" xml:lang="en-US">[custom:DerivativeGainLossOnDerivative]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average contractual term (years), outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average contractual term (years), outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average contractual term (years), exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Outstanding options, weighted average remaining life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Vested options, number exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested options, weighted average remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_lbl" xml:lang="en-US">Weighted average exercise price per share, outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted average remaining life (years), outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_lbl" xml:lang="en-US">Weighted average exercise price per share, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of shares, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_lbl" xml:lang="en-US">Weighted average exercise price per share, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_lbl" xml:lang="en-US">Weighted average exercise price per share, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_2_lbl" xml:lang="en-US">Weighted average exercise price per share, outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_CommitmentShares" xlink:to="JUNS_CommitmentShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="JUNS_CommitmentShares_2_lbl" xml:lang="en-US">Commitment shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US">Commitment shares issued value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Purchase commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PurchaseCommitmentPerShare" xlink:label="JUNS_PurchaseCommitmentPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PurchaseCommitmentPerShare" xlink:to="JUNS_PurchaseCommitmentPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_PurchaseCommitmentPerShare_lbl" xml:lang="en-US">Purchase commitment per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Number of shares issued for service rendered</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of restricted shares issued, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Gross proceeds from offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted stock fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xml:lang="en-US">Compensation expense for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Unvested stock options expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Granted stock option purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Stock option exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">Vested, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Stock options vest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Option vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4_lbl" xml:lang="en-US">Stock options issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Vesting period description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Stock option granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2_lbl" xml:lang="en-US">Fair value of grant date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Vested performance description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Warrant exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Nondeductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">U.S Federal and State net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Accrued salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Orphan drug credit</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DeferredTaxAssetsDerivativeLiability" xlink:label="JUNS_DeferredTaxAssetsDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DeferredTaxAssetsDerivativeLiability" xlink:to="JUNS_DeferredTaxAssetsDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DeferredTaxAssetsDerivativeLiability_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US">Office lease ROU</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated reduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Balance of ROU, net &#160; &#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseLiabilityGross" xlink:label="JUNS_OperatingLeaseLiabilityGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseLiabilityGross" xlink:to="JUNS_OperatingLeaseLiabilityGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OperatingLeaseLiabilityGross_lbl" xml:lang="en-US">Office lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ReductionOfOperatingLeaseLiability" xlink:label="JUNS_ReductionOfOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ReductionOfOperatingLeaseLiability" xlink:to="JUNS_ReductionOfOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="JUNS_ReductionOfOperatingLeaseLiability_lbl" xml:lang="en-US">Reduction of lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest &#160;</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total lease liabilities &#160;</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-current operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="us-gaap_ProductLiabilityContingencyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyTable_lbl" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_ProductLiabilityContingencyLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_lbl" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Non-payment amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_2_lbl" xml:lang="en-US">Convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Base rent</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseYearlyEscalationPercentage" xlink:label="JUNS_OperatingLeaseYearlyEscalationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseYearlyEscalationPercentage" xlink:to="JUNS_OperatingLeaseYearlyEscalationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OperatingLeaseYearlyEscalationPercentage_lbl" xml:lang="en-US">Operating lease yearly escalation percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xml:lang="en-US">Operating lease right-of-use asset, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseIncremetalBorrowingRate" xlink:label="JUNS_OperatingLeaseIncremetalBorrowingRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseIncremetalBorrowingRate" xlink:to="JUNS_OperatingLeaseIncremetalBorrowingRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OperatingLeaseIncremetalBorrowingRate_lbl" xml:lang="en-US">Operating lease incremetal borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RentalExpenses" xlink:label="JUNS_RentalExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RentalExpenses" xlink:to="JUNS_RentalExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RentalExpenses_lbl" xml:lang="en-US">Operating leases rent expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AgreementTerm" xlink:label="JUNS_AgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AgreementTerm" xlink:to="JUNS_AgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_AgreementTerm_lbl" xml:lang="en-US">Agreements term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliers" xlink:to="us-gaap_PaymentsToSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US">Payment for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementAndServiceFeesRate" xlink:label="us-gaap_ManagementAndServiceFeesRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementAndServiceFeesRate" xlink:to="us-gaap_ManagementAndServiceFeesRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementAndServiceFeesRate_lbl" xml:lang="en-US">Success fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RoyaltyPercentage" xlink:label="JUNS_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RoyaltyPercentage" xlink:to="JUNS_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty payments percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_2_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PrepaidContractExpenses" xlink:label="JUNS_PrepaidContractExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PrepaidContractExpenses" xlink:to="JUNS_PrepaidContractExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_PrepaidContractExpenses_lbl" xml:lang="en-US">Prepaid contracts expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDescription_lbl" xml:lang="en-US">Salary payment description</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseFee" xlink:label="JUNS_LicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicenseFee" xlink:to="JUNS_LicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_LicenseFee_lbl" xml:lang="en-US">[custom:LicenseFee]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccruedLicenseFees" xlink:label="JUNS_AccruedLicenseFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AccruedLicenseFees" xlink:to="JUNS_AccruedLicenseFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_AccruedLicenseFees_lbl" xml:lang="en-US">Accrued license fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Other Commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccruedAndOutstandingObligations" xlink:label="JUNS_AccruedAndOutstandingObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AccruedAndOutstandingObligations" xlink:to="JUNS_AccruedAndOutstandingObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_AccruedAndOutstandingObligations_lbl" xml:lang="en-US">Accrued and outstanding obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PromissoryNote" xlink:label="JUNS_PromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PromissoryNote" xlink:to="JUNS_PromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_PromissoryNote_lbl" xml:lang="en-US">Promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xml:lang="en-US">Number of restricted shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_3_lbl" xml:lang="en-US">Employee Benefits and Share-Based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_3_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SegmentNetLoss" xlink:label="JUNS_SegmentNetLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SegmentNetLoss" xlink:to="JUNS_SegmentNetLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_SegmentNetLoss_lbl" xml:lang="en-US">Segment net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xml:lang="en-US">Sale of stock number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from conversion debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" xlink:label="us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" xlink:to="us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_lbl" xml:lang="en-US">Market value of listed securities closed</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_Rule10b51ArrModifiedFlag" xlink:to="JUNS_Rule10b51ArrModifiedFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_Rule10b51ArrModifiedFlag_doc" xml:lang="en-US">Rule 10b5-1 Arrangement modified [Flag]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NonRule10b51ArrModifiedFlag" xlink:to="JUNS_NonRule10b51ArrModifiedFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_NonRule10b51ArrModifiedFlag_doc" xml:lang="en-US">Non-Rule 10b5-1 Arrangement modified [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GrossSalesMember" xlink:label="JUNS_GrossSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GrossSalesMember" xlink:to="JUNS_GrossSalesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GrossSalesMember_doc" xml:lang="en-US">Gross Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DiscountsMember" xlink:label="JUNS_DiscountsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DiscountsMember" xlink:to="JUNS_DiscountsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DiscountsMember_doc" xml:lang="en-US">Discounts [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ReturnsMember" xlink:label="JUNS_ReturnsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ReturnsMember" xlink:to="JUNS_ReturnsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ReturnsMember_doc" xml:lang="en-US">Returns [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" xlink:to="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary_doc" xml:lang="en-US">Stock issued during period value issuance of restricted stock units for forgiveness of accrued salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" xlink:to="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary_doc" xml:lang="en-US">Stock issued during period value of issuance of stock options for forgiveness of accrued salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueStockSplits" xlink:to="JUNS_StockIssuedDuringPeriodValueStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodValueStockSplits_doc" xml:lang="en-US">Stock issued during period value stock splits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="JUNS_StockIssuedDuringPeriodValueWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodValueWarrantExercises_doc" xml:lang="en-US">Stock issued during period value warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="JUNS_StockIssuedDuringPeriodSharesWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodSharesWarrantExercises_doc" xml:lang="en-US">Stock issued during period shares warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueCommitmentShares" xlink:to="JUNS_StockIssuedDuringPeriodValueCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodValueCommitmentShares_doc" xml:lang="en-US">Stock issued during period value commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesCommitmentShares" xlink:to="JUNS_StockIssuedDuringPeriodSharesCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodSharesCommitmentShares_doc" xml:lang="en-US">Stock issued during period shares commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainLossOnForgivenessOfAccruedCompensation" xlink:to="JUNS_GainLossOnForgivenessOfAccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GainLossOnForgivenessOfAccruedCompensation_doc" xml:lang="en-US">Gain loss on forgiveness of accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainLossOnAmortizationOfPrepaidContracts" xlink:to="JUNS_GainLossOnAmortizationOfPrepaidContracts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GainLossOnAmortizationOfPrepaidContracts_doc" xml:lang="en-US">Gain loss on amortization of prepaid contracts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_doc" xml:lang="en-US">(Decrease) increase in operating lease right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RestrictedStockIssuedForForgivenessOfSalary" xlink:to="JUNS_RestrictedStockIssuedForForgivenessOfSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RestrictedStockIssuedForForgivenessOfSalary_doc" xml:lang="en-US">Restricted stock issued for forgiveness of salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockOptionsIssuedForForgivenessOfSalary" xlink:to="JUNS_StockOptionsIssuedForForgivenessOfSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockOptionsIssuedForForgivenessOfSalary_doc" xml:lang="en-US">Stock option issued for forgiveness of salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NotesPayableRelatedPartyAssignToNotePayable" xlink:to="JUNS_NotesPayableRelatedPartyAssignToNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_NotesPayableRelatedPartyAssignToNotePayable_doc" xml:lang="en-US">Notes payable, related party assign to note payable.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedInConnectionWithConvertibleDebt" xlink:label="JUNS_StockIssuedInConnectionWithConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedInConnectionWithConvertibleDebt" xlink:to="JUNS_StockIssuedInConnectionWithConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedInConnectionWithConvertibleDebt_doc" xml:lang="en-US">Stock issued in connection with convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedInConnectionInterestPayment" xlink:to="JUNS_StockIssuedInConnectionInterestPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedInConnectionInterestPayment_doc" xml:lang="en-US">Stock issued in connection interest payment.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ThreeForOneForwardStockSplitMember" xlink:label="JUNS_ThreeForOneForwardStockSplitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ThreeForOneForwardStockSplitMember" xlink:to="JUNS_ThreeForOneForwardStockSplitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ThreeForOneForwardStockSplitMember_doc" xml:lang="en-US">Three for One Forward Stock Split [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OneForTwoReverseStockMember" xlink:label="JUNS_OneForTwoReverseStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OneForTwoReverseStockMember" xlink:to="JUNS_OneForTwoReverseStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OneForTwoReverseStockMember_doc" xml:lang="en-US">One for Two Reverse Stock Split [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_FifteenForFourForwardStockSplitMember" xlink:to="JUNS_FifteenForFourForwardStockSplitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_FifteenForFourForwardStockSplitMember_doc" xml:lang="en-US">Fifteen for Four Forward Stock Split [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_MinimumClosingBidPrice" xlink:to="JUNS_MinimumClosingBidPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_MinimumClosingBidPrice_doc" xml:lang="en-US">Minimum closing bid price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PrepaidContractsPolicyTextBlock" xlink:to="JUNS_PrepaidContractsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PrepaidContractsPolicyTextBlock_doc" xml:lang="en-US">Prepaid contracts [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" xlink:to="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_doc" xml:lang="en-US">Other Current Assets And Prepaid Expenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ClinicalTrialExpensesPolicyTextBlock" xlink:to="JUNS_ClinicalTrialExpensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ClinicalTrialExpensesPolicyTextBlock_doc" xml:lang="en-US">Clinical Trial Expenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" xlink:to="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_doc" xml:lang="en-US">Convertible Notes With Embedded Derivative Liabilities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_InterestPayable" xlink:to="JUNS_InterestPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_InterestPayable_doc" xml:lang="en-US">Interest payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ExecutiveEmploymentAgreementsMember" xlink:to="JUNS_ExecutiveEmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ExecutiveEmploymentAgreementsMember_doc" xml:lang="en-US">Executive Employment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConserveCashPercentage" xlink:to="JUNS_ConserveCashPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConserveCashPercentage_doc" xml:lang="en-US">Conserve cash percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EmploymentAgreementsMember" xlink:to="JUNS_EmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_EmploymentAgreementsMember_doc" xml:lang="en-US">Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EmployeesMember" xlink:label="JUNS_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EmployeesMember" xlink:to="JUNS_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NoteIIHolderMember" xlink:to="JUNS_NoteIIHolderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_NoteIIHolderMember_doc" xml:lang="en-US">Note II Holder [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_TwelveConvertiblePromissoryNotesMember" xlink:to="JUNS_TwelveConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_TwelveConvertiblePromissoryNotesMember_doc" xml:lang="en-US">Twelve Convertible Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OfferingPricePercentage" xlink:to="JUNS_OfferingPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OfferingPricePercentage_doc" xml:lang="en-US">Offering price percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertibleDebtOneMember" xlink:to="JUNS_ConvertibleDebtOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConvertibleDebtOneMember_doc" xml:lang="en-US">Convertible Debt I [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PercenatgeOfOfferingPrice" xlink:label="JUNS_PercenatgeOfOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PercenatgeOfOfferingPrice" xlink:to="JUNS_PercenatgeOfOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PercenatgeOfOfferingPrice_doc" xml:lang="en-US">Percenatge of offering price.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OfferingPrice" xlink:label="JUNS_OfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OfferingPrice" xlink:to="JUNS_OfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OfferingPrice_doc" xml:lang="en-US">Offering price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember" xlink:to="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_SeniorSecuredNoteConvertibleDebtTwoMember_doc" xml:lang="en-US">Senior Secured Note Convertible Debt II [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SecuritiesPurchaseAgreementMember" xlink:to="JUNS_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DebtInstrumentInterestDescription" xlink:label="JUNS_DebtInstrumentInterestDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DebtInstrumentInterestDescription" xlink:to="JUNS_DebtInstrumentInterestDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DebtInstrumentInterestDescription_doc" xml:lang="en-US">Debt instrument interest description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SeniorSecuredNoteMember" xlink:to="JUNS_SeniorSecuredNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_SeniorSecuredNoteMember_doc" xml:lang="en-US">Senior Secured Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertiblePromissoryNoteMember" xlink:to="JUNS_ConvertiblePromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConvertiblePromissoryNoteMember_doc" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConvertibleAmountIntoSharesOfCommonStock" xlink:to="JUNS_ConvertibleAmountIntoSharesOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConvertibleAmountIntoSharesOfCommonStock_doc" xml:lang="en-US">Convertible amount into shares of common stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CommonStockIssuedPercentage" xlink:label="JUNS_CommonStockIssuedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_CommonStockIssuedPercentage" xlink:to="JUNS_CommonStockIssuedPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_CommonStockIssuedPercentage_doc" xml:lang="en-US">Common stock issued percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainsOnExtinguishmentOfDebt" xlink:to="JUNS_GainsOnExtinguishmentOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GainsOnExtinguishmentOfDebt_doc" xml:lang="en-US">Gains on extinguishment of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeGainLossOnDerivative" xlink:to="JUNS_DerivativeGainLossOnDerivative_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DerivativeGainLossOnDerivative_doc" xml:lang="en-US">Derivative gain loss on derivative.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NotesThreeMember" xlink:label="JUNS_NotesThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NotesThreeMember" xlink:to="JUNS_NotesThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_NotesThreeMember_doc" xml:lang="en-US">Notes Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NotesOneTwoAndThreeMember" xlink:label="JUNS_NotesOneTwoAndThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_NotesOneTwoAndThreeMember" xlink:to="JUNS_NotesOneTwoAndThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_NotesOneTwoAndThreeMember_doc" xml:lang="en-US">Notes One, Two and Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeFairValueOfIssuance" xlink:to="JUNS_DerivativeFairValueOfIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DerivativeFairValueOfIssuance_doc" xml:lang="en-US">Derivative fair value of issuance.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeFairValueAdjustmentOfDateofAmendment" xlink:label="JUNS_DerivativeFairValueAdjustmentOfDateofAmendment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeFairValueAdjustmentOfDateofAmendment" xlink:to="JUNS_DerivativeFairValueAdjustmentOfDateofAmendment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DerivativeFairValueAdjustmentOfDateofAmendment_doc" xml:lang="en-US">Derivative fair value adjustment of date of amendment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RepaymentOfDerivativeLiability" xlink:to="JUNS_RepaymentOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RepaymentOfDerivativeLiability_doc" xml:lang="en-US">Repayment of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EntityOneMember" xlink:to="JUNS_EntityOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_EntityOneMember_doc" xml:lang="en-US">Entity One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EntityTwoMember" xlink:to="JUNS_EntityTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_EntityTwoMember_doc" xml:lang="en-US">Entity Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EntityThreeMember" xlink:to="JUNS_EntityThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_EntityThreeMember_doc" xml:lang="en-US">Entity Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_UnderwritingAgreementMember" xlink:to="JUNS_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_UnderwritingAgreementMember_doc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EmployeeAndConsultantsMember" xlink:label="JUNS_EmployeeAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EmployeeAndConsultantsMember" xlink:to="JUNS_EmployeeAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_EmployeeAndConsultantsMember_doc" xml:lang="en-US">Employee and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConsultantMember" xlink:to="JUNS_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConsultantMember_doc" xml:lang="en-US">Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:to="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_doc" xml:lang="en-US">Share based compensation shares authorized under stock option plans exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeOneMember" xlink:to="JUNS_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeOneMember_doc" xml:lang="en-US">Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeTwoMember" xlink:to="JUNS_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeTwoMember_doc" xml:lang="en-US">Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeThreeMember" xlink:to="JUNS_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeThreeMember_doc" xml:lang="en-US">Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeFourMember" xlink:to="JUNS_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeFourMember_doc" xml:lang="en-US">Range Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeFiveMember" xlink:to="JUNS_RangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeFiveMember_doc" xml:lang="en-US">Range Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeSixMember" xlink:to="JUNS_RangeSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeSixMember_doc" xml:lang="en-US">Range Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeSevenMember" xlink:to="JUNS_RangeSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeSevenMember_doc" xml:lang="en-US">Range Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RangeEightMember" xlink:to="JUNS_RangeEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RangeEightMember_doc" xml:lang="en-US">Range Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:to="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_doc" xml:lang="en-US">Schedule of Share Based Compensation Warrant Activity [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments weighted average remaining life.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DeferredTaxAssetsDerivativeLiability" xlink:to="JUNS_DeferredTaxAssetsDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DeferredTaxAssetsDerivativeLiability_doc" xml:lang="en-US">Deferred tax assets derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_TiberendStrategicAdvisorsMember" xlink:to="JUNS_TiberendStrategicAdvisorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_TiberendStrategicAdvisorsMember_doc" xml:lang="en-US">Tiberend Strategic Advisors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseYearlyEscalationPercentage" xlink:to="JUNS_OperatingLeaseYearlyEscalationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OperatingLeaseYearlyEscalationPercentage_doc" xml:lang="en-US">Operating lease yearly escalation percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseIncremetalBorrowingRate" xlink:to="JUNS_OperatingLeaseIncremetalBorrowingRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OperatingLeaseIncremetalBorrowingRate_doc" xml:lang="en-US">Operating lease incremetal borrowing rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:to="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Operating Lease Assets and Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_doc" xml:lang="en-US">Operating lease right-of-use asset before accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization_doc" xml:lang="en-US">Operating lease, right-of-use asset, accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseLiabilityGross" xlink:to="JUNS_OperatingLeaseLiabilityGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_OperatingLeaseLiabilityGross_doc" xml:lang="en-US">Operating lease liability gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ReductionOfOperatingLeaseLiability" xlink:to="JUNS_ReductionOfOperatingLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ReductionOfOperatingLeaseLiability_doc" xml:lang="en-US">Reduction of operating lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RentalExpenses" xlink:to="JUNS_RentalExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RentalExpenses_doc" xml:lang="en-US">Rental expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AgreementTerm" xlink:to="JUNS_AgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_AgreementTerm_doc" xml:lang="en-US">Agreement term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConsultingAgreementsMember" xlink:to="JUNS_ConsultingAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConsultingAgreementsMember_doc" xml:lang="en-US">Consulting Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DominantTreasureAgreementMember" xlink:to="JUNS_DominantTreasureAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DominantTreasureAgreementMember_doc" xml:lang="en-US">Dominant Treasure Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_RoyaltyPercentage" xlink:to="JUNS_RoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_RoyaltyPercentage_doc" xml:lang="en-US">Royalty percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicenseFee" xlink:to="JUNS_LicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_LicenseFee_doc" xml:lang="en-US">License fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicenseAgreementsMember" xlink:to="JUNS_LicenseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_LicenseAgreementsMember_doc" xml:lang="en-US">License Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AquanovaAGMember" xlink:to="JUNS_AquanovaAGMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_AquanovaAGMember_doc" xml:lang="en-US">Aquanova AG [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AccruedLicenseFees" xlink:to="JUNS_AccruedLicenseFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_AccruedLicenseFees_doc" xml:lang="en-US">Accrued license fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicensingAndRoyaltyAgreementsMember" xlink:to="JUNS_LicensingAndRoyaltyAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_LicensingAndRoyaltyAgreementsMember_doc" xml:lang="en-US">Licensing And Royalty Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_LicenseAgreementsTwoMember" xlink:to="JUNS_LicenseAgreementsTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_LicenseAgreementsTwoMember_doc" xml:lang="en-US">License Agreements Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_MurdochChildrensResearchInstituteMember" xlink:to="JUNS_MurdochChildrensResearchInstituteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_MurdochChildrensResearchInstituteMember_doc" xml:lang="en-US">Murdoch Childrens Research Institute [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SegmentNetLoss" xlink:to="JUNS_SegmentNetLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_SegmentNetLoss_doc" xml:lang="en-US">Segment net loss.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_MeasurementInputProbabilityofIPOMember" xlink:label="JUNS_MeasurementInputProbabilityofIPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_MeasurementInputProbabilityofIPOMember" xlink:to="JUNS_MeasurementInputProbabilityofIPOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_MeasurementInputProbabilityofIPOMember_doc" xml:lang="en-US">Measurement Input Probability of IPO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_doc" xml:lang="en-US">Derivative liabilities not disclosed flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_doc" xml:lang="en-US">Derivative liabilities current not disclosed flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainOnExtinguishmentOfDebt" xlink:to="JUNS_GainOnExtinguishmentOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GainOnExtinguishmentOfDebt_doc" xml:lang="en-US">Gain on extinguishment of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PrepaidContractExpenses" xlink:to="JUNS_PrepaidContractExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PrepaidContractExpenses_doc" xml:lang="en-US">Prepaid contract expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_CashPaidForInterest" xlink:to="JUNS_CashPaidForInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_CashPaidForInterest_doc" xml:lang="en-US">Cash paid for interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DecreaseIncreaseInPrepaidContracts" xlink:to="JUNS_DecreaseIncreaseInPrepaidContracts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DecreaseIncreaseInPrepaidContracts_doc" xml:lang="en-US">Decrease (increase) in prepaid contracts.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" xlink:to="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts_doc" xml:lang="en-US">Stock sold in offering, net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" xlink:to="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares_doc" xml:lang="en-US">Stock sold in offering, net of offering costs, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ReceivablesforSaleofCommonStockMember" xlink:to="JUNS_ReceivablesforSaleofCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ReceivablesforSaleofCommonStockMember_doc" xml:lang="en-US">Receivables for Sale of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StatementOfIncomeLocationBalanceAxis" xlink:label="JUNS_StatementOfIncomeLocationBalanceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StatementOfIncomeLocationBalanceAxis" xlink:to="JUNS_StatementOfIncomeLocationBalanceAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StatementOfIncomeLocationBalanceAxis_doc" xml:lang="en-US">Statement Of Income Location Balance [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" xlink:to="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest_doc" xml:lang="en-US">Issuance of common stock for payment of interest value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" xlink:to="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares_doc" xml:lang="en-US">Issuance of common stock for payment of interest, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StandbyEquityPurchaseAgreementMember" xlink:to="JUNS_StandbyEquityPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StandbyEquityPurchaseAgreementMember_doc" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_YAIIPNLtdMember" xlink:to="JUNS_YAIIPNLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_YAIIPNLtdMember_doc" xml:lang="en-US">YA II PN, Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" xlink:to="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_doc" xml:lang="en-US">Original issue discount percentage.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GeneralAndAdministrativeExpensesMember" xlink:label="JUNS_GeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GeneralAndAdministrativeExpensesMember" xlink:to="JUNS_GeneralAndAdministrativeExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GeneralAndAdministrativeExpensesMember_doc" xml:lang="en-US">General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EmbeddedConversionAndSettlementFeatures" xlink:label="JUNS_EmbeddedConversionAndSettlementFeatures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_EmbeddedConversionAndSettlementFeatures" xlink:to="JUNS_EmbeddedConversionAndSettlementFeatures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_EmbeddedConversionAndSettlementFeatures_doc" xml:lang="en-US">Embedded conversion and settlement features.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PaymentPremiumFeature" xlink:label="JUNS_PaymentPremiumFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PaymentPremiumFeature" xlink:to="JUNS_PaymentPremiumFeature_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PaymentPremiumFeature_doc" xml:lang="en-US">Payment premium feature.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementRelatedDerivative" xlink:label="JUNS_StandbyEquityPurchaseAgreementRelatedDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StandbyEquityPurchaseAgreementRelatedDerivative" xlink:to="JUNS_StandbyEquityPurchaseAgreementRelatedDerivative_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StandbyEquityPurchaseAgreementRelatedDerivative_doc" xml:lang="en-US">SEPA-related derivative.</link:label>
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StraightDebtComponent" xlink:label="JUNS_StraightDebtComponent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StraightDebtComponent" xlink:to="JUNS_StraightDebtComponent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StraightDebtComponent_doc" xml:lang="en-US">Straight debt component.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_BoardOfDirectorsMember" xlink:to="JUNS_BoardOfDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_BoardOfDirectorsMember_doc" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_TwoConsultantsMember" xlink:to="JUNS_TwoConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_TwoConsultantsMember_doc" xml:lang="en-US">Two Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ConsultantsMember" xlink:to="JUNS_ConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_ConsultantsMember_doc" xml:lang="en-US">Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_CommitmentShares" xlink:to="JUNS_CommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_CommitmentShares_doc" xml:lang="en-US">Commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PurchaseCommitmentPerShare" xlink:to="JUNS_PurchaseCommitmentPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PurchaseCommitmentPerShare_doc" xml:lang="en-US">Purchase commitment per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_WarrantHolderMember" xlink:to="JUNS_WarrantHolderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_WarrantHolderMember_doc" xml:lang="en-US">Warrant Holder [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DebtForgivenessAndExchangeAgreementMember" xlink:to="JUNS_DebtForgivenessAndExchangeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_DebtForgivenessAndExchangeAgreementMember_doc" xml:lang="en-US">Debt Forgiveness and Exchange Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PromissoryNote" xlink:to="JUNS_PromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PromissoryNote_doc" xml:lang="en-US">Promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PharmaceuticalOperationsMember" xlink:to="JUNS_PharmaceuticalOperationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PharmaceuticalOperationsMember_doc" xml:lang="en-US">Pharmaceutical Operations [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_PremiumNutritionalSupplementsMember" xlink:to="JUNS_PremiumNutritionalSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_PremiumNutritionalSupplementsMember_doc" xml:lang="en-US">Premium Nutritional Supplements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_AccruedAndOutstandingObligations" xlink:to="JUNS_AccruedAndOutstandingObligations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_AccruedAndOutstandingObligations_doc" xml:lang="en-US">Accrued and outstanding obligations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_StructuringFee" xlink:to="JUNS_StructuringFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_StructuringFee_doc" xml:lang="en-US">Structuring fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainLossDerivativeInstrumentsNetPretax" xlink:to="JUNS_GainLossDerivativeInstrumentsNetPretax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GainLossDerivativeInstrumentsNetPretax_doc" xml:lang="en-US">Gain loss derivative instruments net pretax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainsLossesOfExtinguishmentOfDebt" xlink:to="JUNS_GainsLossesOfExtinguishmentOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="JUNS_GainsLossesOfExtinguishmentOfDebt_doc" xml:lang="en-US">Gains losses of extinguishment of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainLossOnForgivenessOfAccruedCompensation" xlink:to="JUNS_GainLossOnForgivenessOfAccruedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_GainLossOnForgivenessOfAccruedCompensation_3_lbl" xml:lang="en-US">GainLossOnForgivenessOfAccruedCompensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_DecreaseIncreaseInPrepaidContracts" xlink:to="JUNS_DecreaseIncreaseInPrepaidContracts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_DecreaseIncreaseInPrepaidContracts_3_lbl" xml:lang="en-US">DecreaseIncreaseInPrepaidContracts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_3_lbl" xml:lang="en-US">IncreaseDecreaseInOperatingLeaseRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_GainsLossesOfExtinguishmentOfDebt" xlink:to="JUNS_GainsLossesOfExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_GainsLossesOfExtinguishmentOfDebt_3_lbl" xml:lang="en-US">GainsLossesOfExtinguishmentOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_2_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" xlink:to="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization_3_lbl" xml:lang="en-US">OperatingLeaseRightOfUseAssetAccumulatedAmortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JUNS_ReductionOfOperatingLeaseLiability" xlink:to="JUNS_ReductionOfOperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="JUNS_ReductionOfOperatingLeaseLiability_3_lbl" xml:lang="en-US">ReductionOfOperatingLeaseLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" xlink:to="us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_2_lbl" xml:lang="en-US">Assets Designated to Closed Block, Fixed Maturity, Available-for-Sale, at Fair Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>juns-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#Cover" roleURI="http://jupiterneurosciences.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#BalanceSheets" roleURI="http://jupiterneurosciences.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://jupiterneurosciences.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfOperations" roleURI="http://jupiterneurosciences.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfChangesInStockholdersEquityDeficit" roleURI="http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StatementsOfCashFlows" roleURI="http://jupiterneurosciences.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPolicies" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#RelatedPartyTransactions" roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiability" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficit" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxes" roleURI="http://jupiterneurosciences.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingencies" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReport" roleURI="http://jupiterneurosciences.com/role/SegmentReport" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SubsequentEvents" roleURI="http://jupiterneurosciences.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiabilityTables" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficitTables" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxesTables" roleURI="http://jupiterneurosciences.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReportTables" roleURI="http://jupiterneurosciences.com/role/SegmentReportTables" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#AccountsPayableAndAccruedExpensesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfKeyAssumptionsInValuationMeasurementDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfFairValueDerivativeLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfDerivativeLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfEmployeeStockOptionsOutstandingDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#StockholdersEquityDeficitDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfIncomeTaxProvisionDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfDeferredTaxAssetsDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#ScheduleOfSegmentReportingInformationDetails" roleURI="http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SegmentReportDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="juns-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainOnExtinguishmentOfDebt" xlink:label="loc_JUNSGainOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_JUNSGainOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ReceivablesforSaleofCommonStockMember" xlink:label="loc_JUNSReceivablesforSaleofCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_JUNSReceivablesforSaleofCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" xlink:label="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" xlink:label="loc_JUNSStockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" xlink:label="loc_JUNSStockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueStockSplits" xlink:label="loc_JUNSStockIssuedDuringPeriodValueStockSplits" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="loc_JUNSStockIssuedDuringPeriodValueWarrantExercises" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesWarrantExercises" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" xlink:label="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodValueCommitmentShares" xlink:label="loc_JUNSStockIssuedDuringPeriodValueCommitmentShares" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodValueCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesCommitmentShares" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesCommitmentShares" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnForgivenessOfAccruedCompensation" xlink:label="loc_JUNSGainLossOnForgivenessOfAccruedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_JUNSGainLossOnForgivenessOfAccruedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossOnAmortizationOfPrepaidContracts" xlink:label="loc_JUNSGainLossOnAmortizationOfPrepaidContracts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_JUNSGainLossOnAmortizationOfPrepaidContracts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NoncashFinancingCost" xlink:label="loc_JUNSNoncashFinancingCost" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_JUNSNoncashFinancingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DecreaseIncreaseInPrepaidContracts" xlink:label="loc_JUNSDecreaseIncreaseInPrepaidContracts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_JUNSDecreaseIncreaseInPrepaidContracts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_JUNSIncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_JUNSIncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CashPaidForInterest" xlink:label="loc_JUNSCashPaidForInterest" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_JUNSCashPaidForInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RestrictedStockIssuedForForgivenessOfSalary" xlink:label="loc_JUNSRestrictedStockIssuedForForgivenessOfSalary" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_JUNSRestrictedStockIssuedForForgivenessOfSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockOptionsIssuedForForgivenessOfSalary" xlink:label="loc_JUNSStockOptionsIssuedForForgivenessOfSalary" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_JUNSStockOptionsIssuedForForgivenessOfSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NotesPayableRelatedPartyAssignToNotePayable" xlink:label="loc_JUNSNotesPayableRelatedPartyAssignToNotePayable" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_JUNSNotesPayableRelatedPartyAssignToNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes" xlink:label="loc_JUNSStockIssuedInConnectionWithConvertiblePromissoryNotes" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_JUNSStockIssuedInConnectionWithConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedInConnectionInterestPayment" xlink:label="loc_JUNSStockIssuedInConnectionInterestPayment" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_JUNSStockIssuedInConnectionInterestPayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_Rule10b51ArrModifiedFlag" xlink:label="loc_JUNSRule10b51ArrModifiedFlag" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_JUNSRule10b51ArrModifiedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NonRule10b51ArrModifiedFlag" xlink:label="loc_JUNSNonRule10b51ArrModifiedFlag" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_JUNSNonRule10b51ArrModifiedFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="999014 - Disclosure - Organization and Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPolicies" xlink:title="999015 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/RelatedPartyTransactions" xlink:title="999016 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses" xlink:title="999017 - Disclosure - Accounts Payable and Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability" xlink:title="999018 - Disclosure - Convertible Debt and Derivative Liability">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficit" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxes" xlink:title="999020 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingencies" xlink:title="999021 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReport" xlink:title="999022 - Disclosure - Segment Report">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SubsequentEvents" xlink:title="999023 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999024 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PrepaidContractsPolicyTextBlock" xlink:label="loc_JUNSPrepaidContractsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_JUNSPrepaidContractsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" xlink:label="loc_JUNSOtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_JUNSOtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ClinicalTrialExpensesPolicyTextBlock" xlink:label="loc_JUNSClinicalTrialExpensesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_JUNSClinicalTrialExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" xlink:label="loc_JUNSConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_JUNSConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="999025 - Disclosure - Accounts Payable and Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables" xlink:title="999026 - Disclosure - Convertible Debt and Derivative Liability (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables" xlink:title="999027 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:label="loc_JUNSScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_JUNSScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxesTables" xlink:title="999028 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables" xlink:title="999029 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_JUNSScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_JUNSScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReportTables" xlink:title="999030 - Disclosure - Segment Report (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="999031 - Disclosure - Organization and Description of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_FifteenForFourForwardStockSplitMember" xlink:label="loc_JUNSFifteenForFourForwardStockSplitMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_JUNSFifteenForFourForwardStockSplitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementMember" xlink:label="loc_JUNSStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_MinimumClosingBidPrice" xlink:label="loc_JUNSMinimumClosingBidPrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_JUNSMinimumClosingBidPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:label="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="loc_JUNSDerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_JUNSDerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999033 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_NoteIIHolderMember" xlink:label="loc_JUNSNoteIIHolderMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSNoteIIHolderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_InterestPayable" xlink:label="loc_JUNSInterestPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_JUNSInterestPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="999034 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative" xlink:title="999035 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccountsPayableAndAccruedExpensesAbstract" xlink:label="loc_JUNSAccountsPayableAndAccruedExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccountsPayableAndAccruedExpensesTable" xlink:label="loc_JUNSAccountsPayableAndAccruedExpensesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_JUNSAccountsPayableAndAccruedExpensesAbstract" xlink:to="loc_JUNSAccountsPayableAndAccruedExpensesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_JUNSAccountsPayableAndAccruedExpensesTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_JUNSAccountsPayableAndAccruedExpensesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_JUNSAccountsPayableAndAccruedExpensesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EmploymentAgreementsMember" xlink:label="loc_JUNSEmploymentAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSEmploymentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConserveCashPercentage" xlink:label="loc_JUNSConserveCashPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_JUNSConserveCashPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails" xlink:title="999036 - Disclosure - Schedule of Key Assumptions in Valuation Measurement (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaapValuationTechniqueAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapValuationTechniqueAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaapValuationTechniqueDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapValuationTechniqueAxis" xlink:to="loc_us-gaapValuationTechniqueDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MonteCarloModelMember" xlink:label="loc_us-gaapMonteCarloModelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapValuationTechniqueDomain" xlink:to="loc_us-gaapMonteCarloModelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails" xlink:title="999037 - Disclosure - Schedule of Fair Value Derivative Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails" xlink:title="999038 - Disclosure - Schedule of Derivative Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:label="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:label="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldToMaturityAllowanceForCreditLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeFairValueOfIssuance" xlink:label="loc_JUNSDerivativeFairValueOfIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSDerivativeFairValueOfIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RepaymentOfDerivativeLiability" xlink:label="loc_JUNSRepaymentOfDerivativeLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSRepaymentOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainLossDerivativeInstrumentsNetPretax" xlink:label="loc_JUNSGainLossDerivativeInstrumentsNetPretax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSGainLossDerivativeInstrumentsNetPretax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainsLossesOfExtinguishmentOfDebt" xlink:label="loc_JUNSGainsLossesOfExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems" xlink:to="loc_JUNSGainsLossesOfExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative" xlink:title="999039 - Disclosure - Convertible Debt and Derivative Liability (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementMember" xlink:label="loc_JUNSStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SecuritiesPurchaseAgreementMember" xlink:label="loc_JUNSSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_YAIIPNLtdMember" xlink:label="loc_JUNSYAIIPNLtdMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSYAIIPNLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TwelveConvertiblePromissoryNotesMember" xlink:label="loc_JUNSTwelveConvertiblePromissoryNotesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSTwelveConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleDebtOneMember" xlink:label="loc_JUNSConvertibleDebtOneMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSConvertibleDebtOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SeniorSecuredNoteConvertibleDebtTwoMember" xlink:label="loc_JUNSSeniorSecuredNoteConvertibleDebtTwoMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSSeniorSecuredNoteConvertibleDebtTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SeniorSecuredNoteMember" xlink:label="loc_JUNSSeniorSecuredNoteMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSSeniorSecuredNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertiblePromissoryNoteMember" xlink:label="loc_JUNSConvertiblePromissoryNoteMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_JUNSConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" xlink:label="loc_JUNSDebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSDebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StructuringFee" xlink:label="loc_JUNSStructuringFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSStructuringFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CommitmentShares" xlink:label="loc_JUNSCommitmentShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaapNotesPayableFairValueDisclosure" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayableFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OriginalIssueDiscounts" xlink:label="loc_JUNSOriginalIssueDiscounts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSOriginalIssueDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent" xlink:label="loc_us-gaapOtherNotesPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OfferingPricePercentage" xlink:label="loc_JUNSOfferingPricePercentage" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSOfferingPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OriginationOfLoanToPurchaseCommonStock" xlink:label="loc_us-gaapOriginationOfLoanToPurchaseCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOriginationOfLoanToPurchaseCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaapSeniorNotes" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSeniorNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConvertibleAmountIntoSharesOfCommonStock" xlink:label="loc_JUNSConvertibleAmountIntoSharesOfCommonStock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSConvertibleAmountIntoSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:label="loc_JUNSDerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSDerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_GainsOnExtinguishmentOfDebt" xlink:label="loc_JUNSGainsOnExtinguishmentOfDebt" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSGainsOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DerivativeGainLossOnDerivative" xlink:label="loc_JUNSDerivativeGainLossOnDerivative" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_JUNSDerivativeGainLossOnDerivative" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999040 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_JUNSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_JUNSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_JUNSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_JUNSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails" xlink:title="999041 - Disclosure - Schedule of Employee Stock Options Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeOneMember" xlink:label="loc_JUNSRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeTwoMember" xlink:label="loc_JUNSRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeThreeMember" xlink:label="loc_JUNSRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeFourMember" xlink:label="loc_JUNSRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeFiveMember" xlink:label="loc_JUNSRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeSixMember" xlink:label="loc_JUNSRangeSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeSevenMember" xlink:label="loc_JUNSRangeSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RangeEightMember" xlink:label="loc_JUNSRangeEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_JUNSRangeEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:label="loc_JUNSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_JUNSShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999042 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare" xlink:label="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="999043 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityOneMember" xlink:label="loc_JUNSEntityOneMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityTwoMember" xlink:label="loc_JUNSEntityTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityThreeMember" xlink:label="loc_JUNSEntityThreeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_UnderwritingAgreementMember" xlink:label="loc_JUNSUnderwritingAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultantMember" xlink:label="loc_JUNSConsultantMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_BoardOfDirectorsMember" xlink:label="loc_JUNSBoardOfDirectorsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TwoConsultantsMember" xlink:label="loc_JUNSTwoConsultantsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSTwoConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultantsMember" xlink:label="loc_JUNSConsultantsMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_WarrantHolderMember" xlink:label="loc_JUNSWarrantHolderMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_JUNSWarrantHolderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_CommitmentShares" xlink:label="loc_JUNSCommitmentShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSCommitmentShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaapPurchaseCommitmentRemainingMinimumAmountCommitted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PurchaseCommitmentPerShare" xlink:label="loc_JUNSPurchaseCommitmentPerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSPurchaseCommitmentPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_JUNSStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_JUNSStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="999044 - Disclosure - Schedule of Income Tax Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999045 - Disclosure - Schedule of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DeferredTaxAssetsDerivativeLiability" xlink:label="loc_JUNSDeferredTaxAssetsDerivativeLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_JUNSDeferredTaxAssetsDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative" xlink:title="999046 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails" xlink:title="999047 - Disclosure - Schedule of Operating Lease Right-of-use Asset and Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="loc_JUNSOperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_JUNSOperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_JUNSOperatingLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_JUNSOperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseLiabilityGross" xlink:label="loc_JUNSOperatingLeaseLiabilityGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_JUNSOperatingLeaseLiabilityGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ReductionOfOperatingLeaseLiability" xlink:label="loc_JUNSReductionOfOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_JUNSReductionOfOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails" xlink:title="999048 - Disclosure - Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999049 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapProductLiabilityContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapProductLiabilityContingencyLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceAgreementsMember" xlink:label="loc_us-gaapServiceAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapServiceAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ConsultingAgreementsMember" xlink:label="loc_JUNSConsultingAgreementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSConsultingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DominantTreasureAgreementMember" xlink:label="loc_JUNSDominantTreasureAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSDominantTreasureAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_ExecutiveEmploymentAgreementsMember" xlink:label="loc_JUNSExecutiveEmploymentAgreementsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSExecutiveEmploymentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseAgreementsMember" xlink:label="loc_JUNSLicenseAgreementsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSLicenseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicensingAndRoyaltyAgreementsMember" xlink:label="loc_JUNSLicensingAndRoyaltyAgreementsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSLicensingAndRoyaltyAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_DebtForgivenessAndExchangeAgreementMember" xlink:label="loc_JUNSDebtForgivenessAndExchangeAgreementMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSDebtForgivenessAndExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseAgreementsTwoMember" xlink:label="loc_JUNSLicenseAgreementsTwoMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSLicenseAgreementsTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_TiberendStrategicAdvisorsMember" xlink:label="loc_JUNSTiberendStrategicAdvisorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_JUNSTiberendStrategicAdvisorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AquanovaAGMember" xlink:label="loc_JUNSAquanovaAGMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSAquanovaAGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_MurdochChildrensResearchInstituteMember" xlink:label="loc_JUNSMurdochChildrensResearchInstituteMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSMurdochChildrensResearchInstituteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_EntityThreeMember" xlink:label="loc_JUNSEntityThreeMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_JUNSEntityThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtStatementGeographicalAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_JP" xlink:label="loc_countryJP" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryJP" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseYearlyEscalationPercentage" xlink:label="loc_JUNSOperatingLeaseYearlyEscalationPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSOperatingLeaseYearlyEscalationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_OperatingLeaseIncremetalBorrowingRate" xlink:label="loc_JUNSOperatingLeaseIncremetalBorrowingRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSOperatingLeaseIncremetalBorrowingRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RentalExpenses" xlink:label="loc_JUNSRentalExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSRentalExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AgreementTerm" xlink:label="loc_JUNSAgreementTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToSuppliers" xlink:label="loc_us-gaapPaymentsToSuppliers" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPaymentsToSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ManagementAndServiceFeesRate" xlink:label="loc_us-gaapManagementAndServiceFeesRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapManagementAndServiceFeesRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_RoyaltyPercentage" xlink:label="loc_JUNSRoyaltyPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PrepaidContractExpenses" xlink:label="loc_JUNSPrepaidContractExpenses" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSPrepaidContractExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDescription" xlink:label="loc_us-gaapRestructuringAndRelatedActivitiesDescription" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapRestructuringAndRelatedActivitiesDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_LicenseFee" xlink:label="loc_JUNSLicenseFee" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccruedLicenseFees" xlink:label="loc_JUNSAccruedLicenseFees" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSAccruedLicenseFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_AccruedAndOutstandingObligations" xlink:label="loc_JUNSAccruedAndOutstandingObligations" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSAccruedAndOutstandingObligations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PromissoryNote" xlink:label="loc_JUNSPromissoryNote" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_JUNSPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails" xlink:title="999050 - Disclosure - Schedule of Segment Reporting Information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PharmaceuticalOperationsMember" xlink:label="loc_JUNSPharmaceuticalOperationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_JUNSPharmaceuticalOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_PremiumNutritionalSupplementsMember" xlink:label="loc_JUNSPremiumNutritionalSupplementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_JUNSPremiumNutritionalSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateAndOtherMember" xlink:label="loc_us-gaapCorporateAndOtherMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateAndOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ReportableGeographicalComponentsMember" xlink:label="loc_srtReportableGeographicalComponentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_srtReportableGeographicalComponentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaapCorporateNonSegmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapCorporateNonSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_SegmentNetLoss" xlink:label="loc_JUNSSegmentNetLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_JUNSSegmentNetLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative" xlink:title="999051 - Disclosure - Segment Report (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative" xlink:title="999052 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="juns-20251231.xsd#JUNS_StandbyEquityPurchaseAgreementMember" xlink:label="loc_JUNSStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_JUNSStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" xlink:label="loc_us-gaapAssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:label="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">JUPITER NEUROSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001679628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4828381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1001 North US HWY 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">406-6154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JUNS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,281,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">677<span></span>
</td>
<td class="text">5036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Cherry Bekaert LLP<span></span>
</td>
<td class="text">ASSURANCE
DIMENSIONS, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tampa, Florida<span></span>
</td>
<td class="text">Coral Springs, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 3,789,342<span></span>
</td>
<td class="nump">$ 3,769,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Account receivable</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid contracts</a></td>
<td class="nump">766,667<span></span>
</td>
<td class="nump">766,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">159,790<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">106,542<span></span>
</td>
<td class="nump">114,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,824,978<span></span>
</td>
<td class="nump">4,650,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset, net</a></td>
<td class="nump">23,214<span></span>
</td>
<td class="nump">69,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid contracts, noncurrent</a></td>
<td class="nump">712,055<span></span>
</td>
<td class="nump">1,478,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="nump">3,783<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,564,030<span></span>
</td>
<td class="nump">6,202,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">638,646<span></span>
</td>
<td class="nump">396,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,397,357<span></span>
</td>
<td class="nump">1,415,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">39,829<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">735<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">21,247<span></span>
</td>
<td class="nump">50,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, fair value</a></td>
<td class="nump">5,298,068<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,395,882<span></span>
</td>
<td class="nump">2,009,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,395,882<span></span>
</td>
<td class="nump">2,030,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively</a></td>
<td class="nump">3,444<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">32,831,730<span></span>
</td>
<td class="nump">30,190,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(34,667,026)<span></span>
</td>
<td class="num">(26,022,129)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(1,831,852)<span></span>
</td>
<td class="nump">4,172,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">5,564,030<span></span>
</td>
<td class="nump">6,202,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 146,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Series A preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Series A preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Series A preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, share issued</a></td>
<td class="nump">34,446,455<span></span>
</td>
<td class="nump">33,103,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, share outstanding</a></td>
<td class="nump">34,446,455<span></span>
</td>
<td class="nump">33,103,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product Revenues, net</a></td>
<td class="nump">$ 21,796<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,231<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">17,565<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,086,574<span></span>
</td>
<td class="nump">492,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,839,712<span></span>
</td>
<td class="nump">2,598,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,926,286<span></span>
</td>
<td class="nump">3,091,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(8,908,721)<span></span>
</td>
<td class="num">(3,091,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Loss on change in fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(53,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on change in fair value of convertible notes</a></td>
<td class="nump">281,932<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(66,020)<span></span>
</td>
<td class="num">(248,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_GainOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">857,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">47,912<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="nump">263,824<span></span>
</td>
<td class="nump">651,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (8,644,897)<span></span>
</td>
<td class="num">$ (2,439,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">34,628,588<span></span>
</td>
<td class="nump">28,783,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">34,628,588<span></span>
</td>
<td class="nump">28,783,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_GainOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_GainOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Receivables for Sale of Common Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 2,652<span></span>
</td>
<td class="nump">$ 17,778,498<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (23,582,504)<span></span>
</td>
<td class="num">$ (5,801,354)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">26,526,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,840,908<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,840,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary', window );">Issuance of restricted stock units for forgiveness of accrued salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary', window );">Issuance of stock options for forgiveness of accrued salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock issued for consulting agreements</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock issued for consulting agreement, shares</a></td>
<td class="nump">3,487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">149,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, shares</a></td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued in connection with automatic conversion of convertible notes</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">636,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued in connection with automatic conversion of convertible notes, shares</a></td>
<td class="nump">227,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts', window );">Stock sold in offering, net of offering costs</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">9,724,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,725,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares', window );">Stock sold in offering, net of offering costs, shares</a></td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodValueStockSplits', window );">Reconciling shares due to forward stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Reconciling shares due to forward stock split, shares</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,439,625)<span></span>
</td>
<td class="num">(2,439,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services rendered, shares</a></td>
<td class="nump">103,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 3,310<span></span>
</td>
<td class="nump">30,190,827<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,022,129)<span></span>
</td>
<td class="nump">4,172,008<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">33,103,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,139,908<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,139,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,644,897)<span></span>
</td>
<td class="num">(8,644,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services rendered</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">65,990<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodValueWarrantExercises', window );">Shares issued for warrant exercises</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodSharesWarrantExercises', window );">Shares issued for warrant exercises, shares</a></td>
<td class="nump">943,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Shares issued in connection with warrant amendments</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">212,593<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">212,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares issued in connection with warrant amendments, shares</a></td>
<td class="nump">143,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest', window );">Issuance of common stock for payment of interest</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">22,519<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares', window );">Issuance of common stock for payment of interest, shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodValueCommitmentShares', window );">Commitment shares issued in connection with SEPA</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">199,987<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodSharesCommitmentShares', window );">Commitment shares issued in connection with SEPA, shares</a></td>
<td class="nump">131,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="nump">$ 32,831,730<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (34,667,026)<span></span>
</td>
<td class="num">$ (1,831,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2025</a></td>
<td class="nump">34,446,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodSharesCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodSharesCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for payment of interest, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock sold in offering, net of offering costs, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodValueCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodValueCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for payment of interest value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of restricted stock units for forgiveness of accrued salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value of issuance of stock options for forgiveness of accrued salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock sold in offering, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodValueStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodValueStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,644,897)<span></span>
</td>
<td class="num">$ (2,439,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Loss on change in fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">53,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on change in fair value of convertible notes</a></td>
<td class="num">(281,932)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discounts</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss (Gain) on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(857,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_GainLossOnForgivenessOfAccruedCompensation', window );">Gain on forgiveness of accrued compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_GainLossOnAmortizationOfPrepaidContracts', window );">Amortization of prepaid contracts</a></td>
<td class="nump">766,666<span></span>
</td>
<td class="nump">54,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_NoncashFinancingCost', window );">Non-cash financing cost</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest expense paid through sale of common stock</a></td>
<td class="nump">22,521<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,418,516<span></span>
</td>
<td class="nump">1,840,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(2,637)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DecreaseIncreaseInPrepaidContracts', window );">Decrease (increase) in prepaid contracts</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Increase in prepaid and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(113,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(159,790)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Increase in other current assets</a></td>
<td class="nump">7,544<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="num">(3,654)<span></span>
</td>
<td class="num">(1,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase in deferred revenue</a></td>
<td class="nump">735<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued expenses</a></td>
<td class="nump">242,163<span></span>
</td>
<td class="num">(149,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Decrease in accrued compensation</a></td>
<td class="num">(17,736)<span></span>
</td>
<td class="num">(46,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Increase in accrued interest</a></td>
<td class="nump">38,765<span></span>
</td>
<td class="nump">46,368<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,413,736)<span></span>
</td>
<td class="num">(3,911,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable, related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">138,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment on convertible note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from issuance convertible note payable, net</a></td>
<td class="nump">5,580,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from offering, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,725,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,433,568<span></span>
</td>
<td class="nump">7,652,036<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Change in Cash</a></td>
<td class="nump">19,832<span></span>
</td>
<td class="nump">3,741,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of period</a></td>
<td class="nump">3,769,510<span></span>
</td>
<td class="nump">28,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of period</a></td>
<td class="nump">3,789,342<span></span>
</td>
<td class="nump">3,769,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_CashPaidForInterest', window );">Cash paid for interest</a></td>
<td class="nump">38,426<span></span>
</td>
<td class="nump">147,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Schedule of Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_RestrictedStockIssuedForForgivenessOfSalary', window );">Restricted stock issued for forgiveness of salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockOptionsIssuedForForgivenessOfSalary', window );">Stock options issued for forgiveness of salary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_NotesPayableRelatedPartyAssignToNotePayable', window );">Notes payable, related party assign to Note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">266,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes', window );">Stock issued in connection with convertible promissory notes</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">636,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedInConnectionInterestPayment', window );">Stock issued in connection interest payment</a></td>
<td class="nump">22,521<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment on notes payable</a></td>
<td class="num">(146,432)<span></span>
</td>
<td class="num">(108,880)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment on notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,102,797)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_CashPaidForInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_CashPaidForInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_DecreaseIncreaseInPrepaidContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease (increase) in prepaid contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_DecreaseIncreaseInPrepaidContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_GainLossOnAmortizationOfPrepaidContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on amortization of prepaid contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_GainLossOnAmortizationOfPrepaidContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_GainLossOnForgivenessOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on forgiveness of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_GainLossOnForgivenessOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>(Decrease) increase in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_NoncashFinancingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_NoncashFinancingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_NotesPayableRelatedPartyAssignToNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes payable, related party assign to note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_NotesPayableRelatedPartyAssignToNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_RestrictedStockIssuedForForgivenessOfSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock issued for forgiveness of salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_RestrictedStockIssuedForForgivenessOfSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedInConnectionInterestPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued in connection interest payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedInConnectionInterestPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockOptionsIssuedForForgivenessOfSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option issued for forgiveness of salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockOptionsIssuedForForgivenessOfSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (8,644,897)<span></span>
</td>
<td class="num">$ (2,439,625)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_Rule10b51ArrModifiedFlag', window );">Rule 10b5-1 Arrangement Modified [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_NonRule10b51ArrModifiedFlag', window );">Non-Rule 10b5-1 Arrangement Modified [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_NonRule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Rule 10b5-1 Arrangement modified [Flag]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_NonRule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_Rule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b5-1 Arrangement modified [Flag]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_Rule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><b>Cybersecurity Risk Management and Strategy</b><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">The cybersecurity risk management program,
processes and strategy described in this section are limited to the personal and business information belonging to or maintained by the
Company (collectively, &#8220;Confidential Information&#8221;), our own <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zrbfYFno3HD2">third-party</span> critical systems and services supporting or used by
the Company (collectively, &#8220;Critical Systems&#8221;), and service providers.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">We will develop and implement a cybersecurity
risk management program intended to protect the confidentiality, integrity, and availability of our Confidential Information and Critical
Systems. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_z2TWOGcqSxAe">Our cybersecurity risk management program will be <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zHurfh1n0cN9">integrated</span> into our overall enterprise risk management program and includes
a cybersecurity incident response plan.</span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cybersecurity risk management program
shall include:</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-family: Times New Roman,serif">&#160;</td>
    <td style="width: 0.25in; font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">risk assessments designed to help identify material cybersecurity risks to our Confidential Information, Critical Systems and the broader enterprise information technology environment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">cybersecurity awareness and spear-phishing resistance training of our employees, and senior management;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-family: Times New Roman,serif">&#160;</td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman,serif; text-align: justify"><span style="font-size: 10pt">a vendor management policy for service providers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250101__20251231_zqtrQTGFAkOl">We have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zOjkOTyYRyxd">no</span>t identified risks from known
cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely
to materially affect us, including our operations, business strategy, results of operations, or financial condition.</span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our cybersecurity risk management program will be <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zHurfh1n0cN9">integrated</span> into our overall enterprise risk management program and includes
a cybersecurity incident response plan.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">We have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zOjkOTyYRyxd">no</span>t identified risks from known
cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely
to materially affect us, including our operations, business strategy, results of operations, or financial condition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><b>Cybersecurity Governance</b>&#160;<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management team meets with our information
technology service provider periodically to discuss then-current cybersecurity issues, which may include efforts to prevent, detect, mitigate,
and remediate cybersecurity risks and incidents through various means, including threat intelligence and other information obtained from
governmental, public or private sources, and external service providers engaged by us; and alerts and reports produced by security tools
deployed in the information technology environment including a spear-phishing report.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zemqe6ytrWa3">Our Board considers cybersecurity risk
as part of its risk oversight function and oversight of cybersecurity and other information technology risks</span>.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board oversees management&#8217;s
implementation of our cybersecurity risk management program. Our executive management team is responsible for updating the Board, as necessary,
regarding significant cybersecurity incidents.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Board also receives periodic reports
from management on our cybersecurity risks and cybersecurity risk management program.</p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board considers cybersecurity risk
as part of its risk oversight function and oversight of cybersecurity and other information technology risks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"> executive management team, along with
our managed information technology service provider<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zkaqbdOSusRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_820_zSCgFWkrLLz7">Organization and Description of Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jupiter Neurosciences, Inc. (the
&#8220;Company&#8221;) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company
incorporated in Delaware in January 2016. The Company is advancing a therapeutic pipeline targeting central nervous system
(&#8220;CNS&#8221;) disorders and rare diseases, while also expanding into the consumer longevity market with its
Nugevia&#160;product line. Both efforts are powered by JOTROL<sup>&#8482;</sup>, the Company&#8217;s proprietary, enhanced
resveratrol formulation that has demonstrated potential for significantly improved bioavailability. The Company&#8217;s prescription
pipeline is focused broadly on CNS disorders, presently with a planned Phase IIa clinical study in Parkinson&#8217;s disease. The
Company&#8217;s Nugevia product line brings clinical-grade science to the supplement space, supporting mental clarity, skin health,
and mitochondrial function.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the State of Delaware to change
its name from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOTROL&#8482;
has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation,
without causing gastrointestinal side effects. We expect JOTROL&#8482;, based on the results of our Phase I study, will resolve the major
obstacle of resveratrol&#8217;s poor bioavailability, which has been documented in various scientific articles describing previously
conducted human trials with resveratrol as well as preclinical trial results in mice and rats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, the Company increased the number of authorized shares of common stock, $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240614_zNYxCPLhKgL9" title="Common stock par value">0.0001</span> par value per share, to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614_z2y5H3zV9Ap5" title="Common stock shares authorized">125,000,000</span> from
<span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220125_znQ20TeeMcT4" title="Common stock shares authorized">45,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, the Company effected a <span id="xdx_90C_eus-gaap--StockholdersEquityNoteStockSplit_c20240614__20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_znjBukBJeCS" title="Stock split">fifteen-for-four</span> (15:4) forward stock split whereby the Company (i) increased the number of issued
and outstanding shares of common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zH9H0etQnlqe" title="Common stock par value">0.0001</span> par value per share, from <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240613__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zloG6gOnJ9O" title="Common stock shares authorized">8,033,706</span> to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zRRuBduY2sg" title="Common stock shares authorized">30,126,413</span> and (ii) increased by a ratio of fifteen-for-four
(15:4) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the forward stock split
were made to the Company&#8217;s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the forward stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 19, 2025, the Company increased the number of authorized shares of common stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251219_zrkepVSD6p4b" title="Common stock par value">0.0001</span> par value per share, to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251219_zahwbiG0QpJ1" title="Common stock shares authorized">500,000,000</span>
from <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614_zCxDixqZ9Dg1" title="Common stock shares authorized">125,000,000</span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial
Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, the Company&#8217;s sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241201__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHzAi6Tl2CX3" title="Sale of shares of common stock">2,750,000</span> shares of Common Stock at a price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7qFBpTjcv17" title="Stock price per share">4.00</span> per share for gross proceeds of $11 million
before underwriting discounts and other related expenses in a registered initial public offering (the &#8220;IPO&#8221;). Net proceeds,
after deducting underwriting discounts, commissions, and offering-related expenses, were approximately $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pp0d_c20241201__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzEuhHsyTJu5" title="Underwriting discounts, commissions and offering expenses">9,725,213</span>. In connection with
the Public Offering, the Company&#8217;s Common Stock began trading on The Nasdaq Capital Market under the symbol &#8220;JUNS.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Standby Equity Purchase Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2025, the Company entered into
a standby equity Purchase Agreement, pursuant to which the Company has the right to sell to an investor up to $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20251024__20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zaauQy9MfXqc" title="Sale of stock, consideration received on transaction">20.0</span> million of its common
stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zSPxR4RPzijj" title="Common stock, par value">0.0001</span> per share, subject to certain limitations and conditions. See <i>Note 5 &#8211; Convertible Debt and Derivative
Liability </i><span style="text-decoration: underline">for further details.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasdaq
Minimum Bid Price Compliance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">On March 21, 2025, the Company received a notification letter
from Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2),
which requires listed securities to maintain a minimum closing bid price of $<span id="xdx_90C_ecustom--MinimumClosingBidPrice_iI_pid_c20250321__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zujTFSbKzJbe" title="Minimum closing bid price">1.00</span> per share for at least 30 consecutive business days.
Based on the 30 consecutive business days from February 6, 2025 through March 20, 2025, the Company&#8217;s Common Stock failed to meet
this requirement.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
the Company was provided 180 calendar days, or until September 17, 2025, to regain compliance by maintaining a minimum closing bid price
of at least $<span id="xdx_90B_ecustom--MinimumClosingBidPrice_iI_pid_c20250917_zOk7dM55NNnl" title="Minimum closing bid price">1.00</span> per share for a minimum of 10 consecutive business days. On July 9, 2025, the Company received a written notice from
the Nasdaq stating that the Company has since regained compliance with Listing Rule 5550(a)(2) because the closing bid price of the Company&#8217;s
Common Stock has been $<span id="xdx_90B_ecustom--MinimumClosingBidPrice_iI_pid_c20250709__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKoatpASfT61" title="Minimum closing bid price">1.00</span> USD per share or greater for a period of thirteen (13) days (June 18, 2025 to July 8, 2025).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2026, the Company received two written notices from the Listing Qualifications Department of Nasdaq notifying the Company
that (i) the listing of the Company&#8217;s Common Stock was not in compliance with the minimum bid price requirement as set forth under
Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the
Common Stock was less than $<span id="xdx_907_ecustom--MinimumClosingBidPrice_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAnOMgoC0367" title="Minimum closing bid price">1.00</span> per share for the previous 30 consecutive business days, and (ii) for the 30 consecutive business days
ended February 26, 2026, the Company&#8217;s market value of listed securities closed below the $<span id="xdx_90B_eus-gaap--AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbwAyRGo4zTh" title="Market value of listed securities closed">35</span> million threshold required for continued
listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until August 25, 2026, to regain compliance by
maintaining a minimum closing bid price of at least $<span id="xdx_909_ecustom--MinimumClosingBidPrice_iI_pid_c20260825_zhYcGx2xrge1" title="Minimum closing bid price">1.00</span> per share for a minimum of 10 consecutive business days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zGby4y30t9X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_820_zzJfldraoCD9">Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zwruQE1u12a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United
States of America (&#8220;U.S. GAAP&#8221;). U.S GAAP contemplates continuation of the Company as a going concern. For the year
ended December 31, 2025 and 2024, the Company had net revenues from product sales of $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20250101__20251231_zUkBEI5QnIHh" title="Net revenues">21,796</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zvrY4vFIRGwl" title="Net revenues">0</span>, respectively and incurred a net
loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20251231_zHh4As08zab4" title="Net loss">8,644,897</span> and $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zpw3Bs3ivFkj" title="Net loss">2,439,625</span>,
respectively. Net cash used in operations for the years ended December 31, 2025 and 2024 was $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20251231_z455uyRWDbBj" title="Net cash flows from operating activities">5,413,736</span>
and $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zMVVATkHhtC9" title="Net cash flows from operating activities">3,911,004</span>,
respectively. As of December 31, 2025 and 2024, the Company had an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_z78fTrKn9Aba" title="Accumulated deficit">34,667,026</span>
and $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20241231_zUaFiIEL5fib" title="Accumulated deficit">26,022,129</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative
cash flows from operations as well as our dependence on private equity and financings. The
Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However,
there is no assurance the Company will be successful. These conditions raise substantial doubt
about the Company&#8217;s ability to continue as a going concern for a period of at least twelve months from the date of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zT7GDUZkWdN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States
of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zeHMnNtEfAb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Segment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the &#8220;management approach&#8221; to identify its reportable segments in accordance with ASC 280, Segment Reporting.
The management approach requires companies to report segment financial information consistent with the information regularly reviewed
by the Chief Operating Decision Maker (&#8220;CODM&#8221;) for purposes of making operating decisions and assessing performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company&#8217;s Chief Executive
Officer serves as the CODM. The CODM evaluates financial performance and allocates resources based on the operating results of the Company&#8217;s
reportable segments. Effective October 1, 2025, the Company operates through two reportable segments: (i) its premium nutritional supplements,
and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM assesses segment performance primarily based on segment net loss (income). Selling, general and administrative expenses are directly
attributable to segments or allocated based on reasonable and consistently applied methodologies. Corporate and other expenses that are
not allocated to reportable segments consist primarily of public company costs, certain executive compensation, certain stock-based compensation,
interest income (expense), other income (expense), and income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
identification of two reportable segments reflects the manner in which the CODM reviews financial information and allocates resources.
Prior-period information has been recast to conform to the current presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_846_eus-gaap--UseOfEstimates_z71Fe3Gq1gai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues
and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other
assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
estimates during the years ended December 31, 2025 and 2024, respectively, include valuation of stock-based compensation, uncertain tax
positions, the valuation of debt instruments, and the valuation allowance on deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9uzzPpbcwEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid
investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents consist
primarily of cash on deposit with financial institutions and amounts held in high-yield savings accounts. The Company maintains its
cash balances with high-credit-quality financial institutions. At times, such balances may exceed federally insured limits provided
by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). In 2025, the Company has implemented a deposit insurance program
in the Company&#8217;s primary account, whereby funds in excess of FDIC insurance limits are insured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the cash balances not subject to insurance or that exceed the FDIC limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20251231_z2XBGEHdTW4k" title="Cash FDIC limit">250,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were
$<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20251231_zrb52hWhkjVj" title="Cash uninsured amount">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_900_eus-gaap--CashUninsuredAmount_iI_c20241231_zdi2rs3X13h" title="Cash uninsured amount">3,519,510</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zBgutkNtGN7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out (&#8220;FIFO&#8221;) method.
Inventory consists primarily of raw materials, work-in-process, and finished goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically reviews inventory quantities on hand and records reserves for excess, obsolete, or slow-moving inventory based on
its assessment of forecasted demand, product shelf life, market conditions, and other factors. Inventory reserves are recorded as a reduction
of inventory and are based on management&#8217;s estimates regarding the recoverability of inventory balances. If actual demand or market
conditions differ from those projected by management, additional inventory write-downs may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zctLCczDjsM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zL4bxtMLJEki">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recognized when
control of promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to
be entitled to in exchange for those goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines revenue recognition through
the following five-step model: (i) identification of the contract with a customer; (ii) identification of the performance obligations
in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations;
and (v) recognition of revenue when, or as, the Company satisfies a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Product Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates revenue from the sale of its
products. Product revenue is recognized when control of the product is transferred to the customer, which generally occurs upon shipment
or delivery, depending on the terms of the arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recorded net of variable consideration,
including estimates for product returns, rebates, chargebacks, discounts, and other allowances. The Company estimates variable consideration
at the time of sale based on historical experience, current market conditions, and contractual terms, and includes such estimates in the
transaction price only to the extent that it is probable that a significant reversal of revenue will not occur in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates whether it is the principal
or agent in its arrangements and records revenue on a gross or net basis accordingly. Shipping and handling activities are considered
fulfillment activities, and the related costs are recorded in cost of goods sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--PrepaidContractsPolicyTextBlock_zUjYtMyKAlug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepaid
Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
contracts generally represent service agreements which the Company would receive services over a period of time and are expensed as the
services are received. The Company&#8217;s prepaid contracts are related to service agreements that span over three years, therefore
the expense will be recognized over the three year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_zm1fAWpp2DAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepaid
Expenses and Other Current Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets generally represent payments made for goods or services to be received within one year and are expensed
as the related benefit is received.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOo5FZckfc4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the years ended December 31, 2025 and 2024 were $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20251231_z4bv9rhUXN2f" title="Research and development costs">2,086,574</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zPLzHX7co2N8" title="Research and development costs">492,660</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zYzetmBaJwui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of December 31, 2025 and
2024, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had no material
amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company is subject
to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not currently
under examination by any tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zv4AC6zD9c9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
Per Share of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock, as calculated using the treasury method. In computing the basic and
diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations
due to the fact that when a net loss exists, dilutive shares are not included in the calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there were <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zK558zCe6Ttk" title="Warrants Outstanding">no</span> warrants outstanding, <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z7iZQKQBF9wi" title="Restricted stock units">1,626,037</span> restricted stock units and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg6EHqelJngb" title="Number of stock options">11,726,093</span> stock options. These securities
are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZ4WJ1KhMMmb" title="Warrants Outstanding">1,359,375</span> warrants outstanding, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzqvaEojyWX" title="Restricted stock units">1,626,037</span> restricted stock units and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfitikcTDajk" title="Number of stock options">10,633,988</span> stock options. These
securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlwYPch16Jje" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records stock-based compensation equal to the grant date fair value of the stock awards issued. For stock options issued to
employees, non-employees and members of our board of directors, the Company estimates the grant-date fair value of options using the
Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with
respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the
option, risk-free interest rates, and, for grants prior to our initial public offering, the value of the common stock. For awards
subject to time-based vesting, the Company recognized stock-based compensation expense, on a straight-line basis over the requisite
service period, which is generally the vesting term of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--ClinicalTrialExpensesPolicyTextBlock_zP79s9OeFwDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztnATQTFkhUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value of Financial Instruments and Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their
short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current
interest rates available for debt with similar terms and maturities are substantially the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value of Financial Instruments and Fair Value Measurements, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
see Note 5 - Convertible Debt and <span id="xdx_908_ecustom--DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_zjcfYYWrQ0Ce" title="Derivative liabilities current not disclosed flag">Derivative Liability</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_zdrcpHOOBB16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative
Instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 815, Derivatives and Hedging (&#8220;ASC Topic 815&#8221;), establishes accounting and reporting standards for derivative instruments
and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or
losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt,
the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any
discounts and records a net gain or loss on debt extinguishment. On January 1, 2020, the Company adopted ASU 2017-11 under which down-round
Features in Financial Instruments will no longer cause derivative treatment. The Company applies the modified prospective method of adoption.
There were no cumulative effects on adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_zOs0iAUFwPz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Notes with Embedded Derivative Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into shares of common stock at a fixed discount to the price of the common stock at
or around the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those
contracts or any potential embedded components of those contracts qualify as derivatives. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zYwY2r4SabCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based
on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit
rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present
value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIAJishjMKl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the
periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted
accounting principles and do not believe that any new or modified principles will have a material impact on the Company&#8217;s reported
financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&#8217;s
financial management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer serves as the CODM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. ASU 2023-09 enhances income tax disclosures by
adding more granular, jurisdiction-specific information, especially for investors and analysts. The amendments in ASU 2023-09 are
effective for public business entities for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09
effective January 1, 2025 on a prospective basis. The Company plans to adopt this update during the year ended December 31, 2026.
Beyond the expanded, required disclosures, management does not believe that this will have a material impact on the Company&#8217;s
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued accounting pronouncements that are not yet effective have been deemed immaterial or nonapplicable.</span></p>

<p id="xdx_85A_z15nw5BRSDUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z20AIeyHahVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82A_z3EEY0BLU5T3">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to
the CEO as of December 31, 2024 was $<span id="xdx_904_eus-gaap--LoansPayable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zClC1YMMPeqj">146,432</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The loan was due on demand and accrues interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_znIZoz0lUyUc">3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
per year. Accrued interest relating to the loan was $<span id="xdx_907_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zGVYBwrcK944">1,064</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of December 31, 2024, and is included in accrued interest on the accompanying 2024 balance sheets. The Company fully settled the
debt in 2025 by repaying a total of $<span id="xdx_900_eus-gaap--RepaymentsOfLongTermDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zZSpWG7aIkr6">150,782</span></span>,
$<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zoEIpUJU4mI3">146,432</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
principal and $<span id="xdx_901_ecustom--InterestPayable_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zmZcu48NNGn7">4,350</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
accrued interest. The Company repaid a total of $<span id="xdx_90C_eus-gaap--RepaymentsOfLongTermDebt_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z2sjP4lcQRKc">100,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during
the year ended December 31, 2024, $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zL29YPmsObl8">83,880</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
principal and $<span id="xdx_909_ecustom--InterestPayable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zMmiuRTuemse">16,120</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2024, a former executive agreed to forgive $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlivuOi7dgY4" title="Share based compensation">100,000</span> of accrued compensation in exchange for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoAXJuehQ9b5" title="Share based compensation">49,605</span> options to purchase common
stock and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTTK7P8i3pbk" title="Restricted stock units">7,500</span> restricted stock units, The options to purchase common stock have a strike price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQQDoT0jjmo" title="Strike price">1.33</span>. The option had a grant date
fair value of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240315__20240315_znOfnj052yCd" title="Share based compensation">50,000</span>. The Company recorded a gain on the forgiveness of accrued compensation in the amount of $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMr4kMoafU92" title="Accrued compensation">40,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 29, 2024, the Company, the Holder of the Note II (See Note 5 &#8211; Convertible Debt and Derivative Liability) and the CEO entered
into an amendment in which the CEO agreed to exchange <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_z92gUHdyldH7">685,867</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares issued to the Holder in exchange for his related party
notes that accrued interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_zOOoRaUJLkf6">3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
that are due from the Company in an aggregate principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentIssuedPrincipal_c20240429__20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_z2ZCsUxB3h1b">266,667</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the Holder agreed to forfeit all rights to all additional
future shares from the Company that would of become due upon a qualified offering as well as the conversion option. Therefore, the principal
amount of the note was increased to $<span id="xdx_908_eus-gaap--ConvertibleDebt_iI_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zjSwVA8L8mq7">1,377,778</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and the exchange debt follows the requirements of Note II.
See Note 5 &#8211; Convertible Debt and Derivative liability &#8211; Senior Secured Note &#8211; Formerly known as the Convertible Debt
I for more details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zi02KV5Bsx3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_821_zLEg1k9D97eb">Accounts Payable and Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgF4I1hpM9Df" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zbvC12QToor1">Schedule
of Accounts Payable and Accrued Expenses</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20251231_zbJtFhDt9NRe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zJk7rN6r3MZ6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALz5RX_zLxVIbAUWVDa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131,130</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278,676</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maAPAALz5RX_zXMhhWaW5k5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">467,167</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,271</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_maAPAALz5RX_zwP7LvlqRHM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALz5RX_zTf5RJXeUFQk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
    cards</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,349</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,536</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALz5RX_ztQsVW3e5Dn1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accounts payable and accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">638,646</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">396,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_zONAsDpMPiM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2025 and 2024, $<span id="xdx_902_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zDkx5Hll3iH4" title="Accounts payable and accrued expenses owned"><span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zVz5vWzlra1f" title="Accounts payable and accrued expenses owned">64,105</span></span>
was due to a Company wholly owned by the Company&#8217;s Chief Financial Officer, who also is an option holder, respectively. The amount
is included in accrued compensation on the Company&#8217;s balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>Accrued
compensation of $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zYkzNTQTzn7j" title="Accrued compensation">1,397,357</span>
and $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zwg5Itr6Osf3" title="Accrued compensation">1,415,093</span>
as of December 31, 2025 and 2024, respectively, includes accrued salaries and health benefits to executives since inception and
board fees. Since inception, executive salaries have been paid in cash when the Company&#8217;s cash flow has permitted such
payment. By November 2022 the Company stopped paying salaries, although they continued to accrue, in an effort to conserve cash and
starting in the fourth quarter of 2023, the Company&#8217;s executives agreed to reduce their salaries by <span id="xdx_904_ecustom--ConserveCashPercentage_iI_dp_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zPqHfmDqeHjk">80</span>%
until an initial public offering to limit the Company&#8217;s compensation expenses. During December 2024, the Company returned to
paying salaries due to the completion of the initial public offering. See Note 3 &#8211; Related Party Transactions for details
related to forgiveness of accrued compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt and Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt and Derivative Liability</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_z55ZLjxq6GNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_82B_zE7PrBDPX4x5">Convertible Debt and Derivative Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standby
Equity Purchase Agreement and 2025 Convertible Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) and related Registration Rights Agreement
with YA II PN, Ltd. (&#8220;Yorkville&#8221;), providing the Company the right, but not the obligation, to sell up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20251024__20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_z9cwqs2naPYb" title="Sale of stock, consideration received on transaction">20.0</span>&#160;million
of common stock from time to time, subject to customary conditions, including an effective resale registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the SEPA, Yorkville agreed to provide up to $<span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn5n6_c20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__dei--LegalEntityAxis__custom--YAIIPNLtdMember_zaqq9xkLJYM" title="Pre-paid advances via convertible promissory notes">6.0</span>&#160;million of pre-paid advances via convertible promissory notes (the
&#8220;2025 Notes&#8221;). On October 27, 2025, the Company received $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0d_c20251027_z4edf7yy5ipj" title="Received debt amount">3,720,000</span>&#160;and issued a $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20251027__20251027_zGawVMCyfmeb" title="Proceeds from issuance of debt">4.0</span>&#160;million note (<span id="xdx_907_ecustom--DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_iI_pid_dp_uPure_c20251027_zHU0c3bdfAs3" title="Original issue discount percentage">7</span>% original
issue discount, &#8220;OID&#8221;). A second $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0d_c20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zXM7uEVAmKWg" title="Received debt amount">1,860,000</span>&#160;tranche was received in December 2025, upon registration effectiveness and
receipt of stockholder approval, against a $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20251027__20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z9x4DrExgXuc" title="Proceeds from issuance of debt">2.0</span>&#160;million note (<span id="xdx_90A_ecustom--DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_iI_pid_dp_uPure_c20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zN2tLY3DMp9a" title="Original issue discount percentage">7</span>% OID). The notes bear interest at&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20251027_zVexUaXwtMDk" title="Interest rate">8</span>% (increasing to&#160;<span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20251027_zoh5Gwzr8Q08" title="Default interest rate">18</span>%
upon default), mature on&#160;<span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20251027__20251027_zc6lgkThrb86" title="Debt instrument, maturity date">October 24, 2026</span>, and are convertible at $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20251027_zonevFYqNhBe" title="Debt instrument, convertible, conversion price">1.50</span>&#160;per share, subject to proportional anti-dilution and
price-protection adjustments (not below a contractual floor).&#160;<span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20251027__20251027_z93PKPYyuqEg" title="Repayments of debt description">Beginning January 7, 2026, and monthly thereafter, the Company must
repay one-tenth (1/10) of the then-outstanding principal plus accrued interest (a 5% premium applies to cash repayments).</span>&#160;Installments
may be satisfied via SEPA advances without the premium, and SEPA proceeds must be applied first to repay the notes until they are repaid
in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for Yorkville&#8217;s commitment to purchase common stock at the Company&#8217;s direction pursuant
the SEPA, the Company (i) paid to Yorkville a cash &#8220;structuring fee&#8221; in the amount of $<span id="xdx_900_ecustom--StructuringFee_iI_c20251023_z424tF4py8Cg">25,000</span> and (ii) upon execution of the
SEPA, issued to Yorkville <span id="xdx_90D_ecustom--CommitmentShares_iI_c20251023_zLV8fYfJyIuf">131,909</span> Commitment Shares, which have a <span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20250101__20251231_zSOPNkR1lVp8">total aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#8217;s
$20.0 million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $1.5162 per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 20, 2026, the Company and Yorkville entered into an Omnibus Amendment (the &#8220;Amendment&#8221;). Among other changes, the
Amendment revises the terms of the convertible promissory notes to defer the commencement of monthly installment payments to April 1,
2026, effectively providing an extension of approximately three months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Convertible Notes include features that allow for settlement through either (i) cash repayment or (ii) issuance of common stock at variable
or fixed conversion prices, subject to certain contractual terms, including a floor price and installment-based repayment structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Convertible Notes are classified as a Level III liability within the fair value hierarchy, as their valuation
is based on significant unobservable inputs and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the fair value option for the Convertible Notes upon issuance. As such, the Convertible Notes are measured at fair value
at inception and remeasured at each reporting date, with changes in fair value recognized in earnings. The fair value of the Convertible
Notes was determined using a Monte Carlo simulation model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
valuation approach incorporates multiple potential stock price paths over the contractual term, the Company&#8217;s ability to settle
in shares or cash, the note holder&#8217;s ability to convert at a fixed price, variable conversion features tied to market prices, and
contractual floors and share caps.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model simulates a large number of potential outcomes and calculates the expected fair value based on probability-weighted results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The convertible notes accounted for under the fair value election are each debt host financial instruments containing
embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently
remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the 2025
Notes are recorded as a component of Other (expense) income in the consolidated statements of operations, except that the change in estimated
fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income.
The instrument specific credit risk associated with the 2025 Notes was de minimis. As a result of electing the fair value method, issuance
costs related to the 2025 Notes, including the structuring fee and the commitment fee were expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zZjmGzpO4Tqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following key assumptions were used in the valuation at each measurement date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_ztawSNgjk8B8" style="display: none">Schedule of Key
Assumptions in Valuation Measurement</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Assumption</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Issuance (Oct 24, 2025)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 24, 2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 22%">Stock Price (VWAP)</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">$<span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_z6zqdjmPkC2d" title="Convertible debt instrument, measurement input">1.50</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center">$<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zz2rgLQAc6If" title="Convertible debt instrument, measurement input">1.09</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center; padding-left: 0.75pt">$<span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zEq8fow7nKKa" title="Convertible debt instrument, measurement input">0.99</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Volatility</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">~<span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zw33tuNrwNCf" title="Convertible debt instrument, measurement input">65</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">~<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zMR8jk3hI3bi" title="Convertible debt instrument, measurement input">65</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt">~<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zVPFAZN72g2k" title="Convertible debt instrument, measurement input">65</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-Free Rates</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zkBe8G0ONahf" title="Convertible debt instrument, measurement input">3.4</span>% &#8211; <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zWPF9urOxwe2" title="Convertible debt instrument, measurement input">4.5</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zIYQNgWk4G9g" title="Convertible debt instrument, measurement input">3.5</span>% &#8211; <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zgAx6149QJnk" title="Convertible debt instrument, measurement input">4.6</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zcBydmO7hgP2" title="Convertible debt instrument, measurement input">3.4</span>% &#8211; <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zkoIh03rIg2h" title="Convertible debt instrument, measurement input">4.7</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation Technique</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte Carlo Simulation</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte Carlo Simulation</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt">Monte Carlo Simulation</td></tr>
  </table>

<p id="xdx_8A3_z7uIzzqoNuE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility
was estimated using a combination of the Company&#8217;s historical volatility and that of comparable publicly traded companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At issuance, the initial
convertible promissory note was measured at a fair value of $<span id="xdx_909_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20251231_zhTXwFh1zHPc" title="Convertible promissory note fair value">3,914,515</span>. As of December 24, 2025, concurrent with the second tranche,
the fair value of the 2025 Notes was remeasured to $<span id="xdx_90D_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20241231_zj0cuRCDGFle" title="Convertible promissory note fair value">5,225,670</span>. As of December 31, 2025, the fair value of the 2025 Notes was $<span id="xdx_904_eus-gaap--NotesPayableFairValueDisclosure_iI_c20251231_z46Mkq8Lhhag" title="Notes payable fair value">5,298,068</span>.
Changes in fair value during the period were recognized in the Statements of Operations as Gain on change in fair value of convertible
notes. The original issue discounts totaling $<span id="xdx_900_ecustom--OriginalIssueDiscounts_iI_c20241231_zlNdrgN4XVKf" title="Original issue discounts">420,000</span> were incorporated into the initial and subsequent fair value measurements of the
2025 Notes. As of December 31, 2025, the outstanding principal balance on the 2025 Notes is $<span id="xdx_90C_eus-gaap--OtherNotesPayableCurrent_iI_c20251231_zbR9XVQ7FBTd" title="Outstanding principal balance">6,000,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2025, the Company recognized a net gain on change in fair value of convertible notes of $<span id="xdx_905_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250101__20251231_z9avYYW6CwA9">281,932</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2025,
the Company incurred $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231_zukm9Z5JmYEg" title="Accrued interest expense">61,723</span> of interest expense and paid $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250101__20251231_zjokPsK6xFp3" title="Sale of stock, consideration received on transaction">22,251</span> through the sale of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231_ztAZRNDl5h0g" title="Sale of stock, consideration received on transaction, shares">20,000</span> shares of common stock at an average price
of approximately $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20251231_zfqtBafAWCx5" title="Sale of stock exercise price">1.11</span> through the SEPA. As of December 31, 2025, $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20251231_z9DZVfhcEaY4" title="Accrued interest">39,829</span> is accrued in Accrued interest on the Company&#8217;s balance
sheets.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; Convertible Debt and Derivative Liability, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Debt I</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
August and December 2021, the Company issued convertible notes (collectively, &#8220;Notes I&#8221;) totaling $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zc5AToFmsBjg">527,650</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
originally maturing on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20210801__20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zfdhuziK0eW1">July
31, 2022</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, with an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_z8gCZqYa7xoe">1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
Notes I featured an automatic conversion feature upon an IPO into Common Stock at <span id="xdx_903_ecustom--OfferingPricePercentage_iI_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5vfmYrKpESd">70</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of the IPO price. Various amendments extended the maturity, ultimately to December 31, 2024, and increased the interest rate to&#160;10%.
In December 2024, following a successful IPO, the then outstanding principal and accrued interest totaling </span>$<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zB88PXUP0BJi">636,852</span>
Notes I converted into <span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220806__20220806__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zYxjLGWIAeEe">227,447</span>
shares of Common Stock at $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241204__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebtOneMember_zOLPUgFCrZlg">2.80</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> Convertible Debt II</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 11, 2022, the Company issued a senior secured convertible note (&#8220;Note II&#8221;) and&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zq8gYmcVDmE8" title="Principal amount shares">514,403</span>&#160;shares of Common Stock
for net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zyVsGAwQ5Wx" title="Common stock for net proceeds">977,333</span>&#160;($<span id="xdx_904_eus-gaap--OriginationOfLoanToPurchaseCommonStock_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zakPbx9FsH14" title="Origination costs">1,000,000</span>&#160;less origination costs and an embedded discount). Note II had an original principal
of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_z2bneYZvT3S9">1,111,111</span>. The original terms of Note II included, among other provisions, penalties and stock conversions at substantial discounts
upon default or qualified offerings. Various amendments were executed which extended principal repayment dates and increased repayment
premiums resulting in losses on debt extinguishment totaling $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zbwAXYt656m7">887,946</span>&#160;in 2023. On April 24, 2024, Note II was further modified,
removing the conversion feature, increasing principal to $1,377,778, and extending the maturity, resulting in a gain on modification
of $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240424__20240424__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zN8HHSB32Wmj" title="Gain on modification">951,868</span>&#160;and an increase to derivative liability of $<span id="xdx_90B_eus-gaap--DerivativeLiabilities_iI_c20240424__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_ztNSckt2diCf" title="Derivative liabilities">407,494</span>. Note II was fully repaid in December 2024 for $<span id="xdx_90F_eus-gaap--SeniorNotes_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteMember_zzszHWyRywvg" title="Senior notes">2,102,797</span>, which
included all outstanding principal and accrued interest</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Debt III</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2023, the Company issued a convertible note (&#8220;Note III&#8221;) with a principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zky8d8N4k0V5" title="Principal amount">150,000</span>
in connection with an investor relations settlement, maturing <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20230301__20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYctXbPjbXv9" title="Maturity date">February
28, 2026</span> and a compounding <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zuJr3fzcomMj" title="Annual percentage">5</span>%
annual interest rate. In December 2024, the then outstanding balance of Note III totaling
$<span id="xdx_90A_ecustom--ConvertibleAmountIntoSharesOfCommonStock_c20230301__20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqNQHHaqXjA2" title="Convertible amount into shares of common stock">178,386</span>
was fully repaid, which included all then outstanding principal and accrued interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, $<span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20241201__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwAr5QCMZr74" title="Repayments of convertible debt">147,705</span>,
was included in interest expense for the combined convertible Notes I, II and III on the accompanying 2024 statements of operations.
These notes were paid in full in December 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; Convertible Debt and Derivative Liability, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_905_ecustom--DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_z7MrmsBuRRql" title="Derivative liabilities not disclosed flag">Derivative
Liability</span> Pursuant to Convertible Debt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of the Notes, the Company determined that the terms of Notes contain an embedded conversion option to be
accounted for as a derivative liability due to the Holder having the potential to gain value upon IPO. Accordingly, the embedded conversion
option contained in Notes was accounted for as derivative liability and debt discount at the date of issuance and has been adjusted to
fair value through earnings at each reporting date. The fair value of the embedded conversion option was determined using the Monte Carlo
valuation model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the derivative liabilities were revalued, and a $<span id="xdx_901_ecustom--GainsOnExtinguishmentOfDebt_c20240101__20241231_zyXcAxUKzA94">857,723</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adjustment
was recorded as a gain on extinguishment of debt to other expenses reflected in the accompanying statements of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also recorded $<span id="xdx_90F_ecustom--DerivativeGainLossOnDerivative_di_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqrCzGuaMc4a">53,257</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a loss on the change in the fair value of the derivative
liability for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zxaosV9PMzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the derivative liability of Notes I, Note II and Note III was estimated using the Monte Carlo Valuation model at issuance
and each reporting period with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zJTLW9kZTMRe">Schedule
of Fair Value Derivative Liability</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzgg7OvEqJEf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTWGlRIHYyTh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPPcuzvNQns1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeCx1gVz7Dr5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityofIPOMember_zhRIXkuHMCsc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none">Derivative liability, measurement input</td>
    <td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">60</td><td style="display: none; text-align: left">%</td></tr>
</table>

<p id="xdx_8A0_z6LK6yUlME65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; Convertible Debt and Derivative Liability, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Derivative
Liability Pursuant to Convertible Debt, continued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zkpSEa8BkWqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity of the derivative liabilities and the 2025 Notes, which represent the Level III fair value measurements, is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zQ1soMR95y4i" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Derivative Liability</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zkWV7fx884c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Liability</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025 Notes</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--DerivativeLiabilities_iS_zv7mgTsyHe4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,505,398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><p style="margin: 0">-</p></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_zf0qLnzUCsmi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value change</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,257</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_z0n48GcePhLe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment
    of derivative liability - Note II</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,359,362</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--DerivativeFairValueOfIssuance_zMnjWj8rj6gk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value at issuance on April 29, 2024 - Senior Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">407,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RepaymentOfDerivativeLiability_zGA2cgMwOX7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(606,787</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">-</p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DerivativeFairValueOfIssuance_zYmBfffLxOd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-bottom: 1pt">Fair value at issuance</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right">407,494</td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zRW5qL6goF13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="margin: 0">-</p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zA96k6M7cCoh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold; padding-bottom: 2.5pt">Derivative liability Balance </td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Issuance of the 2025 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeFairValueOfIssuance_c20250101__20251231_z6c6mFrRavmj" style="width: 14%; text-align: right" title="Issuance of the 2025 Notes">5,580,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--GainLossDerivativeInstrumentsNetPretax_c20250101__20251231_z6CKR0DBCaO5" style="text-align: right" title="Fair value change">(281,932</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Balance at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_ecustom--GainsLossesOfExtinguishmentOfDebt_iE_c20250101__20251231_z4gZnyRxcYhd" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at December 31, 2025">5,298,068</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin-top: 0; margin-bottom: 0"></p>

<p id="xdx_8A7_z2mSmHACZcga" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity (Deficit)</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zQGf1aAT0CZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_821_z87whnGTb7S2">Stockholders&#8217; Equity (Deficit)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zG5x0qPt3uOi" title="Common stock, shares authorized">500,000,000</span> shares of common stock and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zAFdRhxKI5Ib" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock. The Company had <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231_z4zWjqx7lDT5" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zE0IA1GrOvmf" title="Common stock, shares outstanding">34,446,455</span></span>
shares of common stock issued and outstanding as of December 31, 2025. There was <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20251231_zcKDFJDbtu5g" title="Preferred stock, shares issued::XDX::-"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20251231_zmYqnMyN8Q8c" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0896"><span style="-sec-ix-hidden: xdx2ixbrl0898">no</span></span></span></span> preferred stock issued and outstanding as of December
31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On October 24, 2025, As consideration
for Yorkville&#8217;s commitment to purchase common stock at the Company&#8217;s direction pursuant the SEPA, the Company, upon execution
of the SEPA, issued to Yorkville <span id="xdx_90E_ecustom--CommitmentShares_iI_c20251024_zgzNgvfMm5Jk" title="Commitment shares issued">131,909</span> Commitment Shares, which have a total aggregate dollar value equal to $<span id="xdx_90E_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20251024_zUmFTyQB4YKb" title="Commitment shares issued value">200,000</span>, or 1.0% of Yorkville&#8217;s
$<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20251024__20251024_zr3Q9X4848eb" title="Purchase commitment">20.0</span> million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $<span id="xdx_905_ecustom--PurchaseCommitmentPerShare_iI_pid_c20251024_zQT5Kg6BmsTh" title="Purchase commitment per share">1.5162</span> per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).&#160;</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On April 23, 2025, the Company issued&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250423__20250423__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUQWNfaeIZmb" title="Number of shares issued for service rendered">103,186</span>&#160;shares
of common stock, with an aggregate fair value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250423__20250423__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYpXnjxYfhC6" title="Shares issued for services rendered">66,000</span>, as consideration for services rendered related to media and investor relations
activities, strategic communications support, enhancement to the Company&#8217;s market visibility and shareholder engagement. The fair
value of the shares issued was determined based on the market price of the Company&#8217;s common stock at the date of issuance and is
included general and administrative expenses in the accompanying 2024 condensed consolidated statement of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into a three 36-month service agreement with three different entities. The Company issued an
aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXqS2fU3MFMd" title="Number of restricted shares issued">3,487,500</span>
restricted shares of common stock, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityOneMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKwDyz7i2gE1" title="Number of restricted shares issued"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityTwoMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ0UOAS2b5c6" title="Number of restricted shares issued"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityThreeMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3zjAQ0G1se9" title="Number of restricted shares issued">1,162,500</span></span></span>
restricted shares of common stock to each entity. The shares were registered upon the Company&#8217;s offering that closed in
December 2024. In addition, each of the entities purchased <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zroF6PRagc89" title="Number of shares issued">37,500</span>
shares each of the Company&#8217;s common stock at a price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zejSB4UeA4F1" title="Share price">1.33</span>
per share prior to the occurrence of the Company&#8217;s offering. As of December, 31, 2024, the Company issued <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrDGspk8nJHg" title="Aggregate sale of common stock, shares">112,500</span>
common stock and the Company received an aggregate of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5Ej78PzTJ6c" title="Aggregate sale of common stock, value">150,000</span>
for the sale of the Company&#8217;s common stock from the three entities. These shares were also registered upon the closing of the
Company&#8217;s offering. The aggregate value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240603__20240603__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zay8tZNEUaMi" title="Number of restricted shares issued, value">4,638,375</span>
related to the <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9BE5tST4Vi" title="Number of restricted shares issued">3,487,500</span>
restricted shares will be recognize as compensation expense from the date the obligations are met with the remaining expense being
amortized over the remaining term of the 36-months per the services agreements. As of December 31, 2025 and 2024, the Company
recorded compensation expense for services provided of $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250101__20251231_z3xMMwWSMXy6" title="Compensation expense for services"> 1,546,117 </span>and $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231_zLwt9URRUpY4" title="Compensation expense for services">893,781</span>, respectively
related to the restricted shares issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 &#8211; Convertible Debt and Derivative Liability for shares issued upon the conversion of the convertible notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 8 &#8211;
Commitment and Contingencies &#8211; Service agreements for details related to sale of common stock per the service agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; Stockholders&#8217; Equity (Deficit), continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Closing
of Offering</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2024, the Company priced its initial public offering of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241202__20241202__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhDATFx95iSi" title="Number of shares for sale">2,750,000</span> shares of common stock at a price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20241202__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8SOxlpJOBk" title="Stock price per share">4.00</span> per share. The
offering closed on December 4, 2024, and the Company started trading on the Nasdaq Capital Market under the ticker symbol &#8220;JUNS&#8221;.
The Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znOe1LbWrKlc" title="Sale of shares of common stock">2,750,000</span> shares of its Common Stock to the underwriters and yielded proceeds of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2k3alHBdUof" title="Gross proceeds from offering">9,725,213</span>, net of underwriters and
other fees of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPRdladm3EZ6" title="Net proceeds from offering">1,274,787</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants stock awards to officers, employees, directors, and other key persons pursuant to its 2021 Equity Incentive Plan (&#8220;the
Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025 and 2024, the Company recognized stock-based compensation of $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZiDnEsUWEEg" title="Stock based compensation">2,418,516</span> and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLXhU9NG0ene" title="Stock based compensation">947,124</span>, respectively,
related to vested stock options. There was $<span id="xdx_901_eus-gaap--StockOptionPlanExpense_c20250101__20251231_zucCT5kiYDFj" title="Unvested stock options expense">697,835</span> unvested stock options expense as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2024, the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240124__20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJYonpO63oRb" title="Granted stock option purchase shares">180,000</span> stock options to a consultant with an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240124__20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zalcYpiFldR1" title="Stock option exercise price">1.33</span> per share. The option had
a grant date fair value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF9vQs8o45K1" title="Grant date fair value">190,560</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 17, 2024, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240417__20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z84ue6jJaW5f" title="Granted stock option purchase shares">67,500</span> stock options to a consultant with an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240417__20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zviUY4yWYtr9" title="Stock option exercise price">1.33</span> per share. The option had a
grant date fair value of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbqXyleDtdYk" title="Grant date fair value">73,459</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 10, 2025, the Company granted&#160;<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZy9qsNaIsi7" title="Granted stock option purchase shares">250,000</span>&#160;stock options
to a consultant with an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z03rLzrZRXP6" title="Stock option exercise price">0.97</span>&#160;per share and a grant date fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zN2ciPXaMxbf" title="Grant date fair value">191,168</span>, and a&#160;<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdYeOkL276Ye" title="Stock optons term">10</span>-year term. The&#160;<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzK0eq38uyR6" title="Shares vesting percentage">25</span>%
of the stock options vest immediately on the grant date, with the remaining&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKtDBMMR0qXk" title="Stock options vested">187,500</span>&#160;options vesting in equal monthly installments
ratably beginning in July 2025 through May 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2025, the Compensation Committee approved the grant of an
aggregate of&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zWcqWFzRU6i6" title="Stock options issued">357,448</span>&#160;stock options issued to certain executives. The stock options have an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_z27zRM49V2w2" title="Stock options exercise price">1.19</span>&#160;per
share, representing the closing price of the Company&#8217;s Common Stock on Nasdaq on the date of grant.&#160;<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250702__20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zJEBocLQPuy1" title="Vesting period description">The stock options have
a 10-year term and vest in equal installments over a three (3) year period beginning on the grant date of July 2, 2025, subject to the
officers&#8217; continued employment at the time of vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 5, 2025, the Company granted an aggregate of&#160;<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zrUmD6rqLCuf" title="Stock granted">374,755</span>&#160;stock
options to two consultants with an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zHu3IN2TmAP" title="Share price">1.23</span>&#160;per share and a grant date fair value of $<span id="xdx_908_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zAbMwqauwLnl" title="Fair value of grant date">340,900</span>.&#160;The stock options
have a 10 year term and&#160;<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zFk0JjqYmcTf" title="Stock options vest percentage">25</span>% of the stock options vest immediately on the grant date, with&#160;<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_z4GDjMOnyxhb" title="Option vested">281,066</span>&#160;options vesting in equal
monthly installments until September 5, 2027. The Company also granted&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zCKRPbMmiyuc" title="Stock option granted">109,902</span>&#160;stock options to one of the consultants with
an exercise price of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zYdAWJK9Ufx7" title="Exercise price">1.23</span>&#160;per share and a grant date fair value of $<span id="xdx_90C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zOwY6oMsIzPc" title="Fair value of grant date">100,000</span>, and a&#160;<span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z6ApslNrAQ1f" title="Vested, term">10</span>&#160;year term that vest solely upon
achievement of performance conditions as follows:&#160;<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zqNcLYW7jGy3" title="Vested performance description">(a) 15% per Ambassador (maximum of three) referred by consultant and subsequently
engaged by the Company, (b) 20% if consultant is instrumental in arranging a distribution arrangement not previously pursued by the Company,
on terms acceptable to the Company, (c) 20% when such Distribution Contract achieves $1 million in annual sales and (d) 15% when the consultant
arranges the first Celebrity Golf Tournament featuring Nugevia on terms and conditions acceptable to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 24, 2025, in connection with the SEPA and 2025 Convertible
Promissory Notes, the Company issued&#160;<span id="xdx_90F_ecustom--CommitmentShares_iI_c20251024_zNDfLoJMluVb" title="Commitment shares issued">131,909</span>&#160;commitment shares with an aggregate value of $<span id="xdx_904_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20251024_zNxQkP1GHkJf" title="Commitment shares issued value">200,000</span> to the Investor, Yorkville,
representing 1.0% of Yorkville&#8217;s $<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20251024__20251024_z4LIZuQB8RQk" title="Purchase commitment">20.0</span> million aggregate purchase commitment under the SEPA, valued at approximately $<span id="xdx_905_ecustom--PurchaseCommitmentPerShare_iI_pid_c20251024_zA9mR6R6aVul" title="Purchase commitment per share">1.5162</span> per
share, representing the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the
nearest whole share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 &#8211; Related Party Transactions above for details related to options issued for forgiveness of accrued salaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGIcZinqgHIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity for the year ended December 31, 2025 and 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_z6s3DH6Vjt58" style="display: none">Schedule of Stock Option
Activity</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Contractual Term (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zRXeh9xhB171" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of options, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,336,883</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zAukIBM7RD9a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zppaUwdvfs8i" title="Weighted average contractual term (years), outstanding">6.9</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zH7OrpvCEv7i" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,316,119</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z94ZxPCocGK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">297,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zdJVy0WjK3R9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zEty7Y8rB6V9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zrQyyt533Jfi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1026">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231_zzcFG4oHYwNf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zHaH71PxMTjk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,633,988</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zvA4b86SDtvd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_zkWFd1akaaZg" title="Weighted average contractual term (years), outstanding">6.3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zT6GrXlqqjmh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,921,147</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zx6zKK9KnB01" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,092,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_z5zfkOTmdqn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20251231_z1MkBB8ZEwCg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231_z86Tb45OlHj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250101__20251231_zn602cdUyKfl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zUFZwOun8Rwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231_zN1uQNHqhced" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,726,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zAXwfxu9PzVf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_zcgFvM8TTbh6" title="Weighted average contractual term (years), outstanding">5.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_z9pjfgVpYrej" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,772,167</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20251231_zJdfhzxO7qE9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,874,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zWYnYIKqUDv7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_z92T0zqxWbE6" title="Weighted average contractual term (years), exercisable">5.1</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231_zeFIKVBO2SH5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,765,237</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zS8GgP8525Tf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,297,412</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zEvqKuMoU601" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_z6wDBZRYZwrb" title="Weighted average contractual term (years), exercisable">6.18</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240101__20241231_ze5LAHb52fya" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99,768,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A3_zP0Gz6TLUdhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVtEFPVOCc4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarized information about employee stock options outstanding as of December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zr5t7TYd9Hvg" style="display: none">Schedule of Employee
Stock Options Outstanding</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Outstanding Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Vested Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding at December 31,</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Number Exercisable at December 31, 2025</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9lUQANknNKg" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price">0.01</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zinDiVfAqRFl" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z8FXJSD6j8Mj" title="Outstanding options, weighted average contractual term">0.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zw0U37LS9Vk8" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY9qy9o8xny5" title="Vested options, weighted average contractual term">0.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zIX9lQRSzhM5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.74</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxuUjg0j3Yj8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">1,657,560</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_znkzTAYxxTog" title="Outstanding options, weighted average contractual term">3.07</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2Ilpmuw6nc6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">1,657,560</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeQlgjxhvdOk" title="Vested options, weighted average contractual term">3.07</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zAuYWQpnOaTl" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.80</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4AmDF0JAXia" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">2,783,243</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zyixcQx7zNw9" title="Outstanding options, weighted average contractual term">3.29</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXqsfaTF4yV1" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">2,783,243</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zq1ybB4jri56" title="Vested options, weighted average contractual term">3.29</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zJaiFwLYgekh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.97</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zL3SV54Piocj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">250,000</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zP2ebCzUk369" title="Outstanding options, weighted average contractual term">9.42</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWZVbDDqB2cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">111,412</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zU6mdI1AkD81" title="Vested options, weighted average contractual term">9.42</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zot74KmHnvC8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.19</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zioSbChcwch2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">357,448</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zLtyDdRqBKo1" title="Outstanding options, weighted average contractual term">9.51</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoeu40klWFdh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zLehGVqy7CU7" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.23</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zGKnSBD394G5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">484,657</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zh8fC6psLWqd" title="Outstanding options, weighted average contractual term">9.68</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zzJuRHQAMwkg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">128,822</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zUhk8TBWNbhh" title="Vested options, weighted average contractual term">9.68</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z2BLbDR5XzAa" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.33</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zWH2r7yjm8Sc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">5,461,935</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z426LmVrFrL6" title="Outstanding options, weighted average contractual term">7.08</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z5vKDzu3cQG6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">5,461,935</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z9xUocfrltd4" title="Vested options, weighted average contractual term">7.08</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zCWfff1o9cy3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.16</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zZJ3jv16r4I9" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_ziA6nWOzWg7g" title="Outstanding options, weighted average contractual term">5.46</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zwtWFplqtor5" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zc4bj9IuSAEg" title="Vested options, weighted average contractual term">5.06</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231_zCPuvhn7yym4" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">11,726,093</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zTvaVvrr1C67" title="Outstanding options, weighted average remaining life">5.43</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231_zwJCzoNZt6Q3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">10,874,222</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zjxE8JNl1o0h" title="Vested options, weighted average remaining life">5.10</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Outstanding Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Vested Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding at December 31,</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2024</b></p></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Number Exercisable at December 31, 2024</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqTYltrcy2e" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price">0.01</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqw3dafNIj4i" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXLu86SLEExa" title="Outstanding options, weighted average contractual term">1.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIS07948AUSd" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z7EWagbSK6La" title="Vested options, weighted average contractual term">1.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAcYrs8Y3Hfi" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.74</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zCM9gIgDE8P9" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">1,657,560</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrSrDnU8V5Ra" title="Outstanding options, weighted average contractual term">4.32</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxBDMkBYO4Cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">1,657,562</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zYMES0ehNuBi" title="Vested options, weighted average contractual term">4.32</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zy2B6FbHG1n3" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.8</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zOek3sbcecfc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">2,783,243</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmhEz33Ddbad" title="Outstanding options, weighted average contractual term">4.54</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zSRCp95gzeYd" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">2,783,238</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2GAh69BQpWg" title="Vested options, weighted average contractual term">4.54</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCn9DZQlTZah" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.33</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zvvoIopKWEn2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">5,461,935</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWG4ksZui5B9" title="Outstanding options, weighted average contractual term">8.33</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zxPtzl915dFj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">5,125,362</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zY8qsfToPjp5" title="Vested options, weighted average contractual term">8.31</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zHw1l0f826xe" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.16</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zPg6UNOzYGl6" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zMSqF69o5gdf" title="Outstanding options, weighted average contractual term">6.71</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoLf6vkragPg" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zkEq1e4Jf2Tg" title="Vested options, weighted average contractual term">6.71</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231_zerA8b9MNhE8" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">10,633,988</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zOQakm3BnRX4" title="Outstanding options, weighted average remaining life">6.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_z40TkNgv43fb" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">10,297,412</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_ztNWIX9ty3ze" title="Vested options, weighted average remaining life">6.15</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_z11pWrNP2Rdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_z0pCHvqoj6pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s warrant activity for the year ended December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z5tHIdeRHBYk" style="display: none">Schedule of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNc8RiNKKA5f" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,359,375</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgijBH4VCrZ4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price per share, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjCprZX2OrMi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average remaining life (years), outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xMF0O7JPfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAfBgjnckLoj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN4XT3EFXoQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,359,375</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFlhOc9kK5Lj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUDZPLcUEEQ9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3bziOzm6Xw2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5Parh01sAAg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcCMUXTurClc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1242">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zFuTkXtT4jv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 22, 2025, the Company entered into an amendment with
a warrant holder for a warrant to purchase&#160;<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250622__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zFx8WviDoIY6" title="Warrant issued">109,376</span>&#160;shares of Common Stock. The amendment extended the warrant&#8217;s exercise
period through August 31, 2025, and clarified the exercise mechanism applicable to the warrant. The effects of the warrant modification
were de minimis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2025 the Company entered into an amendment with a warrant
holder who holds&#160;<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_ztrwTGbW5xw9" title="Warrant outstanding">1,249,999</span>&#160;warrants that clarified the exercise mechanisms. Concurrently with the amendment, the warrant holder
exercised the warrants via a cashless exercise and received&#160;<span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20250716__20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zmu2wAJsbMIk" title="Warrant exercised">913,299</span>&#160;shares of Common Stock. Pursuant to the amendment, the Company
agreed to issue the warrant holder&#160;<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zu12vCWSuwkf" title="Warrant issued">86,700</span>&#160;shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2025, the Company received an exercise notice from a
warrant holder who holds&#160;<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_z5JWD2Vil4T4" title="Warrant outstanding">109,376</span>&#160;warrants. The warrant was exercised via a cashless exercise, and the warrant holder received&#160;<span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20250812__20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_z9GQniyL2Ska" title="Warrant exercised">30,547</span>&#160;shares
of Common Stock. Pursuant to the amended warrant agreement, the Company agreed to issue the warrant holder&#160;<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zRuStVjLlfK8" title="Warrant issued">56,954</span>&#160;shares of
Common Stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; Stockholders&#8217; Equity (Deficit), continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbnIzLlSxlEb" title="Number of restricted shares issued, shares">7,500</span> restricted stock units with a grant date value of $<span id="xdx_901_eus-gaap--SharePrice_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeCEm65kbQa7" title="Share price">1.33</span> per unit in exchange for the forgiveness
of accrued compensation. The restricted stock units shall vest on the earlier event of either the expiration of the lock-up period by
the underwriters after the initial public offering or in the event of change of control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of both December 31, 2025 and December 31, 2024, the Company had an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8tXdzNlTON1" title="Number of restricted shares issued, shares"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXtLszgDoFtf" title="Number of restricted shares issued, shares">1,626,037</span></span>
restricted stock units outstanding with an aggregate fair value of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPXVVSEwPRRg" title="Restricted stock fair value"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxtITuAyDTHi" title="Restricted stock fair value">2,195,550</span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zKkXI6Ax61Dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_820_zIFy3S9284ea">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWIb6w9Br8Bj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5qxT8107y54" style="display: none">Schedule
of Income Tax Provision</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250101__20251231_zN1Ha8w5zSy7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20241231_z4FLovEWDX4g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_zI1kBVw0Jnl3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zqkq7gT8gjml" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maKL001_z69qxdumrLX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.66</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-2.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zx9GBimZ1Wkc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-39.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-20.74</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zd1Y4tCFDLC9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1286">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zf4GVfqFp4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; Income Taxes, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0oE4sZ2PzCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s deferred tax assets is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B0_zFdtRsfRho29" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231_ztuQUysEC5qh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zdn1x65jeUYi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGze87_zyqf3c82unn2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S
    Federal and State net operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,473,294</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,083,545</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGze87_zaSwqbyCuPY5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,423,288</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,272,925</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_maDTAGze87_zgaey9eS7Jg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">348,012</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">382,288</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGze87_z8SH1dvo1NV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
    drug credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,060,118</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsDerivativeLiability_iI_maDTAGze87_zP09qyBV7u4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGze87_znXhwig8fdQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,699</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260,481</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGze87_maDTANz4iX_zcWR93tE6dPa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,046,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,059,357</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz4iX_zcDqd2p7xaK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,046,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,059,357</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz4iX_z911dkGdqv9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Deferred Tax Asset</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1316">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A6_zJGf3EyY77U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2025, the Company had federal and state (post-apportioned basis) net operating losses (&#8220;NOLs&#8221;)
of $43.14 million, as well as federal orphan drug credit and research and development tax credit carryforwards of approximately $1.72
million. Approximately $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20251231_zwgbot2GWaYe" title="Operating loss carryforward">22.3</span> million of the foregoing federal and state NOLs will expire at various dates from 2036 through 2045, if not limited
by triggering events prior to such time. Under the provisions of the Internal Revenue Code, changes in ownership of the Company, in certain
circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular,
Section 382 of the Internal Revenue Code (&#8220;Section 382&#8221;) imposes limitations on an entity&#8217;s ability to use NOLs upon
certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income,
then the Company will pay more taxes than if it were otherwise able to fully utilize its NOLs. The Company may experience ownership changes
in the future as a result of subsequent shifts in ownership of the Company&#8217;s capital stock that the Company cannot predict or control
that could result in further limitations being placed on the Company&#8217;s ability to utilize its federal NOLs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance, if needed, reduces deferred tax assets to the amount
expected to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company
assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings history, expected
future earnings, carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the
likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the
extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable
income, exclusive of reversing taxable temporary differences, to outweigh objective negative evidence of recent financial reporting losses.
Based on these criteria and the relative weighting of both the positive and negative evidence available, management continues to maintain
a full valuation allowance against its net deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z952iJVkqXY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_826_zigE454ea6yd">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable
outcome in any specific period could have a material adverse effect on the Company&#8217;s results of operations for that period or future
periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 19, 2022, Tiberend Strategic Advisors (&#8220;Tiberend&#8221;), an entity that the Company had previously engaged as a communications
and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging
non-payment by the Company under a services agreement (the &#8220;Services Agreement&#8221;) with Tiberend in the amount of $<span id="xdx_907_eus-gaap--OtherLiabilities_iI_c20220719__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TiberendStrategicAdvisorsMember_zE4ml6Setc82" title="Non-payment amount">130,400</span>.
The Company and Tiberend entered into a full settlement and release agreement in exchange for a $<span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20230331__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TiberendStrategicAdvisorsMember_zu2OUmvQFyd5" title="Convertible promissory note">150,000</span> convertible promissory note
in March 2023. As of December 31, 2024, the note was fully repaid. See Note 5 &#8211; Convertible Debt and Derivative Liability &#8211;
Convertible Debt III for details associated with the note issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Office
Lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2021, the Company entered into a <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210501_zaAdOVt49Z7l" title="Operating lease term">61</span>-month operating lease for office space for a base rent of $<span id="xdx_901_eus-gaap--PaymentsForRent_c20210501__20210501_zTW79l6b0nyf" title="Base rent">3,783</span> subject to a <span id="xdx_90D_ecustom--OperatingLeaseYearlyEscalationPercentage_iI_pid_dp_uPure_c20210501_zXP622lgsFe4" title="Operating lease yearly escalation percentage">3</span>% yearly escalation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the Company&#8217;s operating lease right-of-use asset, net (ROU) is $<span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_zLQ0vuy3oo74" title="Operating lease right-of-use asset, net">23,214</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_zBffG8IzKrp" title="Operating lease right-of-use asset, net">69,642</span>, respectively,
and the total lease liability is $<span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_c20251231_zRyqgG2tiQ8f" title="Operating lease liability">21,247</span> and $<span id="xdx_902_eus-gaap--OperatingLeaseLiability_iI_c20241231_zsWsNimhwdM5" title="Operating lease liability">71,329</span>, respectively, based on an incremental borrowing rate of <span id="xdx_907_ecustom--OperatingLeaseIncremetalBorrowingRate_dp_c20250101__20251231_zSGmwdibyI58" title="Operating lease incremetal borrowing rate"><span id="xdx_90F_ecustom--OperatingLeaseIncremetalBorrowingRate_dp_c20240101__20241231_zm6guN5rHych" title="Operating lease incremetal borrowing rate">0.81</span></span>% at lease inception.</span></p>

<p id="xdx_896_ecustom--ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_z5kCvA4ZX23h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z7QmEYvo2gF6" style="display: none">Schedule
of Operating Lease Right-of-use Asset and  Liability</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_zJlOlxba3tJd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20241231_z9Jgz4Y349F" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use asset (&#8220;ROU&#8221;) is summarized below:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maOLROUzjlN_za62rp1rN3lj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
lease ROU</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msOLROUzjlN_znVCgBvnVIc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
accumulated reduction</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,795</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(166,367</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzjlN_zbzCbLowLBM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
of ROU, net </b>&#160; &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,642</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability related to the ROU asset is summarized below:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--OperatingLeaseLiabilityGross_iI_maOLLzx0H_zr8PnbLINXb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ReductionOfOperatingLeaseLiability_iNI_di_msOLLzx0H_zZz2fBCISKW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
of lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(214,762</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzx0H_zPjY7f1GJEcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zeeS0Dstonz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK9S51ku6N01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease liability payments under non-cancelable operating lease
at December 31, 2025 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zc44k8gm9GXi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20251231_zzuhWvY6rVK2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20241231_zZiY9GW3byKk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPztZn_zqW1PNRo1zJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,476</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPztZn_zBinXdQXUfI1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPztZn_zfUBqoLEwlo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,766</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zYa7afb3L3j8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    imputed interest &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(437</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_z39pbEWmLQLc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzH2R_zf4gvsdgRykk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,082</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzH2R_zW1ovI42HEvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzH2R_z9aX4bp1rUo7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zlufLEKsCF9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; Commitments and Contingencies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Office
Lease, continued</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2021, the Company entered into a month-to-month lease for office space in Charlestown, MA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rental
expenses of $<span id="xdx_90D_ecustom--RentalExpenses_c20250101__20251231_zgGFcpIMWtGf" title="Operating leases rent expenses">16,972</span> and $<span id="xdx_900_ecustom--RentalExpenses_c20240101__20241231_zNQwMQb0CoMk" title="Operating leases rent expenses">17,740</span> for the years ended December 31, 2025 and 2024, respectively, are included in general and administrative
expenses on the accompanying statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant
has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements
have a <span id="xdx_904_ecustom--AgreementTerm_dtY_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zFmf9b9DxB4h" title="Agreements term">2</span>-year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company&#8217;s
Board of Directors and are granted on an individual agreement basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2024, the Company entered into a Strategic Services Agreement (the &#8220;Dominant Treasure Agreement&#8221;) with
Dominant Treasure Health Company Limited (&#8220;Dominant Treasure&#8221;). Pursuant to the terms of the Dominant Treasure
Agreement, Dominant Treasure agreed to provide certain services to the Company to assist the Company in accelerating the
Company&#8217;s desire to get its products developed and distributed in the Southeast Asian market. In exchange for Dominant
Treasure&#8217;s services pursuant to the Dominant Treasure Agreement, the Company agreed to pay Dominant Treasure a one-time
payment of $<span id="xdx_90B_eus-gaap--PaymentsToSuppliers_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zzJ19Ej1iyFf" title="Payment for services">2,300,000</span>.
In addition, if Dominant Treasure is involved in generating negotiations and conclusion of a distribution agreement for the Company
in the countries of China (including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee of <span id="xdx_905_eus-gaap--ManagementAndServiceFeesRate_dp_uPure_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zNnHjB14Y23f" title="Success fee percentage">5</span>%
of any upfront and/or milestone payments to be received by the Company. If such an agreement will include a royalty payment to the
Company, Dominant Treasure will receive <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zlZ9F1el0Ukb" title="Royalty fee percentage">5</span>%
of such royalty payment. The Dominant Treasure Agreement has a term of <span id="xdx_902_ecustom--AgreementTerm_dtM_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zD1pKRzkjsgd" title="Agreements term">36</span>
months and may be terminated at any time upon mutual agreement of the parties. The one-time payment of $<span id="xdx_902_eus-gaap--PrepaidExpenseCurrent_iI_c20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zl7VoPCistdk" title="Prepaid expense">2,300,000</span>
was accounted for as a prepaid contract and will be expensed over a three-year period. For the years ended December 31, 2025 and
December 31, 2024, the Company recorded prepaid contract expense of $<span id="xdx_906_ecustom--PrepaidContractExpenses_c20250101__20251231_z8pNmBAmuDu" title="Prepaid contracts expense">766,667</span>
and $<span id="xdx_908_ecustom--PrepaidContractExpenses_c20240101__20241231_zMSMntVmy6d7" title="Prepaid contracts expense">54,612</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive
Employment Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s standard executive employment agreements have a stated term of six years. Per the agreements, employees are eligible
for a discretionary annual performance bonus, determined by the Board of Directors. If the Company terminates an employee without cause,
the employee is entitled to a pro-rated pay out of the annual performance bonus based on days worked in the fiscal year, severance of
twelve months of the base salary, and automatic vesting of unvested equity grants. If the employee terminates with good reason, as defined
in the employment contract, the employee is entitled to automatic vesting of unvested equity grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, <span id="xdx_90D_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zWFUYt2KGG0l" title="Salary payment description">the Company began consistently paying salaries at 50% of the salaries reflected in the respective employment agreements. As of
September 2021, the Company began paying full salaries. Throughout 2022, the Company returned to paying partial salaries and by October
2023 the company stopped paying 100% in an effort to conserve cash.</span> See Note 3 &#8211; Related Party Transactions for details related
to forgiveness of accrued compensation during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20231218__20231218__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z9d84721NLPf" title="Salary payment description">On
December 18, 2023, various employees agreed to reduce their annual base salary to 20% of their original base salary effective October
1, 2023 until the time the Company raises additional capital from securities in the amount of $1,500,000 (the &#8220;Reduction Period&#8221;).
Upon the expiration of the Reduction Period, the bases salaries shall adjust to be 105% of their original base salary as set forth in
their original agreements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 4, 2024, <span id="xdx_900_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zY7kbRR4KdXc" title="Salary payment description">the base salaries was adjusted to 105% of the original base salaries and the Company started paying a 100% of the
salaries.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; Commitments and Contingencies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Licensing
and Royalty Agreements -</i> Aquanova AG</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 13, 2016, the Company entered into a Development, Collaboration and License Agreement (&#8220;License Agreement&#8221;)
with Aquanova AG, a German company in the field of development, manufacturing and selling of colloidal formulas. The License
Agreement resulted in the creation of the pharmaceutic product, JOTROL&#8482;. The Chief Scientific Officer of the Company and
Aquanova&#8217;s founder, former CEO, and lead scientist, Darius Benham, are the joint inventors of
JOTROL&#8482;. Aquanova is assignee on the patents in the United States, the European Union, China and Japan whereas the Company is
obligated to maintain the patents. The agreement grants ownership to the Company for regulatory approvals and the sole and exclusive
worldwide right to develop, manufacture and commercialize all products, including JOTROL&#8482;. Aquanova is granted the exclusive
license to conduct formulation development and manufacturing. The agreement also defines fees owed to Aquanova for product and
formulation development and licensing of the products. The Company is required to pay Aquanova an annual license fee of $<span id="xdx_909_ecustom--LicenseFee_c20160913__20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_z7QnXt1KzkL9">75,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
acceptance of the product formulation by both parties, with the license fee requirement ending in the year of marketing
authorization approval (&#8220;MMA&#8221;) in a single territory. MMA has not yet been received as of the period ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2025 and 2024, $<span id="xdx_90E_ecustom--AccruedLicenseFees_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zNr4alnqSShh">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90F_ecustom--AccruedLicenseFees_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zfnldRwXQ4Yd">75,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
accrued license fees are included in accounts payable and accrued expenses on the balance sheet, respectively. Upon receipt of
approval of the MMA in each territory (e.g., United States, European Union, China, Japan), the Company will pay $<span id="xdx_908_eus-gaap--OtherCommitment_iI_c20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MinimumMember_z1F7UHrJzzBd">200,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
Aquanova per territory an MMA approval is received, up to a max of $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MaximumMember_zk1SQFVhrCXf">600,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company shall pay Aquanova a royalty of <span id="xdx_90C_ecustom--RoyaltyPercentage_dp_uPure_c20160913__20160913__us-gaap--TypeOfArrangementAxis__custom--LicensingAndRoyaltyAgreementsMember_zjKNcEMlUddg">5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of net sales in each territory through the later of ten years after the first commercial sale, the first date there is no valid
claim within the Aquanova patent rights, or the date of expiration of the MMA in each territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">On December 1, 2021, the Company and Aquanova entered into
a Debt Forgiveness and Exchange Agreement, pursuant to which $<span id="xdx_909_ecustom--AccruedAndOutstandingObligations_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zAqiAypCVokk" title="Accrued and outstanding obligations">225,000</span> of accrued and outstanding obligations owed to Aquanova under the
License Agreement were forgiven in exchange for $<span id="xdx_90B_eus-gaap--Cash_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_z9UJOC8I0Jy9" title="Cash">125,000</span> in cash, a $<span id="xdx_90C_ecustom--PromissoryNote_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zQ9Inlbgy54g" title="Promissory note">100,000</span> promissory note, and the issuance of stock options to Aquanova.
As of December 31, 2025, $<span id="xdx_900_ecustom--AccruedLicenseFees_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zpgooreWIFtb" title="Accrued license fees">0</span> in accrued license fees are recorded in accounts payable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is an option (exercisable by either party) to require the Company to pay a one-time royalty of $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20160915__20160915__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zaDAu90Niu9i" title="Royalty amount">3,000,000</span>
within 180 days of United States marketing approval, with subsequent royalty payments reduced to <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20160915__20160915__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zkMOytbl5cx8" title="Royalty payments percentage">1.25</span>%,
in accordance with the terms set forth above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Murdoch
Children&#8217;s Research Institute</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2015, the Company entered into a Global Development and License Agreement (&#8220;License Agreement II&#8221;) with Murdoch
Children&#8217;s Research Institute (&#8220;MCRI&#8221;), an Australian Institute at the Royal Children&#8217;s Hospital in Australia,
with the know-how in the process of using pharmaceutical grade Resveratrol for the treatment of Friedreich&#8217;s ataxia. The License
Agreement II is for both parties to work jointly to develop an appropriate delivery system and conduct clinical trials for the purpose
of product approval in the treatment of Friedreich&#8217;s ataxia and worldwide commercialization by the Company. The License Agreement
II grants an exclusive worldwide license to the Company to use the MCRI know-how for developing, manufacturing and commercializing the
product for proposed treatment for Friedreich&#8217;s ataxia. MCRI is granted an irrevocable, royalty free, worldwide license to use
the product inventions and patent rights for internal research and development. Upon receipt of approval of the MMA in each territory
(e.g., United States, European Union, China, Japan), the Company will pay $<span id="xdx_907_eus-gaap--OtherCommitment_iI_c20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MinimumMember_zjBGSuLPAOcf">100,000</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to MCRI per each territory up to a maximum of $<span id="xdx_903_eus-gaap--OtherCommitment_iI_c20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember_zvdo48vqMuA8">300,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
MMA has not yet been received as of September 30, 2024. The Company shall pay MCRI a royalty of <span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20150901__20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember_z2sO3Ykg2awa">1.5</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
of net sales in each territory until the product is no longer sold in the respective territory. </span>The Company has presently put
all R&amp;D efforts associated with the treatment of Friedreich&#8217;s Ataxia on hold.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Service Providers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the services received under the licensing agreements noted above, a substantial portion of the research and development (&#8220;R&amp;D&#8221;)
expense included in the statement of operations is incurred pursuant to short term service and consulting agreements with third party
providers for research, development, testing and manufacturing services. The agreements generally provide termination, at any time by
either party without cause, upon a 30-day written notice, unless otherwise disclosed below. There are no pending milestone payments due
as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Service
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2024, the Company entered into three <span id="xdx_900_ecustom--AgreementTerm_dtM_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zCipDpsP0bhj">36</span>-month service agreements with three different entities. The Company issued an aggregate
of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgwOZcPdjLD5" title="Number of restricted shares issued">3,487,500</span> restricted shares of common stock, <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__dei--LegalEntityAxis__custom--EntityThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z71nm19xhkU">1,162,500</span> restricted shares of common stock to each entity. The shares were to be registered
upon an IPO as long as an IPO happens no later than March 31, 2025. Either party is able to terminate the respective agreement with no
liability upon the occurrence of i) the Company failing to raise at least $10 million in gross proceeds from an IPO prior to May 31,
2025, ii) if either party is involved in any illegal activity or iii) at any time as long as both parties agree to it. The shares were
registered in the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially recognized stock-based compensation expense from the effective date of the agreement through the date the
obligations were met with the remaining expense being amortized over the remaining term of the <span id="xdx_900_ecustom--AgreementTerm_dtM_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zchpZqkmzOdg">36</span>-months
per the services agreements. Upon the occurrence of the initial public offering the Company recorded stock- based compensation
expense for services provided of $<span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zuRC2mEoJrD1">779,411</span>,
and through December 31, 2024 the Company recorded an additional stock-based compensation expense of $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_ztRj5UDkPEH3">114,373</span>
for a total stock-based compensation expense of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zwwL2Ukhfxw">893,784</span>.
For the year ended December 31, 2025, the Company recorded $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zF31rTDyWTyd" title="Share based compensation">1,546,117</span>
stock-based compensation expense and the remaining future stock-based compensation expense as of December 31, 2025 is $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20251231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zkNuS7SLqiAg" title="Share based compensation">2,198,474</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, each of the entities agreed to purchase <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0u9m9pmSD74" title="Purchase of common stock">37,500</span> shares each of the Company&#8217;s common stock at a price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdm3m5dQV41d">1.33</span> per share
prior to the occurrence of the IPO and these shares were registered in the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Report<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Report</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_z0ThKYsbqii2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_821_zFlud64cDJy3">Segment Report</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer serves as the Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM evaluates financial
performance and makes resource allocation decisions based on the operating results of the Company&#8217;s reportable segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 1, 2025, the Company operates through <span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uSegments_c20251001__20251001_zeFHsr2NsiG4" title="Number of reportable segments">two</span> reportable segments under ASC 280, Segment Reporting: (i) its premium nutritional supplements, and (ii) pharmaceutical operations
focused on drug candidates for CNS and rare orphan diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Premium
Nutritional Supplements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
segment includes all activities related to the commercialization and sale of the Company&#8217;s Nugevia product line. Activities within
this segment primarily consist of marketing, distribution, sales, customer support, and related supply chain management associated with
Nugevia products.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
segment includes all activities related to the research, development, and regulatory advancement of JOTROL&#8482;, the Company&#8217;s
proprietary resveratrol-based therapeutic candidate, which is being developed to address unmet medical needs and improve patient outcomes.
Activities within this segment primarily consist of clinical development, regulatory, manufacturing development, intellectual property
protection, and related research and development functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM assesses segment performance and allocates resources based on segment net loss (income), which represents the primary measure of
profit or loss reviewed. The CODM does not evaluate segments using discrete asset or liability information. Accordingly, total assets
are reported on a consolidated basis in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allocation
Methodology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
are attributed to each reportable segment based on the nature of the activity and the function to which the expense relates. Costs that
are directly identifiable with a specific segment are recorded to that segment. Selling, general and administrative expenses that benefit
both segments are allocated using reasonable and consistently applied methodologies that reflect the estimated level of effort or resources
consumed by each segment. These allocation methodologies may include time and effort analyses, headcount, relative revenue, or other
activity-based measures, depending on the underlying cost driver.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
allocation methodologies are reviewed periodically and refined as necessary to reflect changes in the business. The Company believes
such allocations are reasonable and consistent with the manner in which the CODM evaluates segment performance and makes resource allocation
decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
and other expenses consist primarily of public company costs (including board, investor relations, and SEC reporting expenses), certain
executive compensation, certain stock-based compensation, interest income (expense), other income (expense), and income taxes. These
costs are not allocated to reportable segments because they are not included in the measures reviewed by the CODM for purposes of assessing
segment performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zvRI8LIbbUIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
information for the year ended December 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z5Rl4GydSAMl">Schedule
of Segment Reporting Information</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalOperationsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zemW6h1G5BPa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical Operations</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PremiumNutritionalSupplementsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zttCJRuYxnx9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Premium Nutritional Supplements</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49E_20250101__20251231__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zTd7UOnNttPf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Reportable Segments</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zxTYVIjYQMM6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    / Other</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49D_20250101__20251231_zX0Hi5JO93Fc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Total</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zQmGzYooq7Ia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1461">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_zsatqpRywO6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,231</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,231</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,231</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_znQtTcNM6Qof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2,086,574</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,086,574</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2,086,574</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_zhb9978HSvy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
    general and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">817,554</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,179,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,997,046</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,842,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,839,712</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--SegmentNetLoss_zptM7uFlbuKd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
    net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,904,128</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,161,927</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,066,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(4,842,666</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(8,908,721</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_zqOlJyeyXXXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other interest
    income (expense), net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1488">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1489">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">263,824</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">263,824</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zLPqSxsOwCe6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,904,128</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(1,161,927</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,066,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,578,842</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,644,897</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p id="xdx_8A8_zgkxfDgYJQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zqz8B85AiAy" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_82A_z2WDLPwZ0283">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SEPA
Activity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to year end and through March 31, 2026, we have issued and sold
approximately <span><span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260101__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zQ7ytTknTee6" title="Sale of stock number of shares">1.1</span></span> million SEPA Shares to Yorkville pursuant to the SEPA, including SEPA
Shares issued in connection with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds
to us of approximately $<span><span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_pid_c20260101__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zA1fg7jAMaba" title="Proceeds from conversion debt">625,748</span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nasdaq
Compliance</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 26, 2026, the Company received two
written notices from the Listing Qualifications Department of Nasdaq notifying the Company that (i) the listing of the Company&#8217;s
Common Stock was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued
listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the Common Stock was less than $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0cmbfKIk0i3" title="Common stock, par value">1.00</span> per share for
the previous 30 consecutive business days, and (ii) for the 30 consecutive business days ended February 26, 2026, the Company&#8217;s
market value of listed securities closed below the $<span id="xdx_900_eus-gaap--AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQBWD4Ks59W5" title="Market value of listed securities closed">35</span> million threshold required for continued listing on The Nasdaq Capital Market under
Nasdaq Listing Rule 5550(b)(2). The Company has 180 calendar days, or until August 25, 2026, to regain compliance with both the minimum bid price
requirement and the market value of listed securities requirement. To regain compliance with the minimum bid price requirement, the Company&#8217;s
common stock must have a closing bid price of at least $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8wnI1NmGwDg" title="Common stock, par value">1.00 </span>per share for a minimum of 10 consecutive business days (or such longer period,
up to 20 consecutive business days, as Nasdaq may require). To regain compliance with the market value of listed securities requirement,
the Company&#8217;s market value of listed securities must be at least $<span id="xdx_90F_eus-gaap--AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx0i3qDfoTld" title="Market value of listed securities closed">35</span> million for a minimum of 10 consecutive business days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2025 Notes Amendment</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 20, 2026, the Company and Yorkville
entered into an Omnibus Amendment. Among other changes, the Amendment revises the terms of the 2025 Convertible Promissory Notes to defer
the commencement of monthly installment payments to April 1, 2026, effectively providing an extension of approximately three months.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zwruQE1u12a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United
States of America (&#8220;U.S. GAAP&#8221;). U.S GAAP contemplates continuation of the Company as a going concern. For the year
ended December 31, 2025 and 2024, the Company had net revenues from product sales of $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20250101__20251231_zUkBEI5QnIHh" title="Net revenues">21,796</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zvrY4vFIRGwl" title="Net revenues">0</span>, respectively and incurred a net
loss of $<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20251231_zHh4As08zab4" title="Net loss">8,644,897</span> and $<span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zpw3Bs3ivFkj" title="Net loss">2,439,625</span>,
respectively. Net cash used in operations for the years ended December 31, 2025 and 2024 was $<span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20251231_z455uyRWDbBj" title="Net cash flows from operating activities">5,413,736</span>
and $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zMVVATkHhtC9" title="Net cash flows from operating activities">3,911,004</span>,
respectively. As of December 31, 2025 and 2024, the Company had an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_z78fTrKn9Aba" title="Accumulated deficit">34,667,026</span>
and $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20241231_zUaFiIEL5fib" title="Accumulated deficit">26,022,129</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative
cash flows from operations as well as our dependence on private equity and financings. The
Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However,
there is no assurance the Company will be successful. These conditions raise substantial doubt
about the Company&#8217;s ability to continue as a going concern for a period of at least twelve months from the date of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zT7GDUZkWdN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States
of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business Segment</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zeHMnNtEfAb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Segment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the &#8220;management approach&#8221; to identify its reportable segments in accordance with ASC 280, Segment Reporting.
The management approach requires companies to report segment financial information consistent with the information regularly reviewed
by the Chief Operating Decision Maker (&#8220;CODM&#8221;) for purposes of making operating decisions and assessing performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company&#8217;s Chief Executive
Officer serves as the CODM. The CODM evaluates financial performance and allocates resources based on the operating results of the Company&#8217;s
reportable segments. Effective October 1, 2025, the Company operates through two reportable segments: (i) its premium nutritional supplements,
and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CODM assesses segment performance primarily based on segment net loss (income). Selling, general and administrative expenses are directly
attributable to segments or allocated based on reasonable and consistently applied methodologies. Corporate and other expenses that are
not allocated to reportable segments consist primarily of public company costs, certain executive compensation, certain stock-based compensation,
interest income (expense), other income (expense), and income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
identification of two reportable segments reflects the manner in which the CODM reviews financial information and allocates resources.
Prior-period information has been recast to conform to the current presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_z71Fe3Gq1gai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues
and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other
assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
estimates during the years ended December 31, 2025 and 2024, respectively, include valuation of stock-based compensation, uncertain tax
positions, the valuation of debt instruments, and the valuation allowance on deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9uzzPpbcwEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid
investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents consist
primarily of cash on deposit with financial institutions and amounts held in high-yield savings accounts. The Company maintains its
cash balances with high-credit-quality financial institutions. At times, such balances may exceed federally insured limits provided
by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). In 2025, the Company has implemented a deposit insurance program
in the Company&#8217;s primary account, whereby funds in excess of FDIC insurance limits are insured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the cash balances not subject to insurance or that exceed the FDIC limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20251231_z2XBGEHdTW4k" title="Cash FDIC limit">250,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were
$<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20251231_zrb52hWhkjVj" title="Cash uninsured amount">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_900_eus-gaap--CashUninsuredAmount_iI_c20241231_zdi2rs3X13h" title="Cash uninsured amount">3,519,510</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zBgutkNtGN7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inventory</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out (&#8220;FIFO&#8221;) method.
Inventory consists primarily of raw materials, work-in-process, and finished goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically reviews inventory quantities on hand and records reserves for excess, obsolete, or slow-moving inventory based on
its assessment of forecasted demand, product shelf life, market conditions, and other factors. Inventory reserves are recorded as a reduction
of inventory and are based on management&#8217;s estimates regarding the recoverability of inventory balances. If actual demand or market
conditions differ from those projected by management, additional inventory write-downs may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zctLCczDjsM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zL4bxtMLJEki">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recognized when
control of promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to
be entitled to in exchange for those goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines revenue recognition through
the following five-step model: (i) identification of the contract with a customer; (ii) identification of the performance obligations
in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations;
and (v) recognition of revenue when, or as, the Company satisfies a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Product Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates revenue from the sale of its
products. Product revenue is recognized when control of the product is transferred to the customer, which generally occurs upon shipment
or delivery, depending on the terms of the arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue is recorded net of variable consideration,
including estimates for product returns, rebates, chargebacks, discounts, and other allowances. The Company estimates variable consideration
at the time of sale based on historical experience, current market conditions, and contractual terms, and includes such estimates in the
transaction price only to the extent that it is probable that a significant reversal of revenue will not occur in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates whether it is the principal
or agent in its arrangements and records revenue on a gross or net basis accordingly. Shipping and handling activities are considered
fulfillment activities, and the related costs are recorded in cost of goods sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_PrepaidContractsPolicyTextBlock', window );">Prepaid Contracts</a></td>
<td class="text"><p id="xdx_841_ecustom--PrepaidContractsPolicyTextBlock_zUjYtMyKAlug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepaid
Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
contracts generally represent service agreements which the Company would receive services over a period of time and are expensed as the
services are received. The Company&#8217;s prepaid contracts are related to service agreements that span over three years, therefore
the expense will be recognized over the three year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_84C_ecustom--OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_zm1fAWpp2DAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prepaid
Expenses and Other Current Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets generally represent payments made for goods or services to be received within one year and are expensed
as the related benefit is received.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOo5FZckfc4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the years ended December 31, 2025 and 2024 were $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20251231_z4bv9rhUXN2f" title="Research and development costs">2,086,574</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zPLzHX7co2N8" title="Research and development costs">492,660</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zYzetmBaJwui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of December 31, 2025 and
2024, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had no material
amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company is subject
to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not currently
under examination by any tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share of Common Stock</a></td>
<td class="text"><p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zv4AC6zD9c9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Loss
Per Share of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock, as calculated using the treasury method. In computing the basic and
diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations
due to the fact that when a net loss exists, dilutive shares are not included in the calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there were <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zK558zCe6Ttk" title="Warrants Outstanding">no</span> warrants outstanding, <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z7iZQKQBF9wi" title="Restricted stock units">1,626,037</span> restricted stock units and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg6EHqelJngb" title="Number of stock options">11,726,093</span> stock options. These securities
are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZ4WJ1KhMMmb" title="Warrants Outstanding">1,359,375</span> warrants outstanding, <span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzqvaEojyWX" title="Restricted stock units">1,626,037</span> restricted stock units and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfitikcTDajk" title="Number of stock options">10,633,988</span> stock options. These
securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlwYPch16Jje" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records stock-based compensation equal to the grant date fair value of the stock awards issued. For stock options issued to
employees, non-employees and members of our board of directors, the Company estimates the grant-date fair value of options using the
Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with
respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the
option, risk-free interest rates, and, for grants prior to our initial public offering, the value of the common stock. For awards
subject to time-based vesting, the Company recognized stock-based compensation expense, on a straight-line basis over the requisite
service period, which is generally the vesting term of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ClinicalTrialExpensesPolicyTextBlock', window );">Clinical Trial Expenses</a></td>
<td class="text"><p id="xdx_84E_ecustom--ClinicalTrialExpensesPolicyTextBlock_zP79s9OeFwDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Trial Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztnATQTFkhUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value of Financial Instruments and Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their
short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current
interest rates available for debt with similar terms and maturities are substantially the same.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value of Financial Instruments and Fair Value Measurements, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
see Note 5 - Convertible Debt and <span id="xdx_908_ecustom--DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_zjcfYYWrQ0Ce" title="Derivative liabilities current not disclosed flag">Derivative Liability</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_zdrcpHOOBB16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative
Instruments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic 815, Derivatives and Hedging (&#8220;ASC Topic 815&#8221;), establishes accounting and reporting standards for derivative instruments
and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or
losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt,
the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any
discounts and records a net gain or loss on debt extinguishment. On January 1, 2020, the Company adopted ASU 2017-11 under which down-round
Features in Financial Instruments will no longer cause derivative treatment. The Company applies the modified prospective method of adoption.
There were no cumulative effects on adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock', window );">Convertible Notes with Embedded Derivative Liabilities</a></td>
<td class="text"><p id="xdx_840_ecustom--ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_zOs0iAUFwPz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Notes with Embedded Derivative Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into shares of common stock at a fixed discount to the price of the common stock at
or around the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those
contracts or any potential embedded components of those contracts qualify as derivatives. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUPITER
NEUROSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; Significant Accounting Policies, continued</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zYwY2r4SabCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based
on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit
rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present
value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIAJishjMKl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the
periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted
accounting principles and do not believe that any new or modified principles will have a material impact on the Company&#8217;s reported
financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&#8217;s
financial management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer serves as the CODM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. ASU 2023-09 enhances income tax disclosures by
adding more granular, jurisdiction-specific information, especially for investors and analysts. The amendments in ASU 2023-09 are
effective for public business entities for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09
effective January 1, 2025 on a prospective basis. The Company plans to adopt this update during the year ended December 31, 2026.
Beyond the expanded, required disclosures, management does not believe that this will have a material impact on the Company&#8217;s
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other newly issued accounting pronouncements that are not yet effective have been deemed immaterial or nonapplicable.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ClinicalTrialExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ClinicalTrialExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes With Embedded Derivative Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Assets And Prepaid Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_PrepaidContractsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid contracts [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_PrepaidContractsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgF4I1hpM9Df" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable and accrued expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zbvC12QToor1">Schedule
of Accounts Payable and Accrued Expenses</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20251231_zbJtFhDt9NRe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20241231_zJk7rN6r3MZ6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALz5RX_zLxVIbAUWVDa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131,130</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278,676</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maAPAALz5RX_zXMhhWaW5k5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">467,167</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,271</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_maAPAALz5RX_zwP7LvlqRHM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0724">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALz5RX_zTf5RJXeUFQk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
    cards</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,349</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,536</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALz5RX_ztQsVW3e5Dn1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accounts payable and accrued expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">638,646</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">396,483</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt and Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Schedule of Key Assumptions in Valuation Measurement</a></td>
<td class="text"><p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zZjmGzpO4Tqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following key assumptions were used in the valuation at each measurement date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_ztawSNgjk8B8" style="display: none">Schedule of Key
Assumptions in Valuation Measurement</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Assumption</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Issuance (Oct 24, 2025)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 24, 2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 22%">Stock Price (VWAP)</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center">$<span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_z6zqdjmPkC2d" title="Convertible debt instrument, measurement input">1.50</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center">$<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zz2rgLQAc6If" title="Convertible debt instrument, measurement input">1.09</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 24%; text-align: center; padding-left: 0.75pt">$<span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zEq8fow7nKKa" title="Convertible debt instrument, measurement input">0.99</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Volatility</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">~<span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zw33tuNrwNCf" title="Convertible debt instrument, measurement input">65</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">~<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zMR8jk3hI3bi" title="Convertible debt instrument, measurement input">65</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt">~<span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zVPFAZN72g2k" title="Convertible debt instrument, measurement input">65</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-Free Rates</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zkBe8G0ONahf" title="Convertible debt instrument, measurement input">3.4</span>% &#8211; <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zWPF9urOxwe2" title="Convertible debt instrument, measurement input">4.5</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zIYQNgWk4G9g" title="Convertible debt instrument, measurement input">3.5</span>% &#8211; <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zgAx6149QJnk" title="Convertible debt instrument, measurement input">4.6</span>%</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zcBydmO7hgP2" title="Convertible debt instrument, measurement input">3.4</span>% &#8211; <span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zkoIh03rIg2h" title="Convertible debt instrument, measurement input">4.7</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation Technique</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte Carlo Simulation</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte Carlo Simulation</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: center; padding-left: 0.75pt">Monte Carlo Simulation</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Fair Value Derivative Liability</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zxaosV9PMzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the derivative liability of Notes I, Note II and Note III was estimated using the Monte Carlo Valuation model at issuance
and each reporting period with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zJTLW9kZTMRe">Schedule
of Fair Value Derivative Liability</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzgg7OvEqJEf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTWGlRIHYyTh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 82%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPPcuzvNQns1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeCx1gVz7Dr5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityofIPOMember_zhRIXkuHMCsc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none">Derivative liability, measurement input</td>
    <td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">60</td><td style="display: none; text-align: left">%</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Derivative Liability</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zkpSEa8BkWqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity of the derivative liabilities and the 2025 Notes, which represent the Level III fair value measurements, is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zQ1soMR95y4i" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Derivative Liability</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zkWV7fx884c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    Liability</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2025 Notes</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--DerivativeLiabilities_iS_zv7mgTsyHe4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,505,398</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="text-align: right; width: 14%"><p style="margin: 0">-</p></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_zf0qLnzUCsmi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value change</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,257</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_z0n48GcePhLe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extinguishment
    of derivative liability - Note II</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,359,362</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--DerivativeFairValueOfIssuance_zMnjWj8rj6gk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value at issuance on April 29, 2024 - Senior Secured Note</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">407,494</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0">-</p></td>
    <td>&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RepaymentOfDerivativeLiability_zGA2cgMwOX7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of derivative liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(606,787</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">-</p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DerivativeFairValueOfIssuance_zYmBfffLxOd" style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-bottom: 1pt">Fair value at issuance</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; text-align: right">407,494</td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zRW5qL6goF13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">$</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><p style="margin: 0">-</p></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zA96k6M7cCoh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold; padding-bottom: 2.5pt">Derivative liability Balance </td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Issuance of the 2025 Notes</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--DerivativeFairValueOfIssuance_c20250101__20251231_z6c6mFrRavmj" style="width: 14%; text-align: right" title="Issuance of the 2025 Notes">5,580,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--GainLossDerivativeInstrumentsNetPretax_c20250101__20251231_z6CKR0DBCaO5" style="text-align: right" title="Fair value change">(281,932</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Balance at December 31, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_ecustom--GainsLossesOfExtinguishmentOfDebt_iE_c20250101__20251231_z4gZnyRxcYhd" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at December 31, 2025">5,298,068</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin-top: 0; margin-bottom: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGIcZinqgHIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity for the year ended December 31, 2025 and 2024 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_z6s3DH6Vjt58" style="display: none">Schedule of Stock Option
Activity</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Contractual Term (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    Intrinsic Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zRXeh9xhB171" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of options, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,336,883</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zAukIBM7RD9a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zppaUwdvfs8i" title="Weighted average contractual term (years), outstanding">6.9</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zH7OrpvCEv7i" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,316,119</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z94ZxPCocGK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">297,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zdJVy0WjK3R9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zEty7Y8rB6V9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zrQyyt533Jfi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1026">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231_zzcFG4oHYwNf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zHaH71PxMTjk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,633,988</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zvA4b86SDtvd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_zkWFd1akaaZg" title="Weighted average contractual term (years), outstanding">6.3</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zT6GrXlqqjmh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,921,147</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zx6zKK9KnB01" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,092,105</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_z5zfkOTmdqn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20251231_z1MkBB8ZEwCg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231_z86Tb45OlHj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250101__20251231_zn602cdUyKfl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zUFZwOun8Rwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231_zN1uQNHqhced" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,726,093</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zAXwfxu9PzVf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.02</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_zcgFvM8TTbh6" title="Weighted average contractual term (years), outstanding">5.4</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_z9pjfgVpYrej" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,772,167</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20251231_zJdfhzxO7qE9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,874,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zWYnYIKqUDv7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.03</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_z92T0zqxWbE6" title="Weighted average contractual term (years), exercisable">5.1</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231_zeFIKVBO2SH5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,765,237</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zS8GgP8525Tf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,297,412</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zEvqKuMoU601" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.01</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_z6wDBZRYZwrb" title="Weighted average contractual term (years), exercisable">6.18</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240101__20241231_ze5LAHb52fya" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99,768,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Employee Stock Options Outstanding</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVtEFPVOCc4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarized information about employee stock options outstanding as of December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zr5t7TYd9Hvg" style="display: none">Schedule of Employee
Stock Options Outstanding</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Outstanding Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Vested Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding at December 31,</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Number Exercisable at December 31, 2025</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9lUQANknNKg" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price">0.01</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zinDiVfAqRFl" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z8FXJSD6j8Mj" title="Outstanding options, weighted average contractual term">0.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zw0U37LS9Vk8" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY9qy9o8xny5" title="Vested options, weighted average contractual term">0.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zIX9lQRSzhM5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.74</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxuUjg0j3Yj8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">1,657,560</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_znkzTAYxxTog" title="Outstanding options, weighted average contractual term">3.07</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2Ilpmuw6nc6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">1,657,560</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeQlgjxhvdOk" title="Vested options, weighted average contractual term">3.07</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zAuYWQpnOaTl" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.80</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4AmDF0JAXia" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">2,783,243</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zyixcQx7zNw9" title="Outstanding options, weighted average contractual term">3.29</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXqsfaTF4yV1" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">2,783,243</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zq1ybB4jri56" title="Vested options, weighted average contractual term">3.29</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zJaiFwLYgekh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.97</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zL3SV54Piocj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">250,000</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zP2ebCzUk369" title="Outstanding options, weighted average contractual term">9.42</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWZVbDDqB2cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">111,412</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zU6mdI1AkD81" title="Vested options, weighted average contractual term">9.42</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zot74KmHnvC8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.19</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zioSbChcwch2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">357,448</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zLtyDdRqBKo1" title="Outstanding options, weighted average contractual term">9.51</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoeu40klWFdh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zLehGVqy7CU7" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.23</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zGKnSBD394G5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">484,657</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zh8fC6psLWqd" title="Outstanding options, weighted average contractual term">9.68</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zzJuRHQAMwkg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">128,822</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zUhk8TBWNbhh" title="Vested options, weighted average contractual term">9.68</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z2BLbDR5XzAa" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.33</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zWH2r7yjm8Sc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">5,461,935</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z426LmVrFrL6" title="Outstanding options, weighted average contractual term">7.08</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z5vKDzu3cQG6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">5,461,935</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z9xUocfrltd4" title="Vested options, weighted average contractual term">7.08</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zCWfff1o9cy3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.16</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zZJ3jv16r4I9" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_ziA6nWOzWg7g" title="Outstanding options, weighted average contractual term">5.46</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zwtWFplqtor5" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zc4bj9IuSAEg" title="Vested options, weighted average contractual term">5.06</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231_zCPuvhn7yym4" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">11,726,093</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zTvaVvrr1C67" title="Outstanding options, weighted average remaining life">5.43</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231_zwJCzoNZt6Q3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">10,874,222</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zjxE8JNl1o0h" title="Vested options, weighted average remaining life">5.10</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Outstanding Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Vested Options</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number Outstanding at December 31,</b></p> <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2024</b></p></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Number Exercisable at December 31, 2024</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Life</td><td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqTYltrcy2e" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price">0.01</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqw3dafNIj4i" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXLu86SLEExa" title="Outstanding options, weighted average contractual term">1.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIS07948AUSd" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable">675,000</td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z7EWagbSK6La" title="Vested options, weighted average contractual term">1.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAcYrs8Y3Hfi" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.74</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zCM9gIgDE8P9" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">1,657,560</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrSrDnU8V5Ra" title="Outstanding options, weighted average contractual term">4.32</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxBDMkBYO4Cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">1,657,562</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zYMES0ehNuBi" title="Vested options, weighted average contractual term">4.32</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zy2B6FbHG1n3" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">0.8</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zOek3sbcecfc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">2,783,243</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmhEz33Ddbad" title="Outstanding options, weighted average contractual term">4.54</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zSRCp95gzeYd" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">2,783,238</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2GAh69BQpWg" title="Vested options, weighted average contractual term">4.54</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCn9DZQlTZah" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.33</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zvvoIopKWEn2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">5,461,935</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWG4ksZui5B9" title="Outstanding options, weighted average contractual term">8.33</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zxPtzl915dFj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">5,125,362</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zY8qsfToPjp5" title="Vested options, weighted average contractual term">8.31</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zHw1l0f826xe" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.16</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zPg6UNOzYGl6" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zMSqF69o5gdf" title="Outstanding options, weighted average contractual term">6.71</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoLf6vkragPg" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">56,250</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zkEq1e4Jf2Tg" title="Vested options, weighted average contractual term">6.71</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231_zerA8b9MNhE8" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding">10,633,988</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zOQakm3BnRX4" title="Outstanding options, weighted average remaining life">6.25</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_z40TkNgv43fb" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable">10,297,412</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_ztNWIX9ty3ze" title="Vested options, weighted average remaining life">6.15</span></td><td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_z0pCHvqoj6pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the Company&#8217;s warrant activity for the year ended December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z5tHIdeRHBYk" style="display: none">Schedule of Warrant Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNc8RiNKKA5f" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,359,375</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgijBH4VCrZ4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price per share, outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjCprZX2OrMi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average remaining life (years), outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xMF0O7JPfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAfBgjnckLoj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN4XT3EFXoQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,359,375</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFlhOc9kK5Lj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUDZPLcUEEQ9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3bziOzm6Xw2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5Parh01sAAg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcCMUXTurClc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1242">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share Based Compensation Warrant Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWIb6w9Br8Bj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z5qxT8107y54" style="display: none">Schedule
of Income Tax Provision</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250101__20251231_zN1Ha8w5zSy7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20240101__20241231_z4FLovEWDX4g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_zI1kBVw0Jnl3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zqkq7gT8gjml" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maKL001_z69qxdumrLX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nondeductible
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.66</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-2.33</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zx9GBimZ1Wkc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-39.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-20.74</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zd1Y4tCFDLC9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1286">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1287">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0oE4sZ2PzCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s deferred tax assets is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B0_zFdtRsfRho29" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231_ztuQUysEC5qh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zdn1x65jeUYi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGze87_zyqf3c82unn2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S
    Federal and State net operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,473,294</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,083,545</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGze87_zaSwqbyCuPY5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,423,288</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,272,925</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_maDTAGze87_zgaey9eS7Jg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">348,012</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">382,288</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGze87_z8SH1dvo1NV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
    drug credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682,207</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,060,118</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsDerivativeLiability_iI_maDTAGze87_zP09qyBV7u4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGze87_znXhwig8fdQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,699</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">260,481</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGze87_maDTANz4iX_zcWR93tE6dPa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,046,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,059,357</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz4iX_zcDqd2p7xaK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,046,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,059,357</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz4iX_z911dkGdqv9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Deferred Tax Asset</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1316">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Operating Lease Right-of-use Asset and Liability</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_z5kCvA4ZX23h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z7QmEYvo2gF6" style="display: none">Schedule
of Operating Lease Right-of-use Asset and  Liability</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_zJlOlxba3tJd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20241231_z9Jgz4Y349F" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use asset (&#8220;ROU&#8221;) is summarized below:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maOLROUzjlN_za62rp1rN3lj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
lease ROU</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msOLROUzjlN_znVCgBvnVIc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
accumulated reduction</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212,795</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(166,367</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzjlN_zbzCbLowLBM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
of ROU, net </b>&#160; &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,214</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,642</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability related to the ROU asset is summarized below:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--OperatingLeaseLiabilityGross_iI_maOLLzx0H_zr8PnbLINXb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">236,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ReductionOfOperatingLeaseLiability_iNI_di_msOLLzx0H_zZz2fBCISKW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
of lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(214,762</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(164,680</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzx0H_zPjY7f1GJEcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK9S51ku6N01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease liability payments under non-cancelable operating lease
at December 31, 2025 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zc44k8gm9GXi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20251231_zzuhWvY6rVK2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20241231_zZiY9GW3byKk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPztZn_zqW1PNRo1zJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,476</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPztZn_zBinXdQXUfI1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPztZn_zfUBqoLEwlo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,290</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,766</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zYa7afb3L3j8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    imputed interest &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(437</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_z39pbEWmLQLc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzH2R_zf4gvsdgRykk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,082</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzH2R_zW1ovI42HEvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1384">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzH2R_z9aX4bp1rUo7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease liabilities &#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,329</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Lease Assets and Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Report (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zvRI8LIbbUIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
information for the year ended December 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z5Rl4GydSAMl">Schedule
of Segment Reporting Information</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_494_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalOperationsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zemW6h1G5BPa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical Operations</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PremiumNutritionalSupplementsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zttCJRuYxnx9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Premium Nutritional Supplements</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49E_20250101__20251231__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zTd7UOnNttPf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Reportable Segments</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zxTYVIjYQMM6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
    / Other</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_49D_20250101__20251231_zX0Hi5JO93Fc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
    Total</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_zQmGzYooq7Ia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1458">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1461">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,796</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_zsatqpRywO6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,231</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,231</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,231</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_znQtTcNM6Qof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2,086,574</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,086,574</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2,086,574</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_zhb9978HSvy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling,
    general and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">817,554</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,179,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,997,046</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,842,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,839,712</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--SegmentNetLoss_zptM7uFlbuKd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment
    net loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,904,128</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,161,927</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,066,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(4,842,666</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(8,908,721</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_zqOlJyeyXXXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other interest
    income (expense), net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1488">-</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1489">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">263,824</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">263,824</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zLPqSxsOwCe6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,904,128</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0">(1,161,927</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,066,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,578,842</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,644,897</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 24, 2025</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 25, 2026</div></th>
<th class="th"><div>Feb. 26, 2026</div></th>
<th class="th"><div>Dec. 19, 2025</div></th>
<th class="th"><div>Sep. 17, 2025</div></th>
<th class="th"><div>Jul. 09, 2025</div></th>
<th class="th"><div>Mar. 21, 2025</div></th>
<th class="th"><div>Jun. 13, 2024</div></th>
<th class="th"><div>Jan. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_MinimumClosingBidPrice', window );">Minimum closing bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_MinimumClosingBidPrice', window );">Minimum closing bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue', window );">Market value of listed securities closed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts, commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,725,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_MinimumClosingBidPrice', window );">Minimum closing bid price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=JUNS_FifteenForFourForwardStockSplitMember', window );">(15:4) Forward Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,126,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,033,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">fifteen-for-four<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_MinimumClosingBidPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum closing bid price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_MinimumClosingBidPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity securities allocated to the segregated group of participating or dividend-paying policies and contracts identified as the closed block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477301/944-805-55-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=JUNS_FifteenForFourForwardStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=JUNS_FifteenForFourForwardStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 21,796<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">8,644,897<span></span>
</td>
<td class="nump">2,439,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">5,413,736<span></span>
</td>
<td class="nump">3,911,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">34,667,026<span></span>
</td>
<td class="nump">26,022,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC limit</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash uninsured amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,519,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 2,086,574<span></span>
</td>
<td class="nump">$ 492,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative liabilities current not disclosed flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,359,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of stock options</a></td>
<td class="nump">1,626,037<span></span>
</td>
<td class="nump">1,626,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of stock options</a></td>
<td class="nump">11,726,093<span></span>
</td>
<td class="nump">10,633,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liabilities current not disclosed flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2024</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,720,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 2,418,516<span></span>
</td>
<td class="nump">$ 1,840,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,546,117<span></span>
</td>
<td class="nump">893,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense, Operating and Nonoperating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,782<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,432<span></span>
</td>
<td class="nump">83,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_InterestPayable', window );">[custom:InterestPayable-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="nump">$ 16,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt</a></td>
<td class="nump">$ 1,377,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Note II Holder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued</a></td>
<td class="nump">685,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Debt Instrument, Issued, Principal</a></td>
<td class="nump">$ 266,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_InterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_InterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=JUNS_NoteIIHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=JUNS_NoteIIHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">$ 131,130<span></span>
</td>
<td class="nump">$ 278,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Professional fees</a></td>
<td class="nump">467,167<span></span>
</td>
<td class="nump">40,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">License fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Credit cards</a></td>
<td class="nump">40,349<span></span>
</td>
<td class="nump">2,536<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 638,646<span></span>
</td>
<td class="nump">$ 396,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses owned</a></td>
<td class="nump">$ 638,646<span></span>
</td>
<td class="nump">$ 396,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,397,357<span></span>
</td>
<td class="nump">1,415,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_EmploymentAgreementsMember', window );">Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,397,357<span></span>
</td>
<td class="nump">1,415,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ConserveCashPercentage', window );">[custom:ConserveCashPercentage-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses owned</a></td>
<td class="nump">$ 64,105<span></span>
</td>
<td class="nump">$ 64,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ConserveCashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conserve cash percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ConserveCashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_EmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_EmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Key Assumptions in Valuation Measurement (Details) - Valuation Technique, Monte Carlo Pricing Model [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>Segments</div>
</th>
<th class="th">
<div>Dec. 24, 2025 </div>
<div>Segments</div>
</th>
<th class="th">
<div>Oct. 24, 2025 </div>
<div>Segments</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible debt instrument, measurement input</a></td>
<td class="nump">0.99<span></span>
</td>
<td class="nump">1.09<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible debt instrument, measurement input</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible debt instrument, measurement input</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible debt instrument, measurement input</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_MonteCarloModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_MonteCarloModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value change</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (53,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of derivative liability - Note II</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">857,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DerivativeFairValueOfIssuance', window );">Issuance of the 2025 Notes</a></td>
<td class="nump">5,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_GainLossDerivativeInstrumentsNetPretax', window );">Fair value change</a></td>
<td class="num">(281,932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_GainsLossesOfExtinguishmentOfDebt', window );">Balance at December 31, 2025</a></td>
<td class="nump">5,298,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems', window );"><strong>Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,505,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of derivative liability - Note II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,359,362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DerivativeFairValueOfIssuance', window );">Issuance of the 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_RepaymentOfDerivativeLiability', window );">Repayment of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(606,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_DerivativeFairValueOfIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative fair value of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_DerivativeFairValueOfIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_GainLossDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss derivative instruments net pretax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_GainLossDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_GainsLossesOfExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains losses of extinguishment of debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_GainsLossesOfExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_RepaymentOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_RepaymentOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt and Derivative Liability (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Oct. 24, 2025</div></th>
<th class="th"><div>Apr. 24, 2024</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Aug. 06, 2022</div></th>
<th class="th"><div>Apr. 11, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 23, 2025</div></th>
<th class="th"><div>Dec. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 3,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage', window );">Original issue discount percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct. 24,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Repayments of debt description</a></td>
<td class="text">Beginning January 7, 2026, and monthly thereafter, the Company must
repay one-tenth (1/10) of the then-outstanding principal plus accrued interest (a 5% premium applies to cash repayments).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StructuringFee', window );">[custom:StructuringFee-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_CommitmentShares', window );">[custom:CommitmentShares-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Other Commitments, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">total aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#8217;s
$20.0 million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $1.5162 per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible promissory note fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,225,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,914,515<span></span>
</td>
<td class="nump">$ 5,225,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,298,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OriginalIssueDiscounts', window );">Original issue discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative, Gain (Loss) on Derivative, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,932<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, consideration received on transaction, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,829<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock Issued During Period, Value, Conversion of Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">857,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative liabilities not disclosed flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_GainsOnExtinguishmentOfDebt', window );">[custom:GainsOnExtinguishmentOfDebt]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DerivativeGainLossOnDerivative', window );">[custom:DerivativeGainLossOnDerivative]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=JUNS_TwelveConvertiblePromissoryNotesMember', window );">Twelve Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 636,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Debt Instrument, Increase, Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=JUNS_TwelveConvertiblePromissoryNotesMember', window );">Twelve Convertible Promissory Notes [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OfferingPricePercentage', window );">[custom:OfferingPricePercentage-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=JUNS_ConvertibleDebtOneMember', window );">Convertible Debt I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=JUNS_SeniorSecuredNoteConvertibleDebtTwoMember', window );">Senior Secured Note Convertible Debt II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Common stock for net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 977,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OriginationOfLoanToPurchaseCommonStock', window );">Origination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock Issued During Period, Value, Conversion of Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 951,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 887,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=JUNS_SeniorSecuredNoteMember', window );">Senior Secured Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,102,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,102,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 1,860,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage', window );">Original issue discount percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | YA II PN, Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Pre-paid advances via convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Senior Secured Note Convertible Debt II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Principal amount shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ConvertibleAmountIntoSharesOfCommonStock', window );">Convertible amount into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_CommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_CommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ConvertibleAmountIntoSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible amount into shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ConvertibleAmountIntoSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original issue discount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_DerivativeGainLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative gain loss on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_DerivativeGainLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liabilities not disclosed flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_GainsOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains on extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_GainsOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OfferingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OfferingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OriginalIssueDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OriginalIssueDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StructuringFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Structuring fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StructuringFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OriginationOfLoanToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for origination of loan for purchasing common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OriginationOfLoanToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=JUNS_TwelveConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=JUNS_TwelveConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=JUNS_ConvertibleDebtOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=JUNS_ConvertibleDebtOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=JUNS_SeniorSecuredNoteConvertibleDebtTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=JUNS_SeniorSecuredNoteConvertibleDebtTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=JUNS_SeniorSecuredNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=JUNS_SeniorSecuredNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=JUNS_YAIIPNLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=JUNS_YAIIPNLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=JUNS_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=JUNS_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding, beginning balance</a></td>
<td class="nump">10,633,988<span></span>
</td>
<td class="nump">10,336,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, beginning balance</a></td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual term (years), outstanding</a></td>
<td class="text">5 years 5 months 4 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding, beginning balance</a></td>
<td class="nump">$ 102,921,147<span></span>
</td>
<td class="nump">$ 3,316,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">1,092,105<span></span>
</td>
<td class="nump">297,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average contractual term (years), outstanding</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding, ending balance</a></td>
<td class="nump">11,726,093<span></span>
</td>
<td class="nump">10,633,988<span></span>
</td>
<td class="nump">10,336,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding, ending balance</a></td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding, ending balance</a></td>
<td class="nump">$ 1,772,167<span></span>
</td>
<td class="nump">$ 102,921,147<span></span>
</td>
<td class="nump">$ 3,316,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="nump">10,874,222<span></span>
</td>
<td class="nump">10,297,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted average contractual term (years), exercisable</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 1,765,237<span></span>
</td>
<td class="nump">$ 99,768,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Employee Stock Options Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">11,726,093<span></span>
</td>
<td class="nump">10,633,988<span></span>
</td>
<td class="nump">10,336,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">5 years 5 months 4 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">10,874,222<span></span>
</td>
<td class="nump">10,297,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">1,657,560<span></span>
</td>
<td class="nump">1,657,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">3 years 25 days<span></span>
</td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">1,657,560<span></span>
</td>
<td class="nump">1,657,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">3 years 25 days<span></span>
</td>
<td class="text">4 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">2,783,243<span></span>
</td>
<td class="nump">2,783,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">3 years 3 months 14 days<span></span>
</td>
<td class="text">4 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">2,783,243<span></span>
</td>
<td class="nump">2,783,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">3 years 3 months 14 days<span></span>
</td>
<td class="text">4 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">5,461,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">9 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">111,412<span></span>
</td>
<td class="nump">5,125,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">9 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeFiveMember', window );">Range Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">357,448<span></span>
</td>
<td class="nump">56,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">56,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeSixMember', window );">Range Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">484,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">128,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeSevenMember', window );">Range Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">5,461,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">7 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">5,461,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">7 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeEightMember', window );">Range Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, outstanding</a></td>
<td class="nump">56,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding options, weighted average remaining life</a></td>
<td class="text">5 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested options, number exercisable</a></td>
<td class="nump">56,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested options, weighted average remaining life</a></td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares authorized under stock option plans exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=JUNS_RangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details) - Warrant [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, outstanding, beginning balance</a></td>
<td class="nump">1,359,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare', window );">Weighted average exercise price per share, outstanding, beginning balance</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife', window );">Weighted average remaining life (years), outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted', window );">Weighted average exercise price per share, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of shares, exercised</a></td>
<td class="num">(1,359,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised', window );">Weighted average exercise price per share, exercised</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of shares, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited', window );">Weighted average exercise price per share, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,359,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare', window );">Weighted average exercise price per share, outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments weighted average remaining life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 24, 2025</div></th>
<th class="th"><div>Sep. 05, 2025</div></th>
<th class="th"><div>Aug. 12, 2025</div></th>
<th class="th"><div>Jul. 16, 2025</div></th>
<th class="th"><div>Jul. 02, 2025</div></th>
<th class="th"><div>Jun. 10, 2025</div></th>
<th class="th"><div>Apr. 23, 2025</div></th>
<th class="th"><div>Dec. 04, 2024</div></th>
<th class="th"><div>Dec. 02, 2024</div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>Apr. 17, 2024</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 19, 2025</div></th>
<th class="th"><div>Oct. 23, 2025</div></th>
<th class="th"><div>Jun. 22, 2025</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Jan. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,103,860<span></span>
</td>
<td class="nump">34,446,455<span></span>
</td>
<td class="nump">33,103,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,103,860<span></span>
</td>
<td class="nump">34,446,455<span></span>
</td>
<td class="nump">33,103,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_CommitmentShares', window );">Commitment shares issued</a></td>
<td class="nump">131,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Commitment shares issued value</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Purchase commitment</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_PurchaseCommitmentPerShare', window );">Purchase commitment per share</a></td>
<td class="nump">$ 1.5162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Compensation expense for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,546,117<span></span>
</td>
<td class="nump">893,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Unvested stock options expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted stock option purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,092,105<span></span>
</td>
<td class="nump">297,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,921,147<span></span>
</td>
<td class="nump">$ 1,772,167<span></span>
</td>
<td class="nump">$ 102,921,147<span></span>
</td>
<td class="nump">$ 3,316,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Vested, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 4 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,633,988<span></span>
</td>
<td class="nump">11,726,093<span></span>
</td>
<td class="nump">10,633,988<span></span>
</td>
<td class="nump">10,336,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Fair value of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,139,908<span></span>
</td>
<td class="nump">$ 1,840,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,626,037<span></span>
</td>
<td class="nump">1,626,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,195,550<span></span>
</td>
<td class="nump">$ 2,195,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Compensation expense for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=JUNS_ConsultantMember', window );">Consultant [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted stock option purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Vested, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Option vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=JUNS_BoardOfDirectorsMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting period description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The stock options have
a 10-year term and vest in equal installments over a three (3) year period beginning on the grant date of July 2, 2025, subject to the
officers&#8217; continued employment at the time of vesting.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=JUNS_TwoConsultantsMember', window );">Two Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Option vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Fair value of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=JUNS_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Vested, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Fair value of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Vested performance description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(a) 15% per Ambassador (maximum of three) referred by consultant and subsequently
engaged by the Company, (b) 20% if consultant is instrumental in arranging a distribution arrangement not previously pursued by the Company,
on terms acceptable to the Company, (c) 20% when such Distribution Contract achieves $1 million in annual sales and (d) 15% when the consultant
arranges the first Celebrity Golf Tournament featuring Nugevia on terms and conditions acceptable to the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=JUNS_WarrantHolderMember', window );">Warrant Holder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,954<span></span>
</td>
<td class="nump">86,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,376<span></span>
</td>
<td class="nump">1,249,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,547<span></span>
</td>
<td class="nump">913,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,418,516<span></span>
</td>
<td class="nump">$ 947,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,638,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for service rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Fair value of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,725,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,274,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member] | Entity One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member] | Entity Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member] | Entity Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_CommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_CommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_PurchaseCommitmentPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase commitment per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_PurchaseCommitmentPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=JUNS_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=JUNS_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=JUNS_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=JUNS_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=JUNS_TwoConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=JUNS_TwoConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=JUNS_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=JUNS_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=JUNS_WarrantHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=JUNS_WarrantHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=JUNS_EntityOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=JUNS_EntityOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=JUNS_EntityTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=JUNS_EntityTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=JUNS_EntityThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=JUNS_EntityThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income Tax Provision (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State</a></td>
<td class="nump">4.19%<span></span>
</td>
<td class="nump">2.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible expenses</a></td>
<td class="nump">14.66%<span></span>
</td>
<td class="num">(2.33%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(39.84%)<span></span>
</td>
<td class="num">(20.74%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">U.S Federal and State net operating loss</a></td>
<td class="nump">$ 5,473,294<span></span>
</td>
<td class="nump">$ 3,083,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,423,288<span></span>
</td>
<td class="nump">1,272,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued salaries</a></td>
<td class="nump">348,012<span></span>
</td>
<td class="nump">382,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Orphan drug credit</a></td>
<td class="nump">1,682,207<span></span>
</td>
<td class="nump">1,060,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_DeferredTaxAssetsDerivativeLiability', window );">Derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">119,699<span></span>
</td>
<td class="nump">260,481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total net deferred tax assets</a></td>
<td class="nump">9,046,500<span></span>
</td>
<td class="nump">6,059,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(9,046,500)<span></span>
</td>
<td class="num">(6,059,357)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_DeferredTaxAssetsDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_DeferredTaxAssetsDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">$ 22.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Lease Right-of-use Asset and Liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Office lease ROU</a></td>
<td class="nump">$ 236,009<span></span>
</td>
<td class="nump">$ 236,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization', window );">Less accumulated reduction</a></td>
<td class="num">(212,795)<span></span>
</td>
<td class="num">(166,367)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Balance of ROU, net &#160; &#160;</a></td>
<td class="nump">23,214<span></span>
</td>
<td class="nump">69,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OperatingLeaseLiabilityGross', window );">Office lease liability</a></td>
<td class="nump">236,009<span></span>
</td>
<td class="nump">236,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_ReductionOfOperatingLeaseLiability', window );">Reduction of lease liability</a></td>
<td class="num">(214,762)<span></span>
</td>
<td class="num">(164,680)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 21,247<span></span>
</td>
<td class="nump">$ 71,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OperatingLeaseLiabilityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OperatingLeaseLiabilityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease, right-of-use asset, accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use asset before accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_ReductionOfOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_ReductionOfOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 50,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">21,290<span></span>
</td>
<td class="nump">21,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments&#160;</a></td>
<td class="nump">21,290<span></span>
</td>
<td class="nump">71,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest &#160;</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(437)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities &#160;</a></td>
<td class="nump">21,247<span></span>
</td>
<td class="nump">71,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">21,247<span></span>
</td>
<td class="nump">50,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 21,247<span></span>
</td>
<td class="nump">$ 71,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 15, 2024</div></th>
<th class="th"><div>Dec. 04, 2024</div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Sep. 15, 2016</div></th>
<th class="th"><div>Sep. 13, 2016</div></th>
<th class="th"><div>Sep. 01, 2015</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,298,068<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OperatingLeaseYearlyEscalationPercentage', window );">Operating lease yearly escalation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,214<span></span>
</td>
<td class="nump">69,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,247<span></span>
</td>
<td class="nump">$ 71,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_OperatingLeaseIncremetalBorrowingRate', window );">Operating lease incremetal borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_RentalExpenses', window );">Operating leases rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,972<span></span>
</td>
<td class="nump">$ 17,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,667<span></span>
</td>
<td class="nump">766,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_PrepaidContractExpenses', window );">Prepaid contracts expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766,667<span></span>
</td>
<td class="nump">54,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,789,342<span></span>
</td>
<td class="nump">3,769,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits and Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546,117<span></span>
</td>
<td class="nump">893,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,418,516<span></span>
</td>
<td class="nump">$ 1,840,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=JUNS_EntityThreeMember', window );">Entity Three [Member] | Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_ServiceAgreementsMember', window );">Service Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_AgreementTerm', window );">Agreements term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits and Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 779,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,198,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,546,117<span></span>
</td>
<td class="nump">893,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_ServiceAgreementsMember', window );">Service Agreements [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_ServiceAgreementsMember', window );">Service Agreements [Member] | Entity Three [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_ServiceAgreementsMember', window );">Service Agreements [Member] | Tiberend Strategic Advisors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Non-payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_AgreementTerm', window );">Agreements term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_DominantTreasureAgreementMember', window );">Dominant Treasure Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_AgreementTerm', window );">Agreements term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliers', window );">Payment for services</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementAndServiceFeesRate', window );">Success fee percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_RoyaltyPercentage', window );">Royalty payments percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expense</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDescription', window );">Salary payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the base salaries was adjusted to 105% of the original base salaries and the Company started paying a 100% of the
salaries.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
December 18, 2023, various employees agreed to reduce their annual base salary to 20% of their original base salary effective October
1, 2023 until the time the Company raises additional capital from securities in the amount of $1,500,000 (the &#8220;Reduction Period&#8221;).
Upon the expiration of the Reduction Period, the bases salaries shall adjust to be 105% of their original base salary as set forth in
their original agreements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company began consistently paying salaries at 50% of the salaries reflected in the respective employment agreements. As of
September 2021, the Company began paying full salaries. Throughout 2022, the Company returned to paying partial salaries and by October
2023 the company stopped paying 100% in an effort to conserve cash.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsMember', window );">License Agreements [Member] | Aquanova AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_RoyaltyPercentage', window );">Royalty payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_LicenseFee', window );">[custom:LicenseFee]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsMember', window );">License Agreements [Member] | Aquanova AG [Member] | JAPAN | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsMember', window );">License Agreements [Member] | Aquanova AG [Member] | JAPAN | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_LicensingAndRoyaltyAgreementsMember', window );">Licensing And Royalty Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_RoyaltyPercentage', window );">Royalty payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_DebtForgivenessAndExchangeAgreementMember', window );">Debt Forgiveness and Exchange Agreement [Member] | Aquanova AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_AccruedAndOutstandingObligations', window );">Accrued and outstanding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_PromissoryNote', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsTwoMember', window );">License Agreements II [Member] | Murdoch Childrens Research Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_RoyaltyPercentage', window );">Royalty payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsTwoMember', window );">License Agreements II [Member] | Murdoch Childrens Research Institute [Member] | JAPAN | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsTwoMember', window );">License Agreements II [Member] | Murdoch Childrens Research Institute [Member] | JAPAN | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_AccruedAndOutstandingObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued and outstanding obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_AccruedAndOutstandingObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OperatingLeaseIncremetalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease incremetal borrowing rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OperatingLeaseIncremetalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_OperatingLeaseYearlyEscalationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease yearly escalation percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_OperatingLeaseYearlyEscalationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_PrepaidContractExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid contract expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_PrepaidContractExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_PromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_PromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_RentalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_RentalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementAndServiceFeesRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate for management and service fees under arrangement to manage operations, including, but not limited to, investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementAndServiceFeesRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to suppliers for goods and services during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of a specific restructuring plan and related activities including the facts and circumstances leading to the restructuring or decision to exit an activity, and the expected completion date. This concept and related items would be utilized for each plan if multiple exit plans have been implemented in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=JUNS_EntityThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=JUNS_EntityThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=JUNS_TiberendStrategicAdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=JUNS_TiberendStrategicAdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_DominantTreasureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_DominantTreasureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_ExecutiveEmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_ExecutiveEmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=JUNS_AquanovaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=JUNS_AquanovaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_LicensingAndRoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_LicensingAndRoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_DebtForgivenessAndExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_DebtForgivenessAndExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_LicenseAgreementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=JUNS_MurdochChildrensResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=JUNS_MurdochChildrensResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Segment Reporting Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 21,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,231<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,086,574<span></span>
</td>
<td class="nump">492,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">6,839,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_SegmentNetLoss', window );">Segment net loss</a></td>
<td class="num">(8,908,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other interest income (expense), net</a></td>
<td class="nump">263,824<span></span>
</td>
<td class="nump">651,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating loss</a></td>
<td class="num">(8,644,897)<span></span>
</td>
<td class="num">$ (2,439,625)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable Geographical Components [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">21,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,086,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,997,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_SegmentNetLoss', window );">Segment net loss</a></td>
<td class="num">(4,066,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other interest income (expense), net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating loss</a></td>
<td class="num">(4,066,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=JUNS_PharmaceuticalOperationsMember', window );">Pharmaceutical Operations [Member] | Reportable Geographical Components [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,086,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">817,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_SegmentNetLoss', window );">Segment net loss</a></td>
<td class="num">(2,904,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other interest income (expense), net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating loss</a></td>
<td class="num">(2,904,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=JUNS_PremiumNutritionalSupplementsMember', window );">Premium Nutritional Supplements [Member] | Reportable Geographical Components [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">21,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,179,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_SegmentNetLoss', window );">Segment net loss</a></td>
<td class="num">(1,161,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other interest income (expense), net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating loss</a></td>
<td class="num">(1,161,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember', window );">Corporate Segment and Other Operating Segment [Member] | Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,842,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_JUNS_SegmentNetLoss', window );">Segment net loss</a></td>
<td class="num">(4,842,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other interest income (expense), net</a></td>
<td class="nump">263,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net operating loss</a></td>
<td class="num">$ (4,578,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_JUNS_SegmentNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment net loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">JUNS_SegmentNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>JUNS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=JUNS_PharmaceuticalOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=JUNS_PharmaceuticalOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=JUNS_PremiumNutritionalSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=JUNS_PremiumNutritionalSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Report (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Oct. 01, 2025 </div>
<div>Segments</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 26, 2026</div></th>
<th class="th"><div>Dec. 19, 2025</div></th>
<th class="th"><div>Oct. 24, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue', window );">Market value of listed securities closed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue', window );">Market value of listed securities closed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from conversion debt</a></td>
<td class="nump">$ 625,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity securities allocated to the segregated group of participating or dividend-paying policies and contracts identified as the closed block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477301/944-805-55-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investments in debt securities that are deemed to be available for sale that are allocated to the segregated group of participating or dividend-paying policies and contracts identified as the closed block. Change in fair of such securities is a component of change in other comprehensive income in the period, which is reflected in the closed block disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477301/944-805-55-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 805<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478072/944-805-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=JUNS_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>207</ContextCount>
  <ElementCount>357</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Convertible Debt and Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability</Role>
      <ShortName>Convertible Debt and Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Segment Report</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SegmentReport</Role>
      <ShortName>Segment Report</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Convertible Debt and Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables</Role>
      <ShortName>Convertible Debt and Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Stockholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Segment Report (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SegmentReportTables</Role>
      <ShortName>Segment Report (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/SegmentReport</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Organization and Description of Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative</Role>
      <ShortName>Organization and Description of Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/RelatedPartyTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Schedule of Key Assumptions in Valuation Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails</Role>
      <ShortName>Schedule of Key Assumptions in Valuation Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Schedule of Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails</Role>
      <ShortName>Schedule of Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Convertible Debt and Derivative Liability (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative</Role>
      <ShortName>Convertible Debt and Derivative Liability (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Employee Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails</Role>
      <ShortName>Schedule of Employee Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails</Role>
      <ShortName>Schedule of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Operating Lease Right-of-use Asset and Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails</Role>
      <ShortName>Schedule of Operating Lease Right-of-use Asset and Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails</Role>
      <ShortName>Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails</Role>
      <ShortName>Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Segment Report (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative</Role>
      <ShortName>Segment Report (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/SegmentReportTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://jupiterneurosciences.com/role/SubsequentEvents</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>juns-20251231.xsd</File>
    <File>juns-20251231_cal.xml</File>
    <File>juns-20251231_def.xml</File>
    <File>juns-20251231_lab.xml</File>
    <File>juns-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="661">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "JUNS",
   "nsuri": "http://jupiterneurosciences.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "juns-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "juns-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "juns-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "juns-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "juns-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 283,
   "keyCustom": 74,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 41,
   "hidden": {
    "total": 119,
    "http://fasb.org/us-gaap/2025": 89,
    "http://jupiterneurosciences.com/20251231": 27,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 207,
   "entityCount": 1,
   "segmentCount": 72,
   "elementCount": 646,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 661,
    "http://xbrl.sec.gov/dei/2025": 44,
    "http://xbrl.sec.gov/cyd/2025": 10,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://jupiterneurosciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://jupiterneurosciences.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://jupiterneurosciences.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GrossProfit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
     "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://jupiterneurosciences.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness",
     "longName": "999014 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://jupiterneurosciences.com/role/SignificantAccountingPolicies",
     "longName": "999015 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://jupiterneurosciences.com/role/RelatedPartyTransactions",
     "longName": "999016 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses",
     "longName": "999017 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability",
     "longName": "999018 - Disclosure - Convertible Debt and Derivative Liability",
     "shortName": "Convertible Debt and Derivative Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://jupiterneurosciences.com/role/StockholdersEquityDeficit",
     "longName": "999019 - Disclosure - Stockholders\u2019 Equity (Deficit)",
     "shortName": "Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://jupiterneurosciences.com/role/IncomeTaxes",
     "longName": "999020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://jupiterneurosciences.com/role/CommitmentsAndContingencies",
     "longName": "999021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://jupiterneurosciences.com/role/SegmentReport",
     "longName": "999022 - Disclosure - Segment Report",
     "shortName": "Segment Report",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://jupiterneurosciences.com/role/SubsequentEvents",
     "longName": "999023 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "999024 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables",
     "longName": "999025 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables",
     "longName": "999026 - Disclosure - Convertible Debt and Derivative Liability (Tables)",
     "shortName": "Convertible Debt and Derivative Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables",
     "longName": "999027 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://jupiterneurosciences.com/role/IncomeTaxesTables",
     "longName": "999028 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables",
     "longName": "999029 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "JUNS:ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "JUNS:ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://jupiterneurosciences.com/role/SegmentReportTables",
     "longName": "999030 - Disclosure - Segment Report (Tables)",
     "shortName": "Segment Report (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
     "longName": "999031 - Disclosure - Organization and Description of Business (Details Narrative)",
     "shortName": "Organization and Description of Business (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-14",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-08-25",
      "name": "JUNS:MinimumClosingBidPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "999032 - Disclosure - Significant Accounting Policies (Details Narrative)",
     "shortName": "Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999033 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-10-27",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-03-152024-03-15_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "longName": "999034 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Schedule of Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
     "longName": "999035 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative)",
     "shortName": "Accounts Payable and Accrued Expenses (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_EmploymentAgreementsMember",
      "name": "us-gaap:DeferredCompensationLiabilityCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails",
     "longName": "999036 - Disclosure - Schedule of Key Assumptions in Valuation Measurement (Details)",
     "shortName": "Schedule of Key Assumptions in Valuation Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails",
     "longName": "999038 - Disclosure - Schedule of Derivative Liability (Details)",
     "shortName": "Schedule of Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31",
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "JUNS:DerivativeFairValueOfIssuance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
     "longName": "999039 - Disclosure - Convertible Debt and Derivative Liability (Details Narrative)",
     "shortName": "Convertible Debt and Derivative Liability (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-272025-10-27",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999040 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails",
     "longName": "999041 - Disclosure - Schedule of Employee Stock Options Outstanding (Details)",
     "shortName": "Schedule of Employee Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999042 - Disclosure - Schedule of Warrant Activity (Details)",
     "shortName": "Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "JUNS:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_WarrantMember13963437",
      "name": "JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "JUNS:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative",
     "longName": "999043 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-24",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails",
     "longName": "999044 - Disclosure - Schedule of Income Tax Provision (Details)",
     "shortName": "Schedule of Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "longName": "999045 - Disclosure - Schedule of Deferred Tax Assets (Details)",
     "shortName": "Schedule of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999046 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails",
     "longName": "999047 - Disclosure - Schedule of Operating Lease Right-of-use Asset and Liability (Details)",
     "shortName": "Schedule of Operating Lease Right-of-use Asset and Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "JUNS:ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "JUNS:ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails",
     "longName": "999048 - Disclosure - Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)",
     "shortName": "Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999049 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ConvertibleNotesPayableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-05-01",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails",
     "longName": "999050 - Disclosure - Schedule of Segment Reporting Information (Details)",
     "shortName": "Schedule of Segment Reporting Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative",
     "longName": "999051 - Disclosure - Segment Report (Details Narrative)",
     "shortName": "Segment Report (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2025-10-012025-10-01",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-012025-10-01",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999052 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-02-26_us-gaap_SubsequentEventMember",
      "name": "us-gaap:AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_AccountsPayableAndAccruedExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "AccountsPayableAndAccruedExpensesAbstract",
     "auth_ref": []
    },
    "JUNS_AccountsPayableAndAccruedExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "AccountsPayableAndAccruedExpensesTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountsPayableAndAccruedExpensesTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts payable and accrued expenses",
        "label": "Accounts payable and accrued expenses owned",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r40",
      "r44",
      "r1147"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1200"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Account receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "JUNS_AccruedAndOutstandingObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "AccruedAndOutstandingObligations",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued and outstanding obligations",
        "documentation": "Accrued and outstanding obligations."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_AccruedLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "AccruedLicenseFees",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued license fees",
        "documentation": "Accrued license fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1235"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fee",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r520",
      "r521",
      "r522",
      "r523",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r520",
      "r521",
      "r522",
      "r523",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r888",
      "r1237"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1160",
      "r1240"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r955",
      "r969",
      "r996"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r958",
      "r972",
      "r999"
     ]
    },
    "JUNS_AgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "AgreementTerm",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreements term",
        "documentation": "Agreement term."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r991",
      "r1000",
      "r1004",
      "r1012"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "verboseLabel": "Share based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r431",
      "r432"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discounts",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r62",
      "r338",
      "r1184"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock options",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "JUNS_AquanovaAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "AquanovaAGMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aquanova AG [Member]",
        "documentation": "Aquanova AG [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r99",
      "r117",
      "r142",
      "r145",
      "r146",
      "r179",
      "r192",
      "r218",
      "r222",
      "r262",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r472",
      "r474",
      "r541",
      "r640",
      "r641",
      "r647",
      "r740",
      "r850",
      "r851",
      "r864",
      "r888",
      "r901",
      "r902",
      "r914",
      "r1115",
      "r1116",
      "r1190"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r126",
      "r142",
      "r145",
      "r146",
      "r262",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r472",
      "r474",
      "r541",
      "r888",
      "r1115",
      "r1116",
      "r1190"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market value of listed securities closed",
        "documentation": "Fair value of equity securities allocated to the segregated group of participating or dividend-paying policies and contracts identified as the closed block."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r1232"
     ]
    },
    "us-gaap_AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Market value of listed securities closed",
        "label": "Assets Designated to Closed Block, Fixed Maturity, Available-for-Sale, at Fair Value",
        "documentation": "Fair value of investments in debt securities that are deemed to be available for sale that are allocated to the segregated group of participating or dividend-paying policies and contracts identified as the closed block. Change in fair of such securities is a component of change in other comprehensive income in the period, which is reflected in the closed block disclosure."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r1232"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r928",
      "r951"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r928",
      "r951"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r928",
      "r951"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "JUNS_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors [Member]",
        "documentation": "Board of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r651",
      "r707",
      "r735",
      "r888",
      "r901",
      "r902",
      "r914",
      "r1041"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r64",
      "r139"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Change in Cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r64"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Non-Cash Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_CashPaidForInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "CashPaidForInterest",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Cash paid for interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r119",
      "r120",
      "r121",
      "r142",
      "r146",
      "r170",
      "r171",
      "r173",
      "r175",
      "r181",
      "r182",
      "r262",
      "r305",
      "r308",
      "r309",
      "r310",
      "r314",
      "r315",
      "r346",
      "r347",
      "r349",
      "r350",
      "r352",
      "r355",
      "r358",
      "r359",
      "r361",
      "r364",
      "r371",
      "r541",
      "r686",
      "r687",
      "r688",
      "r689",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r708",
      "r727",
      "r748",
      "r771",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r1032",
      "r1068",
      "r1070",
      "r1080"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ClinicalTrialExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ClinicalTrialExpensesPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Expenses",
        "documentation": "Clinical Trial Expenses [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "JUNS_CommitmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "CommitmentShares",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CommitmentShares-0]",
        "verboseLabel": "Commitment shares issued",
        "documentation": "Commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r93",
      "r650",
      "r726"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r297",
      "r298",
      "r810",
      "r1106",
      "r1111"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906",
      "r908",
      "r909",
      "r910",
      "r911",
      "r1076",
      "r1077",
      "r1079",
      "r1160",
      "r1233",
      "r1240"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r727"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, share issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, share outstanding",
        "verboseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r727",
      "r746",
      "r1240",
      "r1241"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r347",
      "r354",
      "r653",
      "r888"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r84"
     ]
    },
    "JUNS_ConserveCashPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConserveCashPercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ConserveCashPercentage-0]",
        "documentation": "Conserve cash percentage."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r142",
      "r143",
      "r149",
      "r151",
      "r179",
      "r194",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r644",
      "r850",
      "r851",
      "r1115",
      "r1116"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "auth_ref": [
      "r97",
      "r142",
      "r143",
      "r149",
      "r151",
      "r179",
      "r194",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r644",
      "r850",
      "r851",
      "r1115",
      "r1116"
     ]
    },
    "JUNS_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConsultantMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]",
        "documentation": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "documentation": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]",
        "documentation": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ConvertibleAmountIntoSharesOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConvertibleAmountIntoSharesOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible amount into shares of common stock",
        "documentation": "Convertible amount into shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r92",
      "r1201"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory note fair value",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1172",
      "r1177",
      "r1178",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r317",
      "r318",
      "r328",
      "r329",
      "r330",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "JUNS_ConvertibleDebtOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConvertibleDebtOneMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt I [Member]",
        "documentation": "Convertible Debt I [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r92",
      "r1201"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, fair value",
        "verboseLabel": "Convertible promissory note",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "JUNS_ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes with Embedded Derivative Liabilities",
        "documentation": "Convertible Notes With Embedded Derivative Liabilities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Member]",
        "documentation": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateAndOtherMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Segment and Other Operating Segment [Member]",
        "documentation": "Component of entity providing financial and operational oversight and administrative support considered to be operating segment and operating segment, classified as other. Excludes intersegment elimination and reconciling item."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r1085"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r604",
      "r834",
      "r838",
      "r875",
      "r1059"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1025"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1025"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1027"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1025"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1019"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1019"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r1017"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1020"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1026"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1024"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1021"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt and Derivative Liability",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r142",
      "r144",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r303",
      "r304",
      "r316",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r332",
      "r339",
      "r340",
      "r342",
      "r511",
      "r551"
     ]
    },
    "JUNS_DebtForgivenessAndExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DebtForgivenessAndExchangeAgreementMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Forgiveness and Exchange Agreement [Member]",
        "documentation": "Debt Forgiveness and Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r39",
      "r40",
      "r88",
      "r92",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r887",
      "r1066",
      "r1067",
      "r1069",
      "r1075",
      "r1107",
      "r1108",
      "r1109",
      "r1183",
      "r1185",
      "r1199"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, convertible, conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r319"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of debt description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25",
      "r37",
      "r39",
      "r88",
      "r92",
      "r551"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r551",
      "r552",
      "r860",
      "r861",
      "r887"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1069"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r343",
      "r551",
      "r552",
      "r887"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Annual percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r318"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r511",
      "r644",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r887",
      "r1066",
      "r1067",
      "r1069",
      "r1075",
      "r1183",
      "r1185"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r859",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debt instrument, measurement input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r887",
      "r1066",
      "r1067",
      "r1069",
      "r1075",
      "r1107",
      "r1108",
      "r1109",
      "r1183",
      "r1185",
      "r1199"
     ]
    },
    "JUNS_DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount percentage",
        "documentation": "Original issue discount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25",
      "r26",
      "r36",
      "r74",
      "r75",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r511",
      "r644",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r887",
      "r1066",
      "r1067",
      "r1069",
      "r1075",
      "r1183",
      "r1185"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1118",
      "r1182",
      "r1183",
      "r1185"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "JUNS_DecreaseIncreaseInPrepaidContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DecreaseIncreaseInPrepaidContracts",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in prepaid contracts",
        "documentation": "Decrease (increase) in prepaid contracts.",
        "label": "DecreaseIncreaseInPrepaidContracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r78"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "JUNS_DeferredTaxAssetsDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DeferredTaxAssetsDerivativeLiability",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Deferred tax assets derivative liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred Tax Asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S Federal and State net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Orphan drug credit",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued salaries",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r477",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r716",
      "r718",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r759",
      "r760",
      "r761",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r786",
      "r787",
      "r790",
      "r792",
      "r829",
      "r830",
      "r833",
      "r876",
      "r877",
      "r904",
      "r906",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1173",
      "r1174"
     ]
    },
    "JUNS_DerivativeFairValueOfIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DerivativeFairValueOfIssuance",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of the 2025 Notes",
        "documentation": "Derivative fair value of issuance."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_DerivativeGainLossOnDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DerivativeGainLossOnDerivative",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DerivativeGainLossOnDerivative]",
        "documentation": "Derivative gain loss on derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows",
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on change in fair value of convertible notes",
        "negatedLabel": "Gain on change in fair value of convertible notes",
        "verboseLabel": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r1152"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r477",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r716",
      "r718",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r759",
      "r760",
      "r761",
      "r762",
      "r765",
      "r766",
      "r767",
      "r768",
      "r786",
      "r787",
      "r790",
      "r792",
      "r829",
      "r830",
      "r833",
      "r876",
      "r877",
      "r904",
      "r906",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at December 31, 2023",
        "periodEndLabel": "Derivative liability Balance",
        "label": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r507",
      "r529",
      "r530",
      "r535",
      "r537",
      "r538",
      "r539",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r741",
      "r743",
      "r744",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r829",
      "r831",
      "r832",
      "r833",
      "r1163",
      "r1164",
      "r1165",
      "r1234"
     ]
    },
    "JUNS_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities current not disclosed flag",
        "documentation": "Derivative liabilities current not disclosed flag."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfFairValueDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534"
     ]
    },
    "JUNS_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities not disclosed flag",
        "documentation": "Derivative liabilities not disclosed flag."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative [Member]",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r150",
      "r167",
      "r476",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r512",
      "r513"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r928",
      "r951"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r928",
      "r951",
      "r992"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "JUNS_DominantTreasureAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "DominantTreasureAgreementMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dominant Treasure Agreement [Member]",
        "documentation": "Dominant Treasure Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r136",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r168",
      "r170",
      "r173",
      "r174",
      "r175",
      "r178",
      "r345",
      "r430",
      "r465",
      "r470",
      "r527",
      "r528",
      "r639",
      "r660",
      "r840"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r136",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r170",
      "r173",
      "r174",
      "r175",
      "r178",
      "r345",
      "r430",
      "r465",
      "r470",
      "r527",
      "r528",
      "r639",
      "r660",
      "r840"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share of Common Stock",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r177"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r870"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r439",
      "r457",
      "r870"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r870",
      "r1066",
      "r1072",
      "r1148"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nondeductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444",
      "r1066",
      "r1072",
      "r1148"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r870",
      "r1066",
      "r1072",
      "r1148"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation",
        "label": "Compensation expense for services",
        "terseLabel": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "JUNS_EmploymentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "EmploymentAgreementsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreements [Member]",
        "documentation": "Employment Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_EntityOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "EntityOneMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity One [Member]",
        "documentation": "Entity One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "JUNS_EntityThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "EntityThreeMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Three [Member]",
        "documentation": "Entity Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_EntityTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "EntityTwoMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Two [Member]",
        "documentation": "Entity Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r105",
      "r106",
      "r107",
      "r132",
      "r133",
      "r134",
      "r152",
      "r153",
      "r154",
      "r156",
      "r163",
      "r165",
      "r167",
      "r180",
      "r263",
      "r264",
      "r288",
      "r344",
      "r373",
      "r430",
      "r455",
      "r456",
      "r462",
      "r463",
      "r464",
      "r466",
      "r469",
      "r470",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r553",
      "r554",
      "r559",
      "r658",
      "r675",
      "r676",
      "r677",
      "r695",
      "r771"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r955",
      "r969",
      "r996"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r993"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "JUNS_ExecutiveEmploymentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ExecutiveEmploymentAgreementsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Employment Agreements [Member]",
        "documentation": "Executive Employment Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Key Assumptions in Valuation Measurement",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "JUNS_FifteenForFourForwardStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "FifteenForFourForwardStockSplitMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(15:4) Forward Stock Split [Member]",
        "documentation": "Fifteen for Four Forward Stock Split [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r341",
      "r369",
      "r511",
      "r524",
      "r536",
      "r540",
      "r542",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r646",
      "r659",
      "r857",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r889",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1161",
      "r1163",
      "r1164",
      "r1165",
      "r1172",
      "r1175",
      "r1177",
      "r1178"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r1000"
     ]
    },
    "JUNS_GainLossDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "GainLossDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value change",
        "documentation": "Gain loss derivative instruments net pretax"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_GainLossOnAmortizationOfPrepaidContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "GainLossOnAmortizationOfPrepaidContracts",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of prepaid contracts",
        "documentation": "Gain loss on amortization of prepaid contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows",
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on change in fair value of derivative liability",
        "negatedLabel": "Loss on change in fair value of derivative liability",
        "verboseLabel": "Fair value change",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "JUNS_GainLossOnForgivenessOfAccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "GainLossOnForgivenessOfAccruedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on forgiveness of accrued compensation",
        "documentation": "Gain loss on forgiveness of accrued compensation.",
        "label": "GainLossOnForgivenessOfAccruedCompensation"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_GainOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "GainOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on extinguishment of debt",
        "documentation": "Gain on extinguishment of debt."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_GainsLossesOfExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "GainsLossesOfExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at December 31, 2025",
        "documentation": "Gains losses of extinguishment of debt",
        "label": "GainsLossesOfExtinguishmentOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (Gain) on extinguishment of debt",
        "label": "Extinguishment of derivative liability - Note II",
        "verboseLabel": "Gain on modification",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ]
    },
    "JUNS_GainsOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "GainsOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:GainsOnExtinguishmentOfDebt]",
        "documentation": "Gains on extinguishment of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r751"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r98",
      "r142",
      "r145",
      "r146",
      "r262",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r541",
      "r844",
      "r850",
      "r1081",
      "r1084",
      "r1086",
      "r1087",
      "r1088",
      "r1115"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r928",
      "r951"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r436",
      "r439",
      "r445",
      "r446",
      "r447",
      "r448",
      "r453",
      "r458",
      "r459",
      "r460",
      "r461",
      "r645",
      "r681",
      "r691",
      "r870"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r437",
      "r438",
      "r448",
      "r449",
      "r452",
      "r454",
      "r685"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in accrued compensation",
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accrued interest",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in operating lease right of use asset",
        "documentation": "(Decrease) increase in operating lease right of use asset.",
        "label": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Increase in prepaid and other current assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r991",
      "r1000",
      "r1004",
      "r1012"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1016"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1016"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1016"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r192",
      "r196",
      "r202",
      "r222",
      "r550",
      "r850",
      "r851",
      "r1239"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r835",
      "r838",
      "r1058"
     ]
    },
    "JUNS_InterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "InterestPayable",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InterestPayable-0]",
        "documentation": "Interest payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest expense",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r1200"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r827",
      "r888"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r115",
      "r122",
      "r273",
      "r274",
      "r275",
      "r603",
      "r839"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r195",
      "r222",
      "r850",
      "r1057"
     ]
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "JP",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1187"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1067",
      "r1075",
      "r1199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1067",
      "r1075",
      "r1199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1067",
      "r1075",
      "r1199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r39",
      "r40",
      "r41",
      "r43",
      "r44",
      "r45",
      "r46",
      "r142",
      "r145",
      "r146",
      "r262",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r473",
      "r474",
      "r475",
      "r541",
      "r725",
      "r843",
      "r864",
      "r914",
      "r1115",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r94",
      "r655",
      "r888",
      "r901",
      "r902",
      "r1066",
      "r1071",
      "r1095",
      "r1181"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r114",
      "r142",
      "r145",
      "r146",
      "r262",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r473",
      "r474",
      "r475",
      "r541",
      "r888",
      "r1115",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_LicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "LicenseAgreementsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements [Member]",
        "documentation": "License Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_LicenseAgreementsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "LicenseAgreementsTwoMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreements II [Member]",
        "documentation": "License Agreements Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_LicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "LicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:LicenseFee]",
        "documentation": "License fee."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_LicensingAndRoyaltyAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "LicensingAndRoyaltyAgreementsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing And Royalty Agreements [Member]",
        "documentation": "Licensing And Royalty Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r92",
      "r1201"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase commitment",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementAndServiceFeesRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ManagementAndServiceFeesRate",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Success fee percentage",
        "documentation": "Rate for management and service fees under arrangement to manage operations, including, but not limited to, investment."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r963"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r964"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r965"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r965"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r965"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r965"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r299",
      "r300",
      "r301",
      "r302",
      "r399",
      "r424",
      "r425",
      "r426",
      "r433",
      "r534",
      "r602",
      "r673",
      "r674",
      "r680",
      "r717",
      "r718",
      "r779",
      "r781",
      "r783",
      "r784",
      "r794",
      "r805",
      "r806",
      "r808",
      "r809",
      "r820",
      "r821",
      "r856",
      "r865",
      "r868",
      "r871",
      "r872",
      "r873",
      "r880",
      "r881",
      "r885",
      "r886",
      "r898",
      "r1117",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r532",
      "r533",
      "r534",
      "r871",
      "r872",
      "r873",
      "r880"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r871",
      "r872",
      "r873",
      "r880"
     ]
    },
    "JUNS_MinimumClosingBidPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "MinimumClosingBidPrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum closing bid price",
        "documentation": "Minimum closing bid price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r299",
      "r300",
      "r301",
      "r302",
      "r399",
      "r424",
      "r425",
      "r426",
      "r433",
      "r534",
      "r602",
      "r673",
      "r674",
      "r680",
      "r717",
      "r718",
      "r779",
      "r781",
      "r783",
      "r784",
      "r794",
      "r805",
      "r806",
      "r808",
      "r809",
      "r820",
      "r821",
      "r856",
      "r865",
      "r868",
      "r871",
      "r872",
      "r873",
      "r880",
      "r881",
      "r885",
      "r898",
      "r1117",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_MonteCarloModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MonteCarloModelMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Monte Carlo Pricing Model [Member]",
        "documentation": "Valuation technique estimating price of option using Monte Carlo pricing model."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r1033",
      "r1163",
      "r1164",
      "r1165"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "JUNS_MurdochChildrensResearchInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "MurdochChildrensResearchInstituteMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Murdoch Childrens Research Institute [Member]",
        "documentation": "Murdoch Childrens Research Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash flows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "label": "Net operating loss",
        "verboseLabel": "Net Loss",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r66",
      "r95",
      "r107",
      "r112",
      "r129",
      "r130",
      "r134",
      "r142",
      "r145",
      "r146",
      "r149",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r167",
      "r172",
      "r262",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r345",
      "r348",
      "r351",
      "r356",
      "r430",
      "r465",
      "r470",
      "r528",
      "r541",
      "r657",
      "r747",
      "r769",
      "r770",
      "r835",
      "r837",
      "r838",
      "r912",
      "r1115"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "JUNS_NonRule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "NonRule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Modified [Flag]",
        "documentation": "Non-Rule 10b5-1 Arrangement modified [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "JUNS_NoncashFinancingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "NoncashFinancingCost",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expenses, net",
        "label": "Other interest income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expenses):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1073",
      "r1074"
     ]
    },
    "JUNS_NoteIIHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "NoteIIHolderMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note II Holder [Member]",
        "documentation": "Note II Holder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable, related party",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable fair value",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r39",
      "r40",
      "r1162",
      "r1172",
      "r1177",
      "r1178",
      "r1179",
      "r1180"
     ]
    },
    "JUNS_NotesPayableRelatedPartyAssignToNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "NotesPayableRelatedPartyAssignToNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable, related party assign to Note payable",
        "documentation": "Notes payable, related party assign to note payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://jupiterneurosciences.com/role/SegmentReportDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r855",
      "r1083"
     ]
    },
    "JUNS_OfferingPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OfferingPricePercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:OfferingPricePercentage-0]",
        "documentation": "Offering price percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r835",
      "r838",
      "r844",
      "r1081",
      "r1084",
      "r1086",
      "r1087",
      "r1088"
     ]
    },
    "JUNS_OperatingLeaseIncremetalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OperatingLeaseIncremetalBorrowingRate",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease incremetal borrowing rate",
        "documentation": "Operating lease incremetal borrowing rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails",
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Total lease liabilities",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liability",
        "verboseLabel": "Current operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "JUNS_OperatingLeaseLiabilityGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OperatingLeaseLiabilityGross",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office lease liability",
        "documentation": "Operating lease liability gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/ScheduleOfFutureMinimumLeaseLiabilityPaymentsUnderNon-cancelableOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use asset, net",
        "totalLabel": "Balance of ROU, net",
        "verboseLabel": "Operating lease right-of-use asset, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "JUNS_OperatingLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated reduction",
        "documentation": "Operating lease, right-of-use asset, accumulated amortization.",
        "label": "OperatingLeaseRightOfUseAssetAccumulatedAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office lease ROU",
        "documentation": "Operating lease right-of-use asset before accumulated amortization."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_OperatingLeaseYearlyEscalationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OperatingLeaseYearlyEscalationPercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease yearly escalation percentage",
        "documentation": "Operating lease yearly escalation percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r108",
      "r109",
      "r110",
      "r682",
      "r683"
     ]
    },
    "JUNS_OriginalIssueDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OriginalIssueDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OriginationOfLoanToPurchaseCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OriginationOfLoanToPurchaseCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Origination costs",
        "documentation": "Cash outflow for origination of loan for purchasing common stock."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit cards",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r888"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r1067",
      "r1075",
      "r1199"
     ]
    },
    "us-gaap_OtherCommitmentsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDescription",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments, Description",
        "documentation": "Description of the nature and terms of commitment."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets",
        "documentation": "Other Current Assets And Prepaid Expenses [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r749",
      "r795",
      "r796",
      "r797",
      "r901",
      "r902"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-payment amount",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r648",
      "r721",
      "r722",
      "r864",
      "r901",
      "r902",
      "r914",
      "r1202",
      "r1236"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liability",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r888"
     ]
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal balance",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-paid advances via convertible promissory notes",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1097"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r957",
      "r971",
      "r998"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1001"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1001"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense paid through sale of common stock",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting discounts, commissions and offering expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToSuppliers",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for services",
        "documentation": "Payments of cash to suppliers for goods and services during the current period."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1062"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "JUNS_PharmaceuticalOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "PharmaceuticalOperationsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pharmaceutical Operations [Member]",
        "documentation": "Pharmaceutical Operations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r727"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A preferred stock, shares issued",
        "verboseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheetsParenthetical",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r727",
      "r746",
      "r1240",
      "r1241"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r347",
      "r353",
      "r652",
      "r888"
     ]
    },
    "JUNS_PremiumNutritionalSupplementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "PremiumNutritionalSupplementsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Premium Nutritional Supplements [Member]",
        "documentation": "Premium Nutritional Supplements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_PrepaidContractExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "PrepaidContractExpenses",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid contracts expense",
        "documentation": "Prepaid contract expenses."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_PrepaidContractsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "PrepaidContractsPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Contracts",
        "documentation": "Prepaid contracts [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid contracts",
        "verboseLabel": "Prepaid expense",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r276",
      "r277",
      "r828"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid contracts, noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock for net proceeds",
        "verboseLabel": "Proceeds from conversion debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from offering, net of offering costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock",
        "verboseLabel": "Net proceeds from offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable, related parties",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherDebt",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance convertible note payable, net",
        "documentation": "Amount of cash inflow from debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProductLiabilityContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductLiabilityContingencyLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r1112",
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductLiabilityContingencyTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Liability Contingency [Table]",
        "documentation": "Disclosure of information about product liability contingency arising from reasonably possible loss from liability related to individual product."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r1112",
      "r1113",
      "r1114"
     ]
    },
    "JUNS_PromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "PromissoryNote",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note",
        "documentation": "Promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_PurchaseCommitmentPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "PurchaseCommitmentPerShare",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase commitment per share",
        "documentation": "Purchase commitment per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares issued value",
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r93"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r299",
      "r300",
      "r301",
      "r302",
      "r377",
      "r399",
      "r424",
      "r425",
      "r426",
      "r429",
      "r433",
      "r534",
      "r577",
      "r586",
      "r602",
      "r673",
      "r674",
      "r680",
      "r717",
      "r718",
      "r779",
      "r781",
      "r783",
      "r784",
      "r794",
      "r805",
      "r806",
      "r808",
      "r809",
      "r820",
      "r821",
      "r856",
      "r865",
      "r868",
      "r871",
      "r872",
      "r873",
      "r880",
      "r881",
      "r885",
      "r886",
      "r898",
      "r906",
      "r1110",
      "r1117",
      "r1164",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197"
     ]
    },
    "JUNS_RangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeEightMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Eight [Member]",
        "documentation": "Range Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Five [Member]",
        "documentation": "Range Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeFourMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Four [Member]",
        "documentation": "Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "auth_ref": [
      "r187",
      "r299",
      "r300",
      "r301",
      "r302",
      "r377",
      "r399",
      "r424",
      "r425",
      "r426",
      "r429",
      "r433",
      "r534",
      "r577",
      "r586",
      "r602",
      "r673",
      "r674",
      "r680",
      "r717",
      "r718",
      "r779",
      "r781",
      "r783",
      "r784",
      "r794",
      "r805",
      "r806",
      "r808",
      "r809",
      "r820",
      "r821",
      "r856",
      "r865",
      "r868",
      "r871",
      "r872",
      "r873",
      "r880",
      "r881",
      "r885",
      "r886",
      "r898",
      "r906",
      "r1110",
      "r1117",
      "r1164",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197"
     ]
    },
    "JUNS_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]",
        "documentation": "Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_RangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeSevenMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Seven [Member]",
        "documentation": "Range Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_RangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeSixMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Six [Member]",
        "documentation": "Range Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]",
        "documentation": "Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]",
        "documentation": "Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ReceivablesforSaleofCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ReceivablesforSaleofCommonStockMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables for Sale of Common Stock [Member]",
        "documentation": "Receivables for Sale of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r993"
     ]
    },
    "JUNS_ReductionOfOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ReductionOfOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfOperatingLeaseRight-of-useAssetAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reduction of lease liability",
        "documentation": "Reduction of operating lease liability.",
        "label": "ReductionOfOperatingLeaseLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148",
      "r149",
      "r231",
      "r378",
      "r395",
      "r563",
      "r564",
      "r649",
      "r656",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r745",
      "r778",
      "r1238"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148",
      "r149",
      "r563",
      "r564",
      "r565",
      "r566",
      "r649",
      "r656",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r745",
      "r778"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148",
      "r149",
      "r231",
      "r563",
      "r564",
      "r566",
      "r752",
      "r753",
      "r756"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148",
      "r149",
      "r231",
      "r378",
      "r395",
      "r563",
      "r564",
      "r649",
      "r656",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r745",
      "r778",
      "r1189",
      "r1238"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r564",
      "r567",
      "r692",
      "r693",
      "r694",
      "r754",
      "r755",
      "r756",
      "r775",
      "r777"
     ]
    },
    "JUNS_RentalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RentalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases rent expenses",
        "documentation": "Rental expenses."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_RepaymentOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RepaymentOfDerivativeLiability",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of derivative liability",
        "documentation": "Repayment of derivative liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment on convertible note payable",
        "label": "Repayments of convertible debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r689"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment on notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "srt_ReportableGeographicalComponentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ReportableGeographicalComponentsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails",
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r822",
      "r835",
      "r836",
      "r850",
      "r1198"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r953",
      "r967",
      "r994"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r954",
      "r968",
      "r995"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r961",
      "r975",
      "r1002"
     ]
    },
    "JUNS_RestrictedStockIssuedForForgivenessOfSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RestrictedStockIssuedForForgivenessOfSalary",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock issued for forgiveness of salary",
        "documentation": "Restricted stock issued for forgiveness of salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDescription",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary payment description",
        "documentation": "Description of a specific restructuring plan and related activities including the facts and circumstances leading to the restructuring or decision to exit an activity, and the expected completion date. This concept and related items would be utilized for each plan if multiple exit plans have been implemented in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r68"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r76",
      "r654",
      "r678",
      "r679",
      "r690",
      "r728",
      "r888"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r152",
      "r153",
      "r154",
      "r156",
      "r163",
      "r165",
      "r167",
      "r263",
      "r264",
      "r288",
      "r344",
      "r430",
      "r455",
      "r456",
      "r462",
      "r463",
      "r464",
      "r466",
      "r469",
      "r470",
      "r514",
      "r516",
      "r517",
      "r519",
      "r526",
      "r553",
      "r554",
      "r675",
      "r677",
      "r695",
      "r1240"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Revenues, net",
        "verboseLabel": "Net revenues",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r179",
      "r193",
      "r194",
      "r216",
      "r222",
      "r226",
      "r228",
      "r230",
      "r374",
      "r375",
      "r376",
      "r604"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r135",
      "r142",
      "r145",
      "r146",
      "r179",
      "r193",
      "r194",
      "r216",
      "r222",
      "r226",
      "r228",
      "r230",
      "r262",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r541",
      "r640",
      "r642",
      "r850",
      "r875",
      "r901",
      "r902",
      "r1115"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty amount",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "JUNS_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty payments percentage",
        "documentation": "Royalty percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "JUNS_Rule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "Rule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Modified [Flag]",
        "documentation": "Rule 10b5-1 Arrangement modified [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, consideration received on transaction",
        "verboseLabel": "Gross proceeds from offering",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of shares of common stock",
        "verboseLabel": "Sale of stock, consideration received on transaction, shares",
        "terseLabel": "Sale of stock number of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price per share",
        "verboseLabel": "Sale of stock exercise price",
        "terseLabel": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r29",
      "r30",
      "r31",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liability",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r481",
      "r486",
      "r494",
      "r504"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Derivative Liability",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": [
      "r1151",
      "r1153",
      "r1155"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Provision",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r870",
      "r1148"
     ]
    },
    "JUNS_ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Right-of-use Asset and Liability",
        "documentation": "Schedule of Operating Lease Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148",
      "r149",
      "r563",
      "r564",
      "r566",
      "r752",
      "r753",
      "r756"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SegmentReportTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Stock Options Outstanding",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r80"
     ]
    },
    "JUNS_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity",
        "documentation": "Schedule of Share Based Compensation Warrant Activity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "JUNS_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r179",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r230",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r295",
      "r296",
      "r467",
      "r468",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r847",
      "r850",
      "r851",
      "r858",
      "r900",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r184",
      "r228",
      "r229",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r711",
      "r713",
      "r715",
      "r780",
      "r782",
      "r785",
      "r798",
      "r805",
      "r807",
      "r808",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r825",
      "r841",
      "r866",
      "r867",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r899",
      "r906",
      "r1203",
      "r1204",
      "r1205",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "JUNS_SegmentNetLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "SegmentNetLoss",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment net loss",
        "documentation": "Segment net loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SegmentReport"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Report",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r179",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r205",
      "r207",
      "r208",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r230",
      "r845",
      "r848",
      "r849",
      "r850",
      "r852",
      "r854",
      "r855"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Segment",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r228",
      "r846",
      "r847",
      "r853"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r834",
      "r835",
      "r836",
      "r838",
      "r1059"
     ]
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r1201"
     ]
    },
    "JUNS_SeniorSecuredNoteConvertibleDebtTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "SeniorSecuredNoteConvertibleDebtTwoMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Note Convertible Debt II [Member]",
        "documentation": "Senior Secured Note Convertible Debt II [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_SeniorSecuredNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "SeniorSecuredNoteMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Note [Member]",
        "documentation": "Senior Secured Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1045",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_ServiceAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceAgreementsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Agreements [Member]",
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period description",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested performance description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, forfeited",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, outstanding, beginning balance",
        "periodEndLabel": "Number of shares, outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price per share, outstanding, beginning balance",
        "periodEndLabel": "Weighted average exercise price per share, outstanding, ending balance",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price per share, exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share exercised."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price per share, forfeited",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share forfeited.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price per share, forfeited",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price per share granted."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life (years), outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average remaining life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails",
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, exercisable",
        "label": "Vested options, number exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "verboseLabel": "Granted stock option purchase shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, outstanding, beginning balance",
        "periodEndLabel": "Aggregate intrinsic value, outstanding, ending balance",
        "label": "Grant date fair value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails",
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, outstanding, beginning balance",
        "periodEndLabel": "Number of options, outstanding, ending balance",
        "label": "Number of options, outstanding",
        "verboseLabel": "Stock options issued",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding, beginning balance",
        "periodEndLabel": "Weighted average exercise price, outstanding, ending balance",
        "verboseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vested",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "verboseLabel": "Stock option exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "JUNS_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Share based compensation shares authorized under stock option plans exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options vest percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual term (years), exercisable",
        "documentation": "Share based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested options, weighted average remaining life",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "JUNS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average contractual term (years), outstanding",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfEmployeeStockOptionsOutstandingDetails",
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual term (years), outstanding",
        "verboseLabel": "Outstanding options, weighted average remaining life",
        "terseLabel": "Vested, term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://jupiterneurosciences.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "JUNS_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement [Member]",
        "documentation": "Standby Equity Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r111",
      "r179",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r230",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r296",
      "r467",
      "r468",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r847",
      "r850",
      "r851",
      "r858",
      "r900",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r119",
      "r120",
      "r121",
      "r142",
      "r146",
      "r170",
      "r171",
      "r173",
      "r175",
      "r181",
      "r182",
      "r262",
      "r305",
      "r308",
      "r309",
      "r310",
      "r314",
      "r315",
      "r346",
      "r347",
      "r349",
      "r350",
      "r352",
      "r355",
      "r358",
      "r359",
      "r361",
      "r364",
      "r371",
      "r541",
      "r686",
      "r687",
      "r688",
      "r689",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r708",
      "r727",
      "r748",
      "r771",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r1032",
      "r1068",
      "r1070",
      "r1080"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r51",
      "r52",
      "r105",
      "r106",
      "r107",
      "r132",
      "r133",
      "r134",
      "r152",
      "r153",
      "r154",
      "r156",
      "r163",
      "r165",
      "r167",
      "r180",
      "r263",
      "r264",
      "r288",
      "r344",
      "r373",
      "r430",
      "r455",
      "r456",
      "r462",
      "r463",
      "r464",
      "r466",
      "r469",
      "r470",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r553",
      "r554",
      "r559",
      "r658",
      "r675",
      "r676",
      "r677",
      "r695",
      "r771"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r228",
      "r229",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r711",
      "r713",
      "r715",
      "r780",
      "r782",
      "r785",
      "r798",
      "r805",
      "r807",
      "r808",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r825",
      "r841",
      "r866",
      "r867",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r899",
      "r906",
      "r1203",
      "r1204",
      "r1205",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r180",
      "r346",
      "r347",
      "r349",
      "r352",
      "r554",
      "r604",
      "r684",
      "r696",
      "r708",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r750",
      "r751",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r771",
      "r837",
      "r838",
      "r907",
      "r1238"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r180",
      "r231",
      "r346",
      "r347",
      "r349",
      "r352",
      "r554",
      "r604",
      "r684",
      "r696",
      "r708",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r750",
      "r751",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r771",
      "r837",
      "r838",
      "r907",
      "r1238"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r956",
      "r970",
      "r997"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "verboseLabel": "Fair value of grant date",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "JUNS_StockIssuedDuringPeriodSharesCommitmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesCommitmentShares",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares issued in connection with SEPA, shares",
        "documentation": "Stock issued during period shares commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued in connection with automatic conversion of convertible notes, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r48",
      "r51",
      "r76",
      "r333"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with warrant amendments, shares",
        "verboseLabel": "Principal amount shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r47",
      "r48",
      "r76"
     ]
    },
    "JUNS_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for payment of interest, shares",
        "documentation": "Issuance of common stock for payment of interest, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services rendered, shares",
        "verboseLabel": "Number of shares issued for service rendered",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, shares",
        "verboseLabel": "Number of shares issued",
        "terseLabel": "Purchase of common stock",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r76",
      "r686",
      "r771",
      "r800"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock issued for consulting agreement, shares",
        "verboseLabel": "Number of restricted shares issued, shares",
        "terseLabel": "Number of restricted shares issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r76",
      "r409"
     ]
    },
    "JUNS_StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock sold in offering, net of offering costs, shares",
        "documentation": "Stock sold in offering, net of offering costs, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciling shares due to forward stock split, shares",
        "documentation": "Number of shares issued during the period as a result of a stock split."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r76"
     ]
    },
    "JUNS_StockIssuedDuringPeriodSharesWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercises",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for warrant exercises, shares",
        "documentation": "Stock issued during period shares warrant exercises."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercised",
        "documentation": "Stock issued during period shares warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_StockIssuedDuringPeriodValueCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueCommitmentShares",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares issued in connection with SEPA",
        "documentation": "Stock issued during period value commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued in connection with automatic conversion of convertible notes",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r51",
      "r52",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with warrant amendments",
        "verboseLabel": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48",
      "r51",
      "r52",
      "r76"
     ]
    },
    "JUNS_StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for payment of interest",
        "documentation": "Issuance of common stock for payment of interest value."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted stock units for forgiveness of accrued salary",
        "documentation": "Stock issued during period value issuance of restricted stock units for forgiveness of accrued salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for services rendered",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r76",
      "r695",
      "r771",
      "r800",
      "r913"
     ]
    },
    "JUNS_StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock options for forgiveness of accrued salary",
        "documentation": "Stock issued during period value of issuance of stock options for forgiveness of accrued salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock issued for consulting agreements",
        "verboseLabel": "Restricted stock fair value",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r48",
      "r76"
     ]
    },
    "JUNS_StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock sold in offering, net of offering costs",
        "documentation": "Stock sold in offering, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_StockIssuedDuringPeriodValueStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueStockSplits",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciling shares due to forward stock split",
        "documentation": "Stock issued during period value stock splits."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for warrant exercises",
        "documentation": "Stock issued during period value warrant exercises."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_StockIssuedInConnectionInterestPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedInConnectionInterestPayment",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued in connection interest payment",
        "documentation": "Stock issued in connection interest payment."
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_StockIssuedInConnectionWithConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockIssuedInConnectionWithConvertiblePromissoryNotes",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued in connection with convertible promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1154"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested stock options expense",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "JUNS_StockOptionsIssuedForForgivenessOfSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StockOptionsIssuedForForgivenessOfSalary",
     "crdr": "credit",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options issued for forgiveness of salary",
        "documentation": "Stock option issued for forgiveness of salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://jupiterneurosciences.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets",
      "http://jupiterneurosciences.com/role/StatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r51",
      "r52",
      "r67",
      "r729",
      "r746",
      "r772",
      "r773",
      "r888",
      "r914",
      "r1066",
      "r1070",
      "r1071",
      "r1095",
      "r1181",
      "r1240"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit)",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r373",
      "r511",
      "r525",
      "r774",
      "r776",
      "r804"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock split",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "JUNS_StructuringFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "StructuringFee",
     "crdr": "debit",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:StructuringFee-0]",
        "documentation": "Structuring fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r569"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://jupiterneurosciences.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r570"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "JUNS_TiberendStrategicAdvisorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "TiberendStrategicAdvisorsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tiberend Strategic Advisors [Member]",
        "documentation": "Tiberend Strategic Advisors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1188"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r341",
      "r369",
      "r511",
      "r524",
      "r536",
      "r540",
      "r542",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r646",
      "r659",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r889",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1161",
      "r1163",
      "r1164",
      "r1165",
      "r1172",
      "r1175",
      "r1177",
      "r1178"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "JUNS_TwelveConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "TwelveConvertiblePromissoryNotesMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twelve Convertible Promissory Notes [Member]",
        "documentation": "Twelve Convertible Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "JUNS_TwoConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "TwoConsultantsMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Consultants [Member]",
        "documentation": "Two Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative",
      "http://jupiterneurosciences.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative",
      "http://jupiterneurosciences.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative",
      "http://jupiterneurosciences.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "JUNS_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r183",
      "r185",
      "r186",
      "r187",
      "r640",
      "r642",
      "r842"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r871",
      "r873",
      "r880",
      "r1165"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfKeyAssumptionsInValuationMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r871",
      "r873",
      "r880",
      "r1165"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "JUNS_WarrantHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "WarrantHolderMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Holder [Member]",
        "documentation": "Warrant Holder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ScheduleOfWarrantActivityDetails",
      "http://jupiterneurosciences.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r908",
      "r909",
      "r910",
      "r911"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r175"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://jupiterneurosciences.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r175"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://jupiterneurosciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "JUNS_YAIIPNLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://jupiterneurosciences.com/20251231",
     "localname": "YAIIPNLtdMember",
     "presentation": [
      "http://jupiterneurosciences.com/role/ConvertibleDebtAndDerivativeLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "YA II PN, Ltd [Member]",
        "documentation": "YA II PN, Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480397/718-10-55-16"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477301/944-805-55-4"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-3"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001493152-26-014687-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-014687-xbrl.zip
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M_A[ZC+2,ZV[E5'X LRON0U1**R:Z#]2@GOIB1FRF.!(#:HUF;*A:K8A=+5S
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M>A0Q5[G)W>]SE^?EH7<607R]*8-?NUCP2&G]56(NQ8P.K/U42(L9,( ,S'(
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ML>#H6B7R,G2X90 B&!QWB]US9>!R<,*!P\B;R9B9 F\56? B]FDVA>4CY:]
M<F5S \^\W3G?C1M_YWR_J_.U7K7SQ4," S:#[,U^U<"D;^!P85!S#"#9%IIX
MWQ@E\9)EMQ(9!'D!$<2AXZZU&(4>;7Z,<)E/>"R)%(JZ;+8QMD+:1(%L&<8
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M'V[RPN94Q6^2AA\IQ6^9_A]02P,$%     @ K(6!7&(FS^\^"@  FU0   H
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MW2C< S;2WMWDB<VIAE\N&GW;*'XIZ?\!4$L#!!0    ( *R%@5P4U*0-G ,
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MW:^>P'1YO[<5[:M7FILUS%!,M@*Q1A@=CAQ_C6YENVO:=)O[?U!+ P04
M" "LA8%<!F!E'  (  !1+@  "@   &5X,S$M,BYH=&WM6EU3XS@6?4]5_H.6
MJIV"JH3PT4SMD@Q5@9CIS+) )69K^E&QY42+;;DE.^GLK]]S)3L)(=#T-O3
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M1!JB9T\$(AD)S0[W&XB@@R.F(O9;D4DL-$ 56IE BC0@1/TTV'U;:_4&W7L
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MVU\=?_"_&#@E!0,)7"U9KK*M\C99Q^]5(Y9SCU2>J^28C6(>W+)]&&!/\A9
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M@%$>F$7&/&C!L9E^%(7O4]$?BC@A?',DLZL37%YFVI=,!:A]0XD$BM1"&-&
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MN1.-[B1VO0#ZF<HCDZHL0%.1H</ SX6*&BV-?DV[1P>IK<Z+>]:MG]U(P)V
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MDU/4#1$2B>XD!0]A'B$WN,:[.Z01SYW=$][51+Z#Z4/R8S> F8\WO7ED"T'
M2#A (<65&(VZ<R0  :EC10I:X<_E0'< Z/2T/D&O(^TH1X[4/!<&PQ/0-'NI
M-NQ$:@""9SN;SW\+#=SQ.UCBI0M 0CR\HMK-,?4HP=YNX=#K:K8GI:D?>,J+
M%&(M5,Y.NW5[]42]2_/*H$[1=9< TRMR0>A(<CSYY/67SDU H,8AA$89P)L"
M]+NA_!'1UQ*\<*/6JWKV.1GM8SEW3@3=3!('Y+7_;48.7A7"/#R#6JP_<:'\
M2%"]YB@75-U.<L["2C%?S']5FK5J/R757LX;-_A[!_H9T@?F2J:R*E&%;U&)
M[(@)9E':+3(41Z[*^@Z$P2$]P$=%%5=SD@#GUQC8=745'9KOU0; @/D\(<D
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M.30#-,>6XIJPL$09)+!4_)6## ]-*Y&@ .*&B/*82 T&=XRPWPMSX1 '$ N
M!C2+5>Q1414K+:K#AQ(M8125VJYI<**.' 1V2DT]<6CHPQ 8-L".',2P,+5
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M8-U#@8H::-/4E['!A"*0VG8-!YG2=.EOV$B87T&LR4R7^%!!%.S-O8TJ>S3
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MV,'&D7MS&=4!RO?"Z6RJJ"T0-B8W+5F9B=:/*848BZ3(@=QL>"%I")AJ+I0
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MLGVKWAH ^NG;LZ,_$6F>_GKU[N3-_P-02P,$%     @ K(6!7,9M/ZU:?P0
M*E0E  P   !F;W)M,3 M:RYH=&WLO6ESV\B2+OR=OP)7<\Z,'4'*7+3:;M^@
MM;C5;2TCR>WQO/&&HP@42;1!@,8BB?WK;V96%5  08J4P$W&F3/'%(FEEJS<
M\\GW__=AX!AWW ]LS_WMOQK;]?\RN&MZENWV?ONO]LW1V=E__=\/E??]$"Z#
M2]W@MZU^& [?OGES?W^_?=_:]OS>F\;AX>&;![QF2UST]B'WNF:]WGCS/^>?
M;\P^'[":[08A<TT>W^38[H_)S\=?XTL[OF.G+L5OU$M:;\8>#;]:R0WZQ7MO
MQ(^I2\/<2W?%I:&ZU Z\G69C?]HXQ!7Q#0^3KFW@F&&&_'\^7G].+@_SKT\N
M?1/ZS VZGC]@(6PA/FFW5F_6FGO:0VH!-U,/@K^W>][=H\\YJ+4:ZCECFY.>
M*?[<84&\XA;/++=Z)_P =S1WU8514.LQ-HPO[K*@0X^5/V0O#D=#'N1>3;^D
M+K="/W-]:N#P\QO\&>]IUNHM;;;<M/*'#S^D7F%ZD1OZH_R+Y8^I&P(_'!\]
M?)E^ZFC"Z^&'U(5_?+FXB:_\.QK:(?=='OE>8-IPD'FP;7H#NJ/1A-GA4>;,
M^E Q\#_O0SMT^(?W;\2_E?<#'C(#'U;C/R/[[K>M(\\-N1O6;F&5M@Q3_/7;
M5L@?PC=TWM_ 76_$(]__GUK-.+6Y8[TU;GCXSKA@ _[6>+ >WAEGQ_3A>[W9
M_O[EYM_-XT_M]A7\@P.#?U[=VV$?_CTY.H;_9:X%_WOT[?BU4:O-^-Q6_3LN
MQ?=)2_!=+<'LC]PYH9OJC7KC"7?O'G[G0.HP$?AO>\!="_X_/'58[WN7.0&?
MXTEM[4G'GAG1@^S 9,X5]VW/.H7O@N^GW^9XY+[VR!,7MG]T! _UF7/F6OSA
M3S[Z7@=>O;=_N-<\F/VQ>Q]A<X^_-[Y+MB>>#U_-\8CF]YL^\WGPO?F=F+QX
M1D#?S?&88QS)E7Q4:VQ SWKVX?>KR.??=_2'#.&;.1YQ\/V&]W ?@^^[\<?9
M[]__^/WF\CMRZT8=7OYC&[Z5MW<\:V0$X<CAOVUUX;R^-1KU86C<V@.8XP6_
M-ZZ] 7.KXHLJO,*WN\@6+/M.W6;9P=!AH[>&Z[D<?[,?WN(1YS[P#?K#MBSN
M(A/!O^"J"Z!)WS8%@W@(KWGWMZU3WQO@L:G5&_#?T*//C2;Q6!NXVRDSPSK^
MI[5EN#!'>"^WWZ9.RM8'.BKOWZ3>4M1[=_3W3CQ76Q].ORUH +OZ ')/X=:'
MY!A.'L2I#T\$H2V?)N7FV[9)XB>XYB:W[UC'X1<\/(I\']ZQE1IQ.[CLPBAW
M]%$"135M)/!Z_1!V*')M<2T<'I ]P5O7=D .^!$0B!J9&L?C0SMS[V 0GC^"
M$<TWE,.BAW+,NQR6Q+KF,*2(SS.:1FNWZ-%<>"$/KM@(=VO:5DF"^B[O^W[-
M'19RZXKYX>B<#SK<'QOL3KWHP8)R )9#:"-ES3CN22NYLU/TX"[#/O<_VZQC
M.W9H\V"&U1P?U=XJ1S5QK?8+']60^Z#VN[W/'#1X-;S1A>>:3UBUW6;QA#88
MV"')R+9KH4X*8P75#A9POI$=K'IDD_9TMW"^=N5+QG83>N:/OY@S@;=E.0DJ
M!#QHIV^?P%+V"C^ULXYZYSFC+IQKIU\KE,ZS((BX-1=Y[NL#$T]9^M@F$>C^
M_I+&=AF%Z+I!!]1\BW>X)@.<M(('C04,\,@+PLON)\^SD/_ *;BSP>"]\9S,
M[DJ==$?HI)-'V6P4SB(_@2$>7/E>UPZ?.*9F8Q'Z9T!L^\PUO0$_@U'!?N0/
M<*(BKPUQI_ A?F*V^QE6[M(]!MYV!^+Y#H89P.-(VH#B#,09LH>G#[EPYIT,
M-&_P8ZK^S/N_4QA-HHN(5O;2/7E 41W901_7\[)[S#M/W_[=PBTD8CA].,?<
M#TY^1J"-Y3*;EI2#8*B&WN![8NJA*_>&.=SKHHKBN5,$8O.@<(%(;_OD,QBO
M=1SYL-#"HB:!3KP/7<6@+PV&W W(XSP;;<0"__%9'19^)!<WJV=M7_'F^>*W
M[QI8E^URZX3Y+CP^F#2UPG@4G7R:EU!^QJ:%7V/$Z+)[#8+ M\U02OTO\/[@
MU//AOSU@8RX'MM9MFR8,P((M8OZH>-(MS,);HVG/MN6M>F%NBD?G?ME-9D_7
M70[Q]N5N=JM>V/%=BPG/NLV%NU:F33Q#V^U[YENDESY-(VDUEK=GPO(8.G :
M"R>]XK36!4ZC;5DVOHDY5\RVSMPC-K1#YDR:4F'.I^*G-#[8XOW'7%HTGV<F
M[GGHI7 OU7/&.Q]A[!;N_G[*V)^CZ+5V%Z/1/FYE%#/ZPMW6RQQ]\4[#HI3L
MW9C(LJ[<QV>UO[8VTOBLGK5]^VMK(TW>OADUJ?W"_3B/V0O< FU1^1J7LGN%
MRYU%3''.?3M8GJ'SE?E(J"</W#?M8#E[=K \&_:)TYMWOXKU0A8UH6E^R=;!
M4@^.R ? 3.+++KD/ED%GAXL1S 5/<4Y:.RS,.I[# :2M-3"_*S82CO%98B,%
M;>;.$GTA1<][OAW>J2_/LYGD**BHX^(WLK$\S\(3IS?G?C4*3VIYW'Q\AF:_
MTRC<VGK.>.<RU7>*CT$_9>S/H__%"-['C=U"1M\L7*8N.IJ]4WQVXX*BV3O%
MQ]W; \\/[7_(QA2![&,[H-Q?6-2!'0V>OJJ%>^EQ+0-<3!X4&X/?*<XY&6<)
MB$W/"XW,:M9/'7%QB9(T8DS79$'_U'9!KX%UQ=R@)]+H M(1B>__:;O65+WJ
M\:'M%2Z(03+XF/=ZS,6_9^YXYOP3!UN<?XUV.!FA^A<.^!!6%A-/\?HG6XH[
MQ3O(QI=5#O;D 8\.G'_,A7[Z@ MG3>,#5F4*8]F\,Q- <4Z>R:.D=92)Y&U@
MK$\-1^T<+($&II9;S#[2!:1+>R;G5H!#T(L9GDJ?N\4'N*_A])!M"F)HUB'F
MZ.(@)OQ'JT5VB[=W].%KE2//D?F[C06D<B=T0 =KXO@>I=+=XHT ?73*@7$&
M;[#!L(HZCFU>=N%XC64FS[&BQ>?:YHTYY71Y^EB+]:%DDD3B,$!*_YN2$S/+
MD M.9=63>!8RWN)"SE)%3=B67K(&8LONN;<>_OY<QKN[,,_:F0M\R^5TB=)B
MI;OPB1QBK_#3)NV3:V_$'*W K.U:%T^JYMHO[I"-&]9:(=Q,53[)G?E2ZZ!X
MI7"1@RW<S55,'=)!*OJPAK4^!X<'"QC@!!^S>+S.:%58[FDE-HUZZD05-GI\
MSL=LQD$;XX@]3EK7QU%RC>1:E >9F54 =AI-_"NW>WU@T&W0U%B/J]^O0$0^
M36V'F6>.Y]729O_(Y$%D=KD=1GXR_:=.<8U)\W'IV:BG\B=?$''.-/>=#2?/
MF2:Y".;^[ W.F>%BMOA@3;=83H]0.B*A+LP0W<&'GT[2,!J-YDH.\Z29@@(J
M)BO"5UKX1Z;1S>G(D%DR8NZ-UN%>:Z>UGUV#9J$,65@$Q2_ -%J'TT"/6^0B
MM>J;02@:FUC,.A3)'%=)+'*A%D4N"U%RBE\IS;Z8@:GFKL'8W'>*/"JK))$B
MUF(1\N6DVT47"^8'8,;&+7NX9B$7T"H1[*0$JP&9^50MH'F@'W/$<EOYJ!\U
M+)JI?-KGC5G&$H4Y#B,50:-Q3\?4#)/L (NN8WSR^"8L8*NXC+LL=%@\Q$EH
M9I.6K/CPQ<Q#FK1*C<(]:)\Y#(1/@)B2["PXCO@%C/#VGCN@S<)P^_,@.S5:
M>\4C=16(B=5H'11.?#* .F<VVQ4PZ0$S>13:)G,2IB08_/? #[]?\Z'GAVB(
M?.)>SV?#/EZ*HLES<:OR9<%.\=A:<\XPR8WT80+ ?-NN11$\.;>QWV$K)?+F
MA"D5[YV?$ZYG!=M8/*37L^>\@(TM/#GVF@><^68?AG8,9.MX0WR]S'29<V]%
MSMY%%/HR9_8F&@X=X49Y_@877_)7Q-R+W^/B$YK@E9X2"D++>]K^+NSL%E>A
M5/24%TO2Q6<#/7?>SYC,X5,RQO"[&)09IT;!-@(_I]\1G/]M0%T7X+D&M5)X
MV_?Q%7]';E##H2.\^?9# %Q9_(S ^+]M!?8 -@IAWN5K4D\6KPJ\R)=O@HL(
M%/NM7"8!>#S9,I- ].HN3B#(ZLOX:]O"'[HV]PV:!,]M9G!T]F<:+SE[<_RR
M-WEOD^\:DO-Y; A!R/SP&!C/AV0FZCG);]F[.+#$^!Z:<?)N2[]#?:V_77TG
MEW+B\L:J9WVOUJIOSI**'AWAAV3L\?/E+\4MSI[L[K")BR/'OH#%F>A\V)AE
M2AW+G2<<RYW%'\L-6]+4L4PM3O''<N/H35N<G44OS@P8[RM9M^3P"04\^5[^
M8L%('H:.;=I2.3<L&RZD%E.:U9#,YA9[#PEU)O@X2B4&/MC!UH>\>\23W[_)
M?:$VU#>Y8]V0@U'N_?KM_=+/_31L\PTF@IL0]A-O/W(892H3,E]JSZ?,_%<Y
M^.7FK\_F+_SDM\:\8=E*[9>PY2):G3A"TML^-N<5;79KV9L]'2/AY6_\U/F_
M="*8"Z[AY=*"K,.:81%>.D$\ D_S<DD@T??S)O["MWTC'2$+7YS'@8I?_G%8
M%P:X<!UX/I3GE[_QZZ@6+8T(2K5H,]2BI7.%4BU:![5H<=O^A&8%+W_O5WK:
MUSC2^LQ.$2^?<-9&A]A$(BIUD#7603:1H$H=9N4ZS/J3S3S8SR^?8M:'QZQ7
MZN<S@;=?/N&LI^:S(414:CZ;HOEL"$&5FL]Z:3[K1383TM]^)5:S%OK.,M/=
M2GUE3?6551!!J6^LL;ZQ2JY0Z@OK$.U9W+;/H#"6Y0^K+']88ZUQ!C=K23MK
M0SL;YFO-[Y7QBY%/[B*4W&<V[E-2T-I1T'KQH#C!J;Y7:^QL9 *P'/OB[($F
M[EAS=R,71XY]<5JS7/WDD[*C3^UNR+E+'6$B[ J#F*&B^P(<N'#S61&!H-Z.
MAERSFV>:]"I9CWY29F0]J7L6QGI*LEDGLEDF>Q4O:)4$L-8$T%JPOZUQN)'R
M58Y]D?*UT2QSD-<B,I61I;0O:Z+&QZZ$1KW6W$D^*:9Z@SCTG9%8W*O(-_LL
MX.V>SWF"84FP@>?LP1Y$@\TG*&2PEUT-QE[CMK.LQJ.$-<M@8$7?4I<4\7+\
M,[7 *W1C$'G,Z\;0[UE(Z'U>FBTI=!5Q&)T,%J$.U%NU9BGGUB/62GNQT,T^
MK#7V-U3WH[$O=''VX1WE25B/DX![L;C-WJO5F[7F7@*]%74"_C/"!;I[$?(N
M,Z'$ IYPP4JW6^[&0K?[8%.=RG+LJTC%2'>$VN#3T(:G6K8384>A&VY&/K5V
M/GDPG<CB%JX#<L0H)'3^RZY*P5'MLSZ.\A^0/E&IU2ICIK-F^P2A;YNAQ/S[
MXMIA<'WSI22YF4ANZNJ5)#@;"9X,AHXWXEQKKER2WTSD-W'E2M*;+6.D%+";
M)V#7*Z5DAI3(4L"^- &[8218"MB7(V#7B_0RB&$84SOJV[Q[\@ +B@M[V>W:
MINHLM\GD-D\J)D:^IBS#RC(;EE1)5%+!&E/!P@N+QL5020_K1@]K+%&FMGDL
MJ6AMJ6A=#?]6K;&;?'KA*G$ZUW*ME5C<C3E93NJ>A:1FER2R2A))9^'JF[V0
M-.S49K]<+TW^AJ^-7V4IFSY)'&Q./'J-V>>CLK8\6VOBLUPCHDG8\$ZM>?B8
M<J^29"^\D)^=_>XY5JGVSZ?VSS.N8]X)SX#Y^E$F3W=\^5<G*9!L%BHI\ 4E
MA984^@Q^J]/HK/Q6OV=E_+:DV9?)W28YZD]ME[FFS9R-IP+<T5L[=& CSUS+
MOK.MB#F9S<Z?[8OSQT^*S96;_?)#<%(;$6X=DI&JFNH%X/E-*R6;/..7?K[+
M+5^7+5]:Z_)RR]=ERQ?>EO4I%>[RVF_ML[.KB\^A];)I8FEE[A:WWW[F/>:<
MT,II0\BL].HDSJ)+EO$%FUK%2F-?G.=(OF 3ERD',R%>J#DP$_:3=R\&,V$_
MJ1JE3$XXYQ;F>L(!I61/X98''@'K>'OO;3[;^XL'H>WV,O6CL\]]I8QHF6>M
M)(SU)8Q-X2ZMS6'88V=M@;!EC;3-<7O/G3M^Y+EWW _MCL.OX$C:0>#Y(_3!
MOP#[8V*,8;:IKXCG-A:=WMO :GA*S"PI8GTI(L5LY9;-Q6P;BRX9>1+UQ/+]
M[.JRI*<B(ZJ(1F);-O-'V/[FLDN9*VF](E[SE\K:FG1.]I)/)6M;=]8F-VHN
MUI:Y9T'5</785Z<M'B[SI<M?,+U,FNPJ7?'U1?C"$IX![V@DGV(/+7=MSZ>Z
M4F[A4<FL3&R#)3>H$M07B/XXD5YF7J9"I=U4/_)C^[!*9H<4-B^ST^\I/NWW
M^0>@I.N2FA0UM>*ROTR,LZ2F]::FUA/*_UI+*/_;$0#A\E-)39M!37*[YJ*F
MS#V+RITM:6A]:6@LAW:A?5RFRZ=?:>]7;^(M-MNJCM(MQYQ/^T)*<RYE_N<M
MSJ]IQ*7RQ(B6%N>/D"\HR;8DVZ+U^];\^GWJGD7H]]EN426QE\1>A/FQAMVN
M)L,[9E3OS2?=F[[GA[?<'Y E,59?GSO?5=JJ:P2?E4D75R1RSED VCI._,P=
M1B'EB%WYMJDX8GPA/NN(^8YW[EG<V7Q:RLY\G)P>6YM"&>)?S(DH'^^6FWW7
M_AEE!Y.W_BM25I>12-XLJ;2DTN=2:7/Q5*J)VY)*2RI]&I4NHT!L$I4*4+>_
M/ =6S($9E+0ZVPK]RA2[6NE?4FQ)L?/SV%5J B7%EA0[/\6N4BNXMH,?IS[G
M9W"GSX/PFH4S:;&B>[KMOHSNZ?/3\>1UVP!:GF4$>;W<]>U^P4K) @\,>R@/
MS"]T8/3M?L$'9JH67TJ8\L!LF(19@A%12ICRP+P<";-:J[N4,.6!V3@)LPP0
MT%+"E ?FQ4B89>!I*NH_AD?=,80#WWPRC_&/L[F 29Y@>K(KVN3%(6@^FC]7
M;G>9-Y>IZBE)8W6<8!D@Z>@3VV"<MP4"6L@7;.(RY2 ,SE="FKEG(5UM=VK-
M5O))R^$>##R74)<VG]/<A+!L>+L 8T882L^%/X-L'G=FSBN317(WYB26U#T+
M2?C?J]5;R:?)Q/*R<-$61CYS#6)- =&R.A02QIPZ5.J>U=*MZF! "Q"#197D
M7!@Y3P:KSZQY>7@V^_ D>&+EX5G6X5D,.%EY>)9_>/H^+V7/TH]/LNKE 5KM
M 4H@CDI#HS0TLDZG#-TMTS=?4N"O2X%K'"YX5.%X&=2Y(82Q1H(TA4S33#XI
M??.+:W'_'F%/W%ZV7]^+] 5/0X"9LAC%,KA-\T=+HIF?V27W+ K6OJ3DDI+G
M"^4F-+D(Q9'P_<>;+I3465+GK'QV7ISAU#T+"1)+8RB;R$E+)DIH-Y]@DVR3
M)!\%,RPSS0RS4UYEC'AN V1W"0;(!,.YI)726,VA%86&W]"0S(\\-X@<E,P9
M 2G:K'/^(F@)LYEO[1#MV#/7LN]L*V).&A8SM0J%2D;1?74LPWSB J^6<N='
MWF\L)FTJ<4N7]%K2:ZYCNK'0;$AJ(]#83SZ5-%C28 [/1-*8EV?J]RRH6TE)
MKR6]YO!,G?(6D4%>WZLUZLFGD@9+&LRQII$TYK2F4_<L C6[I->27G-X9H;R
M%E&25-_78BL?/5B6R^ZQ[7,S]/P-;C#]&'7ESW1UV[R_T'"%?$&YX:O<\*P<
MVI\WTIJY9R$1@,-:?3?YE#2B]Q)V_(*))&^>JR01W(-Y242_9R&J2DD8JQ86
M^A8O1%CD<X%?8J?+\S_/^2])XD6<?-T.;<;*X5>&61WA[YYC<?_E;F_.-%=I
M[C4780?HYEYCK]S@51IZC;T%&WJ-O7*K5[/5XR9>LMFSFWC)/0N1WP>U1LGB
M5\@!</T7R@'P!>56KP<'T#=[5@Z@W[/,U+UK'H2^;8;<(O_W%]<.@^N;+V*U
M&BW8U?W6BF"9GD<SCWC]I\Y[E=']]<OEFYPC7!+/.A'/6B8-MV+BD:";&PKQ
MUGK"XK:6?S*EW"=@W1AN9Y-/(#7U_,@";F&%!_Q*:,7T;=".PK[GV_]PBXI.
MM #NE</<X./HY('[IAV(IJ :V# I#>DU*D]M'JIW24X;0$Y+0:^>B>/$&$4E
MB4PDD=EQG'YYCE.2TYJ2TQIQG 36J222R40R!_A5R75*DEI?DEH?SG/J11OL
M45T2E22+5/*=Q_A.25!K2U!KQ'5>1'>011/)ZAO.; [7*0EJ70EJ?;C.C?U0
MTL@C-!*O4<ES'N,Y)3FM*3FM$<?A=WR#ZQR7123)*I5<YU&N4Y+4^I+4^G">
M$[O7#TLR>81,M%4J.<]CG*<DJ34FJ65RGO$TS#+!8@,2+-8X13/32K@DIPT@
MIZ6T'YZ)XY0)%FN:8+&9'*<DIS4EIS7B.&5RQ?HF5VPHURE):GU):GTX3YE>
ML;;I%9O)=TJ"6EN"6B.N4Z97K&MZQ89RG9*@UI6@EL)U,J2A*K$E L(+H(S9
MVGJEYOOB-OE1U(;4]+'0OK73VB^W_9<4%H^B-)3$4D:I)T2I2_'Q$J/-<I.;
MA"MVF'3IX_X=:$QQ4TX);!G#^MKP!Y#:3>C#&O9LLVW=V<%&XX,_TJ\T)IK\
MA7F4+N89PC5W8%6M*SC]HUL81\!,5&E!G=5_T=&'IV_'BHA6TM3BB+95J[=2
MK25+HBV)]IE$*VEJ<40+ A[%_.9 &VF+(\>^."M&OF 3ERFER&46:B9%+G//
M$A&@)'ZUWH3[Y?)$';$[9\:E[C_6QKZQFWQ2)'/L#6P7SOZMSUD0^3S3O?VE
MTLTCTUZAEX%V9WXO0V.!K0!*DEDSDLGZ(QL+;!)2CX5-/2UL3AZX&6''=-%+
MC5;K%Y$Z,TQ]91RD_@3Q4U\\("A2Z4'RJ22BM28BN4MS$5'FG@7I,/6=Y%-)
M1&M-1'*7YM=EDGL*)Z+&'K;6:;223XJ(/MLF+/Q$GU/[9\1<[XZU/[UL@IJP
M#(5XF"QNO_W,>\PYH<72WII=W571K"**>6@V>\_"RPM+2OU%*769<:2=DN9*
MFLLQ-1=(<\^4R-]-+W)#?_3]CZOO@1]^/[==>Q -2H)< X*<Y778[R>.Y'_B
M7L]GP[YMJIX_<G??_G%5V-NT-$+\,T4PJSEC65UB[<\8>RC/6'G&YCAC.L&\
MN#,VFXV)P2K7NO9&S($=_T4<%3-,O33ZTND%Z F)%?!CW@E//;]GWW&7!P&L
MXLF#V:?#E8Y#_&HJ^<P+LV[\>C%*NB2;Q1F&&6=$29<E7:X#S))DR+O)I])U
ML8E:[&)E_%R)%=E["I?QC5U\07VRDRW&#5%7G$>^Y9G]H[[M6#Y<>\T#SGRS
M?P;'R0ZCD)>ND)S56S"-S[@I+\2 6P,GB3PVBW.2S'$NI_A#YCRTY;G<T!,Q
METMC/5C-IIU+J>/)%RQ0<I:'\.53;$HOS-#L3'IAYIY%9#K50?=L)9\>JXQZ
M@63[W)*GQ64UT8[,F=64NF<-""9.G:-ET'#"XAN/O,' <PF(HZ2QA;#&L;4O
MY'US%D6/;7-YL&9#XR@Y\1IPXDU"Y"@)9M4$LZ:5>?.*[E)"+Z;PO928Q22.
MEE1<4O',<<$,/2ZB\5.C'@OD^N8B$<C1SRN\ZJM!(KCJ,W_ 3!Z%Z(J]A%<0
MV*,Z_.@KO^9#SP]9Q^&ZUS:AU\WG!O%1_!@%-B8!W(BG!9H1.'VA"O-9(TZ"
MY]@6/?P,1A4D#NS9-J+4VF8C?)\/[&AP$86^C6O-G)MH.'12HJ^D_ICZ'U^M
M\@ALS!%XV71=TM RO25'G@_+"6]KN]9EV.?^F-D@?[\ +58LU>:2UHPL,]'=
M<]=FX9QR[/W9M2^)6R?NO9BX][+XAE$GX#\C--+N>#9!%HC M3HC8;Y=1;[9
M9T$V9W2CB3P]>329,U9RWNH4:B-/BY3/LOPKH_.])]#Y7AH(\9ET'KFV(/(O
M-\=9*AP(8*0/=N#M-!O[;^$2]2CU4^KY^*S\AXNF ).>+R=/USSQ!3"TJ_R7
M6/8=4/[8@N*=%]$ S3-OG.IFGWMV>#G/U-YXS%U"G9K^SD?7(_O2G,>JG_7I
M/[Z,<#[X]%T:PL>G$H$4?I->((ZKO&BF=[Q_8S^\A47RX%CS +ZA+_J<67AX
MW[^!R7^H5"KOAT80CAS@EETX 6^-1GT8&K? 1@+C@M\;U]Z N=4 #DSWG3%@
M?L]VWQKU=P:>E1IS[![\:<*8D$W_YW\T]NKOWK\9PG/?_Y]:S3BUN6.]-:XC
MA]>N6(\;M=J']_!>]4;QO%KH#>&9PU"]H-;Q0A .\KM[VPK[.*[ZO[=2=W<\
M'Z8B[O[H,/.'L0-#)V'^SI _JB>)WQO)[SC96F#_P]_BM\G8<57D_VHS>).:
MPN(6K;C'O@^&S-6?IB9[@+-]W_GPY>+L]N38N+EMWY[<O'_3@5GC+1^6/Y*;
MDZ,OUV>W9R<W1OOBV#CYGZ/?VQ>?3HRCR_/SLYN;L\N+E0RO*8?WE05]V^V%
MGFL<;Q]M&\WZ[L[A(D>T*HHXO;P^-\15R)$>K(?OA_7#[]SB=JUV[)G10&HP
MWTW4*.N->N/[=_S4:(*Z]\^7Z/;/OLT?(M:$QP&K<3V7&+YM&E*X7O-NUAH*
MO40[W1(*)3/#.FIH.UN&RU"-PZP2_?U;'QKUVI_$SI)W)-NQI)TAZQ=^<IPA
MLRR@D-^VZEOT-[S<5'_GK+?.Z>9A?:&OGG;'??*@JO'!4](#_ANT:[L[ F'R
M/K347?)I==O=>O,AY_OMYJ[MII_C\&Z81SE=-K"=T5L#!)+'C2]GQLUHT/&<
M:L#<H";7,C-E]9B$M#YF2*OMNA%SA&<AG\0N?O2=S]\&WI_'K2>36-?S!RS\
M;<M^"-]V/,_AS W]B&=H;S>/]O0!(C$<[N_LO9M(AO*?T-+7.G>3)J_O!#(=
M7]K.A_;%Q9?V9TUO>OP_UR=7E]>WQM67ZYLO[8M;X_;2 %Y\"PS7:+2,RVNC
ML?O*>FU<GAJWOY\8&IN.673[Z!9_;ARV=E+G#B8-&D;HXT<\)A\V@3\"!_1\
M(^QSHVL'<+J,$6>^ 28$MXS4%M'=%C<]$;YX:T38QLNQ7?XXD5^1Z7$B[))\
M*A^<\/]M_^])[^S"*H3*+?2SP'U]BXUP2MS-$/M>'K&G!CIY7D>1#P\,3VG%
MOL'3ITXM.C[ZZ_STQ+H^ZA0^M;%I[>O3FC3.K0_'W"2#MH)F8^Y9KHY)Q9/,
MKB://85O@OS)GUH]ZX]/%W_<F[P8 7F0MV^9H6R1]V<BDYK.NSJE"%UO$7J0
MU<ZPA04%EZ:)T:O!_LDUO]^[_7)0I!CM,B?(RM'#7!TN,THI2W?61I;>7K<O
M;LY0$);RM AY&L8;;@C7F]$%TC*^J__ Z4O^6#S;*72.F%MD!^AR-4YMX&9
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MQ]\VCF*\'*D6.!D'I'+*P G&&  <6+,O@Q,."GZ!*880RYB@09D\\#4,H\>
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M>_+V2J==<4Z[9NFT6[0$^$C.^&B(V0BQ%RUA?!4'%3,4"Z"!V12V)NX]EO)
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M;Z&B-<A.(P,ES>)]+JJ(DW,__EHQW;C]+W,0)AZX@,.)"20TL\!RM;EXZ.)
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M1T](A<N!1]%Z\D;:(J'S&*2M3;EIMD0F3-Y=Z7).,(!VU^C'K[.I*;;H33_
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MCQVP4*\;B09BB1H=+H'%^;A_9[HBR-*=$D?:L/G^R\/)T\=.R<^PBI/X9==
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MA-U9H8S0Q#[DB_17B3+=0A(A; KBSMU5L0B[?VACC"Q"W7\YWF?=(D659GA
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M''CPWHD.X[*>/IYLSB$]%3(Q[QC$\8K,3H,Y+O(;P-/^>;:XZQOV]^FK'!O
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M%C3MTD-WSFG_WR@*X<=K4X>H"M.0_7Z26=?22'!501[$/('T&(X6X<"C#SS
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MN?R:5H/HNJOUW9KZ'M?4IWP5BC?O7MIW^=+( K325;:.^R%+*C"\-#N'<)M
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M9.G78.$H8D:DY_H.L."&@Z^J.(1R(G!:FKW*$,29V*[A?Y*C18<U_8LS=:5
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MAI'+?_5G?UE/R1D\H-/P9CSYHQ^NZLG?\WZD8T(M\#/IXQY.PPC1UZ7IN_[
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MXNC(V^M[;YX?W>]3OO6H,8J9L8N1AX$"3NK<3:?XRN3="]K09Q+JC!.R#NJ
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M6S!8X'D@C'C@Q+APKES72?HU$YURKU^1)T9&JF+2=$U]*V#197U;(V=/@96
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M294F\0L-3B/RP0"LW4^ ]'V:V'%<5R+8+LKG0HG8Y=(9N+ W=RJ@4:4#! *
M!5R9[$K IHB-W8B%18#&I\V8-E00OT8^1T\^P2'-%0K:[P#2CU])H&T48>YN
M6C\S)P,'0CT-6CVDD&9OXQ8V^;VMT->=+\ J"&3T_N[^HSZSD^)AI)R6QCY_
M<2*'<.MW'V@GG.3U)J;"?<]U^5T*UQ%OPW5$0US')#[N"WKRVG,"[Y\843+R
M1W[M/1)@"T]:>W*Y2V0#77$EMFA[31>":='2KW6:AKB'#;XL'>ZP1A%H;HZ5
M-2,#[1PA.\1]K9(C'(7!*!V</L= !_73,]6C_?)S1!9@X\70>JDKI:[3/8:G
M^\M^\G!W-]G=W57_3'MIL'-G2C)-WA:WZ8O*-5VW6#"?1OR7/?XE_YIF8MX
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MB\$?45@?%%^8["CM-W9,> GW@>O<_"RG,\YFZ7428AC@L*5/G9Z=1I!U7(S
M'F&.B54]SSD_(-@,'VRZCBGN\F)V]*YQSY-$"L!G2X@.1F:;;<]B9(A;7+]7
MZ1!O\KJWS?[^9/<Q)$Z_^NKZU(YZ*<7H:U*]^;J.$-"D'K%,1WOVKXZ6+0LW
M-.#/G)I[N+>[NQ>_J1M0>9S$OURLHSURTCM0*#_>?>3ZB9/X)4T7G6/QPX>/
MGCZU%L8+M-LAC]QG&=Q+]G>?Q*#)X?1HBYM#USEG@\U4W;D0)\+A!1:(+T(.
M"3-72/(E>KC'[LT3^DX8\NK/Y2<6Q@K@! A'OFTO,GN4[#_^@0\V]I6=%DM
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M5S;65_4%CPU,+W#BSNNR8XW/GC?/E6IL)P5+.G[GX>8!J: =WR<@G:<@XH7
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MF UM3\2./AR7]6@']JXP=B=!3?2#&>%=J@6.2V=8UPAJB)8NJFZ\1;;',2Z
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M;OGIW73JI%P?'L>*4U!R)F$V Q8L;Z/>>W1[4I"+G/]%CED&.=*O3I-7DB.
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MEXQPQQX-.99.J;REVIET5B%B!B"80 -7;YTR=,\QJ</D,R6UN&CDP9?D14I
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MY+MGI@X7:?UKZ/=M]AS*F_&XL%@@<J-F+@NDMI!2'/=N886QU%J+!,$5H7U
MT:A5D_+MRU,:&835ZQ$+H=.(6GC*&60(9X>P('J= -R!>]@YJADUCOFN_ 6A
M;SGYYW7R_0'KL:C:6YY1Y0V2T?B&Z]E.ZW\IDM_#V[ _6=JP'[$-^XNE#?LQ
MGQO8WWQM^$/;?0S## DKT(ETVK%%)+RV#TAB'*#<T85O]X<=8JK5?CP!?R[E
M@"/<IP3LYB$)0H]!-2&KPQ<KJ+Y0CAZZF^#;O2?*\Q@^H)LZ:]H&'M9NW(?<
M/_1?Z<D=S8HA,* 1R]DCO2>4(^2^L1%T*03N*Y%T%RJ(B0JIM_:M8*2<PDLK
M#2VCP*ZAO>![6X24SX.R07_+KG;./9E4;@G<I E'*?/L%/DSB(B;]/ D?(-7
MVZ1%E%@>B78-M(>Y/[0 @^(AWN@!#"!S:I87A((6 &<X $[XC8 _XS:^/DQB
M,$+)G HYB IDV"P #/28FH:2;LCEU3U\D8,F3H:QQ0*-2EY;-W3,*<!_08)D
M_Y']L^DI:8?8"TX"R9]DT#HG/?!2B*9<F;\#()1O\5O7W7K<]TBR&Z1Y%:N3
MSJ)IVC/,%QTLHCAS8[VI#SWC=+YWDN3*_/B^WSKB"*D3<B,8<&"RNRE0)V08
MEYO(< < #R-C^\QLF+EQV['&ZAKXD'OX=@= BVZR"!%D^R%V5HBF$$^U1A#R
MN&6 U$;P:.\W-P-S0VV#*#7N<NR)S!'I<P9[W7$MA?<K!,)V4S JF,K[9/H1
M/*;I.-0[]:P$H:,>>KO;BBS\;%LW^ TX9S"INF?D"\;'0'7L&R6"HD%=]#.)
M8GG:L9E-LIE3JU7"*<+1@Q-'@RU]TX2"0T4$4!;1C6UJ DG*0R<E-*GJ3C(7
MB>!(%H("0 FP*AE.A+@JW\"O,O!.)] W^9F"%!WX1N?O=X%I!) SZ%3#ZS%B
M.#8>J%F^SB#-?4!I]HKIQ!OX+M8(8GI,NM69D'?QBX@@X]0&]!]8OIJSZSF#
M 9CIM ;<Y!-7(Z'7,,/MVZ:] \A7RNIJO*X'O8WG?HTDR()^63+&&@<\4-\[
MJV%$2H&-X+X2=N8]&)DF BFT)#V$.XSIMPAQH5,%N]FC-DE"<)0FT3>R&VQH
M*;!JZU'#:%^NBN?-\:'(1+Q:\G3Z!%ERT!1)^?H9*5;"@X"%7J=(HA%^&31I
M(N%T9D"<Y-'$  U?\L(O0G])VB=0R)::K=L33Q.0$@"\H5"QIBYC+=1%C4.D
MIM25XW6.6S\)$=[#]>(E]MY;(EP\1E\3&6J-2-0XYYS%C6K7"/.M(*9(OGMW
MK0%:(6(X8W460U().3:>-.,-</M.T""0:+QX():45[#$&U_C/O!5+S[;2G+D
M\%W"3R&[GO'S[JS9M!&SSH2I^83&I^FN;-+3Z%0/A$AI';T^Q]7J8&]IE!-&
M\-($ZP\\W]KW3H;;)WK1!9T? N[W8&MHC&X(D_P-F?3%<^E&[4.2]7E?5XWY
MONJ&!M!?$RIX[PVP[L?(W"9$WO';A?\V.2'NG,'O/7)L%B&W31')^732\KQI
MG>7F%.M@Z UN,EV-)EV]!Z9C.H:>@'1JGR@:2:=7QY6S']UOMQ:$]<]D>3OI
M@#HE0$/&^=#(A4##8XB[E0!Q,'XE2"1QE2M?B>P1+ 6_DO/=7O**.<F;4GS#
MW5,QC&6\P$",\<D7?S8>]E2R\CA2&>#!TM!]\_$EPO%G!9FGJ&:&^Q3+E<G*
ME9>H(I$H<K[4$R%XP\?#_<YG7]""8'37LF@JB"F5Q;=0(7L+.NS'@+'[UZX=
M#\6W%&@IS0_.I.J+;VRU&VZ0GCO^.TK!=P=WN6!.ZR>[VX'$R-^+CR3M>XMO
MI$."G"E3X7CVR9\_+@+!MC.K-DY+OWC]HC3:+=INJ[K+=J*[':JN"8]=U "^
M%V&=L4AC@^+JA)=/2!\DKP2I_Y_1V6J?ED!>\!F-]@4NVY&/FOFD_.2/S\K/
MGSZ5(PA%C.Y6 *O1&7QOBX]X>J_H:+[!3X79M04TV,L93S00L8Y 7[XXD,4M
MA.3AXW_XY.K33_%TX(O-1Y^6GWWYA1X)G/]K)PG7&*$4!A/_JYG'?E;^\=,O
MRT^_^/QC=#.=M?WD4!U1&FF-0(P(SAZ0_B6^@G)'<S0T1Q2]%1JK"EN)-1#X
M[6 L@J!NBO'@/L&G'R,RK*"))YX4VOPR717?M'?V5D5#DVM 0-#Y#40: N$@
M_PO\B0MB@Z#D3JB_:E@.A&0HVEZ25W?V=SNSLJ*5R?P8D.A>PJ$=G";2"5OD
MH=@Y<^K5-I(TQ+>F>!0AH4]SK;V-!T .+44(;@H(:;D-!@N=%R@>+0,[ UYT
MNYNY#<NPE3BFXP'%!1K1U<;)!O&^AJ-$D60 ,&\).QT^;3RD.T^5;P0 3X'0
M^J G'=B;)*J>,"GI)6.K#B,T%-.&J""-89#]X&/BW.S,T?,2D1,"R^15F>\%
MH.IY:0,9@EY-&*ER]KU]RP-S']Y:5)ILG//LZ*RI\+3LF!>8EJ:8V>I3T_(#
M,TCQP*8">JX<5ZVN*P"42G>]_&!6A!&FH-\2C_K9D@A]Q$3HETLB](,X2I%I
M615O$+K^VIW?B;]$=]A7W[U^];?G?_O1_/C#R^=O_O[#R^*;E\^__?&;XL5W
MK[]__K?_6WS[ZO6K'U]^-76B_).]C<X^$J/L6[#:JWJ3JJ7#V/5 TPD/0<>^
MY*QD\Z2S6Z>9,/ -YQ^<@:$FQ8?JW.E49TTUOJ(W:![QQ$$6KEO$1JD"/Z@S
M&6 XOU1!S3K8$S?G GV2']76O*?P&!&>XC[A$>MW\L1>KDQM"K-#'OGIXL+"
M)LO&%"WF<=W.(3E=9)8WQ8L;MVNX3;&;]$"K/Q)9$.,_/"L_??JT?.HLZX^4
MO_*U#78\Y_.L[3,B398NY]^]%:6M)CXH\XN$X>)P"*AWPVTD1; K"$_S0\S\
M0Q)[B>V7$R\%6Z8_9<KTRG*>/LAXH8D7]8Z"?@,;=.UJ!]E(-IHJ3HA9CM?1
MA[G@$-+&PXYM97A49]U9#\R(%AR1U"@TP6.;L;R*:^<!08^ \]HL<&"[^_LQ
M5F=BJ)FIH19-^,1B%FHQP7_K-CMFB#JI($$JIG,0URBHST1B$QV*@[MP&^_Q
M+]WOYFFWB+D%G@8 7C&=;VF&]EV]C@DYYW&WD/1P!*51[3AQ1.F<E4"(D6>/
M,7J[";%K_*#D^JG2I7$317(<U"!&$;6AIQ08SY">T3UI6^^LYGP(5 \3IMG2
M_U$J8=9 =T.W-);IA(93GR5MH4<&$N\>PQSKA4+0.L@7*&XV%B_QMOV)ZJ@X
MN$>,F8W;L!TP6NW::S#- =Z0 P][\.WW[<ZN1RH&< LQ=O)!($5#EZ!/",J\
MF^T9!(&WR)>I\ ;+QK+:S"6.T]%>%:\:$S):]^4W4%YS8NK9<ZFP#5G8X!Q0
MHH?2'"=0Z" V8N:R.U"JUO?MNL;+!%]W"LV.7S0+9G=_8ENJFQYX1'U_\OL<
MU*1$'^MNNO$PE)Y_Q0A\.1VO*'S<\<G3OT1. +!&JJYK[V#</;4GK [MP?=3
M^T8!+)JY%Q0P63P#FX$7%"@%##V5]'/ =\!!L)+ ^B"L:$#5XWR[QFYKS A(
M,,Y=IE"H!%/P4!#16$CX,+E)94J"'PPTKMU8#[(D&* *N3H""(:G"2"%INF$
M#W/QAU917G-Y2=SY_-]Z5]7[?CZ;AWI7E*64N07*.5@:.+A1E832IC[&)K58
M,YG.?,XPW,?FM\T9?BA%^WW%H-$U62)M0VXASE&J5#-9\;HQH<*1B019N//W
M>!#^2 S!5"4X$5*!I*VR>@1D !^<<CB9";UQ1!676AM*X1XPG=A!V$X=9K@_
MZ#0G=;SR=<*W=I\'-N_>G19GF$E/DBX$N :4%C"RH_J&"1^SNX!HFOE+(%'^
M)<1DB0ZK<J-:06XB6>I4KX-93]\_7A5^QP>N9,2/3)<P9=Q+EQ%5QXJT74="
MD[^F ,:8+3RU\P8Y/*-A4Y$F%H6+RN+ZB%RY^4BK0(Z1(@Y4;+"9T@IR,FHB
MR,#2->2Y97L"^:Z3$Y&3_J#9-FX-;S2>!D\)$M4(L".<85@OD2X0*"_\( H>
M!?B)#5H&X066=1T_""9ZW56WK)2C[W!: "8#.LRF_+<8TB_\14XO#46[QK_;
MJWI>B5A&DN0AT;76-J:A=^/_65>;\7+8&A>"RU8H@3_"LN4W#64%*\4]LKQ4
M^./,>6LOQ[Q]M76:LWM_;8DM"$I;:E9KAH)Q7V2E/"V2L\%D])3<(,QXWV,E
MC]<-;:;>-]!$TZ4,2)J"H@E#D ^!^LQ6B"O32U4YPE>UQ>4FVW;2G%$-&9[Z
M:C>TUUCI"'6%I=0$(V=\.66,G^D#Q:!(\>J'OY >H7[3''Y<IHA+F+VQS-X-
MUYQ GZZ(!99GX\VF6'@I_8N(0N[TM#TMV-@HB^\&BP@(,KI0VC.R^,T;.,G!
MWAH"<[,O/B39P0AACAY8Z).I@ 9!B-H[HK#U)-!$](LI0TW;K?AH#5%Q8YYT
MVXX-=1Q-K@'98A1[SY,KAT.)Q57Q4J41HT=P!2R:#53L[[VT4(S-9"^^G#9K
M-\8M,+-V/!E -_6JSKCOHJ)K/$8[VPF'(^R6DY#D#D@,7S5CL=$E>+0[;:#.
M%;5Y9E^T/)S0FA,]5+@\?78U5!@FM2_H^LEP&[/%MJ,>:"319)T?G$+NUE+%
MP;@"K/"3IB8W,:F_K**<[CWM;,(++MS2ZB-8X@-X[WP+E^:NZD F>EY'ZZ26
MVP\LLXF&)#-V-^TJ=\++*!#CVZNPQ9Q.V]A/@@CL7\$J;KKJSM,R>_E-&J:P
MXILIL=W(-M!^(D7?I^KFF1LY;*$[N#>CN[&$=UWB572"0HDMOMMM8[N64O]<
M-$O%Z?.VNU82J47V6R:K/UV2U8^8K/[3DJQ^_+@Y^"O.R%JSA:X/F.A.I%I'
M9S372<C9(%87V*ZZ33TENJPGYI[D.U2_[)Q+A J^ @;[(W\E](-*UE%L-!4(
M>W +X$7&L*4*2QO!&[MW=P(FF>3V7$&1&YIK%A*Z5.O5M>,U6'O7+?!0@_6^
MVSVA#ADI',5?X05&?EJ^C6 ^_@NW(@D/&C8@&A#[&'NN!7.'""Q,$X(CH; ?
MW7IH5<XU)DU[#+!&*F\F7!5O6!!G8LA>O.D",>DT-ZVE0-+>0G$O3#KO F6K
MXK[&@'+/J9>[?$-5[/KB8SAM:"!D<Y_O!4F%^!'02LI/X%#4_,593X_F5?%]
M#G9SLC1P,J6>4PN>PKQFTXC%P'UY?0P)$#C/U5K7U?LSC%G)F4-L9EPN)[X'
M:"]U#@(WCEQW$*( +4/RGEF&J^*'_-.\R>CS946_;JG2$A4:RPNOQ>B.V XV
MF!S@L!J;,%%X!2U(W%-&V8-L'D^]')MIV'XC1UG%%8W4\8ASS)[#7(MDJZGB
M)^^]I&!'0^$E.62^OE7XS939#&ZT) :<..=D4^XB:=H.Y&89UYVD>)_-VK&?
MUHQ.38'KSKUFVG5G:% XXS$.H?N4O)<KNGK2<AM?ZYN7@ND7L=QE<T._\6X%
M@&C 7S8$TPB%S^XJ->'0)>,)5S4<;_=Z",Y@[08RP*5PBHJ@<2XB/'-O0&O9
M T*_DE()L<M?D,XK/V0$.<D%5Q I[1F^8AO$#=Z-Q'K./*:^(V@J#!D "9?2
MC8SNFNPZUJO0/^%OV%@/%8$UW_QXQ\8[PXWS'"2J,;X+(_"]II1?#-EJ:KW>
M&%X(B&%C*+S,&&IB1EY2I/1$@_/D<K>"^8">,P6DU9VG8$91<HCE(>PT[A$I
M''4]@OQ@5"0XNZ'-4<5?LUA5E[+*Y&G,80! VD'"Q1P[ #$,5+&&>ZDQH&8;
M2;OJ3,K$M8 U4_>:D_A]W?<"-HZH)0>,+ <DVIRAZ6LHN&G?A&O3;B[3:<A
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M=)*2VD9@\$6>%WD^'WFF"!A$>"6<IJ-Z/L0&4G_P 4$N9@C="(A. G'_4V>
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MVM^,'/<QGPX5F'4SK<&<*:WSVP4X#%FVIH062I>%AA)GJM[$:CN F5)P%9J
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M&"$FXBF.BX2CBTYU>A&DAEMR[>HK%ZR3DM4+"-EZ<!>F"1=EA]4I)^4^Q(,
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M-2%]753[-F+#+M7%<V.A[&*-YE%UQ"Y&@<'P1:="B0U;2\7I4?^O]A_8[K[
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M&P*I[]N-9=(P_V<8%EY7T'_<UYTTQH\-],(T $2 R&KT!62+> =\WK6-4>"
M9,4M20_HB06S]EIJT88A!S=[B@1(%35H5F/130+, H#(RQ$\]YF?\Q'4O,08
MRO(QQJ191&'=!B?2G995UU8;NBC IZ&K@\ [&,9<HK@,08>MCQ[0#(SF,(0(
M' 1)%N4@+%)^[C,_9RE_7/N)0&&<2G<"+X;2EH(L&)'6B0'%6;F83HM$/TY3
M7P9_*LHSM,6O%?IY>\J'GP +[<G*-G9;(W)EW:+Z!N . "!K^SB$!OD"#%K"
MZQ?9/_>9GZOL/X8V=]XN6=]>RI]__PH>M@7NOAO%Y2.4PDCA^PA9ND7LSWSF
M_\YB+R%)R80@TE(>6X3J-.CGS=AQ?EO80D*J0L./;"-4ZO!@VW'@U1OV&'X'
MOK6MMHIBL"RD_MG52]7U<FY^[;F9Y*R+D#P2;+S'.%\*H&WG<]@(2.F&VV"2
M 7#L$/]51U(I.SN7FOU7%X,_& K\LT^6*O!'K +_XO=9!?[AB!^=P\%529-$
M8,1VC;QRH5J'L&I9):CD1^*]ET6$.X@G&BY8JH(\5< <JNA.@I!R68HA$,A8
MMT!-<E2[7$9IFH/M6+-QH2-<W$A>TG %%=W=A.^)V63[%M62#D;[U+7/1_-8
M"&ZX@*)M#["<QS97W2Z^#%O*KS%2@JGUP .6S[(31S1FV85?,(H3(F<,SV!2
M4X"0T 4E64_N!95%3I&,->QF5*C1F(CV=NSI8M',V-$PX='TLI*+3VU8N@$@
M8S$O!Z/P3--4T*HAYD)#;5R9922M?<,B'2#H, O-I3W%#R]?ORD.NZK1K$@T
M"5I<*.XCJ%;B*_*%MZ%*B@M9MK3"\G#$+39M/$AAE8IK:3LA<M0$<S!SY,GK
M;?3((GTD\<P)R"WN"1FOOJ(&*J1\W>'-L7?7:D4&JS!*K9DL%3U G^/IKJ&:
MA<GYL!K>V:EX&LKP'@_63GC.S+%^=].2ERCOA4#W$ZC6<F/"@Z)JK/QCP-6L
M DN[;3IW@9'-X,05UNPH2Z)ECYZDEV1B?H2RH1YYG;>&S'T4=J'31&%#&:1C
M&[.1Y.FI+ZK8!$O< 4U8'>A0,#DUZ2)1IG)W*A[/U+1362(Q:N7OAWG\_ZCE
M(!"-);PW"4.K^?$F;X>F92Z U XN&PY:\9G!XP.C'1\@JCZ6^PX[IJJ^;]>$
MIXZ.&Z@5^"Z6WTDUY(9.&]P/*RQ_##<J/V6@$R\12@*^=(H.%H5CYKMVG;02
MU$V^A/VJ>.U^W2+_+I:80K>11EX.?1VA$FQ3.[GNI$P<&>,#R05_ 2=W><36
MH<WK?2N63>JW(.,PU9.&' 975_DB+=@8V"W6ZLPI1F)3=]%>?7!:D _3(3.I
MM ;:IQUX;E1'B!?$4+TEF@@LUDZ8Z&AT##:_OFGADM2T>Z&N-GT79I.$FY"(
MDZV$R[$':HN)I"-MD"I5-[_07\4]3D<1-GNROQU2UF)B-^XL ?* V&"2"] 3
M3)"ELJ[ 0+I#&MP@9G$;2&X+?*D%V&*V(TT#TU\A0R;07F?*)B2_S*N@Z"9/
MLX*&H.YVFK&CJS(N-36D8Y!!^T><''?63+FFP0B=M+V<V*<C \#?>S:-VBZD
M! I!ZNA<0M=E&NA0%>3WB,U1\9/3B)") (95NM<:0:L7CPC>A%TT&,T(LB_W
M(QO&^*V5Y<8)N@+KE%"<O9:*'!EQFGSG)AQ3O-Y,,%)CURSC6<!$J#HS+;@)
MO8=Q,Z0 ^(<R?5XVDZB_2U%[S)<5FF'02*F;X +.]=^:S(+"4C>QR 61V0.W
MJ[ 5A4Y;SWD0D5Z_5]\O=*62^HL-A@N\A7[!1F0HF$YOQ/4(LCU8.]F-A,H(
MBY-I"-GW@['EZZ>C V"^!N:&=Q74DI;8$P+M(>*@7G<(4I:K=<MV]Y3Z6IMK
MO)JQ&@VV4Z(',)OU2-L^?6-HAJ!QKE^*5$*KZ8.OBF_:.XOV:F4DUH(-:SOD
M%;E'W'-[Z(F1H('JFLJL0L#EON+WNJ$.38@#17^C!,]<>Q3E99!]%SO"8M^<
M AA[R)M"[0%5NM_63O(/3N9;=X_Z^U',<+=*)M<$JJO?\RU()XIIP"B8-V=F
M%M.S'N%U1H1/\P*6TS&>ZSI>LA-&1D; C?3\1LVXB2].#;SUD&W<1:J@FO5K
M<N4+.735BXU#?,5R^LF^<N?>Y#F&B1<U\:$OT&$*RO6$"TT"[6E[)=RH5?':
MXX.0<WQ/%*%8)V:1CB=2HV&)9P1"H)Z3D5!LN>F'?N&>8GSL5DJ""51HH)W*
M< O!"X,][C43H6^P]><)Q@*MF$\5XV2/H6M >9'1).LF=F$*3S[=33IAE+4Y
MO0.8\F( 21PD7"47E)!0"W*'!.OQX02CY(M*^:N!+U!6QO\B%VSF%WG,CP<+
M(?VB+-XDPG@8YDRO2=IR+L^9/'J:RY+\X"4,5D[W!0W91UK,:4"=$YS=J&M9
MICM,9]2])84<[KS7W[\I7J%LOW[Y[?,WS#_+IU=9LQ>T=!>XVU^-V%]-Z9<U
MDP0[S;5!G!(J=E<=VPA+F;,8*-I:%7O0ZL-(SOG8U/^ U!=UZC/GI+-MF4D]
M(U_&9RQQ1/5;NZMOVG8CEF@,S/"^PD=,E/U$].H^2%YI$M)+Y2E !SN #H.1
M[E;I0&R(';$70J37=T%S%D==&6@-SJU=.!4!IP+'H: ])#;W2O,(N)6 O?X*
M$AL?O?K;5Q\3W(&@GN@>SN*COWWU_..3C>>8B(%HQ.[(-1PE)+@JK 6\*B(W
MA]8043'T*JL<X(#AH;JGAB,P2$/LF9I7A1 XR>U!+(G^RJ!;)D Y178@[]X,
MP@K\\N7?5;>U>&11*U7)B3_KI&JLM%&! 2@"LZEV1Q @HA_V8:#HCU(Z"75<
M;3<(; AN8-_CM+:U9#=#VO:KD9,%D+X/!U#EYLN4@=5PIIY0.F-L"4S)S9EF
M)% 9G!VPTL5.V.&APGHU:%7V^"8,G;2Q3YP_>XWRF7I<^>C1/$9)=#JOWE]M
M_@(+^W2%S[.EPN<1*WR^7"I\'C]XJ>F3L\ARL^WW6#)QU*A_N9(/). -?LHI
M5=(B+\3US7"!H<?G^0*9WH<)**1.BYE<F2;UH-!,\0OD;KHGURW>V/%:]F-W
M:]WG*4/2 KE!/? ]%3,D4OL@FSADM,BUQV/ VJ:L@8[8+Q"^@*KC*G' =5%%
M%W!"1RQ!4?45&&2AZF?P/]TQN>[:\0!9# 9K00-H78T4=FP98Z12U4"EA_&1
MTI75Z)1;@^&9B.>9<WUP(]3]VYC>-Y$Y->.ZH10=1'VT96+T-9\4 F&8%[B5
M55GXR7(T#F= EV>]2PPZ0M"QON/G>G2W8QD*<(P4T_A2[[&1SX(QUQ=QHLCN
M^,E8&8.MI-C"[78GF*ZR33;!Z]M;9TYN8%L8K(?K:9P%94*BG-;7#6HOM_/0
MMKO4_%+!Z],9.S3/[EG&2?S9'$+5?8 P5,B%>EYEJ+2[I5EY^$,/>JB0#LL0
MS49L!_=9-&'((-O$8(JG0$TR6C+@&>)Z-G3&9Q1DMK!+SD&P"2&U9]399ZRD
M6&_4C1OHOE(A>I@/(9%Q&!H7*A2D> V4!N_6?WW]?51^ L_[ZXOO*:\< >-Q
M4%GTH23U8X+V6&[B'@A&D%2@JP2$5T=M%%C,J)+I!,OI'$$.JV.& D/K]1I0
MY@"]"'RUC3K_O:H04,LX5PH@J#OWK8O/C5^9$$"<0*-BL^P:[T(,4];MV".V
M[]NFO4,80&??[+DEQ$?#PX&.Y+LGKSGXF8#QZOX.V6BW0=N.C*BC,(^H1V,D
M,*PK%1[HY$W=ZPW:E-FYJ'+':5ECY0GD2S-MIN&7'ZG<4?NTH0B0R%40]"LB
M:M3C]""7'-*$JVCLT0OQ'%3AM6YOM A*XBF)Y<:"<;IL)#JR6&C(XDE(6NZK
M#;I:<1H(KL"?1\!RI&*S/36$]D[&^#;TZ[&@&UTLNA$/Y$^?_:_'&$6N<%BT
MY42;SO!B+YW%YS[S<VT58TN> 'Z&>M@!!IU%!H!%J,Y]YN<J5.OZMN;6ULXY
M&5C08-W_@TVR2-6YS_Q<I0IXXIN%5F\1HE_'*QJ<B-3_R(4"&6Y]!;41S;#(
MW;G/_%SE3OS:WM;_A,K#$G./C7B%&*0BI',1.OY=M7,KNRB\1?!^X9MOVYTS
M["$Q3,[CAA2<R",3W3):SPJ@(H8X^K&(WKG/_%Q%;T#H<N3E[@9"M]$1O(,O
MX%S0;A8Q^Q5^ 419ZU"8%H?3 BY$7&"%?5=0(A4'U*+TS6\(0O.XJ""V:-=4
M/;6VDE'V\,KDFD,Q5-S;#+T"=7-3K^HAQ;6(65QG"\FV/F.MV[ #'$:"5]&T
MS1.5DUD=H0Z<:;9R]=H8U)^)V>O-YM0:9]HE%<O?5F%^E0LGL/B(ED-BLD9P
M! YV4U<@:QK+%QH5,/&>KWW?UHV;6ZT#(A?434#%)S]EJR)]_]3AQBT!YOP(
M;1_7Q7B0E:C#2G_:OG/[U=>W(&(G<K+N7Z&[ZL[M4EM24DI_7\:G.P9^1>-P
MR;@M'C $OFD'1;IXB8UW,U1--??.)'11$4E'W /NR<U>_KWDLDK:>,+:X#(_
M9$N\A1*9?@_IORF?$/8S*9'HKXJ_-QOFW?R.?H\UKL\A=0K#"'6<\L+0:019
MU5C"ZBV3^3#LC6ZR1F"2M(J5"EHDJTBE(.[K 4UB8[? *V3@73F")*<VMO8.
M9^ &\>SIT_+ITZ<(EG-;;T;JO&E&!J;(-4YALCGSX&O$48F?F^TO"RE@JL)M
M6N9=0;&'NLXU@SE3Q?0-]21CWCZ@#WG8E-"4@LENJ,"%DP&M6$(=EN(#^(;
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MR\!B0-BZ(.CG'->R%2.!_0R^E?::DH_;CO]UW2ZC?<$_V*9=U5U[;;8%AH+
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M HF>PX@]:[\LU3RCXI^L'VF,8A 18MC(IS'();TANF$<EOJ"Y&U"]HN3Q5L
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MND_#37F/?EM1)?3VJH4<=-TO9D\V2AO-G&E(Q^T_PL)]CK#9S7B_(PPRN_R
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MQWEF'1@G2 /KQ#2S'?67X,'PY@YSE)LL2=X4Y!+S&NTI7( M,HZ%.4FC$=D
MR#.%GY'*Q#V+KT@<@>(9MVD:B5F>HSZ/TR<LI]=#?Q502I;]-MWD_45+C1+"
M R>*XI2C8CD#&GL>V"5+3%ZNVW,2(ZC*]9;@#V0$FK%VBMP&)5M/SV#L.-/
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M<]^MZ(\]IONAEE-N'C^P@>-CT3HJ=%EB4='PLP!-3DZO#K_8\7BMRZ[<.)[
MM)W'.=4[DB=W)USW9E2.E1TP<VG.$\L=Z!*D&3K3)33JOS B,YM7Y=)&)#\/
MI,JG^AK%7/_(T*1E:4E*(7(?"QN&0_=--SRL>481<\Y%""3D$7I9GJ;&M[,=
M( 82FKKP+G&LY^V6-%@EBYG_DRIG?=JHYTXN0'L(LQ]K@5'FGWEN#ZFKC%(
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MI//$>_!]R5D>1,CS^,21,XA%(QKQFN;JHC.@)BZVKOC&4_?%R.UX@1Q>'(X
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M#7%NL_]Y7>YX)00=IR4GI8F?ED$F&@(;V(]',L[03<U7M(OPT,7@KJ&!B>Z
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MJ8)0.1.(#)N\>UKH7JJ1;\^/Y5)NG9C:3?$/3YO48CC4%4AHIR0<ZMG(=6H
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MAZMRG)(())YG<^8#'&+5>##C3LGY).,*TF6&O8R4 <&^D82:4['ME7[.  P
M0&W@ <])"8@JRY2-M@TRQV4X(W;U05_OO,B%*M:X^8G"^9&TGF?(A%$="DJ5
MNLPPR58M5*BU!/:D&: )BL8;QBFX&"CV0U.Y#3N3"E2;==<13(MV&&31.%9
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M/+L!3M#:7.=$B=ID> T[HC'.%PRW*AABO4"?8QMD^\GJL_0$X\K;MELU9[)
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M-4)J%SL6<*5W29TFOT7'G.5_2YG/=A<6A-N$^@ 55O!>/29E,YUT,*O0EP[
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M^PU&R$"^P0W$[KY][?%8U _6'H0-VDXGH]!2V-B?RQBWK433O;X'BXY-H^[
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M/@%AIZAM-<7,&,E^H7'0./+L R!8H$00HD7%#&)F!V"#<US8['YZZ/M(E>R
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MV5!/;^FXI#$[YKWB3G^8$2Z"3FFZI&N5L"6?ON1QJ=,0T[E7V%J93X#PP;T
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M4_,-KF[MS,$2QBHIK&"&42:75<;E!QSD40[TW,$R N3.<)B-,R0@EVA*QWX
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MEGWL)ZSV@@C]0994OH*>S.AG3_\2/=8$W"5]W+.?XZ.FV2B9CV=VD4\PU6\
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M4/!I!(KI1I6T4 Z(?US^8FOA/3;Z%.B^UP\./P(('1EG0GAD")$P"BD2%"\
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MI%(0HX0PRAGI-AO>]KUA-E'.,YN+/55MR +LM*T;JK'H93O%#!E0-UAT3!I
M9C\A'WX"S%>1'0!&:$A\NJ.<"_B<;HI)9@/U]E'O6AO/PMT7ECJ Q<Q10^!\
MX&";_X_4Z<%&F)1X=O5J]RJ9\5D1:Z>ANS6F#YRT.EXA7><.O\RR$)5$H X&
MQG?]8*.'$EY+=0#C#,&8O(,]*Y+U<5[UOBVN_CK<5'\ML?IK=U/]M61M_5A%
M?1!&Q+%7UU\_M_8Q0R6#0,( QA96%9G 14*^-<].=S"ZV?-GOR3CW8SAF/%@
M.W[!_CMH"K-:67P/Q.+5MX4XFN1Q$NQLD[NT76M+H\2XB!3EC$AF#%SJ]!F@
M@"(WQ6_5!%L:A%@6D\>#B!5VHJRZ1Q+=%[N(OY33+93]<(^7HX*-%C;A/T33
M@+VW[8 :C WAI4$%QDTB?JO@$?5E"X[H%[ICTHHJC!"E9ZR:F>3R.^_<B@I)
ME%Q#X?QS$%5E=I_:D@.\#-23.:>\XZ-?6VZR^(+[X9?WM,OG]\H;6F:-0%-!
MP!$S!W/*!7SXT D]3BG  6:_[_W4_@D9>VOWIQWZUTRZTG=(E>_NACN'#\OP
M7U'FFJ9/Q]!G9W59>MV]<'_W$;/T%N1,JF7OF&5W5[CL@[#]F,N>L\5=L];=
M%:[U$)-RGL@6!PFMUJQ[;W7KWFV'V[,G^KLE^SVN%K2H%^;?XU_\SGO!;.<]
MH1Q[)NIZ;J.N*VWG?>?4-<4>KV7SG4T[;=]#8?L>:@0('=&QG=NH*:'NO-="
MXF.@NPR<']D>C??K/DB^)$;.!\T+72'F!6%3LT&G46'@M/>SW<ZHX[W;"NP%
MOM7IQAA<TF]-\T3=OY#:ZC DA'"Q*E3'2-7-,,  .#KK1\:E"6,^0Y_C:6KP
M T+N5M"PTP)!)1 Y0!:J,[9MS#A&: G5BPCT/^YDF$L>4":*XBH?)?3<3#H]
MTO1J?($^04QZ4/MXKGYPQ#]0>REXJPBB4S4!<_:^]HS# .[J.')J5\$Q5#41
MA<?"^!S*K\X_8#9VN5=$]7R/0!)\"9E01=7'_"-O1A145<1$S Z?G/AJ_+2\
MS>H/DOL-6XB9#HUL96%]/S;#- <E*IS 1$^"Y=4*3J+9F: !B @R?4XH90@/
M^D$Y F%R/9I)<W$.EMMBT'06% /)T"*JUW,?^T33P[95)4&B*#M4,9AND,F=
MY3 +Q[A"(Y,GJ9D2N.8F8HA8%3(Q?0XM1HS@#!25XA8%%'!F:$'XL4(3!+,(
M)$V:8$Q)1GD24[X,$4#G/D<:ZH;YV9$AC6MI!4=]U1I;L:5034-JQ".BXK5%
MF#L@;,I$ZA14M/CK.U7KY83O:UJ\)Q%5: \%*OKJB1>=-]$I IL=!'8/D8+,
MQCG/-3)P0('* 9UC"N%$0PQ)DF/ ><$S%)9'A4DCX;@G>E^\/KT89Q4V64&U
M@&'=I=Z@T_'PF!#M(,Y5!-%**W-.7)?0B_@E=W5WA1$P.G&M$H5%F5<J$"J&
M4HM/$U?5P@.NV5U*\4*.>!'#P,24['1R@@\\"145\E[;WFF'A]N'Q'YJX<SG
M^FRKEFIE5D:)L/)K@ X2G4PM$?Y3W?JJ<RY0M]W:_AM.8(;*->7 :5OKTEO-
MIM:;ENX949\MSX/XG^*.7^(QC ?"Z,=V:[>]U[%BKE8T@>/^_L?1.9Y,TU]Z
MQ^VRJ]NE#@AL:RP',8_,B>M*F@Q4*ZTYA"?UCBG/H9^($A-N1QE!OL!?+Y_A
MD5O8'IKT2=N66I4WS*IP)*7BU.TG;1)D*Y6O%<V(.3P9SK4:JKN9S@_<SI@,
MUA])3C257U0YA.Y)=M_DT!F=Q[5IT)#1IW:ATD-YKLZ3@DP@_2A,R?V=^]U+
MORGZOF,<F([0W"4V!UY32]9\.7,OU 2+^'$GW%>]KBG(W" ZHJ"^8#T,G(T4
M4^\25U)UG2/O:OQO:7YS:/<RU,F 4:$GP7N.^&\Q\"1F+I!J9Y0->-D^B!YV
MG3>/'L2F1W,R]3:9[*DF6T5<VN[,0W*%\F-%S$U1%=>!O'';-3^_4WU9]0J*
M,);(R*P#P8U:##FY4C&84%C_Y,!W&LV[G:JUG)WAV$+B(P]E62K\VJNSK/@6
MENW,8=E+GN!<G@WJ/"ONR;-JXO?GS=G.X7?PIGC.O'FJ4_[ >LFIL35O;E:5
MV(B5[G&5]8IJ-:6QS# $45'WQCSX&QUFC(^-/1O"K4^$/]OP0SH+]+H^-E[6
M50\:Q!*;;7,"X4 .HRIA<UPT3V),.4*%IY:P^V?O&>[;'[)F2A,LI9^T3'FA
ME!$'3"UT]P\33'6/YX7SR^""?VF\CXN<"K?226L<QHEC^WYJ76)S:PWJ2O,]
MT9H#J:-%,2,F3H[UVVKS#TP/<O6Q-/5<L.M8D-&;.N1PE$FCG=OJ2.=CL<@X
M;1"B!>D0'[,;)9'W'"4"US^8/V_XXRTFE5UNM8,7;V-BW%:PL[.SU3EL'^QT
M7@I'XSN>OS^7>D1#*IWX/H<2;;8P4,Q[!+$R=R#["54-F<Q(H7+G<";N%=16
M]5'/\$P=&>^&-DXH+5,%<R^HZ3@H5\H5K%0KTLHS=*=Y5E2[U3;WH.L*\>[6
M9@]D(YLVUE%9?O'9=L:5AI,D]G8N.;74NAPM.)'16I@IN5U4"91"\1WZJQ4_
M[L$)V.\>:)!<V\K=>,._F@BSE6-<CF$O*,0I5A#0,RNG:@J]9IIYPX(;'5TU
M%[GK]_I:=N3$L.V99+P:D_J!L#M3 P^V-ZF!2TP-W-ND!CY6_/!2IC$<4-(1
M0+;A:7SD(.;C72\+)J'SX82Z6SNU?#A?J;,P^=;YUZS4S<:1C<*@C2O4^B6(
M.+"W.(L>1:E2)G25:Y/G=@;V8C9PZH4+9J="ABVG 9IE"W?9QKZU5Q%0KRCL
M9<0&K-9L')\+NHLCV+^_!6?:>#RE2^B--AYKG%=W)BTT<=MANTW_UVJW/7J[
M#BSKA:+Q3D^M6JO]SKOM;MC=WG',4[_ 8&*<Q3]NMV"%;6N(^CIS+?3K;UE+
MWR#?-RC_G8\8)RN@=XN%#*<K<$&2XTQOV.YR9/U?=NM#4Y0PPZZ+F92"1]?Q
M#6HVK&LCN V9P//]'&WMFJ.)]#":;$KU/-L;61Z9!(M00ET@S\FN"16U1&!D
M1[DJ4&.+.6AW5#JLH-0$[<M]% 7_2?"-DY'<.=0 #L[>\A_OJ%V%<%GB]-2R
MP<E9O608F$BF UV6Q+:6_JFUF;4O/=@[V T/]O:U.+#N8_OR&=\[FB>SX *Z
M!P=Y= 8>J^S\S?;G0,0) VE@*U#]H'NSDX]0G/;)&>/,SG$$9/E0QM23T6E]
M@7]Y?6"(_=1Z9V;"S2\H$0'+(26UI,8YDR$3.?WS,CA'%/:+$$()7U(XX$]L
M[$RX6\P5QD90+0OGRG<*-^'NDB]2.:P8!*0=[NSOA_O[!V;;S>YQYQ1._!9L
MBMO6$SBL8IA6X.6@-%)/8N/X@9T(G5-,#..F(%EP5%T#-^M[DV&D^*= 3"X=
M',@"V)Z*\:G6%R7#/ E3J%N01GAA'+8SNIFYPL89R2^@XVV4#_CU#;]7M7;,
M?4(5-9IMI,)<):&,'Y 3$PJS$?[2$>.GV6/HL@-Y#1V:T!G!/ 7*L:#-\>OX
M.5[*L!P\H59P5) ?IZ@2,Q>'G8:21:?++MP&#W8\TTYYYVK@MU/=V1:E*+C8
M8N-L #/O1VX4E*$ $ !F%WWT!PI>) 5IUP3"Q>&B[?VP>]@EQC7OM!!J;+]Z
MVT3*SC/TY* \YS-RT"C/U?$5ZNAIV[Z!A>?+=/^@UAAU_H#PF'9/F_/[+#?
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MR5[$+= 5\(DA@B',.JW# '\1^C$+P2V'!QH="2M"V++ N(G22_OR)V8PC:&
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M=D#W][?_-K-(_X@\PVVV\!8>3K>O3XCV]D[8/MB;FQT[YZ*U-^S>'@.91TW
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MJWI5J<LNC(QC-&MB0Z=^#5W&L*T8Z5-&N1)#.!0&3>!G8UF.L@%" L22J@)
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M<\G4W2O^,C@*HO(YY1 KJ5AGIX$&<N [7U3LWM7UK9331;&VAE<9/.I8\,)
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ME1ZP#&?OJ/7GK".*)]^@GXI* 52J6-S8\4T<JTS)&O\<;/U#E=/;FOAF*('
M@1+(3(L1DUS.II*3+<?-*W1^\"!@M"1!/:;5D0CM0.T]BQ8,CY.J_ 9HE19L
M7KU_?XQJ)%"%U=.&)6)PWWA;-'8!YLYQ9,JQ!H9Q/K:UK4?5("X5RE@I;:!/
M!QW?F @E>4TU%(SM&D+5SK"\?!J\EI\CN-9@NN?S9IG"WCLS%7?/U((%*"^6
M3[)G=OSW:L<?U,[CLX]7%V?O^9(XOS@[/GF#6N8Z'>$?L)COQ,O1>6//RC$:
MM%G"!^X<HSD#Q%CA.K_U6& STSAK[)LUYBIB16LDNU>PJU0=;R.); 0#7;=I
MH6U6-+J]>B@;P.J9C%T6A1BB9M%8*#EGLR6-9#OJEYQT)>C,+KQL0]=0#G7H
M#?])/O,<8].ARNY5$AG7$UO?KS:X+7JH 0,^-N(ZKQ(E?W&=Z'R?0TG"HWD0
MZ2AVY-*/7275N&*+F0-SNM\2XU0A&6TV@PL;8<O.3*V4;FQ*(\UM>AH5;A0J
M5"W5LUOM'[=E9PB008$>87;:WC.MX,R;FW%)#4(G)D5NW7ABSAZ!ISU\UL$+
MC*KJ*CJT7X;D.5)?.[# =$-HL:U[[.);!TW[F [<$Q$U9Q+XL$ 7%4'71UOM
MW1>]EW.XNA5POI.*/42EDR88,A%F%X'S4DVG\)%P_GS\]8AYZZ&,LCBUMYCI
MGCN00ZS,3OM3?5:U2PB_'F"N$J&\%%*CI* K"3-;U,\H=NK$>&VG<GTR29E.
M!R*W)9NOW6"/1=)UHF<(!6R+IG(%2%Z_R=U[NDK[3%2'$W7&-D+9F#(H->I2
M%Q<XBWM;Y>C,\L-P&/U!W[:&3*6SG[ 7.J442]HY$!0W<9ZE-'N,8B>1SFDW
M-8EF%U>0__?]43'^D#I.;^)D"JRYX=R*.I\CG/(D9W<N^L-!)<Q4;@VYQU,=
M201N&^91-9@CUKUA,9D.0W.(ACP"\7B+4/=X1$WH6*AB3I!X_<BDV@*#DUF@
MRP1"Q7]%EE0EI95J/=MXGLVE80&:[B&M<FP45+:$QWE\(W'.WIU#C+'QC)N>
M,(SZUB&>2Y5DRP5C%)[&I"XOP;X'0G:(86(:BR,J!*D\&V6,<\Z/!4$@^Y&3
MVA>G(XYYN@C^,:7LWV,5M$]6O(K[+=W=,+TW]:W12%@80:'T/9P00RSRL35B
M5-MLAM.$YK20(NRI:B#^H-W1G<DY1HY7*=9FIB:+W4UIC'H83T1B)O%G$'^C
M+$,;2BC8* XAF5W#E\+Z>R@:ZXOF$ Q-D\X5:"T(Y</E^7 [WQ!F%;8'*$EK
MN<XPY,[7(-+'AI+4NRW&U%K++3(D/IA+QEQ&5E4]U5)=617!&=XC1I<1!KQ@
M_<V+FNI'FKFZ0K'K 49R"G3<Q@6F+ D.T,44S:6K4UW"LQ=A[>HU]VO(D<8A
M0=HSL[GZ%FEE1:#4LN%+8O1V=[#5[L)?K*KJ=XF[WH7+,8J][7;A5G[9,V-T
M9!W\,L$UE  -@ZLC*#AAT"C&C6E?1,@OBD0&*^(;T%?6^@3.\<8E#?I4,2V
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MU904[GG.TEF2U8](+@<5LOG,!6KO_-FK=YAG8W/Y(@O_>-#%?X:!' [942'
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M65/)GVTA%9)N>^?%X"7Q>+N+_U*CNQ/W=)&:!V-*6D,,1S"O*]NA1E\O<W0
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MDVD='CD'J]O;3=Z:EQ9/"YM+75_\< EI-NU#KTPN-0X:SOYA)9?R\Z@=';R
M6#IZ<V*IL=]V.IU*+*V!6'J*U=3U/2Q%=^7YM^Z*M^/PH.X<'JS,=7GD;&"#
MG-:JG<O%W+G5S<*03(=OSIUK-.I.L[DRJ;_)6_,<R211H5L#[7H1L'SO5U4F
ME](F5#E,QF%N)5#^0I>F2"/$!;9UF==)VO.]/N((!18D<:P[3#8<F,T^";;H
MZ[RF,*LA*AB36%X=U/ZLL9#XJUDOG#.$19T'_>ERO9RRKT:G(A.1H*H'$2?F
MY8"4C,3/?J 2?60!$,PV&>(DN"2%%\2)Z_N<VX+%+=S^R.IC:9>!&]GPDRB1
M556*XV"*"HZ%,]15W ?NO4[T%UR%A?"<Q1$=.:3*<I'%'88R)9H2"UQ_>B(]
M0250LFHPG#2)+576++%V1:C-G'S")(M%@)R'>,DJGXSXNA<?70S;^31K[X'K
M<6D !@'2X*6D53I^S@[[2KC>>.1-UE@;+=%]5P?5++UJD?NDFPISSEV/=@I+
ML615T//+6.$E;:-=?I'4HJ+;LQY:Z472LH@RJW5;1I^@0L=8\$&\.1I]D"Y=
MS M7V"!.2X.MI"X+O&-FK?#^R/6BW:?MW"*N3:>,#M?,_YW:/MJ4&;NW0B^P
ME&<W@+YRU=TK,GL:F95O8D5M4]06A)QC+#O"JNJ%6( #9A-P"YY7(<+VQA/A
MH_9V=1MY@%U#7B(TL5%Y^&4N]C>L=*"<7"KH1 7:V.56EFG6CD;6,BWOYJ(\
M2U4A*"MGA04K^EPC(IW@7XU#ZA^3[UB>:^.$)>J*B0I8U?6G3@T>G A9$L+>
M,0I?]&&EL"'1O5E;=%<V:].)'WS#3V6(@#3AM.]M)$Z[M6_#ZY-1/-5+7*]0
M-B[#'%GL%0U,(+A92M:8/%<$3/5U4(VZO'#@3!5/D<D)E%]E=U6MD)K]2?>$
MH#QZ-30>(!8$X*+Z_-JL:!F7.S0J&5(9)%5R@PY/SW4HZ_IANQVPDZG :)KL
MA<.]"9R 2#!? C0*57*DLB"ZJ$JN@0]63>.*IL&]!9ZI[$PS%@+E !8T4>4)
M=/D38T.!BC!9AQO/8Z^=K$%.5AZ#@CB>H+&H,KDN!QOV!>SQ5-=[B]NC]<9>
M',OZ'7(Q6, QC'"?*"PS83"VK&!H#\)^BMN8+WZJ]H&;\NCMY&"+W,6P3V4.
M])9A26!<'=#HP")^*MU957'3V%!LX,2U3G\"*;9KC[&#@6H6?RN;#0UN29;F
M"U>N5^1DQ9+K/#'[%4TU3>"X34_XX9U%Q5^P0G/<C[P>[. X!,G!Y<CH%R B
MLO@AMG^3!3=S/8>P[PI]D<]W#F4<L-"12)4$+,8)C=9>4CA@PG,M:X&FRI-J
M,N,ZF$GDW@J?.\S0RC4)\8 ^$J:O:WQ2V31DE5M9-"DV8YSZ9=;=*.3B15J8
MJ8G&.FZ)15LS9SJW+5.-I8HORI;HZ(SPDJ0 Q\)].AYY8FB?Z#3Q<TX3=^PB
M+HO#K_SSJS[VV,'2:]GO<9?,6TG^_07("6^@:LWPTQ]5Q%,]:]V10,],1E,1
MVH8BA)_=":R*6FBW)4L/1E34PE&;.'C4+E*5WTRKU.PKT+.R"#G5BVI^P"VU
MK[!.<W2?NP^PKY'R565R')JHW<SC=WN8HY*;@M3X9R?G+-%H>.R/CF%W#D47
MBP3(;O&R#WN8E*V*CEPJ!"0UHK+!G 9C)E/05M+[UTFN/5!CIE75F%EBC9FC
MJL;,2U7BRG&<UA#6M&AYS<I<:U5#8_'QEUG?@"/>"[QVF9?>7#%!7GGGW>I'
MS6E&+N?*;N?-B,(3DT,?L;8RV,SREO8OX48;>@8;--6M(9?/8,+38DXX 1EL
MJPNL<XE]@A!Z0-G%&WE$&S35K:$FJ@%$JY%5X;:(?-9REL^GG"<3S9,Q>1)[
MMUI*Q%J%DPSXIF%X]OK/FUF'3G;1_T=LEEOG!M'P!@F%K1'4UQB(L33I;.1A
ME-QJ/M?7>CK0:+&WSB^#LD1'S.N/0M]E(?);S?Y-C,=8Y>S9"L[ F+T(GSUU
M@N78L[6S%W38H!Q>M[SY<BG>)<UVH_;VS9/J3YM#I>TCAK94=%K1Z3K3Z5Y%
MHA6)5B1:D>CZ;><&D>C&:_N7\3__<GQ\<O+Y\]/=SO7DB&I6CR&753N'[>W=
MO.V?U4\;0&/3PGX==FX]SW,]9[4)5+:W;INVGD>YGK.J"&QKCG(]9[4)!+8I
M>I*=GQ6[/C.2.==D!]9M0LNAZ#6-[ZR4Z58PQ[7<QHK^*OJKZ&\#-ZZBOXK^
MUN=L*_JKZ*^BOU??QLV#/ZYR@WY/?4_0U/[ICB?#BE/7@0O6$\>X]IOX%JGO
M^<"%U<;EFEPLJB*]BO1>\\YA[3:OHKJ*ZBJJJZCN+:O9"@BXMO>4VS6K"@A8
MS6K3 0Y3$GX==FX]SW,]9[4)5%;AM#9X5A6!;<U1KN>L-H' -D5/5D# M9O0
M>D8>-N%Z:3,O@BOZJ^AOL[:QHK^*_BKZV\"-J^BOHK_U.=N*_BH@X-0&_1;Z
M-R*BN?TAO+CBU'7@@@H(6%'?EB 4VDNI6E217D5ZCYU>!<FJJ*ZBNHKJW@+5
M;:::K8" :WM/N5VSJH" U:PV'> P)>'78>?6\SS7<U:;0&453FN#9U41V-8<
MY7K.:A,(;%/T9 4$7+L)K6?D81.NES;S(KBBOXK^-FL;*_JKZ*^BOPW<N(K^
M*OI;G[.MZ*\" DYM4-?WO3@,& E8LS]&[N"Y#9 K=EU/=JW0@-M*?>L.4ZAO
M(DRA(KTM(+T*EU51745U%=6]!:K;3#5;H0'7]K)RNV95H0&K66TZRF%*PJ_#
MSJWG>:[GK#:!RBJPU@;/JB*PK3G*]9S5)A#8INA)B09\G[@]7_QJ67^;+#"_
MF(<?N]&-!YM7S^]E7P2)B,I<H#M&!?(LU%PFRWGKO],X\8;WL%O>KY^\2/23
M,+*[-Y$08YA/_+?WWJ_+?]=JUB _](*!P('JM8X7O/OU/(!CG21BW!.1?>C8
M8.TW'#L9"?LX',-YWMNT[V)@>4$2VJ?P]$30$';)?MAW7C*RA=L?V>'0EE=P
M?/?FV%R:@\IR.#8U[.)F7;8;#.PSK__=_DV,QR+R[^T=',*Q7?N__G+8;-8_
MJ%?1GXT/NU8D?#?Q@AL;Y@23]<#'%M&MUQ>V&]N>,<F!?#+&"1G+JO'V;NRY
M7:11G+JP0-@ M=^X/%>?!9VBI0^)OAC@SW&G:)^ _<NVJK!3=#SPV$1$PS :
MTU>#-/%@)?TPB+TXP8?IX.,4)C()8R_QPJ &Q&*[@P']X5@38\)\8I&()_!"
M[S8_ZZ^QO*TMG;(]9E(UYBB"V,5WX!]C+TF$H"EW4WAU]MD'^VM4LY#X%AGW
M+!Q[0=FH]-*1ZT5P?NK'TV^")4C2GOTJZ^$EP*^+[RJ=F/SN8^A&@P_T)*PU
MXZ:221C#6O,F 1PM?+]LAPJ+9B:6DP.^U%_45LX/;6*(EV2^$X/A/FD! ]PP
MA$W%G1ZY29[[O+Q4VH$-)68!T3JV1_!73XB ^"F)4A@!U!ML]2>0<G=N)&SX
M'^8PR3-XECG)IG_9#Z-)&-$YQHI@K?/K8_NK&WT74BK89]VK3]W_8U\E(4C=
MDQ_]D1O<9/2->_2O,/I>^'ZW9M/",Y'BQV%AU4[&WM^#\,X7@QOAP')WZ=ML
M/P8AG$40)B@M8A''< RP%9[KV[TT]@+XQ+'[?A@+%#N@0^ +%OFPK)$W@34#
M(<)[8!+#H>=[_(V#'Z/(&H%4"J-[W!G\D[9Z^@W64]Y QV"(1U1)C8,/<)Y
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M"SQP[>)DS^250*,^6PLTE^^%;Z'A]'RN6T-RFG7E9UY>S:2I]CS#HOZJ)*5
M%\N_V39]4^MO_\_>GOW9$_[@%_O"O0''\DK\)Q5!GXZ@_<'^']=/\=_VWIX\
M](%WJZ8D_5/&M?]B?_3=_G>[ 1.,0]\;J GI[_?Q2 UWV'1_B^YQ_@UE'G#.
M4YZBG/D\69I&D%%S&6+%>!W\UM@VM6$?[.O[";R_&[D]K__!/G/'@C?U+,3=
M@R?-Q]ZKY_"[[.S5P?_M/>QSR8Y'POV^UQ- <3#XA$Y,[C(L2VVQIAE-$2;
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M #\_,ACR*GH+/%9P?L %^LV]QY(!CGTQJGVJ;9U^FK\+;:?>Z#B-@\YSU_T
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M;E9A2!H2)C@+$MQDE]^3J/."AY^S<\])>][)'L7)N>,P#1*Y"MA)E.<".W/
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M$Z<NA+]]86-J 69^"%'4F)F!4T&*ELW0%0)CG1AZ(2@O]I*98%(<4/XG+Q)
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M;GW%F*_-F(?[AP>/8,QOV/KD#F]WBLDULZYK'S)G\>\^T*WK!7:J1H<'8Y'
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M_J)Q@[W;WJ=6J]\KUL:VS__>)K^\B -7Y@;0EAW,>U:W=GD__-%M_8+2S9[
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M6S 9 B-@(8"K)_[[]_[WYJ5,G.7@.:(S"6:\T=!CQG2$OS#>CA602[\YHCO
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MY<Z<IM4=7>NZC#,>@?&L2,#LZ:H\F)B>,]JY,@2]W[BV+RJ%<48CU%FF76Z
M:(FR AX1-5'4=_M]52[CJJ1F*Y^9R9MQFM!GC3HP+:1ZB^7">J>GS^F%4#H$
MH6\'H<$G;9Y-PC*U%&>3Y $7.]LY7!NZ:=X9^@BUL>H/)I9K.4S$;OMF;HC5
MP5S])'\Q^<\31AH5JW8Q3=IB.N&E.<0BOD(>0F.'T^(!G"13VVS4INMK:INI
MTA4AK+M_L1P: I)3 $E$1<HR)S'DJQ >,\%M/ODH=^ M9B",\!_AOYRH@_!
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M,J./<&MQN)4EW$JX]>C<FKTALSD6RB0N6F/+IY%KM'..> =8;4W2)^!&-]%
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M0CF>YGF!YBMA[1 S ^[1O1\B=[(B_G_BF%6%1?*:99 *E!/?"W,0Q#&[_!(
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MKWOW\>HL2$F/AA^H_FP*5] PQ*$B?: Z4((Z=.[HB*!"\$M_>]]"?UG( $\
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MW7OI=U^37RKF5#=%]1IJB2G\!OP9*7)%LX'LCAS1-7.@]!QW.-_I[D>X?KX
MCXJFP><[W5I&U!1;3N2B*@?RYR0NJ@X)\V4COF%V1QM-]QB--[:8[D*=KC G
MFCM$4$]07US4<Z&HY_='/5NC^>J)9J2$VFSEH]ELK0/8;&D6/*P>(7M>R=Z
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MZS2T!^<#@!K9EHVR\A:OPEZS7[:.%^(^>)$Q05./J#\;A08:R,XNG'$ACSB
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MZ,@-##S6N]TO8;_$#Y B7D'MJ=#-)2Y!@KN1Z46M/?0P48O)$7RTVVMS4;I
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M[R-[903H5_A]U"30 "6=H;L=Z08>5W#(K'QDY%YXGHGAQ3,LJ!/1<<&*9G>
M]09"4I8)!2$D0"3PG#QN, I_8J3#A(<VNU+P@"7?'Y'^1&,8*A-8&TE\P8$6
MB+'0R0VY0I@QQG\A89 1TC$C[Y'8[A%8 A-3']%K0'><,2G8A^ZR#C%-X%()
MK"9[$@Q>,3J4WLOK]AS9V+*9L&Y.0# A>\X^ 19D!U_,*EUR=_N]99\I"%)*
M,4 3P9@PI'1M0'(1&&:-#1^W7ZACMS4"VOV(74#P<+SA::\ZQN;%X\:Y7_(.
M&#!<<#JS*E@SA_>&;;K+MD[7Q""ET$PWB<$EH3_4T=%E>WKEGM)C4JJO$L9=
MD&"\DXUN\)*D>!%#7;U7K<B(W7U6KSJ81#^@CB23>\LM40_G>#WNIS]+I>KT
M4"NW1AXT"_V(@TP_5R_."FAELDY)T43/X&%SN?=-)6#X^-$P]I""A9#8"U20
M:28?#SN]..$B8G@PSH>OIA4;8&3ZE;\UI) ,53*7H4T0GDOWUL"&$C ;.9=7
MUTR8*OJ?7S]_'9S47G0^3NJ[:/!:SXR/OH4X)4[.+U[EM 'L:.F2I3+01Q;B
M.9R#US-9-7R%)\6VWX^D'0^&AC71-+P5#6S","GKE8^_/VG&#[/G\8E>>'<[
M;_1LHIC%SBP@8FD#^C$B)DL5D+%:(5;&?"O%&!H]2U3PE\9REHW[$1HKPY<H
M[5Y3/<.WXRV=B&Q 2A)) T,X=#C2]]A3=T;0VHV@8J(15%V)$1257GMC"^A/
M\?:'_+-_?CYH;Z@%%$K]I;& RFD1[^*NJ$*I)A4JI27MH/Q*;J>W%J$9=M#T
MZ5DYMAXFM[\WU@R*EZEYS*"T '];:P:]M: EF$%=]/G'3NM(>7C<7#,H7LS2
MFD%I80UC1"PGE0L%J5:MSF4&<0$Y<6<&;5!]126$A7C(8=I?DO)?7/B7'AHQ
MY1/NI\;+7;/3E\L_'K1-3W#@4P6DVIHJ\//;I3;66XD!#8MQ# R CPZUIB2T
MW -CBM#3=!7=)@"*+/=.=)2"BR!P.![RVB=0,,\K+_H7 '?2J'9%0T7G;\_]
M3WQU#K">Q8%[J-1H6Y##A4H#3)QGL0!ZN&'7'>=>Q#C9(-QXOX Q;/:N.GT+
MV+#)WW$C+7P 0RB17/#8<2<Z^RN)C$,\QQ#4N K^&E>N=D.S!^R=Y"V2_P//
M%@3G&:8>U>-NHB&2!-?]+N &TF\)[.&V[CSN=:%5RDW?VRX1D$2Z((@Y/03"
M-1BPA7N"=9PZHD2 %I2B8#N;D6]H4<,CLD'$1> 2\]!U1@41TD#N@T*U0VJ"
MT+(R6=Q_"PR,D&;9,W13HR5!;FL8WBE<J<RZT$A"S66VX?M#\(3(H'R[@V>Q
MY=?B'#!1A1U,U$IAHN3<#B?J75S>.YRH'4[4#B=J*W&B-GVJ;^+8%GQ]X8>T
MT:L%]:'I&L&/O4;P--^^GS8K-:?6T$Y>CC8>&8--2, S$MF4WH%<;?2 ZXXP
M5.P1U^#(>)^&C#(6>RE1=<9^SP+7<7OD8<RE],A52<49+EJ&P!F'.TN(*CEP
M#NQPT4Y&KB72;<ZS[)Z"G!C%XPT#;PT]76%00J3&V-=,R0-D$,);4R.A4DIA
M8&+H=K,G!)I$B0OKK0#?_NAXH+U.L$C:U'H6<NU\5)_/N)(<YN_B!Q-6;?(S
M]MV5"5TK@ 6FK?1BU[!>*+"':N%Z,[2Z%)J$@DD1MXRU75*&!%_//0S0;1LE
M2X1K$=TI1$*0"!:>$D1$=8>0V^,F".*\#=$#D4,+6XV7R]OP8(<$W[F)P>;1
M^$D@ 7/DLJ^YWG: C]4/FD)1AC7"(:!UT7_PK<)J $[%98WC6EP]; .&)^7B
M([,^7Q=(&8:O.*QQ Y.[#='.$NYS\F'&L4Z1S?#)(7ALUAA:50DL-_]$_P@Y
MP&K<R0I+Z<9EW(8/CFNVZZV("Z/ +P9;""(U(XB>Z"::(5T*C.DV)N,F&-9>
MU25:70?.AT%P'\8CB(V[2#-4A&S<@#NR!/^2V62?*6>S,Q[0?F68.3U/1UY3
M#AJ*38)#2J YVZ]>%!6T'^W;99]CZ#4<7+6@NT0(C*J9;S_VT?4&&00?-1^7
M;Y>U6^"N8D]:\)]P]3"E7P R"8U&]MP&<E9,2O433\!+V(0)SXI"J ;)4/P+
MP,2 B#7!-02!P^"'##_/H.02@"\'[_>ZMY!\N'HE07,24(]17[?5/;@*)DSQ
M[HMU QW-<<^/?Z1:&FGH(,$P$A?SXH<63V]M>+U5(P&O/^N#(5N$V1-9ZS?6
M1VZ1MAL6549CVE/FGBE7[#TE@&%!0$/1$TQ%(/1U(?KKH'.Q:O8K8- ]WH*R
ML9.N(1O>96%:2<ROAWY&*AJK%\R%HD X9&PH-JLQWR*KX$W,XU!?[8FBVSA2
MUNB>L#ODU*,HCH0GX7/$J;Y_/QV9]=:OULEC_UK==",99B3<L)BP.RF1FQ66
M8/@<"3**YUZKX<Z87F-JB%H*A"#>,X%B>F:![0,;(?@ZP;?Q]97XK5YODD _
MZQ/T$]:Z7-T>N&N'TO,*07I>R;. B+% 6DG<7]+F$G:9X"N/&R&C&[7M":\*
ML?7W2@Q]+E?D]5,@>77Z2']R!,3H7HEJA@STN% X6X8[2WI;#$LQN:$:CA4W
M@K;642#I1+L.!7]*1E2>%=W #^EB\. V3?(XZ)(P*,X=S:1YQ,G4O(<K:J2[
M&0UH*]EVW;[1 ^9/%6%J<3F@011[8YV<&MC)60<-S"Q"=&>JD!)5M2XVN#W)
MD9AUZ_B?3,XS6!"<E!'06IJL="&(D,@:%C[\H=<QVXE^"5L*)EH)[IE<;SA:
ME/88BRQ&6\8=[=C$0L(G4 AF;R'0N$T+6HHY#$CV'MQ'; /9;\R;Z$C=*;LC
MA;=B0&3^TPR%#3J*<1<432,RW+?0TXBGH3E<E_5(Z_1-_6G,-\3!>:+XSOA<
M@XW]"7<[V_BPTK]AI&;GLT3QAS *A?=Y!D+GYDXIY#+Y(.[, ]T(#O5G#_87
M _OR+W5&Q-4=&@HMZ&'N#[)@E Y-&P-'$T@:/)9^%D.2P_<_[]3"BM6"*V!C
M2.0#((;""WA?UVSP>B;D,."T.U(#4UKGH)O#,2;*BI1*J%E0.<'G'XS=:$=_
M%=M(7%3! 'P?%B9RN:2@\ M]0-< X,'IV/K0@Q*#@ >!527?_;)%"[]UDG(&
M2RS(7\1&&XXPUB1T[YGB>1I;4-9!%(OX:6R2<(.F?B:F&78MB?8A$21"[]7Q
M+AKT._Z>V:+EV=+]S']!;@]LHN2&,-#S_1OI>NJ6N_.2J.GXXZ04"B@E;(QA
M1_Z+-<G09M[ \V#GF8E(]EWP[WN$M, %$WZ*)S^A1XKA1[)GN?/!-W/G/923
M;O2 B:05OHC7IA72'2Z0$-JGD8$-"XSX@DT4#/W(.L9=R&V&(N?VS'N!,^QW
M<;5MWB?;$_1A22#O\D+OY K!^#7,+,(A)WT(V5K2Y(^NL"V7CSGJJHJ[NJK5
MUE7)N[JJ=Z$H=W55N[JJ;:RKVCKSX2\JJ-KBFK<EDRK;NV=;=Y[JAF,)CJ:)
M<*K$DK@G'G(@64<0Q8_J&ZUZ97-'Z,G/.%%\1CVL">45N6*U*5RRL$D1&8^!
M!\Z!EQR;D._$H2(TAB,2Z=74$T/IW:OM5C1@]T.G>W=W:__*'6IN&Z<W$)^O
MQ[@UP+]3V=/%+GK\AT4SKGQK9=NR# WIGG#RU<]9L\)E^O"5F[K[]%!VF0CE
M-CDO;X@!60GQ>GAK/*.DM,3ER^._=#]5[<[P>Z-Q<""7-SU)[DU#X%3X3C>O
M6#=?'0HM:XCDN2J7))&3):R3OVMJ#RR=3V )Y7/_HH^+[L?Q[^1_/TL0#T'N
MH^[T-5^.C^396!T.2Z<Y-'GKJA,N)RY0\%JQ3U_,$4*V)S0O1FK0((1B&-QS
MG  1&JUC]!=[D2Y+4@T(E5Q>=F!?_(8Q!RT; V"&*U]Y3.M^L,>2'T: FP1]
M7J-]^?MB@WQ9]2KM7+!)&_)P5K=+'M<>24*P Q#6+OQJD@9SGT/@#8$<8& ]
M:W%?8'Q,:OA"FWC?12\67 I9']<G 5CL0>(4XIZ8Z],D&7DDL&BN8R0-!#D;
M3?F'8HZA3(MX,KE@B: UA*'4KZ[17^7*GBS3(E<2.U.M%W//1D-0A1,-TOID
M#Z(M/HI[C4:$]@I2AE!-P$T2D"XY1&]W#"Q)"YE,2T6V/H[[6HQ?@0)CXM2A
M2CI']X66A]&#WM@9#\:TF(U ". 5<3^]13KA+<K(JK*_R\(S$,%H=&[U4?\8
M><.JJJEA*T>?=5WFN Z,)9]\/VTX.;U^??+2G%8V_4[E)BO@V9)R&39?,<*F
MTW?-&^NLC.DKP$<TP@ F.#T=P@^6,.@_:!ZB#N&L@=KE.;K=.V3H=BV@)U+4
M91Y#V65UQL5FK&#,K;(BI$IL#%#=2Y]!\'LEFD&/1!<6"2:__HJA6,B=X17F
MZYW(?GCT)<POC=6[6QP=N!EQX;0+N6_K/=#LP#4=Q,SW^*S!,O!7\'%&!HS*
MK=H'6&B<E>'Z6%@ML(</S0X,%+58)GZ(6Q#@?0]0(Y"L0&::LP=H50UG%[F7
MD%>%1"K*D6 $:O5(L<HDRLS!)7@^$P;^RX6$)E5P]J.F[HVL/5:>,XJK@,>8
MSX2, @IAV'A\Y1-<Z9\")@!G,2@.(P['[%QN,PC=&EJ'Z/%(] .%AVYC >L>
M\=X%%)(T^4LRQEY%$"WNWQ>OL8BX(B/Y$+VA(VI"F-N(Z>/>ZE'6#R;@P.L&
M<N(-4J +PK^%>S(>#7TGMNYHA9+I,[?XO2+[2R9J*(Y#C Z EXB>):9-4^P1
MU,*G,;RV2",NET$L[3*(J\T@YG<9Q'=AR^PRB+L,XC9F$+<X2[5+)*X^=% (
MAM'/-,?1M#--F0G-P(/@)GSK?GKW<I>WBU=*^W#C(1G(#+9,?K;.B6\P-D3!
M@/46+QO7K! 4>06TEP&;_ICI#Y,]DWX$_'F5]A\P=CKR$ ROAKM[/:Y%_ <?
M46,,]35QM*.;*)"GJP_& _HTUN_A <+QKQ]A#UVC'2G4.:P#*Z$S(A]T&)8!
M[;F!=@I] %WH^DB 3BU_@!<F#I_@"(J0?6R3<GO;[;YF--4\6;;7\$6]+Q9/
M)3X69@XGCKSK/Y(5$((KX/6XX//A.E6X22AZ=<!I'T#R8DH&-P-4+["%NN-2
M"P$@!,73(P6C*KP1'D;"Q0'D!0YO :,WTI3LUE>GK_PB"+4BH_%ZMVS3UVA%
M-'QZ+-IY'W4_/:W_0*[XP_E/0][T*^-2 P-4X"T2WPQWE\EZ(\*V]JQK+QJ)
MB)[4KPX8@"SDR.)[![': 4<"*4&":^V0(G8<JT0:M*^XV2FD>$S _5!QO-0+
MP D,E88D;BDV"?0P4SU*_ARD3<5\P!HPLDYX3.X1)EY]B6QR5 PT4M#7SQAI
MQ0,<11/4(",H^&:* ]<&S4O3^Z>M&;KVS KJ:5,F*'0OA>=^#6<&\0(H+M"%
MRUAL\A<6 ]!QET#PPLB,[17>XFEFIKE-C38AD^5AR"PN6BT,T>TJ]1A>71([
MN/<,NOLL7!Y$]?'&XL'L;OO-L-$#Y@ZG*QF'?>@//'[5.@1ROM%%3IU&()LT
MA_7$'C:.SG=;L\(!GYJ"RYV#;(0"L3N]R@#N0KMRJT\.,*HVJV@![<H*65PM
M&_6UZR$V.;U*F&OV->'"VL>OW\O5)/&_.AH6#MVW@-I<_$3J92K%W.<OXND
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M3'0X&=">QTX>SSZ.P? H#I[ 0'D]NIPDU/>MM:Q6#7I4S ?A8P!X<#:H42X
M'QL)6E0J_3E[>'TJ?[M8I*%C_:!%I5C0HH/[Z7&E:1\<-7\77TL?OJ9&,G\_
MP$7+I@36L8O_U;]>C=!6M"?"\=,8P#B;C#3%5=K,""GYX#:;Z/3HCF/9$ZR/
M''3P,MZTA#7P8 ]7]0[Z2]U4-7AH;K^DFQGS!#0Z(PM?&T5B[/FO#HKA+Q(,
M?Y'NDAB_2Y_@*.9S_UX=-^OX1_E?P@K %/^EUM.=D4UNL4L"/.Q^77C1D;ES
M5P<F@N:%))Z-U'WWD7>6_?BL&X;&GBN)0]MZUE5\<_I@B3428)?$]G@$2,'X
M5Q:ZQ'H*,2;1;!R (1X/(U&#>5_R2H&8&.;) "M$5S4R^$MTX2*=H39,[K*[
M'YHELTS]2G014S)J_%-:>XDN,EECML3N$C'(;1R4NX0G<$&Z<^55'XP'+OE
MY^7)R9M*\Z[M4<V@Z<!UBVF() *)Q:8$_"QX3CCNX<UJ)G/!/$L4PWPMY_;R
M1>\G9KZE6@P(>/FF'K@LT[(([95<RZX<*N[([<=:=D01H"-HH%\".I:/ZHG
M9J.#B TM]&\).1SM!^1&82< SU.QL<] @+<=YEEAP&SL,1"?"]POV#Z;/T,.
M@/%CSV4-2F_5"FEM-]BJ)W)J"F@_38T<%ZS60 >!6I1$5Y-QGAI195J<1I*#
MY<1-0NE,H=:X.$E( V6K=U1-W]L[TWJ*<8R\&8:#SIYQ5S\];5X@M<U4D/+T
M5'M]//MQ=^YJ(#3R/<)&K3Y#%-41GW6%(L&36WWHW>J8MB-5'5CD@L1%R>96
M,?2S@?D%]$Q:#JTD/5-.J69 AP_G7DGQ$UHJ@5ZHV)K"9A.[4??%ABFZ%D$E
MRB)PKXA$EM,DSNCA,*>Z\EFYGQ8UM5N93$KZ\('C(Z1OP>#O)& _.Q(W!_TS
MD8%*8 ,7+OTK2)5\(MT5V3LPA"A_C9*<N$2&;0=I!@?N1^"Z@.UM=#%M@?^
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MYMA;[^^Y2C*MD3G1VC:V>_(Y9OCP=P5H.T^%^4MFD" ,3+V-;)@Z$C"5U,C
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MY^ AEB0C(B/)CR[2V9!IU14E?DXWFH!KLG#:N92O2.4DA!#RK\PD21)8U@N
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M)B#!Q5GA+K_^1<I,JP_XQ' A5\BEU=>Q.;L51%8?)U6U>E%\S-V48B.K\Z7
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M5HC,.7%1#EPIRLI.\\PE8W2!5RQJA:1_:MQAC#2'4XTP6@%DO5A)*^.=]7*
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MP<7K6#U3GVHD(S> G!!)R-'\D*?3<+()FV5M0^_1G!K8; /-S2O  VD5E/N
MM@;5%,K LD>X>\)ZII4NWD<A*\84+$M>.+@P ZM?EA9TTQA.T-X30_2W/KM/
M@&G:*LYD14V1SST.;>M9AX]&Z=(Z=]*.!T/#FFC:@69J71V=!9/(T0$XL8?<
M>Z([- NOY^<OMU?GOR=EOB0M>70?OHK) IYZ4 OU8=<*"Y>FR5*I6)9D.0R@
M*%(IA9T++?CAP@L>M)^F9R^CVO7EY?7PKCC/@J]RO4,V3V"U%VYYK=8*4J4J
MQ^??D0X80JGLLV9,@M=+G'+-L#![Z_*\*Q_PE:8)F#5B >IH(K&^:@//G,0/
M<;BZLP[W6!,P2_[F?5U#_A[M+.$#J;*=%;C"3MA3M-%0<:B9'0B$LNV_"B;O
M';S/JC92=,/A2V.B_+;@[<E?GN^0%AZS5VNON.SEZW__;V]//-$U0_TB-I6>
M!FOY-(8X$GI" 0T/^P/H9W%OCX(XJ/IS6@0$W^1!?@+3+^,>B[EX=&>SX\JY
MW,>H5HYX,!(TOLB^Y&BD$[))OM=]^'JRQZ\D6\-_Q=9DB$90MY'ZZ?PK7J +
MD:SSA04+BJYX[EO_85^#/WF0"0POX;__02L?L0>VICSNM34D\.C90[R'_+J7
M(]:=+$@8Z8Z7F*'OA?PP8?QDB)P@O9?3D:%.SWZ\_VU__7'=/&T=7PH7Q]>7
MC:O#T^.+P^,K23R].-Q?99_[2N9RT6@=7PFMAGAR>E&_.#RMGXE7K7KK^/SX
MHG6U=;,)=>>Y#E:&4WFSHT*@%=B!62VHP@I@(0* 'FD .R3LAN@FLA&W;++;
MO%& WT'"NE#YWJ AW"V$\5CG/JRFE-:K2XC*#^)LJRHB1U[4D4.M*X8X'+<-
MO>/5.424P-:72A^"^\_B%/"3^R@PLQK=NFT#*A]N<_,5=5U#C?R+K8/K4&?&
M?3CLNGBRJ']4;YV\UDKZ550(EOJ;V/5$<UY#^E#.[^7RWD^L4B=I'5*FD K+
MU3'EI4IR)BD6YR2Y;$&.EBN<Z.>;^#H;*#R=ZE7CU1C^:!QX;<]7Q#'%\YW9
M01@A.+Z)QU0Z9"X:BY5U\:4/Q?T$R7#7 2?T!%?-T$HJM!RNQBHRC15,23LC
MQ<:A -J/2$,_%XJC*D_BH3+4H0'[G#29>)VFR%U\A+=/!FW+P%9$/O<O-&[B
M'^5_]P6^'< !L/:@A%:7U7Q%5_,5-TAXS88FG[5O[9^&ER:_HD&6Z*.\)O57
M]'[*4,:+R^6?YE%_<+-28)XK5H,(LCAFLT"V*Y;O"?CE2*:'MM71--6)5)"E
MY2HL-E;^\H\%Q?A^H%Y;'IP1SD1ZRX'3<DQ;K*,Z8X7BMW!2J295\B4I+\=6
MEDFBJ>$^M:!\"1:2.EOL:EJT9%5\P#UDS6$I& YWH\M-:L.EJ7FI&HHZ*!S_
MX?H?<+OA(K(T<S76+S\+I\ED*5\I)K&Z_<VID34YDWA;A<80UQ-LH4^Y=<O.
MXUKVD$Y"-S+U1J#@Q8$;&>D"9&G;Z"$:S6^C'PFXD@6_Q4A>6($^:A,P81VH
M!?$PERQ\SZ/#+K, U*D)T3O(6C8--(]/U-J$"C?X!;4X/^_.VPH'3"J>,*[)
M1%.@@QT,K)0E-%ZE$$5UVR,=[+Z"FEE #77#L#J0M8RND3@F!1B1]3+>#1?%
M+W"I.\%:,JQ7B%IA%^$?_<@\=JYOCX][ 9\T/)=9UV"ZJ215V7@U-NY%%QIS
MX*);N-(U+Q7EJE228]$YQ,CJFZ/%]BZ^='GQO3O[W;^N77S+::;VEGL77Z4\
M:^\6+@^M%2N2G(^E#_?7\DA\,0_ 9+@@C!:Y87G(S.2 DS<?T-!)9W,Z[ARV
M2H_ZW=&)QY%S;4:]GA59I2K4#+U]L:*UTN(H)K6*5"W$UN6B3R?-,1:U=(ON
MC*V[Y  M0S''BCUAR).!>PR;/!$]0/5@CUA(+W >W,'$^TB3D%CC<F%JQG[#
M9M6I2:J+^0IKF2+CT9\<>X3\0S@PC>ZIJ>K/NCI6#+]_"![[V!@I$4XA?B>X
MEP']R:H2(_3HCSO+'#;*!>NRS846R)+P4NRAU*5L#\I^R>(5<+[H_<0<R= R
M,<4<NQ@!+;$<#H8<2Y-%0V ^#8'!6CKNB%WX*^U5LSNZHR4D!0KSR*DSUZK?
M8I8<3:T_:[;2TX[I8$BSY(;(KV)T[H;ZB:%>R@$[@,JM?PF7%MOL5G#-XKQ8
MBUS:ELU WH(M?E]1!86H6-(O, /%K9*ATN6PM$_-$7)U'+V#"_V\/M\WDMF3
MVO,OIVH52S]EO\X-KM&JE6SL$L6U#6<JD8OWZ=5R4JD<JUMW]M1J[2F"WRE7
MYK&FRFNQIHIRA=Y&^*?UG^QJ<:R5'WXHMZ7NMEI3R(^M>#]E=MB70T,I)_:S
M96=,S67T9VY,O;GX/NO7=\7)[=W(KKT38VHUTEQ>+$&^O#$E*D)Z8RJW7F/J
MC62V_?0;W6I'(_7N<<N,J4PE<N&<>:4@%4NQ9 Y_LRV%/AHWZ(8I8@Q6.1<%
M8DZ-H&@4\_P:+*%2KBSG*)PU_FG]Q_+/I/;D7"BGCE[92DNH!$W\<L[[*;.3
MNAQ633ZYM(JBJO/VD+"$/73PAO;0!@AQKF"?3>T_E[^;Y?=@#ZU.II<GY<CM
MUV*K;HA0>Z!@&+U\CJA2=9V&T)L)ZT6^HS=_*^>O[>XV&4)9B^+">56Y!IB;
M4:3@C*, Q"X%-0FL37OV\K5G+U_@A+N,4M @#L-#$@4$2/E[=72W*3I3O=,:
MCV?Y2ODNF)A'.A.[YVC$K@@F,W]GIZTXD0 NPR_JV(::%[_L5'(A\O#U[R40
MIX1HTHD([N$R'5@_[!=&BV(HTK;(\/$_;C0'JC O8=P.NG*@8@N-''-$J</[
M<7-L;\Q-/?V9TYX*U?'D,L2U\DRF 4XUG4$J!9CULJWW1J[,E;VD1&9[>4XG
MPNZ"N1FG#S\RDD1_\ U6VT=^19M/O-M:B@"'BA;E6H;W]@TNS*B;*I2. )9-
MRX)?<0>4]&&\^37^<W1T<'Y^F7OZ'6R4XI<X!;39FA9L'9=Z94E\SV0X-")\
M_.J"NM!-RD6)T<>0(",[9J08!K;3!5L!O(J)V-9ZNFG2S_\8H]_@DLE1W[;&
MO;YXKN!?5/97&X[(D+8M.>0!\PM&/-QJST-*;:D1-D+ 1/5./E(6 >:8Z#-_
MM!I;/7BX*] <F>9P'UCPO.X1*W9FQ_2V\W1[,KV\+NO1KF%J!,*LYQAW'BM<
M'V3TI )G;KD>V$*I(A6+L=9T1)R"X]GM:/9(T5U"WF=&1>3_/*&3317'R#+]
M&&_3^6,8V<E:OC*]/"_6;O(O^1A9RS@.D<T*9":)R[?<ROMR;(C;C2X0E'D_
MZZ</@C>1C\W7Q8A^H-VVU/QAS&Q8&>ZO4/6%35!>"K.1QQ_'!U;G[%=S//'J
M5VX\*UNW5+0I3L?6L;BD]/4JI)E_ ?FH1KMMV:P>[H^)4#R"@FY6SR'#P0%B
M^S*[@;<7",@IXV/[5/A,.B[H8GE&1,A8!IGQ7[O.N/V UH(VR@JL-8<!O+AP
M+K15AX#*C6B#]P _D)HX^S%NYKNP5:ZTX8B469<24C1!T/:4T9W,\@_T;$+G
M\KWW4YJSV7JQ/*O:/9GV]>"H;#^='8Z[@9N"3GB]Z94XG[>VERMY/[&S'C6E
MP$E?DIL.FCM+L1XM9Y,(7"W)Z,7BLB?./.D3^2W-CB5%Z?NX<'J1;PWJS849
M2-[.Q)A3K+*HC<W'EG-DFKX Z:1YU!"B?73<*FL=4V^?OSPIXY<STW EX\0W
M V]JJ=IZYIM.YCIEX3+40C$GU>+#"M3*"YD/ O%;T&4G^LR'E#&P=81S,Y.5
MD\?<CX>GNT&G%;R/?/'"#0W-+BQ2<SDL"P5?Q:6"K]&B=OBFX=8E):WX[>CA
MO&%.7OM>'Q,9RY;$2^<3L=J2$#U56<J58[M_DR.B0E1$%+UCI!LAL[OBYY#&
M+#>)Y5%9FDQ9V=H1XG;X\[+9/A_HDW$GNC)D"^SM62*V9 -<KH9NQ_P\ 4!
MFC#= $O0YA;2V=Q9:K'5V=P1(G6GUF]__*Q==U^]BKGC;8KKS2-;FVUQATBR
MUV5Q1XA%X^6N;)T[I]-F9_/-[5G;OGC+5RZQ[#&Q."<45WVSXIQL)*)<'SK&
MA5W_)7=]X5=@19NCN";U#J:JG:E5-[MVAHB&YW!A>F)L+SN6 :8R,*0(2J>O
M:\]X='"RD ;!DP>Z K2(A*_8 1R'KF48UHOS)5KBBEG<04=>"#U3\7FZZ)S=
MW58>ODT* ?'QS7?^"/X"*@$=Z^R"]T?\B#\IGT6Y]!&WTM0'2,8<1;5L\=-
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M)2F B>"9= Y>-E0-N+H-AY1%I_83:2;'3] 31+? _FE)8P[I7@75!/]"J9R
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M2T]!)V9[?UJR]1GM>..<9CZ72>>#,YI/4]Y #I*"@R?4NJ!Q*1!*EH=-)P:
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MS_(%6Y''GU;E_O:N[$TY1[%%P.0;7[EXYJ7QI6M!6;N@ +3!M"P2Y[/S 'L
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M%VI@ 9,PP,1Z078M0[!.6-(N55YUC(2/5$T61YA]3_LIX9(6(GF1B%@)QGT
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MW#J2)>$ \>,  15UC-3<48;B$!5_N^IO:L1@VH]/I%C/'V((&B9].(V(K-0
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M/$4K;AS^1.%C)\!9W IG,X.Q:$^_LZ0P:X<B@)8OP9-]!Y<E^P,:Z:",9:"
M&^W3)644H'2 #6V<PK&F 8Q-IVC/@3[RI3&[%^=\39K1X'%B3G^P+XQMA<HJ
M*<(ASNP+8'O(8QVQHT<$D?9[2K,[0:  ^R:*2>A\'=H$(&7?KJ4*69Q?1P7,
MKOZWL(*Z?62+J^*('PV;)QX2%STX0D8U(! +&(DP<6S-V$4=41Y;^AQ.O:;M
MK!2"[3E1KM.6X0Q/6==\1VBV$/GAJ>EJZ18!=!\"JNHF:H3.3NR/!U"*6Z8$
MAP0"Q8^XC&+&IQ^DV 1Z]%..1S_!O0@W7%,UD!)8'T^GX=#"1X>GVK:):ZU@
M/U16QV1I7Y1),(W3&@7?4@5-3-/.G+I!.2$;;FWY@1L7-4LR><K:=%!5VV"P
M"!(6.ME1)F^"L_/WP&QO9@)AG2S'U%]LK$]7A\79P>9_3XTX]EM#>+/:".@D
MQ4[%^J,8'N%!26O>5]XBM"\+(O[8>6NVAXW-=%URMGN_(JG0EJJLZRP-4C&3
M $=X^Y#.H9-$Z$'WXES0O=TCHDG3)V<"Z%>N+7(VMOX8$(BO>.<F;+CBTV1X
M?U6^OFJU'JY(>,'Y""[*VGG*8ZPY_9 7%=N@[\2R+^T&0W\?.'Z&&.  LW@@
M"[ O0'AB?7YC4VLZ7^*L^C0IW,OY+V.Q4;V1X08M%$W1UI8S\3K.@Z8SO0S9
MH==*E5P[!PC-SK\YP3343]SR/,MR_@_G3=K-F;WZ 3,&/<F6J^]B-BV3Y2!]
ML#(0W63,U5>T@.1D,_&8"QEYPI:/?P!S.0_] ,XU ";@;__[(?O!0?1\)?^T
ML,3*R<8_L_1;.^H]W>)D.D;@A@BF^@C7'%<2_.D*EM4]?8+=6+ZWR[";_6_G
M^)/^8[''?RF<W0FSR<6!^<RK7USD=[1:,.48\.[@#["$</AP"(<%V3TQ=D^(
M/7SJ,8S:MWOS]YOR5CE(ZK'2859)23@&%#SX RRAH0M?&@H/W9MBZ>%6J1O&
M7><0T;V)$1P*0O? MO:9('OL#A"IP/#4/5IN)1PJC;Z7E:3$_.MU5;&^8%/+
M6_/WSZOGWS]N;HJ'2"VNOPWOX2^. N?HD.S@#["$2L[]J&3R*_-5*GR[K>0N
MVX>)FFX0G9Z?<O:CNUI:]VBY$9P;G6J3=,_"9_K3Y$?_R^2WJKZ6KH0-/!_^
M/H=/7 MPH*NIIB*B"T35_N:T;NMC-I-/9W/E=+90^',;OX3E0<EBY6AXX+1@
MLC4FV+L+=7,S+CPO_:Z]P=E4";<6-]0M;PU([SZIA\S=:+C G5H)ZPY.I+>3
MGB2*!+X,Q).5WEJ:S.<+Y0^?3V8=BV&<+L);F$><!*GW#\[=H?;BB=*6&%BQ
M*Y+50G@57PD.Y5K-.IP)<ZW:H&6^EQ*?+E6*P3.-$CI-Z/2=T.FFQ%?<>,Y[
M0GP)\1VSYE?D$\WOG2/U^Y,HTZE)4X)BXR;%QR<H?'TMWO8FF#Y^V_FBJB+M
M\VTU-F^HLO@TT07C=7 _'MT6VY%Z7QY[DD&V<;E$65Z! *([4SM<%\%$!WYN
MB1*'PJT.@47M1>+F(Y2XL0-Z@JTQQ=:%0C28L\?'H5+<N)\Y^NH#9STDM)C0
MXG'1XL8$5DP(+"&PHR"P556S4J*:)=BZ=VR-0!PL\'BL.H?U2+F\KY>C.I51
MPMJM +3/W68K]OR8B?+#:+;K-\4?:N=@TDRB!+$-+KJ[F0XU"<.*$\/:IE .
M'LTL]\0N()PU[<C%U3^;:KBES<."Z4RYF"[XSC<:' [S2VCP:)2&%57<4I3Q
MOM@!/<'6F&)KY()C8Y&P>0!P@4A(Z"RALUA+A5PB%1)L/38[(MCI4<J_<\7?
MU^MQ-C6ZAO;O^\*Z]P'HJU.]^QSW1Z]5J93*7QO#<3[>>1Y+RYC"AKK= 9%N
M.;@+8A3U6;ME<-&4R>V4 49SA!VKS:N1;#P<+QN'%LM\*5TH1*!C[YP_A"21
M$_)/R#\Z\H\P?Z>T\7!Y/LV7*NE\)9MP@80+)%P@.BZP,6EO'%/FTV!.I#/Y
M"!+I$]).2#LA;9NTK46?@IK]S/U]MIO/#,5O7-V<3Y?SV72QF%!\0O$)Q8=-
M\<$NT/+&N0_%=#E729?X(U6_@URC=D--BPO6B7&MZOK39&#<E,Q+N65^%Y,$
M,,-M18Z;LZ=:)0&;. 5L0MOC1W_V]>VAWOA[FDQBX74LKQ';UP%B__UP,A_^
MJ0 )\MGR807Y_TP(,"' F/C]RKFMJ9!/\T4^7<F6$BI,J/ (J7!CTEHCK2&
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M5U)XKP.-#"455(E<!L^@D[:)#;ZXE@EX@%<L"F.@8=1;/DH2PS=\;]'C: L
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M<-^%_J"3V#<QQ.7$OHGIQ23VC0L+RD3HMBU&DN!JK' UT5,.Y%K>&=](\/)
M\#*YEEA>2V+6!*>GL?RTQU/N3!/$)'831X1.;)N87DQBVWCST]P$-9>;) @;
M*X1--)8#N99WQCP2O#P0O$RN)9;7DA@X00;.5U7N$HU[))*>V#8QQ.7$MHGI
MQ22VC0L+QD28:4,928*KL<+51$\YD&OY)[P!KR=P!#K4S?JGK:[XCAO]Q+5
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MV?^\=X'97+S_?)MC'/[SWU!+ P04    " "LA8%<_M"6XYV:  #6PP  $
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MNG8#U%88ZQQ5A'2JMO5FES1C^4L!E!<E'K<VW#EW:7FUT"MFK*GGHGQ//L!
M'T=H3FC'XJ/[/8ZFBJ>A%F1+;3:,_3MA;,M]<V=K$OA:96-9I 7GN(]/_4'
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M;HT)D!_=^Y^/%WE^%U&+K]8;$>,V'4C\(N(1;&D0+!!14/T:OWDQ:D"'S&B
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M>/Y'S.!=LH,#M9;Z_L]ZU8?/1((U L6HIKN@T5C\% F%"(U _EPC.G\QK#6
MRC+:C)JU"-Z\\%=.A[_-ZUOX1'_?*WV9.0Q:LJ6&?^/ A6+.KL&;!_]?<EW[
MO<5L2BI;E20(KMR !T(EB[O:ZR73\HAPF]'R*$%F7LW!.[[@S*9,0'EO;'\2
M'O/R^HR6\1_V.]4<]HXB0Y10==A]"%*L9BO9.5F[G!_K -6)-ZEVRWT:=]+H
M"UOI1K=3^5[*:V8:\ <!AR1SPTB&B-S#$W4(GA-]-8XT(->HA4-XMY&Y6 GF
M4IW,Y?8WLRAIIA!BGF&RHOOT1@(K#=@1/;>3!IRM#P)'NZN#. WR840>A,(N
M  JCT@=)D%N(%5VDS$3/7*1>H?RQL!Y!]?*;Q<-(Y["VL'4!91"X "(-&+:E
M ?=UB($TX/5(%0T@23M2A<MF.%^[:G0EDW,VGI0G81,0/LI[J1S2O>S4$!0+
MJ*0R+"D&AMM#>07V*4\\ELK2!YX/V;X]&M$+WZVHWZS8J1RP+:M=R*&B[T:O
M8=]L8LGB@\I8;_6+,F'0?.DQ5'_0BA!Y<:-G"(T/]6]!+RM[(L"ANIG*B:P2
MVCB#;/D.DE$9HW#\V$;K2BI2PG\4<A'1+%V6P/0;&#3@&QHBW]%PI0%!/N.?
M3OILFHEM//'30BJ7$STA/R/FB@R";.Z,_+[S' VHZ2[W\E\&GWXW$9_*?]V,
MZ<=FYH-DW7]L>&LU\1OVT#_1^.<8:AJR;6[7 "EBG];?8@S^@S&9GQB#$^__
M8$P*B<_V87G:]3R%$6(2O5@_?^8OJFF +1RTE 0MQVD \\_XH\GB \[P1<K4
MM]V8.J*7&A9L[M& 7^#6_YO,S-= ],<VVM<[L)%^_TYJBY1)\ F:1<%<V%.E
M)Z('FNG_KCW4[_JTWU0)^/PFDL!IG;6QU=P*D.'?-DC\/8359ND!%/C,U%FS
M7#WXL_SAW]W_ TA^V@SQ:Y0_X[VUU][O>Q6!D)4M-:PF-FSQ?>D?[S4![@7_
M3@@_^:_D?/]7^_T?1^6?-86_4OQ-TB 0R&_NJU"_I_S3=D;](2O@^/-GX?U<
MG)!?:YYK(0%1)H HV]1S=A'+S]G]Q97HKS%*.>)_TMC_WZ4Y\7]8FO\5*']A
MN8,$_QEPJG",[]&-,^QK\60)_V*P@?JLA0LL!Q_T:?L%RO@\Z0#D;G=$F#=[
MF+)KUJ1W9]9+1V='HKV.M>Z4&-?!5#-,G/OLT8'#%+0[DF[:U?,A3B"9$NC]
M66"DNI ]7FFA@Q$V_67],31R6>'^KA%!61[.I28_6\_B+*.IWEZ_JBO,VI*2
M&RO*!KCFN0,6V3?3<=G<QCI#V3RO>WO=B9?% RF3-Y2/B;P2$2FP[XFX9%$I
M$CY>!'DPR%PJ1SBKX0>KV<=R)\UU5\-B(SW26YXO<%U@J#L\8Q"\R%BW+U$P
MPR+57]3I"91$3'T"#5AJ-60'/X@64FI>-8$.CHI<S#J@W5N/74/KTD=RK@_[
M"_@:XA=J^?>IZ%3WAGL\P1\)#WA?A2R>]#)8R?IX]>D?678BW V"+1B%#I0L
M?ZL09V._&Z9-EEGTS=U_]07UIKR@ :.NI$H:8'D .=LYO]H;7_X4<]7<[-,[
MD[YS[3KB;N?T(^ M].;L&S)H4@;U& WX4C>X(>==6$/LP0_6LL;1)?4G(&>>
M&;U^>/5+K+>_)@'OXERU)!5-[CE;B>4CLXY0=/-H #LIH=Z@_)*4PXA$-NI:
MA0T^:^C"_1L)I.Q'Y;M)]*:=RO)#</YIG90I 3Y\TR-G5P=HG(GI3/YB7S0/
M\X=I;LDXRS(;7VE2:)HN@5T]K-JLZT;;RB.V]7%-.3-GZ?$G&58C<75W_>))
M&X$\4_?"BG"'QX0NF/)4'XN['J]YV\]^Q%%@"L*>]X>[Y,VQN8RQXK#/2N?:
M(,?5>^\&363[.E\@>*#RX'2]QOTSX#1G$3 _?XKG2MVB8\S9^_IY?#8=!,0!
MLRO3W<A<Z*-ABD9-,?J!'+^-P;LKLRLL=XD$GJPX]=UW)%L?:\F5V(UD6B]5
MGNP-FGB0#R/I"!$ZXQ-R+(1:-6=/OXQT&#G_)">2OWR-K]-/RR7U*,(46<E-
M#"]:LSI@AR0Q]0QX7MWF?Q/:\:()%VXC1Y!^((?>6YE$&JES]NPV>50*&\99
M.6!8,DP>?)[D45IZ&E+!=&_*S#]]N(\B2 P/=5?Q7C!X5]Z9F-O^NG4E\MQ[
MOQ<GNR_[&6LI2B[+!59!(\QT+5],99A/KN=]OKM-:^)+^_F9P,"X70GLVB3'
M\Z2'&<V82?.C<+[IO:1A&E"K@VG&H?.M&>\VZ542#5H<]G^]ZS53>^HJ@3OL
MEJ_*</.!VA&S&SIO2(NZPGUP^=.]:Q!;W4\-Y*M:>?0MDHB.7E*2])R0B&UM
M__J2&BDTT3.PUGLU)",K0=?@[#%*\<F@2,LE;A>+!]7.4VV%"RNF#DJ??$I>
M1HG;>_8:W[CF%+9="W::U9.]'K8#PN!I;8IFF6Z=XEXOSY-CU;KMCLB!I[Z]
M:,(S?X7\@J>"I^(J\Q<\+/0@P6:VP2>UMS'U(T.,V7IPYP0W]\'LF!UVL+%7
M#-?DG1@M9@W"XLP??9E\+*9_>X])LNL[?'3]0@A5J=/H?$NI$6::-W!7YGM%
MH]OD[?2P($=/G^'M(<-F-J;MLC,$5[\W39+9.([BM>,<3XZKLPN\S Y?T36H
MYJ4!%8-!Q>J/G"V1A%U7>S(S+I]_Y$[/U! E>GR[3!S!S.-AJ>JP:0DV;%\,
M,FQ[O%!AZ*WKFEGYAZRM0OZ0%,H[_FRCX-J)OOF$E6YE/D?;$N_U+T/!EG($
M=6I"-+1<GJ4E1IFT]*B?*D> 8@APO>Y2>?QT@W:'>ZPDBUX4^2K2UK[!WEF6
M<))A.REUC?M(.%\!C#<WW7/0**1*@+55C@9P3'/W-M9$-S*LRX<>RB^,V?&%
MT2?VLV^;B&Z:ETA<%\(@*CIJ=G#C@M2<AI7K+,$%<Y!OY''PDZ9XY0I7!%OS
MR.#>FTA&,DO6 "G%/MW'O0.A_S[PJME)*E%TK(<O5)J<]V4[>Y:Z=V<VG^]9
M E,HV71?O$WVX)2WFSE_7EF;^8*I[M&&4M5''9\;0GO@C'!ZIJZ@@&=WQN?W
M?!Z.RO%CSUV1O,!_\M/P_+ %8WZI]1;W=$?0?W0G:&VHD[955Z]+Y:;9$R:)
MWI^EG6](CW@.7.E\A[B]DQXCTF$D1[#4[[I!B<AO:)AY<%LN5?E4\?#PQ\!Z
MP>=T/3N& B-<Q!M]C>S]F!Y#F4U(UZMUL:7@*7?3JB ?^SPYEUU(?M]!^=/P
MVZY=D;P<L7EH9"77@]JFB%)NQUKTZ1DTO_).7#SD?&<^A-/8="HFIJ3GZ[:F
M9XQULUQ,*;B8J(D1Z2#4W05?2\LTX9Q7O<)K-NV&39\4F@Q=ZUPTKAI]+O1G
M0 UE/Z"R]WBB]=H_?4R?+EQ][\R?(7PN/-+LR]IV)O.DKN: IH?9GDLCYLFX
MR/LD)8>]GQ)\] MZ3;,EP\,_#!&>/9TQ]3-!BT4X=J<0CUWI+6TZCNC,\C-*
MNGFGMRG6P<].-*9K7"CJ*)/Z92!PC;<-40R-'$6\[VSL')S=/+.E6?;[U^A[
M[()(FG7!R$Z2WL.4UN7LDTE>PL/% IU'%=O#T89*8:)O3_X[9\:_\A*\<22.
M^=&K3R.VY+1:SD"__3CL;J1UGXJIJ2,G26H=SNA9ZU*METL#+CE/YVK$[?9#
M'K,7J4;GJ:<.Q5^&L)*OMM4'Y^^KJLRJCGY7MNSP"7;'VWTDH7.9,W ,VEE'
MAA?A'V$"%TSKZBHF&:Y;O 4,XPCWPN>;S[N:N<VX4N??C).;CV<R:@R^64,*
M9N25!TP/*%Z/M'[4<;R8O_+>I"K_S<\VXHA#_DU1_L((_OSZN]%Z>21U*Z%$
M OLA*AYV@Z<?>GMTI%MN9=3WGKXY*B=:<MXQJ$;YG&+<+2TUSLM,U_35.(%_
MX46WU#Q;3P,$,760#1YP%++.]HUI$^\S"O:,LKUQ!L47MM]8LY+!^WHI"_&&
M0_EQ4KGW1(T#.::,(GQ(?3LT_^NCMI(U?\W%]\1XQB7RIP(E_L<O,6H6-E:L
MR<^UQI(S1/<((4XGAE^^@,;W5?6J5,,M<(UBG^Y(U>GX*(Q<OVJQ>)IZJ'(E
M*Z0)^MRKONW#\]$"FU<XIF(9U#TRU.V%;.Z;*_PGF?:H63L\^_CH7C^/\+$=
MRA-=$0AZ3__A>9]4-UV5>9N84Z'6]C<&C^30@/0[MVZ\)ZIHW.Q=\GN[5)::
MVO"AZ&AY\%E/:=6(MO'.97NFPJ*XJ\U[385[K!@@,L''3 _RK0S')##A%^WG
MLJ1",%+OJUG?LAANJ(Y D/NG3*$>^0*.^7R+$"%HG80Y(WZ6=V1&9M+$Y>9"
M R(S;2>*S+X_&0G&8BH>*]*RO)I;5+1QHT7N/6>$B^K2?N>&4?H/2[6WULH[
MO&KN)"; W[H8F K*(_ )3X?3#]EE3-V)R7SSSIEUE$4LF'\'@]--6]E3+&:R
M=BT]JFQQJ6.22<ZB#PX-O3TM\QC.Y;J)3WE'44)E TM_=6LI$P[+UCQA9[(]
M-N6SY_%>D_H#EM.)LC'1=Y7ETFL]N(B!*0-J7J()8\+YZGLUM],7:$@P[<\<
ME.]%R:X;3$0N./LHV1D+LFU4^/-UY-FZ/<QDN?"A[36@9B64QF-)G])9QS0D
M)HX*@7(7M\])"./GHR4?Q=XN*/!1^.R$OG35POM.5F C-""ZD9C8JU,$_?1L
MTM4#P:I\]*UI;U\_R5XS@45+P-0S^?VCJ'VN19\"2O<IQ[G/&,SX _B)T,L]
M[@[TYSNZ^NEVE.0]ADMX2ZE6$+F*QGWTQ_6;I7"SJ<3C[MF[OLR80TI:K0OU
M4_I-\],K>7I?,T=6W:NHF%KF"L1OX/SCAY!L).2%YRFY/F],8TUU+TPS;)RI
MG]PQ5<?$[VR&>>'<<I&)F'HQXFKJHZH]T2?4+Y<,S;'7;N/(L"4JO0H1EO&Y
M'3';=.)1Q8@"Y,ER!HJ'?*J P'XW'\9B%Y$=XI ]9.\JA=Y&OT>>-=_[1GCX
M1K?I>(QR;[*BY.ZO"MJKZLA@619'%D\?>)O$2(^=U>TH@K13VJM=&P03BAB[
M[...<N?E5(?".U<=."-$WKQ::DX6\%I.=LD*G7RKO#2ED> G^L%L;ZN>UT0;
M2GE=WZGXSS5O<&YP-=4)M#:X3*UJ,B$LL!FD?:+M85"K"A<3: <NXV9YXRW&
M#MJ!RZ2XSRT;@G:)X+*K4O^7W LW\M^$**P;1%WWT>,^E_>R46,<K0U7B/--
M'(QA&'U"5/@HLBV]-"WVQ0=ZIOA^YA%_8=\;^.ZJQF/]]H7I?/,P5XOM N-#
MZT>\&"C>/MU/U!)]U2F)?- <N>;J03I-L"/E#EV/B5^T01U#?P@_Y=S^.A.G
MVCP0F^>[NL;G[BQV?#2@%,O^LHTT0T2%RD7CZZN_JI"=AW,7BXWCN^[XCKBU
M+?.HW%N/2<;!>YJ6:F)*!81)Z6GL7#-I'I48*77T#79\&G+_JK*?=W<ZB067
M=0\_HJ8K7]WKIN3WKM*2=VP,-N"AG+.:A6E0G#$2:PTI4?,=F/VD8'QI-8>-
MJG/CK(,=IXQZ*&]=#CX-H#L]A=)^OUV4GC._,=N@34OH!J>^&OV_?-'1QK,'
ME"M[,AD1=.O029[7[=P?COBXRG4V\'QM\GIPE$$Z=]=$\AV-RY1$;L#6G!E&
M),C3 "[$:09@0C;)*-& 9[HA1N\1!3:4H*:\+5G@2A/":VF!6#]W@ :<AC B
MA\X-DB]!^B!YCA3 EXL&W-N+)%Q:9F/ED4-W&9$W4%]I $/WM"/57V<!ZD_]
M0DE$3M(/99-WQ-* L,0-2^(C&O"*/0"+/^Q(%2N_5YFX'961O;8**:'N\-.E
M <T?_2::!W_U;HB\Y=^*7:;#&U$9P"6U1BT*LM? L9\&0$=6D97LJ=BU->G2
MM8W?G*/F4+WRU+M09G!L#<62TM:9MH?S0M]C)_K]%TB'5L"D84*K:-AOSO4I
M.1OJ-*"%J1)!XO@&S%!KH,:?J4%3:,#$:/G2Q,)O[F$%,-O!=8 D3@.V"=.
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M*X&W/>A=B-8^O;S0T9$#(H+>MRN:5 AAQ-D]2DOJSE^LTWL_HT"!8HL]:V@
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MWX5L\(N0,ZB-5#XF*FRK7N D&PCK!&1+QE.+>K]6>MK?*OWK;Y4^\:/2?91
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MK0]F70IB]&IQZG#A]>*N4$JQ!BO+GJG6C+UA9?0M,24H(;-]O3(I$.ISFX/
MVYW\CE[WHL]1-BOJ61[L/+6R_ 9@ U;05*\^P-/355!7F5*JN@'\<.8H_:W\
MS,F\BNPLS",A5]U0GC?DZZK)3X!-YT.></4>A*I\S7!.><SUR4%.K?[ZV/3O
MI &U #L5+.N"6QQ&@AO XX%JZ,6.,MU][LG<R,JRXYA<N(S8I?IU,4L3S@V
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MKZP3=.'K>2X>\?69X)?>W^>!<B3(C2!N 6X BJ4M(NW<U^O-D$IXDSZ ]-B
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M0;E>)A:*EWJG'5+%VI_?+!YD3]H>U1,2U!="5-,Z.O@0&XG8NQ_C5*0MK"^
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M=05E!0 $ @&W,'\ >A20 \[@X8'Q<,^ P6!\_#-G"<F)" D("*G/DY&0T]-
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MF09.H?%%] KDM?=<5KL?DG?1P]M3?/XX30(6VZZST_]TV/1T.S-#BAV; 7Y
MRXT&EGO-3O#M;\$*,.O]G&,I9I>F#-^^6.@WZ(L%6F(_"Y;!Y2$'GI6;SBN$
M4S]G]<E3Z\?F61%;-GX<U\Q%BP;PC9:[A\=)RHT358Q,":/?5^4P!%1W.=
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MIHWR':^:G=L/N5:S0=0[]6I>0NE('H+8D?KD[B>SJN*'J>JHP"&V.E*/Q4.
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MIJQ6C66<"3]2[^J7W]8@T]O@F&!Z$J<C5BZ>+ $=\O&$RDQYA^E4Y#EL<(;
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M0=)PIB8[]#LD7Q%/ET>N\" X@)I2G[[Y5FR[2G^%+?22K^?V YT$Q0>FW+H
M#<#$30T Z,+W7)LO/ ]8ZF1*LT8)/D'>@<>(*PE]@[R:+I59_>%7UG7HBU_J
ML:.(?F0#UB3PW&<*,.)EG^PS?XD"I$4ML1X^Z]JW@SRQ07JW>_NP&ARQ$OI/
M\]K#3TQ(]X@O,1^7[%AC5+V&9P(JUG;2U.*=5?CN'8F4)TD*1UW1J/B#OL]4
MDI'YC_@3#!AM1V9<_4A$?"% R#1X1&+ PL6U;)^'[F;!%0Y*;+H?8G$QXR%>
MNX4TB$54Z(DTYG2R(VBQBL.1:UJO-#BU2I@\TAAKF<GQXKWFI .#"(=&LK\V
M5WV&>=#MN1\O47[!":P,'I^)!LS2" X1EDDV#UGS>7V]*_9QEX7>"C7@IK9
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M/5QF.L#U=RPY1R:$+OS7/*R=/;CG%F=BR]:VSL1Z4NR]?G-N1O+A=V,UR+A
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M_9\<E4CGJC>ETN'Z_\;I*=/_!5!+ P04    " "LA8%<I6L(OND-  " #@
M$    &9O<FTQ,"UK7S P-"YJ<&>=EFD\U.W7P'^#,?9U1DA-=K)%=F/&$D,3
M4])M"XEN)DGVH0EE7\H:I9 ]98DLV9=A)DG*-J28L9.IF;+,+<M?_\^SO'E>
M/,_S/>?=.=?U.=_K>G,.)@^H@-!92VM+  0" 5Z' 1Q, ^8 .QO;GSR$XS#!
M7& P!P>8!P+AY.+CX>/CY>'EY1<0$>(7$!;@Y142$Q(6A<)@,#[!(^)B4'$1
M* SZYQ(0^^$9#C W&,P-Y>?EA_Z?.>@&A+D 9> =.T@&8!,&L0N##OH . "
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M<Y.D$\WE/JZ%7< $QL!5W]>SGT FI)VS>W/<OJO)?FL'3M?1VU6,T)I9,=5
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M.3):]L'.#\FO?G&PBYW6O4PVW6_%Q :P:NX-HUV7\T-40P_MKK9?>7B[%#"
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M:X9^EZ(&/4#S0.5'OZC+R54FKZ*FU3FY^GH#L%DWN'0151^R53@1:^ W*6(
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MQE!4IB'?!O$G@)&8$, +*?BR=4ORWC^2DF'J4, .!86D2&Y%VBRN :$="I4
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MNW2]DZ-?XGT;,1:"?QY2&5M0":5BQ\AD*<1X)L:.0,CC$)U@?\&(,W6RG1I
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MWXW/7<6*3&G5??$F$BMZC_J\K"+X?D6Z#<-5B25,H+!_8KE<)W<-@0T*5%S
M'_J_A(S'=[E<#F0V%'_X,J'AVGYS*5LW=LDD(+"I?;*DA<8&%#]' <XCX[0*
MN=CP3&-O)9F-;L>E0+RFU#:HEKM,.<(>64+R.NIIU$.&3R@7S\"$]OM_[N.C
MI;ST&3FQ&O=/@(&Z@?Q2R5\BC*2@*MY[[-DI[:I,J6W ,?E<.%K0R\80<D^
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M=SX>'P4L!G@&(H+A^R-,CG[ZVY__%/ _/_YE- HN$8QF[X*/)!R-\9S\$-R
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MXD%(;\U6K?\@=O\@]K]_/]!J##^)C_NWL3G902WM?K)8D3ZXU=U/AE9R![#
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MUCTX&E%]0J1P&LL*G+9^9CA]YQXG,P7X!)G<%MG$Z,H.9B!][QZD%I%]0J?
MI=$FT*M=D4+]ST/S"G=HE!UI[^K1?L<N'/ [=5(_WZA&J:FMLXQH&AY+EN0)
M<VTRM-[8]:)7Z[V>$U6)ZM,\$J?""#:!H][2]=(VQD(EI$] G,UF2(@,HEN
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M!30 \4W]IE&E"H\[U"I5WTRDJ=\IJE:!4PN4K4/QUSU?S_R3_P!02P,$%
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MLLX\.3ZK[D-Y@FYJ5;M_4_@JB )"5W.T,*UP1J]I_= AC&>/J  D>4V_ =1
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MW7?2,=D-)QKM1AUMA^W[U=&.V68\OA?Q*&',V(S<52OZ)R(VE*A^0G_>C(,
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MZ'[X'Z4NG>_A\AI!F]#]1I:+%R(8/$UK#N:[P*N5GU!,65 U[ZHDBVG8;S8
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MIO-30Q43E28.I_A\G7C0HKW3:]'B*"FA07[:(4%^F-_3@+KI8A)Z_MKW4B<
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MJ'[7 2JHCXBC5TW=H@)5=GBE?G,)E**L)B$Y+!,$7'9V[FZ-!#]Y].IXF&!
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M.5!X=?&ND>X5 >GNM1F<<#G40[(U5WX]WQ?>X[OTZ2GP421*=5=O/"A09&R
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MV(;NM1L4& (.0#R,':J%Q9G87MFGU=>SR#5:=^]CA&/AJXTVXPT1WT,X!?7
M6*7++ 4N0N<H)%)GJ0SYI1EAZ)6'&"+:#9D# 3;F'1@';%P$D"U=D-7Z#Q':
M)IR!N!J[X&\Z2X]G2K::?\;>TPG-Q0WZRO[4UK!N^P\2QP:<@;C:\#)E1BP^
M(L0SR@5( CT&B9V0%Q"MDIO#?!7//)_(+7K"$>5[$BYPM&*+"5P;\.UK46W
M?,C1=LQ1:=!2L3\S&@OS6X.;5\Q&I;>AN:B"Z?DF_Z.D,%ZKP;3.WD-JY34!
MN3JGVTN1'U%A4?F\[>/B\S3V:2[\G O57 3\;L9>?AX"%9">0"08BUYGY.1)
MWP_N-S.<CD HVVI]+0Y_5KWJ; & U6\U#P6IUY2U,[+)6CDN2A.:_BP/J145
M'F0>8F$G0YG&^8J.FU"M>W&"@V!6?KJZ29.(B<0)6%2A0E4@A9X=3 U-XE>D
M'03!F(FXP!$QAF16TVL_>@LK3[?![3 W5%E&"(T"R>!:I!<129HM6J 0![['
M)BW;=L*Y#Z&V0]Y?"=@"C;I9?$196>'6_:=0E(A5)'^[,N/J@<#*S94.F"Q*
MR)A-?SK-R]EG=RFJA!DRE?KVO0M3F1ZX!0_]K&UM=@,W.,S7:^7]0+5+[SN"
M!B@IT0[.)F/PW*(U"H47($6+^<]&MV-M/&I[I$.R-YBG)$ZFBX\8>_'NU4U\
MAP-/-#6@/@.$1\*,=;ZOHK0((?:2:%: GUBZ1&E(E:C; &&3\V.=$;I# 1EN
M^1&%*'("0OC86Q$)Q[1^&JU#+8-0K?\ L6S &&B[]'I[<F9N4/*)'_!&6^TW
M&I+< >HAX1H+6R+;%UPD#)B$+E[))PG894CX*/$"H64L&(FH4D8E,&<*KLK-
MAHA*C7X(B5*XD;% AS*?>>3!#:U131=67F3#:2VR82^:81N^,-J.\F.)RRXY
M21]B]%=*C?R:GC95F#FK,;,=9)2-PN7'6#KB$G\U+>1G(^;W,)=0N42/+,*"
MV]J>$ H)')QTRA#O]L=%5(@GGY+GP>9V,.>K%\E?#%6%6XN.>AQ*I3?N<!=S
M6:Y%TI9B8W$0A$9XK/3?ZX70TNS5%7IE;F%N<U/1$]+9(H2FNQB*@T&AK$P7
M8[(C"_.,0$)[!#0?@C42<FJ1\ZI$(?63DJ.IL_M-*9<Z? N6C]1X(#-V2XP+
M/HPE^VR9*7AMMGL=JD"OX8)W-.7!PR:KXC-+(_?1B=$V:Z$P=DVEJR'CUW;2
MX>;<6;<8EXM9I)1*\@-[,)4]I)J$)?X%6YD&HQ@+@VMX#&_*DG7WL;,(NPAY
M\3611*ERPB5Z$&:[ SL-!#@9!];M4$MUSF9.-(U8!+GWFQ.D"H\ %3H/!#=5
M3JQ;0EG:=IKNS5^&E.1[?,$\<>?D<W]>^\_(^^S0-'')9KQV_(#NX*]Q1->7
M<7+M^!%C4; -TC'\0'1 'Z^Z;W>[U9)LWW"'7,J;C^+#%4,PXC'H@HP]A?OG
M[N[1F)QBY+Y:XO4)<KWLUFFV?KIZ)@33BZ$+PM 21X3P:1AL=-UZ@=\=>W^D
M,4L;U\/W)J'GKWTO=8)N/\9RX;"#%?V*13DSRL>)\\VN39Y%G-&])9Z<-V:!
M$])"<E*/;R=?TWD\O/87"4(A69*O<4K^&]'O,HM^]Q3XXO.A8E\3ZU:'*)?/
MD(VD)SQG]+VTD:,03818%LENZN?$T/]Y( (BO_G_4$L#!!0    ( *R%@5SU
MHG!U%HD  $+M!P 5    :G5N<RTR,#(U,3(S,5]L86(N>&UL[+U[<^0VEB_X
M_T;L=\#U;$S8$2K;56[WG7;/W!M9>M2H1R5I)96]LXX)!T4B4VPS21EDJJ3^
M] N ;^+-9 )'-7MC;KN4/ ?\'>*'@X/7P;_^[^=MAIXP*=,B_[>OWG[[_5<(
MYW&1I/GFW[[Z=/MF=7M\?OX5*JLH3Z*LR/&_?9477_WO__5__A^(_K]__1]O
MWJ"S%&?)3^BDB-^<Y^OBK^@RVN*?T ><8Q)5!?DK^CG*=NR7XBS-,$''Q?8Q
MPQ6F#^H7_X3^_.V/$7KSQJ+8GW&>%.33S7E7[$-5/98_???=Y\^?O\V+I^AS
M07XOOXV+K5V!MU54[<JNM.^?OV_^7ZW^KUF:__X3^Y_[J,2(?JZ\_.FY3/_M
M*_;>YK6??_BV()OOWGW__=OO_I^/%[?Q ]Y&;]*<?;88?]5JL5)D>F__\I>_
M?,>?MJ*"Y/,]R=IW_/!="Z<KF3Y--?(#)&7Z4\GA711Q5/%:-[X&*2787V]:
ML3?LIS=OW[WYX>VWSV7R5?OQ^1<D189O\!IQ,W^J7AXID\J4$>&KYK<'@M=R
M,!DAWS'][W*\B2J<L!?]A;WH[9_9B_ZI^?DBNL?95XA)4GXH[?K+J*Q&Z3O?
M8*\Q28OD-)^'>JH="#YM.Z3:PX"AOG<3[HHJRF:!'VIZAWV)YWWQ7L__EZ9N
M'L_[T@/-@\"N1,C.GU?^73/VXP7]UP@B?JYH!X:3%B0K0N.!^1MXQ]"4W95>
MQ*-R,^;-"R+:SGI&7N8Z*N]YP;ORS2:*'ND+WOWX'<ZJLOWE#?N%?X3FA]]N
M<,8;*VVE+W<DRLLH9EU&^?YE^&3UG);MB[G5__;5G *^FYK(BEJ1ULZ(Q(:/
MU4A\%Q>TJWNLWF1UM=3J:U)LY^%J/G,Q1_NW[+Y#4%<4!:DP=21&<%GL2(R=
M>#*T=W9%-)"W&2V"!8$X?_/I]JO_U8@A&@>BRR(GS9],+<4E^I6I_M>_?M>_
M.SAA/^+M/286WZ,5#$7 ,5 5T6HID(0:05,1ATNB7VO9\$QA83_>XKPZSJ*R
MO%K?5D7\N\:3:>1]\L8(>T@?I3 8%ID03LG$Q5"Q1EP0BM>YI<$L+E?7M#1,
M"$XX.*W[T6IXY9,9^HA1:G$XG#)BG+*JUD KU.FT_ +GK4[_V*75"YM!*7+Z
M9VGCL>0Z0;R6#K[4<\D4X##- N64:[4HZF6A.#&*:%OD9M<ED?-))27,(7T$
M(3"442$3.CHN!\T-K9(D9<.&*+N.TN0\/XX>TRK*M'PQZ/CDCA7\(8^T"F X
M98-RRJ]>!S&E-VF.&K7%V/;W75YR"KU]5T\(_]/?/EW>TH%#C-.GZ#[#Y;H@
MMU&&B[7)][@H^B"4NR&,5?9:P:GE#%4<]76ZB"HCILWB=IA^[09749KCY#0B
M>9IO2L/4@5S8[_2!#O!X"D$F&9Q@5O!$4M7"J)6&PZ!^2LP\]Z20]<D?+=PA
M?:2"8-BC0S<ESV32$M!4U.IS1)([^@+-8&XBXS5JDL$;14E# 3#<D*$2HB F
M@YC00J,P1<QSEJXKC/.S@IQ1&^E_V'MY'WC[F*65.N:Q5/06\S@9TL4\5EK!
MB>,,=<JFK]_^^-.?OD&-4A/C<#4XOH9Q_6J](H0"YU,7&I^CD/7I>[1PASY(
M*AB<4C;HQ)%_1K4+$E7I$T8#';[T-OS[JGK !%4/$1V[C90.ZLMNV5:P^Y=Z
M'NN:?J6'J,2K#<$<E-J5V>EY\V0N9G2.S$8I..E<D0JSX;4J:F8J6V74:1_8
MFY6D&G@R^E?OQ>@?O]TP_DN\UN29#R))X3"RC!X$)X0,C:32J[2LTCC*T$<<
ME3O25/4!)Z<-%?TQ>DZWNZW4HTB>^ZIP*:RVTD</052\#-&T\AL9.%'*[>Z^
MQ'_LV,K*$_T?P]A(*>UUB4L/>;2X)1<-3A<[?(+GZ*01%U]R.+4TD?1K\G+9
M@"32K,/+!*$22!]M3.D#Q@FM\BI-TFS'0NI;'.](RG:ZG3['V2[!R1FM.+:(
MNZOX+OJK=3LG>8W)[4-$\/L7>0&Z29Y#OM'KE-'A/]UH NIPKP/3I@YOHS Y
M-E! O084U_Y+Q(;">I<^D?'9!*3PAJ0="8"AF0S5E!B-#!Q/?8/+BJ1QU>SU
M^I2G57ES^\FPBJ?5\;N89P%_O*:G40!#)1N4X@I?J]-,GW(M]#75*[^!0[C3
M[6-6O&#,,5X],I>K)9M&WB?1C+"')%,*@R&8":$0:K*.\,W[J.1+@"]\?F,P
MGWJ$ZC+"3F\=/Z1X??I,NUO6[UZMUVF,B7(.1"OM:T;$ G([/Z(1#4XK.WS"
M=#W30)T*:G3@^*H3?%^=Y]2M[@S+/3)!G]Y)#73HED2IX,0Q0IMRA@FB7O*P
MZS67187/S_^]R!*%'U%*>5N+44/L5EY$D>#5KL<E;C^I,#H_1[5HV#[F+JTR
MZMS.\R1]2I-=E"F64Q1ROOH5+<RV1Y$*!>>&"=F4'5R6+_!>%V5:1R'A5EYX
MGW:6YE$>IU%F%8.HI+W&('K(HQA$+@J"-V9\\ABD4UD\!E'T+'7\S?NZ=FE8
MOG/6*.VMIS%#[GH<M6APEMCA$TX>=0K]4OZ!=M"6./YV4SQ]E^"T]C/T'[V+
MH7_\=H$W47::5ZDT?8!4P@=)-- 8,22/@Y-!C6E* "Z%:K'#QIS_N3H_O[Z\
MJ!*U.Q!$O/D !;BNX4^>!Z]@#:AI#?_GBH68UY='B$K"&8+^C,LJS3>:L>=(
MPN>@4P)M.-H</ [. S6F*0T:"2@K-?4"%)MV8TM4."_Y&E6]/YO0D.4!WWTN
M]$OS+B5X7;!W-VVTC&^O#H9^[IB=YV&;<A MZ- Q[-UGG#WAXR)_PJ1*[S-\
M3>LW+<N"O+ 1NR:>M=7TUJ^YF=)U=W9JP>GGCE488W-E--!&O3KB^G"Z3+8M
M)DW2B+RPDY,6Z6G4\KXW,&EA3S<Q286#D\T6H>#9FE.NH++3G%]?:3O7P7.?
M5!%@#:G1/01#A2FB:=73YX?NJP:>BZT@7.58W3NI9;WU1R:X70^D$@Q>]S;H
MQ.,[??=2K_,<FA:W.$\+PC=HX81U8Q/$JN#:5=G?T1Q7@_KS.;::,*CE"E?,
M6\7T45, #V&0R#\/!&SW!KH<!S,K>22<I0$#HADTH!#,#J9(K&ZWYP&/?]GZ
M,P?O%=Y7V7HF6#31@;/Q.OXBG_&(SRH DJN$B(-TX&7AD$P>!F7L0.J"H\G8
M&]#0^Z$@U1TF6]X%&XZ>R67]3D%JX(XG&R6"P=ED@TZ<0*2R;Y@P#W&.0!TY
MF\1PVJ&W0M9O/D4-W'%.18D@&/KHT!F':&!<S^#D]7G^N#-Y'[6X3P:90 ])
MI)(%PR,#0.'D]."H/)<'Y8JFQO"%EVN2QO*XR5XM)+U41NAH-M4!2S<%4"/M
MCA#71%P5CC]C=VKQY<$['#_DZ1\[G3=3"7O=#J %/-H9()4$0RPM/&&_0"N,
M5H^/I(CB![X5M5,%X\^*O,+'$<F*CT6"]6F'%;)>/9<.[LA=R03!4$F'3LVD
MCCQ'B!> > G<0;&M*;PH.(YJZH?KDV _%QDU)DL-^3QME4/VFGJ#='VG7!,.
M.UW@6O2CS1G O@"X)+U)R]_/",;GM'G1SUK=1(H)L3D%A"2KV3 =8=7:8$EK
MA&Q!7%8&8H6@MA3$B@E[TNACFNMS>(V?>\OA)8/5Y? :/@Q.&14B@1&U#!QO
MU1U'L3I\JI3VZ8<,D(=.1R$:G"YV^*;DZ8\.+7XJ=8'SRR1]XGE-M7V;*.;W
M[+(<Y/CD\E@&#%<4P,13RZW8P0^6\2,JVOU-@HB_(V1R</VYL?'SX+6L 26<
M$*N/!E$Q/S6LW9DDB'BN8?4NH\ES2#5LVC'4U+"'C?4-'BIC;,4C(=^U+ *<
MUG,O :JF!5BJNF:"AZ[M3WF"R6>V92C?6&S^THI[8X %Z(X+&ED8K# #G/)C
MJ.$MN?>LP*\/2MD@5YO"1J<2)B!4@Y<'AZ)\<((Y@-0$C?"&%K;IVP*G;;-*
MUP8W39MM>K;FOH&%D["I=Q26NZQ2)1!5R/C<,RB%-]PD.!((7MLZ5)(-.(W8
MH:OY?1&1Y&I]DA(<4QW-<4Z5I+<JUT/M*EXN!J/ZM=BF).#"[+!<)W[XL[Y%
MSSSMR5Z9G,=SO&J8@U.[HA ,$FB0B2=R"S20]>?S-94?LN;-U0ZTSFTKW&-E
M-TFJ37D/I6+>*EP#LJMRB0R,2E<#4R4,]Y+[<._$)/S7<K6K'@J2_@,G?)P\
M"&*OJ6WE^Y?39TSBM*QWZZDNI3KHF\(G.EGD4YD3HNSUFN"-Y?"V"2.I1KC9
M#LK%#YOPB[]"NV SE?!W3;L46G\?^^AQ<+*H,0FI\GFM>EBKX2_2+M5,)?S6
MK7JA9OP84-V:EFGJNO6P2E.CT2_2B#*>ZU>S1#,5@%3'Q@6:II9]K,_P5[$;
MC0W5/!3Q6\LBN'$E]\\!U;$ 2E[%3,Q/#:MVR<A%/->P='>,[#FD&C;MBFEJ
MV,.N&/ZFV_394,$#";_U*T ;5V_W&%#M3C')*Y=*^:E;_(3E"U$*&<_U*\*;
MU' O *F.!52*6F9R7NKY--T\:):=1!F_]2R!-Z[G@0"@>A91R>N9RP&:@\+D
MB0[2#1GTC=)>YX+TD$?S.7+1X+2QPR=FON'2ATB?KUJR2FGA.$]N*Q)5>)/&
MJ^0I+;4+F485?PM9=N#[-2V]?'#2.( 4[W>IM5"GAEH]3ZM>PVUAYN4OJ;3O
M=3 -Y.F"F$04!EV,^!1+9*,]>0?GR$FQ92= JCM2GRNSV,)I5/'&%DOP'64,
M\C!X8P=2V&W7:*%6S5_6ONX&1,=;@6S4_.T)MS>BWR5NUH%!*7N@DO6DYG;+
MP]XAI*#6!8VY\M(4(NM%O5'( +:CC4(.!E7TX(1[A6IICXQ8_;&+\N(I6GU0
M4T&4\<8!%;RN\J<",&I=@6I:W:T86GT(>[C\MJ*A-./;!UQL2/3XD,;*JRPU
MLKX.G1OAM@?0E8+!:6*#;DJ7H=@A-OZW=\W%Q2ZOR$M-F.:/GB_-#[_][7IB
MTO"!#R:(0%BU][\&KV,!RK1"_[:Z7ET>M*MGHZ4\N2E>HJQZL>_V#6J>0P K
M(R;A@%8G.#,<@<K#!#ZPS1/4Z/H<Y.+[ZHQ:2>/8')<E!7'Z'#_PK506PUU[
M97\#7U>#^B&PK28,SKG"E=ZW/BB 9[=KB_ W1!:B:NVF*IUTN-&,>K.56A0&
MB8SX+(8UA[]+X^..)$7\</R09@FAK[_!):9?ZX$=GDRKG2[CO;6J-_8X&M-1
MR5(/!J_<P IIFVIMU*FC5A]U!0!:K&QC__<[VI%33WJ+-[QEZ+:^ZW7\'J2U
M@#\^5*M1"$X_%Y3B4N:F";H.N2W\^B$BVRC&NXJ-_JX>,>%[WC61O$G#F^^R
M@]ZY++UX<*K88YP29:R$>JVP<S]LF:S(TH1C.:?TE[D@G:"O61\]T';*1RX5
MG#9&:++5RTX8<>F#)GLPL.0&/Q:DBNXS/)R%8L=OBEPYH^"BZ(M%;H:TK++3
M L$R)ZC"QJY.&8UF&WOU0X?MUP1OT]WV<E>Q?#I%'F6WN\?'S#1O9:7FK\NS
M-Z+O]\PZP?GE"%3H 6M--%!% UTXT?EQ06@[H+'@*D^NJ@?%L6>CM-_;A[20
MQ_</246#L\L.G]A1-M*HB<3YG!37:V.L?-,]@T>QRR)OP-F13)0/0C,5;"G1
MIL+PJ*9 J!CLH;J?I,0ZHO]DGRW-&,M8F':$>D;24LM#$J]=L4MP6G.._J.G
M&OV#&OB$R>J^K$@45Y./('GN@TI*6(PZPL/@5%$A$OW0$\O(T$KYKNB3(N89
MX>YHB1(+QH]]5;,,5%O+PV<@*ED"2-P56(OPN\D\5_"*OCAA+S_+HHT$_N2Y
MKRJ6PFKK>/001"7+$ G;<EH9Q(1"5?,)+F.2\LP5.CM&8MXK70)2J/N!#"P*
MB,#43!C(!G+L-WB3LJZ%ISIIYZDU;DPA[]OU:V%/^P*I, C2V"!4]A9#)=1I
M!>+1*L]W458'L!I#QV*^62,#.27+4 841R3 E-2H99OQ1"!&_-^[B%289"]&
M4@B2OGFA@#JEQD0,%#ODV)0$Z<3#<N2.1'G)Y^R,)!%%O0\W%&"%H<=$#A1/
M%.#40Y)./BQ3;A]PQI<;HMSL4&3"OMFB!CSEBR@)BC%*>$K.< W4J,"AS>D3
MB\YIF&1I[$ ^)'D$V#K^=,)@*31%:,DBKH:87B F76.2%@D-LXF)0X*D;_8H
MH$YY,Q$#Q1@Y-B57:G'$Y<.3Y#1/K"C2R84AR 2FG!Z-$$!RC)&9J$&E0Q+C
M+"WC**NQG-'?ICNA#+*^":*$.R6)( B**"IT2K+4"BUGN$I0POPGCH@=70:2
M8<@B0)53I1,#2)0I-A--F'P0DASO"!FA5O<X:E%OB[(&L-WZK$(.!%$,X(15
MVUI\1)1 /= IOV7P+,WPY4ZR$40NXHL;*G M)Z;/07!! 4IQO2.30[5@D)IO
M5PGRZC+:RCR$7,PO ^0@QRP8RP!B@A28@@V]+&+"01AQ3#T381>/)_CY/_"+
MTBY!SB\G%##'I)@( 6*%')F"%HTPXM*(B@<AQC5)MQ%YN4UC0U<A"OJEA@KH
MF!M3*4#D4$!3L*.11K?GQR%[DKOH^3RA1$W7:<P7G0TL4<K[)8L!]I@S"F%
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M-->"@C>+)=!+3JJ.NY/FUB'&?5HCY2[CIWZB#<$\&PV0,8EH?3W$6HCTQL(
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MOQJ4$VA?C<S,G],BXT[U:OWOQ18?,UCDY2+Z;,]4?1$AZ6ICG(ZS.GVPQ+4
M;<O>KBC&7U88:DI#M#A )#Y)RS]V49:NT[BQ_"YZ;A<5[8EL+B8DF6V-U!':
M5 984EL"MR7VM#C&;UI@MQ -@]NT\Z#6-/:>;Q_9C;04\'V:I=6+;I@SLYQ
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M8\L2\X78YN7MJ08+#LTJQANO]C"RX]J,,F#P;SYP%2=;+;[:SHM'3?FH?@&
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M/L%ENLE9DK2[@EF$$[Z\4(^3;ME!O>G9)$63FE^<3W^WK]%#US>WK. L7L@
M@>H1^1U7Z*E-,96E)2T4E5T1O!% F++ICW;G59JDV8[-_?6FGC['V2[!R1FE
M#MM>NJNOFKI:3[-=VBT[+?.20 D!%OQ BA0!"[P!3(LZB%G3=C8L&C5EOQRA
MMFQT>GV+CJ,LWF5U+ )E36G/3W)A6$]:KGBO'=+"'V7402U4-ICFM;!!-@V+
M=5M=RV)5AP:OX,=BFI<,\AD#6$1J[EJI/TE]>0;+>':\HZ.5+2;G.;.(70-/
M0P#Z?VQ+K8Q!,XJ!M^BTCQ%3BES2 (?4Y6GG)@Y8M11"O4N?'6665=I(X+<?
M_53'7^KJR/&&19*ZZI##DWUH&BT&_,CL,C5^!H*V_/<OGTHV*=]M'6Q."*7R
MVPSMM7VU%J?J<<4NJ[N8EH'66?&YK+UFT6VZC+H"@OG&*J(..FD]]RJ.=]L=
M3Q1^@M=I+%_N-&O!JTL'S$)?V(NBI)8-'D R7IZ=G!^?YSR7T&K+9I%5.PWD
MLK[OK53"G=Y3*0B"";ITZ&074"(F3 ?_6R",^42I;\<70=(W6Q10IUR9B(%B
MBAR;E">[5A1%7#98=Z"Y>$G>$V@4((:_-G"UETHEO1Z*V3)?\(:]YTA0ZPH6
M*OL5S2*HW<TB!8-Q4$M:(P2]?!=/MR!( UZ^9_5 *WYB KF7YO9!:6JKHN37
MK9X^5[31LV3EI_ENVZQ57A;525K64_-G6;21+7D=]'7>UAX]?+1N ?. [PK>
MG#P9J+E%(NL/S**XN74S+RJ^M8070X>>T=[Y:!9<:&HNHKJ.2/4RW-+^_F7T
MQ&H]R:FL,,M&,\R5KPXY%!2\62R!7@S#ZB$X%T2#,L"LZBALO#"LUIC5_-XO
M:V?$>!B@UP'#1TN@#M2[L%O?\)-.H*# FB3JB@\P%O&: $ ";G2R?_ <#%\D
MH,0+/*E(F[H^. 5.\'W5IWD]SRM,/TG%LB'Q4"2A\3N[?B+:J CB4H#?F\-<
M#1O?)&:K#89ZSI#%&/&^&MPQ=H3:,A KY C5Q:"^G.#D;0%.)IPF'T:0\GLE
MMA3B^";LD0@80LEQB1=>-R1IQ(X&.4+8_-=ED7?K5\$)<X,?NPWX%T6^N<-D
MRVBO[/U5XGX#+#WH<6 EEP5#*@- ,9!JQ=GL$%-XPS004PG.IK''/8MB_=RH
M6CQ<ORB"5O>"O2P8-AD &GLXIH%6QA64/28;6_<HC[+E(MXF]13@NHFXR?/@
MU:X!-:WJ7V.^1>FGB?2;[T/M*I-GW97.X$@E/2^.:2=I] "%PSY\8]\]OQ8^
M7O!:^/VG&*5V#')=O'_I19J3>ZO/$4G&IX[%'!-6WVNO]WB=FCS49S*3?H^7
M &\M^ULF676N2!KS8R-\%6V7IP!6FSEZV9DZF8!W6@LGZ,2GL(BD.R]W2^O_
M=PSDB%Q[Y<%[G.-URE,5Z;O B;4.^CY9XVS6D%36RM#VP;@"E^R(Y)=SPNO^
MFYPANB;7B7CW3A-P@G]JGL/R4&-0TF"P/$*U4' .3"9-.2CJ8O,X?8PL)UJG
M.@$GN>7P-?/:8P4P/+)!:9Z]YFI'J%,,3K;C(J>^MF([.#23CH*4W_2,4HCC
MI'DC$3"DD>,2,^)U4C F$2<W9#?[@)K$CO4?"H.M-+WNI+0W9;1/TJP&AF3V
M6"4A4'UI^2.0E=\F)KLFQ1KS-$)1=H9QZ49 ^Q(\$]'5M DA;=4A$=,1\Y2@
M0U6TQ@#R1S4VW10O4<:V*[I3TZ :@)-6QDC(J-6#QD(;L,*VF#1FR\>,><&)
MQU,<-[8,[I=QX)]3"3YI.,.T(1L=U,&0TAVS$#02G*3L7"Y)0'C%80A"\>_%
MU/G%!0PMG8W6Q)O697DE=%544::;DMO3BBG%[]C[4#0)4OD.GJB9O%LJKZ1B
MI5QI4+.Q2'I1B9.FMW5U-U.ZY78[M>!^U1VK:BRD5[;9IO^ENQPXB_Y[FV :
M$$M]#2H^Y_M/$RL\#DM?BLD3YCD[5/N<M9+>/(H>:N=!Y&+!.63&IMJ^(U<R
M[.()L'*@.WTFE0RW2J \.281"\X<,S;=+6[C_:*#U8$2S!&PL6$7AI-?2NEP
M=!(@JREU >YXEQZ?88D)UEFNL2D?<<32@]0G01YW=EN21:5PM%(9H&;75 ,H
MR10P=>M4">-=.EC:W/9ET-]I(0#8)YQHMZ:@A:9?'EJ;,B:C40T0(VVQ6N01
M>(')Q_NJSU+R[SA+[HKVQN15EA6?V:T;9P6I9_98-D53!#>K--_^<P^3IXYU
M1E& ^+T/?FFWWQ=WA%B!;ZKB35OD$>H*1>N"H&:ZF)4+*LX<?Q(ZO-)^$IM8
M=':)81N&L^GZQF%='. &XFK#LHT$5B ][1P'F6J-'2F7#1NN*!+K2@6],O*1
M(BB2VRHBE6YE0P=T2KOW4<89%55TB!]CGD;LA[='B-;J#X'FC3]$:<Y8?97W
MA@QF'BYQ=4UP)<\9;JO[VP_0=H@[(Y_6)+LAI;G_)'Y@1V,"5E_)+,'4EM-G
M=FQ]EY8/=4XNU9Y(HQ*@B7Q[K-,J&@NS";9$,AQ ;Q"[(Q:=GQ\\?U]WJ\[5
MNKU)3S;S;% (D$-/ UR2!4\B'9Q-UA"%?!'-8T:?Z@$S3_TC)\RAUI6[% *,
MW<*X5V:62<,;8>R@=XS1B\.@C!5&918(E<\)U%?L&7OY[1/JZ.LTUV:]UP.U
MF0U"34AVH-;<QAEVL=60>;::WEJWFRE=*[=3@]':G;#N%1'N2:DV(%KK(KZI
M908EKT2R,F#$(:T&',_DA-=A>/AC\(F&/M?I[4-!JC83DETB6YE*F'RU:O#R
MM+2B?'!?Y0!2/,]*!0=[#*#,]XX,$.8SIW8KA/T>>-8!'A]]EDG"(9$.GI$^
M%X!F0OG&>=I%/T9INS/SV'SJ0:'@_9"#%KAPID$J#8931HCB82[\A@FC*'EB
M/6")GM*(W;/>;2IXI%\L+<N"O+#L[\$N%%LD'1VX>V.,2,7Z:@ZI6]SGXZ7M
M7Y,BQC@IV<4>[92--!JV4?#9]LW AY122X-I^T:(DH.<7*&^/# =S+<E"QQX
M5T[*#AE_1=)-FD<9S\' [J=@G);^J-]WO42I'J=WE_H$@SG@?8L,3N-E[9AR
MO=7B-,?\#A.FAQ[A)*E6Y^4^7:\QN] 3[Y%D75H&C#SK&O/L4JU+"@A.YWU0
M*U-G$ZH&(OXZ8)I\X#&:%7;QTO-\1WT/6&?3[KTYH?98?86Q0L#=WQ+@FIW?
M VF@#D("<4JF5@0E!F\0@$B#W>CU/UF:$)Z*\JV5^5K]<#2S,$O-.HTR4!*:
M$4MW]0U/'@QF$-H_6"% <HZ.S3W!94S21TV.48U\.%)*8*M).! &2CH1H?Z.
M!W[8)>F5#C1>O:7P8N9P\\T9EHX]IQ+>QI%R:-V8</PX>*VK,:G.](Z%%SC+
MJSS>O=VF%2-6G714!ER4\7BD6PYO<)A[+ "CJA6HU >XQ^(0CF[SV?0>6&GN
M*+0:WE<V]-"%I0VY>' VV6,4)GV8!AJH'*&3Y3J,I=.\=ELCFWMZ=Z(K<M(,
MF Y69XHF1:Q,#0S][+'JCNA.5M/0NMN[%)R.?&]MD[5%8IWBLQBU?-+0TH0A
M!0TJ8.AGAW-*/:[5)<Y9CFR*2$HZ-R^-IU22WJ(J/=0NMI*+!6>%&9OE DCX
M-(6\DQZRVV+KB%3<>WBE 2W$5A+9X"2R!"@P:5>5590G[.+.QVX[PKUY-_=!
M9T;:?<.R\V67V)")0:$$[_2</63U%OPCQ'31UTS[&U3D:/B(%A'<(TRNXG/(
M46JE&>)67\=,]Q9J8+R'/5;593]IN[S9)/,+=?%BQ#?TLBO1QC>JU1>$G.=W
M),K+*%9>Q^B@#V^5<Q9Z89=J5.=3X_?*\7G_,DWXG<[4S1 <8^IC$N9RJKZP
M(U3R]X2O=;["<8T)M]M0PR-9T+4I1ZJM.=H0,8G3$LH5<8,!]#!,,0_4Q]*!
M)D1DD!63($-1, Y>CT\WV5&//J^7N<=$->1<KS%;(6AIKMDDJ!3U-^C4@^U'
MG7*YX)2P *>:WU=H09CF'Z]#?LJC;4$)_ ^<M&-JJ_5+J5ZXU6&-&>I58HE2
M<,ZY(C7>]S901:TN, Z>YS'!48F;"+D-L:V^C%(WY&9/K3FZC8)21:"<U*,U
MWT/8J!^A=F#4EA J-&:Q8!W^G_!5^.LZ+Q,/U_N-05?K3^P":6G [%0"P#!Z
M'G[3H1V+$8_WLSMV=TYJ-4*=WK&XBU(C#L:9F#&*L?9V2P?3]9B-Y<K+<<56
M&'DQP=G5K#A4O(%<%%%^5US3[_5 75P-G+<NU9RTI;+727\G@T9+ %::8)CH
M!%>QT,2G?.*BU*\P^>^]^+KI/IV7O(!7TW<9X OS0MRWU,6@NAQ4%W2$>%%'
MJ"^,32#QXKZLE'S@5H'L(4^KDZ_\T(K:%DFZ3N/(M _*RY+=K)Q8?BM%/PC0
MX;-(A94"" 5O<9X6]2*PRI\,);PF_!"AC=QT_Q@,)41,@E_E$N:,"OO=6M7&
MD'52 3J<+.JAR]5:'8$YZOJ\V<K)G.%=5U:*P=DS!ZUN^KT9;*:T@&;$R3KH
M>#!H".3Z^X,<S"3CX$TC#BA=K@U*_8F68=:5@V9@$-)I\H.L=?AP1F/W/$ZC
M[+HH4Q8>T/@"YR4#=9KOMLUB+G5MS=Y#G)QET4;&Y,.\)T 2WN4_DR1W[W(O
M"=XB#FV974C%^E:^S9&KHS75/V1>2/V 8_AEM.)^<T&:1TDF61AD,P-4+4MJ
M- ]UW$R_AT_?EN0: 7RB#KK$N\G$85#'"J.*/7KE\"O;/&Y\'U'_1R-'MK>.
MN]45(2Q++F/Z^Y=>Y+H.15:?(Y)<\1-2Y6"K;[TI3#7>6?X]?E-*'N@SC;-1
M+OP2B%>R',I(X5P+?\B"YJ)6/$)%KWJ$[O$FS7,V66FQ+_VU-<5?<+IYJ'"R
MHJ.%:(-/F\UZ?&?-X>M%__97VFQM/NF!&K/NU5]X$[<P?=KP6Q44U3J3K:JO
MPPW<F[_>O?/7N\%;&H/0WX^+O")17.VBC.4+?J>K1]](O+N',)]:<!5^802/
MK,/;;O0;<:^'*I96^^L7')'RFY$'@>$NEG&VY]1>.M9-8[YL>WCG/GW?*XT,
MY)_M0+' ^&5?>.\O-58X([;9$+R)*LR6,6KQ^@3[Z^CI]_A2'ZA@59[G]6Z+
M#Z0HU;<R'.!-KZFY:C[5D@U5\AI8/>U!;+,8>F^8,D[@-[G2Z2L<8IR]) )0
M373Y3^O4=)=[_>MITHO;[#S8!M/P=?OT^</FD[16)VZ;)K4%>6V&LPVU/I8A
M+<5/H_A+W2AR'O!IKY^<;8%%;]:2' "M]_4 K?5!NS1'$*^J5YOU@1?MV)P0
M?#E]VQRSG;NW5^0)#)_KK"!KG%8L26'[P0XTD)"^"52;GO^IEAQ,2E[S>EKG
M;-LLNM]UK;Q_HU,E]/8^)RW;=A("A;_$Y,$^<9_\W#L$*(>$PIK_WV7=Q12?
M2%Q@B-C;&0:HGOI 'WG1^-L1P^OIXP]CN',,;A4.  XG ^T-]+L'H%X\/,WU
M<S8',])U=R"ND]>&35G[WV#WVI=-0BO3]]N_]J41->1FBB^;C ICYVZGL"<>
MC'#<;K:0I:$\Z#D&R7M !=1S/].2+51XR9?7+E4FVB\^+9$P%5*K"W!DP?KM
MK[2%^@[Z+%_]1;?F RXR'3!%\KZ3@>H/X'/&>PZ*5S/C/?\3+S;C[0XA^%Q6
M6+OWF.H&U\LO\_W&@Q#5C=^'?.%K.E]D_G!+'B-2OPUHCWU(6QV&Q:"::OR
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M,4D?82RQ+3JU[V7]X)4T*.T'.MP2TNMO5CJSM%/RFWKI*.2FM6;U2MBE)9]
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MN[4L*SZSF9H]OJ736Z"UBAF?R+6Q.+SB5;4A=[N$ \2\!)3F?&Z]/D<<M3I
M6QC;LISF.SI4NGIL<AVXA4CR L*W"YUA9LK+M/UN9R^J*-.M!SGC%C:@M 6@
M*GI&!$*P(S2]QHA\<U&4Y3$=E[^L"\)F[\M1,*?X1/.+\TG??8T>DGEN66 <
M]9X&",=HO[U%S: 517F"N [*<86*MER4T8+A,9_^H_VMB>=&ZUMYTN:YD"^
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MP@M N"O!\M;*U[.#$-RM8'9P315'F-Z;8OUF1__@1]?XOD(0=39K4AIX/8E
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M.T9-3\$Y- V'O=$U?9>_^A3=_XQ0SU-L=C4S*@1:IL^T].IY(,"H:0.=0]=
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M;3@7@4%5)@&]CO,B/]U<O)"PY*/IC(>"9%1RO"N7PMC,E(+8ZKFTZA3*TV-
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M1LKTA,X'UAT&,3G+(=\?<)<YR7U(U7D2_5)6;RGE]]DM";,TC!-R(.=]-MI
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M>DI$8L0@V29&O$J7&5U7I)L374(;@.J6,T?P$-VRA,G1-3>QE YB_G2/X7D
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MD>/IG/VO^@:+M" ^^#KU:8 M[?W$UV&/\R(F$."OES)_#Y<RF\.(%(2NXU1
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M+0DSML82R4JA- &JHF5-[,L7& Y'#QRQA>]3$ OO*.\EP$[R:L9::)D(K7D
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MX 1V"ONYG1Z5/@5 Z.2Q_29AGW\46=Z>29(]B;OFU6N#VLVWKIJ?F^\1;3,
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ML]M.&D,@.@6QPQ=[<J00&)V(6_*TRXYRG:6K>T+77)]T2VM5#>Q8P9[4F"!
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MK:ZU@JM-FJ$:MJ]WD#[ 1,3>4X-,P6XF5;E NKK?KH+MVQUY:,L1<627;ZN
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MF;VL6L'V.Q@V&9I73J ('?%UIP7-0D*B_)+!UG@@X9P\:+/,:2IA#VE+O@$
M'/7]T\9C6(N SJD(<XY^#)(2<+4-5!G]0-B.< M T,VUR-7.$ZS%JY3W\CX[
M2YA"1:?L<[]>QB\D^A3PQ&S%YN0YB!.^*+S,*#=A)\5E$%,AE68A-4[SZ ?)
M=@HP*JA';1NT2%0+FCL2<BABD@_7*&V+Z ?C(RH1 #JKPXOZ+_R_'MCBDOWF
M_P=02P$"% ,4    " "LA8%<C]-AR#X*  #]4P  "P              @ $
M    97@Q,"TQ,BYH=&U02P$"% ,4    " "LA8%<SI?MB&T*  #25   "@
M            @ %G"@  97@Q,"TT+FAT;5!+ 0(4 Q0    ( *R%@5QB)L_O
M/@H  )M4   *              "  ?P4  !E>#$P+3<N:'1M4$L! A0#%
M  @ K(6!7!34I V< P  )1    H              ( !8A\  &5X,C,M,2YH
M=&U02P$"% ,4    " "LA8%<J*A1R4H#   F$@  "@              @ $F
M(P  97@R,RTR+FAT;5!+ 0(4 Q0    ( *R%@5Q\JQOL^@<  -0M   *
M          "  9@F  !E>#,Q+3$N:'1M4$L! A0#%     @ K(6!7 9@91P
M"   42X   H              ( !NBX  &5X,S$M,BYH=&U02P$"% ,4
M" "LA8%<'=H ]G$%  !'(   "@              @ 'B-@  97@S,BTQ+FAT
M;5!+ 0(4 Q0    ( *R%@5PKA%#$W!,  /!N   )              "  7L\
M  !E>#0M,2YH=&U02P$"% ,4    " "LA8%<!6XKD<<<   J)P$ "@
M        @ %^4   97@Y-RTQ+FAT;5!+ 0(4 Q0    ( *R%@5S&;3^M6G\$
M "I4)0 ,              "  6UM  !F;W)M,3 M:RYH=&U02P$"% ,4
M" "LA8%<_M"6XYV:  #6PP  $               @ 'Q[ 0 9F]R;3$P+6M?
M,# Q+FIP9U!+ 0(4 Q0    ( *R%@5Q+@K_M_2X  .-!   0
M  "  ;R'!0!F;W)M,3 M:U\P,#(N:G!G4$L! A0#%     @ K(6!7$DQ708?
M(@  ."4  !               ( !Y[8% &9O<FTQ,"UK7S P,RYJ<&=02P$"
M% ,4    " "LA8%<I6L(OND-  " #@  $               @ $TV04 9F]R
M;3$P+6M?,# T+FIP9U!+ 0(4 Q0    ( *R%@5R'B8\-^A(  !C9   1
M          "  4OG!0!J=6YS+3(P,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( *R%
M@5SWUM=L+Q,  &GY   5              "  73Z!0!J=6YS+3(P,C4Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " "LA8%<W5'CY?\]  !#^P, %0
M    @ '6#08 :G5N<RTR,#(U,3(S,5]D968N>&UL4$L! A0#%     @ K(6!
M7/6B<'46B0  0NT' !4              ( !"$P& &IU;G,M,C R-3$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( *R%@5S)Q[-*VUP  -4$!@ 5
M  "  5'5!@!J=6YS+3(P,C4Q,C,Q7W!R92YX;6Q02P4&     !0 % "M!
&7S('

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:JUNS="http://jupiterneurosciences.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="juns-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ReceivablesforSaleofCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ReceivablesforSaleofCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ReceivablesforSaleofCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ReceivablesforSaleofCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">JUNS:ReceivablesforSaleofCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2022-01-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2022-01-25</instant>
        </period>
    </context>
    <context id="From2024-06-142024-06-14_custom_FifteenForFourForwardStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">JUNS:FifteenForFourForwardStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_custom_FifteenForFourForwardStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">JUNS:FifteenForFourForwardStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-13_custom_FifteenForFourForwardStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">JUNS:FifteenForFourForwardStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-13</instant>
        </period>
    </context>
    <context id="AsOf2025-12-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2025-12-19</instant>
        </period>
    </context>
    <context id="From2024-12-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-242025-10-24_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-24</startDate>
            <endDate>2025-10-24</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="AsOf2025-03-21_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="AsOf2025-09-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2025-09-17</instant>
        </period>
    </context>
    <context id="AsOf2025-07-09_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="AsOf2026-02-26_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-26</instant>
        </period>
    </context>
    <context id="AsOf2026-08-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2026-08-25</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-03-152024-03-15_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-15_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="From2024-03-152024-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="From2024-03-152024-03-15_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:NoteIIHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="From2024-04-292024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:NoteIIHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:EmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember_custom_YAIIPNLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:YAIIPNLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="AsOf2025-10-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2025-10-27</instant>
        </period>
    </context>
    <context id="From2025-10-272025-10-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2025-10-27</startDate>
            <endDate>2025-10-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-27</instant>
        </period>
    </context>
    <context id="From2025-10-272025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-27</startDate>
            <endDate>2025-10-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2025-10-23</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-08-012021-12-31_custom_TwelveConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-08-062022-08-06_custom_TwelveConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:TwelveConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-06</startDate>
            <endDate>2022-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-04_custom_ConvertibleDebtOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertibleDebtOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-04</instant>
        </period>
    </context>
    <context id="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-04-11</endDate>
        </period>
    </context>
    <context id="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-04-11</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-04-242024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteConvertibleDebtTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-24</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeniorSecuredNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:SeniorSecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="From2023-03-012023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="From2024-12-012024-12-31_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">JUNS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="AsOf2025-12-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-24</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="AsOf2025-12-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-24</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-24</instant>
        </period>
    </context>
    <context id="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-24</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:MonteCarloModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2025-10-24</instant>
        </period>
    </context>
    <context id="From2025-10-242025-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2025-10-24</startDate>
            <endDate>2025-10-24</endDate>
        </period>
    </context>
    <context id="From2025-04-232025-04-23_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-23</startDate>
            <endDate>2025-04-23</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityOneMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityTwoMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityThreeMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2024-12-022024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-02</startDate>
            <endDate>2024-12-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-04</startDate>
            <endDate>2024-12-04</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-242024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-24</instant>
        </period>
    </context>
    <context id="From2024-04-172024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-17</startDate>
            <endDate>2024-04-17</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-17</instant>
        </period>
    </context>
    <context id="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-10</startDate>
            <endDate>2025-06-10</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-10</instant>
        </period>
    </context>
    <context id="AsOf2025-07-02_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-02</instant>
        </period>
    </context>
    <context id="From2025-07-022025-07-02_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-02</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="From2025-09-052025-09-05_custom_TwoConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:TwoConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-05</startDate>
            <endDate>2025-09-05</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-05_custom_TwoConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:TwoConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-05</instant>
        </period>
    </context>
    <context id="From2025-09-052025-09-05_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-05</startDate>
            <endDate>2025-09-05</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-05_custom_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-05</instant>
        </period>
    </context>
    <context id="AsOf2025-06-22_custom_WarrantHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-22</instant>
        </period>
    </context>
    <context id="AsOf2025-07-16_custom_WarrantHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-16</instant>
        </period>
    </context>
    <context id="From2025-07-162025-07-16_custom_WarrantHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-16</startDate>
            <endDate>2025-07-16</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-12_custom_WarrantHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-12</instant>
        </period>
    </context>
    <context id="From2025-08-122025-08-12_custom_WarrantHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">JUNS:WarrantHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RangeEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">JUNS:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember13963437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember13963437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-19_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">JUNS:TiberendStrategicAdvisorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">JUNS:TiberendStrategicAdvisorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <instant>2021-05-01</instant>
        </period>
    </context>
    <context id="From2021-05-012021-05-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DominantTreasureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-15</startDate>
            <endDate>2024-12-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-15_custom_DominantTreasureAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DominantTreasureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2023-12-182023-12-18_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="From2024-12-042024-12-04_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-04</startDate>
            <endDate>2024-12-04</endDate>
        </period>
    </context>
    <context id="From2016-09-132016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-13</startDate>
            <endDate>2016-09-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-13</instant>
        </period>
    </context>
    <context id="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-13</instant>
        </period>
    </context>
    <context id="From2016-09-132016-09-13_custom_LicensingAndRoyaltyAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicensingAndRoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-13</startDate>
            <endDate>2016-09-13</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DebtForgivenessAndExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:DebtForgivenessAndExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2016-09-152016-09-15_custom_LicenseAgreementsMember_custom_AquanovaAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:AquanovaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-15</startDate>
            <endDate>2016-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember_country_JP_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:MurdochChildrensResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-01</instant>
        </period>
    </context>
    <context id="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_country_JP_srt_MaximumMember_custom_MurdochChildrensResearchInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:MurdochChildrensResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-01</instant>
        </period>
    </context>
    <context id="From2015-09-012015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:LicenseAgreementsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:MurdochChildrensResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-01</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_custom_EntityThreeMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">JUNS:EntityThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ServiceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_ServiceAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="From2025-10-012025-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">JUNS:PharmaceuticalOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">JUNS:PremiumNutritionalSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_SubsequentEventMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679628</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">JUNS:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segments">
        <measure>JUNS:Segments</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000005">0001679628</dei:EntityCentralIndexKey>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0175"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0177"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0179"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0181"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:GainOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueStockSplits
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest
      contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueCommitmentShares
      contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedDuringPeriodValueCommitmentShares
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_custom_ReceivablesforSaleofCommonStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:GainLossOnForgivenessOfAccruedCompensation
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:NoncashFinancingCost
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:DecreaseIncreaseInPrepaidContracts
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:RestrictedStockIssuedForForgivenessOfSalary
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockOptionsIssuedForForgivenessOfSalary
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:NotesPayableRelatedPartyAssignToNotePayable
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:StockIssuedInConnectionInterestPayment
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0724"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_DerivativeMember"
      id="xdx2ixbrl0876"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-12-31_us-gaap_DerivativeMember"
      id="xdx2ixbrl0878"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0896"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0898"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1024"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1026"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1028"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1042"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1044"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1046"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1048"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeFiveMember"
      id="xdx2ixbrl1122"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437"
      id="xdx2ixbrl1228"
      unitRef="Shares"
      xsi:nil="true"/>
    <JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437"
      id="xdx2ixbrl1230"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437"
      id="xdx2ixbrl1236"
      unitRef="Shares"
      xsi:nil="true"/>
    <JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437"
      id="xdx2ixbrl1238"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1240"
      unitRef="Shares"
      xsi:nil="true"/>
    <JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1242"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1286"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1287"
      unitRef="Pure"
      xsi:nil="true"/>
    <JUNS:DeferredTaxAssetsDerivativeLiability
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <JUNS:DeferredTaxAssetsDerivativeLiability
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember"
      id="xdx2ixbrl1458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember"
      id="xdx2ixbrl1461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember"
      id="xdx2ixbrl1464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember"
      id="xdx2ixbrl1467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember"
      id="xdx2ixbrl1471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember"
      id="xdx2ixbrl1473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember"
      id="xdx2ixbrl1488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember"
      id="xdx2ixbrl1489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember"
      id="xdx2ixbrl1490"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000014">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000015">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000016">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000017">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000018">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000020">001-41265</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000021">JUPITER NEUROSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000023">47-4828381</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000024">1001 North US HWY 1</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000025">Suite 504</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000026">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000027">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000028">33477</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000029">(561)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000030">406-6154</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-12-31" id="Fact000031">Common     Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-12-31" id="Fact000032">JUNS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-12-31" id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000034">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000035">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000036">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000037">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000038">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000039">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000040">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-12-31" id="Fact000041">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000042">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000043">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000044">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact000045"
      unitRef="USD">20200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000046"
      unitRef="Shares">36281252</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000047"
      unitRef="USDPShares">0.0001</dei:EntityListingParValuePerShare>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000048">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000051">&lt;b&gt;Cybersecurity Risk Management and Strategy&lt;/b&gt;&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The cybersecurity risk management program,
processes and strategy described in this section are limited to the personal and business information belonging to or maintained by the
Company (collectively, &#x201c;Confidential Information&#x201d;), our own &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zrbfYFno3HD2"&gt;third-party&lt;/span&gt; critical systems and services supporting or used by
the Company (collectively, &#x201c;Critical Systems&#x201d;), and service providers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;We will develop and implement a cybersecurity
risk management program intended to protect the confidentiality, integrity, and availability of our Confidential Information and Critical
Systems. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_z2TWOGcqSxAe"&gt;Our cybersecurity risk management program will be &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zHurfh1n0cN9"&gt;integrated&lt;/span&gt; into our overall enterprise risk management program and includes
a cybersecurity incident response plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our cybersecurity risk management program
shall include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; font-family: Times New Roman,serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;risk assessments designed to help identify material cybersecurity risks to our Confidential Information, Critical Systems and the broader enterprise information technology environment;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman,serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman,serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;cybersecurity awareness and spear-phishing resistance training of our employees, and senior management;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman,serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="font-family: Times New Roman,serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman,serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;a vendor management policy for service providers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20250101__20251231_zqtrQTGFAkOl"&gt;We have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zOjkOTyYRyxd"&gt;no&lt;/span&gt;t identified risks from known
cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely
to materially affect us, including our operations, business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2025-01-01to2025-12-31" id="Fact000052">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000053">Our cybersecurity risk management program will be &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zHurfh1n0cN9"&gt;integrated&lt;/span&gt; into our overall enterprise risk management program and includes
a cybersecurity incident response plan.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000054">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000055">We have &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20250101__20251231_zOjkOTyYRyxd"&gt;no&lt;/span&gt;t identified risks from known
cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely
to materially affect us, including our operations, business strategy, results of operations, or financial condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2025-01-01to2025-12-31" id="Fact000056">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000060">&lt;b&gt;Cybersecurity Governance&lt;/b&gt;&#160;&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our management team meets with our information
technology service provider periodically to discuss then-current cybersecurity issues, which may include efforts to prevent, detect, mitigate,
and remediate cybersecurity risks and incidents through various means, including threat intelligence and other information obtained from
governmental, public or private sources, and external service providers engaged by us; and alerts and reports produced by security tools
deployed in the information technology environment including a spear-phishing report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zemqe6ytrWa3"&gt;Our Board considers cybersecurity risk
as part of its risk oversight function and oversight of cybersecurity and other information technology risks&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our Board oversees management&#x2019;s
implementation of our cybersecurity risk management program. Our executive management team is responsible for updating the Board, as necessary,
regarding significant cybersecurity incidents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Our Board also receives periodic reports
from management on our cybersecurity risks and cybersecurity risk management program.&lt;/p&gt;

&#160;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2025-01-01to2025-12-31" id="Fact000061">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000062"> executive management team, along with
our managed information technology service provider</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000063">Our Board considers cybersecurity risk
as part of its risk oversight function and oversight of cybersecurity and other information technology risks</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000065">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000067">false</ecd:NonRule10b51ArrAdoptedFlag>
    <JUNS:Rule10b51ArrModifiedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000069">false</JUNS:Rule10b51ArrModifiedFlag>
    <JUNS:NonRule10b51ArrModifiedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000071">false</JUNS:NonRule10b51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-12-31" id="Fact000073">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-01to2025-12-31" id="Fact000075">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000076">677</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="From2024-01-012024-12-31" id="Fact000077">5036</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000078">Cherry Bekaert LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000079">Tampa, Florida</dei:AuditorLocation>
    <dei:AuditorLocation contextRef="From2024-01-012024-12-31" id="Fact000080">Coral Springs, Florida</dei:AuditorLocation>
    <dei:AuditorName contextRef="From2024-01-012024-12-31" id="Fact000081">ASSURANCE DIMENSIONS, LLC</dei:AuditorName>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">3789342</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">3769510</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">2637</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">766667</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">766667</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">159790</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">106542</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">114086</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">4824978</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">4650263</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">23214</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">69642</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">712055</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">1478721</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">3783</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">3783</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000116"
      unitRef="USD">5564030</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">6202409</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">638646</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">396483</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">1397357</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">1415093</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">39829</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000132"
      unitRef="USD">1064</us-gaap:InterestPayableCurrent>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">735</us-gaap:DeferredRevenue>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">50082</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000141"
      unitRef="USD">146432</us-gaap:NotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">5298068</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">7395882</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">2009154</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">7395882</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">2030401</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000167"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000169"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000186"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000188"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000190"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000192"
      unitRef="Shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000194"
      unitRef="Shares">34446455</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000196"
      unitRef="Shares">34446455</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000198"
      unitRef="Shares">33103860</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">33103860</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">3444</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">3310</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">32831730</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">30190827</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">-34667026</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">-26022129</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-1831852</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">4172008</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">5564030</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">6202409</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">21796</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">-0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">4231</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">17565</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">2086574</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">492660</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">6839712</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">2598622</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">8926286</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">3091282</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-8908721</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-3091282</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">5557</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000245"
      unitRef="USD">-53257</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">281932</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">66020</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">248366</us-gaap:InterestExpenseNonoperating>
    <JUNS:GainOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">857723</JUNS:GainOnExtinguishmentOfDebt>
    <us-gaap:OtherIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">47912</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">90000</us-gaap:OtherIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">263824</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">651657</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-8644897</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-2439625</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000268"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000269"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000271"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000272"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000277"
      unitRef="Shares">34628588</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">28783045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">34628588</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">28783045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">26526405</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000283"
      unitRef="USD">2652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">17778498</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-23582504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000287"
      unitRef="USD">-5801354</us-gaap:StockholdersEquity>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">1840908</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000295"
      unitRef="USD">1840908</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000298"
      unitRef="USD">10000</JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">10000</JUNS:StockIssuedDuringPeriodValueIssuanceOfRestrictedStockUnitsForForgivenessOfAccruedSalary>
    <JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">50000</JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary>
    <JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">50000</JUNS:StockIssuedDuringPeriodValueOfIssuanceOfStockOptionsForForgivenessOfAccruedSalary>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000315"
      unitRef="Shares">3487500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">349</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">-349</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000323"
      unitRef="Shares">112500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000317"
      unitRef="USD">11</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">149989</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">150000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000331"
      unitRef="Shares">227447</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">23</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">636843</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">636866</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <JUNS:StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000339"
      unitRef="Shares">2750000</JUNS:StockIssuedDuringPeriodSharesStockSoldInOfferingNetOfOfferingCostsShares>
    <JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000333"
      unitRef="USD">275</JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts>
    <JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">9724938</JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts>
    <JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">9725213</JUNS:StockIssuedDuringPeriodValueStockSoldInOfferingNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000347"
      unitRef="Shares">8</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">-2439625</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-2439625</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000361"
      unitRef="Shares">33103860</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">3310</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">30190827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-26022129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">4172008</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000369"
      unitRef="Shares">33103860</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">3310</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000364"
      unitRef="USD">30190827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000366"
      unitRef="USD">-26022129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000367"
      unitRef="USD">4172008</us-gaap:StockholdersEquity>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">2139908</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">2139908</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000383"
      unitRef="Shares">103186</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000378"
      unitRef="USD">65990</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000381"
      unitRef="USD">66000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <JUNS:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000391"
      unitRef="Shares">943846</JUNS:StockIssuedDuringPeriodSharesWarrantExercises>
    <JUNS:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">94</JUNS:StockIssuedDuringPeriodValueWarrantExercises>
    <JUNS:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">-94</JUNS:StockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">143654</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">15</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">212593</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000397"
      unitRef="USD">212608</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <JUNS:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">20000</JUNS:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPaymentOfInterestShares>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000401"
      unitRef="USD">2</JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">22519</JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest>
    <JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">22521</JUNS:StockIssuedDuringPeriodValueIssuanceOfCommonStockForPaymentOfInterest>
    <JUNS:StockIssuedDuringPeriodSharesCommitmentShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000415"
      unitRef="Shares">131909</JUNS:StockIssuedDuringPeriodSharesCommitmentShares>
    <JUNS:StockIssuedDuringPeriodValueCommitmentShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">13</JUNS:StockIssuedDuringPeriodValueCommitmentShares>
    <JUNS:StockIssuedDuringPeriodValueCommitmentShares
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">199987</JUNS:StockIssuedDuringPeriodValueCommitmentShares>
    <JUNS:StockIssuedDuringPeriodValueCommitmentShares
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">200000</JUNS:StockIssuedDuringPeriodValueCommitmentShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000420"
      unitRef="USD">-8644897</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000421"
      unitRef="USD">-8644897</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000429"
      unitRef="Shares">34446455</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">3444</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">32831730</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-34667026</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">-1831852</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000434"
      unitRef="USD">-8644897</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">-2439625</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">-53257</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">281932</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">43288</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000450"
      unitRef="USD">857723</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <JUNS:GainLossOnForgivenessOfAccruedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">40000</JUNS:GainLossOnForgivenessOfAccruedCompensation>
    <JUNS:GainLossOnAmortizationOfPrepaidContracts
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000455"
      unitRef="USD">766666</JUNS:GainLossOnAmortizationOfPrepaidContracts>
    <JUNS:GainLossOnAmortizationOfPrepaidContracts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">54612</JUNS:GainLossOnAmortizationOfPrepaidContracts>
    <JUNS:NoncashFinancingCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">200000</JUNS:NoncashFinancingCost>
    <us-gaap:PaidInKindInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">22521</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000464"
      unitRef="USD">2418516</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">1840908</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000470"
      unitRef="USD">2637</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <JUNS:DecreaseIncreaseInPrepaidContracts
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">2300000</JUNS:DecreaseIncreaseInPrepaidContracts>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">113826</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000479"
      unitRef="USD">159790</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000482"
      unitRef="USD">-7544</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <JUNS:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">3654</JUNS:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <JUNS:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">1785</JUNS:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">735</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000491"
      unitRef="USD">242163</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-149530</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000494"
      unitRef="USD">-17736</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">-46948</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000497"
      unitRef="USD">38765</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">46368</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000500"
      unitRef="USD">-5413736</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-3911004</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">138500</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000509"
      unitRef="USD">146432</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000510"
      unitRef="USD">108880</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">2102797</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000516"
      unitRef="USD">150000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">5580000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">9725213</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">150000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">5433568</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">7652036</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">19832</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">3741032</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">3769510</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">28478</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">3789342</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">3769510</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <JUNS:CashPaidForInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">38426</JUNS:CashPaidForInterest>
    <JUNS:CashPaidForInterest
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">147776</JUNS:CashPaidForInterest>
    <JUNS:RestrictedStockIssuedForForgivenessOfSalary
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">10000</JUNS:RestrictedStockIssuedForForgivenessOfSalary>
    <JUNS:StockOptionsIssuedForForgivenessOfSalary
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">50000</JUNS:StockOptionsIssuedForForgivenessOfSalary>
    <JUNS:NotesPayableRelatedPartyAssignToNotePayable
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">266667</JUNS:NotesPayableRelatedPartyAssignToNotePayable>
    <JUNS:StockIssuedInConnectionWithConvertiblePromissoryNotes
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">200000</JUNS:StockIssuedInConnectionWithConvertiblePromissoryNotes>
    <JUNS:StockIssuedInConnectionWithConvertiblePromissoryNotes
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">636866</JUNS:StockIssuedInConnectionWithConvertiblePromissoryNotes>
    <JUNS:StockIssuedInConnectionInterestPayment
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">22521</JUNS:StockIssuedInConnectionInterestPayment>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000563">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zkaqbdOSusRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_820_zSCgFWkrLLz7"&gt;Organization and Description of Business&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Jupiter Neurosciences, Inc. (the
&#x201c;Company&#x201d;) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company
incorporated in Delaware in January 2016. The Company is advancing a therapeutic pipeline targeting central nervous system
(&#x201c;CNS&#x201d;) disorders and rare diseases, while also expanding into the consumer longevity market with its
Nugevia&#160;product line. Both efforts are powered by JOTROL&lt;sup&gt;&#x2122;&lt;/sup&gt;, the Company&#x2019;s proprietary, enhanced
resveratrol formulation that has demonstrated potential for significantly improved bioavailability. The Company&#x2019;s prescription
pipeline is focused broadly on CNS disorders, presently with a planned Phase IIa clinical study in Parkinson&#x2019;s disease. The
Company&#x2019;s Nugevia product line brings clinical-grade science to the supplement space, supporting mental clarity, skin health,
and mitochondrial function.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the State of Delaware to change
its name from Jupiter Orphan Therapeutics, Inc. to Jupiter Neurosciences, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;JOTROL&#x2122;
has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation,
without causing gastrointestinal side effects. We expect JOTROL&#x2122;, based on the results of our Phase I study, will resolve the major
obstacle of resveratrol&#x2019;s poor bioavailability, which has been documented in various scientific articles describing previously
conducted human trials with resveratrol as well as preclinical trial results in mice and rats.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 14, 2024, the Company increased the number of authorized shares of common stock, $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240614_zNYxCPLhKgL9" title="Common stock par value"&gt;0.0001&lt;/span&gt; par value per share, to &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614_z2y5H3zV9Ap5" title="Common stock shares authorized"&gt;125,000,000&lt;/span&gt; from
&lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220125_znQ20TeeMcT4" title="Common stock shares authorized"&gt;45,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 14, 2024, the Company effected a &lt;span id="xdx_90C_eus-gaap--StockholdersEquityNoteStockSplit_c20240614__20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_znjBukBJeCS" title="Stock split"&gt;fifteen-for-four&lt;/span&gt; (15:4) forward stock split whereby the Company (i) increased the number of issued
and outstanding shares of common stock, $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zH9H0etQnlqe" title="Common stock par value"&gt;0.0001&lt;/span&gt; par value per share, from &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240613__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zloG6gOnJ9O" title="Common stock shares authorized"&gt;8,033,706&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614__us-gaap--AwardTypeAxis__custom--FifteenForFourForwardStockSplitMember_zRRuBduY2sg" title="Common stock shares authorized"&gt;30,126,413&lt;/span&gt; and (ii) increased by a ratio of fifteen-for-four
(15:4) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the forward stock split
were made to the Company&#x2019;s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the forward stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 19, 2025, the Company increased the number of authorized shares of common stock, $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251219_zrkepVSD6p4b" title="Common stock par value"&gt;0.0001&lt;/span&gt; par value per share, to &lt;span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251219_zahwbiG0QpJ1" title="Common stock shares authorized"&gt;500,000,000&lt;/span&gt;
from &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240614_zCxDixqZ9Dg1" title="Common stock shares authorized"&gt;125,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Initial
Public Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2024, the Company&#x2019;s sold &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241201__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHzAi6Tl2CX3" title="Sale of shares of common stock"&gt;2,750,000&lt;/span&gt; shares of Common Stock at a price of $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7qFBpTjcv17" title="Stock price per share"&gt;4.00&lt;/span&gt; per share for gross proceeds of $11 million
before underwriting discounts and other related expenses in a registered initial public offering (the &#x201c;IPO&#x201d;). Net proceeds,
after deducting underwriting discounts, commissions, and offering-related expenses, were approximately $&lt;span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pp0d_c20241201__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzEuhHsyTJu5" title="Underwriting discounts, commissions and offering expenses"&gt;9,725,213&lt;/span&gt;. In connection with
the Public Offering, the Company&#x2019;s Common Stock began trading on The Nasdaq Capital Market under the symbol &#x201c;JUNS.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Standby Equity Purchase Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 24, 2025, the Company entered into
a standby equity Purchase Agreement, pursuant to which the Company has the right to sell to an investor up to $&lt;span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20251024__20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zaauQy9MfXqc" title="Sale of stock, consideration received on transaction"&gt;20.0&lt;/span&gt; million of its common
stock, par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zSPxR4RPzijj" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, subject to certain limitations and conditions. See &lt;i&gt;Note 5 &#x2013; Convertible Debt and Derivative
Liability &lt;/i&gt;&lt;span style="text-decoration: underline"&gt;for further details.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Nasdaq
Minimum Bid Price Compliance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"&gt;On March 21, 2025, the Company received a notification letter
from Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2),
which requires listed securities to maintain a minimum closing bid price of $&lt;span id="xdx_90C_ecustom--MinimumClosingBidPrice_iI_pid_c20250321__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zujTFSbKzJbe" title="Minimum closing bid price"&gt;1.00&lt;/span&gt; per share for at least 30 consecutive business days.
Based on the 30 consecutive business days from February 6, 2025 through March 20, 2025, the Company&#x2019;s Common Stock failed to meet
this requirement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"&gt;Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
the Company was provided 180 calendar days, or until September 17, 2025, to regain compliance by maintaining a minimum closing bid price
of at least $&lt;span id="xdx_90B_ecustom--MinimumClosingBidPrice_iI_pid_c20250917_zOk7dM55NNnl" title="Minimum closing bid price"&gt;1.00&lt;/span&gt; per share for a minimum of 10 consecutive business days. On July 9, 2025, the Company received a written notice from
the Nasdaq stating that the Company has since regained compliance with Listing Rule 5550(a)(2) because the closing bid price of the Company&#x2019;s
Common Stock has been $&lt;span id="xdx_90B_ecustom--MinimumClosingBidPrice_iI_pid_c20250709__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKoatpASfT61" title="Minimum closing bid price"&gt;1.00&lt;/span&gt; USD per share or greater for a period of thirteen (13) days (June 18, 2025 to July 8, 2025).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2026, the Company received two written notices from the Listing Qualifications Department of Nasdaq notifying the Company
that (i) the listing of the Company&#x2019;s Common Stock was not in compliance with the minimum bid price requirement as set forth under
Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the
Common Stock was less than $&lt;span id="xdx_907_ecustom--MinimumClosingBidPrice_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAnOMgoC0367" title="Minimum closing bid price"&gt;1.00&lt;/span&gt; per share for the previous 30 consecutive business days, and (ii) for the 30 consecutive business days
ended February 26, 2026, the Company&#x2019;s market value of listed securities closed below the $&lt;span id="xdx_90B_eus-gaap--AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbwAyRGo4zTh" title="Market value of listed securities closed"&gt;35&lt;/span&gt; million threshold required for continued
listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until August 25, 2026, to regain compliance by
maintaining a minimum closing bid price of at least $&lt;span id="xdx_909_ecustom--MinimumClosingBidPrice_iI_pid_c20260825_zhYcGx2xrge1" title="Minimum closing bid price"&gt;1.00&lt;/span&gt; per share for a minimum of 10 consecutive business days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-14"
      decimals="INF"
      id="Fact000565"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-14"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-01-25"
      decimals="INF"
      id="Fact000569"
      unitRef="Shares">45000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="From2024-06-142024-06-14_custom_FifteenForFourForwardStockSplitMember"
      id="Fact000571">fifteen-for-four</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-14_custom_FifteenForFourForwardStockSplitMember"
      decimals="INF"
      id="Fact000573"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-13_custom_FifteenForFourForwardStockSplitMember"
      decimals="INF"
      id="Fact000575"
      unitRef="Shares">8033706</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-14_custom_FifteenForFourForwardStockSplitMember"
      decimals="INF"
      id="Fact000577"
      unitRef="Shares">30126413</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-19"
      decimals="INF"
      id="Fact000579"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-19"
      decimals="INF"
      id="Fact000581"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-14"
      decimals="INF"
      id="Fact000583"
      unitRef="Shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-12-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000585"
      unitRef="Shares">2750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000587"
      unitRef="USDPShares">4.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-12-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000589"
      unitRef="USD">9725213</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-10-242025-10-24_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember"
      decimals="-5"
      id="Fact000591"
      unitRef="USD">20000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact000593"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <JUNS:MinimumClosingBidPrice
      contextRef="AsOf2025-03-21_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000595"
      unitRef="USDPShares">1.00</JUNS:MinimumClosingBidPrice>
    <JUNS:MinimumClosingBidPrice
      contextRef="AsOf2025-09-17"
      decimals="INF"
      id="Fact000597"
      unitRef="USDPShares">1.00</JUNS:MinimumClosingBidPrice>
    <JUNS:MinimumClosingBidPrice
      contextRef="AsOf2025-07-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000599"
      unitRef="USDPShares">1.00</JUNS:MinimumClosingBidPrice>
    <JUNS:MinimumClosingBidPrice
      contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000601"
      unitRef="USDPShares">1.00</JUNS:MinimumClosingBidPrice>
    <us-gaap:AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue
      contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="Fact000603"
      unitRef="USD">35000000</us-gaap:AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue>
    <JUNS:MinimumClosingBidPrice
      contextRef="AsOf2026-08-25"
      decimals="INF"
      id="Fact000605"
      unitRef="USDPShares">1.00</JUNS:MinimumClosingBidPrice>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000607">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zGby4y30t9X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_820_zzJfldraoCD9"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zwruQE1u12a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Going Concern&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;). U.S GAAP contemplates continuation of the Company as a going concern. For the year
ended December 31, 2025 and 2024, the Company had net revenues from product sales of $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20250101__20251231_zUkBEI5QnIHh" title="Net revenues"&gt;21,796&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zvrY4vFIRGwl" title="Net revenues"&gt;0&lt;/span&gt;, respectively and incurred a net
loss of $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20251231_zHh4As08zab4" title="Net loss"&gt;8,644,897&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zpw3Bs3ivFkj" title="Net loss"&gt;2,439,625&lt;/span&gt;,
respectively. Net cash used in operations for the years ended December 31, 2025 and 2024 was $&lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20251231_z455uyRWDbBj" title="Net cash flows from operating activities"&gt;5,413,736&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zMVVATkHhtC9" title="Net cash flows from operating activities"&gt;3,911,004&lt;/span&gt;,
respectively. As of December 31, 2025 and 2024, the Company had an accumulated deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_z78fTrKn9Aba" title="Accumulated deficit"&gt;34,667,026&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20241231_zUaFiIEL5fib" title="Accumulated deficit"&gt;26,022,129&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative
cash flows from operations as well as our dependence on private equity and financings. The
Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However,
there is no assurance the Company will be successful. These conditions raise substantial doubt
about the Company&#x2019;s ability to continue as a going concern for a period of at least twelve months from the date of this report.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zT7GDUZkWdN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States
of America (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zeHMnNtEfAb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Business
Segment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the &#x201c;management approach&#x201d; to identify its reportable segments in accordance with ASC 280, Segment Reporting.
The management approach requires companies to report segment financial information consistent with the information regularly reviewed
by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) for purposes of making operating decisions and assessing performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company&#x2019;s Chief Executive
Officer serves as the CODM. The CODM evaluates financial performance and allocates resources based on the operating results of the Company&#x2019;s
reportable segments. Effective October 1, 2025, the Company operates through two reportable segments: (i) its premium nutritional supplements,
and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CODM assesses segment performance primarily based on segment net loss (income). Selling, general and administrative expenses are directly
attributable to segments or allocated based on reasonable and consistently applied methodologies. Corporate and other expenses that are
not allocated to reportable segments consist primarily of public company costs, certain executive compensation, certain stock-based compensation,
interest income (expense), other income (expense), and income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
identification of two reportable segments reflects the manner in which the CODM reviews financial information and allocates resources.
Prior-period information has been recast to conform to the current presentation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_z71Fe3Gq1gai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preparing
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues
and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other
assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
estimates during the years ended December 31, 2025 and 2024, respectively, include valuation of stock-based compensation, uncertain tax
positions, the valuation of debt instruments, and the valuation allowance on deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9uzzPpbcwEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid
investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents consist
primarily of cash on deposit with financial institutions and amounts held in high-yield savings accounts. The Company maintains its
cash balances with high-credit-quality financial institutions. At times, such balances may exceed federally insured limits provided
by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). In 2025, the Company has implemented a deposit insurance program
in the Company&#x2019;s primary account, whereby funds in excess of FDIC insurance limits are insured.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, the cash balances not subject to insurance or that exceed the FDIC limit of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20251231_z2XBGEHdTW4k" title="Cash FDIC limit"&gt;250,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were
$&lt;span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20251231_zrb52hWhkjVj" title="Cash uninsured amount"&gt;0&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_900_eus-gaap--CashUninsuredAmount_iI_c20241231_zdi2rs3X13h" title="Cash uninsured amount"&gt;3,519,510&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zBgutkNtGN7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out (&#x201c;FIFO&#x201d;) method.
Inventory consists primarily of raw materials, work-in-process, and finished goods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically reviews inventory quantities on hand and records reserves for excess, obsolete, or slow-moving inventory based on
its assessment of forecasted demand, product shelf life, market conditions, and other factors. Inventory reserves are recorded as a reduction
of inventory and are based on management&#x2019;s estimates regarding the recoverability of inventory balances. If actual demand or market
conditions differ from those projected by management, additional inventory write-downs may be required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zctLCczDjsM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_zL4bxtMLJEki"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue is recognized when
control of promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to
be entitled to in exchange for those goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines revenue recognition through
the following five-step model: (i) identification of the contract with a customer; (ii) identification of the performance obligations
in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations;
and (v) recognition of revenue when, or as, the Company satisfies a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Product Revenue&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company generates revenue from the sale of its
products. Product revenue is recognized when control of the product is transferred to the customer, which generally occurs upon shipment
or delivery, depending on the terms of the arrangement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue is recorded net of variable consideration,
including estimates for product returns, rebates, chargebacks, discounts, and other allowances. The Company estimates variable consideration
at the time of sale based on historical experience, current market conditions, and contractual terms, and includes such estimates in the
transaction price only to the extent that it is probable that a significant reversal of revenue will not occur in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates whether it is the principal
or agent in its arrangements and records revenue on a gross or net basis accordingly. Shipping and handling activities are considered
fulfillment activities, and the related costs are recorded in cost of goods sold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--PrepaidContractsPolicyTextBlock_zUjYtMyKAlug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prepaid
Contracts&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
contracts generally represent service agreements which the Company would receive services over a period of time and are expensed as the
services are received. The Company&#x2019;s prepaid contracts are related to service agreements that span over three years, therefore
the expense will be recognized over the three year term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_zm1fAWpp2DAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prepaid
Expenses and Other Current Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets generally represent payments made for goods or services to be received within one year and are expensed
as the related benefit is received.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOo5FZckfc4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the years ended December 31, 2025 and 2024 were $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20251231_z4bv9rhUXN2f" title="Research and development costs"&gt;2,086,574&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zPLzHX7co2N8" title="Research and development costs"&gt;492,660&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zYzetmBaJwui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of December 31, 2025 and
2024, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had no material
amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company is subject
to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not currently
under examination by any tax authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zv4AC6zD9c9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss
Per Share of Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock, as calculated using the treasury method. In computing the basic and
diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations
due to the fact that when a net loss exists, dilutive shares are not included in the calculation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, there were &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zK558zCe6Ttk" title="Warrants Outstanding"&gt;no&lt;/span&gt; warrants outstanding, &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z7iZQKQBF9wi" title="Restricted stock units"&gt;1,626,037&lt;/span&gt; restricted stock units and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg6EHqelJngb" title="Number of stock options"&gt;11,726,093&lt;/span&gt; stock options. These securities
are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there were &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZ4WJ1KhMMmb" title="Warrants Outstanding"&gt;1,359,375&lt;/span&gt; warrants outstanding, &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzqvaEojyWX" title="Restricted stock units"&gt;1,626,037&lt;/span&gt; restricted stock units and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfitikcTDajk" title="Number of stock options"&gt;10,633,988&lt;/span&gt; stock options. These
securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlwYPch16Jje" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records stock-based compensation equal to the grant date fair value of the stock awards issued. For stock options issued to
employees, non-employees and members of our board of directors, the Company estimates the grant-date fair value of options using the
Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with
respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the
option, risk-free interest rates, and, for grants prior to our initial public offering, the value of the common stock. For awards
subject to time-based vesting, the Company recognized stock-based compensation expense, on a straight-line basis over the requisite
service period, which is generally the vesting term of the award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--ClinicalTrialExpensesPolicyTextBlock_zP79s9OeFwDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
Trial Expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztnATQTFkhUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value of Financial Instruments and Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their
short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current
interest rates available for debt with similar terms and maturities are substantially the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value of Financial Instruments and Fair Value Measurements, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also
see Note 5 - Convertible Debt and &lt;span id="xdx_908_ecustom--DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_zjcfYYWrQ0Ce" title="Derivative liabilities current not disclosed flag"&gt;Derivative Liability&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_zdrcpHOOBB16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative
Instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 815, Derivatives and Hedging (&#x201c;ASC Topic 815&#x201d;), establishes accounting and reporting standards for derivative instruments
and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or
losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt,
the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any
discounts and records a net gain or loss on debt extinguishment. On January 1, 2020, the Company adopted ASU 2017-11 under which down-round
Features in Financial Instruments will no longer cause derivative treatment. The Company applies the modified prospective method of adoption.
There were no cumulative effects on adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_zOs0iAUFwPz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible
Notes with Embedded Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into shares of common stock at a fixed discount to the price of the common stock at
or around the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those
contracts or any potential embedded components of those contracts qualify as derivatives. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zYwY2r4SabCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based
on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit
rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present
value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIAJishjMKl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the
periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted
accounting principles and do not believe that any new or modified principles will have a material impact on the Company&#x2019;s reported
financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&#x2019;s
financial management.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer serves as the CODM.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;)
No. 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;. ASU 2023-09 enhances income tax disclosures by
adding more granular, jurisdiction-specific information, especially for investors and analysts. The amendments in ASU 2023-09 are
effective for public business entities for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09
effective January 1, 2025 on a prospective basis. The Company plans to adopt this update during the year ended December 31, 2026.
Beyond the expanded, required disclosures, management does not believe that this will have a material impact on the Company&#x2019;s
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
other newly issued accounting pronouncements that are not yet effective have been deemed immaterial or nonapplicable.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85A_z15nw5BRSDUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000609">&lt;p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zwruQE1u12a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt; Going Concern&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;). U.S GAAP contemplates continuation of the Company as a going concern. For the year
ended December 31, 2025 and 2024, the Company had net revenues from product sales of $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20250101__20251231_zUkBEI5QnIHh" title="Net revenues"&gt;21,796&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20240101__20241231_zvrY4vFIRGwl" title="Net revenues"&gt;0&lt;/span&gt;, respectively and incurred a net
loss of $&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_di_c20250101__20251231_zHh4As08zab4" title="Net loss"&gt;8,644,897&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--NetIncomeLoss_iN_di_c20240101__20241231_zpw3Bs3ivFkj" title="Net loss"&gt;2,439,625&lt;/span&gt;,
respectively. Net cash used in operations for the years ended December 31, 2025 and 2024 was $&lt;span id="xdx_907_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20250101__20251231_z455uyRWDbBj" title="Net cash flows from operating activities"&gt;5,413,736&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20240101__20241231_zMVVATkHhtC9" title="Net cash flows from operating activities"&gt;3,911,004&lt;/span&gt;,
respectively. As of December 31, 2025 and 2024, the Company had an accumulated deficit of $&lt;span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20251231_z78fTrKn9Aba" title="Accumulated deficit"&gt;34,667,026&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20241231_zUaFiIEL5fib" title="Accumulated deficit"&gt;26,022,129&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There is substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative
cash flows from operations as well as our dependence on private equity and financings. The
Company plans to finance future operations with proceeds from equity securities, grant awards and strategic collaborations. However,
there is no assurance the Company will be successful. These conditions raise substantial doubt
about the Company&#x2019;s ability to continue as a going concern for a period of at least twelve months from the date of this report.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">21796</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000613"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000615"
      unitRef="USD">-8644897</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000617"
      unitRef="USD">-2439625</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000619"
      unitRef="USD">-5413736</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000621"
      unitRef="USD">-3911004</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000623"
      unitRef="USD">-34667026</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000625"
      unitRef="USD">-26022129</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000627">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zT7GDUZkWdN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States
of America (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000629">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zeHMnNtEfAb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Business
Segment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the &#x201c;management approach&#x201d; to identify its reportable segments in accordance with ASC 280, Segment Reporting.
The management approach requires companies to report segment financial information consistent with the information regularly reviewed
by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) for purposes of making operating decisions and assessing performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company&#x2019;s Chief Executive
Officer serves as the CODM. The CODM evaluates financial performance and allocates resources based on the operating results of the Company&#x2019;s
reportable segments. Effective October 1, 2025, the Company operates through two reportable segments: (i) its premium nutritional supplements,
and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CODM assesses segment performance primarily based on segment net loss (income). Selling, general and administrative expenses are directly
attributable to segments or allocated based on reasonable and consistently applied methodologies. Corporate and other expenses that are
not allocated to reportable segments consist primarily of public company costs, certain executive compensation, certain stock-based compensation,
interest income (expense), other income (expense), and income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
identification of two reportable segments reflects the manner in which the CODM reviews financial information and allocates resources.
Prior-period information has been recast to conform to the current presentation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000631">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_z71Fe3Gq1gai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preparing
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues
and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other
assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
estimates during the years ended December 31, 2025 and 2024, respectively, include valuation of stock-based compensation, uncertain tax
positions, the valuation of debt instruments, and the valuation allowance on deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000633">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z9uzzPpbcwEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers all highly liquid
investments that have maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents consist
primarily of cash on deposit with financial institutions and amounts held in high-yield savings accounts. The Company maintains its
cash balances with high-credit-quality financial institutions. At times, such balances may exceed federally insured limits provided
by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). In 2025, the Company has implemented a deposit insurance program
in the Company&#x2019;s primary account, whereby funds in excess of FDIC insurance limits are insured.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, the cash balances not subject to insurance or that exceed the FDIC limit of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20251231_z2XBGEHdTW4k" title="Cash FDIC limit"&gt;250,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were
$&lt;span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_c20251231_zrb52hWhkjVj" title="Cash uninsured amount"&gt;0&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_900_eus-gaap--CashUninsuredAmount_iI_c20241231_zdi2rs3X13h" title="Cash uninsured amount"&gt;3,519,510&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000635"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000637"
      unitRef="USD">0</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000639"
      unitRef="USD">3519510</us-gaap:CashUninsuredAmount>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000641">&lt;p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zBgutkNtGN7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
is stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out (&#x201c;FIFO&#x201d;) method.
Inventory consists primarily of raw materials, work-in-process, and finished goods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically reviews inventory quantities on hand and records reserves for excess, obsolete, or slow-moving inventory based on
its assessment of forecasted demand, product shelf life, market conditions, and other factors. Inventory reserves are recorded as a reduction
of inventory and are based on management&#x2019;s estimates regarding the recoverability of inventory balances. If actual demand or market
conditions differ from those projected by management, additional inventory write-downs may be required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000643">&lt;p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zctLCczDjsM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_861_zL4bxtMLJEki"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue is recognized when
control of promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to
be entitled to in exchange for those goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines revenue recognition through
the following five-step model: (i) identification of the contract with a customer; (ii) identification of the performance obligations
in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations;
and (v) recognition of revenue when, or as, the Company satisfies a performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Product Revenue&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company generates revenue from the sale of its
products. Product revenue is recognized when control of the product is transferred to the customer, which generally occurs upon shipment
or delivery, depending on the terms of the arrangement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue is recorded net of variable consideration,
including estimates for product returns, rebates, chargebacks, discounts, and other allowances. The Company estimates variable consideration
at the time of sale based on historical experience, current market conditions, and contractual terms, and includes such estimates in the
transaction price only to the extent that it is probable that a significant reversal of revenue will not occur in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates whether it is the principal
or agent in its arrangements and records revenue on a gross or net basis accordingly. Shipping and handling activities are considered
fulfillment activities, and the related costs are recorded in cost of goods sold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <JUNS:PrepaidContractsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000645">&lt;p id="xdx_841_ecustom--PrepaidContractsPolicyTextBlock_zUjYtMyKAlug" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prepaid
Contracts&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
contracts generally represent service agreements which the Company would receive services over a period of time and are expensed as the
services are received. The Company&#x2019;s prepaid contracts are related to service agreements that span over three years, therefore
the expense will be recognized over the three year term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</JUNS:PrepaidContractsPolicyTextBlock>
    <JUNS:OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000647">&lt;p id="xdx_84C_ecustom--OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock_zm1fAWpp2DAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Prepaid
Expenses and Other Current Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets generally represent payments made for goods or services to be received within one year and are expensed
as the related benefit is received.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</JUNS:OtherCurrentAssetsAndPrepaidExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-12-31" id="Fact000649">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOo5FZckfc4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based
on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, monitoring visits, clinical site
activations, or information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. Total research and development costs
for the years ended December 31, 2025 and 2024 were $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20250101__20251231_z4bv9rhUXN2f" title="Research and development costs"&gt;2,086,574&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20241231_zPLzHX7co2N8" title="Research and development costs"&gt;492,660&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000651"
      unitRef="USD">2086574</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">492660</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000655">&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zYzetmBaJwui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis
of our assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws
on deferred taxes, if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial
statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence,
it is more likely than not that some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. As of December 31, 2025 and
2024, the Company concluded that a full valuation allowance is necessary for the net deferred tax assets. The Company had no material
amounts recorded for uncertain tax positions, interest or penalties in the accompanying financial statements. The Company is subject
to taxation in the U.S. Our tax years for 2021 and forward are subject to examination by tax authorities. The Company is not currently
under examination by any tax authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000657">&lt;p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zv4AC6zD9c9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Loss
Per Share of Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common
stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which
would result in the issuance of incremental shares of common stock, as calculated using the treasury method. In computing the basic and
diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations
due to the fact that when a net loss exists, dilutive shares are not included in the calculation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, there were &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_do_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zK558zCe6Ttk" title="Warrants Outstanding"&gt;no&lt;/span&gt; warrants outstanding, &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z7iZQKQBF9wi" title="Restricted stock units"&gt;1,626,037&lt;/span&gt; restricted stock units and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zg6EHqelJngb" title="Number of stock options"&gt;11,726,093&lt;/span&gt; stock options. These securities
are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there were &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZ4WJ1KhMMmb" title="Warrants Outstanding"&gt;1,359,375&lt;/span&gt; warrants outstanding, &lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zzqvaEojyWX" title="Restricted stock units"&gt;1,626,037&lt;/span&gt; restricted stock units and &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfitikcTDajk" title="Number of stock options"&gt;10,633,988&lt;/span&gt; stock options. These
securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000659"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000661"
      unitRef="Shares">1626037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">11726093</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">1359375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000667"
      unitRef="Shares">1626037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000669"
      unitRef="Shares">10633988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000671">&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zlwYPch16Jje" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records stock-based compensation equal to the grant date fair value of the stock awards issued. For stock options issued to
employees, non-employees and members of our board of directors, the Company estimates the grant-date fair value of options using the
Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with
respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the
option, risk-free interest rates, and, for grants prior to our initial public offering, the value of the common stock. For awards
subject to time-based vesting, the Company recognized stock-based compensation expense, on a straight-line basis over the requisite
service period, which is generally the vesting term of the award.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <JUNS:ClinicalTrialExpensesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000673">&lt;p id="xdx_84E_ecustom--ClinicalTrialExpensesPolicyTextBlock_zP79s9OeFwDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Clinical
Trial Expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the process of preparing our financial statements, the Company is required to estimate expenses resulting from obligations under
contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#x2019;s
objective is to reflect the appropriate trial expenses in the financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured
by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates based on estimates of
services received and efforts expended that take into account discussion with applicable personnel and outside service providers as to
the progress or state of consummation of trials. During the course of a clinical trial, the Company adjusts the clinical expense recognition
if actual results differ from its estimates. The Company makes estimates of the accrued expenses as of each balance sheet date based
on the facts and circumstances known at that time. The clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect the estimates to be materially different
from amounts actually incurred, understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low for any particular period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</JUNS:ClinicalTrialExpensesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000675">&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztnATQTFkhUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value of Financial Instruments and Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and
cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their
short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current
interest rates available for debt with similar terms and maturities are substantially the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring
fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all
other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related
to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income
approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement
cost).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad
levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us,
which reflect those that a market participant would use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value of Financial Instruments and Fair Value Measurements, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also
see Note 5 - Convertible Debt and &lt;span id="xdx_908_ecustom--DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_zjcfYYWrQ0Ce" title="Derivative liabilities current not disclosed flag"&gt;Derivative Liability&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <JUNS:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000677">true</JUNS:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000679">&lt;p id="xdx_845_eus-gaap--DerivativesPolicyTextBlock_zdrcpHOOBB16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Derivative
Instruments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
Topic 815, Derivatives and Hedging (&#x201c;ASC Topic 815&#x201d;), establishes accounting and reporting standards for derivative instruments
and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or
losses resulting from changes in the fair value of derivatives are recognized in earnings. On the date of conversion or payoff of debt,
the Company records the fair value of the conversion shares, removes the fair value of the related derivative liability, removes any
discounts and records a net gain or loss on debt extinguishment. On January 1, 2020, the Company adopted ASU 2017-11 under which down-round
Features in Financial Instruments will no longer cause derivative treatment. The Company applies the modified prospective method of adoption.
There were no cumulative effects on adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <JUNS:ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000681">&lt;p id="xdx_840_ecustom--ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock_zOs0iAUFwPz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible
Notes with Embedded Derivative Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and
accrued interest may be converted, by the holder, into shares of common stock at a fixed discount to the price of the common stock at
or around the time of conversion upon certain trigger events. The Company evaluates all its financial instruments to determine if those
contracts or any potential embedded components of those contracts qualify as derivatives. This accounting treatment requires that the
carrying amount of any derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event
that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded
as either other income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value
at the conversion, repayment, or exercise date and then the related fair value amount is reclassified to other income or expense as part
of gain or loss on debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; Significant Accounting Policies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</JUNS:ConvertibleNotesWithEmbeddedDerivativeLiabilitiesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000683">&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_zYwY2r4SabCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based
on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit
rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present
value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included
in general and administrative expenses in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000685">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIAJishjMKl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recent
Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the
periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted
accounting principles and do not believe that any new or modified principles will have a material impact on the Company&#x2019;s reported
financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company&#x2019;s
financial management.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer serves as the CODM.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;)
No. 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;. ASU 2023-09 enhances income tax disclosures by
adding more granular, jurisdiction-specific information, especially for investors and analysts. The amendments in ASU 2023-09 are
effective for public business entities for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09
effective January 1, 2025 on a prospective basis. The Company plans to adopt this update during the year ended December 31, 2026.
Beyond the expanded, required disclosures, management does not believe that this will have a material impact on the Company&#x2019;s
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
other newly issued accounting pronouncements that are not yet effective have been deemed immaterial or nonapplicable.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000687">&lt;p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z20AIeyHahVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82A_z3EEY0BLU5T3"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer (CEO) has loaned the Company working capital since inception. The balance of the loans to
the CEO as of December 31, 2024 was $&lt;span id="xdx_904_eus-gaap--LoansPayable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zClC1YMMPeqj"&gt;146,432&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The loan was due on demand and accrues interest at &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_znIZoz0lUyUc"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
per year. Accrued interest relating to the loan was $&lt;span id="xdx_907_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zGVYBwrcK944"&gt;1,064&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as
of December 31, 2024, and is included in accrued interest on the accompanying 2024 balance sheets. The Company fully settled the
debt in 2025 by repaying a total of $&lt;span id="xdx_900_eus-gaap--RepaymentsOfLongTermDebt_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zZSpWG7aIkr6"&gt;150,782&lt;/span&gt;&lt;/span&gt;,
$&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zoEIpUJU4mI3"&gt;146,432&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
principal and $&lt;span id="xdx_901_ecustom--InterestPayable_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zmZcu48NNGn7"&gt;4,350&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
accrued interest. The Company repaid a total of $&lt;span id="xdx_90C_eus-gaap--RepaymentsOfLongTermDebt_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z2sjP4lcQRKc"&gt;100,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;during
the year ended December 31, 2024, $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zL29YPmsObl8"&gt;83,880&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
principal and $&lt;span id="xdx_909_ecustom--InterestPayable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zMmiuRTuemse"&gt;16,120&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
accrued interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2024, a former executive agreed to forgive $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlivuOi7dgY4" title="Share based compensation"&gt;100,000&lt;/span&gt; of accrued compensation in exchange for &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoAXJuehQ9b5" title="Share based compensation"&gt;49,605&lt;/span&gt; options to purchase common
stock and &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTTK7P8i3pbk" title="Restricted stock units"&gt;7,500&lt;/span&gt; restricted stock units, The options to purchase common stock have a strike price of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQQDoT0jjmo" title="Strike price"&gt;1.33&lt;/span&gt;. The option had a grant date
fair value of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240315__20240315_znOfnj052yCd" title="Share based compensation"&gt;50,000&lt;/span&gt;. The Company recorded a gain on the forgiveness of accrued compensation in the amount of $&lt;span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMr4kMoafU92" title="Accrued compensation"&gt;40,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 29, 2024, the Company, the Holder of the Note II (See Note 5 &#x2013; Convertible Debt and Derivative Liability) and the CEO entered
into an amendment in which the CEO agreed to exchange &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_z92gUHdyldH7"&gt;685,867&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares issued to the Holder in exchange for his related party
notes that accrued interest at &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_zOOoRaUJLkf6"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
that are due from the Company in an aggregate principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentIssuedPrincipal_c20240429__20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--NoteIIHolderMember_z2ZCsUxB3h1b"&gt;266,667&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and the Holder agreed to forfeit all rights to all additional
future shares from the Company that would of become due upon a qualified offering as well as the conversion option. Therefore, the principal
amount of the note was increased to $&lt;span id="xdx_908_eus-gaap--ConvertibleDebt_iI_c20240429__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zjSwVA8L8mq7"&gt;1,377,778&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and the exchange debt follows the requirements of Note II.
See Note 5 &#x2013; Convertible Debt and Derivative liability &#x2013; Senior Secured Note &#x2013; Formerly known as the Convertible Debt
I for more details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LoansPayable
      contextRef="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000688"
      unitRef="USD">146432</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact000689"
      unitRef="Pure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">1064</us-gaap:InterestExpense>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2025-01-012025-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000691"
      unitRef="USD">150782</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000692"
      unitRef="USD">146432</us-gaap:DebtInstrumentFaceAmount>
    <JUNS:InterestPayable
      contextRef="AsOf2025-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000693"
      unitRef="USD">4350</JUNS:InterestPayable>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="From2024-01-012024-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000694"
      unitRef="USD">100000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000695"
      unitRef="USD">83880</us-gaap:DebtInstrumentFaceAmount>
    <JUNS:InterestPayable
      contextRef="AsOf2024-12-31_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000696"
      unitRef="USD">16120</JUNS:InterestPayable>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-03-152024-03-15_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000698"
      unitRef="USD">100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-03-15_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000700"
      unitRef="Shares">49605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000702"
      unitRef="Shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000704"
      unitRef="USDPShares">1.33</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-03-152024-03-15"
      decimals="0"
      id="Fact000706"
      unitRef="USD">50000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-03-152024-03-15_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000708"
      unitRef="USD">40000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember"
      decimals="INF"
      id="Fact000709"
      unitRef="Shares">685867</us-gaap:SharesIssued>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember"
      decimals="INF"
      id="Fact000710"
      unitRef="Pure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2024-04-292024-04-29_srt_ChiefExecutiveOfficerMember_custom_NoteIIHolderMember"
      decimals="0"
      id="Fact000711"
      unitRef="USD">266667</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-04-29_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact000712"
      unitRef="USD">1377778</us-gaap:ConvertibleDebt>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000714">&lt;p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zi02KV5Bsx3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_821_zLEg1k9D97eb"&gt;Accounts Payable and Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgF4I1hpM9Df" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zbvC12QToor1"&gt;Schedule
of Accounts Payable and Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zbJtFhDt9NRe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zJk7rN6r3MZ6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALz5RX_zLxVIbAUWVDa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;131,130&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;278,676&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maAPAALz5RX_zXMhhWaW5k5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;467,167&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40,271&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_maAPAALz5RX_zwP7LvlqRHM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License
    fee&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0724"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALz5RX_zTf5RJXeUFQk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit
    cards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40,349&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,536&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALz5RX_ztQsVW3e5Dn1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;638,646&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;396,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zONAsDpMPiM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2025 and 2024, $&lt;span id="xdx_902_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zDkx5Hll3iH4" title="Accounts payable and accrued expenses owned"&gt;&lt;span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zVz5vWzlra1f" title="Accounts payable and accrued expenses owned"&gt;64,105&lt;/span&gt;&lt;/span&gt;
was due to a Company wholly owned by the Company&#x2019;s Chief Financial Officer, who also is an option holder, respectively. The amount
is included in accrued compensation on the Company&#x2019;s balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;Accrued
compensation of $&lt;span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zYkzNTQTzn7j" title="Accrued compensation"&gt;1,397,357&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zwg5Itr6Osf3" title="Accrued compensation"&gt;1,415,093&lt;/span&gt;
as of December 31, 2025 and 2024, respectively, includes accrued salaries and health benefits to executives since inception and
board fees. Since inception, executive salaries have been paid in cash when the Company&#x2019;s cash flow has permitted such
payment. By November 2022 the Company stopped paying salaries, although they continued to accrue, in an effort to conserve cash and
starting in the fourth quarter of 2023, the Company&#x2019;s executives agreed to reduce their salaries by &lt;span id="xdx_904_ecustom--ConserveCashPercentage_iI_dp_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zPqHfmDqeHjk"&gt;80&lt;/span&gt;%
until an initial public offering to limit the Company&#x2019;s compensation expenses. During December 2024, the Company returned to
paying salaries due to the completion of the initial public offering. See Note 3 &#x2013; Related Party Transactions for details
related to forgiveness of accrued compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000716">&lt;p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgF4I1hpM9Df" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zbvC12QToor1"&gt;Schedule
of Accounts Payable and Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zbJtFhDt9NRe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zJk7rN6r3MZ6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALz5RX_zLxVIbAUWVDa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts
    payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;131,130&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;278,676&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maAPAALz5RX_zXMhhWaW5k5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Professional
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;467,167&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40,271&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_maAPAALz5RX_zwP7LvlqRHM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License
    fee&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0724"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALz5RX_zTf5RJXeUFQk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit
    cards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;40,349&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,536&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALz5RX_ztQsVW3e5Dn1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;638,646&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;396,483&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000718"
      unitRef="USD">131130</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000719"
      unitRef="USD">278676</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000721"
      unitRef="USD">467167</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000722"
      unitRef="USD">40271</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000725"
      unitRef="USD">75000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000727"
      unitRef="USD">40349</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">2536</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">638646</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000731"
      unitRef="USD">396483</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact000733"
      unitRef="USD">64105</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact000735"
      unitRef="USD">64105</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2025-12-31_custom_EmploymentAgreementsMember"
      decimals="0"
      id="Fact000737"
      unitRef="USD">1397357</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2024-12-31_custom_EmploymentAgreementsMember"
      decimals="0"
      id="Fact000739"
      unitRef="USD">1415093</us-gaap:DeferredCompensationLiabilityCurrent>
    <JUNS:ConserveCashPercentage
      contextRef="AsOf2023-12-31_custom_EmploymentAgreementsMember"
      decimals="INF"
      id="Fact000740"
      unitRef="Pure">0.80</JUNS:ConserveCashPercentage>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000742">&lt;p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_z55ZLjxq6GNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_82B_zE7PrBDPX4x5"&gt;Convertible Debt and Derivative Liability&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Standby
Equity Purchase Agreement and 2025 Convertible Promissory Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 24, 2025, the Company entered into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) and related Registration Rights Agreement
with YA II PN, Ltd. (&#x201c;Yorkville&#x201d;), providing the Company the right, but not the obligation, to sell up to $&lt;span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20251024__20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_z9cwqs2naPYb" title="Sale of stock, consideration received on transaction"&gt;20.0&lt;/span&gt;&#160;million
of common stock from time to time, subject to customary conditions, including an effective resale registration statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the SEPA, Yorkville agreed to provide up to $&lt;span id="xdx_901_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn5n6_c20251024__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__dei--LegalEntityAxis__custom--YAIIPNLtdMember_zaqq9xkLJYM" title="Pre-paid advances via convertible promissory notes"&gt;6.0&lt;/span&gt;&#160;million of pre-paid advances via convertible promissory notes (the
&#x201c;2025 Notes&#x201d;). On October 27, 2025, the Company received $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0d_c20251027_z4edf7yy5ipj" title="Received debt amount"&gt;3,720,000&lt;/span&gt;&#160;and issued a $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20251027__20251027_zGawVMCyfmeb" title="Proceeds from issuance of debt"&gt;4.0&lt;/span&gt;&#160;million note (&lt;span id="xdx_907_ecustom--DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_iI_pid_dp_uPure_c20251027_zHU0c3bdfAs3" title="Original issue discount percentage"&gt;7&lt;/span&gt;% original
issue discount, &#x201c;OID&#x201d;). A second $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0d_c20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zXM7uEVAmKWg" title="Received debt amount"&gt;1,860,000&lt;/span&gt;&#160;tranche was received in December 2025, upon registration effectiveness and
receipt of stockholder approval, against a $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20251027__20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_z9x4DrExgXuc" title="Proceeds from issuance of debt"&gt;2.0&lt;/span&gt;&#160;million note (&lt;span id="xdx_90A_ecustom--DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage_iI_pid_dp_uPure_c20251027__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zN2tLY3DMp9a" title="Original issue discount percentage"&gt;7&lt;/span&gt;% OID). The notes bear interest at&#160;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20251027_zVexUaXwtMDk" title="Interest rate"&gt;8&lt;/span&gt;% (increasing to&#160;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20251027_zoh5Gwzr8Q08" title="Default interest rate"&gt;18&lt;/span&gt;%
upon default), mature on&#160;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20251027__20251027_zc6lgkThrb86" title="Debt instrument, maturity date"&gt;October 24, 2026&lt;/span&gt;, and are convertible at $&lt;span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20251027_zonevFYqNhBe" title="Debt instrument, convertible, conversion price"&gt;1.50&lt;/span&gt;&#160;per share, subject to proportional anti-dilution and
price-protection adjustments (not below a contractual floor).&#160;&lt;span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20251027__20251027_z93PKPYyuqEg" title="Repayments of debt description"&gt;Beginning January 7, 2026, and monthly thereafter, the Company must
repay one-tenth (1/10) of the then-outstanding principal plus accrued interest (a 5% premium applies to cash repayments).&lt;/span&gt;&#160;Installments
may be satisfied via SEPA advances without the premium, and SEPA proceeds must be applied first to repay the notes until they are repaid
in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As consideration for Yorkville&#x2019;s commitment to purchase common stock at the Company&#x2019;s direction pursuant
the SEPA, the Company (i) paid to Yorkville a cash &#x201c;structuring fee&#x201d; in the amount of $&lt;span id="xdx_900_ecustom--StructuringFee_iI_c20251023_z424tF4py8Cg"&gt;25,000&lt;/span&gt; and (ii) upon execution of the
SEPA, issued to Yorkville &lt;span id="xdx_90D_ecustom--CommitmentShares_iI_c20251023_zLV8fYfJyIuf"&gt;131,909&lt;/span&gt; Commitment Shares, which have a &lt;span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20250101__20251231_zSOPNkR1lVp8"&gt;total aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#x2019;s
$20.0 million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $1.5162 per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 20, 2026, the Company and Yorkville entered into an Omnibus Amendment (the &#x201c;Amendment&#x201d;). Among other changes, the
Amendment revises the terms of the convertible promissory notes to defer the commencement of monthly installment payments to April 1,
2026, effectively providing an extension of approximately three months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Convertible Notes include features that allow for settlement through either (i) cash repayment or (ii) issuance of common stock at variable
or fixed conversion prices, subject to certain contractual terms, including a floor price and installment-based repayment structure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Convertible Notes are classified as a Level III liability within the fair value hierarchy, as their valuation
is based on significant unobservable inputs and assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company elected the fair value option for the Convertible Notes upon issuance. As such, the Convertible Notes are measured at fair value
at inception and remeasured at each reporting date, with changes in fair value recognized in earnings. The fair value of the Convertible
Notes was determined using a Monte Carlo simulation model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
valuation approach incorporates multiple potential stock price paths over the contractual term, the Company&#x2019;s ability to settle
in shares or cash, the note holder&#x2019;s ability to convert at a fixed price, variable conversion features tied to market prices, and
contractual floors and share caps.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
model simulates a large number of potential outcomes and calculates the expected fair value based on probability-weighted results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The convertible notes accounted for under the fair value election are each debt host financial instruments containing
embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently
remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the 2025
Notes are recorded as a component of Other (expense) income in the consolidated statements of operations, except that the change in estimated
fair value attributable to a change in the instrument-specific credit risks is recognized as a component of other comprehensive income.
The instrument specific credit risk associated with the 2025 Notes was de minimis. As a result of electing the fair value method, issuance
costs related to the 2025 Notes, including the structuring fee and the commitment fee were expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zZjmGzpO4Tqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following key assumptions were used in the valuation at each measurement date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_ztawSNgjk8B8" style="display: none"&gt;Schedule of Key
Assumptions in Valuation Measurement&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Assumption&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Issuance (Oct 24, 2025)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 24, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 22%"&gt;Stock Price (VWAP)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;$&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_z6zqdjmPkC2d" title="Convertible debt instrument, measurement input"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;$&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zz2rgLQAc6If" title="Convertible debt instrument, measurement input"&gt;1.09&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center; padding-left: 0.75pt"&gt;$&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zEq8fow7nKKa" title="Convertible debt instrument, measurement input"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;~&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zw33tuNrwNCf" title="Convertible debt instrument, measurement input"&gt;65&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;~&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zMR8jk3hI3bi" title="Convertible debt instrument, measurement input"&gt;65&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.75pt"&gt;~&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zVPFAZN72g2k" title="Convertible debt instrument, measurement input"&gt;65&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-Free Rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zkBe8G0ONahf" title="Convertible debt instrument, measurement input"&gt;3.4&lt;/span&gt;% &#x2013; &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zWPF9urOxwe2" title="Convertible debt instrument, measurement input"&gt;4.5&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zIYQNgWk4G9g" title="Convertible debt instrument, measurement input"&gt;3.5&lt;/span&gt;% &#x2013; &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zgAx6149QJnk" title="Convertible debt instrument, measurement input"&gt;4.6&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.75pt"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zcBydmO7hgP2" title="Convertible debt instrument, measurement input"&gt;3.4&lt;/span&gt;% &#x2013; &lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zkoIh03rIg2h" title="Convertible debt instrument, measurement input"&gt;4.7&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation Technique&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Monte Carlo Simulation&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Monte Carlo Simulation&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.75pt"&gt;Monte Carlo Simulation&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z7uIzzqoNuE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility
was estimated using a combination of the Company&#x2019;s historical volatility and that of comparable publicly traded companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At issuance, the initial
convertible promissory note was measured at a fair value of $&lt;span id="xdx_909_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20251231_zhTXwFh1zHPc" title="Convertible promissory note fair value"&gt;3,914,515&lt;/span&gt;. As of December 24, 2025, concurrent with the second tranche,
the fair value of the 2025 Notes was remeasured to $&lt;span id="xdx_90D_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20241231_zj0cuRCDGFle" title="Convertible promissory note fair value"&gt;5,225,670&lt;/span&gt;. As of December 31, 2025, the fair value of the 2025 Notes was $&lt;span id="xdx_904_eus-gaap--NotesPayableFairValueDisclosure_iI_c20251231_z46Mkq8Lhhag" title="Notes payable fair value"&gt;5,298,068&lt;/span&gt;.
Changes in fair value during the period were recognized in the Statements of Operations as Gain on change in fair value of convertible
notes. The original issue discounts totaling $&lt;span id="xdx_900_ecustom--OriginalIssueDiscounts_iI_c20241231_zlNdrgN4XVKf" title="Original issue discounts"&gt;420,000&lt;/span&gt; were incorporated into the initial and subsequent fair value measurements of the
2025 Notes. As of December 31, 2025, the outstanding principal balance on the 2025 Notes is $&lt;span id="xdx_90C_eus-gaap--OtherNotesPayableCurrent_iI_c20251231_zbR9XVQ7FBTd" title="Outstanding principal balance"&gt;6,000,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;For the year ended December
31, 2025, the Company recognized a net gain on change in fair value of convertible notes of $&lt;span id="xdx_905_eus-gaap--DerivativeGainLossOnDerivativeNet_c20250101__20251231_z9avYYW6CwA9"&gt;281,932&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025,
the Company incurred $&lt;span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20251231_zukm9Z5JmYEg" title="Accrued interest expense"&gt;61,723&lt;/span&gt; of interest expense and paid $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250101__20251231_zjokPsK6xFp3" title="Sale of stock, consideration received on transaction"&gt;22,251&lt;/span&gt; through the sale of &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231_ztAZRNDl5h0g" title="Sale of stock, consideration received on transaction, shares"&gt;20,000&lt;/span&gt; shares of common stock at an average price
of approximately $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20251231_zfqtBafAWCx5" title="Sale of stock exercise price"&gt;1.11&lt;/span&gt; through the SEPA. As of December 31, 2025, $&lt;span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20251231_z9DZVfhcEaY4" title="Accrued interest"&gt;39,829&lt;/span&gt; is accrued in Accrued interest on the Company&#x2019;s balance
sheets.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; Convertible Debt and Derivative Liability, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Convertible
Debt I&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
August and December 2021, the Company issued convertible notes (collectively, &#x201c;Notes I&#x201d;) totaling $&lt;span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zc5AToFmsBjg"&gt;527,650&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
originally maturing on &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20210801__20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zfdhuziK0eW1"&gt;July
31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;, with an interest rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_z8gCZqYa7xoe"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
Notes I featured an automatic conversion feature upon an IPO into Common Stock at &lt;span id="xdx_903_ecustom--OfferingPricePercentage_iI_dp_uPure_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5vfmYrKpESd"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of the IPO price. Various amendments extended the maturity, ultimately to December 31, 2024, and increased the interest rate to&#160;10%.
In December 2024, following a successful IPO, the then outstanding principal and accrued interest totaling &lt;/span&gt;$&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zB88PXUP0BJi"&gt;636,852&lt;/span&gt;
Notes I converted into &lt;span id="xdx_90F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20220806__20220806__us-gaap--DebtInstrumentAxis__custom--TwelveConvertiblePromissoryNotesMember_zYxjLGWIAeEe"&gt;227,447&lt;/span&gt;
shares of Common Stock at $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20241204__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebtOneMember_zOLPUgFCrZlg"&gt;2.80&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt; Convertible Debt II&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 11, 2022, the Company issued a senior secured convertible note (&#x201c;Note II&#x201d;) and&#160;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zq8gYmcVDmE8" title="Principal amount shares"&gt;514,403&lt;/span&gt;&#160;shares of Common Stock
for net proceeds of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromConvertibleDebt_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zyVsGAwQ5Wx" title="Common stock for net proceeds"&gt;977,333&lt;/span&gt;&#160;($&lt;span id="xdx_904_eus-gaap--OriginationOfLoanToPurchaseCommonStock_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zakPbx9FsH14" title="Origination costs"&gt;1,000,000&lt;/span&gt;&#160;less origination costs and an embedded discount). Note II had an original principal
of $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20220411__20220411__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_z2bneYZvT3S9"&gt;1,111,111&lt;/span&gt;. The original terms of Note II included, among other provisions, penalties and stock conversions at substantial discounts
upon default or qualified offerings. Various amendments were executed which extended principal repayment dates and increased repayment
premiums resulting in losses on debt extinguishment totaling $&lt;span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zbwAXYt656m7"&gt;887,946&lt;/span&gt;&#160;in 2023. On April 24, 2024, Note II was further modified,
removing the conversion feature, increasing principal to $1,377,778, and extending the maturity, resulting in a gain on modification
of $&lt;span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20240424__20240424__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_zN8HHSB32Wmj" title="Gain on modification"&gt;951,868&lt;/span&gt;&#160;and an increase to derivative liability of $&lt;span id="xdx_90B_eus-gaap--DerivativeLiabilities_iI_c20240424__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteConvertibleDebtTwoMember_ztNSckt2diCf" title="Derivative liabilities"&gt;407,494&lt;/span&gt;. Note II was fully repaid in December 2024 for $&lt;span id="xdx_90F_eus-gaap--SeniorNotes_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredNoteMember_zzszHWyRywvg" title="Senior notes"&gt;2,102,797&lt;/span&gt;, which
included all outstanding principal and accrued interest&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Convertible
Debt III&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 1, 2023, the Company issued a convertible note (&#x201c;Note III&#x201d;) with a principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zky8d8N4k0V5" title="Principal amount"&gt;150,000&lt;/span&gt;
in connection with an investor relations settlement, maturing &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20230301__20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYctXbPjbXv9" title="Maturity date"&gt;February
28, 2026&lt;/span&gt; and a compounding &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zuJr3fzcomMj" title="Annual percentage"&gt;5&lt;/span&gt;%
annual interest rate. In December 2024, the then outstanding balance of Note III totaling
$&lt;span id="xdx_90A_ecustom--ConvertibleAmountIntoSharesOfCommonStock_c20230301__20230301__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zqNQHHaqXjA2" title="Convertible amount into shares of common stock"&gt;178,386&lt;/span&gt;
was fully repaid, which included all then outstanding principal and accrued interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Interest&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, $&lt;span id="xdx_906_eus-gaap--RepaymentsOfConvertibleDebt_c20241201__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwAr5QCMZr74" title="Repayments of convertible debt"&gt;147,705&lt;/span&gt;,
was included in interest expense for the combined convertible Notes I, II and III on the accompanying 2024 statements of operations.
These notes were paid in full in December 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; Convertible Debt and Derivative Liability, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_905_ecustom--DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_dbT_c20250101__20251231_z7MrmsBuRRql" title="Derivative liabilities not disclosed flag"&gt;Derivative
Liability&lt;/span&gt; Pursuant to Convertible Debt&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the issuance of the Notes, the Company determined that the terms of Notes contain an embedded conversion option to be
accounted for as a derivative liability due to the Holder having the potential to gain value upon IPO. Accordingly, the embedded conversion
option contained in Notes was accounted for as derivative liability and debt discount at the date of issuance and has been adjusted to
fair value through earnings at each reporting date. The fair value of the embedded conversion option was determined using the Monte Carlo
valuation model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the derivative liabilities were revalued, and a $&lt;span id="xdx_901_ecustom--GainsOnExtinguishmentOfDebt_c20240101__20241231_zyXcAxUKzA94"&gt;857,723&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;adjustment
was recorded as a gain on extinguishment of debt to other expenses reflected in the accompanying statements of
operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also recorded $&lt;span id="xdx_90F_ecustom--DerivativeGainLossOnDerivative_di_c20240101__20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqrCzGuaMc4a"&gt;53,257&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;as a loss on the change in the fair value of the derivative
liability for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zxaosV9PMzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the derivative liability of Notes I, Note II and Note III was estimated using the Monte Carlo Valuation model at issuance
and each reporting period with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zJTLW9kZTMRe"&gt;Schedule
of Fair Value Derivative Liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzgg7OvEqJEf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    Rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTWGlRIHYyTh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPPcuzvNQns1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeCx1gVz7Dr5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityofIPOMember_zhRIXkuHMCsc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none"&gt;Derivative liability, measurement input&lt;/td&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: right"&gt;60&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_z6LK6yUlME65" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; Convertible Debt and Derivative Liability, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Derivative
Liability Pursuant to Convertible Debt, continued&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zkpSEa8BkWqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity of the derivative liabilities and the 2025 Notes, which represent the Level III fair value measurements, is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zQ1soMR95y4i" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Derivative Liability&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B7_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zkWV7fx884c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derivative
    Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025 Notes&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20240101__20241231_eus-gaap--DerivativeLiabilities_iS_zv7mgTsyHe4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,505,398&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_zf0qLnzUCsmi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value change&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;53,257&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_z0n48GcePhLe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Extinguishment
    of derivative liability - Note II&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,359,362&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DerivativeFairValueOfIssuance_zMnjWj8rj6gk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value at issuance on April 29, 2024 - Senior Secured Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;407,494&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RepaymentOfDerivativeLiability_zGA2cgMwOX7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Repayment
    of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(606,787&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DerivativeFairValueOfIssuance_zYmBfffLxOd" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left; padding-bottom: 1pt"&gt;Fair value at issuance&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; display: none; text-align: right"&gt;407,494&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zRW5qL6goF13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zA96k6M7cCoh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-weight: bold; padding-bottom: 2.5pt"&gt;Derivative liability Balance &lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Issuance of the 2025 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DerivativeFairValueOfIssuance_c20250101__20251231_z6c6mFrRavmj" style="width: 14%; text-align: right" title="Issuance of the 2025 Notes"&gt;5,580,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--GainLossDerivativeInstrumentsNetPretax_c20250101__20251231_z6CKR0DBCaO5" style="text-align: right" title="Fair value change"&gt;(281,932&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Balance at December 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--GainsLossesOfExtinguishmentOfDebt_iE_c20250101__20251231_z4gZnyRxcYhd" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at December 31, 2025"&gt;5,298,068&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_z2mSmHACZcga" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-10-242025-10-24_custom_StandbyEquityPurchaseAgreementMember_srt_MaximumMember"
      decimals="-5"
      id="Fact000744"
      unitRef="USD">20000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-10-24_custom_StandbyEquityPurchaseAgreementMember_custom_YAIIPNLtdMember"
      decimals="-5"
      id="Fact000746"
      unitRef="USD">6000000.0</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-10-27"
      decimals="0"
      id="Fact000748"
      unitRef="USD">3720000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-10-272025-10-27"
      decimals="-5"
      id="Fact000750"
      unitRef="USD">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <JUNS:DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage
      contextRef="AsOf2025-10-27"
      decimals="INF"
      id="Fact000752"
      unitRef="Pure">0.07</JUNS:DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="0"
      id="Fact000754"
      unitRef="USD">1860000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-10-272025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="-5"
      id="Fact000756"
      unitRef="USD">2000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <JUNS:DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage
      contextRef="AsOf2025-10-27_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact000758"
      unitRef="Pure">0.07</JUNS:DebtInstrumentOriginalIssueDiscountOriginalIssueDiscountPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2025-10-27"
      decimals="INF"
      id="Fact000760"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-10-27"
      decimals="INF"
      id="Fact000762"
      unitRef="Pure">0.18</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2025-10-272025-10-27" id="Fact000764">2026-10-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-10-27"
      decimals="INF"
      id="Fact000766"
      unitRef="USDPShares">1.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentDescription contextRef="From2025-10-272025-10-27" id="Fact000768">Beginning January 7, 2026, and monthly thereafter, the Company must
repay one-tenth (1/10) of the then-outstanding principal plus accrued interest (a 5% premium applies to cash repayments).</us-gaap:DebtInstrumentDescription>
    <JUNS:StructuringFee
      contextRef="AsOf2025-10-23"
      decimals="0"
      id="Fact000769"
      unitRef="USD">25000</JUNS:StructuringFee>
    <JUNS:CommitmentShares
      contextRef="AsOf2025-10-23"
      decimals="INF"
      id="Fact000770"
      unitRef="Shares">131909</JUNS:CommitmentShares>
    <us-gaap:OtherCommitmentsDescription contextRef="From2025-01-01to2025-12-31" id="Fact000771">total aggregate dollar value equal to $200,000, or 1.0% of Yorkville&#x2019;s
$20.0 million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $1.5162 per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).</us-gaap:OtherCommitmentsDescription>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000773">&lt;p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_zZjmGzpO4Tqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following key assumptions were used in the valuation at each measurement date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_ztawSNgjk8B8" style="display: none"&gt;Schedule of Key
Assumptions in Valuation Measurement&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Assumption&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;Issuance (Oct 24, 2025)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 24, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"&gt;December 31, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 22%"&gt;Stock Price (VWAP)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;$&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_z6zqdjmPkC2d" title="Convertible debt instrument, measurement input"&gt;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;$&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zz2rgLQAc6If" title="Convertible debt instrument, measurement input"&gt;1.09&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center; padding-left: 0.75pt"&gt;$&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zEq8fow7nKKa" title="Convertible debt instrument, measurement input"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;~&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zw33tuNrwNCf" title="Convertible debt instrument, measurement input"&gt;65&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;~&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zMR8jk3hI3bi" title="Convertible debt instrument, measurement input"&gt;65&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.75pt"&gt;~&lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember_zVPFAZN72g2k" title="Convertible debt instrument, measurement input"&gt;65&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-Free Rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zkBe8G0ONahf" title="Convertible debt instrument, measurement input"&gt;3.4&lt;/span&gt;% &#x2013; &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251024__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zWPF9urOxwe2" title="Convertible debt instrument, measurement input"&gt;4.5&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zIYQNgWk4G9g" title="Convertible debt instrument, measurement input"&gt;3.5&lt;/span&gt;% &#x2013; &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251224__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zgAx6149QJnk" title="Convertible debt instrument, measurement input"&gt;4.6&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.75pt"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MinimumMember_zcBydmO7hgP2" title="Convertible debt instrument, measurement input"&gt;3.4&lt;/span&gt;% &#x2013; &lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__us-gaap--MonteCarloModelMember__srt--RangeAxis__srt--MaximumMember_zkoIh03rIg2h" title="Convertible debt instrument, measurement input"&gt;4.7&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation Technique&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Monte Carlo Simulation&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Monte Carlo Simulation&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.75pt"&gt;Monte Carlo Simulation&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-10-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember"
      decimals="INF"
      id="Fact000775"
      unitRef="Segments">1.50</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-24_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Segments">1.09</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-31_us-gaap_MeasurementInputSharePriceMember_us-gaap_MonteCarloModelMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Segments">0.99</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-10-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Pure">65</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-24_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Pure">65</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-31_us-gaap_MeasurementInputOptionVolatilityMember_us-gaap_MonteCarloModelMember"
      decimals="INF"
      id="Fact000785"
      unitRef="Pure">65</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000787"
      unitRef="Pure">3.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-10-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Pure">4.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Pure">3.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-24_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000793"
      unitRef="Pure">4.6</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Pure">3.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2025-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_MonteCarloModelMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Pure">4.7</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000799"
      unitRef="USD">3914515</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000801"
      unitRef="USD">5225670</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000803"
      unitRef="USD">5298068</us-gaap:NotesPayableFairValueDisclosure>
    <JUNS:OriginalIssueDiscounts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000805"
      unitRef="USD">420000</JUNS:OriginalIssueDiscounts>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000807"
      unitRef="USD">6000000</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000808"
      unitRef="USD">281932</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000810"
      unitRef="USD">61723</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000812"
      unitRef="USD">22251</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000814"
      unitRef="Shares">20000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000816"
      unitRef="USDPShares">1.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000818"
      unitRef="USD">39829</us-gaap:InterestPayableCurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000819"
      unitRef="USD">527650</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2021-08-012021-12-31_custom_TwelveConvertiblePromissoryNotesMember"
      id="Fact000820">2022-07-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact000821"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <JUNS:OfferingPricePercentage
      contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Pure">0.70</JUNS:OfferingPricePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-12-31_custom_TwelveConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000823"
      unitRef="USD">636852</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2022-08-062022-08-06_custom_TwelveConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact000824"
      unitRef="USD">227447</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-12-04_custom_ConvertibleDebtOneMember"
      decimals="INF"
      id="Fact000825"
      unitRef="USDPShares">2.80</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Shares">514403</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">977333</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:OriginationOfLoanToPurchaseCommonStock
      contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">1000000</us-gaap:OriginationOfLoanToPurchaseCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-04-112022-04-11_custom_SeniorSecuredNoteConvertibleDebtTwoMember"
      decimals="0"
      id="Fact000832"
      unitRef="USD">1111111</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_custom_SeniorSecuredNoteConvertibleDebtTwoMember"
      decimals="0"
      id="Fact000833"
      unitRef="USD">887946</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-04-242024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember"
      decimals="0"
      id="Fact000835"
      unitRef="USD">951868</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-04-24_custom_SeniorSecuredNoteConvertibleDebtTwoMember"
      decimals="0"
      id="Fact000837"
      unitRef="USD">407494</us-gaap:DerivativeLiabilities>
    <us-gaap:SeniorNotes
      contextRef="AsOf2024-12-31_custom_SeniorSecuredNoteMember"
      decimals="0"
      id="Fact000839"
      unitRef="USD">2102797</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000841"
      unitRef="USD">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-03-012023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember"
      id="Fact000843">2026-02-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000845"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <JUNS:ConvertibleAmountIntoSharesOfCommonStock
      contextRef="From2023-03-012023-03-01_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000847"
      unitRef="USD">178386</JUNS:ConvertibleAmountIntoSharesOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2024-12-012024-12-31_custom_ConvertiblePromissoryNoteMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000849"
      unitRef="USD">147705</us-gaap:RepaymentsOfConvertibleDebt>
    <JUNS:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000851">true</JUNS:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <JUNS:GainsOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000852"
      unitRef="USD">857723</JUNS:GainsOnExtinguishmentOfDebt>
    <JUNS:DerivativeGainLossOnDerivative
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact000853"
      unitRef="USD">-53257</JUNS:DerivativeGainLossOnDerivative>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000855">&lt;p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zxaosV9PMzMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the derivative liability of Notes I, Note II and Note III was estimated using the Monte Carlo Valuation model at issuance
and each reporting period with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zJTLW9kZTMRe"&gt;Schedule
of Fair Value Derivative Liability&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzgg7OvEqJEf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    Rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zTWGlRIHYyTh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zPPcuzvNQns1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeCx1gVz7Dr5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_hus-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityofIPOMember_zhRIXkuHMCsc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none"&gt;Derivative liability, measurement input&lt;/td&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: right"&gt;60&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000862">&lt;p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_zkpSEa8BkWqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity of the derivative liabilities and the 2025 Notes, which represent the Level III fair value measurements, is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zQ1soMR95y4i" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Derivative Liability&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B7_us-gaap--FinancialInstrumentAxis_us-gaap--DerivativeMember_zkWV7fx884c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derivative
    Liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2025 Notes&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20240101__20241231_eus-gaap--DerivativeLiabilities_iS_zv7mgTsyHe4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,505,398&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GainLossOnDerivativeInstrumentsNetPretax_zf0qLnzUCsmi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value change&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;53,257&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_z0n48GcePhLe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Extinguishment
    of derivative liability - Note II&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,359,362&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DerivativeFairValueOfIssuance_zMnjWj8rj6gk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    value at issuance on April 29, 2024 - Senior Secured Note&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;407,494&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RepaymentOfDerivativeLiability_zGA2cgMwOX7j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Repayment
    of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(606,787&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DerivativeFairValueOfIssuance_zYmBfffLxOd" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; text-align: left; padding-bottom: 1pt"&gt;Fair value at issuance&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; display: none; text-align: right"&gt;407,494&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zRW5qL6goF13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;$&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;p style="margin: 0"&gt;-&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_431_c20241001__20241231_eus-gaap--DerivativeLiabilities_iE_zA96k6M7cCoh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; font-weight: bold; padding-bottom: 2.5pt"&gt;Derivative liability Balance &lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Issuance of the 2025 Notes&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DerivativeFairValueOfIssuance_c20250101__20251231_z6c6mFrRavmj" style="width: 14%; text-align: right" title="Issuance of the 2025 Notes"&gt;5,580,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--GainLossDerivativeInstrumentsNetPretax_c20250101__20251231_z6CKR0DBCaO5" style="text-align: right" title="Fair value change"&gt;(281,932&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Balance at December 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--GainsLossesOfExtinguishmentOfDebt_iE_c20250101__20251231_z4gZnyRxcYhd" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at December 31, 2025"&gt;5,298,068&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_DerivativeMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">1505398</us-gaap:DerivativeLiabilities>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember"
      decimals="0"
      id="Fact000866"
      unitRef="USD">53257</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember"
      decimals="0"
      id="Fact000868"
      unitRef="USD">-1359362</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <JUNS:DerivativeFairValueOfIssuance
      contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember"
      decimals="0"
      id="Fact000870"
      unitRef="USD">407494</JUNS:DerivativeFairValueOfIssuance>
    <JUNS:RepaymentOfDerivativeLiability
      contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">-606787</JUNS:RepaymentOfDerivativeLiability>
    <JUNS:DerivativeFairValueOfIssuance
      contextRef="From2024-01-012024-12-31_us-gaap_DerivativeMember"
      decimals="0"
      id="Fact000874"
      unitRef="USD">407494</JUNS:DerivativeFairValueOfIssuance>
    <JUNS:DerivativeFairValueOfIssuance
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000880"
      unitRef="USD">5580000</JUNS:DerivativeFairValueOfIssuance>
    <JUNS:GainLossDerivativeInstrumentsNetPretax
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000882"
      unitRef="USD">-281932</JUNS:GainLossDerivativeInstrumentsNetPretax>
    <JUNS:GainsLossesOfExtinguishmentOfDebt
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000884"
      unitRef="USD">5298068</JUNS:GainsLossesOfExtinguishmentOfDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000886">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zQGf1aAT0CZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_821_z87whnGTb7S2"&gt;Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20251231_zG5x0qPt3uOi" title="Common stock, shares authorized"&gt;500,000,000&lt;/span&gt; shares of common stock and &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20251231_zAFdRhxKI5Ib" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; shares of preferred stock. The Company had &lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20251231_z4zWjqx7lDT5" title="Common stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20251231_zE0IA1GrOvmf" title="Common stock, shares outstanding"&gt;34,446,455&lt;/span&gt;&lt;/span&gt;
shares of common stock issued and outstanding as of December 31, 2025. There was &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_dxL_c20251231_zcKDFJDbtu5g" title="Preferred stock, shares issued::XDX::-"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_dxL_c20251231_zmYqnMyN8Q8c" title="Preferred stock, shares outstanding::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0896"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; preferred stock issued and outstanding as of December
31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On October 24, 2025, As consideration
for Yorkville&#x2019;s commitment to purchase common stock at the Company&#x2019;s direction pursuant the SEPA, the Company, upon execution
of the SEPA, issued to Yorkville &lt;span id="xdx_90E_ecustom--CommitmentShares_iI_c20251024_zgzNgvfMm5Jk" title="Commitment shares issued"&gt;131,909&lt;/span&gt; Commitment Shares, which have a total aggregate dollar value equal to $&lt;span id="xdx_90E_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20251024_zUmFTyQB4YKb" title="Commitment shares issued value"&gt;200,000&lt;/span&gt;, or 1.0% of Yorkville&#x2019;s
$&lt;span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20251024__20251024_zr3Q9X4848eb" title="Purchase commitment"&gt;20.0&lt;/span&gt; million aggregate purchase commitment under the SEPA (each Commitment Share valued at approximately $&lt;span id="xdx_905_ecustom--PurchaseCommitmentPerShare_iI_pid_c20251024_zQT5Kg6BmsTh" title="Purchase commitment per share"&gt;1.5162&lt;/span&gt; per share, representing
the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the nearest whole share).&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On April 23, 2025, the Company issued&#160;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250423__20250423__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUQWNfaeIZmb" title="Number of shares issued for service rendered"&gt;103,186&lt;/span&gt;&#160;shares
of common stock, with an aggregate fair value of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250423__20250423__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYpXnjxYfhC6" title="Shares issued for services rendered"&gt;66,000&lt;/span&gt;, as consideration for services rendered related to media and investor relations
activities, strategic communications support, enhancement to the Company&#x2019;s market visibility and shareholder engagement. The fair
value of the shares issued was determined based on the market price of the Company&#x2019;s common stock at the date of issuance and is
included general and administrative expenses in the accompanying 2024 condensed consolidated statement of operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 3, 2024, the Company entered into a three 36-month service agreement with three different entities. The Company issued an
aggregate of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXqS2fU3MFMd" title="Number of restricted shares issued"&gt;3,487,500&lt;/span&gt;
restricted shares of common stock, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityOneMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKwDyz7i2gE1" title="Number of restricted shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityTwoMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ0UOAS2b5c6" title="Number of restricted shares issued"&gt;&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--EntityThreeMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3zjAQ0G1se9" title="Number of restricted shares issued"&gt;1,162,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
restricted shares of common stock to each entity. The shares were registered upon the Company&#x2019;s offering that closed in
December 2024. In addition, each of the entities purchased &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zroF6PRagc89" title="Number of shares issued"&gt;37,500&lt;/span&gt;
shares each of the Company&#x2019;s common stock at a price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_c20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zejSB4UeA4F1" title="Share price"&gt;1.33&lt;/span&gt;
per share prior to the occurrence of the Company&#x2019;s offering. As of December, 31, 2024, the Company issued &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrDGspk8nJHg" title="Aggregate sale of common stock, shares"&gt;112,500&lt;/span&gt;
common stock and the Company received an aggregate of $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5Ej78PzTJ6c" title="Aggregate sale of common stock, value"&gt;150,000&lt;/span&gt;
for the sale of the Company&#x2019;s common stock from the three entities. These shares were also registered upon the closing of the
Company&#x2019;s offering. The aggregate value of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240603__20240603__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zay8tZNEUaMi" title="Number of restricted shares issued, value"&gt;4,638,375&lt;/span&gt;
related to the &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV9BE5tST4Vi" title="Number of restricted shares issued"&gt;3,487,500&lt;/span&gt;
restricted shares will be recognize as compensation expense from the date the obligations are met with the remaining expense being
amortized over the remaining term of the 36-months per the services agreements. As of December 31, 2025 and 2024, the Company
recorded compensation expense for services provided of $&lt;span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250101__20251231_z3xMMwWSMXy6" title="Compensation expense for services"&gt; 1,546,117 &lt;/span&gt;and $&lt;span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231_zLwt9URRUpY4" title="Compensation expense for services"&gt;893,781&lt;/span&gt;, respectively
related to the restricted shares issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 5 &#x2013; Convertible Debt and Derivative Liability for shares issued upon the conversion of the convertible notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See Note 8 &#x2013;
Commitment and Contingencies &#x2013; Service agreements for details related to sale of common stock per the service agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; Stockholders&#x2019; Equity (Deficit), continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Closing
of Offering&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 2, 2024, the Company priced its initial public offering of &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241202__20241202__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhDATFx95iSi" title="Number of shares for sale"&gt;2,750,000&lt;/span&gt; shares of common stock at a price of $&lt;span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20241202__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8SOxlpJOBk" title="Stock price per share"&gt;4.00&lt;/span&gt; per share. The
offering closed on December 4, 2024, and the Company started trading on the Nasdaq Capital Market under the ticker symbol &#x201c;JUNS&#x201d;.
The Company sold &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znOe1LbWrKlc" title="Sale of shares of common stock"&gt;2,750,000&lt;/span&gt; shares of its Common Stock to the underwriters and yielded proceeds of $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2k3alHBdUof" title="Gross proceeds from offering"&gt;9,725,213&lt;/span&gt;, net of underwriters and
other fees of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPRdladm3EZ6" title="Net proceeds from offering"&gt;1,274,787&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company grants stock awards to officers, employees, directors, and other key persons pursuant to its 2021 Equity Incentive Plan (&#x201c;the
Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025 and 2024, the Company recognized stock-based compensation of $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20251231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZiDnEsUWEEg" title="Stock based compensation"&gt;2,418,516&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLXhU9NG0ene" title="Stock based compensation"&gt;947,124&lt;/span&gt;, respectively,
related to vested stock options. There was $&lt;span id="xdx_901_eus-gaap--StockOptionPlanExpense_c20250101__20251231_zucCT5kiYDFj" title="Unvested stock options expense"&gt;697,835&lt;/span&gt; unvested stock options expense as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 24, 2024, the Company granted &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240124__20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJYonpO63oRb" title="Granted stock option purchase shares"&gt;180,000&lt;/span&gt; stock options to a consultant with an exercise price of $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240124__20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zalcYpiFldR1" title="Stock option exercise price"&gt;1.33&lt;/span&gt; per share. The option had
a grant date fair value of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240124__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF9vQs8o45K1" title="Grant date fair value"&gt;190,560&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 17, 2024, the Company granted &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240417__20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z84ue6jJaW5f" title="Granted stock option purchase shares"&gt;67,500&lt;/span&gt; stock options to a consultant with an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240417__20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zviUY4yWYtr9" title="Stock option exercise price"&gt;1.33&lt;/span&gt; per share. The option had a
grant date fair value of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240417__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbqXyleDtdYk" title="Grant date fair value"&gt;73,459&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 10, 2025, the Company granted&#160;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZy9qsNaIsi7" title="Granted stock option purchase shares"&gt;250,000&lt;/span&gt;&#160;stock options
to a consultant with an exercise price of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z03rLzrZRXP6" title="Stock option exercise price"&gt;0.97&lt;/span&gt;&#160;per share and a grant date fair value of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zN2ciPXaMxbf" title="Grant date fair value"&gt;191,168&lt;/span&gt;, and a&#160;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdYeOkL276Ye" title="Stock optons term"&gt;10&lt;/span&gt;-year term. The&#160;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250610__20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzK0eq38uyR6" title="Shares vesting percentage"&gt;25&lt;/span&gt;%
of the stock options vest immediately on the grant date, with the remaining&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250610__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKtDBMMR0qXk" title="Stock options vested"&gt;187,500&lt;/span&gt;&#160;options vesting in equal monthly installments
ratably beginning in July 2025 through May 2027.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 2, 2025, the Compensation Committee approved the grant of an
aggregate of&#160;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zWcqWFzRU6i6" title="Stock options issued"&gt;357,448&lt;/span&gt;&#160;stock options issued to certain executives. The stock options have an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_z27zRM49V2w2" title="Stock options exercise price"&gt;1.19&lt;/span&gt;&#160;per
share, representing the closing price of the Company&#x2019;s Common Stock on Nasdaq on the date of grant.&#160;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250702__20250702__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zJEBocLQPuy1" title="Vesting period description"&gt;The stock options have
a 10-year term and vest in equal installments over a three (3) year period beginning on the grant date of July 2, 2025, subject to the
officers&#x2019; continued employment at the time of vesting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 5, 2025, the Company granted an aggregate of&#160;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zrUmD6rqLCuf" title="Stock granted"&gt;374,755&lt;/span&gt;&#160;stock
options to two consultants with an exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zHu3IN2TmAP" title="Share price"&gt;1.23&lt;/span&gt;&#160;per share and a grant date fair value of $&lt;span id="xdx_908_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zAbMwqauwLnl" title="Fair value of grant date"&gt;340,900&lt;/span&gt;.&#160;The stock options
have a 10 year term and&#160;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250905__20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_zFk0JjqYmcTf" title="Stock options vest percentage"&gt;25&lt;/span&gt;% of the stock options vest immediately on the grant date, with&#160;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20250905__srt--TitleOfIndividualAxis__custom--TwoConsultantsMember_z4GDjMOnyxhb" title="Option vested"&gt;281,066&lt;/span&gt;&#160;options vesting in equal
monthly installments until September 5, 2027. The Company also granted&#160;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zCKRPbMmiyuc" title="Stock option granted"&gt;109,902&lt;/span&gt;&#160;stock options to one of the consultants with
an exercise price of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zYdAWJK9Ufx7" title="Exercise price"&gt;1.23&lt;/span&gt;&#160;per share and a grant date fair value of $&lt;span id="xdx_90C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zOwY6oMsIzPc" title="Fair value of grant date"&gt;100,000&lt;/span&gt;, and a&#160;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z6ApslNrAQ1f" title="Vested, term"&gt;10&lt;/span&gt;&#160;year term that vest solely upon
achievement of performance conditions as follows:&#160;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20250905__20250905__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zqNcLYW7jGy3" title="Vested performance description"&gt;(a) 15% per Ambassador (maximum of three) referred by consultant and subsequently
engaged by the Company, (b) 20% if consultant is instrumental in arranging a distribution arrangement not previously pursued by the Company,
on terms acceptable to the Company, (c) 20% when such Distribution Contract achieves $1 million in annual sales and (d) 15% when the consultant
arranges the first Celebrity Golf Tournament featuring Nugevia on terms and conditions acceptable to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 24, 2025, in connection with the SEPA and 2025 Convertible
Promissory Notes, the Company issued&#160;&lt;span id="xdx_90F_ecustom--CommitmentShares_iI_c20251024_zNDfLoJMluVb" title="Commitment shares issued"&gt;131,909&lt;/span&gt;&#160;commitment shares with an aggregate value of $&lt;span id="xdx_904_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20251024_zNxQkP1GHkJf" title="Commitment shares issued value"&gt;200,000&lt;/span&gt; to the Investor, Yorkville,
representing 1.0% of Yorkville&#x2019;s $&lt;span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_pn5n6_c20251024__20251024_z4LIZuQB8RQk" title="Purchase commitment"&gt;20.0&lt;/span&gt; million aggregate purchase commitment under the SEPA, valued at approximately $&lt;span id="xdx_905_ecustom--PurchaseCommitmentPerShare_iI_pid_c20251024_zA9mR6R6aVul" title="Purchase commitment per share"&gt;1.5162&lt;/span&gt; per
share, representing the VWAP on October 23, 2025, the trading day immediately prior to the date of execution of the SEPA, rounded to the
nearest whole share.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 3 &#x2013; Related Party Transactions above for details related to options issued for forgiveness of accrued salaries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGIcZinqgHIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity for the year ended December 31, 2025 and 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_z6s3DH6Vjt58" style="display: none"&gt;Schedule of Stock Option
Activity&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    of Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aggregate
    Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zRXeh9xhB171" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of options, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,336,883&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zAukIBM7RD9a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zppaUwdvfs8i" title="Weighted average contractual term (years), outstanding"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zH7OrpvCEv7i" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,316,119&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z94ZxPCocGK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;297,105&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zdJVy0WjK3R9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zEty7Y8rB6V9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zrQyyt533Jfi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1026"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231_zzcFG4oHYwNf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1028"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zHaH71PxMTjk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,633,988&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zvA4b86SDtvd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_zkWFd1akaaZg" title="Weighted average contractual term (years), outstanding"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zT6GrXlqqjmh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;102,921,147&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zx6zKK9KnB01" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,092,105&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_z5zfkOTmdqn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20251231_z1MkBB8ZEwCg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231_z86Tb45OlHj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250101__20251231_zn602cdUyKfl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1046"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zUFZwOun8Rwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231_zN1uQNHqhced" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,726,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zAXwfxu9PzVf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_zcgFvM8TTbh6" title="Weighted average contractual term (years), outstanding"&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_z9pjfgVpYrej" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,772,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20251231_zJdfhzxO7qE9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,874,222&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zWYnYIKqUDv7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_z92T0zqxWbE6" title="Weighted average contractual term (years), exercisable"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231_zeFIKVBO2SH5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,765,237&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zS8GgP8525Tf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,297,412&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zEvqKuMoU601" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_z6wDBZRYZwrb" title="Weighted average contractual term (years), exercisable"&gt;6.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240101__20241231_ze5LAHb52fya" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99,768,543&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zP0Gz6TLUdhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVtEFPVOCc4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarized information about employee stock options outstanding as of December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zr5t7TYd9Hvg" style="display: none"&gt;Schedule of Employee
Stock Options Outstanding&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Vested Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number Outstanding at December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Number Exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9lUQANknNKg" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price"&gt;0.01&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zinDiVfAqRFl" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z8FXJSD6j8Mj" title="Outstanding options, weighted average contractual term"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zw0U37LS9Vk8" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY9qy9o8xny5" title="Vested options, weighted average contractual term"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zIX9lQRSzhM5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.74&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxuUjg0j3Yj8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;1,657,560&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_znkzTAYxxTog" title="Outstanding options, weighted average contractual term"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2Ilpmuw6nc6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;1,657,560&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeQlgjxhvdOk" title="Vested options, weighted average contractual term"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zAuYWQpnOaTl" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.80&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4AmDF0JAXia" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;2,783,243&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zyixcQx7zNw9" title="Outstanding options, weighted average contractual term"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXqsfaTF4yV1" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;2,783,243&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zq1ybB4jri56" title="Vested options, weighted average contractual term"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zJaiFwLYgekh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.97&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zL3SV54Piocj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;250,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zP2ebCzUk369" title="Outstanding options, weighted average contractual term"&gt;9.42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWZVbDDqB2cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;111,412&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zU6mdI1AkD81" title="Vested options, weighted average contractual term"&gt;9.42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zot74KmHnvC8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.19&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zioSbChcwch2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;357,448&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zLtyDdRqBKo1" title="Outstanding options, weighted average contractual term"&gt;9.51&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoeu40klWFdh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zLehGVqy7CU7" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.23&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zGKnSBD394G5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;484,657&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zh8fC6psLWqd" title="Outstanding options, weighted average contractual term"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zzJuRHQAMwkg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;128,822&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zUhk8TBWNbhh" title="Vested options, weighted average contractual term"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z2BLbDR5XzAa" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.33&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zWH2r7yjm8Sc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;5,461,935&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z426LmVrFrL6" title="Outstanding options, weighted average contractual term"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z5vKDzu3cQG6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;5,461,935&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z9xUocfrltd4" title="Vested options, weighted average contractual term"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zCWfff1o9cy3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.16&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zZJ3jv16r4I9" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_ziA6nWOzWg7g" title="Outstanding options, weighted average contractual term"&gt;5.46&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zwtWFplqtor5" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zc4bj9IuSAEg" title="Vested options, weighted average contractual term"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231_zCPuvhn7yym4" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;11,726,093&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zTvaVvrr1C67" title="Outstanding options, weighted average remaining life"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231_zwJCzoNZt6Q3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;10,874,222&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zjxE8JNl1o0h" title="Vested options, weighted average remaining life"&gt;5.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Vested Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number Outstanding at December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Number Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqTYltrcy2e" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price"&gt;0.01&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqw3dafNIj4i" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXLu86SLEExa" title="Outstanding options, weighted average contractual term"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIS07948AUSd" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z7EWagbSK6La" title="Vested options, weighted average contractual term"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAcYrs8Y3Hfi" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.74&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zCM9gIgDE8P9" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;1,657,560&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrSrDnU8V5Ra" title="Outstanding options, weighted average contractual term"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxBDMkBYO4Cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;1,657,562&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zYMES0ehNuBi" title="Vested options, weighted average contractual term"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zy2B6FbHG1n3" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.8&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zOek3sbcecfc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;2,783,243&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmhEz33Ddbad" title="Outstanding options, weighted average contractual term"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zSRCp95gzeYd" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;2,783,238&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2GAh69BQpWg" title="Vested options, weighted average contractual term"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCn9DZQlTZah" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.33&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zvvoIopKWEn2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;5,461,935&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWG4ksZui5B9" title="Outstanding options, weighted average contractual term"&gt;8.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zxPtzl915dFj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;5,125,362&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zY8qsfToPjp5" title="Vested options, weighted average contractual term"&gt;8.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zHw1l0f826xe" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.16&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zPg6UNOzYGl6" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zMSqF69o5gdf" title="Outstanding options, weighted average contractual term"&gt;6.71&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoLf6vkragPg" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zkEq1e4Jf2Tg" title="Vested options, weighted average contractual term"&gt;6.71&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231_zerA8b9MNhE8" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;10,633,988&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zOQakm3BnRX4" title="Outstanding options, weighted average remaining life"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_z40TkNgv43fb" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;10,297,412&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_ztNWIX9ty3ze" title="Vested options, weighted average remaining life"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z11pWrNP2Rdh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_z0pCHvqoj6pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s warrant activity for the year ended December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z5tHIdeRHBYk" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNc8RiNKKA5f" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,359,375&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgijBH4VCrZ4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price per share, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjCprZX2OrMi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average remaining life (years), outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xMF0O7JPfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAfBgjnckLoj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN4XT3EFXoQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,359,375&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFlhOc9kK5Lj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUDZPLcUEEQ9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3bziOzm6Xw2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1238"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5Parh01sAAg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1240"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcCMUXTurClc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1242"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zFuTkXtT4jv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective June 22, 2025, the Company entered into an amendment with
a warrant holder for a warrant to purchase&#160;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250622__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zFx8WviDoIY6" title="Warrant issued"&gt;109,376&lt;/span&gt;&#160;shares of Common Stock. The amendment extended the warrant&#x2019;s exercise
period through August 31, 2025, and clarified the exercise mechanism applicable to the warrant. The effects of the warrant modification
were de minimis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 16, 2025 the Company entered into an amendment with a warrant
holder who holds&#160;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_ztrwTGbW5xw9" title="Warrant outstanding"&gt;1,249,999&lt;/span&gt;&#160;warrants that clarified the exercise mechanisms. Concurrently with the amendment, the warrant holder
exercised the warrants via a cashless exercise and received&#160;&lt;span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20250716__20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zmu2wAJsbMIk" title="Warrant exercised"&gt;913,299&lt;/span&gt;&#160;shares of Common Stock. Pursuant to the amendment, the Company
agreed to issue the warrant holder&#160;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250716__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zu12vCWSuwkf" title="Warrant issued"&gt;86,700&lt;/span&gt;&#160;shares of Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 12, 2025, the Company received an exercise notice from a
warrant holder who holds&#160;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_z5JWD2Vil4T4" title="Warrant outstanding"&gt;109,376&lt;/span&gt;&#160;warrants. The warrant was exercised via a cashless exercise, and the warrant holder received&#160;&lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20250812__20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_z9GQniyL2Ska" title="Warrant exercised"&gt;30,547&lt;/span&gt;&#160;shares
of Common Stock. Pursuant to the amended warrant agreement, the Company agreed to issue the warrant holder&#160;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250812__srt--TitleOfIndividualAxis__custom--WarrantHolderMember_zRuStVjLlfK8" title="Warrant issued"&gt;56,954&lt;/span&gt;&#160;shares of
Common Stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; Stockholders&#x2019; Equity (Deficit), continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2024, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240315__20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbnIzLlSxlEb" title="Number of restricted shares issued, shares"&gt;7,500&lt;/span&gt; restricted stock units with a grant date value of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_c20240315__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeCEm65kbQa7" title="Share price"&gt;1.33&lt;/span&gt; per unit in exchange for the forgiveness
of accrued compensation. The restricted stock units shall vest on the earlier event of either the expiration of the lock-up period by
the underwriters after the initial public offering or in the event of change of control of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of both December 31, 2025 and December 31, 2024, the Company had an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8tXdzNlTON1" title="Number of restricted shares issued, shares"&gt;&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXtLszgDoFtf" title="Number of restricted shares issued, shares"&gt;1,626,037&lt;/span&gt;&lt;/span&gt;
restricted stock units outstanding with an aggregate fair value of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPXVVSEwPRRg" title="Restricted stock fair value"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxtITuAyDTHi" title="Restricted stock fair value"&gt;2,195,550&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000890"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000892"
      unitRef="Shares">34446455</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000894"
      unitRef="Shares">34446455</us-gaap:CommonStockSharesOutstanding>
    <JUNS:CommitmentShares
      contextRef="AsOf2025-10-24"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">131909</JUNS:CommitmentShares>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="AsOf2025-10-24"
      decimals="0"
      id="Fact000902"
      unitRef="USD">200000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="From2025-10-242025-10-24"
      decimals="-5"
      id="Fact000904"
      unitRef="USD">20000000.0</us-gaap:LongTermPurchaseCommitmentAmount>
    <JUNS:PurchaseCommitmentPerShare
      contextRef="AsOf2025-10-24"
      decimals="INF"
      id="Fact000906"
      unitRef="USDPShares">1.5162</JUNS:PurchaseCommitmentPerShare>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-04-232025-04-23_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Shares">103186</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-232025-04-23_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000910"
      unitRef="USD">66000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Shares">3487500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityOneMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Shares">1162500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityTwoMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000916"
      unitRef="Shares">1162500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_custom_EntityThreeMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">1162500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000920"
      unitRef="Shares">37500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000922"
      unitRef="USDPShares">1.33</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000924"
      unitRef="Shares">112500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000926"
      unitRef="USD">150000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_IPOMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">4638375</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">3487500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000932"
      unitRef="USD">1546117</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact000934"
      unitRef="USD">893781</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-12-022024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Shares">2750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-12-02_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000938"
      unitRef="USDPShares">4.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000940"
      unitRef="Shares">2750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">9725213</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-12-042024-12-04_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000944"
      unitRef="USD">1274787</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000946"
      unitRef="USD">2418516</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">947124</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact000950"
      unitRef="USD">697835</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-242024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000952"
      unitRef="Shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-242024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000954"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-01-24_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000956"
      unitRef="USD">190560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-172024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000958"
      unitRef="Shares">67500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-172024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000960"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-04-17_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">73459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000964"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000966"
      unitRef="USDPShares">0.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact000968"
      unitRef="USD">191168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      id="Fact000970">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-06-102025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000972"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2025-06-10_custom_ConsultantMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Shares">187500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-07-02_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000976"
      unitRef="Shares">357448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-07-02_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact000978"
      unitRef="USDPShares">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-07-022025-07-02_custom_BoardOfDirectorsMember"
      id="Fact000980">The stock options have
a 10-year term and vest in equal installments over a three (3) year period beginning on the grant date of July 2, 2025, subject to the
officers&#x2019; continued employment at the time of vesting.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-09-052025-09-05_custom_TwoConsultantsMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Shares">374755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-05_custom_TwoConsultantsMember"
      decimals="INF"
      id="Fact000984"
      unitRef="USDPShares">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-09-052025-09-05_custom_TwoConsultantsMember"
      decimals="0"
      id="Fact000986"
      unitRef="USD">340900</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-09-052025-09-05_custom_TwoConsultantsMember"
      decimals="INF"
      id="Fact000988"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2025-09-05_custom_TwoConsultantsMember"
      decimals="INF"
      id="Fact000990"
      unitRef="Shares">281066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-09-052025-09-05_custom_ConsultantsMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Shares">109902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-05_custom_ConsultantsMember"
      decimals="INF"
      id="Fact000994"
      unitRef="USDPShares">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-09-052025-09-05_custom_ConsultantsMember"
      decimals="0"
      id="Fact000996"
      unitRef="USD">100000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-09-052025-09-05_custom_ConsultantsMember"
      id="Fact000998">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2025-09-052025-09-05_custom_ConsultantsMember"
      id="Fact001000">(a) 15% per Ambassador (maximum of three) referred by consultant and subsequently
engaged by the Company, (b) 20% if consultant is instrumental in arranging a distribution arrangement not previously pursued by the Company,
on terms acceptable to the Company, (c) 20% when such Distribution Contract achieves $1 million in annual sales and (d) 15% when the consultant
arranges the first Celebrity Golf Tournament featuring Nugevia on terms and conditions acceptable to the Company.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <JUNS:CommitmentShares
      contextRef="AsOf2025-10-24"
      decimals="INF"
      id="Fact001002"
      unitRef="Shares">131909</JUNS:CommitmentShares>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="AsOf2025-10-24"
      decimals="0"
      id="Fact001004"
      unitRef="USD">200000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="From2025-10-242025-10-24"
      decimals="-5"
      id="Fact001006"
      unitRef="USD">20000000.0</us-gaap:LongTermPurchaseCommitmentAmount>
    <JUNS:PurchaseCommitmentPerShare
      contextRef="AsOf2025-10-24"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">1.5162</JUNS:PurchaseCommitmentPerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001010">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zGIcZinqgHIb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity for the year ended December 31, 2025 and 2024 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_z6s3DH6Vjt58" style="display: none"&gt;Schedule of Stock Option
Activity&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    of Options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aggregate
    Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20241231_zRXeh9xhB171" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of options, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,336,883&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zAukIBM7RD9a" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zppaUwdvfs8i" title="Weighted average contractual term (years), outstanding"&gt;6.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zH7OrpvCEv7i" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,316,119&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20241231_z94ZxPCocGK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;297,105&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zdJVy0WjK3R9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240101__20241231_zEty7Y8rB6V9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20241231_zrQyyt533Jfi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1026"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20241231_zzcFG4oHYwNf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1028"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zHaH71PxMTjk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,633,988&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zvA4b86SDtvd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_zkWFd1akaaZg" title="Weighted average contractual term (years), outstanding"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231_zT6GrXlqqjmh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;102,921,147&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231_zx6zKK9KnB01" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,092,105&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_z5zfkOTmdqn8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20250101__20251231_z1MkBB8ZEwCg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20251231_z86Tb45OlHj3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20250101__20251231_zn602cdUyKfl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1046"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20250101__20251231_zUFZwOun8Rwc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231_zN1uQNHqhced" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11,726,093&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20251231_zAXwfxu9PzVf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.02&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_zcgFvM8TTbh6" title="Weighted average contractual term (years), outstanding"&gt;5.4&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231_z9pjfgVpYrej" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,772,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20250101__20251231_zJdfhzxO7qE9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,874,222&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20250101__20251231_zWYnYIKqUDv7" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.03&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231_z92T0zqxWbE6" title="Weighted average contractual term (years), exercisable"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231_zeFIKVBO2SH5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,765,237&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20241231_zS8GgP8525Tf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,297,412&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240101__20241231_zEvqKuMoU601" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.01&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20240101__20241231_z6wDBZRYZwrb" title="Weighted average contractual term (years), exercisable"&gt;6.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20240101__20241231_ze5LAHb52fya" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99,768,543&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001012"
      unitRef="Shares">10336883</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001014"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact001016">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">3316119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001020"
      unitRef="Shares">297105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001022"
      unitRef="USDPShares">1.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">10633988</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001032"
      unitRef="USDPShares">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2024-01-012024-12-31" id="Fact001034">P6Y3M18D</JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001036"
      unitRef="USD">102921147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">1092105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">11726093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001052"
      unitRef="USDPShares">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2025-01-01to2025-12-31" id="Fact001054">P5Y4M24D</JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001056"
      unitRef="USD">1772167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001058"
      unitRef="Shares">10874222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001060"
      unitRef="USDPShares">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2025-01-01to2025-12-31" id="Fact001062">P5Y1M6D</JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001064"
      unitRef="USD">1765237</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001066"
      unitRef="Shares">10297412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001068"
      unitRef="USDPShares">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2024-01-012024-12-31" id="Fact001070">P6Y2M4D</JUNS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001072"
      unitRef="USD">99768543</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001074">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zVtEFPVOCc4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarized information about employee stock options outstanding as of December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zr5t7TYd9Hvg" style="display: none"&gt;Schedule of Employee
Stock Options Outstanding&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Vested Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number Outstanding at December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Number Exercisable at December 31, 2025&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z9lUQANknNKg" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price"&gt;0.01&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zinDiVfAqRFl" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z8FXJSD6j8Mj" title="Outstanding options, weighted average contractual term"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zw0U37LS9Vk8" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zY9qy9o8xny5" title="Vested options, weighted average contractual term"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zIX9lQRSzhM5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.74&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxuUjg0j3Yj8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;1,657,560&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_znkzTAYxxTog" title="Outstanding options, weighted average contractual term"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z2Ilpmuw6nc6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;1,657,560&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zeQlgjxhvdOk" title="Vested options, weighted average contractual term"&gt;3.07&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zAuYWQpnOaTl" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.80&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z4AmDF0JAXia" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;2,783,243&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zyixcQx7zNw9" title="Outstanding options, weighted average contractual term"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zXqsfaTF4yV1" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;2,783,243&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zq1ybB4jri56" title="Vested options, weighted average contractual term"&gt;3.29&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zJaiFwLYgekh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.97&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zL3SV54Piocj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;250,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zP2ebCzUk369" title="Outstanding options, weighted average contractual term"&gt;9.42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWZVbDDqB2cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;111,412&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zU6mdI1AkD81" title="Vested options, weighted average contractual term"&gt;9.42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zot74KmHnvC8" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.19&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zioSbChcwch2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;357,448&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zLtyDdRqBKo1" title="Outstanding options, weighted average contractual term"&gt;9.51&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoeu40klWFdh" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;-&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zLehGVqy7CU7" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.23&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zGKnSBD394G5" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;484,657&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zh8fC6psLWqd" title="Outstanding options, weighted average contractual term"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zzJuRHQAMwkg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;128,822&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zUhk8TBWNbhh" title="Vested options, weighted average contractual term"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z2BLbDR5XzAa" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.33&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zWH2r7yjm8Sc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;5,461,935&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z426LmVrFrL6" title="Outstanding options, weighted average contractual term"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z5vKDzu3cQG6" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;5,461,935&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z9xUocfrltd4" title="Vested options, weighted average contractual term"&gt;7.08&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zCWfff1o9cy3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.16&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zZJ3jv16r4I9" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_ziA6nWOzWg7g" title="Outstanding options, weighted average contractual term"&gt;5.46&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zwtWFplqtor5" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zc4bj9IuSAEg" title="Vested options, weighted average contractual term"&gt;5.06&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20251231_zCPuvhn7yym4" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;11,726,093&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zTvaVvrr1C67" title="Outstanding options, weighted average remaining life"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20251231_zwJCzoNZt6Q3" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;10,874,222&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zjxE8JNl1o0h" title="Vested options, weighted average remaining life"&gt;5.10&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Outstanding Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Vested Options&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Number Outstanding at December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Number Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Life&lt;/td&gt;&lt;td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqTYltrcy2e" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Exercise price"&gt;0.01&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zqw3dafNIj4i" style="font: 9pt Times New Roman, Times, Serif; width: 17%; text-align: right" title="Number of options, outstanding"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXLu86SLEExa" title="Outstanding options, weighted average contractual term"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIS07948AUSd" style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Vested options, number exercisable"&gt;675,000&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z7EWagbSK6La" title="Vested options, weighted average contractual term"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zAcYrs8Y3Hfi" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.74&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zCM9gIgDE8P9" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;1,657,560&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zrSrDnU8V5Ra" title="Outstanding options, weighted average contractual term"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxBDMkBYO4Cg" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;1,657,562&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zYMES0ehNuBi" title="Vested options, weighted average contractual term"&gt;4.32&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zy2B6FbHG1n3" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;0.8&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zOek3sbcecfc" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;2,783,243&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zmhEz33Ddbad" title="Outstanding options, weighted average contractual term"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zSRCp95gzeYd" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;2,783,238&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z2GAh69BQpWg" title="Vested options, weighted average contractual term"&gt;4.54&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCn9DZQlTZah" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;1.33&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zvvoIopKWEn2" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;5,461,935&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zWG4ksZui5B9" title="Outstanding options, weighted average contractual term"&gt;8.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zxPtzl915dFj" style="font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;5,125,362&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zY8qsfToPjp5" title="Vested options, weighted average contractual term"&gt;8.31&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zHw1l0f826xe" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.16&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zPg6UNOzYGl6" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zMSqF69o5gdf" title="Outstanding options, weighted average contractual term"&gt;6.71&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zoLf6vkragPg" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;56,250&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zkEq1e4Jf2Tg" title="Vested options, weighted average contractual term"&gt;6.71&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231_zerA8b9MNhE8" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding"&gt;10,633,988&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zOQakm3BnRX4" title="Outstanding options, weighted average remaining life"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231_z40TkNgv43fb" style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right" title="Vested options, number exercisable"&gt;10,297,412&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_ztNWIX9ty3ze" title="Vested options, weighted average remaining life"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001076"
      unitRef="USDPShares">0.01</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001078"
      unitRef="Shares">675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeOneMember"
      id="Fact001080">P0Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001082"
      unitRef="Shares">675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_RangeOneMember"
      id="Fact001084">P0Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001086"
      unitRef="USDPShares">0.74</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001088"
      unitRef="Shares">1657560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeTwoMember"
      id="Fact001090">P3Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001092"
      unitRef="Shares">1657560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_RangeTwoMember"
      id="Fact001094">P3Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001096"
      unitRef="USDPShares">0.80</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001098"
      unitRef="Shares">2783243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeThreeMember"
      id="Fact001100">P3Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001102"
      unitRef="Shares">2783243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_RangeThreeMember"
      id="Fact001104">P3Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact001106"
      unitRef="USDPShares">0.97</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact001108"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeFourMember"
      id="Fact001110">P9Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Shares">111412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_RangeFourMember"
      id="Fact001114">P9Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001116"
      unitRef="USDPShares">1.19</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Shares">357448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeFiveMember"
      id="Fact001120">P9Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeSixMember"
      decimals="INF"
      id="Fact001124"
      unitRef="USDPShares">1.23</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeSixMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">484657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeSixMember"
      id="Fact001128">P9Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeSixMember"
      decimals="INF"
      id="Fact001130"
      unitRef="Shares">128822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_RangeSixMember"
      id="Fact001132">P9Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001134"
      unitRef="USDPShares">1.33</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001136"
      unitRef="Shares">5461935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeSevenMember"
      id="Fact001138">P7Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeSevenMember"
      decimals="INF"
      id="Fact001140"
      unitRef="Shares">5461935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_RangeSevenMember"
      id="Fact001142">P7Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2025-01-012025-12-31_custom_RangeEightMember"
      decimals="INF"
      id="Fact001144"
      unitRef="USDPShares">2.16</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_RangeEightMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Shares">56250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_RangeEightMember"
      id="Fact001148">P5Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_RangeEightMember"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">56250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_RangeEightMember"
      id="Fact001152">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001154"
      unitRef="Shares">11726093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2025-01-01to2025-12-31" id="Fact001156">P5Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001158"
      unitRef="Shares">10874222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-12-31" id="Fact001160">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">0.01</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeOneMember"
      id="Fact001166">P1Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeOneMember"
      decimals="INF"
      id="Fact001168"
      unitRef="Shares">675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_RangeOneMember"
      id="Fact001170">P1Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001172"
      unitRef="USDPShares">0.74</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">1657560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeTwoMember"
      id="Fact001176">P4Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeTwoMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Shares">1657562</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_RangeTwoMember"
      id="Fact001180">P4Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001182"
      unitRef="USDPShares">0.8</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001184"
      unitRef="Shares">2783243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeThreeMember"
      id="Fact001186">P4Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeThreeMember"
      decimals="INF"
      id="Fact001188"
      unitRef="Shares">2783238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_RangeThreeMember"
      id="Fact001190">P4Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-12-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact001192"
      unitRef="USDPShares">1.33</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact001194"
      unitRef="Shares">5461935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeFourMember"
      id="Fact001196">P8Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeFourMember"
      decimals="INF"
      id="Fact001198"
      unitRef="Shares">5125362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_RangeFourMember"
      id="Fact001200">P8Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
      contextRef="From2024-01-012024-12-31_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001202"
      unitRef="USDPShares">2.16</JUNS:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001204"
      unitRef="Shares">56250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_RangeFiveMember"
      id="Fact001206">P6Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_RangeFiveMember"
      decimals="INF"
      id="Fact001208"
      unitRef="Shares">56250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_RangeFiveMember"
      id="Fact001210">P6Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001212"
      unitRef="Shares">10633988</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-012024-12-31" id="Fact001214">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001216"
      unitRef="Shares">10297412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-012024-12-31" id="Fact001218">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <JUNS:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001220">&lt;p id="xdx_893_ecustom--ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_z0pCHvqoj6pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the Company&#x2019;s warrant activity for the year ended December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z5tHIdeRHBYk" style="display: none"&gt;Schedule of Warrant Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNc8RiNKKA5f" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,359,375&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iS_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgijBH4VCrZ4" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average exercise price per share, outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjCprZX2OrMi" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted average remaining life (years), outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xMF0O7JPfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareGranted_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAfBgjnckLoj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN4XT3EFXoQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,359,375&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFlhOc9kK5Lj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUDZPLcUEEQ9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareForfeited_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3bziOzm6Xw2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1238"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5Parh01sAAg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1240"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare_iE_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcCMUXTurClc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1242"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</JUNS:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001222"
      unitRef="Shares">1359375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001224"
      unitRef="Shares">0.80</JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare>
    <JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember13963437"
      id="Fact001226">P0Y11M4D</JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageRemainingLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437"
      decimals="INF"
      id="Fact001232"
      unitRef="Shares">1359375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember13963437"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">0.80</JUNS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-06-22_custom_WarrantHolderMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Shares">109376</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-16_custom_WarrantHolderMember"
      decimals="INF"
      id="Fact001246"
      unitRef="Shares">1249999</us-gaap:ClassOfWarrantOrRightOutstanding>
    <JUNS:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2025-07-162025-07-16_custom_WarrantHolderMember"
      decimals="INF"
      id="Fact001248"
      unitRef="Shares">913299</JUNS:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-07-16_custom_WarrantHolderMember"
      decimals="INF"
      id="Fact001250"
      unitRef="Shares">86700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-08-12_custom_WarrantHolderMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Shares">109376</us-gaap:ClassOfWarrantOrRightOutstanding>
    <JUNS:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2025-08-122025-08-12_custom_WarrantHolderMember"
      decimals="INF"
      id="Fact001254"
      unitRef="Shares">30547</JUNS:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-08-12_custom_WarrantHolderMember"
      decimals="INF"
      id="Fact001256"
      unitRef="Shares">56954</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-03-152024-03-15_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001258"
      unitRef="Shares">7500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-15_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001260"
      unitRef="USDPShares">1.33</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734"
      decimals="INF"
      id="Fact001262"
      unitRef="Shares">1626037</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734"
      decimals="INF"
      id="Fact001264"
      unitRef="Shares">1626037</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734"
      decimals="0"
      id="Fact001266"
      unitRef="USD">2195550</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember13962734"
      decimals="0"
      id="Fact001268"
      unitRef="USD">2195550</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001270">&lt;p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zKkXI6Ax61Dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_820_zIFy3S9284ea"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWIb6w9Br8Bj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z5qxT8107y54" style="display: none"&gt;Schedule
of Income Tax Provision&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231_zN1Ha8w5zSy7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_z4FLovEWDX4g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_zI1kBVw0Jnl3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zqkq7gT8gjml" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maKL001_z69qxdumrLX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nondeductible
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14.66&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zx9GBimZ1Wkc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-39.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-20.74&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zd1Y4tCFDLC9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1286"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zf4GVfqFp4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; Income Taxes, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0oE4sZ2PzCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s deferred tax assets is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zFdtRsfRho29" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Deferred Tax Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_ztuQUysEC5qh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zdn1x65jeUYi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGze87_zyqf3c82unn2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S
    Federal and State net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,473,294&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,083,545&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGze87_zaSwqbyCuPY5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,423,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,272,925&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_maDTAGze87_zgaey9eS7Jg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;348,012&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;382,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGze87_z8SH1dvo1NV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Orphan
    drug credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,060,118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsDerivativeLiability_iI_maDTAGze87_zP09qyBV7u4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derivative
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGze87_znXhwig8fdQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119,699&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;260,481&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGze87_maDTANz4iX_zcWR93tE6dPa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,046,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,059,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz4iX_zcDqd2p7xaK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,046,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,059,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz4iX_z911dkGdqv9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Deferred Tax Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1316"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zJGf3EyY77U4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2025, the Company had federal and state (post-apportioned basis) net operating losses (&#x201c;NOLs&#x201d;)
of $43.14 million, as well as federal orphan drug credit and research and development tax credit carryforwards of approximately $1.72
million. Approximately $&lt;span id="xdx_90D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn5n6_c20251231_zwgbot2GWaYe" title="Operating loss carryforward"&gt;22.3&lt;/span&gt; million of the foregoing federal and state NOLs will expire at various dates from 2036 through 2045, if not limited
by triggering events prior to such time. Under the provisions of the Internal Revenue Code, changes in ownership of the Company, in certain
circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular,
Section 382 of the Internal Revenue Code (&#x201c;Section 382&#x201d;) imposes limitations on an entity&#x2019;s ability to use NOLs upon
certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income,
then the Company will pay more taxes than if it were otherwise able to fully utilize its NOLs. The Company may experience ownership changes
in the future as a result of subsequent shifts in ownership of the Company&#x2019;s capital stock that the Company cannot predict or control
that could result in further limitations being placed on the Company&#x2019;s ability to utilize its federal NOLs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A valuation allowance, if needed, reduces deferred tax assets to the amount
expected to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company
assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings history, expected
future earnings, carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the
likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the
extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable
income, exclusive of reversing taxable temporary differences, to outweigh objective negative evidence of recent financial reporting losses.
Based on these criteria and the relative weighting of both the positive and negative evidence available, management continues to maintain
a full valuation allowance against its net deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001272">&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zWIb6w9Br8Bj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z5qxT8107y54" style="display: none"&gt;Schedule
of Income Tax Provision&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231_zN1Ha8w5zSy7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_z4FLovEWDX4g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_maKL001_zI1kBVw0Jnl3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_maKL001_zqkq7gT8gjml" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.07&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dp_uPure_maKL001_z69qxdumrLX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nondeductible
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14.66&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-2.33&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maKL001_zx9GBimZ1Wkc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-39.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-20.74&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtKL001_zd1Y4tCFDLC9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1286"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1287"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001274"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001275"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001277"
      unitRef="Pure">0.0419</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001278"
      unitRef="Pure">0.0207</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001280"
      unitRef="Pure">0.1466</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001281"
      unitRef="Pure">-0.0233</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001283"
      unitRef="Pure">-0.3984</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001284"
      unitRef="Pure">-0.2074</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001289">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z0oE4sZ2PzCf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s deferred tax assets is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zFdtRsfRho29" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Deferred Tax Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_ztuQUysEC5qh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zdn1x65jeUYi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGze87_zyqf3c82unn2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S
    Federal and State net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,473,294&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,083,545&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGze87_zaSwqbyCuPY5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,423,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,272,925&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_maDTAGze87_zgaey9eS7Jg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;348,012&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;382,288&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_maDTAGze87_z8SH1dvo1NV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Orphan
    drug credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,060,118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsDerivativeLiability_iI_maDTAGze87_zP09qyBV7u4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Derivative
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGze87_znXhwig8fdQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119,699&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;260,481&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGze87_maDTANz4iX_zcWR93tE6dPa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,046,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,059,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz4iX_zcDqd2p7xaK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,046,500&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6,059,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz4iX_z911dkGdqv9c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Deferred Tax Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1316"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001291"
      unitRef="USD">5473294</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001292"
      unitRef="USD">3083545</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001294"
      unitRef="USD">1423288</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001295"
      unitRef="USD">1272925</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001297"
      unitRef="USD">348012</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001298"
      unitRef="USD">382288</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001300"
      unitRef="USD">1682207</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001301"
      unitRef="USD">1060118</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001306"
      unitRef="USD">119699</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001307"
      unitRef="USD">260481</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001309"
      unitRef="USD">9046500</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001310"
      unitRef="USD">6059357</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001312"
      unitRef="USD">9046500</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001313"
      unitRef="USD">6059357</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001318"
      unitRef="USD">22300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001320">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z952iJVkqXY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_826_zigE454ea6yd"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Legal
Matters&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting the Company from selling one or more products or engaging in other activities. The occurrence of an unfavorable
outcome in any specific period could have a material adverse effect on the Company&#x2019;s results of operations for that period or future
periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 19, 2022, Tiberend Strategic Advisors (&#x201c;Tiberend&#x201d;), an entity that the Company had previously engaged as a communications
and investor relations firm, filed a summons for civil action in the District Court of Southern Florida against the Company alleging
non-payment by the Company under a services agreement (the &#x201c;Services Agreement&#x201d;) with Tiberend in the amount of $&lt;span id="xdx_907_eus-gaap--OtherLiabilities_iI_c20220719__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TiberendStrategicAdvisorsMember_zE4ml6Setc82" title="Non-payment amount"&gt;130,400&lt;/span&gt;.
The Company and Tiberend entered into a full settlement and release agreement in exchange for a $&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20230331__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TiberendStrategicAdvisorsMember_zu2OUmvQFyd5" title="Convertible promissory note"&gt;150,000&lt;/span&gt; convertible promissory note
in March 2023. As of December 31, 2024, the note was fully repaid. See Note 5 &#x2013; Convertible Debt and Derivative Liability &#x2013;
Convertible Debt III for details associated with the note issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Office
Lease&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2021, the Company entered into a &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210501_zaAdOVt49Z7l" title="Operating lease term"&gt;61&lt;/span&gt;-month operating lease for office space for a base rent of $&lt;span id="xdx_901_eus-gaap--PaymentsForRent_c20210501__20210501_zTW79l6b0nyf" title="Base rent"&gt;3,783&lt;/span&gt; subject to a &lt;span id="xdx_90D_ecustom--OperatingLeaseYearlyEscalationPercentage_iI_pid_dp_uPure_c20210501_zXP622lgsFe4" title="Operating lease yearly escalation percentage"&gt;3&lt;/span&gt;% yearly escalation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, the Company&#x2019;s operating lease right-of-use asset, net (ROU) is $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20251231_zLQ0vuy3oo74" title="Operating lease right-of-use asset, net"&gt;23,214&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231_zBffG8IzKrp" title="Operating lease right-of-use asset, net"&gt;69,642&lt;/span&gt;, respectively,
and the total lease liability is $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_c20251231_zRyqgG2tiQ8f" title="Operating lease liability"&gt;21,247&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--OperatingLeaseLiability_iI_c20241231_zsWsNimhwdM5" title="Operating lease liability"&gt;71,329&lt;/span&gt;, respectively, based on an incremental borrowing rate of &lt;span id="xdx_907_ecustom--OperatingLeaseIncremetalBorrowingRate_dp_c20250101__20251231_zSGmwdibyI58" title="Operating lease incremetal borrowing rate"&gt;&lt;span id="xdx_90F_ecustom--OperatingLeaseIncremetalBorrowingRate_dp_c20240101__20241231_zm6guN5rHych" title="Operating lease incremetal borrowing rate"&gt;0.81&lt;/span&gt;&lt;/span&gt;% at lease inception.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_z5kCvA4ZX23h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z7QmEYvo2gF6" style="display: none"&gt;Schedule
of Operating Lease Right-of-use Asset and  Liability&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zJlOlxba3tJd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_z9Jgz4Y349F" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease right-of-use asset (&#x201c;ROU&#x201d;) is summarized below:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maOLROUzjlN_za62rp1rN3lj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
lease ROU&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msOLROUzjlN_znVCgBvnVIc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less
accumulated reduction&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(212,795&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(166,367&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzjlN_zbzCbLowLBM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance
of ROU, net &lt;/b&gt;&#160; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,214&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;69,642&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease liability related to the ROU asset is summarized below:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--OperatingLeaseLiabilityGross_iI_maOLLzx0H_zr8PnbLINXb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ReductionOfOperatingLeaseLiability_iNI_di_msOLLzx0H_zZz2fBCISKW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reduction
of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(214,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(164,680&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzx0H_zPjY7f1GJEcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,329&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zeeS0Dstonz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK9S51ku6N01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future minimum lease liability payments under non-cancelable operating lease
at December 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zc44k8gm9GXi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20251231_zzuhWvY6rVK2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20241231_zZiY9GW3byKk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPztZn_zqW1PNRo1zJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,476&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPztZn_zBinXdQXUfI1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,290&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,290&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPztZn_zfUBqoLEwlo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,290&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,766&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zYa7afb3L3j8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    imputed interest &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(43&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(437&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_z39pbEWmLQLc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    lease liabilities &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,329&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzH2R_zf4gvsdgRykk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,082&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzH2R_zW1ovI42HEvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-current
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzH2R_z9aX4bp1rUo7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    lease liabilities &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,329&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zlufLEKsCF9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; Commitments and Contingencies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Office
Lease, continued&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2021, the Company entered into a month-to-month lease for office space in Charlestown, MA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rental
expenses of $&lt;span id="xdx_90D_ecustom--RentalExpenses_c20250101__20251231_zgGFcpIMWtGf" title="Operating leases rent expenses"&gt;16,972&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--RentalExpenses_c20240101__20241231_zNQwMQb0CoMk" title="Operating leases rent expenses"&gt;17,740&lt;/span&gt; for the years ended December 31, 2025 and 2024, respectively, are included in general and administrative
expenses on the accompanying statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consulting
Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes various consultants and advisors for clinical research, scientific advisory services and business strategies. Each consultant
has an executed agreement in place defining term, compensation, duties, confidentiality, intellectual property. The majority of the agreements
have a &lt;span id="xdx_904_ecustom--AgreementTerm_dtY_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zFmf9b9DxB4h" title="Agreements term"&gt;2&lt;/span&gt;-year term. Agreements are evaluated for renewal upon expiration. Bonus provisions are at the discretion of the Company&#x2019;s
Board of Directors and are granted on an individual agreement basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 15, 2024, the Company entered into a Strategic Services Agreement (the &#x201c;Dominant Treasure Agreement&#x201d;) with
Dominant Treasure Health Company Limited (&#x201c;Dominant Treasure&#x201d;). Pursuant to the terms of the Dominant Treasure
Agreement, Dominant Treasure agreed to provide certain services to the Company to assist the Company in accelerating the
Company&#x2019;s desire to get its products developed and distributed in the Southeast Asian market. In exchange for Dominant
Treasure&#x2019;s services pursuant to the Dominant Treasure Agreement, the Company agreed to pay Dominant Treasure a one-time
payment of $&lt;span id="xdx_90B_eus-gaap--PaymentsToSuppliers_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zzJ19Ej1iyFf" title="Payment for services"&gt;2,300,000&lt;/span&gt;.
In addition, if Dominant Treasure is involved in generating negotiations and conclusion of a distribution agreement for the Company
in the countries of China (including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee of &lt;span id="xdx_905_eus-gaap--ManagementAndServiceFeesRate_dp_uPure_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zNnHjB14Y23f" title="Success fee percentage"&gt;5&lt;/span&gt;%
of any upfront and/or milestone payments to be received by the Company. If such an agreement will include a royalty payment to the
Company, Dominant Treasure will receive &lt;span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zlZ9F1el0Ukb" title="Royalty fee percentage"&gt;5&lt;/span&gt;%
of such royalty payment. The Dominant Treasure Agreement has a term of &lt;span id="xdx_902_ecustom--AgreementTerm_dtM_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zD1pKRzkjsgd" title="Agreements term"&gt;36&lt;/span&gt;
months and may be terminated at any time upon mutual agreement of the parties. The one-time payment of $&lt;span id="xdx_902_eus-gaap--PrepaidExpenseCurrent_iI_c20241215__us-gaap--TypeOfArrangementAxis__custom--DominantTreasureAgreementMember_zl7VoPCistdk" title="Prepaid expense"&gt;2,300,000&lt;/span&gt;
was accounted for as a prepaid contract and will be expensed over a three-year period. For the years ended December 31, 2025 and
December 31, 2024, the Company recorded prepaid contract expense of $&lt;span id="xdx_906_ecustom--PrepaidContractExpenses_c20250101__20251231_z8pNmBAmuDu" title="Prepaid contracts expense"&gt;766,667&lt;/span&gt;
and $&lt;span id="xdx_908_ecustom--PrepaidContractExpenses_c20240101__20241231_zMSMntVmy6d7" title="Prepaid contracts expense"&gt;54,612&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Executive
Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s standard executive employment agreements have a stated term of six years. Per the agreements, employees are eligible
for a discretionary annual performance bonus, determined by the Board of Directors. If the Company terminates an employee without cause,
the employee is entitled to a pro-rated pay out of the annual performance bonus based on days worked in the fiscal year, severance of
twelve months of the base salary, and automatic vesting of unvested equity grants. If the employee terminates with good reason, as defined
in the employment contract, the employee is entitled to automatic vesting of unvested equity grants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2020, &lt;span id="xdx_90D_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zWFUYt2KGG0l" title="Salary payment description"&gt;the Company began consistently paying salaries at 50% of the salaries reflected in the respective employment agreements. As of
September 2021, the Company began paying full salaries. Throughout 2022, the Company returned to paying partial salaries and by October
2023 the company stopped paying 100% in an effort to conserve cash.&lt;/span&gt; See Note 3 &#x2013; Related Party Transactions for details related
to forgiveness of accrued compensation during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20231218__20231218__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z9d84721NLPf" title="Salary payment description"&gt;On
December 18, 2023, various employees agreed to reduce their annual base salary to 20% of their original base salary effective October
1, 2023 until the time the Company raises additional capital from securities in the amount of $1,500,000 (the &#x201c;Reduction Period&#x201d;).
Upon the expiration of the Reduction Period, the bases salaries shall adjust to be 105% of their original base salary as set forth in
their original agreements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 4, 2024, &lt;span id="xdx_900_eus-gaap--RestructuringAndRelatedActivitiesDescription_c20241204__20241204__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zY7kbRR4KdXc" title="Salary payment description"&gt;the base salaries was adjusted to 105% of the original base salaries and the Company started paying a 100% of the
salaries.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; Commitments and Contingencies, continued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Licensing
and Royalty Agreements -&lt;/i&gt; Aquanova AG&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 13, 2016, the Company entered into a Development, Collaboration and License Agreement (&#x201c;License Agreement&#x201d;)
with Aquanova AG, a German company in the field of development, manufacturing and selling of colloidal formulas. The License
Agreement resulted in the creation of the pharmaceutic product, JOTROL&#x2122;. The Chief Scientific Officer of the Company and
Aquanova&#x2019;s founder, former CEO, and lead scientist, Darius Benham, are the joint inventors of
JOTROL&#x2122;. Aquanova is assignee on the patents in the United States, the European Union, China and Japan whereas the Company is
obligated to maintain the patents. The agreement grants ownership to the Company for regulatory approvals and the sole and exclusive
worldwide right to develop, manufacture and commercialize all products, including JOTROL&#x2122;. Aquanova is granted the exclusive
license to conduct formulation development and manufacturing. The agreement also defines fees owed to Aquanova for product and
formulation development and licensing of the products. The Company is required to pay Aquanova an annual license fee of $&lt;span id="xdx_909_ecustom--LicenseFee_c20160913__20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_z7QnXt1KzkL9"&gt;75,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon
acceptance of the product formulation by both parties, with the license fee requirement ending in the year of marketing
authorization approval (&#x201c;MMA&#x201d;) in a single territory. MMA has not yet been received as of the period ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2025 and 2024, $&lt;span id="xdx_90E_ecustom--AccruedLicenseFees_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zNr4alnqSShh"&gt;0&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_90F_ecustom--AccruedLicenseFees_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zfnldRwXQ4Yd"&gt;75,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of
accrued license fees are included in accounts payable and accrued expenses on the balance sheet, respectively. Upon receipt of
approval of the MMA in each territory (e.g., United States, European Union, China, Japan), the Company will pay $&lt;span id="xdx_908_eus-gaap--OtherCommitment_iI_c20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MinimumMember_z1F7UHrJzzBd"&gt;200,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to
Aquanova per territory an MMA approval is received, up to a max of $&lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_c20160913__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MaximumMember_zk1SQFVhrCXf"&gt;600,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Company shall pay Aquanova a royalty of &lt;span id="xdx_90C_ecustom--RoyaltyPercentage_dp_uPure_c20160913__20160913__us-gaap--TypeOfArrangementAxis__custom--LicensingAndRoyaltyAgreementsMember_zjKNcEMlUddg"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of net sales in each territory through the later of ten years after the first commercial sale, the first date there is no valid
claim within the Aquanova patent rights, or the date of expiration of the MMA in each territory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"&gt;On December 1, 2021, the Company and Aquanova entered into
a Debt Forgiveness and Exchange Agreement, pursuant to which $&lt;span id="xdx_909_ecustom--AccruedAndOutstandingObligations_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zAqiAypCVokk" title="Accrued and outstanding obligations"&gt;225,000&lt;/span&gt; of accrued and outstanding obligations owed to Aquanova under the
License Agreement were forgiven in exchange for $&lt;span id="xdx_90B_eus-gaap--Cash_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_z9UJOC8I0Jy9" title="Cash"&gt;125,000&lt;/span&gt; in cash, a $&lt;span id="xdx_90C_ecustom--PromissoryNote_iI_c20211201__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zQ9Inlbgy54g" title="Promissory note"&gt;100,000&lt;/span&gt; promissory note, and the issuance of stock options to Aquanova.
As of December 31, 2025, $&lt;span id="xdx_900_ecustom--AccruedLicenseFees_iI_c20251231__us-gaap--TypeOfArrangementAxis__custom--DebtForgivenessAndExchangeAgreementMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zpgooreWIFtb" title="Accrued license fees"&gt;0&lt;/span&gt; in accrued license fees are recorded in accounts payable.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
is an option (exercisable by either party) to require the Company to pay a one-time royalty of $&lt;span id="xdx_902_eus-gaap--RoyaltyExpense_c20160915__20160915__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zaDAu90Niu9i" title="Royalty amount"&gt;3,000,000&lt;/span&gt;
within 180 days of United States marketing approval, with subsequent royalty payments reduced to &lt;span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20160915__20160915__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsMember__dei--LegalEntityAxis__custom--AquanovaAGMember_zkMOytbl5cx8" title="Royalty payments percentage"&gt;1.25&lt;/span&gt;%,
in accordance with the terms set forth above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Murdoch
Children&#x2019;s Research Institute&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 1, 2015, the Company entered into a Global Development and License Agreement (&#x201c;License Agreement II&#x201d;) with Murdoch
Children&#x2019;s Research Institute (&#x201c;MCRI&#x201d;), an Australian Institute at the Royal Children&#x2019;s Hospital in Australia,
with the know-how in the process of using pharmaceutical grade Resveratrol for the treatment of Friedreich&#x2019;s ataxia. The License
Agreement II is for both parties to work jointly to develop an appropriate delivery system and conduct clinical trials for the purpose
of product approval in the treatment of Friedreich&#x2019;s ataxia and worldwide commercialization by the Company. The License Agreement
II grants an exclusive worldwide license to the Company to use the MCRI know-how for developing, manufacturing and commercializing the
product for proposed treatment for Friedreich&#x2019;s ataxia. MCRI is granted an irrevocable, royalty free, worldwide license to use
the product inventions and patent rights for internal research and development. Upon receipt of approval of the MMA in each territory
(e.g., United States, European Union, China, Japan), the Company will pay $&lt;span id="xdx_907_eus-gaap--OtherCommitment_iI_c20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MinimumMember_zjBGSuLPAOcf"&gt;100,000&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to MCRI per each territory up to a maximum of $&lt;span id="xdx_903_eus-gaap--OtherCommitment_iI_c20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__srt--StatementGeographicalAxis__country--JP__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember_zvdo48vqMuA8"&gt;300,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
MMA has not yet been received as of September 30, 2024. The Company shall pay MCRI a royalty of &lt;span id="xdx_900_ecustom--RoyaltyPercentage_dp_uPure_c20150901__20150901__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementsTwoMember__dei--LegalEntityAxis__custom--MurdochChildrensResearchInstituteMember_z2sO3Ykg2awa"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
of net sales in each territory until the product is no longer sold in the respective territory. &lt;/span&gt;The Company has presently put
all R&amp;amp;D efforts associated with the treatment of Friedreich&#x2019;s Ataxia on hold.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Service Providers&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the services received under the licensing agreements noted above, a substantial portion of the research and development (&#x201c;R&amp;amp;D&#x201d;)
expense included in the statement of operations is incurred pursuant to short term service and consulting agreements with third party
providers for research, development, testing and manufacturing services. The agreements generally provide termination, at any time by
either party without cause, upon a 30-day written notice, unless otherwise disclosed below. There are no pending milestone payments due
as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Service
Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 3, 2024, the Company entered into three &lt;span id="xdx_900_ecustom--AgreementTerm_dtM_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zCipDpsP0bhj"&gt;36&lt;/span&gt;-month service agreements with three different entities. The Company issued an aggregate
of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgwOZcPdjLD5" title="Number of restricted shares issued"&gt;3,487,500&lt;/span&gt; restricted shares of common stock, &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__dei--LegalEntityAxis__custom--EntityThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z71nm19xhkU"&gt;1,162,500&lt;/span&gt; restricted shares of common stock to each entity. The shares were to be registered
upon an IPO as long as an IPO happens no later than March 31, 2025. Either party is able to terminate the respective agreement with no
liability upon the occurrence of i) the Company failing to raise at least $10 million in gross proceeds from an IPO prior to May 31,
2025, ii) if either party is involved in any illegal activity or iii) at any time as long as both parties agree to it. The shares were
registered in the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company initially recognized stock-based compensation expense from the effective date of the agreement through the date the
obligations were met with the remaining expense being amortized over the remaining term of the &lt;span id="xdx_900_ecustom--AgreementTerm_dtM_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zchpZqkmzOdg"&gt;36&lt;/span&gt;-months
per the services agreements. Upon the occurrence of the initial public offering the Company recorded stock- based compensation
expense for services provided of $&lt;span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zuRC2mEoJrD1"&gt;779,411&lt;/span&gt;,
and through December 31, 2024 the Company recorded an additional stock-based compensation expense of $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20241231_ztRj5UDkPEH3"&gt;114,373&lt;/span&gt;
for a total stock-based compensation expense of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20240101__20241231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zwwL2Ukhfxw"&gt;893,784&lt;/span&gt;.
For the year ended December 31, 2025, the Company recorded $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20250101__20251231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zF31rTDyWTyd" title="Share based compensation"&gt;1,546,117&lt;/span&gt;
stock-based compensation expense and the remaining future stock-based compensation expense as of December 31, 2025 is $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20251231__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember_zkNuS7SLqiAg" title="Share based compensation"&gt;2,198,474&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, each of the entities agreed to purchase &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240603__20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0u9m9pmSD74" title="Purchase of common stock"&gt;37,500&lt;/span&gt; shares each of the Company&#x2019;s common stock at a price of $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20240603__us-gaap--TypeOfArrangementAxis__us-gaap--ServiceAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdm3m5dQV41d"&gt;1.33&lt;/span&gt; per share
prior to the occurrence of the IPO and these shares were registered in the IPO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;JUPITER
NEUROSCIENCES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2025 and 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2022-07-19_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember"
      decimals="0"
      id="Fact001322"
      unitRef="USD">130400</us-gaap:OtherLiabilities>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-03-31_us-gaap_ServiceAgreementsMember_custom_TiberendStrategicAdvisorsMember"
      decimals="0"
      id="Fact001324"
      unitRef="USD">150000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2021-05-01" id="Fact001326">P61M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForRent
      contextRef="From2021-05-012021-05-01"
      decimals="0"
      id="Fact001328"
      unitRef="USD">3783</us-gaap:PaymentsForRent>
    <JUNS:OperatingLeaseYearlyEscalationPercentage
      contextRef="AsOf2021-05-01"
      decimals="INF"
      id="Fact001330"
      unitRef="Pure">0.03</JUNS:OperatingLeaseYearlyEscalationPercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001332"
      unitRef="USD">23214</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001334"
      unitRef="USD">69642</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001336"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001338"
      unitRef="USD">71329</us-gaap:OperatingLeaseLiability>
    <JUNS:OperatingLeaseIncremetalBorrowingRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001340"
      unitRef="Pure">0.0081</JUNS:OperatingLeaseIncremetalBorrowingRate>
    <JUNS:OperatingLeaseIncremetalBorrowingRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact001342"
      unitRef="Pure">0.0081</JUNS:OperatingLeaseIncremetalBorrowingRate>
    <JUNS:ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001344">&lt;p id="xdx_896_ecustom--ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock_z5kCvA4ZX23h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_z7QmEYvo2gF6" style="display: none"&gt;Schedule
of Operating Lease Right-of-use Asset and  Liability&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zJlOlxba3tJd" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_z9Jgz4Y349F" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease right-of-use asset (&#x201c;ROU&#x201d;) is summarized below:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_maOLROUzjlN_za62rp1rN3lj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
lease ROU&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_di_msOLROUzjlN_znVCgBvnVIc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less
accumulated reduction&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(212,795&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(166,367&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_mtOLROUzjlN_zbzCbLowLBM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance
of ROU, net &lt;/b&gt;&#160; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,214&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;69,642&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    lease liability related to the ROU asset is summarized below:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--OperatingLeaseLiabilityGross_iI_maOLLzx0H_zr8PnbLINXb4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office
lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;236,009&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ReductionOfOperatingLeaseLiability_iNI_di_msOLLzx0H_zZz2fBCISKW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reduction
of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(214,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(164,680&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzx0H_zPjY7f1GJEcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,329&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</JUNS:ScheduleOfOperatingLeaseAssetsAndLiabilitiesTableTextBlock>
    <JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001346"
      unitRef="USD">236009</JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001347"
      unitRef="USD">236009</JUNS:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <JUNS:OperatingLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001349"
      unitRef="USD">212795</JUNS:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <JUNS:OperatingLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001350"
      unitRef="USD">166367</JUNS:OperatingLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001352"
      unitRef="USD">23214</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001353"
      unitRef="USD">69642</us-gaap:OperatingLeaseRightOfUseAsset>
    <JUNS:OperatingLeaseLiabilityGross
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001355"
      unitRef="USD">236009</JUNS:OperatingLeaseLiabilityGross>
    <JUNS:OperatingLeaseLiabilityGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001356"
      unitRef="USD">236009</JUNS:OperatingLeaseLiabilityGross>
    <JUNS:ReductionOfOperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001358"
      unitRef="USD">214762</JUNS:ReductionOfOperatingLeaseLiability>
    <JUNS:ReductionOfOperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001359"
      unitRef="USD">164680</JUNS:ReductionOfOperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001361"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001362"
      unitRef="USD">71329</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001364">&lt;p id="xdx_89A_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK9S51ku6N01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future minimum lease liability payments under non-cancelable operating lease
at December 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zc44k8gm9GXi" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Schedule
of Future Minimum Lease Liability Payments Under Non-cancelable Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20251231_zzuhWvY6rVK2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20241231_zZiY9GW3byKk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPztZn_zqW1PNRo1zJ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,476&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPztZn_zBinXdQXUfI1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,290&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,290&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPztZn_zfUBqoLEwlo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total lease payments&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,290&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,766&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zYa7afb3L3j8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    imputed interest &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(43&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(437&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_z39pbEWmLQLc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    lease liabilities &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,329&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzH2R_zf4gvsdgRykk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,082&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzH2R_zW1ovI42HEvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-current
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1384"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzH2R_z9aX4bp1rUo7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    lease liabilities &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,329&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001367"
      unitRef="USD">50476</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001369"
      unitRef="USD">21290</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001370"
      unitRef="USD">21290</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001372"
      unitRef="USD">21290</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001373"
      unitRef="USD">71766</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001375"
      unitRef="USD">43</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001376"
      unitRef="USD">437</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001378"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001379"
      unitRef="USD">71329</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001381"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001382"
      unitRef="USD">50082</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001385"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001387"
      unitRef="USD">21247</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001388"
      unitRef="USD">71329</us-gaap:OperatingLeaseLiability>
    <JUNS:RentalExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001390"
      unitRef="USD">16972</JUNS:RentalExpenses>
    <JUNS:RentalExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001392"
      unitRef="USD">17740</JUNS:RentalExpenses>
    <JUNS:AgreementTerm
      contextRef="From2025-01-012025-12-31_custom_ConsultingAgreementsMember"
      id="Fact001394">P2Y</JUNS:AgreementTerm>
    <us-gaap:PaymentsToSuppliers
      contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">2300000</us-gaap:PaymentsToSuppliers>
    <us-gaap:ManagementAndServiceFeesRate
      contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember"
      decimals="INF"
      id="Fact001398"
      unitRef="Pure">0.05</us-gaap:ManagementAndServiceFeesRate>
    <JUNS:RoyaltyPercentage
      contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember"
      decimals="INF"
      id="Fact001400"
      unitRef="Pure">0.05</JUNS:RoyaltyPercentage>
    <JUNS:AgreementTerm
      contextRef="From2024-12-152024-12-15_custom_DominantTreasureAgreementMember"
      id="Fact001402">P36M</JUNS:AgreementTerm>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-15_custom_DominantTreasureAgreementMember"
      decimals="0"
      id="Fact001404"
      unitRef="USD">2300000</us-gaap:PrepaidExpenseCurrent>
    <JUNS:PrepaidContractExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001406"
      unitRef="USD">766667</JUNS:PrepaidContractExpenses>
    <JUNS:PrepaidContractExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001408"
      unitRef="USD">54612</JUNS:PrepaidContractExpenses>
    <us-gaap:RestructuringAndRelatedActivitiesDescription
      contextRef="From2020-01-012020-12-31_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact001410">the Company began consistently paying salaries at 50% of the salaries reflected in the respective employment agreements. As of
September 2021, the Company began paying full salaries. Throughout 2022, the Company returned to paying partial salaries and by October
2023 the company stopped paying 100% in an effort to conserve cash.</us-gaap:RestructuringAndRelatedActivitiesDescription>
    <us-gaap:RestructuringAndRelatedActivitiesDescription
      contextRef="From2023-12-182023-12-18_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact001412">On
December 18, 2023, various employees agreed to reduce their annual base salary to 20% of their original base salary effective October
1, 2023 until the time the Company raises additional capital from securities in the amount of $1,500,000 (the &#x201c;Reduction Period&#x201d;).
Upon the expiration of the Reduction Period, the bases salaries shall adjust to be 105% of their original base salary as set forth in
their original agreements.</us-gaap:RestructuringAndRelatedActivitiesDescription>
    <us-gaap:RestructuringAndRelatedActivitiesDescription
      contextRef="From2024-12-042024-12-04_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact001414">the base salaries was adjusted to 105% of the original base salaries and the Company started paying a 100% of the
salaries.</us-gaap:RestructuringAndRelatedActivitiesDescription>
    <JUNS:LicenseFee
      contextRef="From2016-09-132016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001415"
      unitRef="USD">75000</JUNS:LicenseFee>
    <JUNS:AccruedLicenseFees
      contextRef="AsOf2025-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001416"
      unitRef="USD">0</JUNS:AccruedLicenseFees>
    <JUNS:AccruedLicenseFees
      contextRef="AsOf2024-12-31_custom_LicenseAgreementsMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">75000</JUNS:AccruedLicenseFees>
    <us-gaap:OtherCommitment
      contextRef="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MinimumMember"
      decimals="0"
      id="Fact001418"
      unitRef="USD">200000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2016-09-13_custom_LicenseAgreementsMember_custom_AquanovaAGMember_country_JP_srt_MaximumMember"
      decimals="0"
      id="Fact001419"
      unitRef="USD">600000</us-gaap:OtherCommitment>
    <JUNS:RoyaltyPercentage
      contextRef="From2016-09-132016-09-13_custom_LicensingAndRoyaltyAgreementsMember"
      decimals="INF"
      id="Fact001420"
      unitRef="Pure">0.05</JUNS:RoyaltyPercentage>
    <JUNS:AccruedAndOutstandingObligations
      contextRef="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001422"
      unitRef="USD">225000</JUNS:AccruedAndOutstandingObligations>
    <us-gaap:Cash
      contextRef="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001424"
      unitRef="USD">125000</us-gaap:Cash>
    <JUNS:PromissoryNote
      contextRef="AsOf2021-12-01_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001426"
      unitRef="USD">100000</JUNS:PromissoryNote>
    <JUNS:AccruedLicenseFees
      contextRef="AsOf2025-12-31_custom_DebtForgivenessAndExchangeAgreementMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001428"
      unitRef="USD">0</JUNS:AccruedLicenseFees>
    <us-gaap:RoyaltyExpense
      contextRef="From2016-09-152016-09-15_custom_LicenseAgreementsMember_custom_AquanovaAGMember"
      decimals="0"
      id="Fact001430"
      unitRef="USD">3000000</us-gaap:RoyaltyExpense>
    <JUNS:RoyaltyPercentage
      contextRef="From2016-09-152016-09-15_custom_LicenseAgreementsMember_custom_AquanovaAGMember"
      decimals="INF"
      id="Fact001432"
      unitRef="Pure">0.0125</JUNS:RoyaltyPercentage>
    <us-gaap:OtherCommitment
      contextRef="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember_country_JP_srt_MinimumMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">100000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitment
      contextRef="AsOf2015-09-01_custom_LicenseAgreementsTwoMember_country_JP_srt_MaximumMember_custom_MurdochChildrensResearchInstituteMember"
      decimals="0"
      id="Fact001434"
      unitRef="USD">300000</us-gaap:OtherCommitment>
    <JUNS:RoyaltyPercentage
      contextRef="From2015-09-012015-09-01_custom_LicenseAgreementsTwoMember_custom_MurdochChildrensResearchInstituteMember"
      decimals="INF"
      id="Fact001435"
      unitRef="Pure">0.015</JUNS:RoyaltyPercentage>
    <JUNS:AgreementTerm
      contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember"
      id="Fact001436">P36M</JUNS:AgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001438"
      unitRef="Shares">3487500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_custom_EntityThreeMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001439"
      unitRef="Shares">1162500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <JUNS:AgreementTerm
      contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember"
      id="Fact001440">P36M</JUNS:AgreementTerm>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_ServiceAgreementsMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">779411</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="0"
      id="Fact001442"
      unitRef="USD">114373</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_ServiceAgreementsMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">893784</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_ServiceAgreementsMember"
      decimals="0"
      id="Fact001445"
      unitRef="USD">1546117</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_us-gaap_ServiceAgreementsMember"
      decimals="0"
      id="Fact001447"
      unitRef="USD">2198474</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-032024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001449"
      unitRef="Shares">37500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-06-03_us-gaap_ServiceAgreementsMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001450"
      unitRef="USDPShares">1.33</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001452">&lt;p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_z0ThKYsbqii2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_821_zFlud64cDJy3"&gt;Segment Report&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer serves as the Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The CODM evaluates financial
performance and makes resource allocation decisions based on the operating results of the Company&#x2019;s reportable segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
October 1, 2025, the Company operates through &lt;span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uSegments_c20251001__20251001_zeFHsr2NsiG4" title="Number of reportable segments"&gt;two&lt;/span&gt; reportable segments under ASC 280, Segment Reporting: (i) its premium nutritional supplements, and (ii) pharmaceutical operations
focused on drug candidates for CNS and rare orphan diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Premium
Nutritional Supplements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
segment includes all activities related to the commercialization and sale of the Company&#x2019;s Nugevia product line. Activities within
this segment primarily consist of marketing, distribution, sales, customer support, and related supply chain management associated with
Nugevia products.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Pharmaceutical Operations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
segment includes all activities related to the research, development, and regulatory advancement of JOTROL&#x2122;, the Company&#x2019;s
proprietary resveratrol-based therapeutic candidate, which is being developed to address unmet medical needs and improve patient outcomes.
Activities within this segment primarily consist of clinical development, regulatory, manufacturing development, intellectual property
protection, and related research and development functions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
CODM assesses segment performance and allocates resources based on segment net loss (income), which represents the primary measure of
profit or loss reviewed. The CODM does not evaluate segments using discrete asset or liability information. Accordingly, total assets
are reported on a consolidated basis in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Allocation
Methodology&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses
are attributed to each reportable segment based on the nature of the activity and the function to which the expense relates. Costs that
are directly identifiable with a specific segment are recorded to that segment. Selling, general and administrative expenses that benefit
both segments are allocated using reasonable and consistently applied methodologies that reflect the estimated level of effort or resources
consumed by each segment. These allocation methodologies may include time and effort analyses, headcount, relative revenue, or other
activity-based measures, depending on the underlying cost driver.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
allocation methodologies are reviewed periodically and refined as necessary to reflect changes in the business. The Company believes
such allocations are reasonable and consistent with the manner in which the CODM evaluates segment performance and makes resource allocation
decisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate
and other expenses consist primarily of public company costs (including board, investor relations, and SEC reporting expenses), certain
executive compensation, certain stock-based compensation, interest income (expense), other income (expense), and income taxes. These
costs are not allocated to reportable segments because they are not included in the measures reviewed by the CODM for purposes of assessing
segment performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zvRI8LIbbUIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment
information for the year ended December 31, 2025 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_z5Rl4GydSAMl"&gt;Schedule
of Segment Reporting Information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalOperationsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zemW6h1G5BPa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Pharmaceutical Operations&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PremiumNutritionalSupplementsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zttCJRuYxnx9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Premium Nutritional Supplements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20251231__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zTd7UOnNttPf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total
    Reportable Segments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zxTYVIjYQMM6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Corporate
    / Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20251231_zX0Hi5JO93Fc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Consolidated
    Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_zQmGzYooq7Ia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_zsatqpRywO6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
    of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1464"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,231&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,231&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,231&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_znQtTcNM6Qof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;2,086,574&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1471"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,086,574&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1473"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;2,086,574&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_zhb9978HSvy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Selling,
    general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;817,554&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,179,492&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,997,046&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,842,666&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,839,712&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--SegmentNetLoss_zptM7uFlbuKd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment
    net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,904,128&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,161,927&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,066,055&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;(4,842,666&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;(8,908,721&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_zqOlJyeyXXXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other interest
    income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1488"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1489"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;263,824&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;263,824&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NetIncomeLoss_zLPqSxsOwCe6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,904,128&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;(1,161,927&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,066,055&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,578,842&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,644,897&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zgkxfDgYJQPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-10-012025-10-01"
      decimals="INF"
      id="Fact001454"
      unitRef="Segments">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001456">&lt;p id="xdx_892_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zvRI8LIbbUIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment
information for the year ended December 31, 2025 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_z5Rl4GydSAMl"&gt;Schedule
of Segment Reporting Information&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 84%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalOperationsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zemW6h1G5BPa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Pharmaceutical Operations&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--PremiumNutritionalSupplementsMember__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zttCJRuYxnx9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Premium Nutritional Supplements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20251231__srt--ConsolidationItemsAxis__srt--ReportableGeographicalComponentsMember_zTd7UOnNttPf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total
    Reportable Segments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zxTYVIjYQMM6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Corporate
    / Other&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20251231_zX0Hi5JO93Fc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Consolidated
    Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--Revenues_zQmGzYooq7Ia" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1458"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1461"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,796&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_zsatqpRywO6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
    of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1464"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,231&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,231&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1467"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,231&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_znQtTcNM6Qof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;2,086,574&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1471"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,086,574&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1473"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;2,086,574&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_zhb9978HSvy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Selling,
    general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;817,554&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,179,492&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,997,046&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,842,666&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,839,712&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--SegmentNetLoss_zptM7uFlbuKd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment
    net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,904,128&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,161,927&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,066,055&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;(4,842,666&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;(8,908,721&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_zqOlJyeyXXXl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other interest
    income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1488"&gt;-&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1489"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;263,824&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;263,824&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NetIncomeLoss_zLPqSxsOwCe6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,904,128&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="margin: 0"&gt;(1,161,927&lt;/p&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,066,055&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4,578,842&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8,644,897&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001459"
      unitRef="USD">21796</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001460"
      unitRef="USD">21796</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001462"
      unitRef="USD">21796</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">4231</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001466"
      unitRef="USD">4231</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001468"
      unitRef="USD">4231</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001470"
      unitRef="USD">2086574</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001472"
      unitRef="USD">2086574</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001474"
      unitRef="USD">2086574</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001476"
      unitRef="USD">817554</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001477"
      unitRef="USD">1179492</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001478"
      unitRef="USD">1997046</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">4842666</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001480"
      unitRef="USD">6839712</us-gaap:SellingGeneralAndAdministrativeExpense>
    <JUNS:SegmentNetLoss
      contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001482"
      unitRef="USD">-2904128</JUNS:SegmentNetLoss>
    <JUNS:SegmentNetLoss
      contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001483"
      unitRef="USD">-1161927</JUNS:SegmentNetLoss>
    <JUNS:SegmentNetLoss
      contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001484"
      unitRef="USD">-4066055</JUNS:SegmentNetLoss>
    <JUNS:SegmentNetLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember"
      decimals="0"
      id="Fact001485"
      unitRef="USD">-4842666</JUNS:SegmentNetLoss>
    <JUNS:SegmentNetLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001486"
      unitRef="USD">-8908721</JUNS:SegmentNetLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember"
      decimals="0"
      id="Fact001491"
      unitRef="USD">263824</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001492"
      unitRef="USD">263824</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_PharmaceuticalOperationsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001494"
      unitRef="USD">-2904128</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_PremiumNutritionalSupplementsMember_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001495"
      unitRef="USD">-1161927</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_srt_ReportableGeographicalComponentsMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">-4066055</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember_us-gaap_CorporateNonSegmentMember"
      decimals="0"
      id="Fact001497"
      unitRef="USD">-4578842</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="0"
      id="Fact001498"
      unitRef="USD">-8644897</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001500">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zqz8B85AiAy" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_82A_z2WDLPwZ0283"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;SEPA
Activity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent to year end and through March 31, 2026, we have issued and sold
approximately &lt;span&gt;&lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260101__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zQ7ytTknTee6" title="Sale of stock number of shares"&gt;1.1&lt;/span&gt;&lt;/span&gt; million SEPA Shares to Yorkville pursuant to the SEPA, including SEPA
Shares issued in connection with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds
to us of approximately $&lt;span&gt;&lt;span id="xdx_90A_eus-gaap--ProceedsFromConvertibleDebt_pid_c20260101__20260331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zA1fg7jAMaba" title="Proceeds from conversion debt"&gt;625,748&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Nasdaq
Compliance&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 26, 2026, the Company received two
written notices from the Listing Qualifications Department of Nasdaq notifying the Company that (i) the listing of the Company&#x2019;s
Common Stock was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued
listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the Common Stock was less than $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0cmbfKIk0i3" title="Common stock, par value"&gt;1.00&lt;/span&gt; per share for
the previous 30 consecutive business days, and (ii) for the 30 consecutive business days ended February 26, 2026, the Company&#x2019;s
market value of listed securities closed below the $&lt;span id="xdx_900_eus-gaap--AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQBWD4Ks59W5" title="Market value of listed securities closed"&gt;35&lt;/span&gt; million threshold required for continued listing on The Nasdaq Capital Market under
Nasdaq Listing Rule 5550(b)(2). The Company has 180 calendar days, or until August 25, 2026, to regain compliance with both the minimum bid price
requirement and the market value of listed securities requirement. To regain compliance with the minimum bid price requirement, the Company&#x2019;s
common stock must have a closing bid price of at least $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8wnI1NmGwDg" title="Common stock, par value"&gt;1.00 &lt;/span&gt;per share for a minimum of 10 consecutive business days (or such longer period,
up to 20 consecutive business days, as Nasdaq may require). To regain compliance with the market value of listed securities requirement,
the Company&#x2019;s market value of listed securities must be at least $&lt;span id="xdx_90F_eus-gaap--AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue_iI_pn6n6_c20260226__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx0i3qDfoTld" title="Market value of listed securities closed"&gt;35&lt;/span&gt; million for a minimum of 10 consecutive business days.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2025 Notes Amendment&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 20, 2026, the Company and Yorkville
entered into an Omnibus Amendment. Among other changes, the Amendment revises the terms of the 2025 Convertible Promissory Notes to defer
the commencement of monthly installment payments to April 1, 2026, effectively providing an extension of approximately three months.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-01-012026-03-31_us-gaap_SubsequentEventMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001502"
      unitRef="Shares">1.1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2026-01-012026-03-31_us-gaap_SubsequentEventMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001504"
      unitRef="USD">625748</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001506"
      unitRef="USDPShares">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue
      contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="Fact001508"
      unitRef="USD">35000000</us-gaap:AssetsDesignatedToClosedBlockFixedMaturityAvailableForSaleAtFairValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001510"
      unitRef="USDPShares">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue
      contextRef="AsOf2026-02-26_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="Fact001512"
      unitRef="USD">35000000</us-gaap:AssetsDesignatedToClosedBlockEquitySecuritiesAtFairValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
